<SEC-DOCUMENT>0001178913-23-001041.txt : 20230320
<SEC-HEADER>0001178913-23-001041.hdr.sgml : 20230320
<ACCEPTANCE-DATETIME>20230320061050
ACCESSION NUMBER:		0001178913-23-001041
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230320
DATE AS OF CHANGE:		20230320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813676773
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		23744863

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>zk2329403.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:cmmb="http://www.anchiano.com/20221231"  ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>Chemomab Therapeutics Ltd. - 1534248 - 2023</title></head><body><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;"><div style="font-size: 10pt;">
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonNumeric name="us-gaap:LeaseExpirationDate1" contextRef="C_20200501to20200510"  id="Fxbrl_20230131233234992" >2023-05-31</ix:nonNumeric><ix:nonNumeric name="us-gaap:LeaseExpirationDate1" contextRef="C_20211001to20211024"  id="Fxbrl_20230131233722905" >2024-10-31</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20220101to20221231"  id="FFact_0000000000489" >0001534248</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20220101to20221231"  id="FFact_0000000000490" >FY</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20220101to20221231"  id="FFact_0000000000491" >false</ix:nonNumeric><ix:footnote id="FN20230201025135527" xml:lang="en-US">The weighted average share price is based on the Company&#8217;s ordinary share valuation as at the grant date. </ix:footnote>
<ix:footnote id="FN20230201025203207" xml:lang="en-US">Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions and for performance conditions that are probable of achievement. If meeting the performance condition is not probable, the Company will use the awards&#8217; contractual term if the service period is implied, or the simplified method, if the service period is explicitly stated.</ix:footnote>
<ix:footnote id="FN20230201025249960" xml:lang="en-US">Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</ix:footnote>
<ix:footnote id="FN20230201025314607" xml:lang="en-US">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</ix:footnote>
</ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="cmmb-20221231.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20220101to20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200510"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-05-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200501to20200510"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-05-01</xbrli:startDate>
        <xbrli:endDate>2020-05-10</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211001to20211024"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-10-24</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211024"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-10-24</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211212"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-12</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220701to20220731"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">cmmb:CapitalAdditionsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsFifteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsSeventeenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-23</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-15</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-19</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-16</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_srtCurrencyAxis_currencyUSD"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_srtCurrencyAxis_currencyUSD"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_srtCurrencyAxis_currencyILS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_srtCurrencyAxis_currencyILS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_srtCurrencyAxis_currencyXXX"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_srtCurrencyAxis_currencyXXX"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtStatementGeographicalAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_srtStatementGeographicalAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_srtStatementGeographicalAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20231231_srtStatementScenarioAxis_srtScenarioForecastMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:OrdinarySharesNoParValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210316"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-03-16</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cmmb:MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-03-16</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230113_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001534248</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2023-01-13</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_Per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<ix:relationship fromRefs="FFact_0000000000373" toRefs="FN20230201025135527"/><ix:relationship fromRefs="FFact_0000000000377" toRefs="FN20230201025203207"/><ix:relationship fromRefs="FFact_0000000000378" toRefs="FN20230201025203207"/><ix:relationship fromRefs="FFact_0000000000379" toRefs="FN20230201025249960"/><ix:relationship fromRefs="FFact_0000000000380" toRefs="FN20230201025249960"/><ix:relationship fromRefs="FFact_0000000000381" toRefs="FN20230201025314607"/><ix:relationship fromRefs="FFact_0000000000382" toRefs="FN20230201025314607"/></ix:resources></ix:header></div><div>
  <div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-size:14pt;font-weight:bold;margin-top:0pt;margin-bottom:0pt">
      <hr style="border-right:none;border-left:none;border-image:initial;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:rgb(255, 255, 255);background-color:rgb(255, 255, 255);margin:0pt auto;text-align:center" />
    </div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-size:14pt;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">&#160;</span></span></span></div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-size:14pt;font-weight:bold;margin-top:4px;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:14pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">UNITED STATES<br /><span style="margin-top:0pt;margin-bottom:0pt">&#160;</span>SECURITIES AND EXCHANGE COMMISSION</span></span></span></span></div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Washington, D.C. 20549</span></span></span></span></div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <hr style="height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0);margin:0pt auto;border:none;text-align:center" />
      </div>
      <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-size:14pt;font-weight:bold;margin-top:6pt;margin-bottom:6pt"><span style="font-size:14pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">FORM <ix:nonNumeric id="Fxbrl_20230317110031039" name="dei:DocumentType" contextRef="C_20220101to20221231">10-K</ix:nonNumeric></span></span></span></span></div>
      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <hr style="height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0);margin:0pt auto;border:none;text-align:center" />
      </div>
    </div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><br /><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">(Mark One)</span></span></div>
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="vertical-align:top;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:20pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317110047759" name="dei:DocumentAnnualReport" contextRef="C_20220101to20221231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></td>
          <td style="vertical-align:top;text-align:center;margin-top:0pt;margin-bottom:0pt;width:auto">
            <div style="font-family:Times New Roman, serif;font-weight:bold;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">For the fiscal year ended <ix:nonNumeric id="Fxbrl_20230317115904802" name="dei:DocumentPeriodEndDate" contextRef="C_20220101to20221231" format="ixt:date-monthname-day-year-en"><ix:nonNumeric id="Fxbrl_20230317115920444" name="dei:CurrentFiscalYearEndDate" contextRef="C_20220101to20221231" format="ixt:date-monthname-day-en">December 31</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20230317115943030" name="dei:DocumentFiscalYearFocus" contextRef="C_20220101to20221231">2022</ix:nonNumeric></ix:nonNumeric></span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">OR</span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="vertical-align:top;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:20pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317110333107" name="dei:DocumentTransitionReport" contextRef="C_20220101to20221231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></td>
          <td style="vertical-align:top;text-align:center;margin-top:0pt;margin-bottom:0pt;width:auto">
            <div style="font-family:Times New Roman, serif;font-weight:bold;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">For the transition period from to</span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
      <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317110426398" name="dei:EntityFileNumber" contextRef="C_20220101to20221231">001-38807</ix:nonNumeric></span></span></span></div>
      <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:6px"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">(Commission file number)</span></span></span></div>
      <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt">&#160;</div>
      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <hr style="height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0);margin:0pt auto;border:none;text-align:center;margin-bottom:6pt" />
      </div>
    </div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:6pt"><span style="font-size:16pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317110431452" name="dei:EntityRegistrantName" contextRef="C_20220101to20221231">CHEMOMAB THERAPEUTICS LTD.</ix:nonNumeric></span></span></span></span><br /><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">(Exact name of registrant as specified in its charter)</span></span>
      <hr style="height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0);margin-bottom:0pt;border:none;text-align:center;margin-top:4pt" />
    </div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
      <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:51.92%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="text-decoration:underline;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317110501023" name="dei:EntityIncorporationStateCountryCode" contextRef="C_20220101to20221231" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></span></span></span></div>
          </td>
          <td style="width:48.08%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="text-decoration:underline;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317110522585" name="dei:EntityTaxIdentificationNumber" contextRef="C_20220101to20221231">81-3676773</ix:nonNumeric></span></span></span></div>
          </td>
        </tr>
        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:51.92%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">(State or other jurisdiction of</span></span></div>
          </td>
          <td style="width:48.08%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt">
              <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">(I.R.S. Employer</span></span></div>
            </div>
          </td>
        </tr>
        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:51.92%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">incorporation or organization)</span></span></div>
          </td>
          <td style="width:48.08%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt">
              <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Identification No.)</span></span></div>
            </div>
          </td>
        </tr>
        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:51.92%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">&#160;</td>
          <td style="width:48.08%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt">&#160;</div>
          </td>
        </tr>
        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:51.92%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113139733" name="dei:EntityAddressAddressLine1" contextRef="C_20220101to20221231">Kiryat Atidim</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20230317113157615" name="dei:EntityAddressAddressLine2" contextRef="C_20220101to20221231">Building 7</ix:nonNumeric></span></span></div>
          </td>
          <td style="width:48.08%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">&#160;</td>
        </tr>
        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:51.92%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="text-decoration:underline;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113215641" name="dei:EntityAddressCityOrTown" contextRef="C_20220101to20221231">Tel Aviv</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20230317120727388" name="dei:EntityAddressCountry" contextRef="C_20220101to20221231" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></span></span></div>
          </td>
          <td style="width:48.08%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="text-decoration:underline;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113235355" name="dei:EntityAddressPostalZipCode" contextRef="C_20220101to20221231">6158002</ix:nonNumeric></span></span></span></div>
          </td>
        </tr>
        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:51.92%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">(Address of principal executive offices)</span></span></div>
          </td>
          <td style="width:48.08%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">(Zip Code)</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Registrant&#8217;s telephone number, including area code: +<ix:nonNumeric id="Fxbrl_20230317113259509" name="dei:CityAreaCode" contextRef="C_20220101to20221231">972</ix:nonNumeric>-<ix:nonNumeric id="Fxbrl_20230317113315303" name="dei:LocalPhoneNumber" contextRef="C_20220101to20221231">77-331-0156</ix:nonNumeric></span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Securities registered pursuant to Section 12(b) of the Act:</span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <table cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;width:100%;text-align:left;color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:40.02%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Title of each class</span></span></div>
          </td>
          <td style="width:19.96%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Trading Symbol(s)</span></span></div>
          </td>
          <td style="width:40.02%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Name of each exchange on which registered</span></span></div>
          </td>
        </tr>
        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:40.02%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113401299" name="dei:Security12bTitle" contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember">American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share</ix:nonNumeric></span></span></div>
          </td>
          <td style="width:19.96%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113420950" name="dei:TradingSymbol" contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember">CMMB</ix:nonNumeric></span></span></div>
          </td>
          <td style="width:40.02%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113425782" name="dei:SecurityExchangeName" contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</span></span></div>
          </td>
        </tr>
        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:40.02%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">&#160;</td>
          <td style="width:19.96%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">&#160;</td>
          <td style="width:40.02%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">&#160;</td>
        </tr>
        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:40.02%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113407348" name="dei:Security12bTitle" contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember">Ordinary shares, no par value per share</ix:nonNumeric></span></span></div>
          </td>
          <td style="width:19.96%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113501184" name="dei:TradingSymbol" contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember">n/a</ix:nonNumeric></span></span></div>
          </td>
          <td style="width:40.02%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113450391" name="dei:SecurityExchangeName" contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market*</span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">*Not for trading; only in connection with the registration of American Depository Shares.</span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Securities registered pursuant to Section 12(g) of the Act:</span></span></div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">None</span></span></div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
      <div style="break-after:page;margin-top:0pt;margin-bottom:0pt">
        <hr style="border-width:0px;clear:both;margin:0pt 0px;width:100%;height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0)" />
      </div>
    </div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></span></div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Yes <span style="margin-top:0pt;margin-bottom:0pt">&#9744;&#160; &#160;</span> <ix:nonNumeric id="Fxbrl_20230317113557797" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_20220101to20221231">No</ix:nonNumeric> <span style="margin-top:0pt;margin-bottom:0pt">&#9746;</span></span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</span></span></div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Yes <span style="margin-top:0pt;margin-bottom:0pt">&#9744;&#160; &#160;</span> <ix:nonNumeric id="Fxbrl_20230317113613031" name="dei:EntityVoluntaryFilers" contextRef="C_20220101to20221231">No</ix:nonNumeric> <span style="margin-top:0pt;margin-bottom:0pt">&#9746;</span></span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></span></div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113649242" name="dei:EntityCurrentReportingStatus" contextRef="C_20220101to20221231">Yes</ix:nonNumeric> <span style="margin-top:0pt;margin-bottom:0pt">&#9746;</span>&#160; &#160;No <span style="margin-top:0pt;margin-bottom:0pt">&#9744;</span></span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></span></div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113712117" name="dei:EntityInteractiveDataCurrent" contextRef="C_20220101to20221231">Yes</ix:nonNumeric> <span style="margin-top:0pt;margin-bottom:0pt">&#9746;&#160; &#160;</span> No <span style="margin-top:0pt;margin-bottom:0pt">&#9744;</span></span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <table border="0" cellpadding="0" cellspacing="0" style="width:100%">

        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="vertical-align:top;margin-top:0pt;margin-bottom:0pt;width:30%">
            <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Large accelerated filer</span></span></div>
          </td>
          <td style="vertical-align:top;margin-top:0pt;margin-bottom:0pt;width:20%">
            <div><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#9744;</span></span></div>
          </td>
          <td style="vertical-align:top;margin-top:0pt;margin-bottom:0pt;width:30%">
            <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Accelerated filer</span></span></div>
          </td>
          <td style="vertical-align:top;margin-top:0pt;margin-bottom:0pt;width:20%">
            <div><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#9744;</span></span></div>
          </td>
        </tr>
        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="vertical-align:top;margin-top:0pt;margin-bottom:0pt;width:30%">
            <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113737895" name="dei:EntityFilerCategory" contextRef="C_20220101to20221231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></span></span></div>
          </td>
          <td style="vertical-align:top;margin-top:0pt;margin-bottom:0pt;width:20%">
            <div><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#9746;</span></span></div>
          </td>
          <td style="vertical-align:top;margin-top:0pt;margin-bottom:0pt;width:30%">
            <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Smaller reporting company</span></span></div>
          </td>
          <td style="vertical-align:top;margin-top:0pt;margin-bottom:0pt;width:20%">
            <div><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113803418" name="dei:EntitySmallBusiness" contextRef="C_20220101to20221231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></div>
          </td>
        </tr>
        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="vertical-align:top;margin-top:0pt;margin-bottom:0pt;width:30%">&#160;</td>
          <td style="vertical-align:top;margin-top:0pt;margin-bottom:0pt;width:20%">&#160;</td>
          <td style="vertical-align:top;margin-top:0pt;margin-bottom:0pt;width:30%">
            <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Emerging growth company</span></span></div>
          </td>
          <td style="vertical-align:top;margin-top:0pt;margin-bottom:0pt;width:20%">
            <div><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113819251" name="dei:EntityEmergingGrowthCompany" contextRef="C_20220101to20221231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113837997" name="dei:EntityExTransitionPeriod" contextRef="C_20220101to20221231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span></span></div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Yes <span style="margin-top:0pt;margin-bottom:0pt">&#9744;&#160;&#160;</span> No <span style="margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113902158" name="dei:IcfrAuditorAttestationFlag" contextRef="C_20220101to20221231" format="ixt:fixed-false">&#9746;</ix:nonNumeric></span></span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="margin-top:0pt;margin-bottom:0pt">&#9744;</span></span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="margin-top:0pt;margin-bottom:0pt">&#9744;</span></span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></span></div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Yes <span style="margin-top:0pt;margin-bottom:0pt">&#9744;&#160;&#160;</span> No <span style="margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="Fxbrl_20230317113939282" name="dei:EntityShellCompany" contextRef="C_20220101to20221231" format="ixt:fixed-false">&#9746;</ix:nonNumeric></span></span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">The aggregate market value of ordinary shares held by non-affiliates of the registrant on the last business day of the registrant&#8217;s most recently completed second fiscal quarter was $<ix:nonFraction id="Fxbrl_20230317153101775" name="dei:EntityPublicFloat" contextRef="C_20221231" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.9</ix:nonFraction> million, based on the closing sale price of the registrant&#8217;s American Depositary Shares as reported on the Nasdaq Capital Market on June 30, 2022. For purposes of determining this number, all executive officers and directors of the registrant as of June 30, 2022 were considered affiliates of the registrant. This number is provided only for the purposes of this Annual Report on Form 10-K and does not represent an admission by either the registrant or any such person as to the affiliate status of such person.</span></span></span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">As of March 16, 2023, the registrant had <ix:nonFraction id="Fxbrl_20230317153138658" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">220,996,240</ix:nonFraction> ordinary shares outstanding (which is equivalent to 11,049,812 American Depositary Shares, each representing twenty ordinary shares, outstanding).</span></span></span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:center;line-height:1.25;font-family:Times New Roman, serif;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">DOCUMENTS INCORPORATED BY REFERENCE</span></span></div>
    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="text-decoration:underline;margin-top:0pt;margin-bottom:0pt">None.</span></span></span></div>
    <div style="text-align:justify;text-indent:18pt;line-height:1.25;font-family:Times New Roman, serif;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="clear:both;margin-top:0pt;margin-bottom:0pt">
      <div style="break-after:page;margin-top:0pt;margin-bottom:0pt">
        <hr style="border-width:0px;clear:both;margin:0pt 0px;width:100%;height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0)" />
      </div>
    <!-- Field: Include-Text; File: PF\body.htm; Date: 2023%2D03%2D20T09:55:03; Size: 0x00140223; Options: XMLPreprocess -->
<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman,Times,serif"> </span></p>

<div>

<div class="BRPFPageHeader" style="font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">FORM&#160;10-K</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">TABLE OF CONTENTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z4d01f42eb222466083e60fb231fd1ff9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td colspan="2" style="vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold"><a href="#PARTI">PART&#160;I</a></div> </td>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif; text-align: right"><br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#CAUTIONARYSTATEMENTREGARD">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;2</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item1.Business">Item 1.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item1.Business">Business <br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;3</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item1A.">Item 1A.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item1A.">Risk Factors<br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;48</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item1.Business">Item 1B.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item1.Business">Unresolved Staff Comments <br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;76</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item2.">Item 2.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item2.">Properties<br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;76</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item3.">Item 3.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item3.">Legal Proceedings<br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;77</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item4.">Item 4.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item4.">Mine Safety Disclosures<br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;77</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold"><a href="#PARTII">PART&#160;II</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;77</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item5.">Item 5.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item5.">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases
        of Equity Securities</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;77</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item6.">Item 6.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item6.">[Reserved]<br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;77</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item7">Item 7.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item7">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;77</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item7A">Item 7A</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item7A">Quantitative and Qualitative Disclosures About Market Risk<br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;85</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item8.">Item 8.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item8.">Financial Statements and Supplementary Data<br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;86</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item9.">Item 9.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item9.">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;86</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item9A">Item 9A.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item9A">Controls and Procedures<br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;86</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item9B">Item 9B.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item9B">Other Information<br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;86</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item9C">Item 9C</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item9C">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections<br /> </a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;86</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold"><a href="#PARTIII">PART&#160;III</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;87</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item10">Item 10.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item10">Directors, Executive Officers and Corporate Governance<br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;87</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item11">Item 11.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item11">Executive Compensation<br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: right">&#160;93</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item12.">Item 12.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item12.">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
        Matters</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;101</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item13">Item 13.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item13">Certain Relationships and Related Transactions, and Director Independence</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;103</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item14">Item 14.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item14">Principal Accountant Fees and Services<br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">105<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold"><a href="#PARTIV">PART&#160;IV</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">106<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">&#160;</div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item15">Item 15.</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item15">Exhibits and Financial Statement Schedules<br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;106</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item16.">Item 16</a></div> </td>
    <td style="width: 87%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="#Item16.">Form 10-K Summary<br /> </a></div> </td>
    <td style="width: 5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: right">&#160;107</td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>
<!--PROfilePageNumberReset%Num%2%%%-->

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold"><span id="PARTI"><!--Anchor--></span>PART&#160;I</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In this Annual Report
on Form&#160;10-K, unless the context otherwise requires:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7bad21566f7f482d8e8da27177c81a70" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>references to &#8220;Chemomab Therapeutics Ltd.&#8221;, &#8220;Chemomab,&#8221; the &#8220;Company,&#8221; &#8220;us,&#8221; &#8220;we&#8221;
        and &#8220;our&#8221; refer to Chemomab Therapeutics Ltd., an Israeli company and its consolidated subsidiaries; however, with respect
        to the presentation of financial results for historical periods that preceded the Merger (as defined below), these terms refer to the
        financial results of the Company&#8217;s wholly owned subsidiary, Chemomab Ltd., which was the accounting acquirer in the Merger;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfe9bad5bd7f54fa7a4520ab8c0b213bc" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>references to &#8220;ordinary shares,&#8221; &#8220;our shares&#8221; and similar expressions refer to the Company&#8217;s ordinary
        shares, no nominal (par) value;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z081cfb446ce2426f9b3c20a41c832d02" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>references to &#8220;ADS&#8221; refer to the American Depositary Shares listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;)
        under the symbol &#8220;CMMB,&#8221; each representing twenty (20) ordinary shares;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zaa7bc2b45c6f4a029917c10f9ca04404" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>references to &#8220;dollars,&#8221; &#8220;U.S. dollars&#8221; and &#8220;$&#8221; are to United States Dollars;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zce41b7f56afb4796bebfeae29a3fcec1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>references to &#8220;NIS&#8221; are to New Israeli Shekels;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd935ff551f6147428905fff6e949e5a9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>references to the &#8220;Companies Law&#8221; are to Israel&#8217;s Companies Law, 5759-1999, as amended;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5934469f9fa54b4c89c69e366f068010" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>references to the &#8220;SEC&#8221; are to the U.S. Securities and Exchange Commission; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2493da99fefd4c13a32dffb4d0c0508d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>references to the &#8220;Merger&#8221; refer to the merger involving Anchiano Therapeutics Ltd., or Anchiano, and Chemomab Ltd.,
        whereby a wholly owned subsidiary of Anchiano merged with and into Chemomab Ltd., with Chemomab Ltd. surviving as a wholly owned subsidiary
        of Anchiano. Upon consummation of the Merger on March 16, 2021, Anchiano changed its name to &#8220;Chemomab Therapeutics Ltd.&#8221;
        and the business conducted by Chemomab Ltd. became primarily the business conducted by the Company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold"><span id="CAUTIONARYSTATEMENTREGARD"><!--Anchor--></span>CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The statements set forth
under the captions &#8220;Business,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
and &#8220;Risk Factors,&#8221; and other statements included elsewhere in this Annual Report on Form 10-K, which are not historical,
constitute &#8220;forward-looking statements&#8221; within the meanings of Section 27A of the Securities Act of 1933, as amended (the
&#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), including
statements regarding expectations, beliefs, intentions or strategies for the future. These statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking
statements by terms including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221;
&#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221;
&#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions intended to identify forward-looking statements,
but these are not the only ways these statements are identified. Forward-looking statements reflect our current views with respect to
future events and are based on assumptions and subject to risks and uncertainties. Such forward-looking statements include, but are not
limited to: the initiation, timing, progress and results of our preclinical studies and other therapeutic candidate development efforts;
our ability to develop and advance a future therapeutic candidate into clinical trial or to successfully complete our preclinical studies;
our receipt of regulatory approvals for a future therapeutic candidate, and the timing of other regulatory filings and approvals; the
clinical development, commercialization and market acceptance of a future therapeutic candidate; our ability to establish and maintain
corporate collaborations and integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics
of a future therapeutic candidate; the implementation of our business model and strategic plans for our business and future therapeutic
candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering future therapeutic
candidates and our ability to operate our business without infringing the intellectual property rights of others; estimates of our expenses,
future revenues, capital requirements and our needs for additional financing; risks relating to our ability to finance our activities
and research programs; our dependence on performance by third-party providers of services and supplies, including without limitation,
clinical research organizations; the inherent risks and uncertainties in developing the types of preclinical products we are attempting
to develop; competitive companies, technologies and our industry; risks related to our ability to maintain compliance with the continued
listing standards of Nasdaq; <span style="color: rgb(0, 0, 0)">our future revenue, expenses, inflationary pressures, capital requirements
and our needs for additional financing, including our ability to continue as a going concern; our ability to obtain additional financing
in future offerings; the volatility of the trading price of the ADSs; and other risks and uncertainties, including those listed in the
section titled &#8220;Risk Factors.&#8221;</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">2</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span id="Item1.Business"><!--Anchor--></span><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Item
1.</span><span style="font-family: Times New Roman,Times,serif">&#160;&#160; <span style="font-weight: bold">Business</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Overview</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab is a clinical-stage
biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with
high unmet needs. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed
CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe
and life-threatening fibrotic and inflammatory diseases.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab has pioneered
the therapeutic targeting of CCL24, a chemokine that promotes various types of cellular processes that regulate inflammatory and fibrotic
activities through the CCR3 receptor. The chemokine is expressed in various types of cells, including immune cells, endothelial cells
and epithelial cells. We have developed a novel CCL24 inhibiting product candidate with dual anti-fibrotic and anti-inflammatory activity
that modulates the complex interplay of both of these inflammatory and fibrotic mechanisms, which drive abnormal states of fibrosis and
clinical fibrotic diseases. This innovative approach is being developed for difficult to treat rare diseases, also known as orphan indications
or diseases, such as primary sclerosing cholangitis, or PSC, and systemic sclerosis, or SSc, for which patients have no established disease
modifying standard of care treatment options. We estimate that there are approximately 77 thousand patients suffering from PSC in the
U.S., EU and Japan, representing over a $1 billion market opportunity, and approximately 170 thousand patients suffering from SSc in those
same markets, representing over a $1.5 billion market opportunity.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">CM-101, our lead clinical
product candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of the soluble chemokine CCL24,
also known as eotaxin-2, as a regulator of major inflammatory and fibrotic pathways. We have demonstrated that CM-101 interferes with
the underlying biology of inflammation and fibrosis through a novel and differentiated mechanism of action. Based on these findings, we
are actively advancing CM-101 in Phase 2 clinical studies directed toward two distinct clinical indications that include patients with
liver or skin, and/or lung fibrosis. We are currently conducting a Phase 2 clinical study in PSC, a rare obstructive and cholestatic liver
disease. The study is actively recruiting patients in the U.S., Europe and Israel and is being expanded by adding clinical sites, an additional
high dose arm (20mg/kg) as well as an open label extension. We had earlier proposed to add both low and high dose arms to the study but
the recent encouraging results reported from our Phase 2 liver fibrosis trial in NASH patients, dosed at 5mg/kg, along the positive Phase
1b data we previously reported in non-alcoholic fibrotic liver disease (NAFLD) patients dosed at 5mg/kg and 2,5mg/kg, are seen as providing
us sufficient data on the performance of the lower dose to drop it from the current trial, which is focusing on the 10mg/kg and 20g/kg
doses. We believe this change will facilitate timely conduct and completion of the trial. If regulators in the future do not agree that
the existing low dose data are sufficient, we always have the option to add a lower dose group as part of the Phase 3 clinical program.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We are also planning to open a Phase 2 clinical
trial in SSc about midyear 2023. The trial in SSc, a rare autoimmune rheumatic disease characterized by fibrosis in the skin and lung
and other organs, will focus on establishing biological and clinical proof of concept in this patient population. Although our primary
focus is on these two rare indications, as we noted, an additional Phase 2 clinical study in patients with liver fibrosis due to non-alcoholic
steatohepatitis, or NASH has recently been completed.&#160; This trial provided safety and pharmacokinetic (PK) data and is informative
in determining whether the company advances the development of its current subcutaneous formulation of CM-101. Additionally, the trial
measured a number of biomarkers that may be relevant to the potential activity of CM-101 in other fibro-inflammatory conditions. We recently
reported results from this trial, which showed that the trial met its primary endpoint of safety and tolerability, and that CM-101 demonstrated
encouraging activity in secondary endpoints that include a range of liver fibrosis biomarkers and physiologic assessments.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">3</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Fibrosis is the abnormal
and excessive accumulation of collagen and extracellular matrix, the non-cellular component in all tissues and organs, which provides
structural and biochemical support to surrounding cells. When present in excessive amounts, collagen and extracellular matrix lead to
scarring and thickening of connective tissues, affecting tissue properties and potentially leading to organ dysfunction and failure. Fibrosis
can occur in many different tissues, including lung, liver, kidney, muscle, skin, and the gastrointestinal tract, resulting in a wide
array of progressive fibrotic conditions. Fibrosis and inflammation are intrinsically linked. While a healthy inflammatory response is
necessary for efficient tissue repair; after disease or injury, an excessive, uncontrolled inflammatory response can lead to tissue fibrosis
that in turn can further stimulate inflammatory processes in a fibro-inflammatory vicious cycle<span style="color: rgb(0, 0, 0)">.</span></div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Recent
Developments</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">FDA
Clearance of our IND Application for CM-101 in Phase 2 Trial in SSc Patients</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">On February 21, 2023, we reported U.S. Food
and Drug Administration (FDA) clearance of our Investigational New Drug (IND) Application to evaluate CM-101 in a Phase 2 trial in adults
with systemic sclerosis (SSc). The Phase 2 ABATE trial is a multicenter, randomized, double-blind, proof-of-biology study to evaluate
the s<span style="font-weight: bold">A</span>fety, tolera<span style="font-weight: bold">B</span>ility, and <span style="font-weight: bold">A</span>ctivity
of CM-101 in patients with sys<span style="font-weight: bold">TE</span>mic sclerosis. It expects to enroll 45 patients with clinically
active dermatologic, vascular or pulmonary SSc. The study population is expected to be roughly split between patients with diffuse SSc
and patients with limited SSc. The primary outcome measure is safety. Secondary endpoints include multiple serum-based biological markers
and a variety of exploratory biological and clinical outcomes, including the American College of Rheumatology Composite Response Index
in Systemic Sclerosis (ACR-CRISS) score and its revisions (rCRISS). The trial includes a 24-week double blind period during which active
treatment patients will receive 10 mg/kg of CM-101 by intravenous infusion every three weeks, followed by a 24-week open label extension,
where all patients will receive a 10 mg/kg dose. The trial includes multiple clinical assessments of the skin, vasculature and pulmonary
function. It is expected to generate additional information about disease mechanisms, provide data relevant to future patient stratification
strategies and inform the selection of appropriate endpoints for future studies. The trial is expected&#160; to begin enrolling patients
midyear of 2023.A topline data read-out is targeted for the second half of 2024.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Report Topline Results from CM-101 Phase 2a
Liver Fibrosis Biomarker Trial in NASH Patients</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">On January 3, 2023, we reported positive topline results from our
Phase 2a liver fibrosis biomarker trial of CM-101 in NASH patients. This trial was primarily designed to assess a subcutaneous formulation
of CM-101 and to evaluate the drug&#8217;s impact on liver fibrosis biomarkers relevant to both NASH and the fibro-inflammatory conditions
that represent the focus for the company, such as PSC and SSc. The trial met its primary endpoint of safety and tolerability, and CM-101
demonstrated encouraging activity in secondary endpoints that include a range of liver fibrosis biomarkers and physiologic assessments
measured at baseline and at week 20.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The randomized, placebo-controlled
trial enrolled 23 NASH patients with stage F1c, F2 and F3 disease who were randomized to receive either CM-101 or placebo. Patients received
a dose of&#160;5 mg/kg of study drug administered by subcutaneous (SC) injection once every two weeks, for a treatment period of 16 weeks.
Key findings of the CM-101 Phase 2a trial included the following.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4066c7f9f2fb43a99ccb12b51b6ec4a6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 25.2pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">CM-101 appeared to be safe and well tolerated when administered subcutaneously. Most reported adverse
        events observed were mild, with one unrelated serious adverse event reported. No significant injection site reactions were reported and
        no anti-drug antibodies were detected.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zccb5b95f23434222b5906146225a5b63" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 25.2pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">CM-101 administered subcutaneously demonstrated favorable pharmacokinetics and target engagement profiles
        as expected, and were similar to what the company has previously reported.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcc19a188d08a4b6bb0e20c2e0b1e434d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 25.2pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">CM-101-treated patients showed greater improvements than the placebo group in a number of liver fibrosis-related
        biomarkers, including ProC-3, ProC-4, ProC-18, TIMP-1 and ELF.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">4</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z17a92a75140b4e6890c5beda00f6d408" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 25.2pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">A majority of CM-101-treated patients showed improvements in multiple liver fibrosis-related biomarkers&#8212;almost
        60% of CM-101 patients were &#8220;multiple responders&#8221;, responding in at least three biomarkers at week 20, compared to no patients
        in the placebo group.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7245bacf51e14c2ebba4f7e6a602b093" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 25.2pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">CM-101-treated patients with higher CCL24 levels at baseline showed greater reductions in fibrosis-related
        biomarkers than patients with lower levels of CCL24 at baseline. More CM-101-treated patients with higher CCL24 levels also were &#8220;multiple
        responders&#8221;, responding in three or more of the fibrosis-related biomarkers, compared to patients with lower CCL24 levels at baseline.&#160;
        These findings further add to the growing body of evidence validating the role of CCL24 in the pathophysiology of fibrotic liver disease.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z294fa44276f64409832ad199962c45e2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 25.2pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">A higher proportion of patients in the CM-101-treated group showed improvement in a physiologic measure
        of liver stiffness as compared to placebo (reduction of at least one grade of fibrosis score as assessed by the non-invasive elastography
        method known as FibroScan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>).</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfa3822468011479088408aa0cb1e19a1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 25.2pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">After completion of the study, the unblinded data showed that patients in the CM-101-treated group had
        higher baseline levels of fibrosis compared to placebo patients. The impact of this difference on the results, if any, is unknown.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We believe that the data
from this trial provide important insights in support of the CM-101 development program, including the favorable safety and tolerability
of CM-101 in patients with serious liver disease, confirmation of early signs of biomarker activity that are relevant for a number of
fibro-inflammatory disorders, and support for the tolerability and pharmacokinetic data needed to assess next steps in the development
of our SC formulation<span style="font-style: italic">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Results
Reported for Clinical Study of CM-101 in Patients with COVID-19-Derived Lung Damage</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">On November 9, 2022,
positive clinical data from an investigator-initiated clinical study assessing CM-101 activity and safety in hospitalized patients with
severe lung injury derived from COVID-19 was presented at the 2022 Union Conference, an international conference on lung health. Some
of the mechanisms underlying lung inflammation resulting from COVID-19 infection are similar to those seen in systemic sclerosis and other
chronic diseases involving lung inflammation and fibrosis. The objective of the study was to evaluate the drug&#8217;s safety and activity
in hospitalized COVID-19 patients with severe pneumonia, including its impact on biomarkers related to lung inflammation that are also
relevant in SSc.<span style="font-weight: bold">&#160;</span>The open label, single arm trial enrolled 16 hospitalized adult COVID-19
patients with severe respiratory involvement. All patients were receiving standard of care therapy. All were treated with a single 10mg/kg
intravenous dose of CM-101 on the first day of the study and followed for 30 days.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Administration of CM-101
to this acutely ill patient population appeared safe and was well tolerated. CM-101 exposures and target engagement profiles were similar
to what our researchers have seen in previous clinical studies of CM-101. Importantly, rapid reductions in serum biomarkers of lung inflammation,
fibrogenesis and neutrophil activity were observed post-treatment with CM-101.<span style="font-weight: bold">&#160;</span>Overall, this
study confirmed and extended the safety and tolerability profile of CM-101 and demonstrated clinically relevant changes in biomarkers
associated with lung inflammation and fibrogenesis, further supporting CM-101&#8217;s anti-inflammatory and anti-fibrotic effects.<span style="font-weight: bold">&#160;</span>Moreover,
we believe that these results add to the data suggesting that CM-101 has the potential to attenuate lung inflammation and fibrosis, further
strengthening the rationale for treating SSc patients with this drug. These new clinical data also contribute to a growing body of evidence
demonstrating CM-101&#8217;s anti-fibrotic and anti-inflammatory effects in varied organs including the lung, liver and skin.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">5</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Pipeline</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image00032.jpg" alt="" /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab&#8217;s lead
product candidate, CM-101, is a first-in-class humanized monoclonal antibody targeting CCL24 that is being advanced in two orphan indications:
PSC and SSc. CCL24 has been extensively studied in airway inflammation and, more recently, Chemomab has demonstrated in preclinical studies
and early clinical studies that it plays an important role in additional indication areas, including inflammation and fibrosis of the
liver, skin and lung. Although found in low levels in blood or tissue samples taken from healthy volunteers, elevated levels of both CCL24
and its receptor CCR3, have been found in patients with PSC, SSc and NASH. CCL24 levels have even been correlated to different phases
of disease. Chemomab expects that neutralizing CCL24 with an antibody will exert anti-fibrotic and anti-inflammatory effects in patients.
CM-101 has been granted orphan drug designation by both the FDA and the EMA in its primary indications of PSC and SSc based on extensive
preclinical and non-clinical data. This designation provides multiple benefits, including the potential for exclusive marketing and development
rights for a period of time for these indications.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">PSC is a rare, chronic
cholestatic liver disease characterized by progressive inflammation, fibrosis, and destruction of the intrahepatic and extrahepatic bile
ducts with no identifiable cause. Cholestasis is a symptom of liver injury and is characterized as the interruption of bile flow from
hepatocytes to the intestine, which leads to bile acid accumulation in the liver, resulting in oxidative stress, inflammation, apoptosis,
and fibrosis. PSC affects approximately 30,000-45,000 patients in the United States and is commonly associated with inflammatory bowel
disease. Median survival is between 10-12 years.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Fibrosis and inflammatory
responses induce a progressive spread of the fibrotic condition. No treatment aside from a liver transplant has been associated with change
of the disease course or significant long-term improvement in the clinical outcome. PSC is a clear serious unmet medical need with no
FDA approved therapeutics for which the current standard of care is inadequate.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">SSc is a rare connective
tissue disease characterized by excessive fibrosis and extracellular matrix accumulation in the skin, lung, and other visceral organs.
The disease initiates with an early inflammatory phase involving the immune cell network, as well as endothelial cells. As the disease
progresses, the inflammation increases and fibroblasts and myofibroblasts generate tissue fibrosis, while endothelial cells promote vascular
injury, which can lead to skin fibrosis, interstitial lung disease, myocardial insufficiency, vascular obliteration, distal ulcerations,
and gangrene. SSC affects approximately 75,000-100,000 patients in the United States. SSc has the highest mortality rate among the systemic
rheumatic diseases and has high unmet need, as current treatments manage only disease manifestations and there is no disease modifying
drug available.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab is primarily
focused on the orphan indications PSC and SSc, but believes that it may have additional opportunities in other fibrotic-inflammatory disease
areas such as idiopathic pulmonary fibrosis, or IPF and nonalcoholic steatohepatitis, or NASH. CM-101 has shown promising anti-fibrotic
and anti-inflammatory effects in preclinical studies of liver fibrosis and PSC, with significant reductions in fibrotic genes, liver enzymes,
bile acid and cholangiocyte proliferation, all reflecting a potential&#160; improvement in disease status. In preclinical studies of SSc,
CM-101 reduced inflammatory and fibrotic injury resulting in reductions in dermal thickness, collagen concentration in the skin and the
lung,</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">and immune cell infiltration in the lung.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">6</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab has completed
two Phase 1a single ascending dose studies with intravenous, or IV, and subcutaneous, or SC, administrations of CM-101 in 40 healthy volunteers.
The drug was shown to be safe and well-tolerated, with a PK profile supporting dosing once every 2-4 weeks. The Company also completed
a Phase 1b multiple administration ascending dose study in 16 non-alcoholic fatty liver disease (NAFLD) patients, expanding its safety,
tolerability, and pharmacodynamics database with patients with early liver disease. Early evidence of an anti-fibrotic effect was also
seen in this study.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Chemomab recently reported topline results
from its Phase 2a randomized, double-blind, placebo-controlled study in patients with liver fibrosis derived due to NASH. The trial met
its primary endpoint of safety and tolerability, and CM-101 demonstrated promising activity in secondary endpoints that included pharmacokinetic
and target engagement profiles of the SC formulation as well as a range of liver fibrosis biomarkers and physiologic assessments measured
at baseline and at week 20.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The randomized, placebo-controlled
trial enrolled 23 NASH patients with stage F1c, F2 and F3 disease who were randomized to receive either CM-101 or placebo. Patients received
eight doses of 5 mg/kg of study drug administered by SC injection once every two weeks, for a treatment period of 16 weeks. Key findings
of the CM-101 Phase 2a trial included the following.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9ee8a0c2902c44c899b8a80003aa84d4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>CM-101 appeared to be safe and was well tolerated when administered subcutaneously. Most reported adverse events observed were mild,
        with one unrelated serious adverse event reported. No significant injection site reactions were reported and no anti-drug antibodies,
        or ADAs, were detected.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z57b71438b2d04113af1be7d4cacb7d93" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>CM-101 administered subcutaneously demonstrated favorable pharmacokinetics and target engagement profiles as expected, which were
        similar to what the company has previously reported.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za011dfb4a2e2420fb718c8e9e2f28bb5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>CM-101-treated patients showed greater improvements than the placebo group in a number of liver fibrosis-related biomarkers, including
        ProC-3, ProC-4, ProC-18, TIMP-1 and ELF.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zafd3b0763e754e72b47c18aa0ceb7ce2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>A majority of CM-101-treated patients showed improvements in more than one liver fibrosis-related biomarker&#8212;almost 60% of CM-101
        patients responded in at least three biomarkers at week 20, compared to no patients in the placebo group.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2a39378d472b4cc88dae1e5695b42e80" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>A higher proportion of patients in the CM-101-treated group showed improvement in a physiologic measure of liver stiffness as compared
        to placebo (reduction of at least one grade of fibrosis score as assessed by the non-invasive elastography method known as FibroScan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;)</sup>.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3949caed4cf3446bb89bdf8a0e7304e2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>CM-101-treated patients with higher CCL24 levels at baseline showed greater reductions in fibrosis-related biomarkers than patients
        with lower levels. Multiple fibrosis-related biomarkers showed more pronounced reductions in CM-101-treated patients who had higher CCL24
        levels at baseline than in patients with lower CCL24 baseline levels, adding to the growing body of evidence validating the role of CCL24
        in the pathophysiology of fibrotic liver disease.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z196602cc963e4b7e93c57153cdac314b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>After completion of the study, the unblinded data showed that patients in the CM-101-treated group had higher baseline levels of
        fibrosis compared to placebo patients. The impact of this difference on the results, if any, is unknown.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">7</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Data from this trial
provide important insights in support of the CM-101 development program, including the favorable safety and tolerability of CM-101 in
patients with serious liver disease, confirmation of early signs of biomarker activity that are relevant for a number of fibro-inflammatory
disorders, and additional tolerability and pharmacokinetic data needed to assess next steps in the development of our current subcutaneous
formulation.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Recently, Chemomab also
reported positive clinical data from an investigator-initiated clinical study assessing CM-101 activity and safety in hospitalized patients
with severe lung injury derived from COVID-19. The objective of the study was to evaluate the drug&#8217;s safety and activity in hospitalized
COVID-19 patients with severe pneumonia, including its impact on biomarkers related to lung inflammation that are also relevant in systemic
sclerosis. The open label, single arm trial enrolled 16 hospitalized adult COVID-19 patients with severe respiratory involvement. All
patients were receiving standard of care therapy. All were treated with a single 10mg/kg intravenous dose of CM-101 on the first day of
the study and followed for 30 days. Administration of CM-101 to this acutely ill patient population appeared to be safe and was well tolerated.
CM-101 exposures and target engagement profiles were similar to what our researchers have seen in previous clinical studies of CM-101.
Importantly, rapid reductions in serum biomarkers of lung inflammation, fibrogenesis and neutrophil activity were observed post-treatment
with CM-101. Overall, this study confirmed and extended the safety and tolerability profile of CM-101 and demonstrated clinically relevant
changes in biomarkers associated with lung inflammation and fibrogenesis, further supporting CM-101&#8217;s anti-inflammatory and anti-fibrotic
effects.</div> <br />

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Chemomab is currently conducting a randomized, double-blind, placebo-controlled
study of CM-101 in PSC patients, and is planning to initiate a new study in SSc patients around midyear&#160; of 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">The Phase 2 randomized, double-blind, placebo-controlled SPRING
study is currently enrolling patients with PSC who are treated with CM-101 or placebo for 15 weeks. The company has expanded the trial
by&#160; implementing a dose finding component to the CM-101 development program and evaluating&#160; a higher dose level of CM-101 (20mg/kg)
to support future potential registrational trials. In addition, the company is adding an open-label extension to the trial to evaluate
the safety, tolerability and durability of effect over longer treatment durations.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">Chemomab is currently conducting a randomized, double-blind, placebo-controlled
study of CM-101 in PSC patients, and is planning to initiate a new study in SSc patients around midyear of 2023.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab may also explore
CM-101 in other indications, where the dual activity of CM-101 acting on both inflammation and fibrosis could provide new avenues for
treating inflammatory and fibrotic conditions.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab was founded
in 2011, based on a novel discovery originating from the Sourasky Medical Center in Tel-Aviv, Israel, where Professor Jacob George first
identified CCL24 as a key regulator of unstable plaque formation in atherosclerotic patients. In its early years, Chemomab focused on
research directed at clarifying the role and effectiveness of CCL24 blockade. In 2015, Chemomab selected its proprietary lead product
candidate, CM-101, and started product development directed towards human testing.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab has assembled
an executive team with highly relevant experience in inflammation and fibrosis, and biologics drug discovery and clinical development.
Adi Mor, Ph.D., Chemomab&#8217;s Chief Scientific Officer and Co-founder, has 15 years of experience in Immunology and has led the CM-101
program from discovery stage into Phase 2 clinical studies. Matthew Frankel, M.D., Chemomab&#8217;s Chief Medical Officer, brings deep
experience in clinical development. Dr. Frankel, who is based in the U.S., has more than 25 years of experience in the discovery and clinical
development of novel therapeutics and has held senior executive roles at both global pharmaceutical and biotechnology companies. Jack
Lawler, Chemomab&#8217;s Vice President of Global Development Operations, is highly experienced in managing clinical trials across a wide
range of indications and geographies.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">8</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Company strategy</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab aims to become
a world-leading company for the treatment of diseases involving inflammation and fibrosis, developing novel therapies across a wide range
of indications. To achieve this, the company is focused on the following key strategies:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z90effb0a39e145af8570d28c188ffc60" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="font-style: italic; font-weight: bold">Advance Chemomab&#8217;s lead product, CM-101, for the treatment of PSC and SSc, through
        clinical development to approval</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The clinical development
plan of lead product candidate CM-101 was optimized to maximize the clinical information obtained, generating additional important data
to support future advancement to registration trials, and decreasing the overall risk in the CM-101 clinical development program in the
lead indications of PSC and SSc, as well as potentially in additional indications where the scientific rationale is strong.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company expects that
the current trial designs will provide important data on the clinical dose response relationship to inform the broader development program
and to identify the optimal dose to advance in later PSC and SSc trials. The study design is also expected to generate proof of concept
data on clinically relevant aspects of SSc, a complex rheumatological disorder, to best inform the development path for a novel, first-in-class
therapeutic like CM-101, along with relevant safety and tolerability data to support the evaluation of higher doses and inform decisions
on next steps in the development of the subcutaneous formulation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zbf127b7973844e5aa2749a791cde099b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="font-style: italic; font-weight: bold">Expand Chemomab&#8217;s next generation pipeline</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Based on the know-how,
knowledge and experience it has gathered in diseases involving both inflammation and fibrosis, Chemomab is assessing opportunities to
expand its pipeline with novel products developed against new targets. Chemomab may also explore targeting CCL24 with additional, complementary
fibrotic and/or inflammatory mechanisms, including acquiring or in-licensing innovative product candidates.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5ed57c13fe89431fb5574350170ab617" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="font-style: italic; font-weight: bold">Selectively evaluate partnership opportunities</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab continuously
explores partnership opportunities to advance CM-101 development in PSC and SSc, identifying companies with drugs (either approved or
in development) that could possibly be combined with CM-101, extending the development of CM-101 to new indications beyond PSC and SSc,
and seeking additional significant commercial or drug development capabilities that may accelerate CM-101&#8217;s time to market. The
Company also continues to evaluate opportunities to in-license or acquire other novel investigational therapeutics addressing relevant
fibro-inflammatory disorders.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7f52a989e41e431fa491619cee9f2843" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="font-style: italic; font-weight: bold">Explore opportunities for CM-101 in additional inflammatory/fibrotic indications</div>
        </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab continuously
evaluates the potential benefit of CM-101 outside of its two lead indications, PSC and SSc, in order to maximize the product&#8217;s potential.
CM-101 has shown anti-fibrotic activity in animal models and human tissue studies of IPF and NASH. Chemomab will continue to assess ways
to leverage the dual anti-inflammatory an anti-fibrotic activity of CM-101 into new disease areas and to form additional collaborations
with global medical researchers and drug developers.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z646a441224304591a8061cb303645886" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="font-style: italic; font-weight: bold">Strengthen Chemomab&#8217;s intellectual property portfolio</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab believes that
it has developed a strong intellectual property portfolio and will continue to seek, maintain, and defend its patent rights, whether developed
internally or licensed to protect and enhance the proprietary technology, inventions, and improvements that are commercially important
to the development of its business proprietary position in the field of inflammation and fibrosis.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">9</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Fibrosis
and inflammation</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Tissue damage activates
a repair process that includes acute inflammation followed by either successful complete repair or tissue replacement by fibrosis. However,
persistent and repeated damage can result in continuous activation of the repair process leading to chronic inflammation, progressive
tissue fibrosis and sclerosis.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Fibrosis is an accumulation
of non-functional tissue and can occur in many different tissues, including lung, liver, kidney, muscle, skin and the gastrointestinal
tract, resulting in a number of chronic fibrotic conditions. Liver fibrosis is the process of excessive accumulation of extracellular
matrix proteins, predominantly collagen, which occurs as the result of liver injury. In cases of acute temporary damage, these changes
are transient and liver fibrosis may resolve. In chronic cases, however, the liver damage persists and chronic inflammation and accumulation
of the extracellular matrix eventually lead to cirrhosis. The various fibrotic manifestations in conditions like SSc are still not well
understood. Disease progression is characterized by an early inflammatory onset followed by tissue fibrosis, vascular injury and organ
damage. Fibrosis, and specifically lung fibrosis, is the main cause of disease progression and mortality in SSc, although manifestation
of the disease in other organs can cause patients considerable distress and adversely impact their health and their quality of life.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Fibrosis and inflammation
are intrinsically linked; a healthy inflammatory response is necessary for efficient wound healing, however, a prolonged response can
contribute to the pathogenesis of fibrosis. The inflammatory response during chronic liver injury is a dynamic process with intrahepatic
accumulation of diverse immune cells. Recruitment and infiltration of these cells to the liver and their localization is mainly determined
by chemokines and cytokines that are produced by hepatocytes, immune cells, biliary epithelial cells, and endothelial cells. Notably,
activated liver fibroblasts, the hepatic stellate cells, or HSCs, secrete various chemokines, thereby contributing to the ongoing immune
response during fibrotic liver diseases. Similarly, for SSc, the early inflammatory phase leading to fibrosis in multiple organs of the
body includes activation of the immune cell network of lymphocytes, eosinophils, and monocytes, as well as endothelial and endothelial
progenitor cells. In the advanced SSc phase, fibroblasts and myofibroblasts take the lead to generate tissue fibrosis.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemokine
involvement in inflammation and fibrosis</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemokines are a group
of small signaling proteins thought to be involved in the etiology, or causation, of multiple inflammatory diseases. They are not only
implicated in immune cell recruitment during inflammation, but also contribute to immune surveillance, direct cells to target organs in
homeostasis, and exert pleiotropic, or diverse, effects on non-immune cells, for instance, directly influencing the functionality of fibrogenic
cells. Chemokines and their corresponding chemokine receptors are key players in orchestrating the sequential influx of immune cells into
damaged or diseased organs, driving inflammatory responses to specific triggers.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In the liver, chemokines
have a key role in the development of inflammation and wound healing responses, which can lead to either resolution of liver injury or
promote, if ongoing, maladaptive responses with chronic inflammation, fibrosis, and development of clinically manifest liver disease.
Although the pathophysiology underlying PSC has not yet been fully clarified, animal models of PSC have contributed to dissecting the
molecular basis of this disease and highlighting the role of cytokines and chemokines as important pathogenetic mediators of liver inflammation
and fibrosis. Recently published studies demonstrated that in most of the processes suggested for the onset and development of PSC, chemokines
and chemokine receptors play a key role. HSCs may be the main producers of cytokines and play an initial role in the progression of liver
fibrosis by attracting different types of immune cells, resulting in further production of cytokines and liver injury in a vicious disease
cycle. Extensive proliferation, trans-differentiation and activation of HSCs result in ongoing chronic tissue remodeling and severe fibrosis.
In addition, chemokines are also involved in promoting polarization of the recruited immune cells. Therefore, chemokines may participate
in PSC by promoting migration of inflammatory and fibrotic cells, by activating inflammatory and fibrotic cells locally, or by inducing
cytokines that promote collagen and matrix deposition.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">10</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Likewise, in SSc pathogenesis,
chemokines foster migration and activation of inflammatory and fibrotic cells, inducing the secretion of cytokines that promote collagen
and matrix deposition in affected organs. Indeed, patients with SSc exhibit increased systemic levels of proinflammatory chemokines and
some of these have also been shown to correlate with limited or diffuse cutaneous disease phenotype and/or to organ-specific pathology
such as lung disease or skin vascular inflammation.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">The
role of CCL24</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">CCL24 is a chemokine
that promotes various types of cellular processes that regulate inflammatory and fibrotic activities through the CCR3 receptor. This chemokine
is known to be expressed by activated T-cells, monocytes, epithelial cells and endothelial cells, as well as by activated fibroblasts.
CCL24 induces chemotaxis and activation of CCR3-expressing cells, including immune cells and fibroblasts.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab has been the
driving force in establishing the role of CCL24 in the pathogenesis of PSC and SSc, however, others have highlighted its contribution
to other indications. For example, published work has shown that both CCL24 and CCR3 are involved in lung and skin inflammation and fibrosis.
CCR3 is robustly expressed on eosinophils and recent data has suggested that eosinophilic inflammation may be involved in the pathogenesis
and progression of SSc. For example, in SSc patients, eosinophil counts, but not total leukocytes, were significantly higher than in patients
with other connective autoimmune diseases. Eosinophil counts correlated positively with both interstitial lung disease severity and the
modified Rodnan skin thickness score, or mRSS.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Notably, CCR3 was shown
to be expressed on oral and dermal fibroblasts where it modulates wound healing and tissue remodeling processes. A recent academic study
also demonstrated overexpression of CCR3 on monocyte populations isolated from SSc patients. CCL24 was shown to be involved in proinflammatory
reactions, specifically contributing to the type 2 immune reaction involving Th2 lymphocytes and M2 macrophages that were shown to be
present in skin lesions of SSc patients. Accordingly, CCL24 was found to play a dominant role in inducing profibrotic effects and to be
overexpressed in fibrotic lungs and bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis, a disease sharing similar
lung dysfunction features with SSc. Furthermore, CCL24 was shown to promote collagen production in human lung fibroblasts and to be constitutively
expressed by dermal fibroblasts.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Prior studies support
the role of CCL24/CCR3 signaling in the pathogenesis of SSc and these findings have been further explored by Chemomab in SSc and for the
first time, in PSC.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: center"><img src="image00017.jpg" alt="" /><br />
<br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">CCL24 is a critical mediator
promoting inflammation and fibrosis</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">11</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Challenges
to drug development in fibrosis and inflammation</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Successful treatment
of fibrotic disorders has in large part remained elusive, primarily due to incomplete understanding of the complexity and multi-mechanism
contributions to disease progression. This has complicated preclinical investigations for new products and new targets, with animal models
having limited resemblance to human disease. Additionally, preclinical animal data is often of short treatment duration and does not capture
the effects of treating chronic fibrotic indications. This is particularly applicable to complex, orphan indications like SSc, where there
is still no approved standard of care or proven target mechanism. Most drug approvals in this space have been focused on fibrosis of the
lungs i.e., idiopathic pulmonary fibrosis, or IPF, interstitial lung disease, or ILD, and pulmonary arterial hypertension, or PAH.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Most approved anti-fibrotic
products target extracellular components, given their biological accessibility, and inhibition of receptors and ligands preventing downstream
signaling is considered to be a potentially effective option for alleviating fibrosis. PDGF and TGF-&#946; are commonly studied targets
in fibrosis and there are two approved products that target these pathways, pirfenidone and nintedanib. Both pirfenidone and nintedanib
are approved for the treatment of IPF, with nintedanib also recently approved for treatment of systemic sclerosis associated interstitial
lung disease and chronic fibrosing interstitial lung diseases. Due to the strong associations between inflammation and fibrosis, companies
have devoted efforts to anti-inflammatory drugs with the hope that reduction in inflammation will attenuate fibrosis. For example, companies
have targeted TNF-&#945;, a commonly explored anti-inflammatory mechanism in fibrotic indications. Despite the success of targeting cytokines,
inflammatory factors and immune cells in pure inflammatory autoimmune diseases, such as blocking TNF-&#945;, these results have generally
not been reproduced in studies targeting inflammatory fibrotic indications. Nonetheless, tocilizumab, a monoclonal antibody targeting
IL-6R, was recently approved for the treatment of ILD associated with systemic sclerosis. Treatments that inhibit certain pure anti-fibrotic
pathways, such as nintedanib and pirfenidone, have resulted in limited clinical benefit. Chemomab believes that these results highlight
the importance of a dual mechanism that, with adequate selectivity, is designed to target inflammatory processes and also directly prevent
fibrosis resulting in blockage of multiple disease-contributing mechanisms.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Notwithstanding challenges in the field
of fibrosis and inflammation, there is significant and growing industry interest given the associated unmet medical need and the continuing
opportunity to identify better therapeutic targets. For example, in 2019 Novartis completed two transactions related to the treatment
of NASH, a liver metabolic fibrotic disease. It acquired IFM Tre for NLRP3 antagonists for a $310 million upfront payment and total potential
consideration of $1.5 billion and licensed an integrin inhibitor from Pliant Therapeutics for an $80 million upfront payment. Additionally,
Gilead Sciences licensed two preclinical programs, one in NASH for a $15 million upfront payment (total potential consideration of $785
million) and the other for TGF-&#946; inhibitors in fibrosis for an $80 million upfront payment and total potential consideration of $1.4
billion. In 2020, Roche acquired Promedior for a $390 million upfront payment and total potential consideration of $1 billion in milestones
for its Phase 2 product in pulmonary fibrosis, and Bayer partnered with Recursion Pharmaceuticals to develop and commercialize preclinical-stage
small molecule treatments for fibrotic conditions for a $30 million upfront payment and total potential consideration of $1 billion. Boehringer
Ingelheim also acquired Enleofen Bio in a deal potentially worth $1 billion for its NASH and ILD anti-IL11 platform. More recently, Mediar,
a high-profile start-up targeting novel mechanisms for fibrotic diseases, reported a $105 million Series A financing.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Targeting
chemokines as a treatment for fibrotic indications</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab believes that
its approach, selectively targeting fibrotic conditions by attenuating both inflammation and fibrosis, may be an optimal approach for
both effectiveness and reduction of toxicity. As central regulators of initiation and progression of fibrotic disorders, chemokines are
an ideal target to impact both inflammation and fibrosis. Some chemokines are also disease-specific, allowing for potential selectivity.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemokine receptors,
or CCRs, have been more extensively studied as drug targets in fibrotic conditions compared to chemokine ligands, however, the therapeutic
effects of CCR inhibitors have generally fallen short in the clinic. Pharmaceutical companies have previously explored the CCL24 ligand
receptor, CCR3, and its other ligands CCL7 and CCL11, with small or large molecule inhibitors. These programs were directed at inhibiting
eosinophilic trafficking in respiratory and allergic inflammation, however, despite promising preclinical data, most programs were discontinued
largely due to poor safety profiles and limited efficacy of the antagonist used. To Chemomab&#8217;s knowledge, only Alkahest has an active
program that explores CCR3 inhibition, which is under license from Boehringer Ingelheim and is being developed as a treatment for wet
AMD. In contrast, Chemomab believes CCL24 presents a more promising opportunity. Unlike other CCR3 ligands, CCL24 binds only to the CCR3
receptor and is also organ/disease-specific, which together could provide enhanced selectivity and tolerability. For example, in PSC,
CCL24 is elevated in the liver and cholangiocytes (bile duct epithelia) and immune cells that play a key role in the progression of the
disease.&#160; Likewise, elevation of CCL24 has been shown in fibrotic lungs and bronchoalveolar lavage fluid from patients with idiopathic
pulmonary fibrosis, a disease sharing similar lung dysfunction features with SSc and which recently was correlated, by Chemomab, with
disease severity and lung involvement in a cohort of SSc patients from the United Kingdom. Furthermore, CCL24 is constitutively expressed
by skin and dermal fibroblasts. The use of an antibody in targeting this chemokine is a novel approach to targeting fibrosis.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">12</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Chemomab&#8217;s expertise
and approach to drug discovery</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab is a clinical
stage biotechnology company focused on the discovery and development of novel drugs to address fibrotic indications with unmet medical
needs. CCL24 is a key target promoting fibrosis as it regulates the two main processes that drive fibrosis: fibroblast activation and
immune cell migration and activation. Using Chemomab&#8217;s expertise in monoclonal antibody, or mAb, development and deep knowledge
of chemokine biology, Chemomab is developing CM-101, a proprietary, first-in-class, fully humanized mAb that through research and studies
to date, has been shown to neutralize CCL24 and by so doing inhibits its disease-related functions in both inflammation and fibrosis.
This represents an innovative approach to anti-fibrotic drug discovery and is a key differentiator for Chemomab. The ability of CM-101
to directly attenuate fibroblast activation and concurrently attenuate recruitment of immune cells is novel and could address a wide range
of hard-to-treat fibrotic diseases.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab&#8217;s ongoing
collaborations are complementary to both preclinical and clinical aspects of research and development. Chemomab has created an extensive
panel of in vitro, ex vivo and in vivo assays which it has used to further the understanding of fibrotic processes together with the role
of CCL24 in various diseases and the effects of its neutralization by CM-101. These assays have allowed Chemomab to sequentially explore
target validation and proof of mechanism in disease relevant human and animal samples that continues to de-risk the translation of CM-101
into the clinic.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Target
expression and engagement</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab regularly collaborates
with leading academic centers around the world to investigate the role of CCL24 and CM-101 in various indications. For example, Chemomab
works with The Royal Free Hospital, or RFH, in London, and Birmingham University in Birmingham, United Kingdom to access liver biopsy
and serum samples from patients with PSC. Using immunohistochemistry and florescence microscopy to stain CCL24 and CCR3, it explores the
expression patterns of these targets in disease relevant human samples and compares them to healthy volunteers. Similarly, Chemomab has
tested biopsies of SSc patients through a collaboration with the University of Florence in Italy and serum samples of SSc patients through
a collaboration with Leeds University in the UK.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Proof
of mechanism</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab explores fibroblast
activation and immune cell recruitment in response to CM-101 treatment through inhouse ex vivo and in vitro assays. Chemomab has executed
multiple validated genetic and treatment-based disease models in fibrotic and inflammatory indications in which it has investigated CM-101&#8217;s
effects. Additionally, as part of a collaboration with Nordic Biosciences, Copenhagen, Denmark, Chemomab has gained access to proprietary
tools and expertise to explore the effects of CM-101 on key fibrogenesis and fibrolysis biomarkers. Nordic Biosciences is a world-leading
extracellular matrix specialist and continues to contribute additional analyses to Chemomab&#8217;s clinical samples.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">13</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image00018.jpg" alt="" /></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Chemomab
has created a broad array of biological assays to explore CCL24 and CM-101</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab may explore
next-generation biologic products, and, based on its wide database of patient samples and extensive knowledge and experience in fibrosis,
may identify targets that could complement CCL24 inhibition. Next-generation assets may therefore be dual targeting and would be screened
through the panel of assays available at Chemomab that evaluate target expression in fibrotic tissues as well as the anti-fibrotic activity
of potential candidates. Similar to CM-101, this process would establish proof-of-biological-mechanism in both animal models and human
tissue prior to commencing product development and initiating clinical studies.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">The Chemomab pipeline</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">CM-101
in PSC and SSc</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab&#8217;s lead
product, CM-101, is a first-in-class humanized monoclonal antibody targeting CCL24 that is being developed initially for the treatment
of PSC and SSc, with potential future opportunities in other fibrotic-inflammatory indications. Chemomab has completed two Phase 1a studies
of CM-101 in healthy volunteers as well as a Phase 1b safety, tolerability and proof-of-mechanism study in NAFLD patients and a Phase
2a liver fibrosis biomarker study in NASH patients with liver fibrosis, which was recently reported. Topline results showed favorable
safety and tolerability profiles for CM-101 in patients with serious liver disease, confirmed early signs of biomarker activity that are
also relevant for a number of fibro-inflammatory disorders, and reinforced tolerability and pharmacokinetic data relevant to the development
of our current subcutaneous formulation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">A Phase 2 study in PSC is now ongoing in
Europe, the United States and Israel and is currently expanding to include an additional dose level cohort as well as an open label extension.
A global Phase 2 study in SSc that will assess the clinical and biological effects of CM-101 in this patient population is expected to
begin enrolling patients around midyear of 2023.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Primary
Sclerosing Cholangitis</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">PSC is a progressive,
rare, and chronic cholestatic liver disorder that is characterized by thickening, inflammation, and fibrosis of the intra- and extra-hepatic
bile ducts. This generally leads to cholestasis, liver damage, cirrhosis, and eventually liver failure. The exact cause of PSC remains
mostly unknown; however, immune system dysregulation, genes, viruses, and bacteria may be involved. PSC is commonly associated with inflammatory
bowel disease, or IBD. Approximately three in every four individuals with PSC also have ulcerative colitis. Most individuals affected
with PSC are adults with an average age of 40 years at diagnosis; however, it may also occur in children. Disease progression, symptoms,
and severity may vary greatly between individuals. Patients in the initial stages of PSC are generally asymptomatic or have only mild
symptoms.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">14</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Abdominal discomfort,
fatigue, and pruritus, or itching, are common initial symptoms of PSC that can be severe and debilitating. The initial step in diagnosing
PSC is to evaluate liver enzyme levels through blood tests. Physicians will then confirm a diagnosis with cholangiography ultrasound and,
in rare cases, a liver biopsy. As the disease progresses, bile flow from the liver is obstructed and is subsequently absorbed into the
bloodstream leading to the yellowing of the mucous membranes, whites of the eyes, and skin. Furthermore, individuals may also experience
abdominal pain, malaise, light-colored stools, nausea, dark urine, weight loss, and/or hepatomegaly or splenomegaly. PSC patients have
a 40-fold increased risk of liver cancer and a 400-fold increased risk of cholangiocarcinoma, and the disease may lead to other conditions
including osteoporosis, bacterial cholangitis, portal hypertension, bleeding, as well as vitamin deficiencies.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">There are currently no
specific medical therapies that can alter or cure the course of the disease; instead, available treatments are directed towards slowing
the progression of PSC and treating symptoms. In certain individuals, endoscopic surgery may be performed to enlarge the narrowed bile
ducts and to remove blockages. Complications due to vitamin deficiencies can be prevented with the help of vitamin supplements, while
infections and inflammation can be controlled by using antibiotics. Cholestyramine and UCDA can be effective in managing itching and can
be used with or without antihistamines. Patients with advanced symptoms such as end-stage liver disease, recurrent bacterial cholangitis
and intractable pruritus, will often undergo liver transplantation, however, in 30% of cases, PSC will recur even after liver transplantation.
The median survival is 10-12 years without intervention.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Systemic
Sclerosis</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">SSc is an autoimmune
inflammatory condition that results in widespread fibrosis and vascular abnormalities affecting the skin, lungs, gastrointestinal tract,
heart and kidneys. Other key features of SSc include thickening and hardening of the skin, autoantibody production and abnormal nail fold
capillaries. The underlying mechanisms that cause SSc are complex and for the most part unknown but most likely involve a combination
of factors including the immune system, genetics, and environmental triggers. Various pathways are involved in the pathogenesis of SSc
including cytokines that injure blood vessels, growth factors that stimulate collagen, integrin signaling, morphogen pathways, and co-stimulatory
pathways. SSc is generally diagnosed between the age of 30 and 50 years and is more prevalent in women.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Given that SSc can affect
many different parts of the body there are a multitude of different symptoms of the disease. The most widely observed symptoms include
fatigue, arthralgia, and myalgia. However, the earliest sign is often the Raynaud phenomenon in which the body&#8217;s normal response
to cold or emotional stress is exaggerated, resulting in abnormal spasms in arterioles. Cutaneous features include sclerosis of the skin,
particularly the face and hands. Gastrointestinal symptoms of the upper tract include acid reflux and of the lower tract include bloating,
nausea and incontinence. Cardiopulmonary presentations include interstitial lung disease, pulmonary arterial hypertension and cardiac
scleroderma. Renal and ocular symptoms can also present and 20% of SSc patients have an overlapping diagnosis with other connective tissue
diseases and can develop arthritis, lupus or myositis. SSc is subdivided into two main types related to the distribution of skin involvement:
diffuse cutaneous (two-thirds of cases) and limited cutaneous. Diffuse SSc, or dcSSc, is rapidly progressive with more significant organ
involvement.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">There is no cure for
SSc. Established treatments can help with symptoms and may modify the disease outcome only if given early in the disease course. Prescribed
medications, used off-label, primarily focus on suppressing inflammation with NSAIDs and dilating abnormal or constricted blood vessels
with losartan, sildenafil, iloprost and SSRIs, or selective serotonin reuptake inhibitors, as well as treatments to manage individual
organ involvement. The only three drugs that are approved for the treatment of SSc symptoms are bosentan by Actelion Pharmaceuticals,
approved in Europe for the prevention of digital ulcer development, nintedanib by Boehringer Ingelheim, and tocilizumab by Roche, approved
in the United States, Europe and Japan for the treatment of SSc associated interstitial lung disease. The clinical course of SSc is determined
by the extent of vascular and fibrosis complications and has the highest mortality rate among the systemic rheumatic diseases. Forty percent
of patients die within 10 years of disease onset, with pulmonary involvement being the leading cause of death.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">15</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemomab&#8217;s
CM-101may have disease-modifying potential</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The dual anti-fibrotic
and anti-inflammatory activity of CM-101 enables the targeting of a wide range of pathogenic mechanisms and may afford patients a new
treatment that may have a more impactful effect on disease progression.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image00019.jpg" alt="" /></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Targeting
CCL24 offers a dual activity approach</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In order to understand
CCL24&#8217;s role in disease pathophysiology, Chemomab has collected data on CCL24 levels from patients with multiple fibrotic-inflammatory
indications, including those with PSC, SSc and NASH. PSC patients&#8217; liver biopsies and SSc skin samples were stained for CCL24 and
its receptor, CCR3. Blood samples taken from PSC and SSc patients were used to further evaluate the role of the CCL24-CCR3 axis exploring
levels of circulating CCL24 and CCR3. To explore the influence of CCL24 on disease status, CCL24 serum levels were correlated with fibrotic
biomarkers and disease severity markers.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">CCL24
levels in liver biopsies from PSC patients</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">PSC pathology generally
initiates with bile duct damage leading to cholestasis, bile duct inflammation and fibrosis and finally to substantial liver damage. Chemomab
assessed the accumulation and cellular localization of CCL24 in livers of PSC patients focusing on CCL24 levels in the periductal damaged
zone that is most relevant to disease pathology. CCL24 was mainly found in inflammatory cells in the liver of PSC patients. Due to the
robust liver inflammatory insult in PSC, reflected by massive accumulation of resident and recruited immune cells in the periductal space,
CCL24 positive staining was extensive. Specific and robust CCL24 staining was also shown in cholangiocytes, the epithelial cells of the
bile ducts. Activated myofibroblasts that surround the bile ducts, whether they originate from hepatic stellate cells or portal fibroblasts,
are the main drivers of the excess extracellular matrix accumulation in this area, comprising the unique &#8220;onion ring&#8221; shape
seen in PSC liver sections. The collective expression pattern shows high CCL24 levels in areas that are most affected in PSC and highlights
its central role in PSC related liver pathology.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">16</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;<img src="image00020.jpg" alt="" /></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Elevated
CCL24 staining in liver biopsies from PSC patients</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">CCR3
levels in liver biopsies from PSC patients</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">To evaluate the levels
of CCR3, the receptor of CCL24, and identify the cells that can potentially respond to CCL24 secretion, biopsies were stained for CCR3.
As was seen for similar studies with CCL24, specific CCR3 staining was evident in cholangiocytes, surrounding immune cells and fibroblasts.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">CCL24
levels in serum and correlation to a fibrotic biomarker in PSC patients</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Together with the Royal
Free Hospital (RFH), Chemomab analyzed serum levels of CCL24 in PSC patients at various stages of disease. CCL24 levels showed a positive
correlation to the liver fibrosis biomarker ELF score, which is a commercially available test that reflects liver fibrosis stage based
on serum concentrations of several fibrosis-related proteins. When dividing this cohort of PSC serum samples by ALP levels, a circulating
parameter used for monitoring PSC activity, there was a stronger relation of the fibrotic biomarker and CCL24 with increased ALP.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image00021.jpg" alt="" /></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">CCL24
levels correlate with ELF score</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">CCR3
levels in circulating PBMCs in PSC patients</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chronic liver inflammation
is driven in most hepatic injuries by several different immune cell populations originating from either resident hepatic immune cells
or recruited cells from the circulation to the damaged site. In collaboration with the Kaplan Medical Center, Israel, Chemomab explored
systemic changes of CCR3, given that this could impact cell recruitment to the PSC damaged liver. PBMCs from ten PSC patients and healthy
controls were stained for expression of CCR3 and demonstrated that levels were significantly higher in PSC patient samples compared to
healthy donors.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">17</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image00022.jpg" alt="" /></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">PSC
patients showed significantly higher expression of CCR3 on PBMCs</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">CCL24
and CCR3 levels in skin biopsies from SSc patients</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab analyzed skin
samples from diffuse SSc patients and healthy volunteers and the SSc samples showed elevations in CCL24 and CCR3. Specifically, higher
accumulation of CCL24 on immune cells skin infiltration was shown in the SSc samples and CCR3 was evident in skin fibroblasts, immune
cells and endothelial cells. These elevations led to a CCL24-mediated robust activation of CCR3 expressing cells, which enhances the recruitment
of immune cells and fibroblasts to the diseased organ.</div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image00023.jpg" alt="" /></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">SSc
patients showed elevated levels of CCL24 in skin tissue</div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image00024.jpg" alt="" /></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">SSc
patients showed elevated levels of CCR3 in skin tissue</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;<span style="font-style: italic">CCL24
levels in serum samples from SSc patients and correlation with fibrotic biomarkers</span></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab researchers
analyzed SSc serum samples that showed that CCL24 levels were significantly increased in SSc patients compared with healthy individuals.
Notably, in diffuse SSc patients, CCL24 levels were fourfold higher than in healthy control patients.&#160; Additionally, the levels of
CCL24 were correlated with a biomarker of SSc severity, anti-topoisomerase, an autoantibody seen in diffuse SSc patients.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">18</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image00025.jpg" alt="" /></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Preclinical
Efficacy of CM-101 in models of PSC</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Preclinical experiments
in models of PSC</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zbe799478883245bcba825b82afdfa3ab" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Human hepatic stellate cells demonstrated reduced transition to myofibroblasts following incubation of CM-101 with CCL24.</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z815ed480ab164a57b9a719a228512f95" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Human hepatic stellate cells showed reduced motility towards CCL24 following treatment with CM-101.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3abb3bdd1568414cb6897a2c5f9a4167" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>CM-101 demonstrated in vivo activity on liver fibrosis and cholangiocyte proliferation induced by bile duct ligation in the Sprague
        Dawley rat model.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd227040a45084e90ae982f925c9ff61e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>CM-101 (D8-a murine surrogate of CM-101) inhibits the progression of liver fibrosis and bile duct damage in a chronic cholangitis
        cholestasis model using the hepatobiliary toxin ANIT.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfa684285f5a341c8925b32e64ba6e00c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>CM-101 (D8) reduces bile duct epithelial cell (cholangiocyte) proliferation, collagen deposition, macrophage infiltration, liver
        enzymes, bile acid and circulating inflammatory monocytes in an experimental cholangitis model in MDR2 knockout mice.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zda991e27e0ab444a9a58951fe18ab3db" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>CM-101 reduces liver enzymes, fibrosis, collagen, and fibrotic gene expression in a TAA-induced liver fibrosis model in rats.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2913eada4a074366a5f7544e2a9df6a2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>CM-101 (D8) prevented fibrosis and inflammation in a TAA-induced liver fibrosis model in mice.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Results from the multi-drug
resistant 2, or MDR2, knock out mouse model that reflects sclerosing cholangitis and the thioacetamide (TAA) rat model reflecting liver
fibrosis are described below.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">CM-101 demonstrates
anti-cholestatic, anti-inflammatory, and anti-fibrotic activity in MDR2 knock out mouse model in vivo</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Mice with targeted disruption
of the MDR2, transporter gene develop chronic and progressive hepatic sclerosing cholangitis that closely resembles PSC and therefore
this model has been extensively used to study the pathogenesis and progression of PSC. Using MDR2 knockout mice (six weeks of age), the
Company tested the ability of CM-101 (D8) to attenuate PSC related symptoms. Mice (n=15/group) received either vehicle control, or CM-101
10 mg/kg SC twice weekly during weeks 6-12 following established disease and were sacrificed at the end of week 12. In this study mice
were tested for changes in alkaline phosphatase, or ALP, bile acid levels, collagen deposition (histology, Sirius red), macrophage presence
in the liver and cholangiocyte proliferation. The Company observed a significant decrease in all three core pathologies that play a role
in PSC: inflammation, fibrosis and cholangiocyte proliferation after CM-101 (D8) treatment compared to non-active treatment. Reduction
in the serum markers that represent the cholestatic state, ALP and bile acid, was also observed.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">19</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image00026.jpg" alt="" /></div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">
<br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">CM-101
reduces liver fibrosis, inflammation and bile duct epithelial proliferation in MDR2 knockout model</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">CM-101 demonstrates
in vivo activity in a thioacetamide induced liver fibrosis model in rats using a therapeutic model</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">To assess potential efficacy
of CM-101 on liver fibrosis, the Company used the TAA-induced liver fibrosis model. Liver fibrosis was induced by intraperitoneal administration
of TAA at a dose of 250 mg/kg twice weekly for eight weeks. Rats (n=10/group) received either vehicle control or CM-101 2.5 mg/kg IV twice
weekly during weeks four to eight following established fibrosis and were sacrificed at week eight. After eight weeks of TAA treatment,
all vehicle-treated animals had developed liver fibrosis, as confirmed by Sirius-red-stained liver histology.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image00027.jpg" alt="" /></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">CM-101
reduces fibrosis in rat livers</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Plasma ALP, ALT, and
AST levels decreased in the CM-101 study arm. Liver collagen content and fibrotic areas were significantly reduced in the CM-101 treated
group compared to non-active treatment. CM-101 was also shown to reduce fibrotic markers in the TAA treated rats.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">20</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">

<div style="font-weight: normal">

<div style="line-height: 1.25; font-style: italic">Efficacy of CM-101 in models of SSc</div> </div> <br /> Preclinical experiments in
models of SSc</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z98c1ed3c192c4026945475654f6a24fe" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>CM-101 reduces SSc serum-induced dermal fibroblast activation and transition to myofibroblasts and interferes with endothelial cell
        activation.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zed9eb67c7b0e4eb68c7f22bf72d4cd34" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>CM-101 treatment attenuated skin fibrotic remodeling in the bleomycin (BLM)-induced dermal fibrosis mouse model.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z71a873654f3e47019c188931e79bad15" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>CM-101 attenuated lung fibrosis and inflammation in the bleomycin (BLM)-induced pulmonary fibrosis mouse model.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;Results from the bleomycin (BLM)-induced
dermal and lung fibrosis mouse models are discussed below in more detail.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">CM-101 treatment attenuates
skin fibrotic remodeling in the bleomycin (BLM)-induced dermal fibrosis mouse model</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The activity of CM-101
(D8) in SSc was tested in the dermal bleomycin model. Treatment started after the onset of fibrotic signs, eight days following the first
BLM injection. Histological assessment of skin lesions stained with H&amp;E and Masson&#8217;s trichrome revealed significant elevation
of dermal thickness and collagen deposition following 21 days of BLM administration. This elevation was significantly reduced when mice
were treated with 2.5 mg/kg CM-101 with significant reductions in both skin thickness and collagen deposition compared with the mouse
group treated with BLM alone.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image00028.jpg" alt="" /></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">CM-101
treatment attenuates skin fibrotic remodeling in the bleomycin-induced dermal fibrosis mouse model</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Another feature that
characterizes the BLM model and is representative of human SSc is the development of bronchoalveolar inflammation. To evaluate the effect
of CM-101 on lung inflammation, the Company collected bronchoalveolar lavage, or, BAL, fluid, and assessed the number of white blood cells,
or WBC, and mononuclear cells. Treatment with BLM for 21 days significantly increased WBC and mononuclear cells in BAL fluid and the number
of WBC and mononuclear cells was decreased significantly following CM-101 treatment compared with the group that was administered only
BLM. This data supports the anti-inflammatory effect of CM-101 in SSc.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">CM-101 inhibits lung
fibrosis in the BLM-induced pulmonary fibrosis mouse model</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company also tested
CM-101 in the experimental lung SSc model where mice were given a single intratracheal administration of BLM followed by either CM-101,
non-active treatments (PBS or control immunoglobulin G (IgG)) or the approved anti-fibrosis drugs, pirfenidone and nintedanib. CM-101
had a significant anti-fibrotic and anti-inflammatory effect in the experimental BLM-induced lung fibrosis model as compared with non-active
treatment-treated animals. BLM animals treated with non-active treatments showed massive immune cell infiltration, extensive fibrosis
and severe tissue injury. CM-101-treated mice exhibited significantly reduced levels of lung fibrosis similar to levels in healthy animals
and showed superior effects compared to the approved fibrosis drugs pirfenidone and nintedanib.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">21</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image00029.jpg" alt="" /></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">
<br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">CM-101
attenuates lung fibrosis and collagen deposition in the bleomycin (BLM)-induced pulmonary fibrosis mouse model</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Preclinical safety and
toxicology of CM-101</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Preclinical safety evaluation
of CM-101 included tissue cross reactivity, assessment of the effect of CM-101 on pro-inflammatory cytokine secretion ex-vivo, and in
vivo GLP toxicology studies in mice and non-human primates. No safety concerns were observed in these preclinical assessments.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Immunogenicity may be
triggered following administration of humanized monoclonal antibodies, an effect that is frequently seen with approved mAbs. To date,
no meaningful ADA were identified in three completed clinical studies, which supports a preliminary conclusion that CM-101 may have low
immunogenic potential.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">As summarized below,
there were no safety concerns related to CM-101 in any of the other preclinical safety experiments.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">22</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Summary of key preclinical safety experiments</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z9aaf1dd6463747ae820a3fe9d87d1efa" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 49%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Preclinical
        findings</div> </td>
    <td style="width: 2%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 49%; vertical-align: bottom">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Observation</div>
        </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic">Ex
        vivo</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8203;</div> </td>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif"><br /> </div> </td>
        </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 49%; vertical-align: top"><br /> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Antibody dependent
        cell-cytotoxic (ADCC) and complement dependent cell-cytotoxic (CDC) activity was tested in PBMCs from healthy volunteers</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8203;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">CM-101 did not have
        Fc-related effector functions such as ADCC and CDC</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 49%; vertical-align: top"><br /> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Cytokine release was
        assessed in human whole blood from healthy volunteers.</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8203;</div> </td>
    <td style="width: 49%; vertical-align: top">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">CM-101 did not induce pro-inflammatory cytokine
        secretion</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Tissue cross reactivity
        was evaluated from healthy human tissues.</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8203;</div> </td>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">CM-101 does not bind
        non-specifically to healthy tissues, and therefore is expected to only bind to its target, circulating CCL24</div> </td> </tr>
  <tr>
    <td style="width: 49%; vertical-align: top; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic">In
        vivo</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8203;</div> </td>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8203;</div> </td>
        </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">GLP repeated dose 4-week
        toxicity study of CM-101 (IV) in mice</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8203;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">1. No obvious treatment related
        adverse reactions<span style="font-family: Times New Roman,Times,serif"><br /> &#160;</span></div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">2. No gross or microscopic pathological
        findings<span style="font-family: Times New Roman,Times,serif"><br /> &#160;</span></div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">3. No cases of treatment
        related mortality were observed</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><br /> </div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman Greek, serif"><span style="font-family: Times New Roman,Times,serif">4.
        No significant elevation was seen in IL1&#946;, IL2, IL4, IL5, IL10, GM-CSF, IFN and TNF&#945;</span></div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">23</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z5ae24b80340045cf98df2dd1cda910bb" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">GLP repeated dose (up
        to 50 mg/kg) 6-month toxicity study of CM-101 (SC) in Cynomolgus Monkey</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 2%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8203;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 49%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">1. No obvious treatment
        related adverse reactions</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><br /> </div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">2. No clinical signs
        or injection site reactions</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><br /> </div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">3. No cases of treatment
        related mortality were observed</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><br /> </div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">4. Blood and urine tests were
        found to be within normal ranges for monkeys<span style="font-family: Times New Roman,Times,serif"><br /> </span><br /> </div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">5. No treatment-related organ
        weight changes and no treatment-related necropsy findings<span style="font-family: Times New Roman,Times,serif"><br /> &#160;</span></div>
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">6. No treatment-related histopathology findings<br />
        <br /> </div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">7. Three samples from
        treated animals were confirmed ADA positive but there was no obvious correlation between positive ADA results and CM-101 serum concentrations
        or systemic exposure</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Preclinical
proof of mechanism studies for CM-101</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company conducted
a series of in vitro and in vivo studies to demonstrate the proposed mechanism of action and provide proof-of-concept for administering
CM-101 in the clinic for target indications.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;<span style="font-style: italic">Affinity,
selectivity, and binding kinetics</span></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company evaluated
the kinetic binding parameters of CM-101 to human CCL24, as well as the specificity of CM-101 binding to other chemokines using commercial
binding assays. CM-101 demonstrated a strong and stable, high affinity, binding to CCL24.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">CM-101 reduced CCL24
dependent CCR3 activation</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In an <span style="font-style: italic">in
vitro</span> assay, CM-101 was shown to robustly attenuate the ability of CCL24 to induce activation of the CCR3 receptor following pre-incubation
of CCL24 with CM-101.</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: center; line-height: 1.25"><img src="image00030.jpg" alt="" /></div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">24</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Clinical
Development of CM-101</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Completed studies</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The CM-101 Phase 1 program
included two Phase 1a single administration, or SAD, studies, using IV and SC administration with doses ranging from 0.75-10 mg/kg, in
healthy volunteers and a Phase 1b multiple administration (MAD) study (5 administrations) in NAFLD patients with normal liver function,
testing 2.5 mg/kg IV and 5 mg/kg SC. In the Phase 1 studies 42 subjects have received at least one CM-101 dose, the majority by IV infusion
(12/42 subjects received SC).</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Safety</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The first Phase 1a study,
which was a single-center, randomized double-blind, placebo-controlled, single-dose, dose-escalation study, included four escalating dose
groups of eight subjects each. In each dose group subjects were randomized in a 3:1 ratio to receive a single IV infusion of either CM-101
(n=6) or placebo (n=2). A total of 24 subjects were enrolled into the study and randomized to the treatment groups (0.75 mg/ kg, 2.5 mg/kg,
5.0 mg/kg, 10 mg/kg) and eight subjects received a placebo. All 32 subjects completed the study as planned. Single, IV doses of CM-101
were safe and well tolerated up to the highest dose level (10 mg/ kg) in healthy subjects. No severe or serious adverse events, or AEs,
occurred during the study and all CM-101 related AEs were mild, with one moderate AE reported in the placebo group (myalgia).</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The second Phase 1a study
was also a single-center, randomized double-blind, placebo-controlled, single-dose study, but evaluated only one dose group. Subjects
were randomized in a 3:1 ratio to receive a single SC injection of either CM-101 5 mg/kg (n=6) or matching placebo (n=2). A total of eight
subjects were enrolled into the study and randomized; all eight subjects completed the study as planned. Single, SC administration of
5 mg/kg of CM-101 was safe and well tolerated with no severe or serious AEs occurring during the study. A total of 6 AEs were reported
in two subjects treated with CM-101; only one AE was classified as related to CM-101 (change in diastolic blood pressure) and that AE
was classified as mild in intensity.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In both Phase 1a studies,
all AEs reported were resolved; no subjects discontinued the study prematurely due to AEs, and no concomitant medications were required
for treatment of any drug-related AEs. No clinically significant changes in laboratory tests (hematology, chemistry or urinalysis), vital
signs, ECG, physical examination or infusion site examination were observed. In the first Phase 1a study with CM-101 delivered by IV administration,
the effect on cytokine secretion was tested pre-treatment and one hour, eight hours and 24 hours post drug administration. Serum levels
of a panel of cytokines including IL-6, IFN&#947;, GM-CSF, TNF-&#945;, IL-2, IL-4, IL-8 and IL-10 showed no significant change at all
tested CM-101 doses and timepoints. These findings suggest that single CM-101 administration does not cause immune activation nor cytokine
secretion. Additionally, none of the subjects in either of the Phase 1a studies tested positive for anti-drug antibodies (ADA).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The multiple administration
randomized, placebo-controlled, Phase 1b study in NAFLD patients with normal liver function tests evaluated two dose levels. The first
dose level of 2.5 mg/kg CM-101 was administered as an IV infusion and the second dose level of 5 mg/kg was administered as an SC injection.
Both dose levels involved five drug administrations over 12 weeks (Q3W), providing 15 weeks of treatment coverage. At both dose levels,
subjects were randomized in a 3:1 ratio to receive either CM-101 (n=6 per cohort) (2.5 mg/kg IV or 5 mg/kg SC) or matching placebo (n=2
per cohort). Five repeated IV and SC CM-101 administrations were safe and well tolerated and there were no deaths, or severe or serious
drug related AEs reported throughout the study. Only mild to moderate AEs were reported in the CM-101 treatment groups of which only two
AEs were classified as possibly related to CM-101. No injection site reactions or clinically significant trends in laboratory tests (hematology,
chemistry, or urinalysis), vital signs, ECG or physical examination were observed. One patient experienced a non-drug-related SAE. This
patient was a 61-year-old female that was subsequently diagnosed with a non-treatment related meningioma. The tumor was treated surgically,
and the patient was discontinued from the study.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">25</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Pharmacokinetics with
single-dose administration</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">PK analysis was conducted
for the Phase 1 studies and the quantification of CM-101 in plasma samples was performed using a validated ELISA-based assay by Eurofins
(UK). Following IV infusion in healthy volunteers, CM-101 exhibited a biphasic serum concentration vs. time curve (rapid distribution
phase and slow elimination phase) which is typical for monoclonal antibodies. Target-mediated drug disposition (TMDD), or presence of
ADAs, was not evident in the analyzed concentration vs. time curves of CM-101, which exhibited linear terminal slope without apparent
TMDD kinetics or other concentration-dependent changes of the elimination kinetics. Comparison of the PK data of 5 mg/kg CM-101 using
IV administration against SC administration indicates consistent distribution and elimination behavior of CM-101.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">At either IV or SC administration,
the values of the PK parameters obtained in the non-compartmental and compartmental analysis of CM-101 concentration vs. time data appear
to be typical for monoclonal antibodies that undergo FcRn-mediated recycling. The terminal half-life of CM-101 was long for both SC and
IV formulations, which supports administration of CM-101 at a frequency of once every 2-4 weeks.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Pharmacokinetics with
multiple-dose administration</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">PK analysis of the data
from the Phase 1b study was conducted to evaluate CM-101 following multiple IV infusion of 2.5 mg/kg or 5 mg/kg SC injections of CM-101
in NAFLD patients. Following repeated IV infusions (2.5 mg/kg Q3W) and SC injection (5 mg/kg Q3W), CM-101 exhibited a long terminal half-life,
similar to the terminal half-life seen in the single dose studies. CM-101 accumulated over time, resulting in significant systemic exposure
over time and potentially reaching a steady state.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Overall, CM-101 reached
steady state conditions more slowly following SC injection, as compared to IV infusion. The inter-patient variability in CM-101 serum
concentrations was higher for SC dosing injection, as compared to IV. The trough CM-101 serum concentrations after repeated 5 mg/kg SC
injections were proportionally higher than those after 2.5 mg/kg IV infusions, considering the difference in administration modes. Comparison
of the PK data of CM-101 in the Phase 1b to the Phase 1a studies indicates a consistency in PK behavior of CM-101.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Pharmacodynamics and
target engagement of CM-101</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Serum was taken from
patients in all three Phase 1 studies at different times and the levels of both CCL24 and CM-101 were measured. Total CCL24 levels represent
CM-101&#8217;s engagement to its target. Total CCL24 levels were increased following administration of the drug, which indicates that
CM-101 is effective in target engagement, as the higher levels of CCL24 correlated significantly with greater doses of CM-101, and such
levels decreased gradually from the peak of CM-101 administration. These findings demonstrate that CM-101 effectively binds to CCL24 in
the circulation, which reflects a strong drug-target interaction.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In the Phase 1b study,
CM-101 treatment of 2.5mg/kg IV attained the highest levels of total CCL24 by the third administration, maintaining these levels until
the end of treatment. CM-101 5mg/kg administered by SC injection reached the highest levels of CCL24 by the fourth treatment and maintained
these levels until the end of treatment. The matching placebo did not have any effect on CCL24 levels.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">As exemplified in the
in-vitro studies, binding of CCL24 by CM-101 attenuates the binding of CCL24 to its cognate CCR3 receptor, thereby reducing its downstream
activation. Altogether, CCL24 levels following treatment with CM-101 provide strong evidence for target engagement and pharmacodynamic
response of CM-101 in healthy volunteers and patients.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Phase 1b exploratory
endpoints</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Fibrotic biomarkers were
analyzed as part of the Phase 1b study in NAFLD patients with normal liver function. Circulating fibrotic biomarkers were tested in serum
pre- and post-treatment. The analysis included data from patients that presented with more active disease, reflected by baseline elastography
(FibroScan) score &gt;4 kPa. Tissue inhibitor of metalloproteinases-1 (TIMP-1) and tissue inhibitor of metalloproteinases-2 (TIMP-2),
considered well established fibrotic biomarkers, were evaluated, and showed that CM-101 treatment led to reductions of both markers by
week 15. The growth factor PDGF-AA, known as a pro-fibrotic secreted factor, was also reduced in CM-101 treated patients. Conversely,
in the placebo group TIMP-1, TIMP-2 and PDGF-AA all increased.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">26</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Evaluation of the fibrogenesis
and fibrolysis/inflammatory biomarkers, Pro-C3, Pro-C4 and C3M measured in serum, conducted by Nordic Bioscience, Copenhagen, Denmark,
were also used as sensitive indicators of the liver&#8217;s fibrotic state. In accordance with reduced liver stiffness, Pro-C3, Pro-C4
and C3M were all reduced in the CM-101 treated groups. No reductions were identified in the placebo control group.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Changes in liver stiffness,
a measurement of liver fibrosis, were also evaluated using FibroScan measurements taken at screening and end of treatment (EoT) following
15 weeks of treatment coverage. 80% of CM-101 treated patients had significant decreases in FibroScan measurements, unlike placebo patients
where there was no significant change from baseline</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: left; line-height: 1.25; font-family: Times New Roman, Times, serif; font-style: italic">Results of investigator-initiated
clinical study of CM-101 in patients with COVID-19-derived lung damage</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">On November 9, 2022, encouraging clinical
data from an investigator-initiated clinical study assessing CM-101 activity and safety in hospitalized patients with severe lung injury
derived from COVID-19 infection was presented at the 2022 Union Conference, an international conference on lung health. A key rationale
for the study is that some of the mechanisms underlying lung inflammation resulting from COVID-19 infection are similar to those seen
in systemic sclerosis and other chronic diseases involving lung inflammation and fibrosis.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The objective was to evaluate the safety
and activity of CM-101 in hospitalized COVID-19 patients with severe pneumonia, including its impact on biomarkers related to lung inflammation
that are also relevant in SSc.<span style="font-weight: bold">&#160;</span>The open label, single arm trial enrolled 16 hospitalized adult
COVID-19 patients with severe respiratory involvement. All patients were receiving standard of care therapy. All were treated with a single
10mg/kg intravenous dose of CM-101 on the first day of the study and followed for 30 days.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Administration of CM-101 to this acutely
ill patient population appeared safe and was well tolerated. CM-101 exposures and target engagement profiles were similar to what our
researchers have seen in previous clinical studies of CM-101.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Importantly, rapid reductions in serum biomarkers
of lung inflammation, fibrogenesis and neutrophil activity were observed post-treatment with CM-101.<span style="font-weight: bold">&#160;</span>Overall,
this study confirmed and extended the safety and tolerability profile of CM-101 and demonstrated clinically relevant changes in biomarkers
associated with lung inflammation and fibrogenesis, further supporting CM-101&#8217;s anti-inflammatory and anti-fibrotic effects.<span style="font-weight: bold">&#160;</span></div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Moreover, we believe that these results
add to the data suggesting that CM-101 has the potential to attenuate lung inflammation and fibrosis, further strengthening the rationale
for treating SSc patients with this drug. These new clinical data also contribute to a growing body of evidence demonstrating CM-101&#8217;s
anti-fibrotic and anti-inflammatory effects in varied organs including the lung, liver and skin.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Topline results of Phase
2a study in patients with liver fibrosis derived from NASH</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Primary endpoints for
the study were safety and tolerability. Secondary endpoints included the evaluation of the pharmacokinetic and target engagement profile
of the SC formulation as well as changes in relevant biomarkers that may provide further mechanistic understanding of CM-101 effects on
liver fibrosis. This trial was primarily designed to assess a subcutaneous formulation of CM-101 and to evaluate the drug&#8217;s impact
on liver fibrosis biomarkers relevant to both NASH and fibro-inflammatory conditions that represent the focus for the company, such as
PSC and SSc.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The randomized, placebo-controlled
trial enrolled 23 NASH patients with stage F1c, F2 and F3 disease who were randomized to receive either CM-101 or placebo. Patients received
eight doses of 5 mg/kg of study drug administered by subcutaneous injection once every two weeks, for a treatment period of 16 weeks.
Key findings of the CM-101 Phase 2a trial included the following.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25">

<div style="text-indent: 36pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; CM-101 appeared to be safe and
was well tolerated when administered subcutaneously. Most reported adverse events observed were mild, with one unrelated serious adverse
event reported. No significant injection site reactions were reported and no anti-drug antibodies were detected.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CM-101
administered subcutaneously demonstrated favorable pharmacokinetics and target engagement profiles as expected and were similar to what
the company has previously reported.</span></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CM-101-treated
patients showed greater improvements than the placebo group in a number of liver fibrosis-related biomarkers, including ProC-3, ProC-4,
ProC-18, TIMP-1 and ELF.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A
majority of CM-101-treated patients showed improvements in more than one liver fibrosis-related biomarker&#8212;almost 60% of CM-101 patients
responded in at least three biomarkers at week 20, compared to no patients in the placebo group.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
A higher proportion of patients in the CM-101-treated group showed improvement in a physiologic measure of liver stiffness as compared
to placebo (reduction of at least one grade of fibrosis score as assessed by the non-invasive elastography method known as FibroScan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>).</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CM-101-treated
patients with higher CCL24 levels at baseline showed greater reductions in fibrosis-related biomarkers than patients with lower levels.
Multiple fibrosis-related biomarkers showed more pronounced reductions in CM-101-treated patients who had higher CCL24 levels at baseline
than in patients with lower CCL24 levels at baseline, adding to the growing body of evidence validating the role of CCL24 in the pathophysiology
of fibrotic liver disease.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">27</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;After
completion of the study, the unblinded data showed that patients in the CM-101-treated group had higher baseline levels of fibrosis compared
to placebo patients. The impact of this difference on the results, if any, is unknown.</span></div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;We believe that
the data from this trial provide important insights in support of the CM-101 development program, including the favorable safety and tolerability
of CM-101 in patients with serious liver disease, confirmation of early signs of biomarker activity that are relevant for a number of
fibro-inflammatory disorders, and support of the tolerability and pharmacokinetic data needed to assess next steps in the development
of our current subcutaneous formulation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Other
clinical development activities for CM-101</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Recently, Chemomab also
reported positive clinical data from an investigator-initiated clinical study assessing CM-101 activity and safety in hospitalized patients
with severe lung injury derived from COVID-19. The objective of the study was to evaluate the drug&#8217;s safety and activity in hospitalized
COVID-19 patients with severe pneumonia, including its impact on biomarkers related to lung inflammation that are also relevant in systemic
sclerosis. The open label, single arm trial enrolled 16 hospitalized adult COVID-19 patients with severe respiratory involvement. All
patients were receiving standard of care therapy. All were treated with a single 10mg/kg intravenous dose of CM-101 on the first day of
the study and followed for 30 days. Administration of CM-101 to this acutely ill patient population appeared to be safe and was well tolerated.
CM-101 exposures and target engagement profiles were similar to what our researchers have seen in previous clinical studies of CM-101.
Importantly, rapid reductions in serum biomarkers of lung inflammation, fibrogenesis and neutrophil activity were observed post-treatment
with CM-101. Overall, this study confirmed and extended the safety and tolerability profile of CM-101 and demonstrated clinically relevant
changes in biomarkers associated with lung inflammation and fibrogenesis, further supporting CM-101&#8217;s anti-inflammatory and anti-fibrotic
effects.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Together, these promising
results provide initial support for CM-101&#8217;s anti-fibrotic and anti-inflammatory mechanisms in humans and support further testing
of CM-101 in PSC and SSc patients.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Current and planned
clinical studies for PSC and SSc</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The Company is currently recruiting and
treating PSC patients in a Phase 2 study at multiple sites in Israel, the United States and Europe and expanding the trial to include
an additional dose level and an open label extension. The Company is also planning to initiate a Phase 2 study in SSc around midyear of
2023 that will enroll patients across multiple sites in Israel, the United States and Europe.</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The ongoing Phase 2 trial
in PSC is a randomized, double-blind, placebo-controlled, study designed to evaluate the safety and efficacy of CM-101 in adult subjects
with PSC. Participants must have a serum alkaline phosphatase, or ALP, level of at least 1.5 times the upper limit of normal (x 1.5 ULN).
Subjects with concomitant IBD are eligible for recruitment if their disease is stable and there is an absence of high-grade dysplasia
in colonic biopsies within 18 months of randomization. To date, subjects are randomized to receive 10 mg/kg CM-101 IV, or placebo, in
a 2:1 ratio. Chemomab has amended the study to include a higher dose level (20mg/kg) of CM-101. Patients will receive a dose of investigational
product once every three weeks for a total of five administrations resulting in a total coverage of 15 weeks during the double-blind portion
of the study. Chemomab is adding a 33-week long open-label extension to the study.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The primary endpoint
for the study is safety and tolerability. Secondary endpoints include evaluations of changes from baseline in serum alkaline phosphatase,
or ALP, levels and the fibrotic marker enhanced liver function, or ELF, score at week 15. ALP is a liver enzyme that is elevated in cholestasis
and the ELF score is a biochemical test panel made up of serum markers that are indicators of the extracellular matrix. Additional secondary
endpoints include evaluations of changes from baseline in other liver enzymes and additional fibrotic markers, to include AST, ALT, Pro-C3
and Pro-C5. PK, PD and ADA parameters.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">28</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, Times, serif">The planned Phase 2 study in SSc will enable
an expedited path to proof-of-concept data and further elucidation of different CM-101 mechanisms of actions in treating SSc skin, lung
and vascular damage. To that end, we will slightly enrich the study with SSc patients who have higher levels of CCL24 and may therefore
be more likely to respond to neutralization of this critical chemokine Chemomab is currently finalizing the design. The U.S. FDA recently
cleared the Company&#8217;s IND application to commence the Phase 2 SSc trial and we plan to initiate the study around midyear of 2023.
Key design elements include the following.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2a857c04b5fc49fa9695be7de75faada" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>The trial is a randomized, double-blind, placebo-controlled study that will enroll 45 SSc patients.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcba3ecc0622c436f910f99dd1975acc3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>To be eligible for the study, patients must manifest two key characteristics: the presence of clinically active disease, either dermatologic
        or pulmonary, and higher serum levels of circulating CCL24.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd463832666624f938f4416b54f340838" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Thirty patients will be randomized to treatment with CM-101 and 15 will be randomized to placebo.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5940ee096615409d9b2b217a7037ba80" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Of the patients on active treatment, approximately half will have limited SSc, and half will have diffuse cutaneous disease.</div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd8d534e5047b48bf829721cf036860e1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>The study includes a 24-week double blind period during which patients assigned to active treatment will receive CM-101 at a dose
        of 10 mg/kg, via intravenous infusion, every three weeks.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z429cf6a793454eb8874c76b77f0ab701" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Following the double-blind period, patients will enter a 24-week open label treatment period, where all patients will receive CM-101
        at a dose of 10 mg/kg via intravenous infusion every three weeks.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2bf6e8afa95b488da113b4f24c418a04" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>All patients enrolled will undergo a skin biopsy at baseline and again after the double-blind treatment period, along with multiple
        clinical assessments of skin, vascular and pulmonary function.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb9a2e1739d1b4083b352de729b9e7507" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>The primary outcome measure for the trial will be demonstration of the safety and tolerability of treatment with CM-101.</div> </td>
        </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4bc2747255724676802bb2e6d37d4459" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt">&#160;</td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>All other outcome measures will be principally assessed as changes from baseline to the end of the double-blind treatment period.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The secondary outcome
measures of the trial are focused on highly relevant and informative biological read-outs. Key secondary outcomes include: evaluation
of multiple serum-based biological markers that are known to be associated with different manifestations of SSc including:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfd5d80b887414aef82689b008ee67976" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Inflammatory cytokines (such a CCL2, IL6 and CXCL10), vascular and growth factor-related biomarkers (such as VEGF and PDGF), pulmonary-related
        biomarkers (such as KL-6, SPD and CCL18), and fibrogenesis and extracellular matrix biomarkers (collagens, MMPs and ELF score).</div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z360bd6bed9da402ba9429248a2969017" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Inflammatory, fibrotic and target expression markers in skin biopsies, including but not limited to CCL24 and CCR3 expression levels.</div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6124e8e308c64e86abb520b354027cf2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Pharmacokinetics and target engagement of CM-101.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9654dce388f24f78ba0381ab8ad8f65f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Monitoring for the presence of any potential anti-drug antibodies during the study.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Exploratory biological
outcomes assessments will include immune cell phenotyping, assessments of neutrophil function, and ex-vivo biological assays.&#160; Exploratory
clinical outcomes will include evaluation of: vascular involvement, using nail fold capillaroscopy; vascular imaging and digital ulcer
burden; skin involvement using modified Rodnan scoring; pulmonary disease involvement using pulmonary function tests; and multiple patient-reported
outcome measures.&#160; The data collected should also enable evaluation of global effects of intervention with CM-101 using the American
College of Rheumatology CRISS scale (ACR-CRISS) and the revised CRISS scale (rCRISS). We intend to conduct this study at multiple sites
in Israel, the United States and Europe.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;<br /> &#160;<span style="font-weight: bold">Competition</span></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The development and commercialization
of new drug products is highly competitive across major pharmaceutical companies, specialty pharmaceutical companies and biotechnology
companies worldwide. The Company faces competition with respect to its current product and expects to face competition with respect to
any product candidates that it may develop or commercialize in the future. Specifically, there are a number of companies developing treatments
for fibrotic/inflammatory diseases, including multiple major pharmaceutical and biotechnology companies with substantially greater resources
than the Company. The Company is a small biotech company with limited resources compared to the major pharmaceutical companies, however,
the Company believes that the unique CM-101 platform together with its knowledge and experience in inflammatory-fibrotic research provides
it with competitive advantages.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">29</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Therapeutic options for
PSC and SSc are limited and despite significant biopharmaceutical industry investment, the FDA has not approved any disease modifying
therapies for the treatment of PSC or SSc. Liver transplant is currently the only treatment shown to improve clinical outcomes for PSC
patients while SSc patients are being treated with drugs that were approved for different manifestations of the disease like interstitial
lung disease (nintedanib, Boehringer Ingelheim and tocilizumab, Hoffmann-La Roche).</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company is advancing
CM-101, a first-in-class monoclonal antibody that interferes directly with both inflammation and fibrosis, into clinical development for
the treatment of PSC and SSc. There are a number of large biopharmaceutical and biotechnology companies that are currently pursuing the
development of products for the treatment of fibrotic indications like PSC and SSc, such as, Mitsubishi Tanabe Pharma, Horizon Therapeutics,
Pliant Therapeutics,&#160; Prometheus Biosciences and others. However, the Company knows of no other companies currently in clinical development
with a monoclonal antibody that targets CCL24.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Although the approach
is novel with respect to targeting both inflammation and fibrosis, the Company will need to compete with products further advanced in
the pipeline towards market approval. Investigational products, include:</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze9fb2438ae3c48489ea80281048467c5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="font-style: italic">PSC</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">There are currently no
FDA-approved therapies for the treatment of PSC. Companies currently developing product candidates in Phase 3 clinical studies include
Gilead and Dr. Falk Pharma, targeting cholestasis and liver metabolism (Gilead; Cilofexor, Dr. Falk; norUrso). Additional companies with
clinical candidates in earlier stages of development include HighTide Biopharmaceutical, Mirum Pharmaceuticals and Pliant Inc.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4e2f7494b7f34101861fe5d7ec21614c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="font-style: italic">SSc</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">There are currently two
FDA approved products for the treatment of clinical manifestations of SSc--nintedanib, marketed by Boehringer Ingelheim GmbH and tocilizumab,
marketed by Hoffmann-La Roche for the treatment of interstitial lung disease. Companies currently developing product candidates in SSc
in early clinical stage include Horizon, Mitsubishi Tanabe, GS Johnson &amp; Johnson, Vicore, Sanofi, Prometheos Biosciences and others.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The availability of reimbursement
from government and other third-party payors will affect the pricing and competitiveness of CM-101 and any future products. More advanced
competitors also may obtain regulatory approval for their products more rapidly than the Company, which could result in competitors establishing
a strong market position.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Intellectual Property</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Overview</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company strives to
protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of its
business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. The
Company also relies on trade secrets relating to its proprietary technology platform and know-how, continuing technological innovation
and in-licensing opportunities to develop, strengthen, and maintain its proprietary position in the field of inflammation and fibrosis
that may present areas of opportunity for the development of its business. The Company may also rely on regulatory protection afforded
through data exclusivity, market exclusivity, and patent term extensions, where available.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company&#8217;s commercial
success may depend in part on its ability to: obtain and maintain patent and other proprietary protection for commercially important technology,
inventions and know-how related to its business; defend and enforce its patents; preserve the confidentiality of its trade secrets; and
operate without infringing the valid enforceable patents and proprietary rights of third parties. The Company&#8217;s ability to prevent
third parties from making, using, selling, offering to sell, or importing the Company&#8217;s products may depend on the extent to which
it has rights under valid and enforceable licenses, patents, or trade secrets that cover these activities. In certain cases, enforcement
of these rights may depend on third party licensors. With respect to both licensed and company-owned intellectual property rights, the
Company cannot be sure that patents will be granted with respect to any of its pending patent applications or with respect to any patent
applications that may be filed by the Company in the future, nor can the Company be sure that any of its existing patents or any patents
that may be granted to it in the future will be commercially useful in protecting its commercial products and methods of manufacturing
the same.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">30</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">As of the date of this
Annual Report on Form 10-K, the Company owned or licensed seven pending or issued US patents and patent applications as well as patents
and patent applications in other jurisdictions. The first patent family has been issued in each of the United States, Europe (validated
in France, Germany and the United Kingdom) and Israel to the Tel Aviv Souraski Medical Center, whose rights have been licensed to the
Company on an exclusive basis. A composition of matter patent was issued in United States and certain corresponding foreign jurisdictions.
To date, three additional patent families were filed by the Company concerning the use of anti CCL24 antibodies in specific indications,
dosing regimens, and routes of administration. The Company will seek United States and foreign patent protection for a variety of additional
technologies, including: research compounds and methods, candidate compounds and antibodies for modulating the activity of CCL24, methods
for treating diseases of interest, and methods for treating its products. The Company will seek additional protection, in part, through
confidentiality and proprietary information agreements.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Company
Owned Intellectual Property</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company owns multiple
families of patent applications that pertain to anti-CCL24 monoclonal antibody compositions capable of blocking CCL24 activity and methods
for treating or preventing diseases associated with inflammation and fibrosis. Certain applications in these families relate to the Company&#8217;s
CM-101 antibody, backup variants, various unit dosages, dosing regimens, and other routes of administration. Patents that are or will
be issued from these submissions will expire between the years 2035 to 2041, subject to possible patent term adjustments and/or extensions.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition to the above,
the Company has established expertise and development capabilities focused in the areas of preclinical research and development, manufacturing
and manufacturing process development, quality control, quality assurance, regulatory affairs, and clinical study design and implementation.
The Company believes that its focus and expertise will help the Company develop products based on its proprietary intellectual property.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Licensed
IP</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">As mentioned above, the
Company has obtained an exclusive license from the Tel Aviv Souraski Medical Center for one patent, which is expected to expire in 2029.
This patent was issued in each of the United States, Europe and Israel, and pertains to anti CCL24 inhibitors (specifically, anti CCL24
antibodies) and methods of using such inhibitors for treating inflammatory, autoimmune and cardiovascular diseases.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Trade
Secret Protection</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company may rely,
in some circumstances, on trade secrets to protect its technology. The Company seeks to protect its proprietary technology and processes,
in part, by entering into confidentiality agreements with its employees, consultants, scientific advisors, and contractors. The Company
also seeks to preserve the integrity and confidentiality of its data and trade secrets by maintaining physical security of its premises
and physical and electronic security of its information technology systems.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">31</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Material
Agreements</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Tel-Aviv Souraski Medical
Center (TASMC) License Agreement</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In December 2011, the
Company entered into a license agreement, or the TASMC Agreement, with the Medical Research, Infrastructure, Health Services Fund of the
Tel Aviv Souraski Medical Center., or TASMC, for the research, development and commercialization of the CCL24 platform and CCR3 blockade
platform (CM-101), which license includes patent rights covering the foregoing platforms and related know how and products. Under the
terms of the TASMC Agreement, the Company is responsible for the research, development, manufacturing and commercialization of CM-101.
This license was granted on an exclusive basis and the Company was also granted rights to sublicense the instant license to third parties
pursuant to certain terms described therein.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In accordance with the
TASMC Agreement, the Company paid TASMC a non-refundable and non-creditable payment in four milestone installments, related to TASMC&#8217;s
past patent maintenance and prosecution costs.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">Certain additional terms
of the TASMC Agreement include:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9e5a06436481434fb547b0cfe580b34d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; color: #000000">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">The Company will be required to pay TASMC non-refundable and non-creditable milestone payments of up
        to (i) $300,000 upon the submission of an NDA, BLA or equivalent for each of the licensed products to the FDA and to equivalent European
        and Asian foreign regulatory agencies, and (ii) $600,000 upon the grant by the FDA or equivalent European and/or Asian regulatory agencies
        of their marketing approval for each licensed product;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9d83bb0c0e634b4aa86a98fdbe172e4c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">In the event of an &#8220;exit,&#8221; as such term is defined therein, the Company must pay TASMC an
        exit fee of 1% of the transaction consideration (which shall be capped at $3 million);</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze19f8b1b15dd4612a6792ddd4d1f2dd1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">In the event the Company sublicenses a licensed product, the Company must pay TASMC a sublicense fee
        of 10% of all attributed income, in addition to a low-single digit percentage tiered royalty payment of our earned royalties.</div> </td>
        </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Unless terminated earlier,
the TASMC Agreement will expire upon the later of the expiration of the last-to-expire valid patent claim and any extension granted prior
thereto. The termination of the TASMC Agreement will not preclude TASMC from receiving sublicense payments or royalties. In addition to
the foregoing, the TASMC Agreement includes customary termination provisions.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">CMC Collaboration Agreement</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In June 2015, the Company
entered into a collaboration agreement, or the CMC Agreement, with CMC ICOS Biologics, Inc. (acquired by AGC Biologics in 2018), or CMC,
which, under the terms thereof, granted the Company certain licenses to use proprietary rights, materials and know-how of CMC for purposes
of research and development of CM-101 as well as commercialization thereof. Pursuant to the terms of the CMC Agreement, the Company received
(i) a worldwide, non-exclusive, non-transferable, non-sublicensable license for research purposes, or the Research License, and (ii) an
option, or the Option License, to a worldwide, non-exclusive, non-transferable, sublicensable license for commercialization purposes,
subject to a fee schedule in addition to that described below.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In accordance with the
terms of the CMC Agreement, the Company agreed to pay in exchange for the foregoing license payments to CMC upon the achievement of certain
pre-determined clinical and regulatory events, an amount stipulated in the CMC Agreement, aggregating a six-digit number. Additionally,
for any product that is commercialized pursuant to the CMC Agreement, the Company is required to pay CMC a royalty payment based on annual
aggregate worldwide net sales thresholds for such products. In the event CMC exclusively manufactures the Company&#8217;s products, CMC
agrees to waive the foregoing royalty.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Unless terminated earlier
pursuant to the customary termination provisions set forth in the CMC Agreement, the Research License will expire upon the conclusion
of the term as defined therein, and the Option License will expire upon the later of (a) the tenth anniversary following the Company&#8217;s
obtainment of regulatory approval, or (b) the last to expire of the patent rights and country-by-country basis.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">32</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Manufacturing</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company&#8217;s product
candidate, CM-101, is a monoclonal antibody amenable to standard formulation technologies. The Company has developed the biological process
and manufactured kilogram quantities through processes similar to the manufacturing processes that will be required to provide drug product
for the Phase 2 clinical studies. The manufacturing process of the drug substance used for such product candidates is robust, well established
and requires the use of readily available starting materials. The biological route is amenable to large-scale production and does not
require unconventional equipment or handling during the manufacturing process. The Company has obtained an adequate supply chain of the
drug substance for CM-101 from the Company&#8217;s contract manufacturing organization, or CMO, to satisfy both the Company&#8217;s clinical
and preclinical requirements for this year. The Company relies on a sole supplier for the manufacture of CM-101. The Company&#8217;s manufacturer
has the capabilities to support late stage clinical studies as well as product launch and marketing.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company does not
own or operate facilities for clinical drug manufacturing, storage, distribution or quality testing. Currently, all of the Company&#8217;s
clinical manufacturing is outsourced to third-party manufacturers. As the Company&#8217;s development programs expand and it builds new
process efficiencies, the Company expects to continually evaluate this strategy with the objective of satisfying demand for its clinical
studies and, if approved, the manufacture, sale and distribution of commercial products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Commercialization</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company intends to
develop and, if approved by the FDA, to commercialize its product candidates alone or in collaboration with others. The Company may work
in combination with one or more large pharmaceutical partners for certain indications, where specialist capabilities are needed. The Company
intends to enter into distribution or licensing arrangements for global or regional commercialization rights. The Company will, however,
continuously review its partnering strategy in the light of new clinical data and market understanding.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Regulatory Matters</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Food and Drug Administration,
or FDA, and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome
requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those the
Company is developing. These agencies and other federal, state and local entities regulate, among other things, the research and development,
testing, manufacture, quality control, safety, effectiveness, labelling, storage, record keeping, approval, advertising and promotion,
distribution, post-approval monitoring and reporting, sampling and export and import of the Company&#8217;s product candidates.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">United
States government regulation of drug products</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Drugs in the United States
are subject to rigorous regulation under the Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The FDA also regulates
biological products under the FDCA and the Public Health Service Act, or PHSA. If the Company advances clinical development of a biologic
candidate in the future, these development activities will be subject to additional regulatory requirements specific to biologics. The
process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and
regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable United States
requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety
of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve a pending New Drug Application, or NDA, withdrawal
of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension
of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">33</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The process required
by the FDA before a drug or biologic may be marketed in the United States generally involves the following:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" border="0" id="z05e94369d920417bb23fd9c335d90289" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,serif">Completion of preclinical
        laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</div>
        </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">Submission to the FDA of an Investigational
        New Drug application, or IND, which must become effective before human clinical studies may begin;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">Approval by an Institutional
        Review Board, or IRB, at each clinical site before each study may be initiated;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">Performance of adequate and well-controlled
        human clinical studies in accordance with Good Clinical Practice, or GCP requirements to establish the safety and efficacy of the proposed
        drug product for each indication;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">Completion of all manufacturing
        requirements to ensure robust manufacturing process, and product quality and safety as per Good Manufacturing Practice, or cGMP guidelines;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">Completion of non-clinical reproductive
        studies, as applicable, prior to late stage clinical studies and NDA or Biologics License Application, or BLA, submission;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">Development of an appropriate
        pediatric plan for clinical testing or exclusion, pre- or post-approval, as applicable;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">Submission to the FDA of an NDA
        or BLA;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">Satisfactory completion of an
        FDA advisory committee review, if applicable;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">Satisfactory completion of an
        FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements
        and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">Satisfactory completion of FDA
        audits of clinical study sites to assure compliance with GCPs and the integrity of the clinical data;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">Payment of user fees and securing
        FDA approval of the NDA;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">FDA review and approval of an
        NDA or BLA; and</div>
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">Compliance with any post-approval
        requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategies, or REMS, and the potential
        requirement to conduct post-approval studies.</div> </td> </tr>
  </table> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Preclinical
studies</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Preclinical studies include
laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy.
An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available
clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND
is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns
or questions related to one or more proposed clinical studies and places the clinical study on a clinical hold. In such a case, the IND
sponsor and the FDA must resolve any outstanding concerns before the clinical study can begin. As a result, submission of an IND may not
result in the FDA allowing clinical studies to initiate.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">34</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Clinical
studies</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Clinical studies involve
the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with
GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation
in any clinical study. Clinical studies are conducted under protocols detailing, among other things, the objectives of the study, the
parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical study and any
subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating
in the clinical study must review and approve the plan for any clinical study before it initiates at that institution. Information about
certain clinical studies must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination
on their www.clinicaltrials.gov website.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Human clinical studies
are typically conducted in three sequential phases, which may overlap or be combined. A fourth, or post-approval, phase may include additional
clinical studies. These phases generally include the following:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="zae065614293e48eeb918f3a7d4c8f4a5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Phase
        1:</span><span style="font-family: Times New Roman,Times,serif"> The drug or biologic is initially introduced into healthy human subjects
        or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion
        and, if possible, to gain an early indication of its effectiveness. For some products for severe or life-threatening diseases, especially
        if the product may be too toxic to administer to healthy humans, the initial clinical trials may be conducted in individuals having a
        specific disease for which use the tested product is indicated.</span></div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Phase
        2:</span><span style="font-family: Times New Roman,Times,serif"> The drug or biologic is administered is administered to a limited patient
        population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted
        diseases and to determine dosage tolerance and optimal dosage.</span></div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Phase
        3:</span><span style="font-family: Times New Roman,Times,serif"> The drug or biologic is administered to an expanded patient population,
        generally at geographically dispersed clinical study sites, in well-controlled clinical studies to generate enough data to statistically
        evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide
        adequate information for the labeling of the product.</span></div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Phase
        4:</span><span style="font-family: Times New Roman,Times,serif"> Phase 4 clinical trials are studies required of, or agreed to by, a sponsor
        that are conducted after the FDA has approved a product for marketing. These studies are used to gain additional experience from the treatment
        of patients in the intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated
        approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval,
        a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement. Failure
        to promptly conduct Phase 4 clinical trials where necessary could result in withdrawal of approval for products approved under accelerated
        approval regulations.</span></div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Progress reports detailing
the results of the clinical studies must be submitted at least annually to the FDA and more frequently if serious adverse events occur.
Phase 1, Phase 2 and Phase 3 studies may not be completed successfully within any specified period, or at all. Furthermore, the FDA or
the sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects are
being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution
if the clinical study is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected
serious harm to patients.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">35</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Marketing
approval</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Assuming successful completion
of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to
the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an
NDA or BLA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA or BLA is subject
to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the
FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA, for a new molecular entity to review and act on
the submission. This review typically takes twelve months from the date the NDA or BLA is submitted to FDA because the FDA has approximately
two months to make a &#8220;filing&#8221; decision.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, under the
Pediatric Research Equity Act of 2003, or PREA, as amended and reauthorized, certain NDAs/BLAs or supplements thereof must contain data
that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations,
and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on
its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval
of the product for use in adults, or full or partial waivers from the pediatric data requirements. An Agreed Initial Pediatric Study Plan
requesting a waiver from the requirement to conduct clinical studies may be submitted to the FDA.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA also may require
submission of a REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician
communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries,
or other risk minimization tools.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA conducts a preliminary
review of all NDAs/BLAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently
complete to permit substantive review. The FDA may request additional information rather than accept an NDA/BLA for filing. In this event,
the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the
FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews
an NDA/BLA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured,
processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA may refer an
application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and
other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and
under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully
when making decisions.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Before approving an NDA,
the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless
it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent
production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical
study sites to assure compliance with GCP requirements.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">After evaluating the
NDA/BLA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing
facilities and clinical study sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response
letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA/BLA and may
require additional clinical or preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those
conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes
commercial marketing of the drug with specific prescribing information for specific indications.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">36</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Even if the FDA approves
a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included
in the product labeling, require that post-approval studies, including Phase 4 clinical studies, be conducted to further assess a drug&#8217;s
safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions,
including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential
market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing
studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing
changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">FDA
Expedited Development and Review Programs</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA has various programs,
including fast track designation, priority review, accelerated<span style="font-style: italic">&#160;</span>approval, and breakthrough
therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended
for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs.
The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA has a fast track
designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria.
Specifically, new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or
condition and demonstrate the potential to address unmet medical needs for the disease or condition. With regard to a fast track product,
the FDA may consider for review sections of the NDA/BLA on a rolling basis before the complete application is submitted, if the sponsor
provides a schedule for the submission of the sections of the NDA/BLA, the FDA agrees to accept sections of the NDA/BLA and determines
that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA/BLA.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Any product submitted
to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended
to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it
has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement
in the treatment, diagnosis, or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources
to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, a product
may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible
for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict
clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably
likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity,
or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require
a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible
morbidity or mortality, or other clinical endpoint and to submit promotional materials for preapproval and pre-use review, which could
adversely impact the timing of the commercial launch of the product. In addition, the drug may be subject to accelerated withdrawal procedures.
On December 29, 2022, the Consolidated Appropriations Act, 2023, including the Food and Drug Omnibus Reform Act (FDORA), was signed into
law. FDORA made several changes to the FDA&#8217;s authorities and its regulatory framework, including, among other changes, reforms to
the accelerated approval pathway, such as requiring the FDA to specify conditions for post-approval study requirements and setting forth
procedures for the FDA to withdraw a product on an expedited basis for non-compliance with post-approval requirements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The Food and Drug Administration
Safety and Innovation Act established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to
receive breakthrough therapy designation. A sponsor may seek FDA designation of a product candidate as a &#8220;breakthrough therapy&#8221;
if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or
condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation
includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation
is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria
are met. If a product is designated as breakthrough therapy, the FDA will work to expedite the development and review of such drug.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">37</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, the FDA
may review new drug applications under the Oncology Center of Excellence Real-Time Oncology Review (&#8220;RTOR&#8221;), which, according
to the FDA, aims to explore a more efficient review process to ensure that safe and effective treatments are available to patients as
early as possible, while maintaining and improving review quality. Drugs considered for review under RTOR must be likely to demonstrate
substantial improvements over available therapy, which may include drugs previously granted breakthrough therapy designation for the same
or other indications, and must have straight-forward study designs and endpoints that can be easily interpreted. RTOR allows the FDA to
review much of the data in an NDA/BLA earlier, before the applicant formally submits the complete application. This analysis of the pre-submission
package gives the FDA and applicants an early opportunity to address data quality and potential review issues and allows the FDA to provide
early feedback regarding the most effective way to analyze data to properly address key regulatory questions.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Fast track designation,
priority review, accelerated approval, and breakthrough therapy designation do not change the standards for approval, but may expedite
the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the
product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Orphan
drug designation and exclusivity</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the Orphan Drug
Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally
meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation
that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be
recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted,
the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage
in or shorten the duration of the regulatory review and approval process. As of the current date, the Company has obtained orphan drug
designation for three indications, PSC, SSc and IPF.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If a product with orphan
status receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use
within the rare disease or condition for which it was designated, the product generally will be receiving orphan product exclusivity.
Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for
seven years, except in certain limited circumstances. If a drug or drug product designated as an orphan product ultimately receives marketing
approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity.
Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same
active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy
or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market
demand. Further, the FDA may approve more than one product for the same orphan indication or disease as long as the products contain different
active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan product has
exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">38</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In <span style="font-style: italic">Catalyst
Pharms., Inc. v. Becerra</span>, 14 F.4th 1299 (11th Cir. 2021), the court disagreed with the FDA&#8217;s longstanding position that the
orphan drug exclusivity only applies to the approved use or indication within an eligible disease. This decision created uncertainty in
the application of the orphan drug exclusivity. On January 24, 2023, the FDA published a notice in the Federal Register to clarify that
while the agency complies with the court&#8217;s order in <span style="font-style: italic">Catalyst</span>, FDA intends to continue to
apply its longstanding interpretation of the regulations to matters outside of the scope of the <span style="font-style: italic">Catalyst</span>
order &#8211; that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug
is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease
or condition that have not yet been approved. It is unclear how future litigation, legislation, agency decisions, and administrative actions
will impact the scope of the orphan drug exclusivity.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">United
States marketing exclusivity</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Market exclusivity provisions
under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent
marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is
a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule
or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated
New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does
not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four
years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity
for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were
conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications,
dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical
investigations and does not prohibit the FDA from approving ANDAs for the original non-modified version of the drug. Five-year and three-year
exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to
conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical studies necessary to
demonstrate safety and effectiveness.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Abbreviated Licensure
Pathway of Biological Products as Biosimilars or Interchangeable Biosimilars</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">The Patient Protection and Affordable Care
Act (Affordable Care Act or ACA), signed into law in 2010, includes the Biologics Price Competition and Innovation Act of 2009 (BPCIA),
which created an abbreviated approval pathway for biological products shown to be highly similar to an FDA-licensed reference biological
product. The BPCIA attempts to minimize duplicative testing, and thereby lower development costs and increase patient access to affordable
treatments. An application for licensure of a biosimilar product must include information demonstrating biosimilarity based upon the following,
unless the FDA determines otherwise:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6d7f14819b9f4711aecf0611b2625f17" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 33.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 24.5pt; vertical-align: top; color: #000000">&#160;&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Analytical studies demonstrating that the proposed biosimilar product is highly similar to the approved product notwithstanding minor
        differences in clinically inactive components;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd27f1150d23c4351bf642931081a481e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 33.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 24.5pt; vertical-align: top; color: #000000">&#160;&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Animal studies (including the assessment of toxicity); and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb1fc76acdd3642ce9511b9351f97ed43" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 33.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 24.5pt; vertical-align: top; color: #000000">&#160;&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>A clinical trial or trials (including the assessment of immunogenicity and pharmacokinetic or pharmacodynamic) sufficient to demonstrate
        safety, purity and potency in one or more conditions for which the reference product is licensed and intended to be used.</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">In addition, an application must include information
demonstrating that:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfbc9b3e1c61c4cb2a359a9e71e91e093" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 33.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 24.5pt; vertical-align: top; color: #000000">&#160;&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The proposed biosimilar product and reference product utilize the same mechanism of action for the condition(s) of use prescribed,
        recommended or suggested in the proposed labeling, but only to the extent the mechanism(s) of action are known for the reference product;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">39</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0f95f910a8ff4cebaa4291e7fc4d1e1d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 33.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 24.5pt; vertical-align: top; color: #000000">&#160;&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The condition or conditions of use prescribed, recommended or suggested in the labeling for the proposed biosimilar product have
        been previously approved for the reference product;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z94a86b118dd2435088ec49ceac198071" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 33.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 24.5pt; vertical-align: top; color: #000000">&#160;&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The route of administration, the dosage form and the strength of the proposed biosimilar product are the same as those for the reference
        product; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb6bf8bca2f514a70b32a54210d2da52b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 33.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 24.5pt; vertical-align: top; color: #000000">&#160;&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The facility in which the biological product is manufactured, processed, packed or held meets standards designed to assure that the
        biological product continues to be safe, pure and potent.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">Biosimilarity means that the biological product
is highly similar to the reference product notwithstanding minor differences in clinically inactive components, and that there are no
clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency
of the product. In addition, the law provides for a designation of &#8220;interchangeability&#8221; between the reference and biosimilar
products, whereby the biosimilar may be substituted for the reference product without the intervention of the healthcare provider who
prescribed the reference product. The higher standard of interchangeability must be demonstrated by information sufficient to show that:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zdea02cdcded449809c6b2f2a0d9b0e4c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 33.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 24.5pt; vertical-align: top; color: #000000">&#160;&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The proposed product is biosimilar to the reference product;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5407366514ff4d91bd45bccf973a41f9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 33.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 24.5pt; vertical-align: top; color: #000000">&#160;&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The proposed product is expected to produce the same clinical result as the reference product in any given patient; and</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 33.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 24.5pt; vertical-align: top; color: #000000">&#160;&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>For a product that is administered more than once to an individual, the risk to the patient in terms of safety or diminished efficacy
        of alternating or switching between the biosimilar and the reference product is no greater than the risk of using the reference product
        without such alternation or switch.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">FDA approval is required before a biosimilar
may be marketed in the United States. However, complexities associated with the large and intricate structures of biological products
and the process by which such products are manufactured pose significant hurdles to the FDA&#8217;s implementation of the law that are
still being worked out by the FDA. For example, the FDA has discretion over the kind and amount of scientific evidence&#8212;laboratory,
preclinical and/or clinical&#8212;required to demonstrate biosimilarity to a licensed biological product.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">The FDA intends to consider the totality of
the evidence provided by a sponsor to support a demonstration of biosimilarity and recommends that sponsors use a stepwise approach in
the development of their biosimilar products. Biosimilar product applications thus may not be required to duplicate the entirety of preclinical
and clinical testing used to establish the underlying safety and effectiveness of the reference product. However, the FDA may refuse to
approve a biosimilar application if there is insufficient information to show that the active ingredients are the same or to demonstrate
that any impurities or differences in active ingredients do not affect the safety, purity or potency of the biosimilar product. In addition,
as with BLAs, biosimilar product applications will not be approved unless the product is manufactured in facilities designed to assure
and preserve the biological product&#8217;s safety, purity and potency.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">The submission of a biosimilar application
does not guarantee that the FDA will accept the application for filing and review, as the FDA may refuse to accept applications that it
finds are insufficiently complete. The FDA will treat a biosimilar application or supplement as incomplete if, among other reasons, any
applicable user fees assessed under the Biosimilar User Fee Act of 2012 have not been paid. In addition, the FDA may accept an application
for filing but deny approval on the basis that the sponsor has not demonstrated biosimilarity, in which case the sponsor may choose to
conduct further analytical, preclinical or clinical studies and submit a BLA for licensure as a new biological product.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">The timing of final FDA approval of a biosimilar
for commercial distribution depends on a variety of factors, including whether the manufacturer of the branded product is entitled to
one or more statutory exclusivity periods, during which time the FDA is prohibited from approving any products that are biosimilar to
the branded product. The FDA cannot approve a biosimilar application for twelve years from the date of first licensure of the reference
product.</div>

<div style="text-indent: 48.95pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">&#160;Additionally, a
biosimilar product sponsor may not submit an application for four years from the date of first licensure of the reference product. A reference
product may also be entitled to exclusivity under other statutory provisions. For example, a reference product designated for a rare disease
or condition (an orphan drug) may be entitled to seven years of exclusivity, in which case no product that is biosimilar to the reference
product may be approved until either the end of the twelve-year period provided under the biosimilarity statute or the end of the seven-year
orphan drug exclusivity period, whichever occurs later. In certain circumstances, a regulatory exclusivity period can extend beyond the
life of a patent, and thus block biosimilarity applications from being approved on or after the patent expiration date. In addition, the
FDA may under certain circumstances extend the exclusivity period for the reference product by an additional six months if the FDA requests,
and the manufacturer undertakes, studies on the effect of its product in children, a so-called pediatric extension.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">40</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Pediatric exclusivity
is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing
regulatory exclusivity periods. This six-month exclusivity may be granted based on the voluntary completion of a pediatric study in accordance
with an FDA-issued &#8220;Written Request&#8221; for such a study.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Post-approval
requirements</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Drugs and biologics manufactured
or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things,
requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting
of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other
labeling claims are subject to prior FDA review and approval. There are continuing, annual user fee requirements for any marketed products
and the establishments where such products are manufactured, as well as new application fees for supplemental applications with clinical
data.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA may impose a
number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including
Phase 4 clinical studies, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, drug and
biologic manufacturers and other entities involved in the manufacture and distribution of approved drugs and biologics are required to
register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these
state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior
FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements
and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to
use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain
cGMP compliance.</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Once an approval of a
drug or biologic is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained
or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse
events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies
to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include,
among other things:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfd482ae1df5f438ca2624ed11994c3f5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">Restrictions
        on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls</span><span style="font-family: Times New Roman,Times,serif">;</span></div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z45b139dd3f3b4e6e8271eed40066f775" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">Fines, warning
        letters or holds on post-approval clinical studies</span><span style="font-family: Times New Roman,Times,serif">;</span></div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5929cd5801a144ee9932f9a452528abb" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">Refusal of
        the FDA to approve pending NDAs or BLAs or supplements to approved NDAs or BLAs, or suspension or revocation of product approvals</span><span style="font-family: Times New Roman,Times,serif">;</span></div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8e437cce55114cac84133e8a4ac9ab0b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">Product seizure
        or detention, or refusal to permit the import or export of products</span><span style="font-family: Times New Roman,Times,serif">; and</span></div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0d676a473d7242aa97ef06cceb260b44" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">Injunctions
        or the imposition of civil or criminal penalties</span><span style="font-family: Times New Roman,Times,serif">.</span></div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">41</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA strictly regulates
marketing, labeling, advertising and promotion of products that are placed on the market. Drugs and biologics may be promoted by a manufacturer
and any third parties acting on behalf of a manufacturer only for the approved indications and in a manner consistent with the approved
label for the product. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses,
and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Other
healthcare laws</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Healthcare providers,
physicians, and third party payors play a primary role in the recommendation and prescription of drug products for which the Company obtains
marketing approval. Arrangements with third party payors, healthcare providers and physicians, in connection with the clinical research,
sales, marketing and promotion of products, once approved, and related activities, may expose a pharmaceutical manufacturer to broadly
applicable fraud and abuse and other healthcare laws and regulations. In the United States, these laws include, without limitation, state
and federal anti-kickback, physician self-referral prohibitions, false claims, physician transparency, and patient data privacy and security
laws and regulations, including but not limited to those described below:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2f2dc010757c4aa887afc64796e64dbf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">The federal Anti-Kickback Statute, or AKS, which makes it illegal for any person, including a prescription
        drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay any remuneration (including
        any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, that is intended to induce or reward,
        referrals including the purchase recommendation, order or prescription of a particular drug for which payment may be made under a federal
        healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute
        or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including
        items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes
        of the federal False Claims Act, or FCA;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2dd9f639549e4d9b877996fc1236b2f4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">The federal
        civil and criminal false claims laws, including the FCA, which can be enforced through &#8220;qui tam&#8221; or &#8220;whistleblower&#8221;
        actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things,
        knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal health care
        programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation
        to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing
        such an obligation. Similar to the AKS and Stark Law, a person or entity does not need to have actual knowledge of these statutes or specific
        intent to violate them in order to have committed a violation</span><span style="font-family: Times New Roman,Times,serif">;</span></div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z90127a3bddf3432ab53f90b9d6eee1ae" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">The federal
        Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit
        knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of
        false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of,
        any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or
        covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment
        for, healthcare benefits, items or services relating to healthcare matters</span><span style="font-family: Times New Roman,Times,serif">;</span></div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze0fc322181e544278e527b1c041d223a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009,
        or HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans,
        and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the creation,
        use, receipt, maintenance or disclosure of individually identifiable health information, relating to the privacy, security and transmission
        of individually identifiable health information;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">42</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z16c03b47788e4066b0430ad5c41030e6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">The federal
        Physician Payments Sunshine Act, created under Patient Protection and Affordable Care Act, as amended by the Health Care and Education
        Reconciliation Act of 2010, or collectively, the ACA, and its implementing regulations, which require manufacturers of drugs, devices,
        biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program
        to report annually to the Centers for Medicare and Medicaid Services, or CMS, under the Open Payments Program, information related to
        payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors),
        certain non-physician healthcare professionals (such as physician assistants and nurse practitioners, among others),&#160; and teaching
        hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span><span style="font-family: Times New Roman,Times,serif">
        and</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7463b44b6fa640a88d6543adac65d0f1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">Analogous
        state and foreign laws and regulations, such as state and foreign anti-kickback, physician self-referral prohibitions, false claims, consumer
        protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution,
        sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payor,
        including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary
        compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that
        may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with
        states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration
        and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical
        sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many
        of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts</span><span style="font-family: Times New Roman,Times,serif">.</span></div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Because of the breadth of these laws and the
narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of a pharmaceutical manufacturer&#8217;s
business activities could be subject to challenge under one or more of such laws. Efforts to ensure that business arrangements comply
with applicable healthcare laws involve substantial costs. It is possible that governmental and enforcement authorities will conclude
that a pharmaceutical manufacturer&#8217;s business practices do not comply with current or future statutes, regulations or case law interpreting
applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against a pharmaceutical manufacturer,
and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on its business, including
the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, imprisonment, monetary fines, possible
exclusion from participation in Medicare, Medicaid and other federal healthcare programs, reporting obligations and oversight if the Company
becomes subject to integrity and oversight agreements to resolve allegations of non-compliance, contractual damages, reputational harm,
diminished profits and future earnings, and curtailment of operations, any of which could adversely affect a pharmaceutical manufacturer&#8217;s
ability to operate its business and the results of operations. In addition, commercialization of any drug product outside the United States
will also likely be subject to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Prescription drug advertising is subject to
federal, state and foreign regulations. In the United States, the FDA regulates prescription drug promotion, including direct-to-consumer
advertising. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Any distribution
of prescription drug products and pharmaceutical samples must comply with the United States Prescription Drug Marketing Act, or PDMA,
a part of the FDCA. In addition, Title II of the Federal Drug Quality and Security Act of 2013, known as the Drug Supply Chain Security
Act, or DSCSA, has imposed new &#8220;track and trace&#8221; requirements on the distribution of prescription drug products by manufacturers,
distributors, and other entities in the drug supply chain. The DSCSA requires product identifiers (i.e., serialization) on prescription
drug products in order to eventually establish an electronic interoperable prescription product system to identify and trace certain prescription
drugs distributed in the United States and preempts existing state drug pedigree laws and regulations on this topic. The DSCSA also establishes
new requirements for the licensing of wholesale distributors and third-party logistic providers. The FDA is in the process of finalizing
regulations addressing national standards for the licensure of wholesale distributors and third-party logistics providers.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman, Times, serif; color: #000000; font-weight: normal; font-style: normal">43</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">In the United States, numerous federal and
state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state
consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information. For
example, in June&#160;2018, the State of California enacted the California Consumer Privacy Act of 2018, or the CCPA, which came into
effect on January&#160;1, 2020 and provides new data privacy rights for consumers and new operational requirements for companies, which
may increase the Company&#8217;s compliance costs and potential liability. The CCPA gives California residents expanded rights to access
and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their
personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches
that is expected to increase data breach litigation. While there is currently an exception for protected health information that is subject
to HIPAA and clinical study regulations, as currently written, the CCPA may impact certain of the Company&#8217;s business activities.
The CCPA could mark the beginning of a trend toward more stringent state privacy legislation in the United States, which could increase
the Company&#8217;s potential liability and adversely affect its business.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">In the event the Company decides to conduct
clinical studies or continue to enroll subjects in its ongoing or future clinical studies, the Company may be subject to additional privacy
restrictions. The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the European
Economic Area, or EEA, including personal health data, is subject to the EU General Data Protection Regulation, or GDPR, which became
effective on May&#160;25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal
data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the
personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the
security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party
processors. The GDPR also imposes strict rules&#160;on the transfer of personal data to countries outside the EEA, including the United
States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up
to &#8364;20&#160;million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data
subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for
damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR may
increase the Company&#8217;s responsibility and liability with respect to personal data that the Company processes where such processing
is subject to the GDPR, and it may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as
implemented by individual countries. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the Company&#8217;s
cost of doing business or require it to change its business practices, and despite those efforts, there is a risk that the Company may
be subject to fines and penalties, litigation, and reputational harm in connection with its European activities. Further, the United Kingdom&#8217;s
decision to leave the EU, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United
Kingdom and transfers of personal data to the UK and from the UK to both the EEA and countries outside the UK/EEA. For the time being,
transfers of personal data from the EU to the UK are covered by an adequacy decision of the EU Commission, and the UK has recently implemented
its own regime for safeguarding transfers from the UK to countries outside the UK/EEA which sit alongside the new EU safeguards which
were brought in during 2021.&#160; However, both the adequacy decision and the UK regime remain vulnerable to withdrawal or legal challenge.&#160;
Further both the new UK and EU personal data transfer regimes remain relatively untested and therefore impose risk that a transfer of
personal data and/or its subsequent processing would be held unlawful and give rise to liabilities from administrative fines and/or damages
claims from data subjects.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman, Times, serif; color: #000000; font-weight: normal; font-style: normal">44</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Current
and future healthcare reform legislation</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">In both the United States and certain foreign
jurisdictions, there have been a number of legislative and regulatory changes to the health care system. In particular, in 2010 the ACA
was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate
Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations,
subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that
increase the federal government&#8217;s comparative effectiveness research.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August&#160;2011,
the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on
Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the&#160;years 2013 through 2021,
was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This
includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in 2013, and, due to subsequent
legislative amendments, will remain in effect through 2031, </span><span style="font-family: Times New Roman,Times,serif; color: rgb(35, 31, 32)">with
the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020, through March 31, 2022.
Under current legislation, the actual reduction in Medicare payments can vary from 1% in 2022 to up to 4% in the final fiscal year of
this sequester. </span><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">The American Taxpayer Relief Act of
2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute
of limitations period for the government to recover overpayments to providers from three to five&#160;years. The Bipartisan Budget Act
of 2018, also amended the ACA, effective January&#160;1, 2019, by increasing the point-of-sale discount that is owed by pharmaceutical
manufacturers who participate in Medicare Part&#160;D and closing the coverage gap in most Medicare drug plans, commonly referred to as
the &#8220;donut hole&#8221;.</span></div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Additionally, there has been heightened governmental
scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. In
August 2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications
for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price
for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the
drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if
their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for
beneficiaries, among other changes. The impact of these legislative, executive, and administrative actions and any future healthcare measures
and agency rules implemented by the Biden administration on us and the pharmaceutical industry as a whole is unclear. The implementation
of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or
commercialize any of the product candidates for which we receive approval. At the state level, legislatures have increasingly passed legislation
and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints,
discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed
to encourage importation from other countries and bulk purchasing.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Legislative and regulatory proposals, and
enactment of laws, at the foreign, federal and state levels, directed at containing or lowering the cost of healthcare, will continue
into the future.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Rest
of World Regulation</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">For other countries outside of the European
Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing product development,
the conduct of clinical studies, manufacturing, distribution, marketing approval, product licensing, pricing and reimbursement vary from
country to country. Additionally, clinical studies must be conducted in accordance with GCP requirements and the applicable regulatory
requirements and the ethical principles that have their origin in the Declaration of Helsinki.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman, Times, serif; color: #000000; font-weight: normal; font-style: normal">45</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">If the Company fails to comply with applicable
foreign regulatory requirements, the Company may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals,
product recalls, seizure of products, operating restrictions and criminal prosecution.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Additionally, to the extent that any of the
Company&#8217;s product candidates, once approved, are sold in a foreign country, it may be subject to applicable post-marketing requirements,
including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments
or other transfers of value to healthcare professionals.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Coverage
and reimbursement</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Successful commercialization of new drug products
depends in part on the extent to which reimbursement for those drug products will be available from government health administration authorities,
private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health
maintenance organizations, decide which drug products they will pay for and establish reimbursement levels. The availability and extent
of reimbursement by governmental and private payors is essential for most patients to be able to afford a drug product. Sales of drug
products depend substantially, both domestically and abroad, on the extent to which the costs of drugs products are paid for by health
maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration
authorities, private health coverage insurers and other third-party payors.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">A primary trend in the United States healthcare
industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting
coverage and the amount of reimbursement for particular drug products. In many countries, the prices of drug products are subject to varying
price control mechanisms as part of national health systems. In general, the prices of drug products under such systems are substantially
lower than in the United States. Other countries allow companies to fix their own prices for drug products, but monitor and control company
profits. Accordingly, in markets outside the United States, the reimbursement for drug products may be reduced compared with the United
States.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">In the United States, the principal decisions
about reimbursement for new drug products are typically made by CMS, an agency within the U.S. Department of Health and Human Services.
CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors tend to follow
CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists among third-party payors
and coverage and reimbursement levels for drug products can differ significantly from payor to payor.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">The Medicare Prescription Drug,&#160;Improvement,
and Modernization Act of 2003, or the MMA, established the Medicare Part&#160;D program to provide a voluntary prescription drug benefit
to Medicare beneficiaries. Under Part&#160;D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities
that provide coverage of outpatient prescription drugs. While all Medicare drug plans must give at least a standard level of coverage
set by Medicare, Part&#160;D prescription drug plan sponsors are not required to pay for all covered Part&#160;D drugs, and each Part&#160;D
prescription drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However,
Part&#160;D prescription drug formularies must include drugs within each therapeutic category and class of covered Part&#160;D drugs,
though not necessarily all the drugs in each category or class. Any formulary used by a Part&#160;D prescription drug plan must be developed
and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand
for drugs for which the Company obtains marketing approval. Any negotiated prices for any of the Company&#8217;s products covered by a
Part&#160;D prescription drug plan will likely be lower than the prices it might otherwise obtain. Moreover, while the MMA applies only
to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their
own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental
payors.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman, Times, serif; color: #000000; font-weight: normal; font-style: normal">46</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">For a drug product to receive federal reimbursement
under the Medicaid or Medicare Part&#160;B programs or to be sold directly to United States government agencies, the manufacturer must
extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is
calculated based on the average manufacturer price, or AMP, and Medicaid rebate amounts reported by the manufacturer. As of 2010, the
ACA expanded the types of entities eligible to receive discounted 340B pricing, although under the current state of the law these newly
eligible entities (with the exception of children&#8217;s hospitals) will not be eligible to receive discounted 340B pricing on orphan
drugs. As 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP
definition described above could cause the required 340B discount to increase. If third-party payors do not consider the Company&#8217;s
drugs to be cost-effective compared to other available therapies, they may not cover the Company&#8217;s drugs after approval as a benefit
under their plans or, if they do, the level of payment may not be sufficient to allow the Company to sell its drugs on a profitable basis.</div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">These laws, and state and federal healthcare
reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding and otherwise
affect the prices the Company may obtain for any product candidates for which it may obtain regulatory approval or the frequency with
which any such product candidate is prescribed or used.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Outside of the United States, the pricing
of pharmaceutical products and medical devices is subject to governmental control in many countries. For example, in the European Union,
pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after
a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness
of a particular therapy to currently available therapies or so-called health technology assessments, in order to obtain reimbursement
or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes
and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products and medical
devices will likely continue as countries attempt to manage healthcare expenditures.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Employees
and Human Capital Resources</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">As
of December 31, 2022, the Company had 37 full-time employees/consultants, including 10 with Ph.D. or M.D. degrees and 13 who are engaged
in research and development activities. The Company is dependent on its management and scientific personnel, and it is crucial that it
continues to attract and retain valuable employees. To facilitate attraction and retention, the Company strives to make itself an inclusive
and safe workplace, with opportunities for its employees to grow and develop in their careers, supported by strong compensation and benefits
programs. None of the Company&#8217;s employees are represented by labor unions or covered by collective bargaining agreements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Corporate
Information and History</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,serif; text-indent: 18pt"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family: Times New Roman,Times,serif">We
were incorporated on September 22, 2011, under the laws of the State of Israel. In March 2021, in connection with the Merger, we changed
our name from Anchiano Therapeutics Ltd. to Chemomab Therapeutics Ltd. Our principal executive offices are located at Kiryat Atidim, Building
7, Tel Aviv, Israel 6158002, and our phone number is +972-77-331-0156. Our website is:&#160;<span style="font-style: italic">www.chemomab.com.</span>&#160;The
information contained on, or that can be accessed through, our website is not incorporated by reference into this Annual Report.</span></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Available Information</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our investor relations
website is<span style="font-style: italic"> https://investors.chemomab.com/</span>. We promptly make available on our investor relations
website, free of charge, the reports that we file or furnish with the SEC, corporate governance information (including our Code of Business
Conduct and Ethics) and all press releases. We file annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form
8-K, proxy and information statements and amendments to reports filed or furnished pursuant to the Exchange Act. The SEC maintains a website
at www.sec.gov that contains reports, proxy and information statements and other information regarding Chemomab and other issuers that
file electronically with the SEC.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">47</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold"><span id="Item1A."><!--Anchor--></span>Item
1A. </span><span style="font-family: Times New Roman,Times,serif"><span style="font-weight: bold">Risk Factors</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">&#160;You
should consider carefully the following information about the risks described below, together with the other information contained in
this Annual Report on Form 10-K and in our other public filings, in evaluating our business. If any of the following risks actually occurs,
our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected.
In these circumstances, the market price of our common stock would likely decline.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Risks Related to Chemomab&#8217;s
Business, Research and Development and the Biopharmaceutical Industry</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemomab
has a limited operating history and funding, which may make it difficult to evaluate its prospects and likelihood of success.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;Chemomab is a clinical-stage
biopharmaceutical company with a limited operating history. Chemomab was incorporated in 2015, has no products approved for commercial
sale and has not generated any revenue. Its operations to date have been limited to organizing and staffing the company, business planning,
raising capital, establishing its intellectual property portfolio and conducting research and development of its product candidates, technology
related to CCL24 and novel therapies for the treatment of inflammation and fibrosis. Chemomab&#8217;s approach to the discovery and development
of product candidates is unproven, and Chemomab does not know whether it will be able to develop any products of commercial value. In
addition, Chemomab&#8217;s lead product candidate, CM-101, is in early clinical development for the treatment of PSC and SSc. The clinical
programs will require substantial additional development and clinical research, both in time and resources, before Chemomab is in a position
to apply for or receive regulatory approvals and begin generating revenue in connection with the sale of such product candidates. Chemomab
has not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture
a commercial scale product, or arrange for a third party to do so on its behalf, or conduct sales and marketing activities necessary for
successful product commercialization. Consequently, predictions about Chemomab&#8217;s future success or viability may not be as accurate
as they could be if Chemomab had a longer operating history or a history of successfully developing and commercializing pharmaceutical
products.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;In addition, as
a business with a limited operating history, Chemomab may encounter unforeseen expenses, difficulties, complications, delays and other
known or unknown factors and risks frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields. Consequently,
Chemomab has no meaningful history of operations upon which to evaluate its business, and predictions about its future success or viability
may not be as accurate as they could be if Chemomab had a longer operating history or a history of successfully developing and commercializing
drug products. Chemomab will eventually need to transition from a company with a research and development focus to a company capable of
supporting commercial activities. Chemomab may not be successful in such a transition and, as a result, its business may be adversely
affected.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;As Chemomab continues
to build its business, it expects its financial condition and operating results to fluctuate significantly from quarter to quarter and
year to year due to a variety of factors, many of which are beyond Chemomab&#8217;s control.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemomab&#8217;s
business is highly dependent on the success of its lead product candidate, CM-101, and any other product candidates that it advances into
clinical studies. All of Chemomab&#8217;s programs will require significant additional clinical development.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;Chemomab currently
has no products that are approved for commercial sale and may never be able to develop marketable products. Chemomab is very early in
its development efforts and has only one product candidate, CM-101, in early clinical development. Because CM-101 is Chemomab&#8217;s
lead product candidate, if CM-101 encounters safety or efficacy problems, development delays, regulatory issues or other problems, Chemomab&#8217;s
development plans and business would be significantly harmed. Chemomab has completed a Phase 1a SAD study with healthy volunteers, a Phase
1b MAD study of CM-101 in non-alcoholic fatty liver disease, or NAFLD, a Phase 2a safety, Pk and liver fibrosis biomarker study in NASH
patients, an open-label exploratory study in severe lung injury in hospitalized COVID-19 patients and is recruiting patients in a Phase
2 PSC trial. Chemomab plans to initiate a Phase 2 SSc study around midyear of 2023.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">48</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">Chemomab expects that
a substantial portion of its efforts and expenditures over the next few years will be devoted to CM-101, which will require additional
clinical development, management of clinical and manufacturing activities, regulatory approval in multiple jurisdictions, obtaining manufacturing
supply, building of a commercial organization, substantial investment and significant marketing efforts before it can generate any revenues
from any commercial sales. Chemomab cannot be certain that it will be able to successfully complete any of these activities. In addition,
if one or more of Chemomab&#8217;s product candidates are approved, Chemomab may need to ensure access to sufficient commercial manufacturing
capacity and conduct significant marketing efforts in connection with any commercial launch. These efforts will require substantial investment,
and Chemomab may not have the financial resources to continue the development of its product candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemomab
will need to raise substantial additional funds through public or private equity or debt transactions and/or complete one or more strategic
transactions or partnerships, to complete development of CM-101 or any other product candidates. If Chemomab is unable to raise such financing
or complete such a transaction, it may not be able to fund the clinical trials of its product candidates and potentially commercialize
those product candidates.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; text-indent: 36pt">As
a result of the expected development timeline to potentially obtain FDA approval for CM-101, the substantial additional costs associated
with the development of our product candidates, including the costs associated with clinical trials related thereto, and the substantial
cost of commercializing CM-101, Chemomab will need to raise substantial additional funding through public or private equity or debt transactions
or a strategic combination or partnership. If Chemomab is delayed in obtaining funding or is unable to complete a strategic transaction,
Chemomab may have to delay or discontinue development activities on CM-101 and our other product candidates. Even if Chemomab is able
to fund continued development of CM-101 or any of our other product candidates is approved, Chemomab expects that it will need to raise
substantial additional funding through public or private equity or debt securities or complete a strategic transaction or partnership
to successfully commercialize CM-101 or any other product candidate.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; text-indent: 36pt">

<div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">Chemomab believes its cash and
cash equivalents and bank deposits as of December 31, 2022 will be sufficient to fund its operations at least through March 31, 2024.
Sales of Chemomab&#8217;s ADSs dilute the ownership interest of its shareholders and may cause the price per ADS to decrease. Changing
circumstances may cause us to consume capital significantly faster or slower than Chemomab currently anticipates. Chemomab has based these
estimates on assumptions that may prove to be wrong, and Chemomab could exhaust its available financial resources sooner than currently
anticipated.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; text-indent: 36pt">Chemomab&#8217;s
liquidity, and ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but
not limited to, the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5e7a1e435414486ab8f6dd7465442ff2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; color: #000000">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">the costs and timing for potential additional clinical trials in order to gain possible regulatory approval
        for CM-101and our other product candidates;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z529ca32df3e34fba9c71785deb184e09" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; color: #000000">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">the market price of Chemomab&#8217;s ADSs and the availability and cost of additional equity capital
        from existing and potential new investors;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8b3ffda48d2740c489d2150257d90883" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; color: #000000">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">Chemomab&#8217;s ability to retain the listing of its ADSs on the Nasdaq Capital Market;</div> </td>
        </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman, Times, serif; color: #000000; font-weight: normal; font-style: normal">49</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za3cb467d78ef4a609dba911693b9df5a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; color: #000000">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">general economic and industry conditions affecting the availability and cost of capital, including as
        a result of deteriorating market conditions due to investor concerns regarding inflation and continued hostilities between Russia and
        Ukraine;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za0e06853855e4bcaac7f272af3bccfd8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; color: #000000">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">Chemomab&#8217;s ability to control costs associated with its operations;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4d94f8cbdcae4747a9eb383350e33786" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; color: #000000">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property
        rights; and</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc2d02bc1ad8b483d9da83b81facc771b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; color: #000000">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">the terms and conditions of our existing collaborative and licensing agreements.</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">The
sale of additional equity or convertible debt securities would likely result in substantial dilution to our stockholders. If Chemomab
raise additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights
of holders of our capital stock and could contain covenants that would restrict our operations. Chemomab also cannot predict what consideration
might be available, if any, to us or our stockholders, in connection with any strategic transaction. Should strategic alternatives or
additional capital not be available to us, or not be available on acceptable terms, Chemomab may be unable to realize value from its assets
and discharge its liabilities in the normal course of business which may, among other alternatives, cause Chemomab to further delay, substantially
reduce or discontinue operational activities to conserve our cash resources.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemomab&#8217;s
approach in the area of fibrotic diseases is novel and unproven and may not result in marketable products.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab&#8217;s central
objective is to design and develop targeted treatments for inflammation and fibrosis with an initial focus on the neutralization of CCL24
signaling, which is known to regulate fibrotic and inflammatory processes. While several studies are currently underway, this mechanism
has not yet been definitively proven to successfully treat inflammation and fibrosis. Targeting CCL24 to treat inflammation and fibrosis
is a novel approach in a rapidly developing field, and there can be no assurance that Chemomab can avoid unforeseen problems or delays
in the development of its product candidates, that such problems or delays will not result in unanticipated costs, or that any such development
problems can or will be solved. Chemomab has only tested its lead product candidate, CM-101, in early trials in healthy volunteers, NAFLD,
NASH and COVID-19 lung injury patients. Therefore, Chemomab may ultimately discover that its approach does not possess properties required
for therapeutic effectiveness. As a result, Chemomab may elect to abandon the program or never succeed in developing a marketable product,
which would have a significant effect on the success and profitability of its business.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Clinical
development involves a lengthy, complex and expensive process, with an uncertain outcome.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Before obtaining the
requisite regulatory approvals from the FDA or other comparable foreign regulatory authorities for the sale of any of its product candidates,
Chemomab must support its application with clinical studies that prove that such product candidate is safe and effective in humans. Clinical
testing is expensive and can take many years to complete, and its outcome is inherently uncertain. In particular, the general approach
for FDA approval of a new drug requires positive data from two well-controlled Phase 3 clinical studies of the relevant drug in the relevant
patient population. Failure can occur at any time during the clinical study process. Chemomab may experience delays in initiating and
completing any clinical studies that it is conducting or intends to conduct, including as a result of the COVID-19 pandemic or other public
health emergencies, and Chemomab does not know whether its ongoing or planned clinical studies will begin or progress on schedule, need
to be redesigned, enroll patients on time or be completed on schedule, or at all.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">50</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Phase 3 clinical studies
typically involve hundreds of patients, have significant costs and take years to complete. A product candidate can fail at any stage of
testing, even after observing promising signals of activity in earlier preclinical studies or clinical trials. The results of preclinical
studies and early clinical trials of Chemomab&#8217;s product candidates may not be predictive of the results of later-stage clinical
studies. In addition, initial or interim success in clinical studies may not be indicative of results obtained when such studies are completed.
There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical studies. Product
candidates in later stages of clinical studies may fail to show the desired safety and efficacy profile despite having progressed through
preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks
in advanced clinical studies due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier studies.
Most product candidates that commence clinical studies are never approved as products and there can be no assurance that any of Chemomab&#8217;s
future clinical studies will ultimately be successful or support further clinical development of CM-101. Product candidates that appear
promising in the early phases of development may fail to reach the market for several reasons, including:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zac2d3bf7a861485f9853268876967c46" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the FDA or comparable
        foreign regulatory authorities disagreeing as to the design or implementation of Chemomab&#8217;s clinical studies;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">obtaining regulatory
        authorizations to commence a trial or consensus with regulatory authorities on trial&#8217;s design;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">reaching an agreement
        on acceptable terms with prospective clinical research organizations, or CROs, and clinical trial sites, the terms of which can be subject
        to extensive negotiation and may vary significantly among different CROs and trial sites;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">obtaining IRB approval
        at each site, or Independent Ethics Committee, or IEC, approval at sites outside the United States;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">imposition of a clinical
        hold by regulatory authorities, including as a result of unforeseen safety issues or side effects or failure of trial sites to adhere
        to regulatory requirements or follow trial protocols;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">clinical studies may
        show the product candidates to be less effective than expected (e.g., a clinical study could fail to meet its primary endpoint(s)) or
        to have unacceptable side effects or toxicities;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">failure to establish
        clinical endpoints that applicable regulatory authorities would consider clinically meaningful;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the occurrence of serious
        adverse events in trials of the same class of agents conducted by other companies;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">adding a sufficient
        number of clinical study sites;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">manufacturing sufficient
        quantities of product candidate with sufficient quality for use in clinical studies;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">having patients complete
        a trial or return for post-treatment follow-up;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">recruiting suitable
        patients to participate in a trial in a timely manner and in sufficient numbers;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">a facility manufacturing
        Chemomab&#8217;s product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to
        temporarily or permanently shut down due to violations of current good manufacturing practice, or cGMP, regulations or other applicable
        requirements, or infections or cross-contaminations of product candidates in the manufacturing process;</div> </td> </tr>
  </table>

<div><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">51</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">third-party clinical
        investigators losing the licenses or permits necessary to perform Chemomab&#8217;s clinical studies, not performing its clinical studies
        on its anticipated schedule or consistent with the clinical study protocol, GCP, or other regulatory requirements;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">third-party contractors
        not performing data collection or analysis in a timely or accurate manner;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">manufacturing costs,
        formulation issues, pricing or reimbursement issues, or other factors that make a product candidate uneconomical; or</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the proprietary rights
        of others and their competing products and technologies that may prevent Chemomab&#8217;s product candidates from being commercialized.</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, differences
in trial design between early-stage clinical studies and later-stage clinical studies make it difficult to extrapolate the results of
earlier clinical studies to later clinical studies. Moreover, clinical data are often susceptible to varying interpretations and analyses,
and many companies that have believed their product candidates performed satisfactorily in clinical studies have nonetheless failed to
obtain marketing approval of their products.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, the standards
used by the FDA and comparable foreign regulatory authorities when regulating Chemomab require judgment and can change, which makes it
difficult to predict with certainty how they will be applied. For more information, see &#8220;<span style="font-style: italic">Risk Factors
- Risks Related to Chemomab&#8217;s Regulatory Approvals.&#8221;</span></div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Successful completion
of clinical studies is a prerequisite to submitting a marketing application to the FDA and similar marketing applications to comparable
foreign regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product
candidates. Chemomab may experience negative or inconclusive results, which may result in it deciding, or it being required by regulators,
to conduct additional clinical studies or trials or abandon some or all of its product development programs, which could have a material
adverse effect on Chemomab&#8217;s business.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemomab
may incur additional costs or experience delays in completing the development and commercialization of CM-101 or any other product candidates.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab may experience
delays in initiating or completing clinical studies. It also may experience numerous unforeseen events during, or as a result of, any
future clinical studies that could delay or prevent its ability to receive marketing approval or commercialize CM-101 or any other product
candidates, including:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd7460b8d8e4b4d0da1e39b4a4aba912a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">regulators, IRBs, or
        IECs may not authorize Chemomab or its investigators to commence a clinical study or conduct a clinical study at a prospective trial site;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif"> <br /> </div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the FDA or other comparable
        regulatory authorities may disagree with Chemomab&#8217;s clinical study design, including with respect to dosing levels administered
        in its planned clinical studies, which may delay or prevent Chemomab from initiating its clinical studies with its originally intended
        trial design;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Chemomab may experience delays in reaching, or fail to reach,
        agreement on acceptable terms with prospective trial sites and prospective CROs, which can be subject to extensive negotiation and may
        vary significantly among different CROs and trial sites;</div> </td> </tr>
  </table>

<div><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">52</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">the number of subjects required for clinical studies of any product
        candidates may be larger than Chemomab anticipates or subjects may drop out of these clinical studies or fail to return for post-treatment
        follow-up at a higher rate than it anticipates;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)"> <br /> </div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Chemomab&#8217;s third-party contractors may fail to comply with
        regulatory requirements or meet its contractual obligations to Chemomab in a timely manner, or at all, or may deviate from the clinical
        study protocol or drop out of the trial, which may require that Chemomab add new clinical study sites or investigators;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)"> <br /> </div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">due to the impact of the COVID-19 pandemic, or other emerging
        public health threats, Chemomab has experienced, and may continue to experience, delays and interruptions to clinical studies, it may
        experience delays or interruptions to its manufacturing supply chain, or it could suffer delays in reaching, or it may fail to reach,
        agreement on acceptable terms with third-party service providers on whom it relies;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)"> <br /> </div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">additional delays and interruptions to Chemomab&#8217;s clinical
        studies could extend the duration of the trials and increase the overall costs to finish the trials as its fixed costs are not substantially
        reduced during delays;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)"> <br /> </div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Chemomab may elect to, or regulators, IRBs, Data Safety Monitoring
        Boards or ethics committees may require that it or its investigators, suspend or terminate clinical research or trials for various reasons,
        including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)"> <br /> </div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Chemomab may not have the financial resources available to begin
        and complete the planned trials, or the cost of clinical studies of any product candidates may be greater than it anticipates; and</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)"> <br /> </div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226; <br /> </div>
        </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">the supply or quality of Chemomab&#8217;s product candidates
        or other materials necessary to conduct clinical studies of its product candidates may be insufficient or inadequate to initiate or complete
        a given clinical study.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab&#8217;s product
development costs will increase if it experiences additional delays in clinical testing or in obtaining marketing approvals. Chemomab
does not know whether any of its clinical studies will begin as planned, will need to be restructured or will be completed on schedule,
or at all. If Chemomab does not achieve its product development goals in the time frames it announces and expects, the approval and commercialization
of its product candidates may be delayed or prevented entirely. Significant clinical study delays also could shorten any periods during
which it may have the exclusive right to commercialize its product candidates and may allow its competitors to bring products to market
before Chemomab does, potentially impairing its ability to successfully commercialize its product candidates and harming its business
and results of operations. Any delays in Chemomab&#8217;s clinical development programs may harm its business, financial condition and
results of operations significantly.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemomab&#8217;s
ongoing and future clinical studies may reveal significant adverse events or immunogenicity related responses and may result in a safety
profile that could delay or prevent regulatory approval or market acceptance of its product candidate.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab completed its
Phase 1a and Phase 1b and Phase 2a clinical studies of its lead product candidate, CM-101, in healthy volunteers, NAFLD, NASH and COVID-19
lung injury patients, and, with the exception of a number of reported minor adverse events (including mild headaches, changes in blood
pressure and mild-moderate increases in liver enzymes,) and one serious adverse event (a transient ischemic attack or seizure judged to
be unrelated to administration of CM-101), CM-101 was observed to be generally well-tolerated across all doses in about 70 trial participants.
Some potential therapeutics developed in the biopharmaceutical industry that initially showed therapeutic promise in early-stage trials
have later been found to cause side effects that prevented their further development and ultimately commercialization. Even if side effects
do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance
of the approved product due to its tolerability versus other therapies.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">53</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Protein biopharmaceuticals,
including, monoclonal antibodies, or mAbs, may be immunogenic and promote immune responses against themselves. In particular, anti-drug
antibodies, or ADAs, may be produced by patients following infusion mAbs and may disturb the pharmacokinetics of mAbs, neutralize their
therapeutic activities or induce allergic or autoimmune symptoms. Clinical immunogenicity can range from mild, transient antibody responses
with no apparent clinical manifestations to loss of therapeutic efficacy and even life-threatening reactions. Several approved therapeutic
antibodies have been found to induce neutralizing antibodies, as illustrated by the approved anti-TNFa antibodies infliximab and adalimumab
as well as the approved anti-IL-17 mAb ixekizumab. Chemomab&#8217;s product candidate, CM-101, is a humanized antibody that, similar to
other humanized approved mAbs, was shown to include several non-germline sequences that may serve as a source for immunogenicity in therapeutic
antibodies. Clinical studies to date have not identified any anti-drug antibodies, or ADAs. Additional larger clinical studies will be
needed to address the risk of immunogenicity and, if discovered, Chemomab&#8217;s business will be materially and adversely affected.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Additionally, if unacceptable
side effects, including materialized risks of immunogenicity, do arise in the development of Chemomab&#8217;s product candidates, Chemomab,
the FDA or the IRBs at the institutions in which its studies are conducted, or the Data Safety Monitoring Board, if constituted for its
clinical studies, could recommend a suspension or termination of Chemomab&#8217;s clinical studies, or the FDA or comparable foreign regulatory
authorities could order Chemomab to cease further development of or deny approval of a product candidate for any or all targeted indications.
In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result
in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating
medical staff. Chemomab expects to have to train medical personnel using its product candidates to understand the side effect profiles
for its clinical studies and upon any commercialization of any of its product candidates. Inadequate training in recognizing or managing
the potential side effects of its product candidates could result in patient injury or death. Any of these occurrences may harm Chemomab&#8217;s
business, financial condition and prospects significantly.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Additionally, if one
or more of Chemomab&#8217;s product candidates receives marketing approval, and Chemomab or others later identify undesirable side effects
caused by such products, a number of potentially significant negative consequences could result, including:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6f64e235f8304e25aad05cf837c3b6e1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">regulatory authorities may withdraw approvals of such product;</div>
        </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">regulatory authorities may require additional warnings on the
        label, such as a &#8220;black box&#8221; warning or contraindication;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zfbdd723b7f734d4fbaedf2b3ff2a2d11" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">additional restrictions may be imposed on the marketing of the
        particular product or the manufacturing processes for the product or any component thereof;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Chemomab may be required to implement a Risk Evaluation and Mitigation
        Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)"> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Chemomab could be sued and held liable for harm caused to patients;</div>
        </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the product may become
        less competitive; and</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Chemomab&#8217;s reputation
        may suffer.</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">54</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Any of these events could
prevent Chemomab from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm Chemomab&#8217;s
business, results of operations and prospects.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Interim,
topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become
available or as additional analyses are conducted and are subject to audit and verification procedures that could result in material changes
in the final data.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">From time to time, we
may publicly disclose preliminary, interim or topline data from our clinical trials. The preliminary data is based on a preliminary analysis
of then available data, and the results and related findings and conclusions are subject to change following a more comprehensive review
of the data related to the particular study or trial. For example, we may report tumor responses in certain patients that are unconfirmed
at the time and which do not ultimately result in confirmed responses to treatment after follow-up evaluations. We also make assumptions,
estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully
and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or
different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline
data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary
data we previously published. As a result, topline data should be viewed with caution until the final data are available. In addition,
we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete
are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient
data become available. Adverse changes between interim data and final data could significantly harm our business and prospects. Further,
additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our common
stock.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">In addition, the information
we choose to publicly disclose regarding a particular clinical trial is typically selected from a more extensive amount of available information.
You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure,
and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views,
activities or otherwise regarding a particular product candidate or our business. If the preliminary or topline data that we report differ
from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability
to obtain approval for any product candidates that we may develop in the future may be harmed, which could harm our business, financial
condition, results of operations and prospects.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Changes
in methods of product candidate manufacturing or formulation may result in additional costs or delay.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">As product candidates
progress through preclinical studies and clinical trials to regulatory approval and commercialization, it is common that various aspects
of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and
manufacturing batch size, minimize costs and achieve consistent quality and results. Any material manufacturing changes made to any product
candidate that we may develop could perform differently and affect the results of planned clinical trials or other clinical trials conducted
with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition
of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to
commercialize any product candidates that we may develop in the future, if approved, and generate revenue.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">55</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">If
Chemomab encounters difficulties enrolling patients in its clinical studies, including due to COVID-19 or other public health emergencies,
its clinical development activities could be delayed or otherwise adversely affected.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab may experience
difficulties in patient enrollment in its clinical studies for a variety of reasons. The timely completion of clinical studies in accordance
with its protocols depends, among other things, on Chemomab&#8217;s ability to enroll a sufficient number of patients who remain in the
trial until its conclusion. The enrollment of patients depends on many factors, including:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z820f16711b864d53ac04f6102e7d978c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the patient eligibility
        and exclusion criteria defined in the protocol;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif"><br /> </div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td rowspan="1" style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the need to receive
        study drug via an IV infusion;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif"> <br /> </div> </td>
        </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the size of the patient
        population required for analysis of the trial&#8217;s primary endpoints and the process for identifying patients;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the willingness or
        availability of patients to participate in Chemomab&#8217;s trials (including due to fears of contracting COVID-19);</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the proximity of patients
        to trial sites;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the design of the trial;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Chemomab&#8217;s ability
        to recruit clinical study investigators with the appropriate competencies and experience;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">clinicians&#8217; and
        patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied with respect to other available
        therapies, including any new products that may be approved for the indications Chemomab is investigating;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the availability of
        competing commercially available therapies and other competing product candidates&#8217; clinical studies;</div> </td> </tr>
  </table>

<div> <br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">56</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" id="z847a899eb2a24df08474391b92b861be" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Chemomab&#8217;s ability to obtain and maintain patient informed
        consents; and</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the risk that patients
        enrolled in clinical studies will drop out of the trials before completion.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Further, timely enrollment
in clinical studies is reliant on clinical study sites which may be adversely affected by global health matters, including, among other
things, pandemics. For example, Chemomab&#8217;s clinical study sites have been affected by the COVID-19 pandemic. Commencement of the
enrollment of Chemomab&#8217;s clinical studies of CM-101 in PSC had been delayed due to the pandemic.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Some factors from a resurgent
COVID-19 pandemic or other emerging public health emergencies that Chemomab believes could potentially adversely affect enrollment in
its trials include:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z455ba115a3a34dd3969a9c3e336a13ca" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the diversion of healthcare
        resources away from the conduct of clinical study matters to focus on pandemic concerns, including the attention of infectious disease
        physicians serving as Chemomab&#8217;s clinical study investigators, hospitals serving as Chemomab&#8217;s clinical study sites and hospital
        staff supporting the conduct of its clinical studies;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the inability of patients
        to come to hospitals to participate in Chemomab&#8217;s trials, which may force Chemomab to conduct its trials in patients&#8217; homes,
        rendering the trials more difficult and costly to conduct;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">limitations on travel
        that interrupt key trial activities, such as clinical study site initiations and monitoring; and</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">employee furlough days
        that delay necessary interactions with local regulators, ethics committees and other important agencies and contractors.</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">These and other factors
arising from a resurgent COVID-19 pandemic or other emerging public health emergencies could adversely impact Chemomab&#8217;s clinical
studies.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">The
market opportunities for CM-101, if approved, may be smaller than Chemomab anticipates.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab expects to initially
seek approval of CM-101 for the treatment of PSC and SSc. Its projections of the number of PSC and SSc patients is based on its beliefs
and estimates. These estimates have been derived from a variety of sources, including scientific literature, patient foundations and publicly
available databases, and may prove to be incorrect. Further, new sources may reveal a change in the estimated number of patients, and
the number of patients may turn out to be lower than Chemomab expected. The potential addressable patient population for Chemomab&#8217;s
current programs or future product candidates may be limited. The ultimate market opportunity for Chemomab&#8217;s product candidates
will depend on, among other things, the final labeling for such product candidates as agreed with the FDA or comparable foreign regulatory
authorities, acceptance by the medical community and patient access, potential competition and drug pricing and reimbursement. Even if
Chemomab obtains significant market share for any product candidate, if approved, if the potential target populations are small, Chemomab
may never achieve profitability without obtaining marketing approval for additional indications.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemomab
may not be successful in its efforts to identify or discover additional product candidates in the future.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab&#8217;s research
programs may initially show promise in identifying potential product candidates, yet may fail to yield product candidates for clinical
development for a number of reasons, including:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4a557d829aa94f24ad436c473dcc4b00" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Chemomab&#8217;s inability
        to design such product candidates with the pharmacological properties that it desires or attractive pharmacokinetics; or</div> </td> </tr>
  </table>

<div><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">57</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">potential product candidates
        may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be medicines
        that will receive marketing approval and achieve market acceptance.</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Research programs to
identify new product candidates require substantial technical, financial and human resources. If Chemomab is unable to identify suitable
compounds for preclinical and clinical development, it will not be able to obtain product revenue in future periods, which likely would
result in significant harm to Chemomab&#8217;s financial position and adversely impact the price of its ADSs.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Certain
of Chemomab&#8217;s key strategic initiatives, including investing in the internal discovery of new product candidates and in-licensing
or acquiring new assets to expand Chemomab&#8217;s current pipeline, involve various risks that may impair Chemomab&#8217;s ability to
actualize the foregoing strategies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z526e89ef78ec4c128360305981981d79" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<br /> <span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">The competitive landscape
        for in-licensing or acquiring assets in the biopharmaceutical sector is intense with several companies employing this growth and diversification
        strategy.</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<br /> <span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Even if appropriate
        assets are identified, there can be no assurance that a potential transaction can be consummated between the parties.</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif"><br />
        &#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">If a transaction is
        concluded on acceptable terms, there can be assurance that the assets in-licensed or acquired will be successful in preclinical and subsequent
        clinical development.</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: middle">
        <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><br /> </div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">The Company will likely
        need to raise additional capital to close any transaction of significance. As such, there can be no assurance that a fundraising effort
        will be successful and if successful, it could result in dilution to current shareholders.</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">
<br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Due
to Chemomab&#8217;s limited resources and access to capital, it must make decisions on the allocation of resources to certain programs
and product candidates; these decisions may prove to be wrong and may adversely affect Chemomab&#8217;s business.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab has limited
financial and human resources and intends to initially focus on research programs and product candidates for a limited set of indications.
As a result, Chemomab may forgo or delay pursuit of opportunities with other product candidates or for other indications that later prove
to have greater commercial potential or a greater likelihood of success.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">There can be no assurance
that Chemomab will ever be able to identify additional therapeutic opportunities for its product candidates or to develop suitable potential
product candidates through internal research programs, which could materially adversely affect its future growth and prospects. Chemomab
may focus its efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">If
product liability lawsuits are brought against Chemomab, it may incur substantial financial or other liabilities and may be required to
limit commercialization of its product candidates.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab faces an inherent
risk of product liability as a result of testing CM-101, and will face an even greater risk if Chemomab commercializes any products. For
example, Chemomab may be sued if any of its product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable
during clinical studies, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing,
defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims
could also be asserted under state consumer protection acts. If Chemomab cannot successfully defend itself against product liability claims,
it may incur substantial liabilities or be required to limit commercialization of its product candidates. Even successful defense would
require significant financial and management resources. Chemomab&#8217;s inability to obtain sufficient product liability insurance at
an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products Chemomab
develops. Chemomab will need to obtain additional insurance for clinical studies as it continues clinical development of CM-101 and as
additional product candidates enter clinical studies. However, Chemomab may be unable to obtain, or may obtain on unfavorable terms, clinical
study insurance in amounts adequate to cover any liabilities from any of its clinical studies. Chemomab&#8217;s insurance policies may
also have various exclusions, and Chemomab may be subject to a product liability claim for which it has no coverage. Chemomab may have
to pay any amount awarded by a court or negotiated in a settlement that exceed its coverage limitations or that are not covered by insurance,
and Chemomab may not have, or be able to obtain, sufficient capital to pay such amounts. Even if Chemomab&#8217;s agreements with any
future corporate collaborators entitles Chemomab to indemnification against losses, such indemnification may not be available or adequate
should any claim arise.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">58</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemomab
has been granted Orphan Drug Designation for CM-101 in connection with three indications and may seek Orphan Drug Designation for other
indications or product candidates, and Chemomab may be unable to maintain the benefits associated with Orphan Drug Designation, including
the potential for market exclusivity, and may not receive Orphan Drug Designation for other indications or for its other product candidates.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Regulatory authorities
in some jurisdictions, including the United States and Europe, may designate drugs intended for relatively small patient populations as
orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease
or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient
population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will
be recovered from sales in the United States. In the United States, Orphan Drug Designation has entitled a party to financial incentives
such as opportunities for grant funding toward clinical study costs, tax advantages and user-fee waivers. In addition, if a product that
has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product
is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full NDA to market
the same product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to
the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. However, Orphan Drug
Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory
review or approval process. In 2022, the Eleventh Circuit&#8217;s decision in <span style="font-style: italic">Catalyst Pharmaceuticals,
Inc. v. FDA</span> challenges FDA&#8217;s long-standing interpretation and provides that the orphan drug exclusivity should be applied
to block FDA approval of the same drug for the &#8220;same disease or condition&#8221; instead of the approved indication during the exclusivity
period. If the <span style="font-style: italic">Catalyst</span> decision is applied beyond the facts of that case, FDA may revoke approvals
or the grant of subsequent orphan exclusivity periods for the same drugs approved for different indications within the same orphan-designated
disease or condition. <span style="font-style: italic">Catalyst</span> has created some uncertainty with respect to the scope of the orphan
drug exclusivity and may increase legal challenges in the field. FDA may work with the Congress to amend the orphan drug provisions in
the law to provide more clarity to stakeholders. The extent of the impact of the <span style="font-style: italic">Catalyst</span> decision
on the industry and on FDA&#8217;s regulation and policies with respect to orphan exclusivity as well as the impact of any future legislation
on orphan drug approval and exclusivity is unclear.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In <span style="font-style: italic">Catalyst
Pharms., Inc. v. Becerra</span>, 14 F.4th 1299 (11th Cir. 2021), the court disagreed with the FDA&#8217;s longstanding position that the
orphan drug exclusivity only applies to the approved use or indication within an eligible disease. This decision created uncertainty in
the application of the orphan drug exclusivity. On January 24, 2023, the FDA published a notice in the Federal Register to clarify that
while the agency complies with the court&#8217;s order in <span style="font-style: italic">Catalyst</span>, FDA intends to continue to
apply its longstanding interpretation of the regulations to matters outside of the scope of the <span style="font-style: italic">Catalyst</span>
order &#8211; that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug
is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease
or condition that have not yet been approved. It is unclear how future litigation, legislation, agency decisions, and administrative actions
will impact the scope of the orphan drug exclusivity.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">59</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA and EMA granted
Orphan Drug Designation to CM-101 in its primary indications of PSC, SSc and idiopathic pulmonary fibrosis, or IPF. Chemomab may seek
Orphan Drug Designations for CM-101 in other indications or for other product candidates. There can be no assurance that Chemomab will
be able to obtain such designations.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Even if Chemomab obtains
Orphan Drug Designation for any product candidate in specific indications, it may not be the first to obtain marketing approval of such
product candidate for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In
addition, exclusive marketing rights in the United States may be limited if Chemomab seeks approval for an indication broader than the
orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if
the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Further, even if Chemomab
obtains orphan drug exclusivity in the United States for a product, that exclusivity may not effectively protect the product from competition
because different drugs with different active moieties can be approved for the same condition. Even after an orphan product is approved,
the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later
drug is safer, more effective or makes a major contribution to patient care.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemomab
will need to expand its organization, and it may experience difficulties in managing this growth, which could disrupt its operations.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">As of December 31, 2022,
the Company had 37 employees / full time consultants. The Company expect to experience significant growth in the number of its employees
and the scope of its operations, particularly in the areas of product candidate development, regulatory affairs and sales and marketing.
Chemomab may have difficulty identifying, hiring and integrating new personnel. Future growth would impose significant additional responsibilities
on its management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors.
Also, Chemomab&#8217;s management may need to divert a disproportionate amount of its attention away from its day-to-day activities and
devote a substantial amount of time to managing these growth activities. Chemomab may not be able to effectively manage the expansion
of its operations, which may result in weaknesses in its infrastructure, give rise to operational mistakes, loss of business opportunities,
loss of employees and reduced productivity among remaining employees. Chemomab&#8217;s expected growth could require significant capital
expenditures and may divert financial resources from other projects, such as the development of product candidates. If Chemomab&#8217;s
management is unable to effectively manage its growth, its expenses may increase more than expected, its ability to generate and/or grow
revenues could be reduced, and it may not be able to implement its business strategy. Chemomab&#8217;s future financial performance and
its ability to commercialize its product candidates and compete effectively will depend, in part, on its ability to effectively manage
any future growth.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Many of the biopharmaceutical
companies that Chemomab competes against for qualified personnel and consultants have greater financial and other resources, different
risk profiles and a longer history in the industry than Chemomab does. If Chemomab is unable to continue to attract and retain high-quality
personnel and consultants, the rate and success at which it can discover and develop product candidates and operate its business will
be limited.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemomab
has incurred significant operating losses since its inception and anticipates it will incur continued losses for the foreseeable future.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif">The Company has funded its operations to date through
proceeds from sales of its equity and grants from the Israel Innovation Authority, or the IIA, which as of December 31, 2022, resulted
in gross proceeds of approximately $96 million. As of December 31, 2022, Chemomab&#8217;s cash, cash equivalents and deposits were approximately
$40million. Chemomab has incurred net losses in each year since its inception, and it has an accumulated deficit of $63.8 million as of
December 31, 2022. Chemomab expects its existing cash,&#160; cash equivalents and bank deposits will allow it to fund its operating expenses
and capital expenditure requirements at least through March 31, 2024.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">60</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Substantially all of
Chemomab&#8217;s operating losses have resulted from general and administrative costs associated with its operations, and costs associated
with its research and development programs, including for its preclinical and clinical product candidates. Chemomab expects to incur increasing
levels of operating losses over the next several years and for the foreseeable future. Chemomab&#8217;s prior losses, combined with expected
future losses, have had and will continue to have an adverse effect on its shareholders&#8217; deficit and working capital. In any particular
quarter or quarters, Chemomab&#8217;s operating results could be below the expectations of securities analysts or investors, which could
cause the price of Chemomab&#8217;s ADSs to decline.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab expects its
research and development expenses to significantly increase in connection with its clinical studies of its product candidates. In addition,
if Chemomab obtains marketing approval for its product candidates, it will incur significant sales and marketing, legal, and outsourced-manufacturing
expenses. As a public company, Chemomab expects to continue to incur significant and increasing operating losses for the foreseeable future.
Because of the numerous risks and uncertainties associated with developing pharmaceutical products, Chemomab is also unable to predict
the extent of any future losses or when it will become profitable, if at all. Even if Chemomab does become profitable, it may not be able
to sustain or increase its profitability on a quarterly or annual basis.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">A
possible resurgent COVID-19 pandemic or the future outbreak of other highly infectious or contagious diseases could seriously harm Chemomab&#8217;s
research, development and potential future commercialization efforts, increase its costs and expenses and have a material adverse effect
on its business, financial condition and results of operations.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Broad-based business
or economic disruptions have, and could continue to, adversely affect Chemomab&#8217;s ongoing or planned research and development activities.
For example, over the past few years the COVID-19 pandemic has caused significant disruptions to the Israeli, United States, European
and global economy and has contributed to significant volatility and negative pressure in financial markets and created many barriers
to the successful conduct of clinical trials.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab cannot presently
predict the scope and severity of any potential business shutdowns or disruptions from crises related to either disease outbreaks or possible
political or social turmoil,. If Chemomab or any of the third parties with whom it engages, however, were to experience shutdowns or other
business disruptions, Chemomab&#8217;s ability to conduct its business in the manner and on the timelines presently planned could be materially
and negatively affected, which could have a material adverse impact on its business and its results of operation and financial condition.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Risks Related to Chemomab&#8217;s
Intellectual Property Rights</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">If
Chemomab is unable to protect its patents or other proprietary rights, or if Chemomab infringes the patents or other proprietary rights
of others, its competitiveness and business prospects may be materially damaged.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Patent and other proprietary
rights are essential to Chemomab&#8217;s business. Chemomab&#8217;s success depends to a significant degree on its ability to obtain and
enforce patents and licenses to patent rights, both in the United States and in other countries. Chemomab cannot guarantee that pending
patent applications will result in issued patents, that patents issued or licensed will not be challenged or circumvented by competitors,
that the patents and other intellectual property rights of Chemomab and its business partners will not be found to be invalid or that
the intellectual property rights of others will not prevent Chemomab from selling its products or from executing on its strategies.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">61</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The patent position of
a biopharmaceutical company is often uncertain and involves complex legal and factual questions. Significant litigation concerning patents
and products is pervasive in Chemomab&#8217;s industry. Patent claims include challenges to the coverage and validity of Chemomab&#8217;s
patents on products or processes as well as allegations that its products infringe patents held by competitors or other third parties.
A loss in any of these types of cases could result in a loss of patent protection or the ability to market products, which could lead
to a significant loss of sales, or otherwise materially affect future results of operations. Chemomab also relies on trademarks, copyrights,
trade secrets and know-how to develop, maintain and strengthen its competitive positions. Third parties may know, discover or independently
develop equivalent proprietary information or techniques, or they may gain access to Chemomab&#8217;s trade secrets or disclose such trade
secrets to the public.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Although Chemomab&#8217;s
employees, consultants, parties to collaboration agreements and other business partners are generally subject to confidentiality or similar
agreements to protect its confidential and proprietary information, these agreements may be breached, and Chemomab may not have adequate
remedies for any breach. In addition, Chemomab&#8217;s trade secrets may otherwise become known or be independently discovered by competitors.
To the extent that Chemomab&#8217;s employees, consultants, parties to collaboration agreements and other business partners use intellectual
property owned by others in their work for the company, disputes may arise as to the rights in related or resulting know-how and inventions.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Furthermore, Chemomab&#8217;s
intellectual property, other proprietary technology and other sensitive company data is potentially vulnerable to loss, damage or misappropriation
from system malfunction, computer viruses, unauthorized access to data or misappropriation or misuse thereof by those with permitted access
and other events. While Chemomab has invested to protect its intellectual property and other data, and continue to work diligently in
this area, there can be no assurance that its precautionary measures will prevent breakdowns, breaches, cyber incidents or other events.
Such events could have a material adverse effect on Chemomab&#8217;s reputation, business, financial condition or results of operations.
Misappropriation or other loss of Chemomab&#8217;s intellectual property from any of the foregoing could have a material adverse effect
on its competitive position and may cause it to incur substantial litigation costs.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemomab
may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent,
which might adversely affect its ability to develop, manufacture and market its product candidates.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">From time to time Chemomab
may identify patents or applications in the same general area as its products and product candidates. Chemomab may determine these third-party
patents are irrelevant to its business based on various factors, including its interpretation of the scope of the patent claims and its
interpretation of when the patent expires. If the patents are asserted against Chemomab, however, a court may disagree with its determinations.
Further, while Chemomab may determine that the scope of claims that will issue from a patent application does not present a risk, it is
difficult to accurately predict the scope of claims that will issue from a patent application, its determination may be incorrect, and
the issuing patent may be asserted against Chemomab. Chemomab cannot guarantee that it will be able to successfully settle or otherwise
resolve such infringement claims. If Chemomab fails in any such dispute, in addition to being forced to pay monetary damages, it may be
temporarily or permanently prohibited from commercializing its product candidates or be required to obtain a license under such patent,
which may not be available on reasonable terms or at all. Chemomab might, if possible, also be forced to redesign its product candidates
so that it no longer infringes, misappropriates or otherwise violates the third-party intellectual property rights. Any of these events,
even if Chemomab were ultimately to prevail, could require it to divert substantial financial and management resources that it would otherwise
be able to devote to its business. Any of the foregoing could have a material adverse effect on Chemomab&#8217;s business, financial condition,
results of operations, and prospects.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">62</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Changes
in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing Chemomab&#8217;s ability to protect
its product candidates.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">As is the case with other
biopharmaceutical and pharmaceutical companies, Chemomab&#8217;s success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the biopharmaceutical and pharmaceutical industries involve both technological and legal complexity.
Therefore, obtaining and enforcing biopharmaceutical and pharmaceutical patents is costly, time-consuming and inherently uncertain. In
addition, the Leahy-Smith America Invents Act, or the AIA, which was passed in September 2011, resulted in significant changes to the
United States patent system.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">An important change introduced
by the AIA is that, as of March 16, 2013, the United States transitioned from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221;
system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming
the same invention. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor
to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the
invention earlier. A third party that files a patent application in the USPTO after that date but before Chemomab could therefore be awarded
a patent covering an invention of ours even if it made the invention before it was made by the third party. This will require Chemomab
to be cognizant of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances
could prevent it from promptly filing patent applications on its inventions.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Among some of the other
changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities
for third parties to challenge any issued patent with the USPTO. This applies to all of Chemomab&#8217;s United States patents, even those
issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United
States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient
for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in
a district court action.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Accordingly, a third
party may attempt to use the USPTO procedures to invalidate Chemomab&#8217;s patent claims that would not have been invalidated if first
challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the
operation of its business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution
of Chemomab or its licensors&#8217; patent applications and the enforcement or defense of Chemomab or its licensors&#8217; issued patents.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab may become involved
in opposition, interference, derivation, <span style="font-style: italic">inter partes</span> review, post-grant review, reexamination
or other proceedings challenging Chemomab or its licensors&#8217; patent rights, and the outcome of any proceedings are highly uncertain.
An adverse determination in any such proceeding could reduce the scope of, or invalidate, Chemomab&#8217;s owned or in-licensed patent
rights, in whole or in part, allow third parties to commercialize its technology or products and compete directly with Chemomab, without
payment to it, or result in Chemomab&#8217;s inability to manufacture or commercialize products without infringing third-party patent
rights.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Additionally, the United
States Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain
circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to Chemomab&#8217;s
ability to obtain patents in the future, this combination of events has created uncertainty with respect to the validity, enforceability
and value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, as well as similar bodies in
other jurisdictions, the laws and regulations governing patents could change in unpredictable ways that could weaken Chemomab&#8217;s
ability to obtain new patents or to enforce its existing patents and patents that it might obtain in the future. Similarly, the complexity
and uncertainty of European patent laws have also increased in recent years. In addition, the European patent system is relatively stringent
in the type of amendments that are allowed during prosecution. Complying with these laws and regulations could limit Chemomab&#8217;s
ability to obtain new patents in the future that may be important for its business, and these laws and regulations patents could continue
to change in unpredictable ways that could have a material adverse effect on Chemomab&#8217;s existing patent rights and its ability to
protect and enforce its intellectual property in the future.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">63</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Obtaining
and maintaining Chemomab&#8217;s patent protection depends on compliance with various procedural, document submission, fee payment and
other requirements imposed by governmental patent agencies, and Chemomab&#8217;s patent protection could be reduced or eliminated for
non-compliance with these requirements.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The USPTO and European
and other patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during
the patent application process. In addition, periodic maintenance, renewal and annuity fees on any issued patent are due to be paid to
the USPTO and European and other patent agencies over the lifetime of a patent. While an inadvertent failure to make payment of such fees
or to comply with such provisions can in many cases be cured by additional payment of a late fee or by other means in accordance with
the applicable rules, there are situations in which such noncompliance will result in the abandonment or lapse of the patent or patent
application, and the partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in
abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment
of fees and failure to properly legalize and submit formal documents within prescribed time limits. If Chemomab or its licensors fails
to maintain the patents and patent applications covering its product candidates or if Chemomab or its licensors otherwise allow its patents
or patent applications to be abandoned or lapse, its competitors might be able to enter the market, which would hurt Chemomab&#8217;s
competitive position and could impair its ability to successfully commercialize its product candidates in any indication for which they
are approved, which could have a material adverse effect on Chemomab&#8217;s business, financial condition, results of operations, and
prospects.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Risks Related to Chemomab&#8217;s
Regulatory Approvals</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">The
regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable,
and if Chemomab is ultimately unable to obtain regulatory approval for CM-101 or any other product candidates, its business will be substantially
harmed.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The time required to
obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement
of clinical studies and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition,
approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product
candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to
approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application
or may decide that Chemomab&#8217;s data is insufficient for approval and require additional preclinical, clinical or other data. Even
if Chemomab eventually completes clinical testing and receives approval of any regulatory filing for its product candidates, the FDA and
other comparable foreign regulatory authorities may approve Chemomab&#8217;s product candidates for a more limited indication or a narrower
patient population than it originally requested. Chemomab has not obtained regulatory approval for any product candidate and it is possible
that it will never obtain regulatory approval for CM-101 or any other product candidate. Chemomab is not permitted to market any of its
product candidates in the United States until it receives regulatory approval of an NDA from the FDA.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Prior to obtaining approval
to commercialize a product candidate in the United States or abroad, Chemomab must demonstrate with substantial evidence from well-controlled
clinical studies, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidate is safe and effective
for its intended use. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if Chemomab believes
the preclinical or clinical data for its product candidates are promising, such data may not be sufficient to support approval by the
FDA and other regulatory authorities.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">64</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The FDA or any foreign
regulatory bodies can delay, limit or deny approval of Chemomab&#8217;s product candidates or require it to conduct additional preclinical
or clinical testing or abandon a program for many reasons, including:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6adfff9d27f1491aa68bf1cd7d4d9526" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the FDA or comparable
        foreign regulatory authorities may disagree with the design or implementation of Chemomab&#8217;s clinical studies;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Chemomab may be unable
        to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective
        for its proposed indication;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">serious and unexpected
        drug-related side effects experienced by participants in Chemomab&#8217;s clinical studies or by individuals using drugs similar to its
        product candidates, or other products containing the active ingredient in Chemomab&#8217;s product candidates;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">negative or ambiguous results from Chemomab&#8217;s clinical
        studies or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities
        for approval;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)"> <br /> </div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the population studied
        in the clinical study may not be sufficiently broad or representative to assure efficacy and safety in the full population for which Chemomab
        seeks approval;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Chemomab may be unable
        to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the FDA or comparable
        foreign regulatory authorities may disagree with Chemomab&#8217;s interpretation of data from preclinical studies or clinical trials;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the data collected
        from clinical studies of Chemomab&#8217;s product candidates may not be acceptable or sufficient to support the submission of an NDA or
        other submission or to obtain regulatory approval in the United States or elsewhere, and Chemomab may be required to conduct additional
        clinical studies;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the FDA&#8217;s or
        the applicable foreign regulatory agency&#8217;s disagreement regarding the formulation, labeling and/or the specifications of Chemomab&#8217;s
        product candidates;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the FDA or comparable
        foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party
        manufacturers with which Chemomab contracts for clinical and commercial supplies; and</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the approval policies
        or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering Chemomab&#8217;s
        clinical data insufficient for approval.</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Moreover, preclinical
and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates
performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or comparable foreign regulatory
authority approval. Chemomab cannot guarantee that the FDA or foreign regulatory authorities will interpret trial results as it does,
and more trials could be required before Chemomab is able to submit applications seeking approval of its product candidates. To the extent
that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application,
Chemomab may be required to expend significant resources, which may not be available to it, to conduct additional trials in support of
potential approval of Chemomab&#8217;s product candidates. Furthermore, the approval policies or regulations of the FDA or comparable
foreign regulatory authorities may significantly change in a manner rendering Chemomab&#8217;s clinical data insufficient for approval,
which may lead to the FDA or comparable foreign regulatory authorities delaying, limiting or denying approval of its product candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Of the large number of
drugs in development, only a small percentage successfully complete the regulatory approval processes and are commercialized. This lengthy
approval process, as well as the unpredictability of future clinical trial results, may result in Chemomab failing to obtain regulatory
approval to market CM-101 or any other product candidate, which would significantly harm Chemomab&#8217;s business, results of operations
and prospects.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">65</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, the FDA
or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient population than
Chemomab originally requested, and the FDA or applicable foreign regulatory agency may approve a product candidate with a REMS or a label
that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Regulatory
authorities may also grant approval contingent on the performance of costly post-marketing clinical trials. Any of the foregoing scenarios
could materially harm the commercial prospects for Chemomab&#8217;s product candidates.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Obtaining
and maintaining regulatory approval of Chemomab&#8217;s product candidates in one jurisdiction does not mean that it will be successful
in obtaining regulatory approval of its product candidates in other jurisdictions.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In order to market any
product outside of the United States, Chemomab must establish and comply with the numerous and varying safety, efficacy, and other regulatory
requirements of other countries. Obtaining and maintaining regulatory approval of its product candidates in one jurisdiction does not
guarantee that Chemomab will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining
regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Chemomab&#8217;s product
candidates may not receive marketing approval even if they achieve their primary endpoints in future Phase 3 clinical studies or registrational
trials. The FDA or comparable foreign regulatory authorities may disagree with Chemomab&#8217;s trial designs and its interpretation of
data from preclinical studies or clinical trials. In addition, any of these regulatory authorities may change requirements for the approval
of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 or registrational clinical
study. In addition, any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than
Chemomab&#8217;s request or may grant approval contingent on the performance of costly post-marketing clinical trials. The FDA or comparable
foreign regulatory authorities may not approve the labeling claims that Chemomab believes would be necessary or desirable for the successful
commercialization of its product candidates, if approved.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Furthermore, even if
the FDA or other comparable foreign regulatory authority grants marketing approval of a product candidate, comparable regulatory authorities
in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of the product candidate in those countries. Approval
procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United
States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted
by regulatory authorities in other jurisdictions. The marketing approval processes in other countries may implicate all of the risks detailed
above regarding FDA approval in the United States, as well as other risks. In many jurisdictions outside the United States, a product
candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that Chemomab
intends to charge for its products is also subject to approval.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Obtaining foreign regulatory
approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for Chemomab
and could delay or prevent the introduction of its products in certain countries. Failure to obtain marketing approval in other countries
or any delay or other setback in obtaining such approval would impair its ability to market its product candidates in such foreign markets.
Any such impairment would reduce the size of its potential market, which could have a material adverse impact on its business, results
of operations, and prospects.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Even
if Chemomab obtains regulatory approval for CM-101 or any product candidate, it will still face extensive and ongoing regulatory requirements
and obligations and any product candidates, if approved, may face future development and regulatory difficulties.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Any product candidate
for which Chemomab obtains marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging,
distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product,
among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These
requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing
requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding
maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and GCP requirements
for any clinical studies that Chemomab conducts post-approval.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">66</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Even if marketing approval
of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may
be marketed or to the conditions of approval, including a requirement to implement a REMS. If any of Chemomab&#8217;s product candidates
receives marketing approval, the accompanying label may limit the approved indicated use of the product candidate, which could limit sales
of the product candidate. The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to
monitor the safety or efficacy of a product. Violations of the Federal Food, Drug, and Cosmetic Act, or FDCA, relating to the promotion
of prescription drugs may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud
and abuse laws, as well as state consumer protection laws.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, later discovery
of previously unknown adverse events or other problems with Chemomab&#8217;s products, manufacturers or manufacturing processes or failure
to comply with regulatory requirements, may yield various results, including:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd53608bac0b543a097e5a528a73c8661" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">restrictions on manufacturing
        such products;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">restrictions on the
        labeling or marketing of products;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">restrictions on product
        manufacturing, distribution or use;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">requirements to conduct
        post-marketing studies or clinical trials;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">warning letters or
        untitled letters;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">withdrawal of the products
        from the market;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">refusal to approve
        pending applications or supplements to approved applications that Chemomab submits;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">recall of products;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">fines, restitution
        or disgorgement of profits or revenues;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">suspension or withdrawal
        of marketing approvals;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">refusal to permit the
        import or export of Chemomab&#8217;s products;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">product seizure; or</div> </div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">injunctions or the
        imposition of civil or criminal penalties.</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Further, the FDA&#8217;s
policies may change, and additional government regulations may be enacted that could impose extensive and ongoing regulatory requirements
and obligations on any product candidate for which Chemomab obtains marketing approval. If Chemomab is slow or unable to adapt to changes
in existing requirements or the adoption of new requirements or policies, or if Chemomab is not able to maintain regulatory compliance,
it may lose any marketing approval that it may have obtained, which would adversely affect its business, prospects and ability to achieve
or sustain profitability.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">67</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Disruptions
at the FDA and other government agencies caused by funding shortages or global health concerns could hinder Chemomab&#8217;s ability to
hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved
or commercialized in a timely manner or at all, which could negatively impact its business.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The ability of the FDA
to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to
hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times
at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research
and development activities is subject to the political process, which is inherently fluid and unpredictable.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Disruptions at the FDA
and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which
would harm Chemomab&#8217;s business. For example, over the last several years, including for 35 days beginning on December 22, 2018,
the United States government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical
FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the
FDA to timely review and process Chemomab&#8217;s regulatory submissions, which could harm its business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The COVID-19 pandemic
has also resulted in the FDA imposing preventive measures, including postponements of non-United States manufacturing and product inspections.
If global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews,
or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review
and process Chemomab&#8217;s regulatory submissions, which could have a material adverse effect on its business.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Risks Related to Commercialization
of Chemomab&#8217;s Product Candidates</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">If
Chemomab does not achieve its projected development and commercialization goals in the timeframes it announces and expects, the commercialization
of its product candidates may be delayed and Chemomab&#8217;s business will be harmed.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">For planning purposes,
Chemomab sometimes estimates the timing of the accomplishment of various scientific, clinical, regulatory and other product development
objectives. These milestones may include Chemomab&#8217;s expectations regarding the commencement or completion of scientific studies
and clinical trials, the regulatory submissions or commercialization objectives. From time to time, Chemomab may publicly announce the
expected timing of some of these milestones, such as the completion of an ongoing clinical study, the initiation of other clinical studies,
receipt of regulatory approval or the commercial launch of a product. The achievement of many of these milestones may be outside of Chemomab&#8217;s
control. All of these milestones are based on a variety of assumptions which may cause the timing of achievement of the milestones to
vary considerably from Chemomab&#8217;s estimates, including:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0e888982bec74586945fd852d6942b02" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Chemomab&#8217;s available capital resources or capital constraints
        it experiences;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the rate of progress,
        costs and results of Chemomab&#8217;s clinical studies and research and development activities, including the extent of scheduling conflicts
        with participating clinicians and collaborators;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Chemomab&#8217;s ability
        to identify and enroll patients who meet clinical study eligibility criteria;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Chemomab&#8217;s receipt
        of authorizations by the FDA and comparable foreign regulatory authorities, and the timing thereof;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">other actions, decisions
        or rules issued by regulators;</div> </td> </tr>
  </table>

<div><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">68</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div> <br /> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Chemomab&#8217;s ability
        to access sufficient, reliable and affordable supplies of materials used in the manufacture of its product candidates;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Chemomab&#8217;s ability
        to manufacture and supply clinical study materials to its clinical sites on a timely basis;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the severity, duration
        and impact of the COVID-19 pandemic;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the efforts of Chemomab&#8217;s
        collaborators with respect to the commercialization of its products, if any; and</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the securing of, costs
        related to, and timing issues associated with, commercial product manufacturing as well as sales and marketing activities.</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If Chemomab fails to
achieve announced milestones in the timeframes it expects, the commercialization of any of its product candidates may be delayed, and
its business, results of operations, financial condition and prospects may be adversely affected.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemomab
faces substantial competition, which may result in others discovering, developing or commercializing products before or more successfully
than it.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The development and commercialization
of new drug products is highly competitive. Chemomab may face competition with respect to any product candidates that it seeks to develop
or commercialize in the future from major biopharmaceutical companies, specialty biopharmaceutical companies, and biotechnology companies
worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations
that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and
commercialization.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">There are a number of
large biopharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of inflammation
and fibrosis. Companies that Chemomab is aware of that are targeting the treatment of inflammation and fibrosis include large companies
with significant financial resources such as Biogen, Inc., AbbVie Inc., Gilead Sciences, Inc., FibroGen, Inc., Galapagos NV, Bristol Myers
Squibb Co., and Novartis AG. However, Chemomab does not know of any other companies currently in clinical development with an anti CCL24
mAb. For additional information regarding Chemomab&#8217;s competition, see &#8220;<span style="font-style: italic">Chemomab Business
- Competition.</span>&#8221;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Many of Chemomab&#8217;s
current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise
in research and development, manufacturing, preclinical testing, conducting clinical studies, obtaining regulatory approvals, and marketing
approved products than Chemomab does.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Even
if CM-101 or any other product candidate Chemomab develops receives marketing approval, it may fail to achieve market acceptance by physicians,
patients, third-party payors or others in the medical community necessary for commercial success.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If CM-101 or any other
product candidate Chemomab develops receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians,
patients, third-party payors and others in the medical community. If it does not achieve an adequate level of acceptance, Chemomab may
not generate significant product revenues or become profitable. The degree of market acceptance of Chemomab&#8217;s product candidates,
if approved, will depend on a number of factors, including but not limited to:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfb30818306734af58de3d4dfd560bfb8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the efficacy and potential
        advantages compared to alternative treatments;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">effectiveness of sales
        and marketing efforts;</div> </td> </tr>
  </table>

<div><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">69</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div> <br /> </div>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the cost of treatment
        with respect to alternative treatments, including any similar generic treatments;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Chemomab&#8217;s ability to offer its products for sale at competitive
        prices;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">the convenience and ease of administration compared to alternative
        treatments;</div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the willingness of
        the target patient population to try new therapies and of physicians to prescribe these therapies;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the strength of marketing
        and distribution support;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the timing of market
        introduction of competitive products;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the availability of
        third-party coverage and adequate reimbursement;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">product labeling or
        product insert requirements of the FDA, EMA or other regulatory authorities, including any limitations on warnings contained in a product&#8217;s
        approved labeling;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the prevalence and
        severity of any side effects; and</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">any restrictions on the use of Chemomab&#8217; product together
        with other medications.</div> </td> </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Because Chemomab expects
sales of its product candidates, if approved, to generate substantially all of its revenues for the foreseeable future, the failure of
its product candidates to find market acceptance would harm its business and could require it to seek additional financing.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemomab
relies completely on third-party suppliers to manufacture its clinical drug supplies for its product candidates, and Chemomab intends
to rely on third parties to produce preclinical, clinical, and commercial supplies of any future product candidates.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab does not currently
have, nor does Chemomab plan to acquire, the infrastructure or capability to internally manufacture its clinical drug supply of its product
candidates, or any future product candidates, for use in the conduct of its preclinical studies and clinical trials.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab lacks the internal
resources and the capabilities to manufacture any product candidates on a clinical or commercial scale. The facilities used by its contract
manufacturers to manufacture the active pharmaceutical ingredient and final drug product must complete a pre-approval inspection by the
FDA and other comparable foreign regulatory agencies to assess compliance with applicable requirements, including cGMPs, after Chemomab
submits its NDA or relevant foreign regulatory market application to the applicable regulatory agency.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160; &#160; Chemomab is responsible for setting the product specifications and approving master batch records, but does not oversee
the manufacturing process itself, and is completely dependent on its contract manufacturers to comply with cGMPs for manufacture of both
active drug substances and finished drug products. If its contract manufacturers cannot successfully manufacture material that conforms
to its specifications and the strict regulatory requirements of the FDA or applicable foreign regulatory agencies, they will not be able
to pass a pre-approval inspection or secure and/or maintain regulatory approval for their manufacturing facilities. In addition, Chemomab
has no direct control over its contract manufacturers&#8217; ability to maintain adequate quality control, quality assurance, and qualified
personnel. Furthermore, all of its contract manufacturers are engaged with other companies to supply and/or manufacture materials or products
for such companies, which exposes its manufacturers to regulatory risks for the production of such materials and products. As a result,
failure to satisfy the regulatory requirements for the production of those materials and products may affect the regulatory clearance
of its contract manufacturers&#8217; facilities generally. If the FDA or an applicable foreign regulatory agency determines now or in
the future that these facilities for the manufacture of its product candidates are noncompliant, Chemomab may need to find alternative
manufacturing facilities, which would adversely impact its ability to develop, obtain regulatory approval for or market its product candidates.
Its reliance on contract manufacturers also exposes Chemomab to the possibility that they, or third parties with access to their facilities,
will have access to and may compromise its trade secrets or other proprietary information.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">70</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">If
Chemomab is unable to establish sales, marketing and distribution capabilities either on its own or in collaboration with third parties,
it may not be successful in commercializing CM-101, if approved.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab does not have
any infrastructure for the sales, marketing or distribution of CM-101, and the cost of establishing and maintaining such an organization
may exceed the cost-effectiveness of doing so. In order to market and successfully commercialize CM-101 or any other product candidate
Chemomab develops, if approved, it must build its sales, distribution, marketing, managerial and other non-technical capabilities or make
arrangements with third parties to perform these services. Chemomab expects to build a focused sales, distribution and marketing infrastructure
to market CM-101, if approved. There are significant expenses and risks involved with establishing Chemomab&#8217;s own sales, marketing
and distribution capabilities, including its ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient
sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing
team. Any failure or delay in the development of Chemomab&#8217;s internal sales, marketing and distribution capabilities could delay
any product launch, which would adversely impact the commercialization of that product. Additionally, if the commercial launch of CM-101
for which Chemomab recruits a sales force and establishes marketing capabilities is delayed or does not occur for any reason, it would
have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and Chemomab&#8217;s investment would
be lost if it cannot retain or reposition its sales and marketing personnel.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Factors that may inhibit
Chemomab&#8217;s efforts to commercialize its product candidates on its own include:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd4cb9a4e358048738330dd247c66f384" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Chemomab&#8217;s inability
        to recruit, train and retain adequate numbers of effective sales and marketing personnel;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">the inability of sales
        personnel to obtain access to physicians or attain adequate numbers of physicians to prescribe Chemomab&#8217;s products; and</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">unforeseen costs and
        expenses associated with creating an independent sales and marketing organization.</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab does not anticipate
having the resources in the foreseeable future to allocate to the sales and marketing of its product candidates, if approved, in certain
markets overseas. Therefore, Chemomab&#8217;s future success will depend, in part, on its ability to enter into and maintain collaborative
relationships for such capabilities, the collaborator&#8217;s strategic interest in a product and such collaborator&#8217;s ability to
successfully market and sell the product. Chemomab intends to pursue collaborative arrangements regarding the sale and marketing of CM-101,
if approved, for certain markets overseas; however, Chemomab cannot guarantee that it will be able to establish or maintain such collaborative
arrangements, or if able to do so, that it will have effective sales forces. To the extent that Chemomab depends on third parties for
marketing and distribution, any revenues it receives will depend upon the efforts of such third parties, and there can be no assurance
that such efforts will be successful.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If Chemomab is unable
to build its own sales force or negotiate a collaborative relationship for the commercialization of CM-101, Chemomab may be forced to
delay the potential commercialization of CM-101 or reduce the scope of its sales or marketing activities for CM-101. If Chemomab needs
to increase its expenditures to fund commercialization activities for CM-101, it will need to obtain additional capital, which may not
be available to it on acceptable terms, or at all. Chemomab may also have to enter into collaborative arrangements for CM-101 at an earlier
stage than otherwise would be ideal and it may be required to relinquish rights to CM-101 or otherwise agree to terms unfavorable to it.
Any of these occurrences may have an adverse effect on Chemomab&#8217;s business, operating results and prospects.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">71</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If Chemomab is unable
to establish adequate sales, marketing and distribution capabilities, either on its own or in collaboration with third parties, it will
not be successful in commercializing its product candidates and may never become profitable. Chemomab will be competing with many companies
that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party
to perform marketing and sales functions, it may be unable to compete successfully against these more established companies.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">A
variety of risks associated with operating internationally could materially adversely affect Chemomab&#8217;s business.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab&#8217;s research
and development facilities and certain of its executives are located in Israel and certain of its product candidates may be manufactured
at third-party facilities located in Europe. In addition, Chemomab&#8217;s business strategy includes potentially expanding internationally
if any of its product candidates receives regulatory approval. Doing business internationally involves a number of risks, including but
not limited to:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z5e9018d7e6eb4b4b810ee6b85d2ea924" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">multiple, conflicting
        and changing laws and regulations, such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory
        requirements and other governmental approvals, permits and licenses;</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">failure by Chemomab
        to obtain and maintain regulatory approvals for the use of its products in various countries;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">additional potentially
        relevant third-party patent rights;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">complexities and difficulties
        in obtaining protection and enforcing Chemomab&#8217;s intellectual property;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">difficulties in staffing
        and managing foreign operations;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">complexities associated
        with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">limits in Chemomab&#8217;s
        ability to penetrate international markets;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">financial risks, such
        as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment
        for Chemomab&#8217;s products and exposure to foreign currency exchange rate fluctuations;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">natural disasters,
        political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade
        and other business restrictions;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">certain expenses including,
        among others, expenses for travel, translation and insurance; and</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  <tr>
    <td style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;<span style="color: rgb(0, 0, 0)">&#160;</span></div> </td>
    <td style="width: 1.47%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
    <td style="width: 94%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">regulatory and compliance
        risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the United
        States Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions.</div>
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </td>
        </tr>
  </table>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Any of these factors
could significantly harm Chemomab&#8217;s international expansion and operations and, consequently, its results of operations.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Risks Related to Chemomab&#8217;s
Incorporation and Location in Israel</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Conditions
in Israel could materially and adversely affect Chemomab&#8217;s business.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Many of Chemomab&#8217;s
employees, including certain management members operate from its offices that are located in Tel Aviv, Israel. In addition, a number of
Chemomab&#8217;s officers and directors are residents of Israel. Accordingly, political, economic, and military conditions in Israel and
the surrounding region may directly affect its business and operations. In recent years, Israel has been engaged in sporadic armed conflicts
with Hamas, an Islamist terrorist group that controls the Gaza Strip, with Hezbollah, an Islamist terrorist group that controls large
portions of southern Lebanon, and with Iranian-backed military forces in Syria. In addition, Iran has threatened to attack Israel and
may be developing nuclear weapons. Some of these hostilities were accompanied by missiles being fired from the Gaza Strip against civilian
targets in various parts of Israel, including areas in which Chemomab&#8217;s employees and some of its consultants are located, and negatively
affected business conditions in Israel. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and
its trading partners could adversely affect Chemomab&#8217;s operations and results of operations.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">72</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab&#8217;s commercial
insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government
currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, Chemomab cannot guarantee
that this government coverage will be maintained or that it will sufficiently cover its potential damages. Any losses or damages incurred
by Chemomab could have a material adverse effect on its business. Any armed conflicts or political instability in the region would likely
negatively affect business conditions and could harm Chemomab&#8217;s results of operations.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Further, in the past,
the State of Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the
State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on Chemomab&#8217;s operating
results, financial condition or the expansion of its business. A campaign of boycotts, divestment and sanctions has been undertaken against
Israel, which could also adversely impact Chemomab&#8217;s business. The recent installation of a new government in Israel that includes
far right wing parties and personnel may lead to greater international sanctions or other actions that are detrimental to international
business for Israeli companies.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, many Israeli
citizens are obligated to perform several days, and in some cases more, of annual military reserve duty each year until they reach the
age of 40 (or older, for reservists who are military officers or who have certain occupations) and, in the event of a military conflict,
may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military
reservists. It is possible that there will be military reserve duty call-ups in the future. Chemomab&#8217;s operations could be disrupted
by such call-ups, which may include the call-up of members of Chemomab&#8217;s management. Such disruption could materially adversely
affect Chemomab&#8217;s business, prospects, financial condition and results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Furthermore, the Israeli
government is currently pursuing extensive changes to Israel&#8217;s judicial system. In response to the foregoing developments, individuals,
organizations and institutions, both within and outside of Israel, have voiced concerns that the proposed changes may negatively impact
the business environment in Israel including due to reluctance of foreign investors to invest or conduct business in Israel, as well as
to increased currency fluctuations, downgrades in credit rating, increased interest rates, increased volatility in securities markets,
and other changes in macroeconomic conditions. Such proposed changes may also adversely affect the labor market in Israel or lead to political
instability or civil unrest. To the extent that any of these negative developments do occur, they may have an adverse effect on our business,
our results of operations and our ability to raise additional funds, if deemed necessary by our management and board of directors.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Because
a certain portion of Chemomab&#8217;s expenses are incurred in currencies other than the U.S. Dollar, its results of operations may be
harmed by currency fluctuations and inflation.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Chemomab&#8217;s reporting
and functional currency is the United States Dollar, but some portion of its clinical studies and operations expenses are in NIS. As a
result, Chemomab is exposed to some currency fluctuation risks. Fluctuation in the exchange rates of foreign currency has an influence
on the cost of goods sold and Chemomab&#8217;s financing revenues and expenses. Chemomab may, in the future, decide to enter into currency
hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the currencies mentioned above
with respect to the U.S. Dollar. These measures, however, may not adequately protect Chemomab from adverse effects.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">73</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Chemomab
received Israeli government grants for certain of their research and development activities as detailed below. The terms of those grants
require us to satisfy specified conditions in order to transfer outside of Israel the manufacture of products based on know-how funded
by the Israel Innovation Authority or to transfer outside of Israel the know-how itself. If we fail to comply with the requirements of
Israeli law in this regard, we may be required to pay penalties, and it may impair our ability to sell our technology outside of Israel.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Some of Chemomab&#8217;s
research and development efforts were financed through grants that were received from the Israel Innovation Authority of the Israeli Ministry
of Economy and Industry, or the IIA (formerly known as the Office of the Chief Scientist). When know-how is developed using IIA grants,
the Encouragement of Research, Development and Technological Innovation in Industry Law 5744-1984, or the Innovation Law, and the regulations
thereunder, restrict our ability to transfer outside of Israel either the manufacture of products based on IIA-funded know-how or the
know-how itself. Such restrictions continue to apply even after financial obligations to the IIA are paid in full. The consideration available
to our shareholders in a future transaction involving the transfer outside of Israel of know-how developed with IIA funding (such as a
merger or similar transaction) may be reduced by any amounts that we are required to pay to the IIA.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Risks Related to our
ADSs</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
will need to raise additional capital to fund our operations, which may be unavailable to us on acceptable terms or at all, or may cause
dilution or place significant restrictions on our ability to operate our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: 24.5pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; text-align: justify">&#160;&#160;&#160;&#160;
If our available cash resources are insufficient to satisfy our liquidity requirements, we will be required to raise additional capital
through issuances of equity or convertible debt securities, or seek debt financing or other form of third-party funding.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: justify">&#160;</div>

<div style="text-indent: 24.5pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; text-align: justify">&#160;&#160;&#160;&#160;
If we are unable to obtain adequate financing or financing on terms satisfactory to us when needed, our ability to continue to pursue
our business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited,
and could have a material adverse effect on our business, financial condition, results of operations and prospects.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-align: justify">&#160;</div>

<div style="text-indent: 24.5pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; text-align: justify">&#160;&#160;&#160;&#160;
The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to
our shareholders would result. If we raise funds by issuing debt securities, those debt securities would have rights, preferences and
privileges senior to those of holders of our ADSs. The terms of debt securities issued or borrowings pursuant to a credit agreement could
impose significant restrictions on our operations. If we raise funds through collaborations or licensing arrangements, we might be required
to relinquish significant rights to our product candidates or grant licenses on terms that are not favorable to us.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">The
trading price of the ADSs has been highly volatile, and is expected to continue to be volatile.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The trading price of
the ADSs has been highly volatile, particularly over the last year. For example, on January 11, 2022, the closing price of the ADSs was
$6.98 per ADS and on March 13, 2023, it was $1.48 per ADS. This volatility may affect the price at which you are able to sell ADSs. Our
ADS price is likely to continue to be volatile and subject to significant price and volume fluctuations in response to market and economic
factors that are beyond our control. In addition, while the stock market in general has experienced high volatility, biotechnology companies
in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to operating performance.
Broad market and industry factors may negatively affect the market price of the ADSs, regardless of our actual operating performance.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
have not paid dividends in the past and do not expect to pay dividends in the future, and, as a result, any return on investment may be
limited to the value of the ADSs.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We have never paid dividends
and do not anticipate paying dividends in the foreseeable future. The payment of dividends will depend on our earnings, capital requirements,
financial condition, prospects and other factors our board of directors may deem relevant. If we do not pay dividends, the ADSs may be
less valuable because a return on your investment will only occur if our ADS price appreciates and you sell your ADS thereafter. In addition,
the Companies Law imposes restrictions on our ability to declare and pay dividends.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">74</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">If
we fail to continue to meet all applicable Nasdaq requirements, Nasdaq may delist the ADSs, which could have an adverse impact on the
liquidity and market price of the ADSs.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The ADSs are currently
listed on Nasdaq, which has qualitative and quantitative listing criteria. If we are unable to meet any of the Nasdaq listing requirements
in the future, including, for example, if the closing bid price for the ADSs falls below $1.00 per share for 30 consecutive trading days,
Nasdaq could determine to delist the ADSs, which could adversely affect the market liquidity of the ADSs and the market price of the ADSs
could decrease. Such delisting could also adversely affect our ability to obtain financing for the continuation of our operations and
could result in the loss of confidence by investors, customers and employees.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Holders
of ADSs are not treated as holders of our ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Holders of ADSs are not
treated as holders of our ordinary shares, unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit
agreement and applicable laws and regulations. The depositary is the holder of the ordinary shares underlying the ADSs. Holders of ADSs
therefore do not have any rights as holders of our ordinary shares, other than the rights that they have pursuant to the deposit agreement.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">You
may not have the same voting rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise
your right to vote.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Except as described in
the deposit agreement, holders of the ADSs will not be able to exercise voting rights attaching to the ordinary shares represented by
the ADSs. If we request the depositary to solicit your voting instructions (and we are not required to do so), the depositary will notify
you of a shareholders&#8217; meeting and send or make voting materials available to you. Those materials will describe the matters to
be voted on and explain how ADS holders may instruct the depositary how to vote. We cannot guarantee that ADS holders will receive the
voting materials in time to ensure that they can instruct the depositary to vote the ordinary shares underlying their ADSs. For instructions
to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to
the laws of Israel and the provisions of our articles of association or similar documents, to vote or to have its agents vote the ordinary
shares or other deposited securities as instructed by ADS holders. If we do not request the depositary to solicit your voting instructions,
you can still send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do
so.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Otherwise, ADS holders
will not be able to exercise their right to vote, unless they withdraw the ordinary shares underlying the ADSs they hold. However, ADS
holders may not know about the meeting far enough in advance to withdraw those ordinary shares. In any event, the depositary will not
exercise any discretion in voting deposited securities and it will only vote or attempt to vote as instructed. In addition, the depositary
and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions.
This means that you may not be able to exercise your right to vote and there may be nothing you can do if your ordinary shares are not
voted as you requested.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Holders
of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">ADSs are transferable
on the books of the depositary. However, the depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books
of the depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so. These limitations
on transfer may have a material adverse effect on the value of the ADSs.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
are entitled to amend the deposit agreement and to change the rights of ADS holders under the terms of such agreement, or to terminate
the deposit agreement, without the prior consent of the ADS holders.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We are entitled to amend
the deposit agreement and to change the rights of the ADS holders under the terms of such agreement without the prior consent of the ADS
holders. We and the depositary may agree to amend the deposit agreement in any way we decide is necessary or advantageous to us or to
the depositary. Amendments may reflect, among other things, operational changes in the ADS program, legal developments affecting ADSs
or changes in the terms of our business relationship with the depositary. If an amendment adds or increases fees or charges, except for
taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar
items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary
notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold the ADSs,
to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended. If we make an amendment to the deposit agreement
that is disadvantageous to ADS holders or terminate the deposit agreement, the ADS holders may choose to sell their ADSs or surrender
their ADSs and become direct holders of the underlying ordinary shares, but they will have no right to any compensation whatsoever.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">75</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">ADSs
holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable
outcomes to the plaintiff(s) in any such action.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The deposit agreement
governing the ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, holders and beneficial owners
of ADSs irrevocably waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating
to the ADSs or the deposit agreement.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If this jury trial waiver
provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. If we
or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based
on the facts and circumstances of that case in accordance with the applicable state and federal law. We believe that a contractual pre-dispute
jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which governs the deposit agreement.
In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party
knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit
agreement and the ADSs.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If any holders or beneficial
owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs,
including claims under federal securities laws, such holder or beneficial owner may not be entitled to a jury trial with respect to such
claims, which may have the effect of limiting and discouraging lawsuits against us or the depositary. If a lawsuit is brought against
us or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would
be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including
results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims,
the judge or justice hearing such claims, and the venue of the hearing.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">No condition, stipulation
or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary
of compliance with any substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
presently anticipate that we will be classified as a passive foreign investment company, which could result in adverse U.S. federal income
tax consequences to U.S. Holders of our ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We would be classified
as a passive foreign investment company, or PFIC, for any taxable year if, after the application of certain look-through rules, either:
(i) 75% or more of our gross income for such year is &#8220;passive income&#8221; (as defined in the relevant provisions of the Internal
Revenue Code of 1986, as amended, or the Code), or (ii) 50% or more of the value of our assets (generally determined on the basis of a
quarterly average) during such year is attributable to assets that produce or are held for the production of passive income. Passive income
generally includes, among other things, rents, dividends, interest, royalties, gains from the disposition of passive assets, and gains
from commodities and securities transactions. For purposes of this test, we will be treated as owning a proportionate share of the assets
and earning a proportionate share of the income of any other corporation of which we own, directly or indirectly, at least 25% (by value)
of the stock. Based on the nature, composition and value of our income, operations and assets currently and in the future, we presently
anticipate that we will be a PFIC for United States federal income tax purposes for the current taxable year and in the foreseeable future.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Item 1B.</span><span style="font-family: Times New Roman,Times,serif">
<span style="font-weight: bold">Unresolved Staff Comments</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">None.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Item 2.<span id="Item2."><!--Anchor--></span></span><span style="font-family: Times New Roman,Times,serif">&#160;
<span style="font-weight: bold">Properties</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We lease a facility containing
3,961 square feet of laboratory and office space, which is located at Kiryat Atidim, Building 7, Tel Aviv,&#160;Israel 6158002. The lease
expires in October 30,&#160;2024 with an option to extend for an additional 36&#160;months. We believe that our current facilities are
sufficient to meet our current and near-term needs and that, should it be needed, suitable additional space will be available.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">76</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Item 3.</span><span style="font-family: Times New Roman,Times,serif">
<span id="Item3."><!--Anchor--></span>&#160; <span style="font-weight: bold">Legal Proceedings</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">From time to time, we
may be party to litigation or other legal proceedings that we consider to be a part of the ordinary course of our business. We are not
currently involved in any legal proceedings that could reasonably be expected to have a material adverse effect on our business, prospects,
financial condition or results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Item 4.</span><span style="font-family: Times New Roman,Times,serif">
<span id="Item4."><!--Anchor--></span>&#160; <span style="font-weight: bold">Mine Safety Disclosures</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold"><span id="PARTII"><!--Anchor--></span>PART&#160;II</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <span style="font-weight: bold">Item 5.<span id="Item5."><!--Anchor--></span>&#160;&#160;
Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Market
for our ADSs</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The ADSs, representing
our ordinary shares, have traded on Nasdaq under the symbol &#8220;CMMB&#8221; since the closing of the Merger on March 16, 2021. From
February 12, 2019 until the Merger, the ADSs, representing our ordinary shares, traded on Nasdaq under the symbol &#8220;ANCN&#8221;.
Prior to February 12, 2019, there was no public trading market for our ADSs.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">As of March 15, 2023,
there were seven holders of record of our ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Dividend
Policy</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We have never declared
nor paid any cash dividends on our shares. We currently intend to retain any future earnings and do not expect to pay any dividends in
the foreseeable future. Any future determination to declare cash dividends will be made at the discretion of our Board of Directors, subject
to applicable laws, and will depend on a number of factors, including our financial condition, results of operations, capital requirements,
contractual restrictions, general business conditions, and other factors that our Board of Directors may deem relevant.</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Purchases
of Equity Securities by the Issuer and Affiliated Purchasers</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 40.5pt; line-height: 1.25; color: rgb(0, 0, 0)">The following table summarizes the stock
repurchase activity for the three months ended December&#160;31, 2022:</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div> </div>

<table cellspacing="0" cellpadding="0" border="0" class="cfttable" id="zac2c0aa8208c4330b4c7adc29d389cf8" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 40%">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Period</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Total Number of ADSs Purchased</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Average Price Paid per Share</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Total Number of ADSs Purchased as Part of Publicly
        Announced Programs</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Approximate Dollar Value of Shares that May
        Yet Be Purchased Under the Programs(1)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 40%; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">November 16, 2022 <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 12%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">582,023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 12%; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">2.0848</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 12%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">582,023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 12%; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">1,218,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 40%; padding-bottom: 4px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Total</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 12%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">582,023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 12%; padding-bottom: 4px">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 12%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">582,023</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 12%; padding-bottom: 4px">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">(1) For additional
information about the Repurchase Arrangement, see&#160;Item 13 &#8211; Certain Relationships and Related Transactions.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Item 6.</span><span style="font-family: Times New Roman,Times,serif">
<span id="Item6."><!--Anchor--></span>&#160; [<span style="font-weight: bold">Reserved]</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160; <br /> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Item 7<span id="Item7"><!--Anchor--></span>.</span><span style="font-family: Times New Roman,Times,serif">
&#160; <span style="font-weight: bold">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">You
should read the following discussion and analysis of our financial condition and results of operations together with our consolidated
financial statements and the related notes included elsewhere in this Annual Report on Form&#160;10-K. Some of the information contained
in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes
forward-looking statements that involve risks and uncertainties. You should read &#8220;Cautionary Statement Regarding Forward-Looking
Statements&#8221; and Item 1A &#8220;Risk Factors&#8221; of this Annual Report on Form&#160;10-K for a discussion of important factors
that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained
in the following discussion and analysis.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">77</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Overview</div>

<div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25; color: rgb(0, 0, 0)">We are a clinical-stage biotechnology company
focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs. Based
on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, we developed CM-101, a monoclonal
antibody designed to bind and block CCL24 activity. We believe CM-101 has demonstrated the potential to treat multiple severe and life-threatening
fibrotic and inflammatory diseases.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25; color: rgb(0, 0, 0)">We have pioneered the therapeutic targeting
of CCL24, a chemokine that promotes various types of cellular processes that regulate inflammatory and fibrotic activities through the
CCR3 receptor. The chemokine is expressed in various types of cells, including immune cells, endothelial cells and epithelial cells. We
have developed a novel CCL24 inhibiting product candidate with dual anti-fibrotic and anti-inflammatory activity that modulates the complex
interplay of both of these inflammatory and fibrotic mechanisms, which drive abnormal states of fibrosis and clinical fibrotic diseases.
This innovative approach is being developed for difficult to treat rare diseases, also known as orphan indications or diseases, such as
PSC and SSc, for which patients have no established disease-modifying treatment options. We estimate that there are approximately 77 thousand
patients suffering from PSC in the U.S., EU and Japan, representing over a $1 billion market opportunity, and approximately 170 thousand
patients suffering from SSc in those same markets, representing over a $1.5 billion market opportunity.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">CM-101,
our lead clinical product candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of the soluble
chemokine CCL24, also known as eotaxin-2, as a regulator of major inflammatory and fibrotic pathways. We have demonstrated that CM-101
interferes with the underlying biology of inflammation and fibrosis through a novel and differentiated mechanism of action. Based on these
findings, we are actively advancing CM-101 in Phase 2 clinical studies directed toward two distinct clinical indications that include
patients with liver or skin, and/or lung fibrosis. We are currently conducting a Phase 2 clinical study in PSC, a rare obstructive and
cholestatic liver disease. The study is actively recruiting patients in the U.S., Europe and Israel and is being expanded by adding clinical
sites, an additional high dose arm (20mg/kg) as well as an open label extension. We had earlier proposed to add both low and high dose
arms to the study but the recent encouraging results reported from our Phase 2 liver fibrosis trial in NASH patients, dosed at 5mg/kg,
along with the positive Phase 1b data we previously reported in NAFLD patients dosed at 5mg/kg and 2.5mg/kg, are seen as providing us
sufficient data on the performance of the lower dose to drop it from the current trial, which is focusing on the 10mg/kg and 20g/kg doses.
We believe this change will facilitate timely conduct and completion of the trial. If regulators in the future do not agree that the existing
low dose data is sufficient, we always have the option to add a lower dose group as part of the Phase 3 clinical program.</div>

<div style="text-align: justify; text-indent: 35.25pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">&#160;</div>

<div style="text-indent: 35.25pt; line-height: 1.25; font-family: Times New Roman, Times, serif">We are also planning to open a Phase
2 clinical trial in SSc around midyear of 2023. The trial in SSc, a rare autoimmune rheumatic disease characterized by fibrosis in the
skin and lung and other organs, will focus on establishing biological and clinical proof of concept in this patient population. Although
our primary focus is on these two rare indications, as we noted, an additional Phase 2 clinical study in patients with liver fibrosis
due to non-alcoholic steatohepatitis (NASH) has recently been completed. This trial provided safety and pharmacokinetic (PK) data and
was informative in providing data that will help us determine whether we will advance the development of our current subcutaneous formulation
of CM-101. Additionally, the trial measured a number of biomarkers that may be relevant to the potential activity of CM-101 in other fibro-inflammatory
conditions. We recently reported results from this trial, which showed that the trial met its primary endpoint of safety and tolerability,
and that CM-101 demonstrated encouraging activity in secondary endpoints that include a range of liver fibrosis biomarkers and physiologic
assessments.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">78</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Components
of Operating Results</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Revenues</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">To date, we have not generated any revenue
from product sales and do not expect to generate any revenue from product sales in the near future. If development efforts for our product
candidates are successful and result in our receipt of necessary regulatory approvals, or if our development efforts otherwise lead to
any commercialized products or additional license agreements with third parties, then we may generate revenue in the future from product
sales.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Research
and Development Expenses, net</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Research and development expenses consist
primarily of costs incurred in connection with the development of our product candidates. These expenses include:</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z3a0267b9ab4b42fb889284562be67294" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">expenses incurred under agreements with clinical research organizations
        and contract manufacturing organizations, as well as investigative sites and consultants that conduct our clinical trials, preclinical
        studies and other scientific development services;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z0f92652cd90145ed9a347aff218f1981" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">manufacturing scale-up expenses and the cost of acquiring and
        manufacturing preclinical and clinical trial materials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z7081a8a7964e4262aaccf97137ef76e8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">employee-related expenses, including salaries, related benefits,
        travel and share-based compensation expenses for employees engaged in research and development functions, as well as external costs, such
        as fees paid to outside consultants engaged in such activities;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z9ac2a21f21fb493ba7bae0aec6b59d0c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">license maintenance fees and milestone fees incurred in connection
        with various license agreements;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="zfb7e9388f1d24dd0b050f3361c0ab5be" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">costs related to compliance with regulatory requirements; and</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="zc7ab63c581dc4ec4973b92d783031c82" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">depreciation and other expenses.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">We recognize external development costs based
on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">We do not allocate employee costs or facility
expenses, including depreciation or other indirect costs, to specific programs because these resources are deployed across multiple programs
and, as such, the related costs are not separately classified. We use internal resources primarily to oversee our research, as well as
for managing our preclinical development, process development, manufacturing and clinical development activities. Our employees work across
multiple programs; therefore, we do not track the related expenses by program.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Research and development activities are fundamental
to our business. Product candidates in later stages of clinical development generally have higher development costs than those in earlier
stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect
that our research and development expenses will increase substantially over the next several years as we continue to advance the development
of our product candidates. We also expect to incur additional expenses related to milestone and royalty payments payable to third parties
with whom we have entered into license agreements.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman, Times, serif; color: #000000; font-weight: normal; font-style: normal">79</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic">General
and Administrative Expenses</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">General and administrative expenses consist
primarily of salaries and related benefits, share-based compensation expenses for personnel in executive and administrative functions,
insurance and professional fees for legal, consulting, accounting and audit services.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">We anticipate that our general and administrative
expenses will increase in the future due to increased headcount and professional fees to support our continued research activities and
development of our product candidates. We also anticipate that we will continue to incur accounting, audit, legal, regulatory, compliance,
director and officer insurance costs, as well as investor and public relations expenses associated with being a public company. Additionally,
once we believe that regulatory approval of a product candidate appears likely, we will begin to incur a material increase in payroll
and related expenses as a result of preparation for commercial operations, particularly in respect of sales and marketing.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Financing
Expenses, Net</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Financing expenses, net consist primarily
of income or expenses related to revaluation of foreign currencies and interest income on our bank deposits.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Results
of Operations</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">The following table summarizes our results
of operations for the years ended December 31, 2022 and 2021:</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="zaf95e567aab642f2bb6987d76ccc532d" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Year ended December 31,</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold"> 2022</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">2021</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td rowspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
    <td rowspan="1" colspan="6" style="vertical-align: bottom; vertical-align: bottom">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">(in
        thousands</span><span style="font-family: Times New Roman,Times,serif">)</span></div> </td>
    <td rowspan="1" class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Operating Expenses:</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; vertical-align: bottom; background-color: #CCEEFF">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,serif"><br /> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: #CCEEFF; vertical-align: bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Research and development</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">16,977</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">6,334</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 76%; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">General and administrative</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">11,556</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">6,033</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Total operating expenses</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">28,533</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">12,367</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 76%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 76%; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Financing (income) expense, net</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">(353</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">111</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 76%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Loss before taxes</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">28,180</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">12,478</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Taxes on income (benefit)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">(534</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#8212;</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 76%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Net loss</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">27,646</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">12,478</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Our
results of operations have varied in the past and can be expected to vary in the future due to numerous factors. We believe that period-to-period
comparisons of our operating results are not necessarily meaningful and should not be relied upon as indications of future performance.</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>
</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Year
ended December 31, 2022 Compared to the Year Ended December 31, 2021</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic">Research
and development expenses</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Research and development expenses increased
by approximately $10.7 million, or 168%, to approximately $17.0 million for the year ended December 31, 2022 compared to approximately
$6.3 million for the year ended December 31, 2021. The increase resulted primarily from an increase in headcount and payments to consultants
and subcontractors for clinical and pre-clinical activities.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman, Times, serif; color: #000000; font-weight: normal; font-style: normal">80</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic">General
and administrative expenses</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">General and administrative expenses increased
by approximately $5.6 million, or 92%, to approximately $11.6 million for the year ended December 31, 2022 compared to approximately $6.0
million for the year ended December 31, 2021. This increase was primarily due to increase in headcount and professional fees and insurance
expense and share-based compensation.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; color: rgb(0, 0, 0); font-style: italic">Financing (income) expense,
net</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Financing expenses, net, increased by approximately
$464 thousand, or 418%, to net income of $353 thousand for the year ended December 31, 2022 compared to a net loss of $111 thousand for
the year ended December 31, 2021. Financing expense, net for the year ended December 31, 2022 was primarily related to foreign currency
exchange rate differences, offset by interest income on deposits. Financing income, net for 2021 was primarily related to interest income
on deposits, offset by foreign currency exchange rate differences.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; color: rgb(0, 0, 0); font-style: italic">Taxes on Income</div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Taxes on income, net, for the year ended December
31, 2022 were $534 thousand. The tax benefit is related to a tax return of Chemomab Therapeutics Inc., a wholly owned subsidiary of the
Company, derived by carryback of net operating losses. Chemomab Therapeutics Inc. received $351 thousand in December 2022 on account of
previous years and expects to receive the remainder $183 thousand in 2023.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Cash
Flows</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">The following table summarizes our cash flows
for the years ended December 31, 2022 and 2021:</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z0fd9049272834f989e234c26391eb1c9" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Year ended<br /> December 31,</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Increase/(decrease)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold"> 2022</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">2021</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: center; font-weight: bold">$</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td rowspan="1" class="cftcurrcell" colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; font-family: Times New Roman,Times,serif; text-align: center; vertical-align: bottom; font-weight: bold">%<br />
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-style: italic">(in thousands)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 52%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Net cash used in operating activities</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">(20,370</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">(12,374</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">(7,996</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">65</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 52%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Net cash provided by (used in) investing activities</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">19,533</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">(45,186</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">64,719</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">(143</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">)%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 52%; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Net cash provided by (used in) financing activities</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">(808</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">61,074</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">(61,882</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">(101</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">)%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 52%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Net increase (decrease) in cash, cash equivalents
        and restricted cash</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">(1,645</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">3,514</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">(5,159</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">(147</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">)%</div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic">Operating
activities</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Net cash used in operating activities for
the year ended December 31, 2022 was approximately $20.4 million and included net loss of $27.6 million, partially offset by net cash
used by changes in operating assets and liabilities of approximately $4.0 million and non-cash charges of $3.3 million, which mainly included
share-based compensation expenses.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Net cash used in operating activities for
the years ended December 31, 2021 was approximately $12.4 million and included net loss of $12.5 million, partially offset by net cash
provided by changes in operating assets and liabilities of $1.9 million and non-cash charges of $2.0 million, which mainly included share-based
compensation expenses.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic">Investing
activities</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Net cash provided by investing activities
for the year ended December 31, 2022 was approximately $19.5 million, which was primarily related to investment in short-term deposits
offset by purchasing of fixed assets.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman, Times, serif; color: #000000; font-weight: normal; font-style: normal">81</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Net cash used in investing activities for
the year ended December 31, 2021 was $45.2 million, which was primarily related to purchase of fixed assets and investment in bank deposits.</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic">Financing
activities</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Net cash used in financing activities for
the year ended December 31, 2022 was approximately $0.8 million, consisting of $0.3 million of proceeds from the sale of ADSs, $0.1 million
of proceeds from the exercise of stock options offset by the repurchase of shares in the amount of $1.2 million.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Net cash provided by financing activities
for the year ended December 31, 2021 was $61.1 million, consisting of $58.7 million of proceeds from the sale of ADSs, primarily from
the Private Placement (as defined and described below) and issuances under the Sales Agreement with Cantor, and $2.4 million of cash acquired
in the Merger.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Funding
Requirements</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">We expect our expenses to increase substantially
as we advance the clinical trials of our product candidate. In addition, we expect to continue to incur additional costs associated with
operating as a public company.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">We believe that our existing cash, cash equivalents
and bank deposits will enable us to fund our operating expenses and capital expenditure requirements at least through March 31, 2024.
We have based these estimates on assumptions that may prove to be wrong, and we could expend our capital resources sooner than we expect.
If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related
to product manufacturing, sales, marketing and distribution.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Until such time, if ever, that we generate
product revenue sufficient to achieve profitability, we expect to finance our cash needs through the sales of our securities and through
other outside funding sources. Debt financing and preferred equity financing, if available, may involve agreements that include covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring
dividends. If we raise additional funds through government and other third-party funding, collaboration agreements, strategic alliances,
licensing arrangements or marketing and distribution arrangements, then we may have to relinquish valuable rights to our technologies,
future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are
unable to raise additional funds through equity or debt financings when needed, then we may be required to delay, limit, reduce or terminate
our product development or future commercialization efforts or grant rights to develop and market products or product candidates that
we would otherwise prefer to develop and market.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Liquidity
and Capital Resources</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">In connection with the Merger, on March 15,
2021, we entered into Securities Purchase Agreements with certain investors, pursuant to which we agreed to sell approximately $45.5 million
of the ADSs in a private placement transaction (the Private Placement). The Private Placement closed on March 22, 2021, at which time
we sold 2,619,270 ADSs together with warrants to purchase up to 261,929 ADSs at an exercise price of $17.35 per ADS. The warrants expire
five years from the date of issuance, and, if exercised in full, will provide proceeds of approximately $4.5 million.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">On
April 30, 2021, we entered into the Sales Agreement with Cantor Fitzgerald &amp; Co. (Cantor). Pursuant to the Sales Agreement, we may
offer and sell, from time to time, &#160;ADSs having an aggregate offering price of up to $75 million through Cantor (the ATM Facility).
Sales of &#160;ADSs, if any, under the Sales Agreement will be issued and sold pursuant to our Registration Statement on Form S-3 which
was declared effective on May 17, 2021 and will be made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule
415(a)(4) promulgated under the Securities Act. &#160;Pursuant to the Sales Agreement, Cantor has agreed to act as sales agent on a best
efforts basis and use commercially reasonable efforts to sell on our behalf all of the ADSs we requested to be sold in accordance with
the Sales Agreement, consistent with Cantor&#8217;s normal trading and sales practices, on mutually agreed terms.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">82</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">On
April 25, 2022, we filed a prospectus supplement with the SEC for the issuance and sale of up to $18,125,000 of ADSs in connection with
the reactivation of the ATM Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits
the amount of securities we are able to offer and sell under such registration statement during any twelve month period to one-third of
our unaffiliated public float.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">During the year ended December 31, 2022,&#160;we&#160;sold
130,505 ADSs at an average price of USD 2.11 per ADS, through the ATM facility, resulting in gross proceeds of $275,000.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">As shown in the accompanying consolidated
financial statements, we have incurred losses and cash flow deficits from operations since inception, resulting in an accumulated deficit
at December 31, 2022 of approximately $64 million. We have financed operations to date primarily through public and private placements
of equity securities. We anticipate that we will continue to incur net losses for the foreseeable future. We believe that our existing
cash, cash equivalents and bank deposits will be sufficient to fund our projected cash needs at least&#160; through March 31, 2024. To
meet future capital needs we would need to raise additional capital through equity or debt financing or other strategic transactions.
However, any such financing may not be available to us on favorable terms or at all. Our failure to obtain sufficient funds on commercially
acceptable terms when needed would have a material adverse effect on our business, results of operations and financial condition.</div>
</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Current
Outlook</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">

<div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">

<div style="text-indent: 36pt; line-height: 1.25; color: #000000">We estimate that our current liquidity resources will allow us to execute
our business plans at least through March 31, 2024.</div>

<div style="line-height: 1.25">&#160;</div> </div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Developing drugs, conducting preclinical and
clinical trials, obtaining commercial manufacturing capabilities and commercializing products is expensive, and we will need to raise
substantial additional funds to achieve our strategic objectives. We will require significant additional financing in the future to fund
our operations, including if and when we progress into clinical trials of our product candidates, obtain regulatory approval for one or
more of our product candidates, obtain commercial manufacturing capabilities and commercialize one or more of our product candidates.
Our future capital requirements will depend on many factors, including, but not limited to:</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z3235fc600f7f4239aae5586c478d8688" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#9679;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">the progress and costs of our preclinical and clinical trials
        and other research and development activities;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z65e25cd03aeb4082be12d179e1eb3aef" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#9679;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">the scope, prioritization and number of our preclinical and clinical
        trials and other research and development programs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z0ce20ba2298845df91170ea553d1787e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#9679;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">the amount of revenues and contributions we receive under future
        licensing, collaboration, development and commercialization arrangements with respect to our product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="zcf3f1f37fe7d4ebeb7b1512460b837e4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#9679;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">the costs of development and expansion of our operational infrastructure;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z2082eb5ce19b40de8246130b86621a53" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#9679;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">the costs and timing of obtaining regulatory approval for one
        or more of our product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="zba68d422aa1b4c7bbc83f9bf87387ea8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#9679;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">our ability, or that of our collaborators, to achieve development
        milestones, marketing approval and other events or developments under potential future licensing agreements;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman, Times, serif; color: #000000; font-weight: normal; font-style: normal">83</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<table cellspacing="0" cellpadding="0" id="zddaf83a2cc27455998206ba4e1f318b3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#9679;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">the costs of filing, prosecuting, enforcing and defending patent
        claims and other intellectual property rights;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z2b98b6d6fd8e464d82638545e7b01a1c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#9679;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">the costs and timing of securing manufacturing arrangements for
        clinical or commercial production;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z1211b8333496468d837f27443d2079b3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#9679;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">the costs of contracting with third parties to provide sales
        and marketing capabilities for us or establishing such capabilities ourselves;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="zfae1b01c3fef406b8bb6f627eb54c7ef" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#9679;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">the costs of acquiring or undertaking development and commercialization
        efforts for any future products, product candidates or technology;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z6f5c1d5dc856455787f195202e81bc3d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#9679;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">the magnitude of our general and administrative expenses; and</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z21ee91f2f6704314a04198dbc84c948b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 5%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#9679;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">any additional costs that we may incur under future in- and out-licensing
        arrangements relating to one or more of our product candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Until we can generate significant recurring
revenues, we expect to satisfy our future cash needs through capital raising or by out-licensing and/or co-developing applications of
one or more of our product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, if at
all. If funds are not available, we may be required to delay, reduce the scope of or eliminate research or development plans for, or commercialization
efforts with respect to, one or more of our product candidates and make the necessary change to our operations to reduce the level of
our expenditures in line with available resources.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">We
are a development-stage company and it is not possible for us to predict with any degree of accuracy the outcome of our research and development
efforts. As such, it is not possible for us to predict with any degree of accuracy any significant trends, uncertainties, demands, commitments
or events that are reasonably likely to have a material effect on our net loss, liquidity or capital resources, or that would cause financial
information to not necessarily be indicative of future operating results or financial condition. However, to the extent possible, certain
trends, uncertainties, demands, commitments and events are described in this item.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Critical
Accounting Estimates</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Our financial statements are prepared in accordance
with generally accepted accounting principles in the United States (GAAP). The preparation of our financial statements and related disclosures
in accordance with GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue,
costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical
experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions
or conditions.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">While our significant accounting policies
are described in more detail in Note 2 to our consolidated financial statements, we believe that the following accounting estimates are
those that include a higher degree of judgment or complexity and are reasonably likely to have a material impact on our financial condition
or results of operations and are therefore considered critical accounting estimates.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman, Times, serif; color: #000000; font-weight: normal; font-style: normal">84</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic">Share-Based
Compensation</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">We apply Accounting Standard Codification
(ASC) 718-10, &#8220;Share-Based Payment,&#8221; which requires the measurement and recognition of compensation expenses for all share-based
payment awards made to employees and directors, including employee options under our option plans based on estimated fair values.</div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">ASC 718-10 requires that we estimate the fair
value of equity-based payment awards on the date of grant using an option-pricing model. The fair value of the award is recognized as
an expense over the requisite service periods in our statements of comprehensive loss. We recognize share-based award forfeitures as they
occur, rather than estimate by applying a forfeiture rate.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">In June 2018, the Financial Accounting Standards
Board (FASB) issued Accounting Standards Update (ASU) 2018-07, &#8220;Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee
Share-Based Payment Accounting&#8221;, which simplifies the accounting for nonemployee share-based payment transactions by aligning the
measurement and classification guidance, with certain exceptions, to that for share-based payment awards to employees. The amendments
expand the scope of the accounting standard for share-based payment awards to include share-based payment awards granted to non-employees
in exchange for goods or services used or consumed in an entity&#8217;s own operations and supersedes the guidance related to equity-based
payments to non-employees. We adopted these amendments on January 1, 2019.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">We recognize compensation expenses for the
fair value of non-employee awards over the requisite service period of each award.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">We estimate the fair value of options granted
as equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the
most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are
exercised or expire). We determine the fair value per share of the underlying stock by taking into consideration our most recent sales
of stock, as well as additional factors that we deem relevant. Our board determined the fair value of ordinary shares based on valuations
performed using the Option Pricing Method subject to relevant facts and circumstances. We have historically been a private company and
lack company-specific historical and implied volatility information of our stock. Expected volatility is estimated based on volatility
of similar companies in the biotechnology sector. Historically, we have not paid dividends and have no foreseeable plans to issue dividends.
The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term
is calculated for options granted to employees and directors using the &#8220;simplified&#8221; method. Grants to non-employees are based
on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the options granted and our results
of operations.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Quantitative
and Qualitative Disclosures about Market Risks</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Foreign
Currency Exchange Risk</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Our functional currency is the U.S. Dollar.
We are exposed to foreign exchange rate risk. We are located in Israel, where part of our general and administrative expenses costs is
incurred in New Israeli Shekels. During each of the years ended December 31, 2022 and 2021, we recognized foreign currency transaction
loss of $609 thousand and $176 thousand, respectively. These foreign currency transaction gains and losses were recorded in financial
expenses. We believe that a 10% change in the exchange rate between the U.S. Dollar and New Israeli Shekel would not have a material impact
on our financial position or results of operations.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">As we continue to grow our business, our results
of operations and cash flows will be subject to fluctuations due to changes in foreign currency exchange rates, which could adversely
impact our results of operations. To date, we have not entered into any foreign currency hedging contracts to mitigate our exposure to
foreign currency exchange risk.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Item 7A<span id="Item7A"><!--Anchor--></span>.</span><span style="font-family: Times New Roman,Times,serif">
<span style="font-weight: bold">Quantitative and Qualitative Disclosures About Market Risk.</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">As a smaller reporting
company, we are not required to provide the information required by this item.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">85</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Item 8.<span id="Item8."><!--Anchor--></span></span><span style="font-family: Times New Roman,Times,serif">&#160;&#160;
<span style="font-weight: bold">Financial Statements and Supplementary Data</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">See the Index to Consolidated
Financial Statements on Page&#160;F-1 attached hereto.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Item 9.<span id="Item9."><!--Anchor--></span></span><span style="font-family: Times New Roman,Times,serif">&#160;&#160;
<span style="font-weight: bold">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">None.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Item 9A<span id="Item9A"><!--Anchor--></span>.</span><span style="font-family: Times New Roman,Times,serif">
<span style="font-weight: bold">Controls and Procedures</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 18pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">A.</span><span style="font-family: Times New Roman,Times,serif">&#160;&#160;&#160;
<span style="font-weight: bold">Disclosure Controls and Procedures</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We have evaluated, with
the participation of our chief executive officer and chief financial officer, the effectiveness of our disclosure controls and procedures
(as that term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2022. There are inherent limitations
to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention
or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable
assurance of achieving their control objectives. Based upon our evaluation, our chief executive officer and chief financial officer concluded
that our disclosure controls and procedures were effective as of December 31, 2022 to provide reasonable assurance that information required
to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within
the time periods specified in the applicable rules and forms, and that it is accumulated and communicated to our management, including
our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">B.</span><span style="font-family: Times New Roman,Times,serif">&#160;&#160;&#160;
<span style="font-weight: bold">Management&#8217;s Annual Report on Internal Controls Over Financial Reporting</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our management is responsible
for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is
defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;promulgated under the Exchange Act as a process designed by, or under the supervision
of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP and includes those policies and procedures that:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd4574da6861448f7a0b1b05da15f4576" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of
        our assets;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z03124f601f904fa8a068e5f6495fffd7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
        with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management; and</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3cc6d727c274460ea38afc4386f7eb8c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets
        that could have a material effect on the financial statements.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Because of its inherent
limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness
to future periods are subject to the risks that controls may become inadequate because of changes in conditions or that the degree of
compliance with the policies or procedures may deteriorate.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our management, including
our Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting at
December&#160;31, 2022. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations
of the Treadway Commission (COSO) in Internal Control&#8212;Integrated Framework (2013). Based on that assessment under those criteria,
management determined that, as of December&#160;31, 2022, our internal control over financial reporting was effective.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">C.</span><span style="font-family: Times New Roman,Times,serif">&#160;&#160;&#160;
<span style="font-weight: bold">Attestation Report of the Registered Public Accounting Firm</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">This Annual Report on
Form 10-K does not include an attestation report of our registered public accounting firm due to the Company&#8217;s status as an emerging
growth company, as defined in Rule 12b-2 of the Exchange Act.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">D.</span><span style="font-family: Times New Roman,Times,serif">&#160;&#160;&#160;
<span style="font-weight: bold">Changes in Internal Control over Financial Reporting</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">There were no changes
in our internal controls over financing reporting during the last fiscal year.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Item 9B<span id="Item9B"><!--Anchor--></span>.</span><span style="font-family: Times New Roman,Times,serif">
<span style="font-weight: bold">Other Information</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">None.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Item 9C<span id="Item9C"><!--Anchor--></span>.</span><span style="font-family: Times New Roman,Times,serif">
<span style="font-weight: bold">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">None.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">86</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold"><span id="PARTIII"><!--Anchor--></span>PART&#160;III</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Item 10<span id="Item10"><!--Anchor--></span>.</span><span style="font-family: Times New Roman,Times,serif">
<span style="font-weight: bold">Directors, Executive Officers and Corporate Governance</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our directors and executive
officers, their ages and positions as of the date of this Annual Report on Form 10-K are as follows:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z92725b6641a249a3b5888071d96cd489" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Name</div> </td>
    <td class="cftguttercell" colspan="1" style="font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Age</div> </td>
    <td class="cftfncell" colspan="1" style="white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Position</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-style: italic">Executive Officers:</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Dale Pfost&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9.08%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); text-align: left">65</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Chairman of the Board, Chief Executive Officer</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Donald Marvin&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9.08%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); text-align: left">70</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Chief Financial Officer, Executive Vice President and Chief Operating
        Officer</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Adi Mor</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9.08%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); text-align: left">41</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Director, Chief Scientific Officer</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Matthew Frankel</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9.08%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); text-align: left">54</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Chief Medical Officer</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-style: italic">Non-Employee Directors:</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 9.08%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 44.42%">&#160;&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Nissim Darvish&#8224;(2)(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9.08%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); text-align: left">57</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Director</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Alan Moses&#8224;(1)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9.08%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); text-align: left">74</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Director</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Claude Nicaise&#8224;(1)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9.08%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); text-align: left">69</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Director</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Neil Cohen&#8224;(2)(3)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9.08%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); text-align: left">58</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Director</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Jill Quigley&#8224;(1)</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9.08%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); text-align: left">47</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1.04%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255); font-family: Times New Roman,Times,serif; width: 44.42%">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Director</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">&#8224;
Independent Director</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" border="0" id="z383fb32471eb4f21ade40190b7f9aa7f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 3%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">(1)</div> </td>
    <td style="width: 97%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Member of Audit Committee</div> </td> </tr>
  <tr>
    <td style="width: 3%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">(2)</div> </td>
    <td style="width: 97%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Member of Compensation Committee</div> </td> </tr>
  <tr>
    <td style="width: 3%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">(3)</div> </td>
    <td style="width: 97%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Member of Corporate Governance and Nominating Committee</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Executive Officers</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Dr.
Dale Pfost</span><span style="font-family: Times New Roman,Times,serif">&#160;has served as our Chief Executive Officer and a member of
our Board since October 2021, and also as chairman of our Board since February 2022. Dr. Pfost has 35 years of experience as an entrepreneur,
investor and business executive. From 2019 to 2021, Dr. Pfost served as Chief Executive Officer and Chairman of the Board of Lodo Therapeutics
Corporation. From 2009 until 2019, Dr. Pfost served in a variety of roles at Microbiome Therapeutics, LLC, a company which he co-founded,
including as a board member and Chief Executive Officer from 2009 until 2010 and again from 2016 until 2019. From 2010 until 2019, he
served as a General Partner at Advent Life Sciences. From 2013 until 2017, Dr. Pfost served in a variety of roles at Vestagen Protective
Technologies, including Chairman, Executive Chairman from 2013 until 2017, and Chief Executive Officer from 2015 until 2016. Prior to
that, Dr. Pfost held various executive positions at the following companies: Chief Executive Officer at Receptor Biologix Inc. (from 2008
until 2009), President, Chief Executive Officer and Chairman at Acuity Pharmaceuticals, Inc. (from 2003 until 2007), President, Chief
Executive Officer and Chairman at Orchid BioSciences, Inc. (from 1996 until 2002), President, Chief Executive Officer and Managing Director
at Oxford Glycosciences Ltd. (from 1988 until 1996) and Director of Robotics and Automated Chemistry Systems at SmithKline Beckman (1984
until 1988). In addition to the foregoing, Dr. Pfost has served on the board of directors of several companies, including Bioelectronica
Corp., AxoSim, Inc., JMB Companies LLC, Aura Bioscience, Louisiana BIO, CN Creative and Ancilia Biosciences. Dr. Pfost earned his BS degree
from the University of California, Santa Barbara, and a PhD in physics from Brown University.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Donald
Marvin </span><span style="font-family: Times New Roman,Times,serif">has served as our Chief Financial Officer, Executive Vice President
and Chief Operating Officer since November 8, 2021. Mr. Marvin has more than 35 years of experience at growth enterprises in corporate
finance and fundraising, strategy, corporate development, mergers and acquisitions, and operations. Mr. Marvin served as Executive Vice
President and Chief Financial Officer of Lodo Therapeutics from 2020 until 2021. He was previously Chairman, President and CEO of Concentric
from 2014 to 2021. Prior to his positions at Concentric, Mr. Marvin was Managing Partner of Cairn Associates from 2006 until 2014. He
was President and CEO of IdentiGEN from 2006 until 2009. Mr. Marvin was a co-founder of Orchid BioSciences, where he served as Chief Operating
Officer, CFO and Senior Vice President of Corporate Development from 1997 to 2003, and President and Chief Executive Officer of Diatron
Corporation from 1986 until 1994. Earlier in his career, Mr. Marvin held positions of increasing responsibility at Abbott, Boehringer
Ingelheim, Bayer, and PepsiCo. Mr. Marvin earned a Bachelor of Science degree from The Ohio State University and an MBA from Iona College.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">87</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Dr.
Adi Mor</span><span style="font-family: Times New Roman,Times,serif">&#160;is the co-founder of Chemomab Ltd. and served as Chemomab Ltd.&#8217;s
Chief Executive Officer, Chief Scientific Officer and a member of Chemomab Ltd.&#8217;s board of directors from its formation in 2011
until the Chemomab Ltd.-Anchiano Therapeutics Ltd. merger that was consummated on March 16, 2021 (the &#8220;Merger&#8221;), and has continued
to serve in those capacities for our company thereafter. Dr. Mor&#8217;s tenure as the Company&#8217;s Chief Executive Officer concluded
simultaneously with the approval of Dr. Dale Pfost&#8217;s employment by the Company&#8217;s shareholders on October 25, 2021. Dr. Mor
has in-depth knowledge in immunology focusing on rare diseases and broad experience in designing, developing and patenting a novel class
of monoclonal antibodies to treat inflammatory and fibrotic diseases. Dr. Mor received her Ph.D. in immunology from Tel Aviv University
in the Department of Neurobiochemistry in Israel and is the lead author of numerous scientific journal publications in immunology and
inflammatory disorders.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Dr.
Matthew B. Frankel</span><span style="font-family: Times New Roman,Times,serif"> has 20 years of experience in the pharmaceutical industry,
encompassing clinical development and medical affairs. From 2018 until November 2022, Dr. Frankel served as Vice President, Clinical Development
and Medical Affairs, Specialty Pharma at Boehringer-Ingelheim Pharmaceuticals, Inc. Prior to that, he served as the Vice President &amp;
Head, Immunology and Dermatology Medical Unit at Novartis Pharmaceuticals Corporation from 2016 to 2018. From 2012 to 2016, Dr. Frankel
served as the Executive Medical Director of Sandoz and from 2010 through 2012 held the role of Global Medical Director, Clinical Development
at Reata Pharmaceuticals (RETA). From 2003 through 2010, he held various senior roles across different companies in the research field.
Dr. Frankel received his undergraduate degree from Vassar College, his MD from the University of California, Los Angeles School of Medicine,
and his MBA from the J. L. Kellogg Graduate School of Management.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Directors</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 30.7pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">&#160;
Nissim Darvish</span><span style="font-family: Times New Roman,Times,serif">, M.D., Ph.D.&#160;has served on our Board since March 16,
2021. Dr. Darvish is a General Partner at MeOhr Ventures, a venture capital fund. Dr. Darvish currently serves as a director of several
private companies. Prior to his current position, Dr. Darvish served as a Venture Partner at OrbiMed Israel and as a member of the boards
of directors of 9 Meters Biopharma Inc. and Medigus Ltd. Previously, Dr. Darvish was employed at Pitango Venture Capital, where he was
a General Partner managing life sciences investments. He was also the founder and CEO of Impulse Dynamics, where he oversaw a $250 million
realization event. Dr. Darvish obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently
conducted his post-doctoral research at NIH. He has published over 100 patents and authored over 20 publications.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 30.7pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">&#160;
Alan Moses, MD, FACP</span><span style="font-family: Times New Roman,Times,serif">&#160;has served on our Board since March 16, 2021.
Dr. Moses is board certified by the ABIM with subspecialty certification in Endocrinology and Metabolism and is a Fellow of the American
College of Physicians. Dr. Moses currently serves on the board of directors of BioFabUSA, a position he has held since 2018. Prior to
that time, from 2008 to 2018, Dr. Moses served as the Global Chief Medical Officer of Novo Nordisk A/S (CPH: NOVO-B), a company he joined
in 2004. Dr. Moses served as a Professor of Medicine at Harvard Medical School from 2002 to 2006, and in collaboration with MIT, he co-founded
and co-directed the Clinical Investigator Training Program, which focused on training physician-scientists in translational research.
Dr. Moses previously served as the Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center from 1998 to 2004. Dr.
Moses holds a BS from Duke University, North Carolina and an MD from Washington University School of Medicine, Missouri.</span></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Claude
Nicaise, MD</span><span style="font-family: Times New Roman,Times,serif">&#160;has served on our Board since March 16, 2021. Dr. Nicaise
is a physician with extensive U.S. and international experience in clinical drug development, strategic management, worldwide regulatory
strategy, pharmaceuticals, biotechnology, including clinical cancer research, infectious diseases and neuroscience. Dr. Nicaise is the
owner and founder of Clinical Regulatory Services, which provides consulting services to the life science and biotechnology industry in
support of all aspects of clinical and regulatory development. Since 2015, Dr. Nicaise has served on the board of directors and as the
Chairman of the Compensation Committee of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Dr Nicaise has also served on the board of directors
of Mynoryx Therapeutics since 2017. Prior to that time, from 2008 to 2014, Dr. Nicaise served as the Senior Vice President of Alexion
Pharmaceuticals Inc. (NASDAQ: ALXN), and between 1984 and 2008, he held numerous senior management roles at Bristol Myers Squibb (NYSE:
BMY). Dr. Nicaise holds an MD and a degree in Internal Medicine, Clinical Oncology, from Brussels University, Belgium.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">88</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160; <span style="font-style: italic">Neil Cohen</span>&#160;has served as a member of our Board since April 2020 and served as
our interim Chief Executive Officer from October 2020 until the consummation of the Merger. Mr. Cohen has served as the Chairman and Chief
Executive Officer of Castel Partners Ltd. since January 2012. In 1994, he co-founded Israel Seed Partners, a leading venture capital firm,
and managed the firm until 2019. Mr. Cohen has invested in and served on the boards of directors of many private technology companies,
including a large number which were acquired or completed successful initial public offerings, including Compugen (Nasdaq: CGEN), Shopping.com
(Nasdaq: SHOP, acquired by EBAY), Broadlight (acquired by Broadcom, Nasdaq: AVGO) and Cyota (acquired by RSA). He is a venture partner
at SKY, an Israeli middle-market private equity firm, Hetz Ventures Management Ltd., an early-stage Israeli venture capital fund, and
Shavit Capital. Mr. Cohen was previously the Business Editor of The Jerusalem Post and began his career in the private equity group at
N M Rothschild &amp; Sons Limited in London. Mr. Cohen received a B.A. and M.A. in Oriental Studies, with first class honors, from Oxford
University.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Jill
M. Quigley</span><span style="font-family: Times New Roman,Times,serif"> has served as a member of our Board since June 2022. Since December
2020, Ms. Quigley has served as a member of the board of directors of Terns Pharmaceuticals, Inc. (Nasdaq: TERN), including her role as
chairperson of its audit committee. From November 2018 until December 2021, Ms. Quigley served as Chief Operating Officer of Passage BIO,
Inc. (Nasdaq: PASG). Previously, she served as the Interim Chief Executive Officer and General Counsel of Nutrinia, Inc., from January
2016 to November 2018. From July 2012 to January 2016, Ms. Quigley served in various roles at Shire plc, most recently as Senior Legal
Counsel. Ms. Quigley received her undergraduate degree in Communications, Legal Institutions, Economics &amp; Governance (CLEG) from American
University and J.D. from Rutgers School of Law.</span></div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Overall
Role of the Board and Board Leadership Structure</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 34.5pt; line-height: 1.25; color: rgb(0, 0, 0)">&#160;Under the Israeli Companies Law, 5759-1999
(the &#8220;Companies Law&#8221;), our Board is responsible for setting our general policies and supervising the performance of management.
Our Board may exercise all powers and may take all actions that are not specifically granted by the Companies Law or our articles of association
to our shareholders or to management. Our executive officers are responsible for our day-to-day management and have individual responsibilities
established by our Board.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 34.5pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;Under
the Companies Law, the chief executive officer of a public company, or a relative of the chief executive officer, may not serve as the
chairperson of the board of directors of such public company, and the chairperson of the board of directors of a public company, or a
relative of the chairperson, may not be vested with authorities of the chief executive officer of such public company without obtaining
shareholder approval pursuant to special majority requirements set forth in the Companies Law.</div>

<div style="text-align: justify; text-indent: 25.5pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 34.5pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;During
a special general meeting of our shareholders held on February 10, 2022, our shareholders approved the appointment of Dr. Dale Pfost as
Chairperson of our board of directors in addition to his role as our Chief Executive Officer. According to the Companies Law and the regulations
promulgated thereunder, such appointment is valid for a three-year term and such re-appointment shall be subject to shareholder approval.</div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 34.5pt; line-height: 1.25; font-family: Times New Roman,serif"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">&#160;Our
Board is currently composed of seven (7) members. Our Board consists of three classes of directors (as illustrated below), each serving
staggered three-year terms. Upon expiration of the term of a class of directors, directors in that class will be elected for a three-year
term at the Annual General Meeting of shareholders in the year in which that term expires. Each director&#8217;s term continues until
the election and qualification of his or her successor, or his or her earlier death, resignation or removal. Any increase or decrease
in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of&#160;one-third&#160;of
the directors. </span><span style="font-family: Times New Roman,Times,serif">The division of our board of directors into three classes
with staggered three-year terms may delay or prevent a change of management or a change of control of our company.</span></div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd30e617ae9524fa08955c170bc9c9a9e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td colspan="1" style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Class I consists of Nissim Darvish and Jill Quigley, each with
        a term expiring at the 2025 annual meeting of shareholders.</div> </td> </tr>
  <tr>
    <td colspan="1" style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Class II consists of Neil Cohen and Claude Nicaise, each with
        a term expiring at the 2023 annual meeting of shareholders.</div> </td> </tr>
  <tr>
    <td colspan="1" style="width: 5%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 1.47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#8226;</div> </td>
    <td style="width: 94%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Class III consists of Adi Mor, Alan Moses and Dale Pfost, each
        with a term expiring at the 2024 annual meeting of shareholders.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">89</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Board
Leadership Structure</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 34.5pt; line-height: 1.25; color: rgb(0, 0, 0)">&#160;The Company is led by Dr. Dale Pfost,
who has served as our Chief Executive Officer and Chairman of the Board since October 2021 and February 2022, respectively.&#160;<span style="font-weight: bold">&#160;</span>Although
the Board does not have a formal policy on whether the roles of Chief Executive Officer and Chairman of the Board should be separated,
we believe that our current board leadership structure is suitable for us.&#160; The Chief Executive Officer is the individual selected
by the Board to manage our company on a day to day basis, and his direct involvement in our business operations makes him best positioned
to lead productive Board strategic planning sessions and determine the time allocated to each agenda item in discussions of our company&#8217;s
short- and long-term objectives.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Role
of the Board in Risk Oversight</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 34.5pt; line-height: 1.25; color: rgb(0, 0, 0)">&#160;Our Board is responsible for overseeing
our risk management process. Our Board focuses on our general risk management strategy, the most significant risks facing us, and oversees
the implementation of risk mitigation strategies by management. Our Board is also apprised by management of particular risk management
matters in connection with its general oversight and approval of corporate matters and significant transactions.&#160; The Board&#8217;s
independent oversight function is further enhanced by the fact that all of the Board&#8217;s Committees are composed entirely of independent
directors, the directors have complete access to management and the Board and its committees may retain their own respective advisors.</div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Corporate
Governance Guidelines</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 30.7pt; line-height: 1.25; color: rgb(0, 0, 0)">&#160; Our Board strongly supports effective
corporate governance and has developed and followed a program of strong corporate governance. Our Corporate Governance and Nominating
Committee is responsible for overseeing our guidelines and reporting and making recommendations to the Board concerning corporate governance
matters. Our guidelines are published on our website at https://investors.chemomab.com/documents and are available in print to any shareholder
who requests them from our Corporate Secretary (or, in the absence thereof, by the Chief Executive Officer of the Company).</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Director
Independence</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">&#160;Based upon information requested from
and provided by each director concerning their background, employment and affiliations, including family relationships, our Board has
determined that each of the directors is independent as defined under Nasdaq listing standards, with the exceptions of Dr. Mor and Dr.
Pfost. Our Board also determined that Nissim Darvish and Neil Cohen, who comprise the Compensation Committee and Neil Cohen and Nissim
Darvish, who comprise the Corporate Governance and Nominating Committee, all satisfy the independence standards for such committees established
by the SEC and Nasdaq listing standards, as applicable. With respect to the Audit Committee, our Board has determined that Jill Quigley,
Alan Moses and Claude Nicaise satisfy the independence standards for such committee established by Rule 10A-3 under the Exchange Act,
the SEC and Nasdaq listing standards, as applicable, and that Jill Quigley is a financial expert under the rules of the SEC. The Board
considered the relationships between such directors and certain of the investors of the Company and determined that such relationships
did not affect such directors&#8217; independence under the standards of Nasdaq, or, where applicable, under SEC rules.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Code
of Business Conduct and Ethics</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">We
have adopted a Code of Business Conduct and Ethics that includes provisions ranging from restrictions on gifts to conflicts of interest.
All of our employees and directors are bound by this Code of Business Conduct and Ethics. Violations of our Code of Business Conduct and
Ethics may be reported to the Audit Committee. The Code of Business Conduct and Ethics includes provisions applicable to all of our employees,
including senior financial officers and members of our Board and is posted on our website (</span><span style="font-family: Times New Roman,Times,serif; font-style: italic">https://investors.chemomab.com/</span><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">).
We intend to post amendments to or waivers from any such Code of Business Conduct and Ethics.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">90</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Other
Policies</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Our insider trading and blackout policy prohibits
directors, officers and employees from engaging in transactions in publicly traded options, such as puts and calls, and other derivative
securities with respect to our securities. This prohibition extends to any hedging or similar transactions designed to decrease the risks
associated with holding our securities.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Board
Meetings</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">The Board meets regularly during the year
and holds special meetings and acts by unanimous written consent whenever circumstances require. Independent directors meet at regular
executive sessions without management present. During fiscal year 2022, the Board held 12 meetings and conducted certain business by unanimous
consent. All of our directors are encouraged to attend our Annual Meeting of shareholders. Each of our directors attended at least 75%
of the aggregate of the total number of meetings of the Board and the total number of meetings held by all committees of the Board on
which such director served. Directors are expected to attend the Annual General Meeting.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Board
Committees</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Our Board has established the following committees.
Each committee operates in accordance with a written charter that sets forth the committee&#8217;s structure, operations, membership requirements,
responsibilities and authority to engage advisors.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Audit
Committee</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Under the Companies Law, the Exchange Act
and Nasdaq rules, we are required to establish an Audit Committee, and we have a separately-designated standing audit committee established
in accordance with section 3(a)(58)(A) of the Exchange Act.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">The responsibilities of an Audit Committee
under the Companies Law include identifying and addressing flaws in the business management of the company, reviewing and approving related
party transactions, establishing whistleblower procedures, overseeing the company&#8217;s internal audit system and the performance of
its internal auditor, and assessing the scope of the work and recommending the fees of the company&#8217;s independent accounting firm.
In addition, the Audit Committee is required to determine whether certain related party actions and transactions are &#8220;material&#8221;
or &#8220;extraordinary&#8221; for the purpose of the requisite approval procedures under the Companies Law and to establish procedures
for considering proposed transactions with a controlling shareholder.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">In accordance with U.S. law and Nasdaq requirements,
our Audit Committee is also responsible for the appointment, compensation and oversight of the work of our independent auditors and for
assisting our Board in monitoring our financial statements, the effectiveness of our internal controls and our compliance with legal and
regulatory requirements.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Under the Companies Law and related regulations,
the Audit Committee must consist of at least three directors who meet certain independence criteria. Under the Nasdaq rules, we are required
to maintain an Audit Committee consisting of at least three independent directors, all of whom are financially literate and one of whom
has accounting or related financial management expertise. Each of the members of the Audit Committee is required to be &#8220;independent&#8221;
as such term is defined in Rule 10A-3(b)(1) under the Exchange Act.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">The members of the Audit Committee are Jill
Quigley, Alan Moses and Claude Nicaise. Jill Quigley is the chairperson of the Audit Committee and is a financial expert under the rules
of the SEC. Our Board has concluded that the composition of the Audit Committee meets the requirements for independence under the rules
and regulations of Nasdaq and the SEC.&#160;During fiscal year 2022, the Audit Committee held 5 meetings.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Compensation
Committee</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">Under both the Companies Law and Nasdaq rules,
we are required to establish a Compensation Committee.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman, Times, serif; color: #000000; font-weight: normal; font-style: normal">91</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">The responsibilities of a Compensation Committee
under the Companies Law include recommending to the Board, for ultimate shareholder approval by a special majority, a policy governing
the compensation of directors and officers based on specified criteria, reviewing modifications to and implementing such compensation
policy from time to time, and approving the actual compensation terms of directors and officers prior to approval by the Board.</div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">In accordance with U.S. law and Nasdaq requirements,
our Compensation Committee is also responsible for the appointment, compensation and oversight of the work of any compensation consultant,
independent legal counsel and other advisors retained by the Compensation Committee.</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">The Companies Law and related regulations
require the appointment of a Compensation Committee that complies with the requirements of Nasdaq. Under Nasdaq rules, we are required
to maintain a Compensation Committee consisting of at least two independent directors; each of the members of the Compensation Committee
is required to be independent under Nasdaq rules relating to Compensation Committee members, which are different from the general test
for independence of board and committee members. The members of the Compensation Committee are Nissim Darvish and Neil Cohen. Nissim Darvish
is the chairperson of the Compensation Committee. Our Board has determined that each member of the Compensation Committee is independent
within the meaning of the independent director guidelines of Nasdaq and under Rule 10C-1 under the Exchange Act. During fiscal year 2022,
the Compensation Committee held six meetings and conducted certain business by unanimous consent.</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Corporate
Governance and Nominating Committee</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">We have established a Corporate Governance
and Nominating Committee, responsible for making recommendations to the Board regarding candidates for directorships and the size and
composition of the board. In addition, the committee is responsible for overseeing our corporate governance guidelines and reporting and
making recommendations to the board concerning corporate governance matters. Under the Companies Law, nominations for director may also,
under certain circumstances, be made by shareholders in accordance with the conditions prescribed by applicable law and our articles of
association. The members of the Corporate Governance and Nominating Committee are Neil Cohen and Nissim Darvish. Neil Cohen is the chairperson
of the Corporate Governance and Nominating Committee. Our Board has determined that each member of the Corporate Governance and Nominating
Committee is independent within the meaning of the independent director guidelines of Nasdaq.&#160;During fiscal year 2022, the Compensation
Committee held one meeting and conducted certain business by unanimous consent.</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Board
Diversity</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;&#160;
While we do not currently have a formal diversity policy with respect to Board composition, the Board believes it is important for the
Board to have gender, race and ethnicity diversity along with diversity of knowledge base, professional experience and skills. The Corporate
Governance and Nominating Committee takes these qualities into account when considering director nominees for recommendation to the Board.
We believe diversity enhances our effectiveness. Our Board currently has two female directors and two members with racial diversity. However,
the Board remains committed to achieving a Board composition that represents a diversity of background and experience, inclusive of race,
ethnicity, gender and sexual orientation. We will disclose a matrix with additional information about our board diversity in our proxy
statement on Schedule 14A in connection with our annual general meeting of the shareholders to be convened in 2023.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Internal
Auditor</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160; Under
the Companies Law, the board of directors is required to appoint an internal auditor recommended by the Audit Committee. The role of the
internal auditor is to examine, among other things, whether the company&#8217;s actions comply with applicable law and proper business
procedures. The internal auditor may not be an interested party, a director or an officer of the company, or a relative of any of the
foregoing, nor may the internal auditor be our independent accountant or a representative thereof. Grant Thornton Israel currently serves
as our internal auditor.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Section 16(a) Beneficial
Ownership Reporting Compliance</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section
16(a) of the Exchange Act requires our directors, executive officers and holders of more than 10% of our ADSs to file with the SEC reports
regarding their ownership and change in ownership of our equity securities.&#160; We believe that all Section 16 filings requirements
were met by such persons during the fiscal year ended December 31, 2022.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">92</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Code of Business Conduct
and Ethics</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">We have adopted a Code
of Business Conduct and Ethics that includes provisions ranging from restrictions on gifts to conflicts of interest. All of our employees
and directors are bound by this Code of Business Conduct and Ethics. Violations of our Code of Business Conduct and Ethics may be reported
to the Audit Committee. The Code of Business Conduct and Ethics includes provisions applicable to all of our employees, including senior
financial officers and members of our Board of Directors and is posted on our website. We intend to post amendments to or waivers from
any such Code of Business Conduct and Ethics.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Item 11<span id="Item11"><!--Anchor--></span>.</span><span style="font-family: Times New Roman,Times,serif">
<span style="font-weight: bold">Executive Compensation</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Summary Compensation Table</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">The table and summary
below outline the compensation granted to individuals who served in the role of chief executive officer during the previous fiscal year
and our three most highly compensated executive officers with respect to the year ended December 31, 2022. For purposes of the table and
the summary below, &#8220;compensation&#8221; includes base salary, bonuses, equity-based compensation, retirement or termination payments,
benefits and perquisites such as car, phone and social benefits and any undertaking to provide such compensation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="zcfa1c46078d545129df5f5da2ffb77aa" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif; font-weight: bold; width: 19%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Name and Principal Position</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; font-weight: bold; width: 1%; padding-bottom: 2px">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 20%">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Year</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Salary (1) ($)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Bonus (2) ($)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Option<br /> Awards (3) ($)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; font-weight: bold; padding-bottom: 2px; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; font-weight: bold; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">All Other<br /> Compensation (4) ($)</div>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; font-weight: bold; padding-bottom: 2px; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; font-weight: bold; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Total ($)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 19%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Dale Pfost&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 20%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">2021</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">182,557</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">300,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">22,868</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">505,425</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 19%">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Chief
        Executive Officer and Chairman</span><span style="font-family: Times New Roman,Times,serif"> (5)</span></div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 20%; text-align: center">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">2022</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">600,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">300,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">1,500,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">75,160</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">2,475,160</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 19%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 20%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 19%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Adi Mor&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 20%">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">2021</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">248,547</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">167,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">8,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">64,453</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">488,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 19%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Chief
        Scientific Officer, Director and Previous Chief Executive Officer </span><span style="font-family: Times New Roman,Times,serif">(6)</span></div>
        </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 20%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">2022</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">298,470</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">120,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">16,926</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">435,396</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 19%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 20%">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 19%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Donald Marvin&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 20%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">2021</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">88,276</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">102,390</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">11,590</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">202,256</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 19%">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Chief
        Financial Officer, Executive Vice President and Chief Operating Officer</span><span style="font-family: Times New Roman,Times,serif">
        (7)</span></div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 20%; text-align: center">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">2022</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">460,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">207,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">660,252</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">60,397</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">1,387,649</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 19%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 20%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 19%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Sigal Fattal&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 20%">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">2021</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">127,050</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">122,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">616,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">8,952</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">874,002</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; width: 19%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Previous
        Interim Chief Financial Officer</span><span style="font-family: Times New Roman,Times,serif"> (8)</span></div> </td>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 20%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">(1) Salary includes gross base salary.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">(2) Bonuses disclosed under row &#8220;2021&#8221;
relate to bonuses accrued in 2021 and paid in 2021 and 2022. Bonuses disclosed under &#8220;2022&#8221; represent target bonuses for 2022
(the information&#160;is not final and based on certain estimates due to the fact that the Company has not yet determined actual bonuses
for 2022).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">(3) Represents the equity-based compensation
expenses recorded in our consolidated financial statements for the years ended December 31, 2021 and 2022, based on the options&#8217;
fair value on the grant date, calculated in accordance with applicable accounting guidance for equity-based compensation. For a discussion
of the assumptions used in reaching this valuation, see Note 8C to our consolidated financial statements filed with our Annual Report
on Form 10-K for the year ended December 31, 2021 incorporated by reference in this Annual Report.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">93</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">(4) Represents payments by us of social
benefits on behalf of the officer. Such benefits may include, to the extent applicable, payments, contributions and/or allocations for
risk insurance (e.g., life, or work disability insurance), payments for social security, vacation, medical insurance and benefits, and
other benefits and perquisites consistent with our policies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">(5) Dr. Dale Pfost&#8217;s terms of compensation
were approved by the Company&#8217;s shareholders on October 25, 2021, which includes an annual base salary of $600,000. Dr. Pfost&#8217;s
compensation data set forth in the above table is pro-rated to reflect time served as the Company&#8217;s chief executive officer in 2021.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">(6) In addition to her current positions
of Chief Scientific Officer and a member of our Board, Dr. Adi Mor previously served as our Chief Executive Officer, and resigned from
such role concurrent with the commencement of Dr. Dale Pfost&#8217;s service as our Chief Executive Officer on October 25, 2021.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">(7) Mr. Donald Marvin&#8217;s employment
with the Company commenced on November 4, 2021, which include an annual base salary of $460,000. The compensation data set forth in the
above table is pro-rated to reflect time served as the Company&#8217;s Chief Financial Officer, Executive Vice President and Chief Operating
Officer in 2021.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">(8)&#160; Ms. Sigal Fattal previously served
as our interim Chief Financial Officer, and resigned from such role concurrent with the commencement of Mr. Marvin&#8217;s service as
our Chief Financial Officer on November 8, 2021.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Outstanding Equity Awards at Fiscal Year-End</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">The table below outlines the options to purchase
ADSs held by our named executive officers outstanding as of December 31, 2022.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" class="cfttable" id="z85be19b807c2453dbc2af057216982df" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; padding-bottom: 2px; width: 32%">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="11" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Option awards</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Name</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Number of securities<br /> underlying<br />
        unexercised options<br /> (#) exercisable</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Number of<br /> securities<br /> underlying<br />
        unexercised options<br /> (#)<br /> unexercsiable</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Option<br /> exercise<br /> price ($)</div>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 15%">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Option expiration<br /> date</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Dale Pfost,&#160;<span style="font-style: italic">Chief Executive Officer and Chairman
        of the Board</span></div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">133,977</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">325,376<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td class="cftfncell" colspan="1" style="white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: top; width: 1%; background-color: rgb(204, 238, 255)"><br />
        </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">10.05</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 15%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">October 25, 2031</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 15%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 15%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 15%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 15%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Adi Mor,&#160;<span style="font-style: italic">Chief Scientific Officer, Director
        and Previous Chief Executive Officer</span></div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">131,698</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">1.49</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 15%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">March 15, 2028</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 15%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 15%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%"><br />
        </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 15%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 15%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Donald Marvin,&#160;<span style="font-style: italic">Chief Financial Officer, Executive
        Vice President and Chief Operating Officer</span>&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">53,320</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">143,555<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td class="cftfncell" colspan="1" style="white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: middle; width: 1%; background-color: rgb(204, 238, 255)"><br />
        </td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"><br />
        </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">9.77</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 15%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">November 8, 2031</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">(1) The options granted to Dr. Pfost vest
and become exercisable over a period of four (4) years with one quarter (1/4) of the options vesting on October 25, 2022, the first anniversary
of the grant date, and the remainder in equal amounts over the ensuing 36 monthly periods, subject to Dr. Pfost&#8217;s continued service.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">(2) The options granted to Mr. Marvin vest
and become exercisable over a period of four (4) years, with one quarter (1/4) of the options vesting on November 8, 2022, the first anniversary
of the grant date, and the remainder in equal amounts over the ensuing 36 monthly periods, subject to Mr. Marvin&#8217;s continued service.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> <br />

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">94</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-weight: bold">Employment Agreements</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25; font-style: italic">Employment Agreement with Dr. Dale Pfost, our Chief Executive Officer</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">On September 1,&#160;2021,
the Company&#8217;s board of directors approved the appointment of Dr. Dale Pfost as Chief Executive Officer of the Company, and on October
25, 2021, the shareholders of the Company approved the terms of employment of Dr. Pfost, pursuant to an Executive Employment Agreement
entered into between Dr. Pfost and Chemomab Therapeutics Inc., the Company&#8217;s wholly owned subsidiary. In accordance with terms of
Dr. Pfost&#8217;s employment agreement, Dr. Pfost receives: (i) an annual base salary of $600,000 (the &#8220;Base Salary&#8221;); (ii)
an initial target annual cash incentive bonus of 50% of the Base Salary and an additional potential bonus of 10% of the Base Salary based
on Dr. Pfost&#8217;s achievement of certain predetermined goals, which shall be determined at the discretion of the Company&#8217;s board
of directors; (iii) options to purchase&#160;459,353 ADSs of the Company (the &#8221;Options&#8221;), constituting 3.5% of the outstanding
and issued ADSs of the Company (on a fully diluted basis) which will vest over a period of four (4) years with one quarter (1/4) of the
Options vesting on the first anniversary of the grant date and the remainder in equal amounts over the ensuing 36 monthly periods, unless
such options have been cancelled in accordance with the terms and conditions of the 2015 Plan (as defined below); (iv) a one-time signing
bonus in an amount of $80,000; (v) a one-time bonus in an amount of $80,000 upon the establishment of a new office in the United State
and Dr. Pfost&#8217;s domiciling in the location of the new office, which will be payable within 15 days of such domiciling; (vi) 25 days
of paid time off (&#8220;PTO&#8221;) per year, capped at 50 days of accrued PTO; and (vii) certain severance benefits payable in the event
that the Company terminates Dr. Pfost&#8217;s employment without Cause (as defined in the employment agreement), provided that the total
amount of the cash portion of severance benefits will not exceed two hundred percent (200%) of Dr. Pfost&#8217;s annual base salary at
the rate in effect on the date of termination.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">Additionally, in the
event of termination of Dr. Pfost&#8217;s employment without Cause (as defined therein) as the result of a merger or sale of all or substantially
all of the Company&#8217;s capital stock or assets, (i.e. a change in control of the Company), vesting of all unvested Options will accelerate
and all unvested Options will immediately vest and become exercisable. Furthermore, in the event of termination of Dr. Pfost&#8217;s employment
without Cause, other than as a result of a merger or sale of all or substantially all of the Company&#8217;s capital stock or assets (i.e.
a change in control of the Company) or if Dr. Pfost terminates his employment for Good Reason (as defined in the employment agreement):
(a) any time-based Options then outstanding and due to vest on the twelve (12) month anniversary of Dr. Pfost&#8217;s employment commencement
date will accelerate and become exercisable if Dr. Pfost has been employed by the Company at such time for six (6) months or more but
less than twelve (12) months; and (b) all time-based Options then outstanding will accelerate and become exercisable if Dr. Pfost has
been employed by the Company at such time for twelve (12) months or longer.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">The foregoing description
of Dr. Pfost&#8217;s employment agreement is qualified in its entirety by reference to the full text of the employment agreement, a copy
of which is filed as Exhibit 10.9 hereto.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Employment
Agreement with Dr. Adi Mor, our Chief Scientific Officer (and former Chief Executive Officer</span><span style="font-family: Times New Roman,Times,serif">)</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">Dr. Adi Mor provides
services to the Company pursuant to the terms of a consulting agreement among Dr. Mor, an Israeli company co-owned by Dr. Mor, and the
Subsidiary, dated April 18, 2022 (the &#8220;Consulting Agreement&#8221;).&#160; Pursuant to the terms of the Consulting Agreement, Dr.
Mor is entitled to a gross monthly payment, an annual performance bonus, subject to her meeting certain performance milestones, as to
be determined by our board of directors on an annual basis, and certain other benefits.&#160; Dr. Mor&#8217;s current monthly payment
and annual performance bonus target were set and approved by the Company&#8217;s shareholders as described below.&#160; In addition, Dr.
Mor is entitled to other benefits that are provided for by Israeli law or that are customary for senior executives in Israel, including
reimbursement for reasonable expenses incurred in connection with her services and payment for variable and fixed costs of a car. The
Consulting Agreement is terminable by either party upon 60 days prior written notice, and contains customary provisions regarding noncompetition,
confidentiality of information, and assignment of inventions.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">As required under Israeli
law, the terms of Dr. Mor&#8217;s Consulting Agreement with the Subsidiary were approved by the board of directors and presented to the
shareholders for approval.&#160; At the annual meeting of our shareholders that took place on June 7, 2022, our shareholders approved
for following terms of employment for Dr. Mor: (a) an increase to her base gross monthly salary from 67,500 NIS (approximately $21,090)
(plus social benefits) to 74,250 NIS (approximately $23,200), (plus social benefits) which represents an increase of 6,750 NIS (approximately
$2,110), effective as of March 7, 2022; (b) an increase in her 2021 gross annual bonus from $100,000 to $110,250, an increase of approximately
10%; and (c) an increase in her annual gross target bonus opportunity from $100,000 to 45% of Dr. Mor&#8217;s annual gross payment, effective
as of January 1, 2022.&#160; In lieu of the monthly salary payment of 74,250 NIS (plus social benefits), as approved by the shareholders,
Dr. Mor receives the equivalent amount in the form of a monthly payment equal to 98,730 NIS under the Consulting Agreement.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">95</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">The foregoing description
of the Consulting Agreement is qualified in its entirety by reference to the full text of the consulting agreement, a copy of which is
filed as Exhibit 10.11 hereto.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Employment Agreement with Mr. Donald Marvin,
our Chief Financial Officer, Executive Vice President and Chief Operating Officer</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">On November 8, 2021,
Chemomab Therapeutics Inc. entered into an Executive Employment Agreement with Mr. Donald Marvin. In accordance with his employment agreement,
Mr. Marvin receives an annual base salary of $460,000, and is a part of the Company&#8217;s bonus program with a yearly bonus potential
of 45% of his base annual base salary, which bonus will be based on the achievement of mutually agreeable objectives to be determined
by Mr. Marvin and the Chief Executive Officer of the Company. Additionally, in accordance with his employment agreement, Mr. Marvin received
(i) 1.5% of the outstanding equity of the Company, which exercise price is based on the average of the ADS market value over the 30 calendar
days preceding November 8, 2021, and vesting over four years, (ii) an additional 0.5% of the outstanding equity of the Company for the
achievement of strategic goals as agreed upon with the Compensation Committee and approved by the Board of Directors, (iii) a $25,000
signing bonus, and (iv) a 12-month initial severance package, which will increase by one month every two years that Mr. Marvin is employed
by the Company, provided however that such amount does not exceed 18 months.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">Additionally, in the
event of termination of Mr. Marvin&#8217;s employment without Cause as the result of a merger or sale of all or substantially all of the
Company&#8217;s capital stock or assets, (i.e. a change in control of the Company), vesting of all unvested Options will accelerate and
all unvested Options will immediately vest and become exercisable. Furthermore, in the event of termination of Mr. Marvin&#8217;s employment
without Cause, other than as a result of a merger or sale of all or substantially all of the Company&#8217;s capital stock or assets (i.e.
a change in control of the Company) or if Mr. Marvin terminates his employment for Good Reason (as defined in the employment agreement):
(a) any time-based Options then outstanding and due to vest on the twelve (12) month anniversary of Mr. Marvin&#8217;s employment commencement
date will accelerate and become exercisable if Mr. Marvin has been employed by the Company at such time for six (6) months or more but
less than twelve (12) months; and (b) all time-based Options due to vest on or before December 31 of the year in which termination occurs
then outstanding will accelerate and become exercisable if Mr. Marvin has been employed by the Company at such time for twelve (12) months
or longer.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">The foregoing description
of Mr. Marvin&#8217;s employment agreement is qualified in its entirety by reference to the full text of the employment agreement, a copy
of which is filed as Exhibit 10.10 hereto.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Director Compensation Table</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">The table below outlines
compensation earned by our non-executive directors for the fiscal year ended December 31, 2022, including fees earned in cash and options
awarded for services provided as a director:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb924b4e9e0af4e7db9ff20b14445cf24" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 62.37%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Name</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 11.41%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Fees earned<br /> or paid<br /> in cash ($)</div>
        </td>
    <td style="white-space: nowrap; width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 9.68%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Option<br /> awards ($)</div> </td>
    <td style="white-space: nowrap; width: 2.5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; width: 9.71%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Total ($)</div> </td>
    <td style="white-space: nowrap; width: 0.82%; vertical-align: bottom; font-family: Times New Roman,Times,serif; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 62.37%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Nissim Darvish&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 10.54%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0)">47,000</div> </td>
    <td style="white-space: nowrap; width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 8.81%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0)">76,000</div> </td>
    <td style="white-space: nowrap; width: 2.5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">(1)</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 8.82%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0)">123,000</div> </td>
    <td style="white-space: nowrap; width: 0.82%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 62.37%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Jill Quigley&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 10.54%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0)">23,000</div> </td>
    <td style="white-space: nowrap; width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 8.81%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0)">15,000</div> </td>
    <td style="white-space: nowrap; width: 2.5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">(2)</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 8.82%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0)">38,000</div> </td>
    <td style="white-space: nowrap; width: 0.82%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 62.37%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Alan Moses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 10.54%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0)">43,000</div> </td>
    <td style="white-space: nowrap; width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 8.81%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0)">76,000</div> </td>
    <td style="white-space: nowrap; width: 2.5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">(3)</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 8.82%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0)">119,000</div> </td>
    <td style="white-space: nowrap; width: 0.82%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 62.37%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Claude Nicaise&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 10.54%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0)">47,000</div> </td>
    <td style="white-space: nowrap; width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 8.81%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0)">76,000</div> </td>
    <td style="white-space: nowrap; width: 2.5%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">(4)</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 8.82%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0)">123,000</div> </td>
    <td style="white-space: nowrap; width: 0.82%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 62.37%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Neil Cohen&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 10.54%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0)">47,000</div> </td>
    <td style="white-space: nowrap; width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.87%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 8.81%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0)">76,000</div> </td>
    <td style="white-space: nowrap; width: 2.5%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">(5)</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 0.89%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 8.82%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0)">123,000</div> </td>
    <td style="white-space: nowrap; width: 0.82%; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">96</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">(1) (i) 11,884 of the options granted to
Dr. Darvish vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, and (ii) 6,820
options vest and become exercisable on March 16, 2023, subject to Dr. Darvish&#8217;s continued service. Additional 10,123 options have
fully vested.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">(2) The options granted to Ms. Quigley vest
and become exercisable&#160;in equal monthly installments over a 36 month period commencing on June 16, 2022, subject to Ms. Quigley&#8217;s
continued service.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">(3)&#160; (i) 11,884 of the options granted
to Dr. Moses vest and become in equal monthly installments over a 36 month period commencing on March 16, 2021, and (ii) 6,820 of the
options granted to Dr. Moses vest and become exercisable on March 16, 2023, subject to Dr. Moses&#8217; continued service.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">(4) (i) 11,884 of the options granted to
Dr. Nicaise vest and become in equal monthly installments over a 36 month period commencing on March 16, 2021, and (ii) 6,820 of the options
granted to Dr. Nicaise vest and become exercisable on March 16, 2023, subject to Dr. Nicaise's continued service.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">(5) (i) 11,884 of the options granted to
Mr. Cohen vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, (ii) 6,820 options
vest and become exercisable on March 16, 2023, and (iii) 688 options vest and become exercisable over a period of three (3) years with
one quarter (1/4) of the options vesting on July 16, 2021, the first anniversary of the grant date, and the remainder in equal amounts
over the ensuing 24 monthly periods commencing on October 16, 2021, subject to Mr. Cohen&#8217;s continued service.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Director Compensation</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">We have adopted a Compensation
Policy regarding the terms of office and employment of its &#8220;office holders&#8221; (as defined in the Israeli Companies Law, 5759-1999),
including cash compensation, equity-based awards, releases from liability, indemnification and insurance, severance and other benefits.
Chemomab compensates its directors and senior management team in accordance with the recommendation of its compensation committee and,
generally, subject to the approval of our Board and shareholders. That compensation will generally need to be consistent with the terms
of our Compensation Policy, which will require periodic approval, in accordance with the requirements of the Companies Law.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">In addition to the Compensation
Policy, on March 15, 2021, our shareholders approved certain actual compensation terms applicable to our current and future directors
(the &#8220;Director Compensation Package&#8221;), pursuant to which (and among other terms) (i) our non-employee directors are entitled
to receive an annual option grant of up to 0.05% of the Company&#8217;s share capital on a fully diluted basis, (ii) the chairman of our
Board is entitled to receive an annual option grant of up to 0.2% of the Company&#8217;s share capital on a fully diluted basis and (iii)
our non-employee directors are entitled to receive an annual cash fee of $35,000. The Director Compensation Policy implements terms for
actual equity compensation that will be granted to directors on a regular basis and determines the annual cash fee that may be paid to
non-employee directors. In accordance with the Companies Law, equity grants to our directors that are within the limitations of the Director
Compensation Package require the approval of our compensation committee and Board, but not our shareholders, while any contemplated compensation
made in excess of the Director Compensation Package will require the approval of our shareholders. Furthermore, any such compensation,
including the annual cash fee payable to our non-employee directors, must be limited to the framework of the Director Compensation Package.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">97</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;

<div style="line-height: 1.25; font-weight: bold">Outstanding Equity Awards at Fiscal Year End</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25; text-indent: 36pt">The table below outlines options to purchase ADSs held by our non-employee
directors outstanding as of December 31, 2022.</div>

<div style="text-align: justify; line-height: 1.25; text-indent: 36pt"> <br /> </div> </div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z7af8fd97883c479691aaa66aee0c9764" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; padding-bottom: 2px">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="12" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Option awards</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Name</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Number of ADSs<br /> underlying<br /> unexercised
        options<br /> (#) exercisable</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Number of<br /> ADSs<br /> underlying<br />
        unexercised options<br /> (#)<br /> unexercsiable</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Option<br /> exercise<br /> price ($)</div>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Option<br /> expiration<br /> date</div> </td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Nissim Darvish&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">10,123</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">0.80</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">October 27, 2026</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Nissim Darvish&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">6,932</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">4,952</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">27.26</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">April 19, 2031</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Nissim Darvish&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">6,820</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">3.53</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">March 7, 2032</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Alan Moses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">6,932</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">4,952</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">27.26</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">April 19, 2031</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Alan Moses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">6,820</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">3.53</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">March 7, 2032</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Claude Nicaise&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">6,932</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">4,952</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">27.26</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">April 19, 2031</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Claude Nicaise&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">6,820</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">3.53</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">March 7, 2032</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Neil Cohen&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">515</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">173</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">13.20</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">July 16, 2030</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Neil Cohen&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">6,932</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">4,952</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">27.26</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">April 19, 2031</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Neil Cohen&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">6,820</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">3.53</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">March 7, 2032</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Jill Quigley&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">2,273</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">11,367</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">3.25</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 32%; background-color: rgb(204, 238, 255)">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0)">June 16, 2032</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Equity Incentive Plans</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">We maintain (i) the 2011
Share Option Plan (the &#8220;2011 Plan&#8221;), (ii) the 2017 Plan and (iii) the 2015 Plan, which was assumed by our company from the
Subsidiary upon the effectiveness of the Merger. At that time, outstanding options under the 2015 Plan became exercisable for such number
of ADSs of our company (formerly known as Anchiano Therapeutics Ltd.) as was determined based on the exchange ratio in the Merger Agreement,
with a reciprocal adjustment to exercise price. As of December 31, 2022, a total of 1,422,153 of ADSs were reserved for issuance under
the 2015 Plan, of which 172,276 ADSs had been issued pursuant to previous exercises options, and 1,173,037 ADSs&#160;were issuable under
outstanding options. Of such outstanding options, options to purchase 620,036 ADSs had vested and were exercisable as of that date, with
a weighted average exercise price of $5.96 per ADS.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">As of December 31, 2022,
a total of&#160;625,581 of ADSs were reserved for issuance under the 2017 Plan, of which&#160;586,540 ADSs&#160;were issuable under outstanding
options. Of such outstanding options, options to purchase 21,377 ADSs had vested and were exercisable as of that date, with a weighted
average exercise price of $6.98 per ADS. No ADSs had been issued pursuant to previous exercises options.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">2011 Plan</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">On December 19, 2011,
our board of directors adopted the 2011 Plan to allocate options to purchase our ordinary shares to our directors, officers, employees
and consultants, and those of our affiliated companies (as such term is defined under the 2011 Plan), or the Grantees. The 2011 Plan is
administered by our board of directors or a committee that was designated by our board of directors for such purpose (the &#8220;Administrator&#8221;).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">Under the 2011 Plan,
we may grant options to purchase ordinary shares (&#8220;Options&#8221;), under four tracks: (i) Approved 102 capital gains Options through
a trustee, which was approved by the Israeli Tax Authority in accordance with Section 102(a) of the Israeli Income Tax Ordinance (&#8220;ITO&#8221;),
and granted under the tax track set forth in Section 102(b)(2) of the ITO, or the Approved 102 Capital Gains Options. The holding period
under this tax track is 24 months from the date of allocation of Options to the trustee or such period as may be determined in any amendment
of Section 102 of the ITO, or any applicable tax ruling or guidelines; (ii) Approved 102 Earned Income Options through a trustee, granted
under the tax track set forth is Section 102(b)(1) of the ITO, or the Approved 102 Earned Income Options. The holding period under this
tax track is 12 months from the date of allocation of Options to the trustee or such period as may be determined in any amendment of Section
102 of the ITO; (iii) Unapproved 102 Options (the Options will not be allocated through a trustee and will not be subject to a holding
period), or the Unapproved 102 Options; and (iv) 3(i) Options (the Options will not be subject to a holding period). These Options shall
be subject to taxation pursuant to Section 3(i) of the ITO, or Section 3(i).</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">98</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">Options pursuant to the
first three tax tracks (under Section 102 of the ITO) can be granted to our employees and directors and the grant of Options under Section
3(i) can be granted to our consultants and controlling shareholders (a controlling shareholder is defined under the Section 102 of the
ITO is a person who holds, directly or indirectly, alone or together with a &#8220;relative,&#8221; (i) the right to at least 10% of the
company&#8217;s issued capital or 10% of the voting power; (ii) the right to hold at least 10% of the company&#8217;s issued capital or
10% of the voting power, or the right to purchase such rights; (iii) the right to receive at least 10% of the company&#8217;s profits;
or (iv) the right to appoint a company&#8217;s director). Grantees who are not Israeli residents may be granted options that are subject
to the applicable tax laws in their respective jurisdictions.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">We determine, in our
sole discretion, under which of the first three tax tracks above the Options are granted and we notify the Grantee in a grant letter,
as to the elected tax track. As mentioned above, consultants and controlling shareholders can only be granted Section 3(i) Options.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">The number of ordinary
shares authorized to be issued under the 2011 Plan will be proportionately adjusted for any increase or decrease in the number of ordinary
shares issued as a result of a distribution of bonus shares, change in our capitalization (split, combination, reclassification of the
shares or other capital change), or issuance of rights to purchase ordinary shares or payment of a dividend. We will not allocate fractions
of ordinary shares and the number of ordinary shares shall be rounded up to the closest number of ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">Unless otherwise determined
by the Administrator, the exercise price of an Option granted under the 2011 Plan will be the average of the market price of the Company&#8217;s
ordinary shares during the 22 business days prior to the date on which our board of directors authorized the grant of Options; provided,
however, that such exercise price cannot be lower than the market price at the close of the trading day at which it was granted by our
board of directors. The exercise price will be specified in the grant letter every Grantee received from us in which the Grantee notifies
of the decision to grant him/her Options under the 2011 Plan.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">Unless otherwise determined
by the Administrator, the Options granted under the 2011 Plan will become vested and may be exercised in 16 equal portions of 6.25% of
the total number of Options, at the end of each quarter following the day the Options were granted. Unless otherwise determined by our
board of directors, the Options may be exercised for ten years following the date of grant, unless terminated earlier, and as long as
the Grantee is employed by the Company (or by an affiliated company), or provides service to the Company (or an affiliated company).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">The Administrator may,
in its absolute discretion, accelerate the time at which Options granted under the 2011 Plan or any portion of which will vest.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">Unless otherwise determined
by the Administrator, in the event that the Grantee&#8217;s employment was terminated, not for Cause (as defined in the 2011 Plan), the
Grantee may exercise that portion of the Options that had vested as of the date of such termination until the end of the specified term
in the grant letter or the 2011 Plan. The portion of the Options that had not vested at such date, will be forfeited and can be re-granted
according to the terms of the 2011 Plan.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">2015
Plan</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">In November 2015, the
Subsidiary&#8217;s board of directors adopted, and its shareholders subsequently approved, the 2015 Plan. The 2015 Plan provides for the
grant of options, restricted shares, restricted share units and other share-based awards to the Subsidiary&#8217;s (following the Merger,
the Company&#8217;s) and its subsidiaries&#8217; and affiliates&#8217; directors, employees, officers, consultants, advisors, and any
other person whose services are considered valuable to Chemomab or its affiliates. Any such grants are intended to incentivize the foregoing
persons to continue as service providers, to increase their efforts on Chemomab&#8217;s behalf or on behalf of its subsidiaries or affiliates,
and to promote the success of its business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">The 2015 Plan is administered
by Chemomab&#8217;s board of directors or by a committee designated by the board of directors, which determines, subject to Israeli law,
the grantees of awards and the terms of the grant, including, exercise prices, vesting schedules, acceleration of vesting and the other
matters necessary in the administration of the 2015 Plan. The 2015 Plan enables Chemomab to issue awards under various tax regimes, including,
without limitation, pursuant to Section 102 of the Israeli Income Tax Ordinance, or the Ordinance, and under Section 3(i) of the Ordinance
and Section 422 of the United States Internal Revenue Code of 1986, as amended, or the Code.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">99</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">The 2015 Plan provides
that options granted to Chemomab&#8217;s employees, directors and officers who are not controlling shareholders and who are considered
Israeli residents are intended to qualify for special tax treatment under the &#8220;capital gain track&#8221; provisions of Section 102(b)
of the Ordinance. Chemomab&#8217;s Israeli non-employee service providers and controlling shareholders may only be granted options under
Section 3(i) of the Ordinance, which does not provide for similar tax benefits.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">Options granted under
the 2015 Plan to U.S. residents may qualify as &#8220;incentive stock options&#8221; within the meaning of Section 422 of the Code, or
may be non-qualified. The exercise price for &#8220;incentive stock options&#8221; must not be less than the fair market value on the
date on which an option is granted, or 110% of the fair market value if the option holder holds more than 10% of Chemomab&#8217;s share
capital.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">Options and other awards
granted under the 2015 Plan generally vest over four years commencing on the date of grant, such that 25% vests on the first anniversary
of the date of grant and an additional 6.25% vests at the end of each subsequent calendar quarter over the course of the next three years,
provided that the participant remains continuously employed or engaged by Chemomab.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">Options, other than certain
incentive share options, that are not exercised within ten years from the grant date expire, unless otherwise determined by Chemomab&#8217;s
board of directors or its designated committee, as applicable. Share options that qualify as &#8220;incentive stock options&#8221; and
are granted to a person holding more than 10% of Chemomab&#8217;s voting power will expire within five years from the date of the grant.
In the event of the death of a grantee while employed by or performing service for Chemomab or its subsidiary or within three months after
the date of the employee&#8217;s termination, or the termination of a grantee&#8217;s employment or services for reasons of disability,
the grantee, or in the case of death, his or her legal successor, may exercise options or other awards that have vested prior to termination
within a period of one year from the date of disability or death. If Chemomab terminates a grantee&#8217;s employment or service for cause,
all of the grantee&#8217;s vested and unvested options or other awards will expire on the date of termination. If a grantee&#8217;s employment
or service is terminated for any other reason, the grantee may generally exercise his or her vested options or other award within three
months of the date of termination. Any expired or unvested options return to the pool and become available for reissuance. From time to
time, Chemomab may consider issuing options with slightly different terms or accelerating, extending or otherwise modifying options in
accordance with applicable law and regulation and the terms of the 2015 Plan.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">In the event of a merger
or consolidation of Chemomab, or a sale of all, or substantially all, of Chemomab&#8217;s shares or assets or other transaction having
a similar effect on Chemomab, then without the consent of the option holder, Chemomab&#8217;s board of directors or its designated committee,
as applicable, may, but is not required, to (i) cause any outstanding award to be assumed or an equivalent award to be substituted by
such successor corporation, or (ii) in case the successor corporation does not assume or substitute the award (a) provide the grantee
with the option to exercise the award as to all or part of the shares or (b) cancel the options and pay in cash an amount determined by
the board of directors or the committee as fair in the circumstances. Notwithstanding the foregoing, Chemomab&#8217;s board of directors
or its designated committee may upon such event amend, modify or terminate the terms of any award, including conferring the right to purchase
any other security or asset that the board of directors or the committee shall deem, in good faith, appropriate.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">The 2015 plan was assumed
by our company from the Subsidiary upon the effectiveness of the Merger.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">2017
Plan</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 36pt">On February 22, 2017,
our board of directors adopted the 2017 Plan to allocate a variety of share-based awards to our directors, officers, employees, consultants,
advisors and service providers, and those of our affiliates (companies that control us, are controlled by us or are under common control
with us) (the &#8220;Participants&#8221;). The 2017 Plan is currently administered by our board of directors, and may be administered
by a committee designated by our board of directors for such purpose.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the 2017 Plan,
we may grant options to purchase ordinary shares or ADSs, restricted shares or ADSs, restricted share units and other awards based on
our ordinary shares, all of which are referred to as Awards. We may grant Awards under the same four tracks as described above with respect
to the 2011 Plan, subject to the same conditions as apply for the 2011 Plan. In addition, we may grant incentive stock options and nonqualified
stock options to Participants who are residents of the United States, and we may grant awards to Participants who are residents of other
countries that comply with the laws of those jurisdictions.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">100</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The number of ordinary
shares authorized to be issued under the 2017 Plan will be proportionately adjusted for any increase or decrease in the number of ordinary
shares issued as a result of a distribution of bonus shares, change in our capitalization (split, combination, reclassification of the
shares or other capital change), issuance of rights to purchase ordinary shares or payment of a dividend. We will not allocate fractions
of ordinary shares and the number of ordinary shares shall be rounded down to the closest number of ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <span style="font-weight: bold">Item 12.<span id="Item12."><!--Anchor--></span>
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table sets
forth information, as of March 16, 2023, regarding beneficial ownership of our ordinary shares represented by ADSs:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3deef86132c7435b958d8a9c3e95046d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 8.65pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">each person who is known by us to own beneficially more than 5% of our ordinary shares;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc08724b880b34eaf9ae59aeae7b9a864" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 8.65pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">each director;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z14192c19de8846e69a919a1bf4d1b67b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 8.65pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">each executive officer; and</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z23514de25cb940ec9eca5f39f535cc0c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 8.65pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">all of our directors and executive officers collectively.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The percentages of ordinary
shares beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial ownership of securities.
Under the rules of the SEC, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which
includes the power to vote or to direct the voting of the security, or investment power, which includes the power to dispose of or to
direct the disposition of the security.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Unless otherwise noted,
the address of each director and current and former executive officer of Chemomab is Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z0aee411fb3ee4b428fd1c05ed1c8f665" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">NAME OF BENEFICIAL OWNER</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Total</div>
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Beneficial</div>
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Ownership (ADSs)</div>
        </td>
    <td class="cftfncell" colspan="1" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Percentage of</div>
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">ADSs Beneficially</div>
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Owned</span><span style="font-family: Times New Roman,Times,serif">&#8224;</span></div>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-style: italic">5% and Greater Shareholders</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">OrbiMed Israel (1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">2,270,091</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">20.5</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">The Centillion Fund(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">661,370</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">6.0</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Rivendell Investments 2017-9(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">1,131,563</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">10.2</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Kobi George(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">747,445</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">6.7</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Apeiron Group(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">770,388</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">6.9</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-style: italic">Directors and Executive Officers</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Dale Pfost (6)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">174,757</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">1.6</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Donald Marvin (7)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">75,828</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Adi Mor (8)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">747,445</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">6.7</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Neil Cohen (9)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">25,702</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Nissim Darvish (10)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">26,395</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Alan Moses (11)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">15,072</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Claude Nicaise (12)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">15,072</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Jill Quigley (13)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">3,788</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">*</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Matthew Frankel&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">All current executive officers and directors as a group (9 persons)</div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,084,059</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">9.40</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">%</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#8224; Percentage ownership based on 11,049,812 ADSs outstanding
as of March 16, 2023</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">* Less than one percent (1%)</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">101</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z803b80a1039d4e828051265fc4ddb4ed" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 20.15pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">Pursuant to a Schedule 13D/A filed with the SEC by OrbiMed Israel BioFund GP Limited Partnership (&#8220;OrbiMed
        BioFund&#8221;) and OrbiMed Israel GP Ltd. (&#8220;OrbiMed GP&#8221;, and together with OrbiMed BioFund, &#8220;OrbiMed Israel&#8221;)
        on January 5, 2023, such amount consists of (i) 2,241,274 ADSs and (ii) 28,817 ADSs issuable upon the exercise of warrants to purchase
        ADSs. OrbiMed GP, a company that acts as general partner of certain limited partnerships, is the general partner of OrbiMed BioFund, which
        is the general partner of OrbiMed Israel Partners Limited Partnership, which is the entity that holds the foregoing securities.&#160;The
        address of OrbiMed Israel is 89 Medinat HaYehudim St., Build E, 11th Floor, Herzliya 46766 Israel.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z87eca8667f824912a2a4c1b4b2378901" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 20.15pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">The address of Centillion Fund, Inc. is 10 Manoel Street, Castries, Saint Lucia.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zdf38b2319bdb407e8f026dd2cbf270b9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 20.15pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">(3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">Represents 1,108,509 ADSs, representing 22,170,180 ordinary shares, held by Rivendell Investments 2017-9
        LLC, or Rivendell, as reported by Rivendell on Schedule 13G filed with the SEC on March 26, 2021, and 23,054 ADSs, representing 461,080
        Ordinary Shares, issuable upon the exercise of warrants. Rivendell is the shareholder of record. Peter Thiel is the beneficial owner of
        Rivendell and has sole voting and investment power over the securities held by Rivendell. The address of Rivendell is 1209 Orange Street,
        Wilmington, Delaware 19801.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z46c41a52f2604f6581fb8920b0d18ce3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 20.15pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">(4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">Consists of (i) 257,247 ADSs owned directly by Dr. George, (ii) 324,775 ADSs owned by Dr. Adi Mor (Dr.
        George&#8217;s spouse), (iii) 33,725 options to purchase 33,725 ADSs issued directly to Dr. George, issuable upon the exercise of options,
        and (iv) 131,698 options to purchase 131,698 ADSs, issued to Dr. Mor, (Dr. George&#8217;s spouse), as reported by Dr. Adi Mor on Schedule
        13D/A filed with the SEC on November 17, 2022.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb767930791924a94bf8d9c75df09b7aa" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 20.15pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">(5)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">The Apeiron Group consists of (i) Apeiron SICAV Ltd. - Presight Capital Fund One, of which owns 438,993
        ADSs, (ii) Apeiron Presight Capital Fund II, LP, of which owns 288,170 ADSs and 28,817 ADSs issuable upon the exercise of warrants and
        (iii) Apeiron Investment Group Ltd., of which owns 14,408 ADSs issuable upon the exercise of warrants. Each of Fabian Hansen and Christian
        Angermayer may be deemed to share voting and investment power with respect to the ADSs held by the Apeiron Group.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za93c0d0b261f49e98aef3adbac8601da" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 20.15pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">(6)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">Includes 2,500 ADSs and 172,257ADSs issuable upon the exercise of options within 60 days of the date
        hereof as reported by Dr. Dale Pfost on Form 4 filed with the SEC on March 15, 2022.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zdc5bebd27a0941a1af29d9cc6bdd2831" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 20.15pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">(7)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">Includes 2,000 ADSs and 73,828ADSs issuable upon the exercise of options within 60 days of the date hereof
        as reported by Mr. Donald Marvin on Form 4 filed with the SEC on June 21, 2022.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zaaa86e98b9b54c229f57a4a219aa182f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 20.15pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">(8)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">Consists of (i) 324,775 ADSs owned directly by Dr. Mor, (ii) 257,247 ADSs owned by Dr. George, (Dr. Mor&#8217;s
        spouse), (iii) 131,698 ADSs issued to Dr. Mor, issuable upon the exercise of options within 60 days of the date hereof, and (iv) 33,725
        options to purchase 33,725 ADSs issued to Dr. George, (Dr. Mor&#8217;s spouse) issuable upon the exercise of options within 60 days of
        the date hereof, as reported by Dr. Adi Mor on Schedule 13D/A filed with the SEC on November 17, 2022.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z081d6801d84343d1a64197379317e9e6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 20.15pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">(9)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">Includes 10,000 ADSs, and 15,702 ADSs issuable upon the exercise of options within 60 days of the date
        hereof, as reported by Mr. Neil Cohen on Form 4 filed with the SEC on November 11, 2022.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">102</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z988008484b824dce96306df5670624a2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 20.15pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">(10)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">Includes 1,200 ADSs, and 25,195 ADSs issuable upon the exercise of options within 60 days of the date
        hereof, as reported by Dr. Nissim Darvish on Form 4 filed with the SEC on March 14, 2022.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z31ddc1d7118d491d9e6358291372faed" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 20.15pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">(11)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">Represents 15,072 ADSs issuable upon the exercise of options within 60 days of the date hereof, as reported
        by Dr. Alan Moses on Form 4 filed with the SEC on March 9, 2022.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb33cc45909234bdf9602d992d415ed61" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 20.15pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">(12)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">Represents&#160;15,072 ADSs issuable upon the exercise of options within 60 days of the date hereof,
        as reported by Dr. Claude Nicaise on Form 4 filed with the SEC on March 9, 2022.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8d99b00a01154bf29c2d0312d9c6bdda" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 20.15pt; vertical-align: top; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">(13)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="color: rgb(0, 0, 0)">Represents&#160;3,788 ADSs issuable upon the exercise of options within 60 days of the date hereof, as
        reported by Ms. Jill Quigley on Form 4 filed with the SEC on June 16, 2022.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Securities Authorized
for Issuance under Equity Compensation Plans</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table provides
certain information as of December 31, 2022, with respect to our equity compensation plans under which our equity securities are authorized
for issuance:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z53553d5b625e43f5b32d6528b92d8fe8" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Plan Category</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Number of securities to be issued upon exercise of outstanding
        options, warrants and rights</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Weighted-average exercise price of outstanding options, warrants
        and rights</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Number of securities remaining available for future issuance under
        equity compensation plans (excluding securities reflected in column (a))</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold"> (a)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">(b)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; font-weight: bold">
        <div style="text-align: justify; line-height: 1.25">(c)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); width: 64%">
        <div style="text-align: justify; line-height: 1.25">Equity compensation plans approved by security holders</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,350,163</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">7.65</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">107,755</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; width: 64%">
        <div style="text-align: justify; line-height: 1.25">Equity compensation plans not approved by security holders</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 64%">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">Total&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">1,350,163</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">7.65</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">107,755</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold"><span id="Item13"><!--Anchor--></span>Item
13.</span><span style="font-family: Times New Roman,Times,serif"> <span style="font-weight: bold">Certain Relationships and Related Transactions,
and Director Independence</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Certain Relationships
and Related Transactions</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Described below are any
transactions occurring since the beginning of our last fiscal year, and any currently proposed transactions to which either the Company
was a party and in which:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8f78f2140e8b45af964f8543e9c7e5c2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 8.65pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>The amounts involved exceeded or will exceed$120,000; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z865650660a964e57b38f1d79619e3895" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 8.65pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>A director, executive officer, holder of more than 5% of the outstanding share capital of the Company, or any member of such person&#8217;s
        immediate family had or will have a direct or indirect material interest.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif; text-indent: 18pt">The
following transactions relate to the Registrant, formerly known as Anchiano Therapeutics Ltd., prior to the consummation of the Merger.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Related
Party Transactions</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the Israel&#8217;s
Companies Law, 5759-1999, or the Companies Law, a related party transaction in which an &#8220;office holder&#8221; has a personal interest
may be approved only if it is for the benefit of the company. An office holder is defined in the Companies Law as a director, a general
manager, chief business manager, deputy general manager, vice general manager, any other person assuming the responsibilities of any of
these positions regardless of such person&#8217;s title, and any other manager directly subordinate to the general manager. A transaction
that is not an extraordinary transaction in which an office holder has a personal interest requires the approval of the board of directors,
unless the articles of association of the company provide otherwise. If the transaction is an extraordinary transaction, it must be approved
by the audit committee and the board of directors, and, under certain circumstances, by the shareholders of the company. An &#8220;extraordinary
transaction&#8221; is a transaction other than in the ordinary course of business, other than on market terms or that is likely to have
a material impact on the company&#8217;s profitability, assets or liabilities.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">103</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Pursuant to the Companies
Law, extraordinary transactions in which a controlling shareholder has a personal interest require the approval of the audit committee,
or the compensation committee if the transaction is in connection with employment or service with the company, the board of directors
and the shareholders of the company. The shareholder approval must be by a simple majority of all votes cast, provided that (i)&#160;such
majority includes a simple majority of the votes cast by non-controlling shareholders having no personal interest in the matter or (ii)&#160;the
total number of votes of shareholders mentioned in clause&#160;(i)&#160;above who voted against such transaction does not exceed 2% of
the total voting rights in the company.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In most cases, the Companies
Law prohibits any director who has a personal interest in a transaction from being present for the discussion or voting pertaining to
such transaction in the audit committee or board of directors. Nevertheless, a director who has a personal interest may be present at
the meeting and vote on the matter if a majority of the directors or members of the audit committee have a personal interest in the approval
of such transaction; in this case, however, the transaction also requires shareholder approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Director
and Officer Compensation</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the Companies Law,
Chemomab is required to approve, at least once every three&#160;years, a compensation policy with respect to office holders. Following
the recommendation of Chemomab&#8217;s compensation committee, the compensation policy must be approved by the board of directors and
shareholders. The shareholder approval must be by a simple majority of all votes cast, provided that (i)&#160;such majority includes a
simple majority of the votes cast by non-controlling shareholders having no personal interest in the matter or (ii)&#160;the total number
of votes of shareholders mentioned in clause (i)&#160;above who voted against such transaction does not exceed 2% of the total voting
rights in the company. In general, the terms of compensation of directors, the chief executive officer and any employee or service provider
who is considered a controlling shareholder must be approved separately by the compensation committee, the board of directors and the
shareholders. The compensation terms of other officers who report directly to the chief executive officer requires the approval of the
compensation committee and the board of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25"><br /> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-style: italic; font-weight: bold">The Repurchase Arrangement</div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0)">As previously reported in&#160; our Registration
Statement on Form S-4 (File No. 333-252070), filed with SEC on January 13, 2021 and declared effective by the SEC on February 10, 2021,
Chemomab Ltd. filed an application with the Israel Tax Authority for a tax ruling (the &#8220;Tax Ruling&#8221;) in connection with the
Merger, pursuant to which certain of Chemomab Ltd.&#8217;s shareholders were entitled to defer an immediate Israeli tax liability resulting
from the exchange of shares that otherwise would have been deemed a sale. The deferral of the aforementioned tax liability is set to lapse
on March 16, 2023, which is the two-year anniversary of the closing date of the Merger. Dr. Adi Mor, co-founder of Chemomab Ltd. and both
our Chief Scientific Officer and a Class III director, and Professor Kobi George, co-founder of Chemomab Ltd. (together with Dr. Adi Mor,
the &#8220;Co-Founders&#8221;), will be required to pay a substantial tax liability to the Israeli Tax Authority upon the expiration date
of the deferral period. In order to pay this tax liability, the Co-Founders had to sell part of their holdings in the Company.&#160;In
light of the foregoing, we elected to enter into a share purchase agreement (the &#8220;Repurchase Arrangement&#8221;) with the Co-Founders
whereby we agreed, subject to the requisite court approval required under Section 303(a) of the Companies Law, which we received on November
14, 2022, to repurchase up to 582,023 of our ADSs owned by the Co-Founders, for consideration not to exceed an aggregate amount of $2,500,000,
depending on the market price of the ADSs at the time of any repurchase. Accordingly, on November 16, 2022, we repurchased the entire
amount of 582,023 ADSs from the Co-Founders at a weighted average price of $2.0848 and for total consideration of approximately $1,213,400.</div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We do not expect any
change in our cash runway as a result of the Repurchase Arrangement. Our current cash, cash equivalents and&#160; bank deposits are expected
to last through at least March 31, 2024.&#160;<span style="text-decoration: line-through">&#160;</span>We are likely to need to secure
additional financing to complete our clinical development programs for PSC and SSc that are projected to have topline readouts in the
second half of 2024. We continue to manage our cash runway and believe additional capital will be available when required.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">104</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Corporate Governance
and Independent Directors</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In compliance with the
listing requirements of Nasdaq, we have a comprehensive plan of corporate governance for the purpose of defining responsibilities, setting
high standards of professional and personal conduct and assuring compliance with such responsibilities and standards. We currently regularly
monitor developments in the area of corporate governance to ensure we are in compliance with the standards and regulations required by
Nasdaq.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Based upon information
requested from and provided by each director concerning their background, employment and affiliations, including family relationships,
our board of directors has determined that each of the directors is independent as defined under Nasdaq listing standards, with the exceptions
of Dr. Mor and Dr. Pfost. Our board of directors also determined that Nissim Darvish and Neil Cohen, who comprise each of the compensation
committee and the corporate governance and nominating committee, all satisfy the independence standards for such committees established
by the SEC and Nasdaq listing standards, as applicable. With respect to the audit committee, our board of directors has determined that
Jill Quigley, Alan Moses and Claude Nicaise satisfy the independence standards for such committee established by Rule 10A-3 under the
Exchange Act, the SEC and Nasdaq listing standards, as applicable, and that Jill Quigley is a financial expert under the rules of the
SEC. The board of directors considered the relationships between such directors and certain of the investors of the Company and determined
that such relationships did not affect such directors&#8217; independence under the standards of Nasdaq, or, where applicable, under SEC
rules.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">In
addition, our articles of association allow our board of directors to appoint new directors to fill vacancies which occurred for any reason
or as additional directors, provided that the number of board members shall not exceed the maximum numbers of directors mentioned above.
The appointment of a director by the board shall be in effect until the following annual general meeting of the shareholders or until
the end of his tenure in accordance with our articles of association. Our board of directors may continue to operate for as long as the
number of directors is not less than the minimum number of directors mentioned above.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">In
addition, under the Companies Law, our board of directors must determine the minimum number of directors who are required to have financial
and accounting expertise. Under applicable regulations, a director with financial and accounting expertise is a director who, by reason
of his or her education, professional experience and skill, has a high level of proficiency in and understanding of business accounting
matters and financial statements. He or she must be able to thoroughly comprehend the financial statements of the company and initiate
discussion regarding the manner in which financial information is presented. In determining the number of directors required to have such
expertise, the board of directors must consider, among other things, the type and size of the company and the scope and complexity of
its operations. Our board of directors has determined that we require at least one director with the requisite financial and accounting
expertise and that Jill Quigley has such expertise.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <span style="font-weight: bold"><span id="Item14"><!--Anchor--></span>Item
14.<span id="Item14."><!--Anchor--></span> Principal Accountant Fees and Services</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: Times New Roman,serif">

<div style="text-indent: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="color: #000000">Somekh Chaikin, a
member firm of KPMG International, </span>located in Tel Aviv, Israel, PCAOB ID 1057,<span style="color: #000000"> has served as our independent
registered public accounting firm for 2022 and 2021. The following table sets forth fees billed to us by our independent registered public
accounting firm during the fiscal years ended December&#160;31, 2022 and 2021 for (i)&#160;services rendered for the audit of our annual
financial statements and the review of our quarterly financial statements; (ii)&#160;services by our independent registered public accounting
firm that are reasonably related to the performance of the audit or review of our financial statements and that are not reported as audit
fees; (iii)&#160;services rendered during the period in connection with tax compliance, tax advice and tax planning; and (iv)&#160;all
other fees for services rendered.</span></div>

<div style="line-height: 1.25">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z8dc502cfa74140baa090fafe5e37da56" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Year Ended December 31,</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; font-family: Times New Roman,Times,serif; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold"> 2022</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">2021</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" rowspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">Audit
        Fees</span><span style="font-family: Times New Roman,Times,serif"><br /> </span></div> </td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" rowspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" rowspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">223</div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" rowspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" rowspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" rowspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">173</div> </td>
    <td class="cftfncell" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">Tax Fees</span><span style="font-family: Times New Roman,Times,serif"><br />
        </span></div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">30</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">29</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%; padding-bottom: 2px">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">All Other
        Fees</span><span style="font-family: Times New Roman,Times,serif"><br /> </span></div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">-
        <br /> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 76%">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0)">Total</span><span style="font-family: Times New Roman,Times,serif"><br />
        </span></div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">253</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">202</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">Policy
on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Our
audit committee has the sole authority to approve the scope of the audit and any audit-related services, as well as all audit fees and
terms. The audit committee must pre-approve any audit and non-audit services provided by our independent registered public accounting
firm. The audit committee will not approve the engagement of the independent registered public accounting firm to perform any services
that the independent registered public accounting firm would be prohibited from providing under applicable laws, rules&#160;and regulations,
including those of self-regulating organizations. The audit committee will approve permitted non-audit services by our independent registered
public accounting firm only if it determines that using a different firm to perform such services will be less efficient or cost-effective.
The audit committee reviews and pre-approves the statutory audit fees that can be provided by the independent registered public accounting
firm on an annual basis.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">105</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold"><span id="PARTIV"><!--Anchor--></span>PART
IV</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <span style="font-weight: bold">Item 15<span id="Item15"><!--Anchor--></span>.
Exhibits and Financial Statement Schedules</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z36b47b4bca3e46c7b0f0ef2d504ef61e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 8%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Exhibit&#160;No.</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Description</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921037294/tm219877d1_ex3-1.htm">3.1</a></div>
        </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921037294/tm219877d1_ex3-1.htm">Amended
        and Restated Articles of Association (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s current report on Form 8-K filed
        with the SEC on March 17, 2021)</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_4-1.htm">4.1</a></div>
        </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_4-1.htm">Description
        of Share Capital (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s annual report on Form 10-K for the year-ended December
        31, 2021, filed with the SEC on March 30, 2022)</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_4-1.htm">4.2</a></div>
        </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_4-1.htm">Form
        of Deposit Agreement between Chemomab Therapeutics Ltd. (f/k/a Anchiano Therapeutics Ltd.), the Bank of New York Mellon as Depositary,
        and owners and holders from time to time of ADSs issued by the Company, dated February 14, 2019 (incorporated by reference to Exhibit
        4.1 to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921019580/tm211883-4_s4a.htm#">10.1</a></div>
        </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921019580/tm211883-4_s4a.htm">Form
        of Indemnification Agreement (incorporated by reference to Exhibit 10.7 of the Company&#8217;s Amendment No. 1 to its Registration Statement
        on Form S-4 filed with the Securities and Exchange Commission on February 10, 2021)</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_10-2.htm">10.2+</a></div>
        </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_10-2.htm">Compensation
        Policy for Officers and Directors (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Annual Report on Form 10-K for the
        fiscal year ended December 31, 2021, filed with the SEC on March 30, 2022)</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-6.htm">10.3+</a></div>
        </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-6.htm">2011
        Incentive Plan for Employees, Officers and Consultants (previously filed as Exhibit&#160;10.6 of our Registration Statement on Form&#160;F-1
        (File No.&#160;333-229155) as filed with the SEC on January&#160;7, 2019 and incorporated by reference herein).</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-8.htm">10.4+</a></div>
        </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000114420419000925/tv507924_ex10-8.htm">2017
        Equity-Based Incentive Plan (previously filed as Exhibit&#160;10.8 of our Registration Statement on Form&#160;F-1 (File No.&#160;333-229155)
        as filed with the SEC on January&#160;7, 2019 and incorporated by reference herein).</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-4.htm">10.5+</a></div>
        </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-4.htm">Chemomab
        Ltd. 2015 Share Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s registration statement on Form S-4
        (SEC file number 333- 252070), filed with the SEC on January 13, 2021)</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-8.htm">10.6++</a></div>
        </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-8.htm">Tel-Aviv
        Souraski Medical Center (TASMC) License Agreement between Chemomab Ltd. and the Medical Research, Infrastructure, Health Services Fund
        of the Tel Aviv Souraski Medical Center., dated December 1, 2011, as amended on May 9, 2013 (incorporated by reference to Exhibit 10.8
        of the Company&#8217;s Amendment No. 1 to its Registration Statement on Form S-4 filed with the Securities and Exchange Commission on
        February 10, 2021)</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-9.htm">10.7++</a></div>
        </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921003702/tm211883d2_ex10-9.htm">CMC
        Collaboration Agreement between Chemomab Ltd. and CMC ICOS Biologics, Inc., dated June 7, 2015 (incorporated by reference to Exhibit 10.9
        of the Company&#8217;s Amendment No. 1 to its Registration Statement on Form S-4 filed with the Securities and Exchange Commission on
        February 10, 2021)</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921058967/tm2114615d1_ex1-2.htm">10.8</a></div>
        </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000110465921058967/tm2114615d1_ex1-2.htm">Controlled
        Equity Offering<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">SM</sup>&#160;Sales Agreement, dated April 30,
        2021, by and between the Company and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.2 of the Company&#8217;s Registration
        Statement on Form S-3 filed with the Securities and Exchange Commission on April 30, 2021)</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-9.htm">10.9+</a></div>
        </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-9.htm">Employment
        Agreement, dated September 1, 2021, by and between Chemomab Therapeutics, Inc. and Dale Pfost (incorporated by reference to Exhibit 10.9
        to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></div> </td> </tr>
  </table>

<div><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">106</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div> <br /> </div>

<table cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-10.htm">10.10+</a></div>
        </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-10.htm">Employment
        Agreement, dated November 8, 2021, by and between Chemomab Therapeutics, Inc. and Donald Marvin (incorporated by reference to Exhibit
        10.10 to the Registrants registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-11.htm">10.11+</a></div>
        </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891323000164/exhibit_10-11.htm">Consulting
        Agreement, dated April 18, 2022, by and between Chemomab Ltd. and Dr. Adi Mor (incorporated by reference to Exhibit 10.11 to the Registrants
        registration statement on Form S-1 filed with the SEC on January 13, 2023)</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_21-1.htm">21.1</a></div>
        </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1534248/000117891322001304/exhibit_21-1.htm">List
        of Subsidiaries (incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s annual report on Form 10-K for the year-ended December
        31, 2021, filed with the SEC on March 30, 2022)</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_23-1.htm">23.1</a></div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_23-1.htm">Consent of Independent Registered Public Accounting Firm</a></div>
        </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="#POWEROFATTORNEY">24.1</a></div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="#POWEROFATTORNEY">Power of Attorney (included on the signature page hereto)</a></div>
        </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_31-1.htm">31.1</a></div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_31-1.htm">Certification of the Chief Executive Officer required by
        Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_31-2.htm">31.2</a></div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_31-2.htm">Certification of the Chief Financial Officer required by
        Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_32-1.htm">32.1&#8224;</a></div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_32-1.htm">Certification of the Chief Executive Officer Pursuant to
        Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_32-2.htm">32.2&#8224;</a></div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_32-2.htm">Certification of the Chief Financial Officer Pursuant to
        Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">101.INS</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Inline XBRL Instance Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">101.SCH</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Inline XBRL Taxonomy Extension Schema Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">101.CAL</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Inline XBRL Taxonomy Extension Calculation Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">101.DEF</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Inline XBRL Taxonomy Extension Definition Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">101.LAB</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Inline XBRL Taxonomy Extension Label Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">101.PRE</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Inline XBRL Taxonomy Extension Presentation Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">&#160;</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">104</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit
        101)</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif"> <br /> </div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">+ Indicates management
contract or compensatory plan.</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#8224; The certifications
furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Annual Report on Form&#160;10-K&#160;and will not be deemed &#8220;filed&#8221;
for purposes of Section&#160;18 or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically
incorporates it by reference.</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">++ Portions of this
Exhibit (indicated with [***]) have been omitted as the Registrant has determined that (i)&#160;the omitted information is not material
and (ii)&#160;the omitted information would likely cause competitive harm to the Registrant if publicly disclosed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <span style="font-weight: bold">Item 16.<span id="Item16."><!--Anchor--></span>
Form 10-K Summary</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 18pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;
Not applicable.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">107</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold">SIGNATURES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z49c14df07460454ba65677b743dbc050" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 50%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td colspan="2" style="vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">CHEMOMAB THERAPEUTICS LTD.</div> </td> </tr>
  <tr>
    <td style="width: 50%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 3%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 50%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Date: March 20, 2023</div> </td>
    <td style="width: 3%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">By:</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">/s/ Dale Pfost</div> </td> </tr>
  <tr>
    <td style="width: 50%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 3%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 47%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; color: rgb(0, 0, 0)">Dale Pfost<br /> Chief Executive Officer</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif; font-weight: bold"><span id="POWEROFATTORNEY"><!--Anchor--></span>POWER
OF ATTORNEY</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">KNOW ALL PERSONS BY
THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dale Pfost&#160;and Donald Marvin, and each of
them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her
and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K,
and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing
requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person,
hereby ratifying and confirming that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes,
may lawfully do or cause to be done by virtue hereof.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in
the capacities and on the dates indicated.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z0d7725d4dc32424c9a080e38b0fca0b4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 33.08%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Signature</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 33.86%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Title</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 30.63%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold">Date</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">/s/ Dale Pfost</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Chief Executive Officer and Chairman of the Board</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">March 20, 2023</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Dale Pfost</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">(Principal Executive Officer)</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">/s/ Donald Marvin</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Chief Financial Officer, Executive Vice President and Chief Operating
        Officer</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">March 20, 2023</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Donald Marvin</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">(Principal Financial and Accounting Officer)</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">/s/ Adi Mor</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Director, Chief Scientific Officer</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">March 20, 2023</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Adi Mor</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">/s/ Nissim Darvish</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Director</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">March 20, 2023</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Nissim Darvish</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">/s/ Jill Quigley</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Director</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">March 20, 2023</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Jill Quigley</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">/s/ Alan Moses</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Director</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">March 20, 2023</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Alan Moses</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">/s/ Claude Nicaise</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Director</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">March 20, 2023</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Claude Nicaise</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">/s/ Neil Cohen</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Director</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">March 20, 2023</div> </td> </tr>
  <tr>
    <td style="width: 33.08%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">Neil Cohen</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 33.86%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 1.22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td>
    <td style="width: 30.63%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0)">&#160;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman,Times,serif"> </span></p>

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">108</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div> <br /> </div>
<!-- Field: /Include-Text -->
</div>
    <div style="margin-top:0pt;margin-bottom:0pt">&#160;</div>
  </div>

  <div>
    <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

        <tr>
          <td style="width:100%;vertical-align:top">
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;font-size:12pt;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Chemomab Therapeutics Ltd.</span></span></span></span></div>
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;font-size:12pt;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">and its subsidiaries</span></span></span></span></div>
            <div style="line-height:1.25;font-family:Times New Roman, Times, serif;font-size:12pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</span></span></span></span></span></div>
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;font-size:12pt;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Consolidated Financial Statements</span></span></span></span></div>
            <div style="text-align:center;line-height:1.25;font-family:Times New Roman, Times, serif;font-size:12pt;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">As of December 31, 2022</span></span></span></span></div>
          </td>
        </tr>

    </table>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
      </div>
    </div>
    <div style="text-align:right;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. and its subsidiaries</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
      <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consolidated Financial Statements as of December 31, 2022</span></span>
        <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
      </div>
    </div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Contents</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
      <table border="0" cellpadding="0" cellspacing="0" style="width:100%">

          <tr>
            <td rowspan="1" style="width:92%">&#160;</td>
            <td rowspan="1" style="width:8%">
              <div>
                <div style="text-align:right;text-indent:12pt;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Page</span></span></div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width:92%">
              <div>&#160;</div>
            </td>
            <td style="width:8%">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width:92%">
              <div>
                <div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#ReportofIndependentRegist_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Report of Independent Registered Public Accounting Firm</span></span></a> </span></span></div>
                <div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong style="color:rgb(0, 0, 0);font-family:'Times New Roman', Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;font-variant-caps:normal;letter-spacing:normal;orphans:2;text-align:left;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;-webkit-text-stroke-width:0px;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial"><span style="color:rgb(33, 37, 41)">(PCAOB ID <ix:nonNumeric id="Fxbrl_20230317114952055" name="dei:AuditorFirmId" contextRef="C_20220101to20221231">1057</ix:nonNumeric>)</span></strong></span></span></div>
              </div>
            </td>
            <td style="text-align:right;vertical-align:top;width:8%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 2</span></span></td>
          </tr>
          <tr>
            <td style="width:92%">
              <div>&#160;</div>
            </td>
            <td style="width:8%">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width:92%">
              <div>
                <div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#ConsolidatedBalanceSheets_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consolidated Balance Sheets</span></span></span></span></a></span></span> </span></span></div>
              </div>
            </td>
            <td style="text-align:right;width:8%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 3</span></span></td>
          </tr>
          <tr>
            <td style="width:92%">
              <div>&#160;</div>
            </td>
            <td style="width:8%">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width:92%">
              <div>
                <div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#Operationsfortheyearended_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consolidated Statements of Operations</span></span></a></span></span></div>
              </div>
            </td>
            <td style="text-align:right;width:8%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 4</span></span></td>
          </tr>
          <tr>
            <td style="width:92%">
              <div>&#160;</div>
            </td>
            <td style="width:8%">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width:92%">
              <div>
                <div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#ChangesinEquity_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Consolidated Statements of Changes in Equity</span></span></a> </span></span></div>
              </div>
            </td>
            <td style="text-align:right;width:8%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 5</span></span></td>
          </tr>
          <tr>
            <td style="width:92%">
              <div>&#160;</div>
            </td>
            <td style="width:8%">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width:92%">
              <div style="text-align:left;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><a href="#Cashflows_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Consolidated Statements of Cash Flows</span></span></span></a></span></span></span></div>
            </td>
            <td rowspan="1" style="text-align:right;width:8%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 6</span></span></td>
          </tr>
          <tr>
            <td rowspan="1" style="width:92%">&#160;</td>
            <td rowspan="1" style="width:8%">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width:92%">
              <div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#FinancialStatements_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Notes to the Consolidated Financial Statements</span></span></a> </span></span></div>
            </td>
            <td rowspan="1" style="text-align:right;width:8%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F - 7</span></span></td>
          </tr>

      </table>
    </div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
      <div style="page-break-after:always">
        <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
      </div>
    </div>
    <div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><img alt="cmmb_img01.jpg" src="cmmb_img01.jpg" /></span></span><br />&#160;</div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Somekh Chaikin</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">KPMG Millennium Tower</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">17 Ha&#8217;arba&#8217;a Street, PO Box 609</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel Aviv 61006, Israel</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">+972 3 684 8000</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    </div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span id="ReportofIndependentRegist_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Report of Independent Registered Public Accounting Firm</span></span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To the Shareholders and Board of Directors,</span></span></div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd.:</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Opinion on the Consolidated Financial Statements</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif">
      <div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have audited the accompanying consolidated balance sheets of Chemomab Therapeutics Ltd. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, changes in equity, and cash flows for each of the years in the two-year period ended December 31, 2022, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></span></div>
      <div style="line-height:1.25">&#160;</div>
    </div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basis for Opinion</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:justify;margin-right:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230317115222105" name="dei:AuditorName" contextRef="C_20220101to20221231">Somekh Chaikin</ix:nonNumeric></span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:justify;margin-right:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Member Firm of KPMG International</span></span></div>
    <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div style="text-align:justify;margin-right:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have served as the Company&#8217;s auditor since 2015.</span></span></div>
    <div style="text-align:justify;margin-right:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230317115227929" name="dei:AuditorLocation" contextRef="C_20220101to20221231">Tel Aviv, Israel</ix:nonNumeric></span></span></div>
    <div style="text-align:justify;margin-right:42.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 20, 2023</span></span></div>
    <div style="text-align:justify;margin-right:42.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
    <div>
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:8pt"><span><span>&#169; 2023 KPMG Somekh Chaikin, an Israeli partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.</span></span></span></span></div>
      <div style="clear:both;margin-top:10pt;margin-bottom:10pt">
        <div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">F - 2</span></span></span></div>
        <div style="page-break-after:always">
          <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
        </div>
      </div>
    </div>
  </div>

  <table cellpadding="0" style="border-spacing:0;margin:auto" width="100%">

      <tr>
        <td style="width:100%;vertical-align:bottom">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">Chemomab Therapeutics Ltd. and its subsidiaries</p>
        </td>
      </tr>
      <tr>
        <td style="width:100%;vertical-align:bottom">&#160;</td>
      </tr>
      <tr>
        <td style="width:100%;vertical-align:bottom;border-bottom:1.5pt solid #000000">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:4pt"><span id="ConsolidatedBalanceSheets_integixAnchor"><span id="consolidatedBalanceSheets_integixAnchor"><span style="font-weight:bold">Con</span></span><span><span style="font-weight:bold">solidated Balance Sheets as of</span></span></span></p>
        </td>
      </tr>
      <tr>
        <td style="width:100%;vertical-align:bottom">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:4pt;margin-bottom:0pt">In USD thousands (except share and per share amounts)</p>
        </td>
      </tr>

  </table>
  <div style="margin-top:0px">
    <p style="text-align:center;margin-bottom:0px">&#160; &#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%">

        <tr>
          <td style="vertical-align:bottom">&#160;</td>
          <td style="vertical-align:bottom">&#160;</td>
          <td style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note</span></p>
          </td>
          <td style="vertical-align:bottom">&#160;</td>
          <td style="vertical-align:bottom">&#160;</td>
          <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
          </td>
          <td style="vertical-align:bottom;text-align:right">&#160;</td>
          <td style="vertical-align:bottom;text-align:right">&#160;</td>
          <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
          </td>
          <td style="vertical-align:bottom">&#160;</td>
        </tr>


        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Assets</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Current assets</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Cash and cash equivalents</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">3</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000038" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,519</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000039" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,186</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Short-term bank deposit</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000040" name="us-gaap:DepositsAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,374</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000041" name="us-gaap:DepositsAssetsCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,975</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Restricted cash</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230213102216110_Fact_0000000000040" name="us-gaap:RestrictedCashCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></strong></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:9%"><ix:nonFraction id="Fxbrl_20230213102216110_Fact_0000000000041" name="us-gaap:RestrictedCashCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Other receivables and prepaid expenses</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">4</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000042" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,766</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000043" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,527</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total current assets</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000044" name="us-gaap:AssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,736</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000045" name="us-gaap:AssetsCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,688</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Non-current assets</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash</span></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:9%"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207200450049_Fact_0000000000050" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></strong></td>
          <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230207200450049_Fact_0000000000051" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></span></td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Long-term prepaid expenses</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000048" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">733</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span><ix:nonFraction id="Fxbrl_20230131220311598" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">908</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Property and equipment, net</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">5</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000052" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">367</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000053" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">357</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Operating lease right-of-use assets</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">6</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000054" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">227</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000055" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total non-current assets</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000056" name="us-gaap:AssetsNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,327</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000057" name="us-gaap:AssetsNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,665</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total assets</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000058" name="us-gaap:Assets" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,063</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000059" name="us-gaap:Assets" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,353</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Current liabilities</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Trade payables</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000060" name="us-gaap:AccountsPayableTradeCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,688</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000061" name="us-gaap:AccountsPayableTradeCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,336</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accrued expenses</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000062" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,378</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000063" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">555</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Employee and related expenses</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000064" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,560</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000065" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">653</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Operating lease liabilities</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">6</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000066" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000067" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total current liabilities</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000068" name="us-gaap:LiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,749</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000069" name="us-gaap:LiabilitiesCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,650</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Non-current liabilities</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Non-current operating lease liabilities</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">6</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000070" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000071" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total non-current liabilities</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000072" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000073" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Commitments and contingent liabilities</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">7</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:9%"><ix:nonFraction id="Fxbrl_20230207202310124" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20221231" unitRef="usd" xsi:nil="true"></ix:nonFraction></td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:9%"><ix:nonFraction id="Fxbrl_20230207202348403" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20211231" unitRef="usd" xsi:nil="true"></ix:nonFraction></td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total liabilities</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000074" name="us-gaap:Liabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,840</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000075" name="us-gaap:Liabilities" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,887</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Shareholders' equity</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">8</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-10pt;padding-left:10pt;margin-bottom:0pt">Ordinary Shares <ix:nonFraction id="Fxbrl_20230201163052384" name="us-gaap:CommonStockNoParValue" contextRef="C_20211231" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20230131220607422" name="us-gaap:CommonStockNoParValue" contextRef="C_20221231" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> par value - Authorized: <ix:nonFraction id="Fxbrl_20230131221123913" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230131221114549" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">650,000,000 </ix:nonFraction></ix:nonFraction>shares as of December 31, 2022 and 2021;&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-10pt;padding-left:10pt;margin-bottom:0pt">Issued and outstanding: <ix:nonFraction id="Fxbrl_s_20230213101830929" name="us-gaap:SharesOutstanding" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230213101830930" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">232,636,700</ix:nonFraction></ix:nonFraction> Ordinary shares at December 31, 2022 and <ix:nonFraction id="Fxbrl_s_20230131221353660" name="us-gaap:SharesOutstanding" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230131221353661" name="us-gaap:CommonStockSharesIssued" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,090,300</ix:nonFraction></ix:nonFraction> Ordinary shares at December 31, 2021</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="Fxbrl_20230131221528825" name="us-gaap:CommonStockValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20230131221535249" name="us-gaap:CommonStockValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, serif">Treasury share at cost (<ix:nonFraction id="Fxbrl_20230207202558860" name="us-gaap:TreasuryStockShares" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,640,460</ix:nonFraction> shares as of </span><span style="font-size:10pt;font-family:Times New Roman, serif">December 31, 2022</span><span style="font-size:10pt;font-family:Times New Roman, serif">)</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><strong><span style="font-size:10pt;font-family:Times New Roman, serif">(<ix:nonFraction id="Fxbrl_20230207202444619" name="us-gaap:TreasuryStockValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,218</ix:nonFraction></span></strong></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">)</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:9%"><ix:nonFraction id="Fxbrl_20230207202534021" name="us-gaap:TreasuryStockValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Additional paid-in capital</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000086" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,260</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000087" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,639</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accumulated deficit</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000088" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">63,819</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-weight:bold">)</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000089" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36,173</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">)</p>
          </td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total shareholders&#8217; equity</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000090" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,223</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000091" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,466</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Total liabilities and shareholders&#8217; equity</span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000092" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,063</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000093" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,353</ix:nonFraction></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>

    </table>
  </div>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:16pt;margin-bottom:0pt">_____________________&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;_____________________</p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt">Chief Executive Officer&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; Chief Financial Officer</p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt">&#160;</p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt">Date of approval of the financial statements: February 20, 2023</p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0px">&#160;</p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0px;margin-bottom:0px">The accompanying notes are an integral part of the consolidated financial statements.</p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0px;margin-bottom:0px;text-align:center">&#160;</p>
  <div>
    <div style="width:100%;clear:both">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:5pt">F - 3</p>
    </div>
    <hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-bottom:10pt" />
  </div>

  <table cellpadding="0" style="border-spacing:0;margin:auto" width="100%">

      <tr>
        <td style="width:100%;vertical-align:bottom">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Therapeutics Ltd. and its subsidiaries</span></span></p>
        </td>
      </tr>
      <tr>
        <td style="width:100%;vertical-align:bottom">&#160;</td>
      </tr>
      <tr>
        <td style="width:100%;vertical-align:bottom;border-bottom:1.5pt solid #000000">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:4pt"><span id="Operationsfortheyearended_integixAnchor"><strong><span id="consolidatedStatementsOfOperationsForTheYearEnded_integixAnchor"><span>Consolidated Statements of Operations for the year ended</span></span></strong></span></p>
        </td>
      </tr>
      <tr>
        <td style="width:100%;vertical-align:bottom">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:4pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In USD thousands (except share and per share amounts)</span></span></p>
        </td>
      </tr>

  </table>
  <div style="margin-top:0px;margin-bottom:0px">
    <p style="margin-bottom:0px;text-align:center;margin-top:0px">&#160; &#160; &#160; &#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%">

        <tr>
          <td style="vertical-align:bottom">&#160;</td>
          <td style="vertical-align:bottom">&#160;</td>
          <td style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Note</span></span></span></p>
          </td>
          <td style="vertical-align:bottom">&#160;</td>
          <td style="vertical-align:bottom">&#160;</td>
          <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
          </td>
          <td style="vertical-align:bottom;text-align:right">&#160;</td>
          <td style="vertical-align:bottom;text-align:right">&#160;</td>
          <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
          </td>
          <td style="vertical-align:bottom">&#160;</td>
        </tr>


        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Operating expenses</span></span></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9</span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000094" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,977</ix:nonFraction></span></span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000095" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,334</ix:nonFraction></span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative</span></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000096" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,556</ix:nonFraction></span></span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000097" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,033</ix:nonFraction></span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Total operating expenses</span></span></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000098" name="us-gaap:OperatingExpenses" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,533</ix:nonFraction></span></span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000099" name="us-gaap:OperatingExpenses" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,367</ix:nonFraction></span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Financing (income) expenses, net</span></span></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);border-bottom:1.5pt solid black;width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);border-bottom:1.5pt solid black;width:9%">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230131223230473" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction>)</span></span></strong></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);border-bottom:1.5pt solid black;width:1%">&#160;</td>
          <td style="vertical-align:top;text-align:right;background-color:rgb(204, 238, 255);border-bottom:1.5pt solid black;width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230131223237304" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">111</ix:nonFraction></span></span></span></td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span>Loss before taxes</span></strong></span></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><strong><span style="font-size:11pt;font-family:Times New Roman, serif"><ix:nonFraction id="Fxbrl_20230207212310873_Fact_0000000000102" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">28,180</ix:nonFraction></span></strong></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);text-align:right;width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);text-align:right;width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);text-align:right;width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:11pt;font-family:Times New Roman, serif"><ix:nonFraction id="Fxbrl_20230207212310873_Fact_0000000000103" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Taxes on income (benefit)</span></span></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">11</p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(<ix:nonFraction id="Fxbrl_20230131223639023" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">534</ix:nonFraction></span></span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></strong></td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000101" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">&#160;</p>
          </td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Net loss for the year</span></span></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000102" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></span></span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000103" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per Ordinary Share</span></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);border-bottom:3pt double black;width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);border-bottom:3pt double black;width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="Fxbrl_20230131213305203" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000104" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.121</ix:nonFraction></ix:nonFraction></span></span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);border-bottom:3pt double black;width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);border-bottom:3pt double black;width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131213312166" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000105" name="us-gaap:EarningsPerShareBasic" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.060</ix:nonFraction></ix:nonFraction></span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:65%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of Ordinary Shares outstanding, basic, and diluted</span></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);border-bottom:3pt double black;width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);border-bottom:3pt double black;width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="Fxbrl_20230214141238310" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000106" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">227,589,288</ix:nonFraction></ix:nonFraction></span></span></span></p>
          </td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);border-bottom:3pt double black;width:1%">&#160;</td>
          <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);border-bottom:3pt double black;width:9%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230131213329528" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000107" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">207,468,650</ix:nonFraction></ix:nonFraction></span></span></p>
          </td>
          <td style="vertical-align:top;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>

    </table>
  </div>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, serif;font-size:10pt;color:black;margin-top:0pt;margin-bottom:0pt">The accompanying notes are an integral part of the consolidated financial statements.</span></p>
  <div style="margin-top:0pt;margin-bottom:0pt">
    <div style="width:100%;clear:both;margin-top:0pt;margin-bottom:0pt">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:5pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">F - 4</span></span></p>
    </div>
    <hr style="border-top:1.5pt solid rgb(0, 0, 0);break-after:page;margin-bottom:10pt;margin-top:0pt" />
  </div>

  <table cellpadding="0" style="border-spacing:0;margin:auto" width="100%">

      <tr>
        <td style="width:100%;vertical-align:bottom">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">Chemomab Therapeutics Ltd. and its subsidiaries</p>
        </td>
      </tr>
      <tr>
        <td style="width:100%;vertical-align:bottom">&#160;</td>
      </tr>
      <tr>
        <td style="width:100%;vertical-align:bottom;border-bottom:1.5pt solid #000000">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:4pt"><span id="ChangesinEquity_integixAnchor"><span id="consolidatedStatementsOfChangesInEquity_integixAnchor"><span style="font-weight:bold">Consolidated S</span></span><span><span style="font-weight:bold">tatements of Changes in Equity</span></span></span></p>
        </td>
      </tr>
      <tr>
        <td style="width:100%;vertical-align:bottom">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:4pt;margin-bottom:0pt">In USD thousands (except share amounts)</p>
        </td>
      </tr>

  </table>
  <div style="margin-top:0px">
    <table border="0" cellpadding="0" cellspacing="0" style="width:100%">

        <tr>
          <td style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px" valign="bottom">&#160; &#160;</td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px">&#160;</td>
          <td colspan="2" rowspan="1" style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>
          </td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
          <td colspan="2" rowspan="1" style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>
          </td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
          <td style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px" valign="bottom">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>
          </td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
          <td style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px" valign="bottom">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>
          </td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
          <td colspan="2" rowspan="1" style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>
          </td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
          <td colspan="2" rowspan="1" style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>
          </td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center">&#160;</td>
          <td colspan="2" rowspan="1" style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</p>
          </td>
          <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)">&#160;</td>
          <td colspan="6" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
            <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">Ordinary</span></p>
            <p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">Shares</span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)">&#160;</td>
          <td colspan="6" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>Treasury<br />share</strong></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center">&#160;</td>
          <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center;border-bottom:2px solid black">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>Additional<br />paid in<br />capital</strong></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center">&#160;</td>
          <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center;border-bottom:2px solid black">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>Accumulated Deficit</strong></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center">&#160;</td>
          <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);text-align:center;border-bottom:2px solid black">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><strong>Total Shareholders'<br />equity</strong></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)">&#160;</td>
          <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">Number</span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
          <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">USD</span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
          <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">Number</span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
          <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">USD</span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
          <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">USD</span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
          <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">USD</span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255)">&#160;</td>
          <td colspan="2" rowspan="1" style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;text-align:center;background-color:rgb(255, 255, 255);border-bottom:2px solid black">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">USD</span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255)">&#160;</td>
        </tr>
        <tr style="height:15px;background-color:rgb(204, 238, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:37%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>Balance as of January 1, 2021 </strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207232832534" name="us-gaap:SharesOutstanding" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">9,274,838</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004148281" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004108785" name="us-gaap:SharesOutstanding" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004208753" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207232638785_Fact_0000000000128" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,497</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>(<ix:nonFraction id="Fxbrl_20230207232638785_Fact_0000000000129" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">23,695</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:left;margin:0px"><strong>)</strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207232638785_Fact_0000000000130" name="us-gaap:StockholdersEquity" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,802</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="height:15px;background-color:rgb(255, 255, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:37%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px">&#160;</p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right">&#160;</p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right">&#160;</p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right">&#160;</p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right">&#160;</p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right">&#160;</p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right">&#160;</p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right">&#160;</p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="height:15px;background-color:rgb(204, 238, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:37%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Share-based compensation</span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right">-</span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004236209" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right">-</span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004232608" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207232932528" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,019</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004229458" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207232938175" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,019</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="height:15px;background-color:rgb(255, 255, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:37%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Effect of reverse capitalization transaction</span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207232946871" name="cmmb:EffectOfReverseCapitalizationTransactionShares" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">152,299,702</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004310594" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004631164" name="cmmb:EffectOfReverseCapitalizationTransactionShares" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004302609" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207232952864" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004258843" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207232958504" name="cmmb:EffectOfReverseCapitalizationTransaction" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="height:15px;background-color:rgb(204, 238, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:37%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Issuance of shares and warrants, net of issuance costs</span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207233006128" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">66,381,520</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004339738" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004626295" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004335122" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207233012248" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,637</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004332317" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207233018475" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,637</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="height:15px;background-color:rgb(255, 255, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:37%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Exercise of options</span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207233039147" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">134,240</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004521301" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004621028" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004724885" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207233033563" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230208004807831" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><ix:nonFraction id="Fxbrl_20230207233028090" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="height:15px;background-color:rgb(204, 238, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:37%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Net loss for the year</span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:2px solid black">&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
              <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>-</strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:2px solid black">&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
              <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208004352160" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:2px solid black">&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
              <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>-</strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:2px solid black">&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
              <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208004349447" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:2px solid black">&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
              <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><ix:nonFraction id="Fxbrl_20230208004345432" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:2px solid black">&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
              <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">(<ix:nonFraction id="Fxbrl_20230207233044479" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:0px;padding:0in 0in 1pt;text-align:left;margin:0px;border-top:0px">
              <p style="margin:0px;border:none;padding:0px 0in 0in;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">)</span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:2px solid black">&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
              <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">(<ix:nonFraction id="Fxbrl_20230207233049858" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:0px;padding:0in 0in 1pt;text-align:left;margin:0px;border-top:0px">
              <p style="margin:0px;border:none;padding:0px 0in 0in;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">)</span></span></span></p>
            </div>
          </td>
        </tr>
        <tr style="height:15px;background-color:rgb(255, 255, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;padding:0px;vertical-align:bottom;background-color:rgb(255, 255, 255);width:37%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>Balance as of December 31, 2021</strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
            <div>&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <div style="padding:0in 0in 1pt;text-align:right">
              <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230207234506438" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,090,300</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
            <div>&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <div style="padding:0in 0in 1pt;text-align:right">
              <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208004359870" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
            <div>&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:6%" valign="top">
            <div style="padding:0in 0in 1pt;text-align:right">
              <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><ix:nonFraction id="Fxbrl_20230208004449318" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
            <div>&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:6%" valign="top">
            <div style="padding:0in 0in 1pt;text-align:right">
              <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208004357072" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
            <div>&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <div style="padding:0in 0in 1pt;text-align:right">
              <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230207233106443" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,639</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
            <div>&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <div style="padding:0in 0in 1pt;text-align:right">
              <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>(</strong><strong><ix:nonFraction id="Fxbrl_20230207234203847" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36,173</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px 0px 2pt;background-color:rgb(255, 255, 255);width:1%">
            <div style="padding:0in 0in 1pt;text-align:left;margin:0px">
              <p style="margin:0px;padding:0px 0in 0in;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>)</strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
            <div>&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <div style="padding:0in 0in 1pt;text-align:right">
              <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230207233116634" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,466</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="background-color:rgb(204, 238, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:37%" valign="bottom">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="top">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="height:15px;background-color:rgb(255, 255, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:37%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>Balance as of January 1, 2022 </strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207234515566" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">228,090,300</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004830175" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004835440" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="top">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208004846448" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233129314" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,639</ix:nonFraction> </strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>(<ix:nonFraction id="Fxbrl_20230207233133644" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">36,173</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>)</strong></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233141194" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,466</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="height:15px;background-color:rgb(204, 238, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:37%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Share-based compensation</span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>-</strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004855201" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>-</strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="top">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004852649" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233154315" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004943313" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233147476" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="height:15px;background-color:rgb(255, 255, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:37%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Issuance of shares, net of issuance costs</span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233201211" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,576,400</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004904248" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004910523" name="cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="top">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208004901083" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233210018" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004950211" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233216009" name="cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>
        <tr style="height:15px;background-color:rgb(204, 238, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:37%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Exercise of options</span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233237975" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,970,000</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004927217" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004915442" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="top">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004923369" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233227671" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004959684" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230207233221400" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        </tr>
        <tr style="height:15px;background-color:rgb(255, 255, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:37%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Treasury share at cost</span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>- </strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004938057" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>(<ix:nonFraction id="Fxbrl_20230207233301376" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" sign="-">11,640,460</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">
            <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:left;margin:0px"><strong>)</strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="top">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>(<ix:nonFraction id="Fxbrl_20230207233406606" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,218</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">
            <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:left;margin:0px"><strong>)</strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004934609" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong><ix:nonFraction id="Fxbrl_20230208004932393" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:right"><strong>(<ix:nonFraction id="Fxbrl_20230207233411324" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,218</ix:nonFraction></strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding:0px;background-color:rgb(255, 255, 255);width:1%">
            <p style="margin:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%;text-align:left;margin:0px"><strong>)</strong></span></span></span></p>
          </td>
        </tr>
        <tr style="height:15px;background-color:rgb(204, 238, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:37%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%">Net loss for the year</span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:2px solid black">&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
              <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>-</strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:2px solid black">&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
              <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208005011611" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:2px solid black">&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
              <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>-</strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:2px solid black">&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="top">
            <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
              <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208005008418" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:2px solid black">&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
              <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208005005802" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:2px solid black">&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
              <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>(<ix:nonFraction id="Fxbrl_20230207233416622" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:0px;padding:0in 0in 1pt;text-align:left;margin:0px;border-top:0px">
              <p style="margin:0px;border:none;padding:0px 0in 0in;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>)</strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:2px solid black">&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(204, 238, 255);width:6%" valign="bottom">
            <div style="border-bottom:2px solid black;padding:0in 0in 1pt;text-align:right;border-top:0px">
              <p style="margin-top:0px;margin-bottom:0pt;border:none;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>(<ix:nonFraction id="Fxbrl_20230207233422744" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding:0px;background-color:rgb(204, 238, 255);width:1%">
            <div style="border-bottom:0px;padding:0in 0in 1pt;text-align:left;margin:0px;border-top:0px">
              <p style="margin:0px;border:none;padding:0px 0in 0in;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>)</strong></span></span></span></p>
            </div>
          </td>
        </tr>
        <tr style="height:15px;background-color:rgb(255, 255, 255)">
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:37%" valign="bottom">
            <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>Balance as of December 31, 2022</strong></span></span></span></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
            <div>&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <div style="padding:0in 0in 1pt;text-align:right">
              <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230207233430996" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">232,636,700</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
            <div>&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <div style="padding:0in 0in 1pt;text-align:right">
              <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230208005022333" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
            <div>&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <div style="padding:0in 0in 1pt;text-align:right">
              <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>(<ix:nonFraction id="Fxbrl_20230207233657770" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" sign="-">11,640,460</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;padding:0px 0px 3pt;background-color:rgb(255, 255, 255);vertical-align:bottom;width:1%">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>)</strong></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
            <div>&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:6%" valign="top">
            <div style="padding:0in 0in 1pt;text-align:right">
              <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>(<ix:nonFraction id="Fxbrl_20230207233728393" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,218</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;padding:0px 0px 3pt;background-color:rgb(255, 255, 255);vertical-align:bottom;width:1%">
            <div style="padding:0in 0in 1pt;text-align:left;margin:0px">
              <p style="margin:0px;padding:0px 0in 0in;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>)</strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
            <div>&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <div style="padding:0in 0in 1pt;text-align:right">
              <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230207233439472" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,260</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
            <div>&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <div style="padding:0in 0in 1pt;text-align:right">
              <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong>(<ix:nonFraction id="Fxbrl_20230207233445148" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">63,819</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;padding:0px 0px 3pt;background-color:rgb(255, 255, 255);vertical-align:bottom;width:1%">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>)</strong></p>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">
            <div>&#160;</div>
          </td>
          <td style="height:15px;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding:0px;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:6%" valign="bottom">
            <div style="padding:0in 0in 1pt;text-align:right">
              <p style="margin-top:0px;margin-bottom:0pt;padding:0px 0in 0in;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:115%"><strong><ix:nonFraction id="Fxbrl_20230207233450251" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,223</ix:nonFraction></strong></span></span></span></p>
            </div>
          </td>
          <td style="font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding:0px;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        </tr>

    </table>
  </div>
  <div>
    <div style="width:100%;clear:both">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0px">&#160;</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:0px;margin-top:0pt">F - 5</p>
    </div>
    <hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-bottom:10pt" />
  </div>

  <table cellpadding="0" style="border-spacing:0px;margin-top:auto;margin-bottom:auto" width="100%">

      <tr>
        <td style="width:100%;vertical-align:bottom">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
        </td>
      </tr>
      <tr>
        <td style="width:100%;vertical-align:bottom">&#160;</td>
      </tr>
      <tr>
        <td style="width:100%;vertical-align:bottom;border-bottom:1.5pt solid #000000">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:4pt"><span id="Cashflows_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span id="statementsOfCashFlows_integixAnchor"><span style="font-weight:bold">Statem</span></span><span><span style="font-weight:bold">ents of Cash flows for the year ended</span></span></span></span></span></span></span></p>
        </td>
      </tr>
      <tr>
        <td style="width:100%;vertical-align:bottom">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:4pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In USD thousands</span></span></span></span>&#160;</p>
        </td>
      </tr>

  </table>
  <p style="margin-bottom:0px;text-align:center">&#160; &#160; &#160; &#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%">

      <tr>
        <td style="vertical-align:bottom">&#160;</td>
        <td style="vertical-align:bottom">&#160;</td>
        <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">December&#160;31, </span></span></span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">2022</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;text-align:right">&#160;</td>
        <td style="vertical-align:bottom;text-align:right">&#160;</td>
        <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">December&#160;31, </span></span></span></span></span></span></span></p>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">2021</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">Cash flows from operating activities</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Net loss for the year</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000149" name="us-gaap:ProfitLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">)</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(<ix:nonFraction id="FFact_0000000000150" name="us-gaap:ProfitLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></p>
        </td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0px">&#160;</p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">Adjustments for operating activities:</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Depreciation</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000151" name="us-gaap:Depreciation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="FFact_0000000000152" name="us-gaap:Depreciation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Share-based compensation</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000153" name="us-gaap:ShareBasedCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="FFact_0000000000154" name="us-gaap:ShareBasedCompensation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,019</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Change in other receivables and prepaid expenses</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000155" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">)</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(<ix:nonFraction id="FFact_0000000000156" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,058</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></p>
        </td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Change in trade payables</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000157" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">352</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="FFact_0000000000158" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,175</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Change in accrued expenses</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000159" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,823</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(<ix:nonFraction id="Fxbrl_20230201002431792" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,279</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></p>
        </td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Change in employees and related expenses</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000161" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">907</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="FFact_0000000000162" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">215</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:baseline;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Change in operating leases&#160;</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:baseline;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000163" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:baseline;background-color:rgb(204, 238, 255);width:1%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">)</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:baseline;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>(<ix:nonFraction id="Fxbrl_20230201002424683" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:baseline;background-color:rgb(204, 238, 255);width:1%">
          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></p>
        </td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">Net cash used in operating activities</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000165" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">20,370</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">)</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(<ix:nonFraction id="FFact_0000000000166" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,374</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></p>
        </td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">Cash flows from investing activities</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Investment in deposits</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000167" name="cmmb:PaymentsForInvestmentInDeposits" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">19,601</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(<ix:nonFraction id="FFact_0000000000168" name="cmmb:PaymentsForInvestmentInDeposits" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,951</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></p>
        </td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Long-term lease deposit</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000169" name="cmmb:LongTermLeaseDeposit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><ix:nonFraction id="Fxbrl_20230131235620864" name="cmmb:LongTermLeaseDeposit" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Sale of asset held for sale</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000171" name="us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><ix:nonFraction id="Fxbrl_20230131235631064" name="us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Purchase of property and equipment</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000173" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">)</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(<ix:nonFraction id="FFact_0000000000174" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></p>
        </td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">Net cash provided by (used in) investing activities</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000175" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,533</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(<ix:nonFraction id="FFact_0000000000176" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">45,186</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></p>
        </td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">Cash flows from financing activities</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Cash acquired in Merger</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000177" name="cmmb:CashAcquiredInMerger" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><ix:nonFraction id="Fxbrl_20230131235649216" name="cmmb:CashAcquiredInMerger" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,427</ix:nonFraction></span></span></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Exercise of options</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold"><span><ix:nonFraction id="FFact_0000000000179" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><ix:nonFraction id="Fxbrl_20230131235658097" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Treasury share at cost</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">(<ix:nonFraction id="Fxbrl_20230201000241409" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,218</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">
          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">)</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="FFact_0000000000182" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Issuance of shares and warrants, net of issuance costs</span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000183" name="us-gaap:ProceedsFromOtherEquity" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">267</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="FFact_0000000000184" name="us-gaap:ProceedsFromOtherEquity" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,637</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">Net cash provided by (used in) financing activities</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">(<ix:nonFraction id="Fxbrl_20230201002754453" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">808</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">
          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">)</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="FFact_0000000000186" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,074</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">Change in cash, cash equivalents and restricted cash</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">(<ix:nonFraction id="Fxbrl_20230201002721687" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,645</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">)</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="FFact_0000000000188" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,514</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">Cash, cash equivalents and restricted cash at beginning of the year</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000189" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,241</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="FFact_0000000000190" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,727</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">Cash, cash equivalents and restricted cash at end of the year</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000191" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,596</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="FFact_0000000000192" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,241</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><strong><span style="text-decoration:underline">Supplementary cash flows information:</span></strong></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><span>A.&#160; &#160; &#160; &#160; Cash paid and received during the year for:</span></strong></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;height:15px;background-color:rgb(204, 238, 255);width:76%">
          <p style="margin-left:30pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Income taxes received</span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;height:15px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="border-bottom:4px double black;vertical-align:bottom;height:15px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="border-bottom:4px double black;vertical-align:bottom;text-align:right;height:15px;background-color:rgb(204, 238, 255);width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><ix:nonFraction id="Fxbrl_20230214142748754" name="cmmb:IncomeTaxesReceived" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">351</ix:nonFraction></span></span></strong></span></span></td>
        <td style="vertical-align:bottom;height:15px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;height:15px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="border-bottom:4px double black;vertical-align:bottom;height:15px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="border-bottom:4px double black;vertical-align:bottom;text-align:right;height:15px;background-color:rgb(204, 238, 255);width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230214143241770" name="cmmb:IncomeTaxesReceived" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;height:15px;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:30pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span>Income taxes paid</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="border-bottom:4px double black;vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="border-bottom:4px double black;vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-bottom:0pt;margin-top:0pt;text-align:right"><span style="font-weight:bold">(<ix:nonFraction id="Fxbrl_20230214142431448" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></span></span></span></span></td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%;padding-bottom:2pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></strong></td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="border-bottom:4px double black;vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="display:none">&#160;</span>&#160;</span></span></span></span></td>
        <td style="border-bottom:4px double black;vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-bottom:0pt;margin-top:0pt;text-align:right"><ix:nonFraction id="Fxbrl_20230207233750059" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:30pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Interest received</span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="text-align:right;vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><ix:nonFraction id="Fxbrl_20230207233819452" name="cmmb:InterestReceived" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">972</ix:nonFraction></span></span></strong></span></span></td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="border-bottom:4px double black;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230207233829491" name="cmmb:InterestReceived" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></span></span></span></span></td>
        <td style="background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold">B.&#160; &#160; &#160; &#160; Significant non- cash transaction:</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:30pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span><span style="font-weight:normal">Right-of-use asset recognized with corresponding lease liability</span></span></span></span></span></strong></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000193" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(255, 255, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="FFact_0000000000194" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
      </tr>
      <tr style="background-color:rgb(204, 238, 255)">
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:76%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:30pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span style="font-weight:normal">Liabilities assumed, net of non-cash assets received in Merger</span></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span><span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000195" name="us-gaap:LiabilitiesAssumed1" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></span></strong></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:4px double black;background-color:rgb(204, 238, 255);width:9%">
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><ix:nonFraction id="Fxbrl_20230131235456185" name="us-gaap:LiabilitiesAssumed1" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></span></span></span></span></span></p>
        </td>
        <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
      </tr>

  </table>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt">&#160;</p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0px;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The accompanying notes are an integral part of the consolidated financial statements.</span></span></span></span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0px;margin-bottom:0px">&#160;</p>
  <div style="margin-top:0pt;margin-bottom:0pt">
    <div style="width:100%;clear:both;margin-top:0pt;margin-bottom:0pt">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:5pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">F - 6</span></span></span></span></p>
    </div>
    <hr style="border-top:1.5pt solid rgb(0, 0, 0);break-after:page;margin-bottom:10pt;margin-top:0pt" />
  </div>
  <div style="margin-top:0pt;margin-bottom:0pt">
    <table cellpadding="0" style="border-spacing:0px;margin-top:0pt;margin-bottom:0pt" width="100%">

        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:100%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p>
          </td>
        </tr>
        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:100%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">&#160;</td>
        </tr>
        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:100%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:4pt"><span id="FinancialStatements_integixAnchor"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></span></span></p>
          </td>
        </tr>
        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:100%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <hr style="height:1.5pt;border-width:0px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0);width:100%;margin-top:0pt;text-align:left;margin-bottom:0pt" />
          </td>
        </tr>
        <tr style="margin-top:0pt;margin-bottom:0pt">
          <td style="width:100%;vertical-align:top;margin-top:0pt;margin-bottom:0pt">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">&#160;&#8201;</span></span></span></span></p>
          </td>
        </tr>

    </table>
  </div>

  <ix:nonNumeric id="FFact_0000000000208" name="us-gaap:NatureOfOperations" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 1 - General</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt">1.<span style="padding-left:28.5pt">Chemomab Therapeutics Ltd. (hereinafter - "the Company") is an Israeli-based company incorporated under the laws of the State of Israel in September 2011. The Company&#8217;s registered office is located in Kiryat Atidim, Tel Aviv, Israel.&#160;</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0px;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt;text-align:justify"><br />The Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical need that involve inflammation and fibrosis.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0px;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><br />The wholly owned subsidiaries of the Company are: Chemomab Ltd. ("Chemomab"), Chemomab Therapeutics Israel Ltd. and Chemomab Therapeutics Inc.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt">2.<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="padding-left:28.5pt">The Company currently has no products approved for sale. The Company&#8217;s operations are funded primarily by its Shareholders. The Company has incurred operating losses in each year since its inception and does not expect to generate significant revenue unless and until it obtains marketing approval for its products. Continuation of the Company&#8217;s development programs depend on its future ability to raise sources of financing.</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.<span style="padding-left:28.5pt">Since </span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">January 2020, the COVID-19 pandemic has dramatically expanded into a worldwide pandemic, creating macro-economic uncertainty and disruption in the business and financial markets. Many countries around the world, including Israel, had taken&#160; measures designated to limit the continued spread of the COVID-19 pandemic, including the closure of workplaces, restricting travel, prohibiting assembling, closing international borders and quarantining populated areas. The Company's clinical trial sites have been affected by the COVID-19 pandemic, and as a result, commencement of the enrollment in our clinical trials of CM-101 in PSC was delayed, and the enrollment rate has been, and is still, affected as well. As a result, The Company expanded its patient recruiting efforts to additional territories. In addition, after enrollment in these trials, patients might still drop out because of possible COVID-19 implications. Based on management&#8217;s assessment, the extent to which the lingering effects of the COVID-19 pandemic will further impact the Company's operations will depend on future developments. These developments, which are highly uncertain and cannot be predicted with confidence,including the duration and severity of the impact on patient enrollment following the attenuation of the outbreak The Company is carefully monitoring the impacts arising from&#160; the COVID-19 pandemic and will adjust activities accordingly<span><span><span>.</span></span></span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.<span style="padding-left:28.5pt">On </span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 14, 2020, the Company (formerly known as Anchiano Therapeutics Ltd.) entered into an Agreement and Plan of Merger (the "Merger" and &#8220;Merger Agreement&#8221;) with Chemomab Ltd., an Israeli limited company, and CMB Acquisition Ltd., an Israeli limited company and a wholly owned subsidiary of the Company (&#8220;Merger Sub&#8221;). On March 16, 2021, (the &#8220;Effective Time&#8221;), the Company consummated the Merger pursuant to the Merger Agreement Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Chemomab Ltd., with Chemomab Ltd. surviving the Merger as the Company's wholly owned subsidiary. In connection with the Merger, on March 16, 2021, the Company changed its name from &#8220;Anchiano Therapeutics Ltd.&#8221; To &#8220;Chemomab Therapeutics Ltd" and the business conducted by Chemomab Ltd. became primarily the business conducted by the Company.</span></span></p>
    <div>
      <div style="width:100%;clear:both">
        <p style="margin:0pt">&#160;</p>
      </div>
    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0px;padding-left:72pt;margin-bottom:10pt">At the Effective Time(a) each Chemomab Ltd. ordinary share outstanding immediately prior to the Effective Time was converted solely into number of American Depository Shares equal to the exchange ratio described in the Merger Agreement, and each outstanding Chemomab Ltd. option was assumed by the Company, based on the same exchange ratio.</p>
    <div><ix:exclude>
      <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;7</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
      <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><br /><strong>Note 1 - General (cont&#8217;d)</strong></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:11pt;margin-bottom:0pt;margin-left:36pt">4.<span style="padding-left:20pt">&#160;</span> (cont'd)</p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For&#160;<span>accounting purposes, Chemomab Ltd. is considered to have acquired the Company based upon the terms of the Merger as well as other factors. The Merger has been accounted for as an asset acquisition (reverse recapitalization transaction) rather than a business combination, as the assets acquired, and the liabilities assumed by Chemomab Ltd. do not meet the definition of a business under U.S. GAAP. The net assets acquired in connection with the Merger were recorded at their estimated acquisition date fair market value as of March 16, 2021, the date of completion of the Merger.</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">The exchange ratio was calculated by a formula that was determined through arms-length negotiations between the Company and Chemomab Ltd. The combined Company assumed all of the outstanding options of Chemomab Ltd., vested and not vested, under the Chemomab&#160;Share Incentive Plan (the &#8220;2015 Plan&#8221;), with such options representing the right to purchase a number of ADSs equal to approximately <ix:nonFraction id="Fxbrl_20230131220949272" name="cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger" contextRef="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">12.86</ix:nonFraction> multiplied by the number of Chemomab Ltd. ordinary shares previously represented by such options.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:11pt">The following table summarizes the net assets acquired based on their estimated fair values as of March 16, 2021, immediately prior to completion of the Merger (in USD thousands):</p>
    <div style="margin-left:72pt">
      <ix:nonNumeric id="Fxbrl_20230201024915457" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" contextRef="C_20220101to20221231" escape="true">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Cash and cash equivalents</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000202" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="C_20210316" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,427</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Asset held for sale</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000203" name="cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" contextRef="C_20210316" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Prepaid and other assets</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000204" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="C_20210316" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">236</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accrued liabilities</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000205" name="cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" contextRef="C_20210316" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,187</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">)</p>
              </td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net acquired assets</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000206" name="cmmb:EstimatedFairValueOfNetAssetsAcquired" contextRef="C_20210316" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,476</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
    </div>
  </ix:nonNumeric>
  <div>
    <div style="width:100%;clear:both">
      <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;8</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
      <p style="margin:0pt">&#160;</p>
    </div>
  </div>

  <ix:nonNumeric id="FFact_0000000000234" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 2 - Summary of Significant Accounting Policies</span></p>
    <ix:nonNumeric id="FFact_0000000000209" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Basis of Preparation</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S GAAP&#8221;).</p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000210" name="us-gaap:UseOfEstimates" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="font-weight:bold;padding-left:26.83pt">Use of estimates</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000211" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Foreign currency</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#8220;dollar&#8221; or &#8220;$&#8221;), thus; the dollar is the functional currency of the Company.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.</p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000212" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">D.</span><span style="font-weight:bold;padding-left:26.28pt">Cash and cash equivalents</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at the date acquired.</p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000213" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">E.</span><span style="font-weight:bold;padding-left:26.83pt">Restricted cash</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt">Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office rent payments.</p>
    </ix:nonNumeric>
    <ix:nonNumeric id="Fxbrl_20230201130501547" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <div>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">F.</span><span style="font-weight:bold;padding-left:28.31pt">Property and equipment</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets are ready for their intended use.</p>
        <div>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">Annual rates at depreciation are as follows:</p>
          <div style="margin-left:36pt">
            <ix:nonNumeric id="Fxbrl_20230201131108956" name="cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock" contextRef="C_20220101to20221231" escape="true">
              <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

                  <tr>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">%</span></p>
                    </td>
                    <td style="vertical-align:bottom">&#160;</td>
                  </tr>


                  <tr style="background-color:#CCEEFF">
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Computers</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000214" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction></p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Laboratory equipment</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000215" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:#CCEEFF">
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Furniture and equipment</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000216" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">7</ix:nonFraction></p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Leasehold improvement - <ix:nonNumeric id="FFact_0000000000217" name="cmmb:AnnualRatesOfDepreciation" contextRef="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">over the shorter of the lease term or the estimated useful life of the improvement</ix:nonNumeric></p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>

              </table>
            </ix:nonNumeric>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
    <div><ix:exclude>
      <div>
        <div style="width:100%;clear:both">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;9</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
          <p style="margin:0pt">&#160;</p>
        </div>
      </div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></p>
    </ix:exclude></div>
    <ix:nonNumeric id="FFact_0000000000220" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">G.</span><span style="font-weight:bold;padding-left:25.72pt">Impairment of long-lived assets</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company&#8217;s property and equipment are reviewed for impairment in accordance with ASC 360, &#8220;Property and Equipment&#8221;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2022 and 2021, no impairment losses have been recorded.</p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000221" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">H.</span><span style="font-weight:bold;padding-left:25.72pt">Research and Development</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and wages.</p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000222" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">I.</span><span style="font-weight:bold;padding-left:26.83pt">Income taxes</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.</p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000223" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">J.</span><span style="font-weight:bold;padding-left:28.5pt">Fair value of financial instruments</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.</p>
      <div><ix:exclude>
        <div>
          <div style="width:100%;clear:both">
            <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;10</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
            <p style="margin:0pt">&#160;</p>
          </div>
        </div>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">J.</span><span style="font-weight:bold;padding-left:28.5pt">Fair value of financial instruments (cont&#8217;d)</span></p>
      </ix:exclude></div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company&#8217;s own credit risk.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company&#8217;s non<span style="font-weight:bold">- </span>financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000224" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">K.</span><span style="font-weight:bold;padding-left:25.72pt">Share-based compensation</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The fair value for the Company&#8217;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C).</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt">The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000225" name="cmmb:GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">L.</span><span style="font-weight:bold;padding-left:26.83pt">Government-sponsored research and development</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Chemomab records grants received from the office of the Israel Innovation Authority (the &#8220;IIA&#8221;) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.</p>
    </ix:nonNumeric>
    <div><ix:exclude>
      <div>
        <div style="width:100%;clear:both">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;11</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
          <p style="margin:0pt">&#160;</p>
        </div>
      </div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></p>
    </ix:exclude></div>
    <ix:nonNumeric id="FFact_0000000000229" name="cmmb:SeverancePayPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">M.</span><span style="font-weight:bold;padding-left:24.06pt">Severance pay</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of <ix:nonFraction id="Fxbrl_20230215220314714" name="cmmb:PercentageOfMonthlyDepositsRate" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.33</ix:nonFraction>% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $<ix:nonFraction id="Fxbrl_20230215220321806" name="us-gaap:SeveranceCosts1" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">142</ix:nonFraction> thousand and $<ix:nonFraction id="Fxbrl_20230215220329094" name="us-gaap:SeveranceCosts1" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction> thousand for the year ended December 31, 2022 and 2021, respectively.</span></span></p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000230" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">N.</span><span style="font-weight:bold;padding-left:26.28pt">Concentrations of credit risk:</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash <span>and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold the Company&#8217;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments</span>.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</p>
    </ix:nonNumeric>
    <ix:nonNumeric id="Fxbrl_20230213125125767" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <div>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">O.</span><span style="font-weight:bold;padding-left:25.72pt">Leases</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Under </span></span>Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be <ix:nonFraction id="Fxbrl_20230213132631771" name="cmmb:IncrementalBorrowingRateOfLeases" contextRef="C_20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>% and <ix:nonFraction id="Fxbrl_20230213132641931" name="cmmb:IncrementalBorrowingRateOfLeases" contextRef="C_20211231" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.2</ix:nonFraction>% in 2022 and 2021, respectively. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants<span><span>.</span></span></span></span><br />&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></span><br />&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment &#8211; Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize. See Note 2(G).</span></span></p>
      </div>
    </ix:nonNumeric>
    <div><ix:exclude>
      <div>
        <div style="width:100%;clear:both">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;12</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
          <p style="margin:0pt">&#160;</p>
        </div>
      </div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 2 - Summary of Significant Accounting Policies (cont&#8217;d)</span></p>
    </ix:exclude></div>
    <ix:nonNumeric id="FFact_0000000000232" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">P.</span><span style="font-weight:bold;padding-left:28.31pt">Principles of consolidation</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The <span>consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.</span></span></span></p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000233" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">Q.</span><span style="font-weight:bold;padding-left:25.72pt">Earnings per ordinary share</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt">Basic earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant, gives effect to dilutive potential ordinary shares outstanding during the year. &#160;Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.</p>
    </ix:nonNumeric>
  </ix:nonNumeric>

  <ix:nonNumeric id="FFact_0000000000244" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note 3 - Cash and Cash Equivalents</span></p>
    <ix:nonNumeric id="FFact_0000000000243" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="C_20220101to20221231" escape="true">
      <div style="margin-left:36pt;margin-bottom:11pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In USD</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000235" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231_srtCurrencyAxis_currencyUSD" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,663</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000236" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231_srtCurrencyAxis_currencyUSD" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,720</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In NIS</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000237" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231_srtCurrencyAxis_currencyILS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,756</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000238" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231_srtCurrencyAxis_currencyILS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,116</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In other currencies</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000239" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231_srtCurrencyAxis_currencyXXX" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000240" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231_srtCurrencyAxis_currencyXXX" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,350</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000241" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,519</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000242" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,186</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>
    </ix:nonNumeric>
  </ix:nonNumeric>

  <ix:nonNumeric id="FFact_0000000000252" name="cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note 4 - Other Receivables and Prepaid Expenses</span></p>
    <ix:nonNumeric id="FFact_0000000000251" name="cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" contextRef="C_20220101to20221231" escape="true">
      <div style="margin-left:36pt;margin-bottom:11pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Government institutions</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000245" name="cmmb:ReceivablesFromGovernmentInstitutions" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">459</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000246" name="cmmb:ReceivablesFromGovernmentInstitutions" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">179</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Prepaid expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000247" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,307</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000248" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,348</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000249" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,766</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000250" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,527</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>
    </ix:nonNumeric>
  </ix:nonNumeric>
  <div>
    <div style="width:100%;clear:both">
      <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;13</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
      <p style="margin:0pt">&#160;</p>
    </div>
  </div>

  <ix:nonNumeric id="FFact_0000000000270" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note 5 - Property and Equipment, Net</span></p>
    <ix:nonNumeric id="FFact_0000000000269" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_20220101to20221231" escape="true">
      <div style="margin-left:36pt;margin-bottom:11pt">
        <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Cost:</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Computers</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000253" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000254" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Furniture and equipment</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000255" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000256" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Laboratory equipment</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000257" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">399</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000258" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">364</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Website development</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000259" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000260" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Leasehold improvements</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000261" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000262" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><strong><strong><strong><ix:nonFraction id="Fxbrl_20230201032006902" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">532</ix:nonFraction></strong><strong> </strong></strong><strong> </strong></strong><strong> </strong></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000264" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">464 </ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Less - accumulated depreciation</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000265" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">165</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-weight:bold">)</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000266" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">107</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">)</p>
              </td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><strong><strong><strong><ix:nonFraction id="Fxbrl_20230201033845372" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">367</ix:nonFraction></strong><strong> </strong></strong><strong> </strong></strong><strong> </strong></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000268" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">357 </ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>

        </table>
      </div>
    </ix:nonNumeric>
  </ix:nonNumeric>

  <ix:nonNumeric id="FFact_0000000000294" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 6 - Leases</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">On May 10, 2020, Chemomab entered into an office and lab space lease agreement (hereinafter &#8211; &#8220;The Agreement&#8221; .(According to the Agreement, Chemomab &#160;rented a space in Atidim Park, Tel-Aviv for a period of <ix:nonNumeric id="Fxbrl_20230131233210356" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_20200510" format="ixt-sec:durwordsen">three years</ix:nonNumeric>, through <span style="-sec-ix-hidden:Fxbrl_20230131233234992">May 2023</span>. Chemomab was granted an option to extend the lease term by additional <ix:nonNumeric id="Fxbrl_20230131233301410" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_20200501to20200510">three years</ix:nonNumeric>.&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">On October 24, 2021, Chemomab signed an amendment to the Agreement ("The Amendment"). According to the Amendment, On December 12, 2021 Chemomab returned the previous office and lab space to the property owner and rented a larger space in Atidim Park Tel-Aviv, for a term of <ix:nonNumeric id="Fxbrl_20230131233734834" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_20211024" format="ixt-sec:duryear">3</ix:nonNumeric> years, through <span style="-sec-ix-hidden:Fxbrl_20230131233722905">October 2024</span>. In addition, Chemomab was granted an option to extend the lease term by additional <ix:nonNumeric id="Fxbrl_20230201000916081" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_20211001to20211024">three years</ix:nonNumeric>. The annual rent and management fees are approximately $<ix:nonFraction id="Fxbrl_20230131234005244" name="cmmb:AnnualRentAndManagementFees" contextRef="C_20211001to20211024" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">122</ix:nonFraction> thousand. Pursuant to the Amendment, the bank guarantee issued in 2020 was canceled and a substitute bank guarantee of approximately $<ix:nonFraction id="Fxbrl_20230131234014829" name="cmmb:BankGuaranteesToPropertyOwner" contextRef="C_20211001to20211024" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction> thousand was issued to the property owner during 2022.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The above operating leases are included in &#8220;Operating lease right-of-use assets&#8221; on the Company&#8217;s Consolidated Balance sheets as of December 31, 2022 and 2021 and represent the Company&#8217;s right to use the underlying asset for the lease term. The Company&#8217;s obligations to pay lease payments are included in the current liabilities as &#8220;Operating lease liabilities&#8221; and in the non-current liabilities as &#8220;Non-current operating lease liabilities&#8221; on the Company&#8217;s Consolidated Balance sheets as of December 31, 2022 and 2021. Based on the present value of the lease payments for the remaining lease term of the Company&#8217;s existing lease agreement, the Company recognized operating right-of-use assets and operating lease liabilities of approximately $<ix:nonFraction id="Fxbrl_20230131234456429" name="cmmb:OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" contextRef="C_20211212" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction> thousand on December 12, 2021.&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">During the years ended December 31, 2022 and 2021, the Company recognized an increase in right of use assets of $<ix:nonFraction id="Fxbrl_20230131234508150" name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction> thousand and $<ix:nonFraction id="Fxbrl_20230131234513790" name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction> thousand, respectively.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As&#160;of December 31, 2022, and 2021 operating right-of-use asset was $<ix:nonFraction id="Fxbrl_20230214143811730" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">227</ix:nonFraction> thousand and $<ix:nonFraction id="Fxbrl_20230214143818906" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction> thousand, respectively. The operating lease liabilities were $<ix:nonFraction id="Fxbrl_20230214143827206" name="us-gaap:OperatingLeaseLiability" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">214</ix:nonFraction> thousand and $<ix:nonFraction id="Fxbrl_20230214143833566" name="us-gaap:OperatingLeaseLiability" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">343</ix:nonFraction> thousand, respectively.</span></span></p>
    <div><ix:exclude>
      <div>
        <div style="width:100%;clear:both">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;14</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
          <p style="margin:0pt">&#160;</p>
        </div>
      </div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 6 - Leases (cont&#8217;d)</span></p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">As most of the Chemomab&#8217;s leases do not provide an implicit rate, Chemomab uses its incremental borrowing rate based on the information available at the commencement date of each lease in determining the present value of lease payments. Chemomab&#8217;s incremental borrowing rate is a hypothetical rate based on its estimation of what its credit rating would be the rate was <ix:nonFraction id="Fxbrl_20230131234937485" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>% in 2022 and <ix:nonFraction id="Fxbrl_20230131234957047" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="C_20210101to20211231" unitRef="Pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.2</ix:nonFraction>% in 2021.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">Maturities of lease liabilities under noncancellable leases as of December 31, 2022, are as follows: (in thousands):</p>
    <div style="margin-left:36pt;margin-bottom:11pt">
      <ix:nonNumeric id="Fxbrl_20230201025037730" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_20220101to20221231" escape="true">
        <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">2023</p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000288" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">126 </ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">2024</p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000289" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">93 </ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Total future minimum lease payments</p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000290" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">219 </ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Less imputed interest:</p>
              </td>
              <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000291" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px"><span style="font-weight:bold">)</span></p>
              </td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Present value of operating lease liabilities</p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000292" name="us-gaap:OperatingLeaseLiability" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">214 </ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
    </div>
  </ix:nonNumeric>

  <ix:nonNumeric id="FFact_0000000000311" name="us-gaap:CommitmentsDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt"><span style="font-weight:bold">Note 7 - Commitments and Contingent Liabilities</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Exclusive License Agreement (hereinafter- &#8220;the License Agreement&#8221;)</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:72pt">In December 2011, Chemomab entered into a License Agreement with the Medical Research, Infrastructure, Health Services Fund of the Tel-Aviv Souraski Medical Center (&#8220;Fund&#8221;), pursuant to which it was granted with an exclusive license to certain inventions (as defined in the License Agreement) including patents, knowhow and products and the right to sublicense to third parties the rights granted, pursuant to and subject to certain terms and limitation fully set in the License Agreement.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:72pt">Chemomab has agreed to pay the Fund a non-refundable and non-creditable sublicense fees as a percentage of all Attributed Income (as such term defined in the License Agreement), and shall further pay the Fund royalties from sales made by sublicensee;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(i)<span style="padding-left:26.56pt">Royalties in percentage of the Net sales or Service Income (as defined in the License Agreement), subject to </span>certain additional terms set forth therein.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"><span>In addition, with respect to each Licensed Product (as defined therein), Chemomab has agreed to &#160;pay the Fund the following non-refundable, non-creditable amounts:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:144pt;margin-bottom:11pt">(a)<span style="padding-left:24.9pt"><ix:nonNumeric id="Fxbrl_20230215222406006" name="us-gaap:LongTermPurchaseCommitmentDescription" contextRef="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember">$100 thousand upon submission of a New Drug Application (&#8220;NDA&#8221;), Biological License Application (&#8220;BLA&#8221;) or equivalent for each Licensed Product to the United States Food and Drug Administration (&#8220;FDA&#8221;), $100 thousand upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;</ix:nonNumeric></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;text-indent:-36pt;padding-left:144pt;margin-bottom:0pt">(b)<span style="padding-left:24.34pt"><ix:nonNumeric id="Fxbrl_20230215222519809" name="us-gaap:LongTermPurchaseCommitmentDescription" contextRef="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember">$200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once.</ix:nonNumeric></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:108pt">As of December 31, 2022&#160;no payments were made to the Fund.</p>
    <div><ix:exclude>
      <div>
        <div style="width:100%;clear:both">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;15</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
          <p style="margin:0pt">&#160;</p>
        </div>
      </div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 7 - Commitments and Contingent Liabilities (cont&#8217;d)</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Exclusive License Agreement (hereinafter- &#8220;the License Agreement&#8221;) (cont&#8217;d)</span></p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:72pt">In addition to the payments described above, <ix:nonNumeric id="Fxbrl_20230215222713212" name="us-gaap:OtherCommitmentsDescription" contextRef="C_20220101to20221231">upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than $3,000 thousand.</ix:nonNumeric></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:72pt"><span>Chemomab partially financed its research and development expenditures under programs sponsored by the Israel </span>Innovation Authority (&#8220;IIA&#8221;) for the support of certain research and development activities conducted in Israel.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:72pt">In return for the IIA&#8217;s participation, Chemomab is committed to pay royalties at rate of <ix:nonFraction id="Fxbrl_20230201002925810" name="cmmb:PercentageOfRoyaltyPaymentsOnSaleOfProduct" contextRef="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>% of sales of the developed product (linked to U.S. dollar), up to <ix:nonFraction id="Fxbrl_20230201002935951" name="cmmb:MaximumPercentageOfPaymentsOfRoyalties" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the amount of grants received (100% plus interest at LIBOR). In addition, the IIA may impose certain conditions to transfer technology or development out of Israel.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt">Chemomab did not receive any grants from the IIA in the years ended December 31, 2022, and 2021.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">Since Chemomab &#8217;s incorporation through December 31, 2022 Chemomab received $<ix:nonFraction id="Fxbrl_20230201002951961" name="cmmb:CumulativeAmountsOfGrantsReceivedAndRecognized" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,227</ix:nonFraction> thousand from the IIA, which were recognized as a reduction of research and development expenses.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">As of December 31, 2022, Chemomab has no commitment for royalties payable.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="padding-left:26.28pt">In </span></span></span>June 2015, Chemomab entered into a license agreement with subcontractor (&#8220;the Subcontractor&#8221;), under which the Subcontractor granted to Chemomab certain licenses to use proprietary rights of the subcontractor, materials and know how in the techniques and use of the same, for purposes of research and development of Chemomab 's product CM-101, as well as commercialization thereof. Further to the agreement, the Subcontractor also provides manufacturing services of intermediates and active pharmaceutical ingredients. According to the related manufacturing agreement, the manufacturing of the product is carried out by the Subcontractor in accordance with Chemomab's specifications and timeline.&#160; From time to time, Chemomab and the Subcontractor have been signing additional agreements for additional manufacturing and final process lock of the product for clinical use Under the agreement, Chemomab is also obligated to pay the Subcontractor royalties determined as a percentage of net sales of each licensee product.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:0pt;padding-left:72pt;margin-bottom:0pt">During 2022 and 2021, Chemomab recorded expenses related to the above agreements in the amounts of $<ix:nonFraction id="Fxbrl_20230213125722009" name="us-gaap:RoyaltyExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,222</ix:nonFraction> thousand and $<ix:nonFraction id="Fxbrl_20230213125731080" name="us-gaap:RoyaltyExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,590</ix:nonFraction> thousand, respectively. The expenses were recorded under research and development expenses.</p>
    <div><ix:exclude>
      <div>
        <div style="width:100%;clear:both">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;16</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
          <p style="margin:0pt">&#160;</p>
        </div>
      </div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 7 - Commitments and Contingent Liabilities (cont&#8217;d)</span></p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:11pt"><span style="font-weight:bold">C.</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><span style="padding-left:26.28pt">As&#160;</span></span>of December 31, 2022, the bank imposed restriction on a bank deposit in the amount of $<ix:nonFraction id="Fxbrl_20230213125744104" name="us-gaap:RestrictedInvestments" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction> thousand for the purpose of secure lease payments under an office lease agreement.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">D.</span><span><span style="padding-left:26.28pt">During&#160;</span></span><span>2022, the Israeli tax authority ("ITA&#8221;) notified the Company that it had initiated a routine VAT audit to include tax years 2017 through 202</span><span>2</span><span>. The ITA raised several claims, mainly in respect with the recoverability of VAT with respect to Merger Agreement related expenses and the classification of the Company as a holding company. On July 2022, the ITA proposed a settlement, which the Company rejected. As a result, the ITA issued assessments in the aggregate amount of $<ix:nonFraction id="Fxbrl_20230207215117039" name="cmmb:RecoverabilityOfVatAmount" contextRef="C_20220701to20220731" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,046</ix:nonFraction> thousand. The Company filed an appeal against the ITA&#8217;s assessments. The Company has recorded an appropriate provision which considers inherent uncertainty of these matters and the judicial process. Therefore, the outcome may differ from the estimated liability recorded by the Company during the period</span><span>.</span></span></span></p>
  </ix:nonNumeric>

  <ix:nonNumeric id="FFact_0000000000385" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 8 - Share Capital</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Right attached to shares</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-weight:bold;font-style:italic">Ordinary shares</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:72pt;margin-bottom:0pt">All of the issued and outstanding ordinary shares of the Company are duly authorized, validly issued, fully paid and non-assessable. The ordinary shares are not redeemable, and each ordinary share is entitled to one vote. The holders of the ordinary shares have the right to vote and participate in shareholders' meetings, the right to receive profits, and the right to participate in the accumulated earnings when the Company is dissolved.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">1.</span><span style="font-weight:bold;padding-left:28.5pt">Voting</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:108pt">The holders of ordinary shares are entitled to vote on all matters submitted to shareholders for a vote.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">2.</span><span style="font-weight:bold;padding-left:28.5pt">Dividends</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:108pt">The holders of the ordinary shares are entitled to receive dividends, when and as declared by the Board of Directors, and out of funds legally available.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:108pt">Since its inception, the Company has not declared any dividends.</p>
    <div><ix:exclude>
      <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;17</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
      <p style="margin:0pt">&#160;</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 8 - Share Capital (cont&#8217;d)</span></p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="padding-left:26.83pt;font-weight:bold">Financing rounds</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.</span><span style="padding-left:28.5pt">In&#160;</span></span></span>connection with the Merger, on March 15, 2021, the Company entered into Securities Purchase Agreements with certain purchasers, pursuant to which the Company agreed to sell approximately $<ix:nonFraction id="Fxbrl_20230213133908909" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">45.5</ix:nonFraction> million of its American Depositary Shares (ADSs)&#160;in a private placement transaction, (or "The Private Placement"). The Private Placement closed on March 22, 2021, at which time the Company sold to the purchasers <ix:nonFraction id="Fxbrl_20230213133843633" name="cmmb:NumberOfWarrantsPurchaseUpAdss" contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,619,270</ix:nonFraction> ADSs together with warrants to purchase up to <ix:nonFraction id="Fxbrl_20230213133849363" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">261,929</ix:nonFraction> ADSs at an exercise price of $<ix:nonFraction id="Fxbrl_20230213133830904" name="cmmb:SaleOfStocksPricePerShare" contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">17.35</ix:nonFraction> per ADS. The warrants will expire five years from the date of issuance, and if exercised in full, will provide to the Company proceeds of approximately $<ix:nonFraction id="Fxbrl_20230213133820824" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction> million. 20 Ordinary Shares are equal to 1 American Depositary Share (ADS).</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.</span><span style="padding-left:28.5pt">On&#160;</span></span></span>April 30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Cantor Fitzgerald &#38; Co., ("Cantor"). According to the ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $<ix:nonFraction id="Fxbrl_20230213133808746" name="cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">75</ix:nonFraction> million through Cantor or the ATM Agreement. From April 30, 2021, through December 31, 2022, the Company issued <ix:nonFraction id="Fxbrl_20230213133801744" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">699,806</ix:nonFraction> ADSs at an average price of $<ix:nonFraction id="Fxbrl_20230213133754484" name="cmmb:SaleOfStocksPricePerShare" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">22.75</ix:nonFraction> per ADS under the ATM Agreement, resulting in gross proceeds of $<ix:nonFraction id="Fxbrl_20230213133747440" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,917</ix:nonFraction> thousand.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>3.</span><span style="padding-left:28.5pt">On </span></span></span></span></span></span>April 25, 2022, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $<ix:nonFraction id="Fxbrl_20230213133711976" name="cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">18,125,000</ix:nonFraction>&#160;of its ADSs in connection with the reactivation of the ATM Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits the amount of securities the Company is able to offer and sell under such registration statement to one-third of our unaffiliated public float. During the year ended &#160;December 31, 2022, the Company issued&#160;<ix:nonFraction id="Fxbrl_20230213133726969" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">130,505</ix:nonFraction> ADSs at an average price of $<ix:nonFraction id="Fxbrl_20230213133719951" name="cmmb:SaleOfStocksPricePerShare" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">2.11</ix:nonFraction> per ADS under the ATM Agreement, resulting in gross proceeds of $<ix:nonFraction id="Fxbrl_20230213133734136" name="cmmb:ProceedsFromSaleOfAdss" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">275</ix:nonFraction> thousand.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>4.</span><span style="padding-left:28.5pt">O</span></span></span></span>n September 19, 2022, the Company entered &#160;into a share purchase agreement (the &#8220;Repurchase Arrangement&#8221;) with Dr. Adi Mor, co-founder of Chemomab Ltd., Chief Scientific Officer and a director of the Company and Professor Kobi George, co-founder of Chemomab Ltd. (together with Dr. Adi Mor, the &#8220;Co-Founders&#8221;), whereby the Company agreed, subject to the requisite court approval required under Section 303(a) of the Israeli Companies Law, 5759-1999 (the &#8220;Companies Law&#8221;), which the Company received on November 14, 2022, to repurchase up to <ix:nonFraction id="Fxbrl_20230317122555966" name="cmmb:RepurchaseOfAmericanDepositaryReceiptsShares" contextRef="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">582,023</ix:nonFraction> ADSs owned by the Co-Founders, for consideration not to exceed an aggregate amount of $<ix:nonFraction id="Fxbrl_20230317122603582" name="cmmb:RepurchaseOfAmericanDepositaryReceipts" contextRef="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">2,500,000</ix:nonFraction>, depending on the market price of the ADSs at the time of any repurchase. Accordingly, on November 16, 2022, the company repurchased the entire amount of <ix:nonFraction id="Fxbrl_20230317122610135" name="cmmb:RepurchaseOfAmericanDepositaryReceiptsShares" contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">582,023</ix:nonFraction> ADSs from the Co-Founders at a weighted average price of $<ix:nonFraction id="Fxbrl_20230317122616711" name="cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="USD_Per_Share" scale="0" decimals="4" format="ixt:num-dot-decimal">2.0848</ix:nonFraction> and for total consideration of approximately $<ix:nonFraction id="Fxbrl_20230317122623672" name="cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,218</ix:nonFraction> thousand.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:110%">The Company accounted for the repurchased shares as treasury share&#160;in accordance with ASC 505-30, "Treasury Stock".</span></span></span></p>
    <div><ix:exclude>
      <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;18</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
      <p style="margin:0pt">&#160;</p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 8 - Share Capital (cont&#8217;d)</span></p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Share-based compensation</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt">(1)<span style="padding-left:24.34pt">Share-based compensation plan:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:108pt;margin-bottom:0pt">The Company maintains (i) the 2011 Share Option Plan (the &#8220;2011 Plan&#8221;), (ii) the 2017 Equity-Based Incentive Plan (the &#8220;2017 Plan&#8221;) and (iii) the Chemomab 2015 Share Incentive Plan (the &#8220;2015 Plan&#8221;), which was assumed by the Company from Chemomab upon the effectiveness of the Merger. At that time, outstanding options under the 2015 Plan became exercisable for such number of ADSs of the Company as was determined based on the exchange ratio in the Merger Agreement, with a reciprocal adjustment to exercise price.<br />&#160;</p>
    <p style="margin-top:0pt;margin-left:108pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>As of December 31, 2022, a total of <ix:nonFraction id="Fxbrl_20230207224906305" name="cmmb:NumberOfStockReservedForIssuance" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">28,443,060</ix:nonFraction> of our Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223247056" name="cmmb:NumberOfStockAdssResveredForIssuance" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,422,153</ix:nonFraction> of ADSs) were reserved for issuance under the 2015 Plan, of which <ix:nonFraction id="Fxbrl_20230207225529762" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">3,445,520</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223254041" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">172,276</ix:nonFraction> ADSs) had been issued pursuant to previous exercises options, and <ix:nonFraction id="Fxbrl_20230207225556251" name="cmmb:NumberOfOptionsIssuableOutstanding" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">23,460,740</ix:nonFraction> &#160;Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223300376" name="cmmb:NumberOfAdssOptionsIssuableOutstanding" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,173,037</ix:nonFraction> ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase <ix:nonFraction id="Fxbrl_20230207225618055" name="cmmb:NumberOfOptionsVestedAndExercisable" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">12,400,720</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223309640" name="cmmb:NumberOfAdssVestedAndExercisable" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">620,036</ix:nonFraction> ADSs) had vested and were exercisable as of that date, with a weighted average exercise price of $<ix:nonFraction id="Fxbrl_20230207224602275" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.30</ix:nonFraction> per Ordinary Share (or $<ix:nonFraction id="Fxbrl_20230207223316544" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">5.96</ix:nonFraction> per ADS). During the year ended December 31, 2022, options to purchase <ix:nonFraction id="Fxbrl_20230207224845387" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,240,120</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207223324626" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">62,006</ix:nonFraction> ADS) were canceled.</span></span></span></p>
    <p style="margin-top:0pt;margin-left:96px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    <p style="margin-top:0pt;margin-left:108pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>As of December 31, 2022, a total of <ix:nonFraction id="Fxbrl_20230207225827725" name="cmmb:NumberOfStockReservedForIssuance" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">12,511,620</ix:nonFraction> of our Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207225729518" name="cmmb:NumberOfStockAdssResveredForIssuance" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">625,581</ix:nonFraction>&#160;ADSs) were reserved for issuance under the 2017 Plan, of which <ix:nonFraction id="Fxbrl_20230207225858382" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,730,800</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207225738550" name="cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">586,540</ix:nonFraction> ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase <ix:nonFraction id="Fxbrl_20230207225916606" name="cmmb:NumberOfOptionsVestedAndExercisable" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">427,540</ix:nonFraction> Ordinary Shares (equal to <ix:nonFraction id="Fxbrl_20230207225743877" name="cmmb:NumberOfAdssVestedAndExercisable" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">21,377</ix:nonFraction> ADSs) had vested and were exercisable as of that date, with a weighted average exercise price of $<ix:nonFraction id="Fxbrl_20230207225929980" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.35</ix:nonFraction> per Ordinary Share (or $<ix:nonFraction id="Fxbrl_20230207225750293" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">6.98</ix:nonFraction> per ADS). During the year ended December 31, 2022 no options were canceled.</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:11pt">(2)<span style="padding-left:24.34pt">The expenses that were recognized in the consolidated statements of operations for services received from employees </span>and service providers are as follows:</p>
    <div style="margin-left:108pt">
      <ix:nonNumeric id="Fxbrl_20230201040228557" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="C_20220101to20221231" escape="true">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Research and development</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000338" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000339" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">General and administrative</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000340" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000341" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,882</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Total share-based compensation expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000342" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000343" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,019</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
    </div>
    <div><ix:exclude>
      <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;19</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">Note 8 - Share Capital (cont&#8217;d)</span></p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:11pt">(3)<span style="padding-left:24.34pt">The number and weighted average exercise price of options are as follows:</span></p>
    <div style="margin-left:108pt">
      <ix:nonNumeric id="Fxbrl_20230201040244110" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" contextRef="C_20220101to20221231" escape="true">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted </span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">exercise </span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">price</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Number of </span><span style="font-weight:bold">options</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average </span><span style="font-weight:bold">remaining </span><span style="font-weight:bold">contractual </span><span style="font-weight:bold">life (in years)</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average </span><span style="font-weight:bold">exercise price</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Number of </span><span style="font-weight:bold">options</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average </span><span style="font-weight:bold">remaining </span><span style="font-weight:bold">contractual </span><span style="font-weight:bold">life (in years)</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding at January 1</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000345" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.38</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000346" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">27,003,260</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="FFact_0000000000347" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20210101to20211231" format="ixt-sec:duryear">8.12</ix:nonNumeric></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:10%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000348" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20201231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.07</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000349" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20201231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">10,455,580</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="FFact_0000000000350" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20200101to20201231" format="ixt-sec:duryear">7.8</ix:nonNumeric></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Acquired in Merger</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%;text-align:right"><ix:nonFraction id="Fxbrl_20230214225414206" name="cmmb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000351" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:10%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><ix:nonFraction id="Fxbrl_20230201024457584" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">609,535</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Exercised</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000352" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000353" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,970,000</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">)</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">-</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:10%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201024523067" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.08</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230201024530820" name="cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">134,220</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Forfeited</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000356" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.32</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000357" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,240,120</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">)</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:10%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000358" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">1.25</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000359" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,712,275</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Granted</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000360" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000361" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,398,400</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000362" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" contextRef="C_20220101to20221231" format="ixt-sec:duryear">7.8</ix:nonNumeric></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:10%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000363" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.62</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000364" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">17,784,640</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="FFact_0000000000365" name="cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" contextRef="C_20210101to20211231" format="ixt-sec:duryear">9.79</ix:nonNumeric></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:10%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding at December 31</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000366" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.33</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">35,191,540</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000368" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231" format="ixt-sec:duryear">7.42</ix:nonNumeric></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:10%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000369" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.38</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000370" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">27,003,260</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="FFact_0000000000371" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20210101to20211231" format="ixt-sec:duryear">8.12</ix:nonNumeric></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt">(4)<span style="padding-left:24.34pt">Fair value measurement:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:108pt;margin-bottom:11pt">The fair value of the options is measured at the grant date using the Black-Scholes Option pricing model and the assumptions used to calculate the fair value of the options are as follows:</p>
    <div style="margin-left:108pt">
      <ix:nonNumeric id="Fxbrl_20230201040432498" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20220101to20221231" escape="true">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">2022&#160;grants</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Weighted average share price (in U.S. dollar)<sup>(a)</sup></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000373" name="us-gaap:SharePrice" contextRef="C_20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Exercise price (in U.S. dollar)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000375" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_20221231_srtRangeAxis_srtMinimumMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.10</ix:nonFraction></span><span style="font-weight:bold">-</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000376" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_20221231_srtRangeAxis_srtMaximumMember" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.257</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Expected life of options (in years)<sup>(b)</sup></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000377" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember" format="ixt-sec:duryear">5.51</ix:nonNumeric></span><span style="font-weight:bold">-</span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000378" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember" format="ixt-sec:duryear">6.28</ix:nonNumeric></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Expected volatility<sup>(c)</sup></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000379" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">83.69</ix:nonFraction></span><span style="font-weight:bold">%-</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000380" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">84.31</ix:nonFraction></span><span style="font-weight:bold">%</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Risk-free interest rate<sup>(d)</sup></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000381" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.75</ix:nonFraction></span><span style="font-weight:bold">%-</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000382" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.14</ix:nonFraction></span><span style="font-weight:bold">%</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Dividend yield</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000383" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20221231" unitRef="Pure" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="font-weight:bold">%</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
    </div>
    <div><ix:exclude>
      <div>
        <div style="width:100%;clear:both">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;20</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
          <p style="margin:0pt">&#160;</p>
        </div>
      </div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 8 - Share Capital (cont&#8217;d)</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Share-based compensation (cont&#8217;d)</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.</span></span><span style="padding-left:20pt">&#160;</span>&#160;&#160;<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(cont'd)</span></span></p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(a)<span style="padding-left:24.34pt">The weighted average share price is based on the Company&#8217;s Ordinary Share valuation as at the grant date.</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(b)<span style="padding-left:24.34pt">Expected life for the periods presented was determined according to the simplified method since, at the date of </span>grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions and for performance conditions that are probable of achievement. If meeting the performance condition is not probable, the Company will use the awards&#8217; contractual term if the service period is implied, or the simplified method, if the service period is explicitly stated.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(c)<span style="padding-left:24.34pt">Expected volatility is based on historical volatility over the most recent period commensurate with the expected </span>term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:11pt">(d)<span style="padding-left:24.34pt">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the </span>yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</p>
  </ix:nonNumeric>

  <ix:nonNumeric id="FFact_0000000000399" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note 9 - Research and Development</span></p>
    <ix:nonNumeric id="FFact_0000000000398" name="cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock" contextRef="C_20220101to20221231" escape="true">
      <div style="margin-left:36pt;margin-bottom:11pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Consultants and subcontractors</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000386" name="cmmb:ConsultantsAndSubcontractorsExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,052</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000387" name="cmmb:ConsultantsAndSubcontractorsExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,894</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000388" name="us-gaap:OfficersCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,867 </ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000389" name="us-gaap:OfficersCompensation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,789</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Rent and maintenance</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000390" name="cmmb:RentAndMaintenanceResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">245</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000391" name="cmmb:RentAndMaintenanceResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based compensation</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000392" name="cmmb:ShareBasedCompensationResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">448</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000393" name="cmmb:ShareBasedCompensationResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Other expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000394" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000395" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">400</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000396" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,977</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000397" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,334</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>
    </ix:nonNumeric>
  </ix:nonNumeric>
  <div>
    <div style="width:100%;clear:both">
      <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;21</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
      <p style="margin:0pt">&#160;</p>
    </div>
  </div>

  <ix:nonNumeric id="FFact_0000000000417" name="cmmb:GeneralAndAdministrativeDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note 10 - General and Administrative&#160;</span></p>
    <ix:nonNumeric id="FFact_0000000000416" name="cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock" contextRef="C_20220101to20221231" escape="true">
      <div style="margin-left:36pt;margin-bottom:11pt">
        <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000400" name="us-gaap:SalariesAndWages" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,435</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000401" name="us-gaap:SalariesAndWages" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">943</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Professional services</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000402" name="us-gaap:ProfessionalFees" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,596</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000403" name="us-gaap:ProfessionalFees" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,695</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based compensation</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000404" name="cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,763</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000405" name="cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,882</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Fees to Directors</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000406" name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span><ix:nonFraction id="Fxbrl_20230201004651041" name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Insurance</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000408" name="us-gaap:GeneralInsuranceExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,084</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000409" name="us-gaap:GeneralInsuranceExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,024</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Rent and maintenance</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000410" name="cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000411" name="cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Other expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000412" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,423</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000413" name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">216</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000414" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,556</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000415" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,033</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>

        </table>
      </div>
    </ix:nonNumeric>
  </ix:nonNumeric>

  <ix:nonNumeric id="FFact_0000000000458" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Note 11 - Income Taxes</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Tax rates</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary taxable income in Israel is subject to a corporate tax rate of <ix:nonFraction id="FFact_0000000000418" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryIL" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction>%.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s US subsidiary, Chemomab Therapeutics Inc. ("Chemomab Inc.) is taxed separately under the U.S. tax laws.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Inc. is subject to a federal flat tax rate of <ix:nonFraction id="FFact_0000000000419" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">21</ix:nonFraction>% and state tax as applicable.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Capital gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">B.</span><span style="font-weight:bold;padding-left:26.83pt">Tax assessments</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2022, the Company&#8217;s tax reports through December 31, 2017&#160;are considered closed to audit inspections by the Israeli Tax Authority (&#8220;ITA&#8221;) due to statute of limitation rules effective in Israel.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has not yet been assessed by the ITA since inception.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Losses for tax purposes carried forward to future years</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2022, the Company and its subsidiaries had approximately $<ix:nonFraction id="Fxbrl_20230213140532094" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_20221231_srtStatementGeographicalAxis_countryIL" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">159</ix:nonFraction> million&#160;(approximately $<ix:nonFraction id="Fxbrl_20230213140537759" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_20211231_srtStatementGeographicalAxis_countryIL" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">143</ix:nonFraction> million as of December 31, 2021) of net operating loss carryforwards which are available to reduce future taxable income with no limitation on the period of use.</span></span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On March 27, 2020 and December 27, 2020, the President of the United States signed and enacted into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and the Consolidated Appropriations Act, 2021 (CAA). Among other provisions, the CARES Act and the CAA provide relief to U.S. federal corporate taxpayers through temporary adjustments to net operating loss rules, changes to limitations on interest expense deductibility, and the acceleration of available refunds for minimum tax credit carryforwards. The CARES Act also includes provisions for a carryback of any net operating loss (NOL) arising in a taxable year beginning after December 31, 2017, and before January 1, 2021, to each of the five taxable years preceding the taxable year in which the loss arises (carryback period).</span></span></span></p>
    <div><ix:exclude>
      <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;22</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;font-weight:bold">Note 11 - Income Taxes (cont&#8217;d)</span></p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">C.<span style="font-weight:bold;padding-left:26.28pt">Losses for tax purposes carried forward to future years (cont'd)</span></span></span></span></p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Chemomab Therapeutics Inc., a wholly owned subsidiary of the Company, filed an application with the US Internal Revenue Service to carryback net operating losses. Chemomab Therapeutics Inc received $<ix:nonFraction id="Fxbrl_20230213140710654" name="cmmb:ReceivedAmountOfChemomabTherapeuticsInc" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">351</ix:nonFraction> thousand in December 2022 on account of 2016 and 2017 and expects to receive the remainder $<ix:nonFraction id="Fxbrl_20230213140716671" name="cmmb:ExpectsToReceiveAmountOfChemomabTherapeuticsInc" contextRef="C_20230101to20231231_srtStatementScenarioAxis_srtScenarioForecastMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">183</ix:nonFraction> thousand in 2023. Accordingly, a tax benefit in the total amount of $<ix:nonFraction id="Fxbrl_20230213140722797" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">534</ix:nonFraction> thousand was recorded in the Company&#8217;s statement of operations during 2022.</span></span></span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">D.</span><span style="font-weight:bold;padding-left:26.28pt">Deferred taxes</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In respect of:</span></span></p>
    <div style="margin-left:72pt">
      <ix:nonNumeric id="Fxbrl_20230201025152633" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_20220101to20221231" escape="true">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD thousands</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD thousands</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net operating loss carry-forwards</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000422" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,550</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000423" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,396</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation expense</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000424" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,774</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000425" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,147</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000426" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,858</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000427" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,449</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000428" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000429" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross deferred tax assets</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000430" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,195</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000431" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,030</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less - Valuation allowance</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000432" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,195</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000433" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,030</ix:nonFraction>)</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201010225989_Fact_0000000000426" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201010225989_Fact_0000000000427" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. A valuation allowance is provided when it is more likely than not that the deferred tax assets will not be realized.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has established a valuation allowance to offset deferred tax assets on December 31, 2022 and 2021 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The net change in the total valuation allowance for the year ended at December 31, 2022 was an increase of approximately $<ix:nonFraction id="Fxbrl_20230201010356964" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_20220101to20221231" unitRef="usd" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction> million.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">E.</span><span style="font-weight:bold;padding-left:26.83pt">Roll forward of valuation allowance</span></span></span></p>
    <div style="margin-left:72pt">
      <ix:nonNumeric id="Fxbrl_20230201025212924" name="us-gaap:SummaryOfValuationAllowanceTextBlock" contextRef="C_20220101to20221231" escape="true">
        <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at January 1, 2021</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000438" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,200</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency transaction loss</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000439" name="cmmb:CurrencyTransactionLossValuationAllowance" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,425</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax assets acquired through merger</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201010515039" name="cmmb:TaxAssetsAcquiredThroughMergerValuationAllowance" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,535</ix:nonFraction></span></span></strong></td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000440" name="cmmb:IncomeTaxExpenseValuationAllowance" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,870</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2021</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000441" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,030</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency transaction Income</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(<ix:nonFraction id="Fxbrl_20230201010936607" name="cmmb:CurrencyTransactionLossValuationAllowance" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,316</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000444" name="cmmb:IncomeTaxExpenseValuationAllowance" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,481</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2022</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000445" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,195</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
    </div>
    <div><ix:exclude>
      <div>
        <div style="width:100%;clear:both">
          <p style="margin:0pt">&#160;</p>
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;23</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
          <p style="margin:0pt">&#160;</p>
        </div>
      </div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Note 11 - Income Taxes (cont&#8217;d)</span></span></span></p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">F.</span><span style="font-weight:bold;padding-left:28.31pt">Reconciliation of theoretical income tax expense to actual income tax expense</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A reconciliation of the Company&#8217;s theoretical income tax expense to actual income tax expense is as follows:</span></span></p>
    <div style="margin-left:72pt">
      <ix:nonNumeric id="Fxbrl_20230201025228669" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_20220101to20221231" escape="true">
        <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD thousands</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD thousands</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before income taxes</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(</span><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000447" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">28,180</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000448" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p>
              </td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statutory tax rate</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000449" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">%</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000450" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_20210101to20211231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></p>
              </td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical tax benefit</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000451" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,481</ix:nonFraction></span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000452" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,870</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p>
              </td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in temporary differences for which deferred taxes were not recognized</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20230213113429979_Fact_0000000000453" name="cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,696</ix:nonFraction></strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230213113429979_Fact_0000000000454" name="cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,332</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax rate differential</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20230213113425908_Fact_0000000000453" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230213113425908_Fact_0000000000454" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">101</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-deductible expenses</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20230213113423827_Fact_0000000000453" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">744</ix:nonFraction></strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230213113423827_Fact_0000000000454" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20230213113421604_Fact_0000000000453" name="cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,879</ix:nonFraction></strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230213113421604_Fact_0000000000454" name="cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,064</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Actual income tax expense (Benefit)</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>(<ix:nonFraction id="Fxbrl_20230219165815757" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">534</ix:nonFraction></span></span></span></strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:1.5px">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230201011121606_Fact_0000000000454" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">G.</span><span style="font-weight:bold;padding-left:25.72pt">Accounting for uncertainty in income taxes</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the year ended December 31, 2022, the Company did not have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12 months. The Company&#8217;s accounting policy is to accrue interest and penalties related to unrecognized tax benefits as a component of income tax expense.</span></span></p>
  </ix:nonNumeric>

  <ix:nonNumeric id="FFact_0000000000477" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 12 - Related Parties Balances and Transactions</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:10.28pt">Balances with Related Parties:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">The following Related Party payables are included in the consolidated Balance Sheets:</p>
    <div style="margin-left:36pt">
      <ix:nonNumeric id="Fxbrl_20230207220029774" name="cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock" contextRef="C_20220101to20221231" escape="true">
        <div>
          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
                </td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
                </td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
                </td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>


              <tr style="background-color:#CCEEFF">
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Employee and related expenses</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000459" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">891</ix:nonFraction></span></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000460" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">278</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accrued expenses</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000461" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000462" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr style="background-color:#CCEEFF">
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
                <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000463" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">949</ix:nonFraction></span></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
                <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000464" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">350</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%">
                  <p>&#160;</p>
                </td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
      <p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On September 19, 2022, the Company entered into a share purchase agreement with the Company's Co- Founders, see Note 8B(4).</span></span></span></p>
    </div>
    <div><ix:exclude>
      <div>
        <div style="width:100%;clear:both">
          <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;24</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
        </div>
      </div>
      <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt"><span style="font-weight:bold">Note 12 - Related Parties Balances and Transactions (cont'd)</span></p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="font-weight:bold;padding-left:10.83pt">Transactions with Related Parties:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">The following transactions with related parties are included in the consolidated Statements of Operations:</p>
    <div style="margin-left:36pt;margin-bottom:11pt">
      <ix:nonNumeric id="Fxbrl_20230201025305978" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_20220101to20221231" escape="true">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000466" name="cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,409</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000467" name="cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,255</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based payments</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000468" name="cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,466</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000469" name="cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,775</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Professional Services</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000470" name="cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000471" name="cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Research and development</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000472" name="cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000473" name="cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000474" name="us-gaap:RelatedPartyCosts" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,142</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000475" name="us-gaap:RelatedPartyCosts" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,310</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
    </div>
  </ix:nonNumeric>

  <ix:nonNumeric id="FFact_0000000000488" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share, as the effect of potentially dilutive securities is antidilutive.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt">The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented:</p>
    <div style="margin-left:36pt">
      <ix:nonNumeric id="Fxbrl_20230201025331788" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20220101to20221231" escape="true">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year ended</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year ended</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">In USD thousands, except share and per </span><span style="font-weight:bold">share data</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Numerator:</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net loss</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000478" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">27,646</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000479" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12,478</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Denominator:</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-10pt;padding-left:10pt;margin-bottom:0pt">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="Fxbrl_s_20230215224008037" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230215224008037" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">227,589,288</ix:nonFraction></ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20230131213429326" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000481" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20210101to20211231" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">207,468,650</ix:nonFraction></ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net loss per share attributable to ordinary shareholders, basic and diluted</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="Fxbrl_20230131213444247" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000482" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="C_20220101to20221231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.121</ix:nonFraction></ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20230131213458553" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000483" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="C_20210101to20211231" unitRef="USD_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.060</ix:nonFraction></ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
    </div>
    <div><ix:exclude>
      <div style="width:100%;clear:both"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:10pt;text-align:center;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F -&#160;25</span></span></span></span></p></div><hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:5pt" /><div style="margin-top:10pt"><table cellpadding="0" style="border-spacing:0" width="100%"><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Chemomab Therapeutics Ltd. and its subsidiaries</span></span></span></span></p><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">&#160;</p></td></tr><tr><td style="width:100%;vertical-align:top"><p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:5pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span style="font-weight:bold">Notes to the Financial Statements as at December 31, 2022</span></span></span></span></span></p></td></tr><tr><td style="width:100%;vertical-align:top"><hr style="height:1.5pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-top:-1.34pt;margin-left:0pt;text-align:left" /></td></tr></table></div>
      <p style="margin:0pt">&#160;</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders (Cont'd)</span></p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt">The potential number of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows:</p>
    <div style="margin-left:36pt">
      <ix:nonNumeric id="Fxbrl_20230201025347421" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_20220101to20221231" escape="true">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year ended</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year ended</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:center">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:center">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:center">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Number of shares</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding options to purchase ordinary shares</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000485" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">35,191,540</ix:nonFraction></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000486" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">27,003,260</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20230201020943165" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20220101to20221231" escape="true">
    <div>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Note 14&#160;- Subsequent Events</span></span></span></p>
      <p style="margin-top:11pt;margin-bottom:0pt;padding-left:36pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">On January 13, 2023 the Company filed with the SEC a registration statement on form S-1 for the issuance and sale of up to $<ix:nonFraction id="Fxbrl_20230213104715713" name="cmmb:SaleOfStockValueOfSharesIssuedInTransaction" contextRef="C_20230113_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction> of its ADSs.</p>
    </div>
  </ix:nonNumeric>
  <p style="margin:11pt 0pt 0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F - 26</span></span></p>
  <div>
    <div style="width:100%;clear:both">
      <hr style="height:0.75pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left" />
      <hr style="height:3pt;border-width:0;color:#000000;background-color:#000000;width:100%;margin-left:0pt;text-align:left" />
    </div>
  </div>
</div></div></div></div></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>exhibit_23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 23.1</u></div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">The Board of Directors<br>
      Chemomab Therapeutics Ltd.:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif;">
      <div style="line-height: 1.25; color: #000000;">We consent to the incorporation by reference in the registration statements (No. 333-255249 and No. 333-255658) on Form S-3
        and registration statements (No. 333-259489 and No. 333-266868) on Form S-8 of our report dated February 20, 2023, with respect to the consolidated financial statements of Chemomab Therapeutics Ltd.</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 100%; vertical-align: middle;">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">/s/ Somekh Chaikin</div>
            </div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 100%; vertical-align: middle;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">Member Firm of KPMG International</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><font style="font-family: 'Times New Roman', serif;">Tel Aviv, Israel</font><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><font style="font-family: 'Times New Roman', serif;"> <br>
      </font></div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif;">March 20, 2023</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif;"> <br>
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit_31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left;">
  <head>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff">
  <font style="font-size: 10pt;"><br>
  </font>
  <div>
    <div style="text-align: right;"> <font style="font-size: 10pt;"><u><font style="font-weight: bold;"> </font></u></font>
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><font style="font-size: 10pt;"><u><font style="font-weight: bold;">Exhibit 31.1</font></u></font></div>
    <div> <font style="font-size: 10pt;"><br>
      </font></div>
    <div style="font-weight: bold; text-align: center; font-size: 10pt;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14a OF</div>
    <div style="font-weight: bold; text-align: center; font-size: 10pt;">THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="font-weight: bold; text-align: center; font-size: 10pt;">AS ADOPTED PURSUANT TO SECTION 302</div>
    <div style="font-weight: bold; text-align: center; font-size: 10pt;">OF THE SARBANES OXLEY ACT OF 2002</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt;">I, Dale Pfost, certify that:</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="font-size: 10pt;">1. I have reviewed this Annual Report on Form 10-K of Chemomab Therapeutics Ltd.;</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by this report;</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
      registrant as of, and for, the periods presented in this report;</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
      financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt; text-indent: 36pt;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the
      registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt; text-indent: 36pt;">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the
      reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt; text-indent: 36pt;">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of
      the end of the period covered by this report based on such evaluation; and</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt; text-indent: 36pt;">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal
      quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s
      board of directors (or persons performing the equivalent functions):</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt; text-indent: 36pt;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to
      record, process, summarize and report financial information; and</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt; text-indent: 36pt;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
    <div> <font style="font-size: 10pt;"><br>
      </font></div>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" border="0" id="z34645c07d4dd4851ab917d58044f374b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

        <tr>
          <td style="width: 50.00%;">
            <div>
              <div>Date: March 20, 2023</div>
            </div>
          </td>
          <td style="width: 50.00%;">
            <div>
              <div style="font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
              <div> <br>
              </div>
              <div>
                <div><u>/s/ Dale Pfost</u></div>
                <div>
                  <div>Dale Pfost</div>
                  <div>
                    <div>Chief Executive Officer</div>
                    <div>
                      <div style="font-style: italic;">(Principal Executive Officer)</div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </td>
        </tr>

    </table>
    <font style="font-size: 10pt;"> </font></div>
  <div><font style="font-size: 10pt;"><br>
    </font>
    <div style="font-size: 10pt;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    <font style="font-size: 10pt;"></font></div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit_31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 31.2</u></div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14a OF</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 302</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">OF THE SARBANES OXLEY ACT OF 2002</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">I, Donald Marvin, certify that:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">1. I have reviewed this Annual Report on Form 10-K of Chemomab Therapeutics Ltd.;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
      respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as
      defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; text-indent: 36pt;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
      designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
      prepared;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; text-indent: 36pt;">b. Designed such internal control over financial reporting, or caused such internal control over financial
      reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
      principles;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; text-indent: 36pt;">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this
      report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; text-indent: 36pt;">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that
      occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over
      financial reporting; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
      reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; text-indent: 36pt;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over
      financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; text-indent: 36pt;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role
      in the registrant&#8217;s internal control over financial reporting.</div>
    <div style="text-align: justify; text-indent: 54pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"> <br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z7874fd4f531b4f6eb10c0384c5787b85">

          <tr>
            <td style="width: 50.00%;">
              <div>
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Date: March 20, 2023</div>
              </div>
            </td>
            <td style="width: 50.00%;">
              <div>
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;"> <font style="font-weight: normal;"><br>
                  </font></div>
                <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;"><font style="font-weight: normal;"> </font>
                  <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-weight: normal;"><u>/s/ Donald Marvin</u></div>
                  <div style="line-height: 1.25; color: #000000;">
                    <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-weight: normal;">Donald Marvin</div>
                    <div style="line-height: 1.25; color: #000000;">
                      <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-weight: normal;">Chief Financial Officer</div>
                      <div style="line-height: 1.25; color: #000000;">
                        <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-style: italic; font-weight: normal;">(Principal Financial Officer)</div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit_32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 32.1</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">PURSUANT TO 18 U.S.C. SECTION 1350,</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 906</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">I, Dale Pfost, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
      2002, that the Annual Report on Form 10-K of Chemomab Therapeutics Ltd. for the fiscal year ended December 31, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information
      contained in such Annual Report on Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Chemomab Therapeutics Ltd.</div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.84%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: middle;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 50.16%; vertical-align: middle;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Date: March&#160; 20, 2023</div>
          </td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"><u>/s/ Dale Pfost</u></div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Dale Pfost</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Chief Executive Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">(Principal Executive Officer)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exhibit_32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 32.2</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">PURSUANT TO 18 U.S.C. SECTION 1350,</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 906</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">I, Donald Marvin, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
      2002, that the Annual Report on Form 10-K of Chemomab Therapeutics Ltd. for the fiscal year ended December 31, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information
      contained in such Annual Report on Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Chemomab Therapeutics Ltd.</div>
    <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.84%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: middle;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 50.16%; vertical-align: middle;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Date: March 20, 2023</div>
          </td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"><u>/s/ Donald Marvin</u></div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Donald Marvin</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">Chief Financial Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.84%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 50.16%; vertical-align: bottom;">
            <div style="line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-style: italic;">(Principal Financial Officer)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div class="BRPFPageFooter">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>cmmb-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:cmmb="http://www.anchiano.com/20221231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" targetNamespace="http://www.anchiano.com/20221231" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>0002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>0003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementsOfOperations" id="StatementsOfOperations">
        <link:definition>0004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementsOfChangesInEquity" id="StatementsOfChangesInEquity">
        <link:definition>0005 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>0006 - Statement - Statements of Cash flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/General" id="General">
        <link:definition>0007 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
        <link:definition>0009 - Disclosure - Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses" id="OtherReceivablesAndPrepaidExpenses">
        <link:definition>0010 - Disclosure - Other Receivables and Prepaid Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
        <link:definition>0011 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/Leases" id="Leases">
        <link:definition>0012 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilities" id="CommitmentsAndContingentLiabilities">
        <link:definition>0013 - Disclosure - Commitments and Contingent Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapital" id="ShareCapital">
        <link:definition>0014 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ResearchAndDevelopment" id="ResearchAndDevelopment">
        <link:definition>0015 - Disclosure - Research and Development</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralAndAdministrative" id="GeneralAndAdministrative">
        <link:definition>0016 - Disclosure - General and Administrative</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>0017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions" id="RelatedPartiesBalancesAndTransactions">
        <link:definition>0018 - Disclosure - Related Parties Balances and Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders" id="NetLossPerShareAttributableToOrdinaryShareholders">
        <link:definition>0019 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/EventsAfterBalanceSheetDate" id="EventsAfterBalanceSheetDate">
        <link:definition>0020 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>0021 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralTables" id="GeneralTables">
        <link:definition>0022 - Disclosure - General (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>0023 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsTables" id="CashAndCashEquivalentsTables">
        <link:definition>0024 - Disclosure - Cash and Cash Equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables" id="OtherReceivablesAndPrepaidExpensesTables">
        <link:definition>0025 - Disclosure - Other Receivables and Prepaid Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
        <link:definition>0026 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/LeasesTables" id="LeasesTables">
        <link:definition>0027 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalTables" id="ShareCapitalTables">
        <link:definition>0028 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentTables" id="ResearchAndDevelopmentTables">
        <link:definition>0029 - Disclosure - Research and Development (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeTables" id="GeneralAndAdministrativeTables">
        <link:definition>0030 - Disclosure - General and Administrative (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>0031 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables" id="RelatedPartiesBalancesAndTransactionsTables">
        <link:definition>0032 - Disclosure - Related Parties Balances and Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables" id="NetLossPerShareAttributableToOrdinaryShareholdersTables">
        <link:definition>0033 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralDetails" id="GeneralDetails">
        <link:definition>0034 - Disclosure - General (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails" id="GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails">
        <link:definition>0035 - Disclosure - General (Schedule of net assets acquired based on their estimated fair value) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" id="SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0036 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" id="SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails">
        <link:definition>0037 - Disclosure - Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsDetails" id="CashAndCashEquivalentsDetails">
        <link:definition>0038 - Disclosure - Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails" id="OtherReceivablesAndPrepaidExpensesDetails">
        <link:definition>0039 - Disclosure - Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails" id="PropertyAndEquipmentNetDetails">
        <link:definition>0040 - Disclosure - Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/LeasesNarrativeDetails" id="LeasesNarrativeDetails">
        <link:definition>0041 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails" id="LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails">
        <link:definition>0042 - Disclosure - Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails" id="CommitmentsAndContingentLiabilitiesDetails">
        <link:definition>0043 - Disclosure - Commitments and Contingent Liabilities (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalNarrativeDetails" id="ShareCapitalNarrativeDetails">
        <link:definition>0044 - Disclosure - Share Capital (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails" id="ShareCapitalShare-basedCompensationExpensesDetails">
        <link:definition>0045 - Disclosure - Share Capital (Schedule of Share-based Compensation Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails" id="ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails">
        <link:definition>0046 - Disclosure - Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails" id="ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails">
        <link:definition>0047 - Disclosure - Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails" id="ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails">
        <link:definition>0048 - Disclosure - Research and Development (Schedule of Research and Development) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails" id="GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails">
        <link:definition>0049 - Disclosure - General and Administrative (Schedule of General and Administrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>0050 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails" id="IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails">
        <link:definition>0051 - Disclosure - Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails" id="IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails">
        <link:definition>0052 - Disclosure - Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails" id="IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails">
        <link:definition>0053 - Disclosure - Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" id="RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
        <link:definition>0054 - Disclosure - Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails" id="RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails">
        <link:definition>0055 - Disclosure - Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails" id="NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails">
        <link:definition>0056 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails" id="NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails">
        <link:definition>0057 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails" id="EventsAfterBalanceSheetDateNarrativeDetails">
        <link:definition>0058 - Disclosure - Subsequent Events (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cmmb-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AdditionalWorkOrderAmount" id="cmmb_AdditionalWorkOrderAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AggregateAmountCommitmentToPay" id="cmmb_AggregateAmountCommitmentToPay" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AggregateAmountOfCommitmentPaid" id="cmmb_AggregateAmountOfCommitmentPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AggregateOfferingPriceOfAtMarketOfferingAgreement" id="cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmericanDepositarySharesMember" id="cmmb_AmericanDepositarySharesMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AnnualRatesOfDepreciation" id="cmmb_AnnualRatesOfDepreciation" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AnnualRentAndManagementFees" id="cmmb_AnnualRentAndManagementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AtmAgreementMember" id="cmmb_AtmAgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BankGuaranteesToPropertyOwner" id="cmmb_BankGuaranteesToPropertyOwner" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" id="cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" id="cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CantorMember" id="cmmb_CantorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CapitalAdditionsOneMember" id="cmmb_CapitalAdditionsOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashAcquiredInMerger" id="cmmb_CashAcquiredInMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CashPaidAndReceivedDuringYearForAbstract" id="cmmb_CashPaidAndReceivedDuringYearForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" id="cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ConsultantsAndSubcontractorsExpense" id="cmmb_ConsultantsAndSubcontractorsExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CumulativeAmountsOfGrantsReceivedAndRecognized" id="cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CurrencyTransactionLossValuationAllowance" id="cmmb_CurrencyTransactionLossValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" id="cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EarningsPerShareCalculationNumeratorAbstract" id="cmmb_EarningsPerShareCalculationNumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EffectOfReverseCapitalizationTransaction" id="cmmb_EffectOfReverseCapitalizationTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EffectOfReverseCapitalizationTransactionShares" id="cmmb_EffectOfReverseCapitalizationTransactionShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EstimatedFairValueOfNetAssetsAcquired" id="cmmb_EstimatedFairValueOfNetAssetsAcquired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ExpectsToReceiveAmountOfChemomabTherapeuticsInc" id="cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FinanceIncomeExpensesNet" id="cmmb_FinanceIncomeExpensesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FormerChemomabSecurityHoldersMember" id="cmmb_FormerChemomabSecurityHoldersMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GeneralAndAdministrativeDisclosureTextBlock" id="cmmb_GeneralAndAdministrativeDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" id="cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncomeTaxDisclosureLineItems" id="cmmb_IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncomeTaxDisclosureTable" id="cmmb_IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="IncomeTaxesReceived" id="cmmb_IncomeTaxesReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncomeTaxExpenseValuationAllowance" id="cmmb_IncomeTaxExpenseValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncrementalBorrowingRateOfLeases" id="cmmb_IncrementalBorrowingRateOfLeases" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InterestReceived" id="cmmb_InterestReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InvestorsMember" id="cmmb_InvestorsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LaboratoryEquipmentMember" id="cmmb_LaboratoryEquipmentMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LienOnBankDeposit" id="cmmb_LienOnBankDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LongTermLeaseDeposit" id="cmmb_LongTermLeaseDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" id="cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MaximumPercentageOfPaymentsOfRoyalties" id="cmmb_MaximumPercentageOfPaymentsOfRoyalties" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" id="cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsDisclosureAbstract" id="cmmb_NatureOfOperationsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfAdsIssuedAndOutstandingAfterMerger" id="cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfAdssOptionsIssuableOutstanding" id="cmmb_NumberOfAdssOptionsIssuableOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfAdssVestedAndExercisable" id="cmmb_NumberOfAdssVestedAndExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOptionsIssuableOutstanding" id="cmmb_NumberOfOptionsIssuableOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOptionsVestedAndExercisable" id="cmmb_NumberOfOptionsVestedAndExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfOrdinarySharesConsistedInDs" id="cmmb_NumberOfOrdinarySharesConsistedInDs" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfStockAdssResveredForIssuance" id="cmmb_NumberOfStockAdssResveredForIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfStockReservedForIssuance" id="cmmb_NumberOfStockReservedForIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfVestedAndExercisable" id="cmmb_NumberOfVestedAndExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsPurchaseUpAdss" id="cmmb_NumberOfWarrantsPurchaseUpAdss" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" id="cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="OrdinarySharesNoParValuePerShareMember" id="cmmb_OrdinarySharesNoParValuePerShareMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherAccountsReceivableAndPrepaidExpensesTextBlock" id="cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" id="cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PaymentsForInvestmentInDeposits" id="cmmb_PaymentsForInvestmentInDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PercentageOfMonthlyDepositsRate" id="cmmb_PercentageOfMonthlyDepositsRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfRoyaltyPaymentsOnSaleOfProduct" id="cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProceedsFromSaleOfAdss" id="cmmb_ProceedsFromSaleOfAdss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ReceivablesFromGovernmentInstitutions" id="cmmb_ReceivablesFromGovernmentInstitutions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ReceivedAmountOfChemomabTherapeuticsInc" id="cmmb_ReceivedAmountOfChemomabTherapeuticsInc" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RecoverabilityOfVatAmount" id="cmmb_RecoverabilityOfVatAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RelatedPartyMember" id="cmmb_RelatedPartyMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" id="cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RentAndMaintenanceGeneralAndAdministrativeExpense" id="cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RentAndMaintenanceResearchAndDevelopmentExpense" id="cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RepurchaseArrangementMember" id="cmmb_RepurchaseArrangementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RepurchaseOfAmericanDepositaryReceipts" id="cmmb_RepurchaseOfAmericanDepositaryReceipts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RepurchaseOfAmericanDepositaryReceiptsShares" id="cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfStockLineItems" id="cmmb_SaleOfStockLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfStocksPricePerShare" id="cmmb_SaleOfStocksPricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfStockTable" id="cmmb_SaleOfStockTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="SaleOfStockValueOfSharesIssuedInTransaction" id="cmmb_SaleOfStockValueOfSharesIssuedInTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ScheduleOfAnnualRateOfDeprecationTableTextBlock" id="cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfGeneralAndAdministrativeTableTextBlock" id="cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" id="cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfRelatedPartyPayablesTableTextBlock" id="cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfResearchAndDevelopmentTableTextBlock" id="cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" id="cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeverancePayPolicyTextBlock" id="cmmb_SeverancePayPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" id="cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" id="cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" id="cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" id="cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationGeneralAndAdministrativeExpense" id="cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareBasedCompensationResearchAndDevelopmentExpense" id="cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareholdingPercentageImmediatelyFollowingMerger" id="cmmb_ShareholdingPercentageImmediatelyFollowingMerger" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockAndWarrantsIssuedDuringPeriodNewIssues" id="cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockAndWarrantsIssuedDuringPeriodValueNewIssues" id="cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" id="cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" id="cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesStockOptionsExercised1" id="cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxAssetsAcquiredThroughMergerValuationAllowance" id="cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" id="cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="TwoThousandsFifteenPlanMember" id="cmmb_TwoThousandsFifteenPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandsSeventeenPlanMember" id="cmmb_TwoThousandsSeventeenPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" id="cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>cmmb-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementsOfOperations" roleURI="http://www.anchiano.com/role/StatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementsOfCashFlows" roleURI="http://www.anchiano.com/role/StatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails" roleURI="http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#OtherReceivablesAndPrepaidExpensesDetails" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails" roleURI="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails" roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails" roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedCashCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_DepositsAssetsCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsNoncurrent_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_6" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_8" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_Liabilities_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_12" xlink:to="loc_us-gaap_LiabilitiesCurrent_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_13" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_14" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_15" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_12" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_17" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_CommitmentsAndContingencies_20" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_StockholdersEquity_21" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_CommonStockValue_21" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_TreasuryStockValue_22" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_AdditionalPaidInCapital_23" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:to="loc_us-gaap_OperatingExpenses_3" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashAcquiredInMerger" xlink:label="loc_cmmb_CashAcquiredInMerger_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_18"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ProfitLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" xlink:to="loc_cmmb_PaymentsForInvestmentInDeposits_10" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" xlink:to="loc_cmmb_LongTermLeaseDeposit_11" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_12" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_13" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_cmmb_CashAcquiredInMerger_15" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_16" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_17" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_18" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xlink:to="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xlink:to="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_cmmb_ReceivablesFromGovernmentInstitutions_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_5"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_cmmb_ConsultantsAndSubcontractorsExpense_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_us-gaap_OfficersCompensation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_0" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_5" order="40" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaap_NoninterestExpenseDirectorsFees_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_SalariesAndWages_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_ProfessionalFees_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_NoninterestExpenseDirectorsFees_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_GeneralInsuranceExpense_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_0" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7" order="60" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent_0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyCosts" xlink:label="loc_us-gaap_RelatedPartyCosts_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyCosts_0" xlink:to="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyCosts_0" xlink:to="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyCosts_0" xlink:to="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyCosts_0" xlink:to="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4" order="30" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>cmmb-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementsOfChangesInEquity" roleURI="http://www.anchiano.com/role/StatementsOfChangesInEquity"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralDetails" roleURI="http://www.anchiano.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#CashAndCashEquivalentsDetails" roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#LeasesNarrativeDetails" roleURI="http://www.anchiano.com/role/LeasesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#CommitmentsAndContingentLiabilitiesDetails" roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalNarrativeDetails" roleURI="http://www.anchiano.com/role/ShareCapitalNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalShare-basedCompensationExpensesDetails" roleURI="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails" roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxesDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#EventsAfterBalanceSheetDateNarrativeDetails" roleURI="http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_49"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentInformationTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_AmericanDepositarySharesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AmendmentFlag_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentType_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_13" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentAnnualReport_14" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_DocumentTransitionReport_15" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityFileNumber_16" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityRegistrantName_17" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_18" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityTaxIdentificationNumber_19" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine1_20" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine2_21" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressCityOrTown_22" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressCountry_23" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityAddressPostalZipCode_24" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_CityAreaCode_25" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_LocalPhoneNumber_26" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityInformationFormerLegalOrRegisteredName_27" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_Security12bTitle_28" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_TradingSymbol_29" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_SecurityExchangeName_30" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_31" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityVoluntaryFilers_32" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityCurrentReportingStatus_33" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_34" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityFilerCategory_35" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntitySmallBusiness_36" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_37" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityExTransitionPeriod_38" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_39" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityShellCompany_40" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityPublicFloat_41" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_42" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorName_43" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorLocation_44" order="380" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_AuditorFirmId_45" order="390" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_WrittenCommunications_46" order="400" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_SolicitingMaterial_47" order="410" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_PreCommencementTenderOffer_48" order="420" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_49" order="430" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfChangesInEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_TreasuryStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_14" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransaction_15" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_16" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_17" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_18" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_20" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_21" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_22" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_23" order="150" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" xlink:label="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_cmmb_FormerChemomabSecurityHoldersMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0" xlink:to="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_14" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_cmmb_AnnualRatesOfDepreciation_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3" order="20" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ComputerEquipmentMember_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_cmmb_LaboratoryEquipmentMember_4" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="loc_currency_USD_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_XXX" xlink:label="loc_currency_XXX_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_USD_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_XXX_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cmmb_LaboratoryEquipmentMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LeaseExpirationDate1_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_cmmb_AnnualRentAndManagementFees_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_cmmb_BankGuaranteesToPropertyOwner_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_11" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_12" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_13" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_14" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_15" order="100" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalAdditionsMember" xlink:label="loc_us-gaap_CapitalAdditionsMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="loc_currency_EUR_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentDescription_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_21"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_22"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_34"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_CapitalAdditionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_cmmb_CapitalAdditionsOneMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_LeaseAgreementsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_CurrencyAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_7" xlink:to="loc_currency_AllCurrenciesDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_7" xlink:to="loc_currency_EUR_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_7" xlink:to="loc_currency_ILS_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_7" xlink:to="loc_currency_AllCurrenciesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_12" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_12" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_StatementScenarioAxis_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_15" xlink:to="loc_srt_ScenarioUnspecifiedDomain_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_15" xlink:to="loc_srt_ScenarioForecastMember_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_15" xlink:to="loc_srt_ScenarioUnspecifiedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentDescription_20" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentsDescription_21" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_22" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_23" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_24" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_25" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_26" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_27" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_RoyaltyExpense_28" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_AggregateAmountCommitmentToPay_29" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_AggregateAmountOfCommitmentPaid_30" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_AdditionalWorkOrderAmount_31" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_LienOnBankDeposit_32" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_RestrictedInvestments_33" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cmmb_RecoverabilityOfVatAmount_34" order="150" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalNarrativeDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_32"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_34"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_35"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_36"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_38"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_41"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_42"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_43"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_44"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_45"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_46"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_SaleOfStockTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cmmb_CantorMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cmmb_InvestorsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_us-gaap_PrivatePlacementMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cmmb_AtmAgreementMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5" xlink:to="loc_cmmb_RepurchaseArrangementMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12" xlink:to="loc_us-gaap_ClassOfStockDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_12" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_12" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_PlanNameAxis_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_16" xlink:to="loc_us-gaap_PlanNameDomain_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_16" xlink:to="loc_cmmb_TwoThousandsFifteenPlanMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_16" xlink:to="loc_cmmb_TwoThousandsSeventeenPlanMember_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_16" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_24" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_25" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_26" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_ProceedsFromSaleOfAdss_27" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_28" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_29" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_SaleOfStocksPricePerShare_30" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfStockReservedForIssuance_31" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfStockAdssResveredForIssuance_32" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_33" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfOptionsIssuableOutstanding_34" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfVestedAndExercisable_35" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfAdssVestedAndExercisable_36" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_NumberOfOptionsVestedAndExercisable_37" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_38" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_39" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_40" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_41" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_42" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_43" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_44" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_45" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_SaleOfStockLineItems_0" xlink:to="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_46" order="250" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2" order="10" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharePrice_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9" order="80" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9" xlink:to="loc_srt_RangeAxis_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MinimumMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MaximumMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9" xlink:to="loc_us-gaap_AwardTypeAxis_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL" xlink:label="loc_country_IL_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_20"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_cmmb_IncomeTaxDisclosureTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_srt_ScenarioForecastMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementGeographicalAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_IL_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5" xlink:to="loc_country_US_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5" xlink:to="loc_srt_SegmentGeographicalDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_10" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_10" xlink:to="loc_us-gaap_DomesticCountryMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_10" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_19" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_20" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyMember" xlink:label="loc_cmmb_RelatedPartyMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4" order="30" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4" xlink:to="loc_us-gaap_RelatedPartyDomain_4" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4" xlink:to="loc_cmmb_RelatedPartyMember_4" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_2" order="10" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_6" order="10" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>cmmb-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_11"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_19"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_20"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_21"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_22"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_24"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_32"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashAcquiredInMerger" xlink:label="loc_cmmb_CashAcquiredInMerger_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashAcquiredInMerger" xlink:label="loc_cmmb_CashAcquiredInMerger_34"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_35"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_36"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_37"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_38"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_39"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_40"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_41"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_42"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_43"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_44"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_45"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_46"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_47"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_48"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_49"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_50"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_51"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_52"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_53"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_54"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_55"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_56"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_57"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_58"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_59"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_60"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_61"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_62"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_63"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_64"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_65"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_66"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_67"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_68"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_FinanceIncomeExpensesNet" xlink:label="loc_cmmb_FinanceIncomeExpensesNet_69"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_70"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_71"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_72"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_73"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_74"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_75"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_76"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_77"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_78"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_79"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_80"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_81"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_82"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_83"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_84"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_85"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_86"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_87"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_88"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_89"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_90"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_91"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_92"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_93"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_94"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_95"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_96"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_97"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_98"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_99"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_100"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_101"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_102"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_103"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_104"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_105"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_106"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_107"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_108"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_109"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_110"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_111"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_112"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_113"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_114"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_115"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_116"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_117"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_118"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_119"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_120"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_121"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_122"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_123"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_124"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_125"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_126"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_127"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_128"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_129"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_130"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_131"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_132"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_133"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_134"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_135"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_136"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_137"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_138"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_139"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_140"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_141"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_142"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_143"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_144"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_145"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_146"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_147"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_148"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_149"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_150"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_151"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_152"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_153"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_154"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_155"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_156"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfMonthlyDepositsRate" xlink:label="loc_cmmb_PercentageOfMonthlyDepositsRate_157"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfMonthlyDepositsRate" xlink:label="loc_cmmb_PercentageOfMonthlyDepositsRate_158"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_159"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_160"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_161"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_162"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_163"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_164"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_165"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_166"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_167"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_168"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_169"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_170"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_171"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_172"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyMember" xlink:label="loc_cmmb_RelatedPartyMember_173"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyMember" xlink:label="loc_cmmb_RelatedPartyMember_174"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_175"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_176"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_177"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_178"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_179"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_180"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_181"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_182"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_183"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_184"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_185"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_186"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_187"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_188"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_189"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_190"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_191"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_192"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_193"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_194"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_195"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_196"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_197"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_198"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_199"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_200"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_201"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_202"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_203"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_204"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_205"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_206"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_207"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_208"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_209"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_210"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_211"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_212"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_213"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_214"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_215"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_216"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_217"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_218"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_219"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_220"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_221"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_222"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_223"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_224"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_225"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_226"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" xlink:label="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_227"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" xlink:label="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_228"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_229"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_230"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_231"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_232"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_233"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_234"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_235"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_236"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_237"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_238"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_239"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_240"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_241"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_242"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_243"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_244"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_245"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_246"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_247"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_248"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_249"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_250"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_251"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_252"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_253"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_254"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_255"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_256"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_257"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_258"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_259"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_260"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_261"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_262"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_263"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_264"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_265"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_266"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_267"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_268"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_269"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_270"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_271"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_272"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_273"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_274"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_275"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_276"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_277"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_278"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_279"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_280"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_281"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_282"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_283"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_284"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_285"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_286"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_287"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_288"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_289"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_290"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_291"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_292"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_293"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_294"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_295"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_296"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_297"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_298"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_299"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_301"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_302"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_303"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_304"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_305"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_306"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_307"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_308"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_309"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_311"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_312"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_313"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_314"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_315"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_316"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_317"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_318"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_319"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_321"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_322"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_323"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_324"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_325"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_326"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_327"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_328"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_329"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_331"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_332"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_333"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_334"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_335"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_336"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL" xlink:label="loc_country_IL_337"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_338"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="loc_currency_EUR_339"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_341"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="loc_currency_USD_342"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_XXX" xlink:label="loc_currency_XXX_343"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_344"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_345"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_346"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_347"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_348"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_349"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_351"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_352"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_353"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_354"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_355"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_356"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_357"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_358"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_359"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_361"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_362"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_363"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_364"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_365"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_366"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_367"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_368"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_369"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_370"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_371"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_372"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_373"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_374"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_375"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_376"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_377"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_378"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_379"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_380"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_381"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_382"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_383"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_384"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_385"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_386"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_387"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_388"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_389"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_390"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_391"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_392"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_393"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_394"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_395"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_396"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_397"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_398"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_399"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_400"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_401"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_402"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_403"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_404"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_405"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_406"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_407"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_408"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_409"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_410"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_411"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_412"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_413"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_414"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_415"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_416"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_417"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_418"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_419"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_420"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_421"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_422"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_423"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_424"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_425"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_426"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalAdditionsMember" xlink:label="loc_us-gaap_CapitalAdditionsMember_427"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_428"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_429"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_430"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_431"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_432"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_433"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_434"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_435"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_436"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_437"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_438"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_439"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_440"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_441"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_442"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_443"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_444"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_445"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_446"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_447"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_448"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_449"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_450"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_451"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_452"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_453"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_454"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_455"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_456"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_457"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_458"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_459"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_460"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_461"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_462"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_463"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_464"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_465"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_466"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_467"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_468"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_469"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_470"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_471"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_472"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_473"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_474"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_475"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_476"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_477"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_478"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_479"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_480"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_481"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_482"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_483"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_484"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_485"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_486"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_487"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_488"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense_489"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_490"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_491"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_492"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_493"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_494"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_495"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_496"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_497"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_498"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_499"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_500"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_501"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_502"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_503"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_504"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_505"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_506"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_507"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_508"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_509"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_510"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_511"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_512"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_513"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_514"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_515"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_516"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_517"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_518"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_519"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_520"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_521"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_522"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_523"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_524"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_525"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_526"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_527"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_528"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_529"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_530"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_531"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_532"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_533"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_534"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_535"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_536"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_537"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_538"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_539"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_540"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_541"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_542"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_543"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_544"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_545"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_546"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_547"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_548"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentDescription_549"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_550"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_551"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_552"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_553"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_554"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_555"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_556"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_557"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_558"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_559"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_560"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_561"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaap_NoninterestExpenseDirectorsFees_562"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_563"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_564"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_565"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_566"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_567"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_568"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_569"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_570"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_571"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_572"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_573"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_574"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_575"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_576"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_577"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_578"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_579"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_580"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_581"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_582"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_583"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_584"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_585"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_586"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_587"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_588"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_589"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_590"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_591"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_592"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_593"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_594"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_595"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_596"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_597"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_598"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_599"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_600"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_601"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_602"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_603"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_604"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_605"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_606"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_607"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_608"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_609"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_610"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_611"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_612"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_613"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_614"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_615"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_616"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_617"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_618"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_619"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyCosts" xlink:label="loc_us-gaap_RelatedPartyCosts_620"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyCosts" xlink:label="loc_us-gaap_RelatedPartyCosts_621"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_622"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_623"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_624"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_625"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_626"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_627"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_628"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_629"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_630"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_631"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_632"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_633"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_634"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_635"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_636"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_637"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_638"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_639"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_640"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_641"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_642"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_643"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_644"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_645"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_646"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_647"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_648"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_649"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_650"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_651"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_652"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_653"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_654"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_655"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_656"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_657"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_658"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_659"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_660"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_661"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_662"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_663"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_664"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_665"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_666"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_667"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_668"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_669"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_670"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_671"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_672"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_673"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_674"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_675"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_676"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_677"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_678"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_679"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_680"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_681"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_682"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_683"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_684"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_685"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_686"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_687"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_688"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_689"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_690"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_691"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_692"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_693"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_694"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_695"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_696"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_697"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_698"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_699"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_700"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_701"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_702"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_703"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_704"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_705"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_706"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_707"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_708"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_709"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_710"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_711"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_712"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_713"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_714"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_715"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_716"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_717"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_718"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_719"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_720"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_721"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_722"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_723"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_724"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_725"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_726"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_727"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_728"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_729"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_730"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_731"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_732"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_733"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_734"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_735"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_736"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_737"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_738"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_739"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_740"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_741"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_742"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_743"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_744"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_745"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_746"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AdditionalWorkOrderAmount_0" xml:lang="en-US">Additional work order amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AdditionalWorkOrderAmount_1" xml:lang="en-US">Additional Work Order Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_AdditionalWorkOrderAmount_2" xml:lang="en-US">Additional work order</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AggregateAmountCommitmentToPay_0" xml:lang="en-US">Aggregate amount commitment to pay.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AggregateAmountCommitmentToPay_1" xml:lang="en-US">Aggregate amount commitment to pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AggregateAmountOfCommitmentPaid_0" xml:lang="en-US">Aggregate amount of commitment paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AggregateAmountOfCommitmentPaid_1" xml:lang="en-US">Aggregate amount of commitment paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_0" xml:lang="en-US">It represents as a aggregate offering price of at the market offering agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_1" xml:lang="en-US">Aggregate Offering Price Of At Market Offering Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_2" xml:lang="en-US">Aggregate offering price of at the market offering agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AmericanDepositarySharesMember_0" xml:lang="en-US">American Depositary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AmericanDepositarySharesMember_1" xml:lang="en-US">American Depositary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AnnualRatesOfDepreciation_0" xml:lang="en-US">Annual rates of depreciation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AnnualRatesOfDepreciation_1" xml:lang="en-US">Annual Rates Of Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_AnnualRatesOfDepreciation_2" xml:lang="en-US">Annual rates of depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AnnualRentAndManagementFees_0" xml:lang="en-US">Annual rent and management fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AnnualRentAndManagementFees_1" xml:lang="en-US">Annual rent and management fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_AtmAgreementMember_0" xml:lang="en-US">ATM agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_AtmAgreementMember_1" xml:lang="en-US">ATM agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_BankGuaranteesToPropertyOwner_0" xml:lang="en-US">Bank guarantees to property owner.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_BankGuaranteesToPropertyOwner_1" xml:lang="en-US">Bank guarantees to property owner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_0" xml:lang="en-US">The amount of of asset held for sale recogized prior to the completion of merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Asset Held For Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2" xml:lang="en-US">Asset held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_0" xml:lang="en-US">Amount of accrued liabilities to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1" xml:lang="en-US">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_2" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CantorMember_0" xml:lang="en-US">Represents about Cantor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CantorMember_1" xml:lang="en-US">Cantor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CapitalAdditionsOneMember_0" xml:lang="en-US">FDA or equivalent agency marketing approval [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CapitalAdditionsOneMember_1" xml:lang="en-US">Capital Additions One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_CapitalAdditionsOneMember_2" xml:lang="en-US">FDA or equivalent agency marketing approval [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CashAcquiredInMerger_0" xml:lang="en-US">Cash acquired in merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CashAcquiredInMerger_1" xml:lang="en-US">Cash acquired in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_0" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_1" xml:lang="en-US">Cash Paid And Received During Year For [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_2" xml:lang="en-US">A. Cash paid and received during the year for:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_0" xml:lang="en-US">It represents as a change in temporary differences for which deferred taxes were not recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_1" xml:lang="en-US">Change In Temporary Differences For Deferred Taxes Not Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_2" xml:lang="en-US">Change in temporary differences for which deferred taxes were not recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ConsultantsAndSubcontractorsExpense_0" xml:lang="en-US">Consultants and subcontractors expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ConsultantsAndSubcontractorsExpense_1" xml:lang="en-US">Consultants And Subcontractors Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ConsultantsAndSubcontractorsExpense_2" xml:lang="en-US">Consultants and subcontractors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_0" xml:lang="en-US">The cumulative amounts of grants received from the IIA and recognized by the company, as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_1" xml:lang="en-US">Cumulative Amounts Of Grants Received And Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_2" xml:lang="en-US">Cumulative amounts of grants received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_CurrencyTransactionLossValuationAllowance_0" xml:lang="en-US">Amount of increase (decrease) in the valuation allowance due to currency transaction loss.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_CurrencyTransactionLossValuationAllowance_1" xml:lang="en-US">Currency Transaction Loss Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_CurrencyTransactionLossValuationAllowance_2" xml:lang="en-US">Currency transaction income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_0" xml:lang="en-US">Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_1" xml:lang="en-US">Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_2" xml:lang="en-US">Denominator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_0" xml:lang="en-US">Earnings Per Share Calculation Numerator Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_1" xml:lang="en-US">Earnings Per Share Calculation Numerator [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_2" xml:lang="en-US">Numerator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransaction_0" xml:lang="en-US">The amount of effect due reverse capitalization transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransaction_1" xml:lang="en-US">Effect of reverse capitalization transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_0" xml:lang="en-US">The number of shares isued due to effect of reverse capitalization transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_1" xml:lang="en-US">Effect Of Reverse Capitalization Transaction Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_2" xml:lang="en-US">Effect of reverse capitalization transaction (In shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_0" xml:lang="en-US">The amount of estimated fair value of the net assets acquired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_1" xml:lang="en-US">Estimated Fair Value Of Net Assets Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_2" xml:lang="en-US">Net acquired assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_0" xml:lang="en-US">The amount expects to receive of Chemomab Therapeutics Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_1" xml:lang="en-US">Expects To Receive Amount Of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_2" xml:lang="en-US">Expects to receive amount of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_0" xml:lang="en-US">The net amount of finance income earned and finance expenses incurred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_1" xml:lang="en-US">Financing expenses (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_FinanceIncomeExpensesNet_2" xml:lang="en-US">Finance Income (Expenses), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_FormerChemomabSecurityHoldersMember_0" xml:lang="en-US">This represents former Chemomab security holders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_FormerChemomabSecurityHoldersMember_1" xml:lang="en-US">Former Chemomab Security Holders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_0" xml:lang="en-US">The entire disclosure of general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1" xml:lang="en-US">General And Administrative Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_2" xml:lang="en-US">General and Administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_1" xml:lang="en-US">Government Sponsored Research And Development [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_2" xml:lang="en-US">Government-sponsored research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxDisclosureLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxDisclosureLineItems_1" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxDisclosureTable_0" xml:lang="en-US">Disclosure of information pertaining to income taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxDisclosureTable_1" xml:lang="en-US">Income Tax Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxesReceived_0" xml:lang="en-US">It represents income taxes received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxesReceived_1" xml:lang="en-US">Income Taxes Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_IncomeTaxesReceived_2" xml:lang="en-US">Income taxes received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncomeTaxExpenseValuationAllowance_0" xml:lang="en-US">Amount of increase (decrease) in the valuation allowance due to income tax expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncomeTaxExpenseValuationAllowance_1" xml:lang="en-US">Income Tax Expense Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_IncomeTaxExpenseValuationAllowance_2" xml:lang="en-US">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_IncrementalBorrowingRateOfLeases_0" xml:lang="en-US">It represents incremental borrowing rate of leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_IncrementalBorrowingRateOfLeases_1" xml:lang="en-US">Incremental Borrowing Rate Of Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_IncrementalBorrowingRateOfLeases_2" xml:lang="en-US">incremental borrowing rate of leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_InterestReceived_0" xml:lang="en-US">The amount of interest received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_InterestReceived_1" xml:lang="en-US">Interest Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_InterestReceived_2" xml:lang="en-US">Interest received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_InvestorsMember_0" xml:lang="en-US">Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_InvestorsMember_1" xml:lang="en-US">Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LaboratoryEquipmentMember_0" xml:lang="en-US">Laboratory equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LaboratoryEquipmentMember_1" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_LaboratoryEquipmentMember_2" xml:lang="en-US">Laboratory equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LienOnBankDeposit_0" xml:lang="en-US">Lien on bank deposit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LienOnBankDeposit_1" xml:lang="en-US">Lien on bank deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LongTermLeaseDeposit_0" xml:lang="en-US">Long-term lease deposit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LongTermLeaseDeposit_1" xml:lang="en-US">Long Term Lease Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_LongTermLeaseDeposit_2" xml:lang="en-US">Long-term lease deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_0" xml:lang="en-US">Represents losses and benefits for tax purposes for the year, for which deferred taxes were not recorded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_1" xml:lang="en-US">Losses And Benefits For Tax Purposes For The Year For Which Deferred Taxes Were Not Recorded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_2" xml:lang="en-US">Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_0" xml:lang="en-US">The maximum percentage of royalties payable on the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_1" xml:lang="en-US">Maximum Percentage Of Payments Of Royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_2" xml:lang="en-US">Maximum percentage of payments of royalties (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_0" xml:lang="en-US">This represents Merger Agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company inclued proposed merger of CMB Acquisition Ltd, wholly owned subsidiary of our company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1" xml:lang="en-US">Merger Agreement With Cmb Acquisition Ltd Subsidiary Of Ours And Chemomb [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_2" xml:lang="en-US">Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NatureOfOperationsDisclosureAbstract_0" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NatureOfOperationsDisclosureAbstract_1" xml:lang="en-US">Nature Of Operations Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NatureOfOperationsDisclosureAbstract_2" xml:lang="en-US">NATURE OF OPERATIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_0" xml:lang="en-US">Number of ADS issued and outstanding after the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_1" xml:lang="en-US">Number of ADS issued and outstanding after the merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_0" xml:lang="en-US">Number of ADSs options issuable outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_1" xml:lang="en-US">Number of ADSs options issuable outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfAdssVestedAndExercisable_0" xml:lang="en-US">Number of ADSs vested and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfAdssVestedAndExercisable_1" xml:lang="en-US">Number of ADSs vested and exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfOptionsIssuableOutstanding_0" xml:lang="en-US">It represents number of options issuable outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfOptionsIssuableOutstanding_1" xml:lang="en-US">Number Of Options Issuable Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfOptionsIssuableOutstanding_2" xml:lang="en-US">Number of options issuable outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfOptionsVestedAndExercisable_0" xml:lang="en-US">It represents number of options vested and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfOptionsVestedAndExercisable_1" xml:lang="en-US">Number Of Options Vested And Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfOptionsVestedAndExercisable_2" xml:lang="en-US">Number of options vested and exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_0" xml:lang="en-US">Represent the number of ordinary shares consisted in one American depository share (ADS).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_1" xml:lang="en-US">Number Of Ordinary Shares Consisted In Ds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_2" xml:lang="en-US">Number of ordinary shares represented by each ADS (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfStockAdssResveredForIssuance_0" xml:lang="en-US">Number of stock option ADSs resvered for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfStockAdssResveredForIssuance_1" xml:lang="en-US">Number Of Stock Adss Resvered For Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfStockAdssResveredForIssuance_2" xml:lang="en-US">Number of stock option ADSs reversed for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfStockReservedForIssuance_0" xml:lang="en-US">It represents number of stock resvered for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfStockReservedForIssuance_1" xml:lang="en-US">Number Of Stock Reserved For Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfStockReservedForIssuance_2" xml:lang="en-US">Number of stock reserved for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfVestedAndExercisable_0" xml:lang="en-US">It represents number of vested and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfVestedAndExercisable_1" xml:lang="en-US">Number Of Vested And Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfVestedAndExercisable_2" xml:lang="en-US">Number of vested and exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_0" xml:lang="en-US">Number of warrants purchase ADS's.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_1" xml:lang="en-US">Number Of Warrants Purchase Up Adss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_2" xml:lang="en-US">Number of warrants purchase ADS's</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_0" xml:lang="en-US">Operating right-of-use assets and operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_1" xml:lang="en-US">Operating Right Of Use Assets And Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_2" xml:lang="en-US">Operating right-of-use assets and operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_OrdinarySharesNoParValuePerShareMember_0" xml:lang="en-US">Ordinary Shares, No Par Value Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_OrdinarySharesNoParValuePerShareMember_1" xml:lang="en-US">Ordinary Shares, No Par Value Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_0" xml:lang="en-US">Other accounts receivable and prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1" xml:lang="en-US">Other Accounts Receivable And Prepaid Expenses [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_2" xml:lang="en-US">Other Receivables and Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_0" xml:lang="en-US">Payment on commencement of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_1" xml:lang="en-US">Payment On Long Term Purchase Commitment Commencement Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_2" xml:lang="en-US">Payment on commencement of agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PaymentsForInvestmentInDeposits_0" xml:lang="en-US">The amount of payments for investm,ents in deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_PaymentsForInvestmentInDeposits_1" xml:lang="en-US">Investment in deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PaymentsForInvestmentInDeposits_2" xml:lang="en-US">Payments for Investment in Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PercentageOfMonthlyDepositsRate_0" xml:lang="en-US">Percentage of monthly deposits rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PercentageOfMonthlyDepositsRate_1" xml:lang="en-US">Percentage of monthly deposits rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_0" xml:lang="en-US">The percentage of royalty payments on sale of product developed with funding received from the IIA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_1" xml:lang="en-US">Percentage Of Royalty Payments On Sale Of Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_2" xml:lang="en-US">Royalty payments on sale of product (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ProceedsFromSaleOfAdss_0" xml:lang="en-US">Proceeds from sale of ADS's.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ProceedsFromSaleOfAdss_1" xml:lang="en-US">Proceeds from sale of ADS's</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ReceivablesFromGovernmentInstitutions_0" xml:lang="en-US">Government institutions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ReceivablesFromGovernmentInstitutions_1" xml:lang="en-US">Receivables From Government Institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ReceivablesFromGovernmentInstitutions_2" xml:lang="en-US">Government institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_0" xml:lang="en-US">The received amount of Chemomab Therapeutics Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_1" xml:lang="en-US">Received Amount Of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_2" xml:lang="en-US">Received amount of Chemomab Therapeutics Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RecoverabilityOfVatAmount_0" xml:lang="en-US">It represents recoverability of VAT amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RecoverabilityOfVatAmount_1" xml:lang="en-US">Recoverability Of Vat Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RecoverabilityOfVatAmount_2" xml:lang="en-US">Recoverability of VAT amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyMember_0" xml:lang="en-US">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyMember_1" xml:lang="en-US">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to professional services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Professional Services From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_2" xml:lang="en-US">Professional services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to research and develeopment expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Research And Development Expense From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_2" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to salaries and related expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Salaries And Related Expenses From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_2" xml:lang="en-US">Salaries and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related party expenses related to share based payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related Party Transaction Share Based Payments From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2" xml:lang="en-US">Share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative related rent and maintenance expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_1" xml:lang="en-US">Rent And Maintenance General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_2" xml:lang="en-US">Rent and maintenance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development related rent and maintenance expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_1" xml:lang="en-US">Rent And Maintenance Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_2" xml:lang="en-US">Rent and maintenance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RepurchaseArrangementMember_0" xml:lang="en-US">This member stands for Repurchase Arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RepurchaseArrangementMember_1" xml:lang="en-US">Repurchase Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RepurchaseArrangementMember_2" xml:lang="en-US">Repurchase Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_0" xml:lang="en-US">Represents the amount of repurchase of american depositary receipts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_1" xml:lang="en-US">Repurchase Of American Depositary Receipts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_2" xml:lang="en-US">Repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_0" xml:lang="en-US">It represents repurchase of American Depositary Receipts shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_1" xml:lang="en-US">Repurchase Of American Depositary Receipts Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_2" xml:lang="en-US">Number of shares repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStockLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStockLineItems_1" xml:lang="en-US">Sale Of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStocksPricePerShare_0" xml:lang="en-US">Per share amount received by the company for each share of common stock issued or sold in the stock transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStocksPricePerShare_1" xml:lang="en-US">Sale Of Stocks Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_SaleOfStocksPricePerShare_2" xml:lang="en-US">Share price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStockTable_0" xml:lang="en-US">Different names of stock transactions and the different attributes of each transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStockTable_1" xml:lang="en-US">Sale Of Stock [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_0" xml:lang="en-US">Represents the amount of sale of stock value of shares issued in transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_1" xml:lang="en-US">Sale Of Stock Value Of Shares Issued In Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_2" xml:lang="en-US">Issuance and sale of of ADS upto</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_0" xml:lang="en-US">Tabular disclosure of the annual rate of deprecation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1" xml:lang="en-US">Schedule Of Annual Rate Of Deprecation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_2" xml:lang="en-US">Schedule of annual rate of deprecation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_0" xml:lang="en-US">Tabular disclosure of general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1" xml:lang="en-US">Schedule Of General And Administrative [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_2" xml:lang="en-US">Schedule of general and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_0" xml:lang="en-US">Schedule of other accounts receivable and prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1" xml:lang="en-US">Schedule Of Other Accounts Receivable And Prepaid Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_2" xml:lang="en-US">Schedule of other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_0" xml:lang="en-US">Tabular disclosure of related party payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1" xml:lang="en-US">Schedule Of Related Party Payables [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_2" xml:lang="en-US">Schedule of related party payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_0" xml:lang="en-US">Tabular disclosure of research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1" xml:lang="en-US">Schedule Of Research And Development [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_2" xml:lang="en-US">Schedule of research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_0" xml:lang="en-US">This represents security holders of Anchiano as of immediately prior to the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_1" xml:lang="en-US">Security holders of Anchiano as of immediately prior to the merger [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_SeverancePayPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for severance pay.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_SeverancePayPolicyTextBlock_1" xml:lang="en-US">Severance Pay [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_SeverancePayPolicyTextBlock_2" xml:lang="en-US">Severance pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_0" xml:lang="en-US">It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Forfeitures In Period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Ads Forfeitures In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_2" xml:lang="en-US">Options to purchase ordinary shares cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0" xml:lang="en-US">It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Outstanding Period Increase Decrease Weighted Average Exercise Price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Ads Outstanding Period Increase Decrease Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_2" xml:lang="en-US">Weighted average exercise price of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_0" xml:lang="en-US">Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants In Period, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_2" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_0" xml:lang="en-US">Weighted average price of shares acquired in merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_1" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award, Options, Acquired In Merger, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2" xml:lang="en-US">Acquired in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative related share-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_1" xml:lang="en-US">Share Based Compensation General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development related share-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_1" xml:lang="en-US">Share Based Compensation Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_2" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_0" xml:lang="en-US">shareholding percentage immediately following the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_1" xml:lang="en-US">Shareholding percentage immediately following the merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_0" xml:lang="en-US">it represents number of shares and warrants issued during period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_1" xml:lang="en-US">Stock And Warrants Issued During Period New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_2" xml:lang="en-US">Issuance of shares and warrants, net of issuance costs (In shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Value of stock issued in lieu contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US">Stock And Warrants Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_2" xml:lang="en-US">Issuance of shares and warrants, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_0" xml:lang="en-US">Number of new stocks of American Depository Shares ("ADS") issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_1" xml:lang="en-US">Stock Issued During Period American Depository Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_2" xml:lang="en-US">Number of ADSs issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_0" xml:lang="en-US">Number of options acquired, including both vested and non-vested options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_1" xml:lang="en-US">Stock Issued During Period Shares Stock Options Acquired In Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_2" xml:lang="en-US">Acquired in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_0" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_1" xml:lang="en-US">Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_2" xml:lang="en-US">Stock Issued During Period Shares Stock Options Exercised 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_0" xml:lang="en-US">Amount of increase (decrease) in the valuation allowance due to tax assets acquired through merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_1" xml:lang="en-US">Tax Assets Acquired Through Merger Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_2" xml:lang="en-US">Tax assets acquired through merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_0" xml:lang="en-US">It represents Total consideration of repurchase of american depositary receipts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_1" xml:lang="en-US">Total Consideration Of Repurchase Of American Depositary Receipts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_2" xml:lang="en-US">Total consideration of repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TwoThousandsFifteenPlanMember_0" xml:lang="en-US">2015 plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TwoThousandsFifteenPlanMember_1" xml:lang="en-US">Two Thousands Fifteen Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_TwoThousandsFifteenPlanMember_2" xml:lang="en-US">2015 plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_TwoThousandsSeventeenPlanMember_0" xml:lang="en-US">2017 plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_TwoThousandsSeventeenPlanMember_1" xml:lang="en-US">Two Thousands Seventeen Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cmmb_TwoThousandsSeventeenPlanMember_2" xml:lang="en-US">2017 plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_0" xml:lang="en-US">It represents weighted average price of repurchase of american depositary receipts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_1" xml:lang="en-US">Weighted Average Price Of Repurchase Of American Depositary Receipts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_2" xml:lang="en-US">Weighted average price of repurchase of ADSs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" xml:lang="en-US">Less - accumulated depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Less - valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Balance at December 31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2" xml:lang="en-US">Balance at January 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Loss before income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xml:lang="en-US">Loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_0" xml:lang="en-US">Income taxes paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_1" xml:lang="en-US">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_2" xml:lang="en-US">Income taxes paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0" xml:lang="en-US">Change in other receivables and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0" xml:lang="en-US">Less imputed interest:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_0" xml:lang="en-US">Financing (income) expenses, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_1" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_2" xml:lang="en-US">Financing expenses (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_3" xml:lang="en-US">Nonoperating Income (Expense), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Treasury share at cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1" xml:lang="en-US">Options to purchase ADS cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_TreasuryStockValue_0" xml:lang="en-US">Treasury share at cost (11,640,460 shares as of December 31, 2022)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockValue_1" xml:lang="en-US">Treasury Stock, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockValue_2" xml:lang="en-US">Treasury stock (11,640,460 shares as of December 31, 2022)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Outstanding at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Outstanding at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Outstanding at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Outstanding at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding_0" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding_1" xml:lang="en-US">Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding_2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Total shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Taxes on income (benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Actual income tax expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3" xml:lang="en-US">Income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IL_0" xml:lang="en-US">Israel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US_0" xml:lang="en-US">U.S. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_EUR_0" xml:lang="en-US">Euro [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_ILS_0" xml:lang="en-US">ILS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_ILS_1" xml:lang="en-US">NIS [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_USD_0" xml:lang="en-US">USD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_XXX_0" xml:lang="en-US">Other currencies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId_0" xml:lang="en-US">Auditor Firm Id</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation_0" xml:lang="en-US">Auditor Location</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName_0" xml:lang="en-US">Auditor Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode_0" xml:lang="en-US">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport_0" xml:lang="en-US">Document Annual Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems_0" xml:lang="en-US">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable_0" xml:lang="en-US">Document Information [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport_0" xml:lang="en-US">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address, Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInformationFormerLegalOrRegisteredName_0" xml:lang="en-US">Entity Information, Former Legal or Registered Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat_0" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness_0" xml:lang="en-US">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber_0" xml:lang="en-US">Entity Tax Identification Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers_0" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0" xml:lang="en-US">Entity Well Known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag_0" xml:lang="en-US">Auditor Attestation Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber_0" xml:lang="en-US">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_0" xml:lang="en-US">Pre-commencement Issuer Tender Offer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_PreCommencementTenderOffer_0" xml:lang="en-US">Pre-commencement Tender Offer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName_0" xml:lang="en-US">Name of Exchange on which Security is Registered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SolicitingMaterial_0" xml:lang="en-US">Soliciting Material</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_WrittenCommunications_0" xml:lang="en-US">Written Communications</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CurrencyAxis_0" xml:lang="en-US">Currency [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioForecastMember_0" xml:lang="en-US">Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain_0" xml:lang="en-US">Scenario [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis_0" xml:lang="en-US">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis_0" xml:lang="en-US">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis_0" xml:lang="en-US">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent_0" xml:lang="en-US">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_0" xml:lang="en-US">Recognized liability for royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital_0" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1" xml:lang="en-US">Additional paid in capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_0" xml:lang="en-US">Exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments for operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Share-based compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Outstanding options to purchase ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">Current assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract_1" xml:lang="en-US">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent_0" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent_1" xml:lang="en-US">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_0" xml:lang="en-US">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0" xml:lang="en-US">Basis of presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US">Basis of Presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_0" xml:lang="en-US">Business Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_0" xml:lang="en-US">Prepaid and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalAdditionsMember_0" xml:lang="en-US">New Drug Application and Biological License Application [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract_0" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_0" xml:lang="en-US">Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xml:lang="en-US">Change in cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain_0" xml:lang="en-US">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">Commitments and contingent liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock_0" xml:lang="en-US">Commitments and Contingent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockMember_1" xml:lang="en-US">Ordinary shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockNoParValue_0" xml:lang="en-US">Common Stock, No Par Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2021 and 500,000,000 shares as of December 31, 2020; Issued and outstanding: 228,090,300 shares at December 31, 2021 and 9,274,838 shares at December 31, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2022 and 2021; Issued and outstanding: 232,636,700 Ordinary shares at December 31, 2022 and 228,090,300 Ordinary shares at December 31, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0" xml:lang="en-US">Deferred taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember_0" xml:lang="en-US">Computers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_0" xml:lang="en-US">Concentration of credit risks</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_0" xml:lang="en-US">Principles of consolidation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_0" xml:lang="en-US">Incremental borrowing rate based on credit rating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_1" xml:lang="en-US">Gross deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0" xml:lang="en-US">Research and development costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1" xml:lang="en-US">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0" xml:lang="en-US">Net operating loss carry-forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_0" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0" xml:lang="en-US">Share-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepositsAssetsCurrent_0" xml:lang="en-US">Short-term bank deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember_0" xml:lang="en-US">Federal [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_0" xml:lang="en-US">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_1" xml:lang="en-US">Related Party Payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract_0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Basic and diluted loss per Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Basic loss per Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Diluted loss per Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Earnings per ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0" xml:lang="en-US">Net Loss Per Share Attributable to Ordinary Shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0" xml:lang="en-US">Statutory tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Corporate tax rate (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US">Corporate tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0" xml:lang="en-US">Employee and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0" xml:lang="en-US">Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0" xml:lang="en-US">Fair value of financial instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0" xml:lang="en-US">Functional currency</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_0" xml:lang="en-US">Furniture and Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_1" xml:lang="en-US">Furniture and equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_2" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xml:lang="en-US">General and Administrative Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0" xml:lang="en-US">General and administrative [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralInsuranceExpense_0" xml:lang="en-US">Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0" xml:lang="en-US">Impairment of long-lived assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_0" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0" xml:lang="en-US">Theoretical tax benefit on the above amount Decrease (increase) in tax refund resulting from:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_0" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1" xml:lang="en-US">Tax rate differential</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Theoretical tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1" xml:lang="en-US">Non-deductible expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0" xml:lang="en-US">Change in trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0" xml:lang="en-US">Change in accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0" xml:lang="en-US">Change in employees and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0" xml:lang="en-US">Change in leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1" xml:lang="en-US">Change in operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseAgreementsMember_0" xml:lang="en-US">2020 Lien [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseExpirationDate1_0" xml:lang="en-US">Lease expiry date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_1" xml:lang="en-US">Leasehold improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeDisclosureAbstract_0" xml:lang="en-US">Lessee Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_0" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_0" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_1" xml:lang="en-US">Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0" xml:lang="en-US">Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" xml:lang="en-US">Schedule of maturity of lease liabilities under our non-cancelable operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xml:lang="en-US">Total future minimum lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0" xml:lang="en-US">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1" xml:lang="en-US">2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0" xml:lang="en-US">2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" xml:lang="en-US">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_1" xml:lang="en-US">Lease term, option to extend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_0" xml:lang="en-US">Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0" xml:lang="en-US">Lease term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities_0" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities_1" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAssumed1_0" xml:lang="en-US">Liabilities assumed, net of non-cash assets received in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAssumed1_1" xml:lang="en-US">Liabilities assumed, net of non-cash assets received in Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">Current liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US">Total non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount_0" xml:lang="en-US">Payment for licensed agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_0" xml:lang="en-US">Category of Item Purchased [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentDescription_0" xml:lang="en-US">Description of application payment for licensed product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations_0" xml:lang="en-US">General</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Cash flows from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Cash flows from investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Cash flows from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0" xml:lang="en-US">Significant non- cash transaction:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1" xml:lang="en-US">B. Significant non- cash transaction:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoninterestExpenseDirectorsFees_0" xml:lang="en-US">Fees to Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficersCompensation_0" xml:lang="en-US">Salaries and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_0" xml:lang="en-US">Decrease in the carrying amount of the right-of-use asset due to impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_1" xml:lang="en-US">Increase in the carrying amount of the right-of-use asset due to impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability_0" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_1" xml:lang="en-US">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_2" xml:lang="en-US">Operating Lease, Liability, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_1" xml:lang="en-US">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Non-current operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1" xml:lang="en-US">Non-current&#160;operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Operating lease right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsDescription_0" xml:lang="en-US">Decsription of occurrence for payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsLineItems_0" xml:lang="en-US">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsTable_0" xml:lang="en-US">Other Commitments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense_0" xml:lang="en-US">Other General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense_1" xml:lang="en-US">Other expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense_0" xml:lang="en-US">Other expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain_0" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0" xml:lang="en-US">Preferred shares par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0" xml:lang="en-US">Preferred shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xml:lang="en-US">Prepaid Expense and Other Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xml:lang="en-US">Other receivables and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xml:lang="en-US">Other accounts receivable and prepaid expenses, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_0" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent_0" xml:lang="en-US">Long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember_0" xml:lang="en-US">The Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_0" xml:lang="en-US">Proceeds from preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_1" xml:lang="en-US">Exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromOtherEquity_0" xml:lang="en-US">Proceeds from Other Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromOtherEquity_1" xml:lang="en-US">Issuance of shares and warrants, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_0" xml:lang="en-US">Sale of asset held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_0" xml:lang="en-US">Proceeds from Sale of Treasury Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_1" xml:lang="en-US">Treasury stock at cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0" xml:lang="en-US">Exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfessionalFees_0" xml:lang="en-US">Professional services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss_0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss_1" xml:lang="en-US">Loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss_2" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0" xml:lang="en-US">Property and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_0" xml:lang="en-US">Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0" xml:lang="en-US">Property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_0" xml:lang="en-US">Annual rates of depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0" xml:lang="en-US">Schedule of Property And Equpment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xml:lang="en-US">Schedule of property and equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyCosts_0" xml:lang="en-US">Related Party Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RelatedPartyCosts_1" xml:lang="en-US">Total related party expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_0" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">Related Parties Balances and Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract_0" xml:lang="en-US">Research and Development [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0" xml:lang="en-US">Research and development expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xml:lang="en-US">Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_0" xml:lang="en-US">Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent_0" xml:lang="en-US">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedInvestments_0" xml:lang="en-US">Bank restricted deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_0" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember_1" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyExpense_0" xml:lang="en-US">Royality expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalariesAndWages_0" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SalariesAndWages_1" xml:lang="en-US">Salaries and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0" xml:lang="en-US">Schedule of Weighted Average Number of Shares Excluded From Computation of Diluted Net Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xml:lang="en-US">Schedule of weighted average number of shares excluded from computation of diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0" xml:lang="en-US">Schedule of components of cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0" xml:lang="en-US">Summary of the effect of share-based compensation on the statements of operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" xml:lang="en-US">Schedule of the effect of share-based compensation on the statements of operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of Significant Components of the Company's Deferred Tax Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of significant components of the company's deferred tax asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xml:lang="en-US">Schedule of computation of basic and diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0" xml:lang="en-US">Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xml:lang="en-US">Schedule of reconciliation of theoretical income tax expense to actual income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0" xml:lang="en-US">Schedule of net assets acquired based on their estimated fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0" xml:lang="en-US">Schedule of Transaction With Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xml:lang="en-US">Schedule of transaction with related parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Summary of assumptions used to calculate the fair value of the options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US">Schedule of assumptions used to calculate the fair value of the options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_0" xml:lang="en-US">Summary of number and weighted average exercise prices of option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_1" xml:lang="en-US">Schedule of number and weighted average exercise prices of option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_0" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1_0" xml:lang="en-US">Severance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0" xml:lang="en-US">Exercise price (in U.S. dollar)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Expected life of options (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0" xml:lang="en-US">Expected volatility, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0" xml:lang="en-US">Expected volatility, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0" xml:lang="en-US">Risk-free interest rate, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0" xml:lang="en-US">Risk-free interest rate, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0" xml:lang="en-US">Weighted average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Number of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0" xml:lang="en-US">Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0" xml:lang="en-US">Share Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice_0" xml:lang="en-US">Weighted average share price (in U.S. dollar)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareDevelopmentMember_0" xml:lang="en-US">Website Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareDevelopmentMember_1" xml:lang="en-US">Website development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0" xml:lang="en-US">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0" xml:lang="en-US">Shareholders' equity:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1" xml:lang="en-US">Shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0" xml:lang="en-US">Reverse stock split conversion ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Exercise of Options, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_1" xml:lang="en-US">Treasury share at cost (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Issuance of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Exercise of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_0" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1" xml:lang="en-US">Treasury share at cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember_1" xml:lang="en-US">Subsequent event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">Events After Balance Sheet Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_0" xml:lang="en-US">Schedule of Roll Forward of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_1" xml:lang="en-US">Schedule of roll forward of valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_0" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_1" xml:lang="en-US">Supplementary cash flows information:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_0" xml:lang="en-US">Capital losses carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockMember_0" xml:lang="en-US">Treasury Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TreasuryStockMember_1" xml:lang="en-US">Treasury share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockShares_0" xml:lang="en-US">Treasury Stock, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use of estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" xml:lang="en-US">Net change in the total valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Weighted average number of Ordinary Shares outstanding, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2" xml:lang="en-US">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted average number of Ordinary Shares outstanding, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" xml:lang="en-US">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AdditionalWorkOrderAmount_1" xlink:to="lab_cmmb_AdditionalWorkOrderAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AdditionalWorkOrderAmount_2" xlink:to="lab_cmmb_AdditionalWorkOrderAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AdditionalWorkOrderAmount_3" xlink:to="lab_cmmb_AdditionalWorkOrderAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountCommitmentToPay_4" xlink:to="lab_cmmb_AggregateAmountCommitmentToPay_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountCommitmentToPay_5" xlink:to="lab_cmmb_AggregateAmountCommitmentToPay_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountOfCommitmentPaid_6" xlink:to="lab_cmmb_AggregateAmountOfCommitmentPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateAmountOfCommitmentPaid_7" xlink:to="lab_cmmb_AggregateAmountOfCommitmentPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_8" xlink:to="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_9" xlink:to="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_10" xlink:to="lab_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmericanDepositarySharesMember_11" xlink:to="lab_cmmb_AmericanDepositarySharesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AmericanDepositarySharesMember_12" xlink:to="lab_cmmb_AmericanDepositarySharesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRatesOfDepreciation_13" xlink:to="lab_cmmb_AnnualRatesOfDepreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRatesOfDepreciation_14" xlink:to="lab_cmmb_AnnualRatesOfDepreciation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRatesOfDepreciation_15" xlink:to="lab_cmmb_AnnualRatesOfDepreciation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRentAndManagementFees_16" xlink:to="lab_cmmb_AnnualRentAndManagementFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AnnualRentAndManagementFees_17" xlink:to="lab_cmmb_AnnualRentAndManagementFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AtmAgreementMember_18" xlink:to="lab_cmmb_AtmAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_AtmAgreementMember_19" xlink:to="lab_cmmb_AtmAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BankGuaranteesToPropertyOwner_20" xlink:to="lab_cmmb_BankGuaranteesToPropertyOwner_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BankGuaranteesToPropertyOwner_21" xlink:to="lab_cmmb_BankGuaranteesToPropertyOwner_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_22" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_23" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_24" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_25" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_26" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_27" xlink:to="lab_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CantorMember_28" xlink:to="lab_cmmb_CantorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CantorMember_29" xlink:to="lab_cmmb_CantorMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CapitalAdditionsOneMember_30" xlink:to="lab_cmmb_CapitalAdditionsOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CapitalAdditionsOneMember_31" xlink:to="lab_cmmb_CapitalAdditionsOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CapitalAdditionsOneMember_32" xlink:to="lab_cmmb_CapitalAdditionsOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashAcquiredInMerger_33" xlink:to="lab_cmmb_CashAcquiredInMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashAcquiredInMerger_34" xlink:to="lab_cmmb_CashAcquiredInMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_35" xlink:to="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_36" xlink:to="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_37" xlink:to="lab_cmmb_CashPaidAndReceivedDuringYearForAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_38" xlink:to="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_39" xlink:to="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_40" xlink:to="lab_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ConsultantsAndSubcontractorsExpense_41" xlink:to="lab_cmmb_ConsultantsAndSubcontractorsExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ConsultantsAndSubcontractorsExpense_42" xlink:to="lab_cmmb_ConsultantsAndSubcontractorsExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ConsultantsAndSubcontractorsExpense_43" xlink:to="lab_cmmb_ConsultantsAndSubcontractorsExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_44" xlink:to="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_45" xlink:to="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_46" xlink:to="lab_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CurrencyTransactionLossValuationAllowance_47" xlink:to="lab_cmmb_CurrencyTransactionLossValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CurrencyTransactionLossValuationAllowance_48" xlink:to="lab_cmmb_CurrencyTransactionLossValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_CurrencyTransactionLossValuationAllowance_49" xlink:to="lab_cmmb_CurrencyTransactionLossValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_50" xlink:to="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_51" xlink:to="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_52" xlink:to="lab_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_53" xlink:to="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_54" xlink:to="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_55" xlink:to="lab_cmmb_EarningsPerShareCalculationNumeratorAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransaction_56" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransaction_57" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_58" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_59" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_60" xlink:to="lab_cmmb_EffectOfReverseCapitalizationTransactionShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_61" xlink:to="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_62" xlink:to="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_63" xlink:to="lab_cmmb_EstimatedFairValueOfNetAssetsAcquired_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_64" xlink:to="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_65" xlink:to="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_66" xlink:to="lab_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_67" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_68" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FinanceIncomeExpensesNet_69" xlink:to="lab_cmmb_FinanceIncomeExpensesNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FormerChemomabSecurityHoldersMember_70" xlink:to="lab_cmmb_FormerChemomabSecurityHoldersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_FormerChemomabSecurityHoldersMember_71" xlink:to="lab_cmmb_FormerChemomabSecurityHoldersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_72" xlink:to="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_73" xlink:to="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_74" xlink:to="lab_cmmb_GeneralAndAdministrativeDisclosureTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_75" xlink:to="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_76" xlink:to="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_77" xlink:to="lab_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_78" xlink:to="lab_cmmb_IncomeTaxDisclosureLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_79" xlink:to="lab_cmmb_IncomeTaxDisclosureLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_80" xlink:to="lab_cmmb_IncomeTaxDisclosureTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_81" xlink:to="lab_cmmb_IncomeTaxDisclosureTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxesReceived_82" xlink:to="lab_cmmb_IncomeTaxesReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxesReceived_83" xlink:to="lab_cmmb_IncomeTaxesReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxesReceived_84" xlink:to="lab_cmmb_IncomeTaxesReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxExpenseValuationAllowance_85" xlink:to="lab_cmmb_IncomeTaxExpenseValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxExpenseValuationAllowance_86" xlink:to="lab_cmmb_IncomeTaxExpenseValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncomeTaxExpenseValuationAllowance_87" xlink:to="lab_cmmb_IncomeTaxExpenseValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncrementalBorrowingRateOfLeases_88" xlink:to="lab_cmmb_IncrementalBorrowingRateOfLeases_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncrementalBorrowingRateOfLeases_89" xlink:to="lab_cmmb_IncrementalBorrowingRateOfLeases_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_IncrementalBorrowingRateOfLeases_90" xlink:to="lab_cmmb_IncrementalBorrowingRateOfLeases_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InterestReceived_91" xlink:to="lab_cmmb_InterestReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InterestReceived_92" xlink:to="lab_cmmb_InterestReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InterestReceived_93" xlink:to="lab_cmmb_InterestReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InvestorsMember_94" xlink:to="lab_cmmb_InvestorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_InvestorsMember_95" xlink:to="lab_cmmb_InvestorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LaboratoryEquipmentMember_96" xlink:to="lab_cmmb_LaboratoryEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LaboratoryEquipmentMember_97" xlink:to="lab_cmmb_LaboratoryEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LaboratoryEquipmentMember_98" xlink:to="lab_cmmb_LaboratoryEquipmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LienOnBankDeposit_99" xlink:to="lab_cmmb_LienOnBankDeposit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LienOnBankDeposit_100" xlink:to="lab_cmmb_LienOnBankDeposit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LongTermLeaseDeposit_101" xlink:to="lab_cmmb_LongTermLeaseDeposit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LongTermLeaseDeposit_102" xlink:to="lab_cmmb_LongTermLeaseDeposit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LongTermLeaseDeposit_103" xlink:to="lab_cmmb_LongTermLeaseDeposit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_104" xlink:to="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_105" xlink:to="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_106" xlink:to="lab_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_107" xlink:to="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_108" xlink:to="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_109" xlink:to="lab_cmmb_MaximumPercentageOfPaymentsOfRoyalties_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_110" xlink:to="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_111" xlink:to="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_112" xlink:to="lab_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_113" xlink:to="lab_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_114" xlink:to="lab_cmmb_NatureOfOperationsDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_115" xlink:to="lab_cmmb_NatureOfOperationsDisclosureAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_116" xlink:to="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_117" xlink:to="lab_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_118" xlink:to="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_119" xlink:to="lab_cmmb_NumberOfAdssOptionsIssuableOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssVestedAndExercisable_120" xlink:to="lab_cmmb_NumberOfAdssVestedAndExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfAdssVestedAndExercisable_121" xlink:to="lab_cmmb_NumberOfAdssVestedAndExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsIssuableOutstanding_122" xlink:to="lab_cmmb_NumberOfOptionsIssuableOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsIssuableOutstanding_123" xlink:to="lab_cmmb_NumberOfOptionsIssuableOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsIssuableOutstanding_124" xlink:to="lab_cmmb_NumberOfOptionsIssuableOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsVestedAndExercisable_125" xlink:to="lab_cmmb_NumberOfOptionsVestedAndExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsVestedAndExercisable_126" xlink:to="lab_cmmb_NumberOfOptionsVestedAndExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOptionsVestedAndExercisable_127" xlink:to="lab_cmmb_NumberOfOptionsVestedAndExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_128" xlink:to="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_129" xlink:to="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_130" xlink:to="lab_cmmb_NumberOfOrdinarySharesConsistedInDs_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockAdssResveredForIssuance_131" xlink:to="lab_cmmb_NumberOfStockAdssResveredForIssuance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockAdssResveredForIssuance_132" xlink:to="lab_cmmb_NumberOfStockAdssResveredForIssuance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockAdssResveredForIssuance_133" xlink:to="lab_cmmb_NumberOfStockAdssResveredForIssuance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockReservedForIssuance_134" xlink:to="lab_cmmb_NumberOfStockReservedForIssuance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockReservedForIssuance_135" xlink:to="lab_cmmb_NumberOfStockReservedForIssuance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfStockReservedForIssuance_136" xlink:to="lab_cmmb_NumberOfStockReservedForIssuance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfVestedAndExercisable_137" xlink:to="lab_cmmb_NumberOfVestedAndExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfVestedAndExercisable_138" xlink:to="lab_cmmb_NumberOfVestedAndExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfVestedAndExercisable_139" xlink:to="lab_cmmb_NumberOfVestedAndExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_140" xlink:to="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_141" xlink:to="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_142" xlink:to="lab_cmmb_NumberOfWarrantsPurchaseUpAdss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_143" xlink:to="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_144" xlink:to="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_145" xlink:to="lab_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OrdinarySharesNoParValuePerShareMember_146" xlink:to="lab_cmmb_OrdinarySharesNoParValuePerShareMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OrdinarySharesNoParValuePerShareMember_147" xlink:to="lab_cmmb_OrdinarySharesNoParValuePerShareMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_148" xlink:to="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_149" xlink:to="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_150" xlink:to="lab_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_151" xlink:to="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_152" xlink:to="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_153" xlink:to="lab_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsForInvestmentInDeposits_154" xlink:to="lab_cmmb_PaymentsForInvestmentInDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsForInvestmentInDeposits_155" xlink:to="lab_cmmb_PaymentsForInvestmentInDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PaymentsForInvestmentInDeposits_156" xlink:to="lab_cmmb_PaymentsForInvestmentInDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfMonthlyDepositsRate_157" xlink:to="lab_cmmb_PercentageOfMonthlyDepositsRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfMonthlyDepositsRate_158" xlink:to="lab_cmmb_PercentageOfMonthlyDepositsRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_159" xlink:to="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_160" xlink:to="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_161" xlink:to="lab_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromSaleOfAdss_162" xlink:to="lab_cmmb_ProceedsFromSaleOfAdss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ProceedsFromSaleOfAdss_163" xlink:to="lab_cmmb_ProceedsFromSaleOfAdss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivablesFromGovernmentInstitutions_164" xlink:to="lab_cmmb_ReceivablesFromGovernmentInstitutions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivablesFromGovernmentInstitutions_165" xlink:to="lab_cmmb_ReceivablesFromGovernmentInstitutions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivablesFromGovernmentInstitutions_166" xlink:to="lab_cmmb_ReceivablesFromGovernmentInstitutions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_167" xlink:to="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_168" xlink:to="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_169" xlink:to="lab_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RecoverabilityOfVatAmount_170" xlink:to="lab_cmmb_RecoverabilityOfVatAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RecoverabilityOfVatAmount_171" xlink:to="lab_cmmb_RecoverabilityOfVatAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RecoverabilityOfVatAmount_172" xlink:to="lab_cmmb_RecoverabilityOfVatAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyMember_173" xlink:to="lab_cmmb_RelatedPartyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyMember_174" xlink:to="lab_cmmb_RelatedPartyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_175" xlink:to="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_176" xlink:to="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_177" xlink:to="lab_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_178" xlink:to="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_179" xlink:to="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_180" xlink:to="lab_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_181" xlink:to="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_182" xlink:to="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_183" xlink:to="lab_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_184" xlink:to="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_185" xlink:to="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_186" xlink:to="lab_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_187" xlink:to="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_188" xlink:to="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_189" xlink:to="lab_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_190" xlink:to="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_191" xlink:to="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_192" xlink:to="lab_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseArrangementMember_193" xlink:to="lab_cmmb_RepurchaseArrangementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseArrangementMember_194" xlink:to="lab_cmmb_RepurchaseArrangementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseArrangementMember_195" xlink:to="lab_cmmb_RepurchaseArrangementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_196" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_197" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_198" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceipts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_199" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_200" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_201" xlink:to="lab_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockLineItems_202" xlink:to="lab_cmmb_SaleOfStockLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockLineItems_203" xlink:to="lab_cmmb_SaleOfStockLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStocksPricePerShare_204" xlink:to="lab_cmmb_SaleOfStocksPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStocksPricePerShare_205" xlink:to="lab_cmmb_SaleOfStocksPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStocksPricePerShare_206" xlink:to="lab_cmmb_SaleOfStocksPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockTable_207" xlink:to="lab_cmmb_SaleOfStockTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockTable_208" xlink:to="lab_cmmb_SaleOfStockTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_209" xlink:to="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_210" xlink:to="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_211" xlink:to="lab_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_212" xlink:to="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_213" xlink:to="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_214" xlink:to="lab_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_215" xlink:to="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_216" xlink:to="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_217" xlink:to="lab_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_218" xlink:to="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_219" xlink:to="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_220" xlink:to="lab_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_221" xlink:to="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_222" xlink:to="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_223" xlink:to="lab_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_224" xlink:to="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_225" xlink:to="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_226" xlink:to="lab_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_227" xlink:to="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_228" xlink:to="lab_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SeverancePayPolicyTextBlock_229" xlink:to="lab_cmmb_SeverancePayPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SeverancePayPolicyTextBlock_230" xlink:to="lab_cmmb_SeverancePayPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_SeverancePayPolicyTextBlock_231" xlink:to="lab_cmmb_SeverancePayPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_232" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_233" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_234" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_235" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_236" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_237" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_238" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_239" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_240" xlink:to="lab_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_241" xlink:to="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_242" xlink:to="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_243" xlink:to="lab_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_244" xlink:to="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_245" xlink:to="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_246" xlink:to="lab_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_247" xlink:to="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_248" xlink:to="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_249" xlink:to="lab_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_250" xlink:to="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_251" xlink:to="lab_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_252" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_253" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_254" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_255" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_256" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_257" xlink:to="lab_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_258" xlink:to="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_259" xlink:to="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_260" xlink:to="lab_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_261" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_262" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_263" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_264" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_265" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_266" xlink:to="lab_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_267" xlink:to="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_268" xlink:to="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_269" xlink:to="lab_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_270" xlink:to="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_271" xlink:to="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_272" xlink:to="lab_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsFifteenPlanMember_273" xlink:to="lab_cmmb_TwoThousandsFifteenPlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsFifteenPlanMember_274" xlink:to="lab_cmmb_TwoThousandsFifteenPlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsFifteenPlanMember_275" xlink:to="lab_cmmb_TwoThousandsFifteenPlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsSeventeenPlanMember_276" xlink:to="lab_cmmb_TwoThousandsSeventeenPlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsSeventeenPlanMember_277" xlink:to="lab_cmmb_TwoThousandsSeventeenPlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_TwoThousandsSeventeenPlanMember_278" xlink:to="lab_cmmb_TwoThousandsSeventeenPlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_279" xlink:to="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_280" xlink:to="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_281" xlink:to="lab_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_282" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_283" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_284" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_285" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_286" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_287" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_288" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_289" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_290" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_291" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_292" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_293" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_294" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_295" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_296" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_297" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_298" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_299" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_300" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_301" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_302" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_303" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_304" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_305" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_306" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_307" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_308" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_309" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_310" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_311" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_312" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_313" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_314" xlink:to="lab_us-gaap_TreasuryStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_315" xlink:to="lab_us-gaap_TreasuryStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_316" xlink:to="lab_us-gaap_TreasuryStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_317" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_318" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_319" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_320" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_321" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_322" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_323" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_324" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_325" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_326" xlink:to="lab_us-gaap_SharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_327" xlink:to="lab_us-gaap_SharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_328" xlink:to="lab_us-gaap_SharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_329" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_330" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_331" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_332" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_333" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_334" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_335" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_336" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL_337" xlink:to="lab_country_IL_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_338" xlink:to="lab_country_US_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_339" xlink:to="lab_currency_EUR_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_ILS_340" xlink:to="lab_currency_ILS_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_ILS_341" xlink:to="lab_currency_ILS_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD_342" xlink:to="lab_currency_USD_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_XXX_343" xlink:to="lab_currency_XXX_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_344" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId_345" xlink:to="lab_dei_AuditorFirmId_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation_346" xlink:to="lab_dei_AuditorLocation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName_347" xlink:to="lab_dei_AuditorName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_348" xlink:to="lab_dei_CityAreaCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_349" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_350" xlink:to="lab_dei_DocumentAnnualReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_351" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_352" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems_353" xlink:to="lab_dei_DocumentInformationLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable_354" xlink:to="lab_dei_DocumentInformationTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_355" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_356" xlink:to="lab_dei_DocumentTransitionReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_357" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_358" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_359" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_360" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_361" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_362" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_363" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_364" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_365" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_366" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_367" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_368" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_369" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_370" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationFormerLegalOrRegisteredName_371" xlink:to="lab_dei_EntityInformationFormerLegalOrRegisteredName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_372" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_373" xlink:to="lab_dei_EntityPublicFloat_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_374" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_375" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_376" xlink:to="lab_dei_EntitySmallBusiness_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_377" xlink:to="lab_dei_EntityTaxIdentificationNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_378" xlink:to="lab_dei_EntityVoluntaryFilers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_379" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag_380" xlink:to="lab_dei_IcfrAuditorAttestationFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_381" xlink:to="lab_dei_LocalPhoneNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer_382" xlink:to="lab_dei_PreCommencementIssuerTenderOffer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer_383" xlink:to="lab_dei_PreCommencementTenderOffer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_384" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_385" xlink:to="lab_dei_SecurityExchangeName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial_386" xlink:to="lab_dei_SolicitingMaterial_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_387" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications_388" xlink:to="lab_dei_WrittenCommunications_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis_389" xlink:to="lab_srt_CurrencyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_390" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_391" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_392" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember_393" xlink:to="lab_srt_ScenarioForecastMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain_394" xlink:to="lab_srt_ScenarioUnspecifiedDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_395" xlink:to="lab_srt_StatementGeographicalAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis_396" xlink:to="lab_srt_StatementScenarioAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_397" xlink:to="lab_srt_TitleOfIndividualAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_398" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent_399" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_400" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_401" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_402" xlink:to="lab_us-gaap_AdditionalPaidInCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_403" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_404" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_405" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_406" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_407" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_408" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_409" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_410" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_411" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_412" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_413" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_414" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_415" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_416" xlink:to="lab_us-gaap_AssetsCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_417" xlink:to="lab_us-gaap_AssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_418" xlink:to="lab_us-gaap_AssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_419" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_420" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_421" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_422" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_423" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_424" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_425" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_426" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalAdditionsMember_427" xlink:to="lab_us-gaap_CapitalAdditionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_428" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_429" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_430" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_431" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_432" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_433" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_434" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_435" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_436" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_437" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_438" xlink:to="lab_us-gaap_ClassOfStockDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_439" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_440" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock_441" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_442" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_443" xlink:to="lab_us-gaap_CommonStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue_444" xlink:to="lab_us-gaap_CommonStockNoParValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_445" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_446" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_447" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_448" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_449" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_450" xlink:to="lab_us-gaap_ComputerEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_451" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_452" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_453" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_454" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_455" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_456" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_457" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_458" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_459" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_460" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_461" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent_462" xlink:to="lab_us-gaap_DepositsAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_463" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_464" xlink:to="lab_us-gaap_DomesticCountryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent_465" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent_466" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_467" xlink:to="lab_us-gaap_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_468" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_469" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_470" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_471" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_472" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_473" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_474" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_475" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_476" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_477" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_478" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_479" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_480" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_481" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_482" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_483" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_484" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_485" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_486" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_487" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_488" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralInsuranceExpense_489" xlink:to="lab_us-gaap_GeneralInsuranceExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_490" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_491" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_492" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_493" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_494" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_495" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_496" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_497" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_498" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_499" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_500" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_501" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_502" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_503" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_504" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_505" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_506" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_507" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_508" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_509" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_510" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_511" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAgreementsMember_512" xlink:to="lab_us-gaap_LeaseAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1_513" xlink:to="lab_us-gaap_LeaseExpirationDate1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_514" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_515" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_516" xlink:to="lab_us-gaap_LesseeDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_517" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_518" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_519" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_520" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_521" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_522" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_523" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_524" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_525" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_526" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_527" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_528" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_529" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_530" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_531" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_532" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_533" xlink:to="lab_us-gaap_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_534" xlink:to="lab_us-gaap_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_535" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_536" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_537" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1_538" xlink:to="lab_us-gaap_LiabilitiesAssumed1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1_539" xlink:to="lab_us-gaap_LiabilitiesAssumed1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_540" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_541" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_542" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_543" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_544" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_545" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_546" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount_547" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_548" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentDescription_549" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_550" xlink:to="lab_us-gaap_NatureOfOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_551" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_552" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_553" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_554" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_555" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_556" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_557" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_558" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_559" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_560" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_561" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoninterestExpenseDirectorsFees_562" xlink:to="lab_us-gaap_NoninterestExpenseDirectorsFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation_563" xlink:to="lab_us-gaap_OfficersCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_564" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_565" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_566" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss_567" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss_568" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_569" xlink:to="lab_us-gaap_OperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_570" xlink:to="lab_us-gaap_OperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_571" xlink:to="lab_us-gaap_OperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_572" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_573" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_574" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_575" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_576" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_577" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDescription_578" xlink:to="lab_us-gaap_OtherCommitmentsDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_579" xlink:to="lab_us-gaap_OtherCommitmentsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable_580" xlink:to="lab_us-gaap_OtherCommitmentsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense_581" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense_582" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherResearchAndDevelopmentExpense_583" xlink:to="lab_us-gaap_OtherResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_584" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_585" xlink:to="lab_us-gaap_PlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_586" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_587" xlink:to="lab_us-gaap_PreferredStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_588" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_589" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_590" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_591" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent_592" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_593" xlink:to="lab_us-gaap_PrivatePlacementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_594" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_595" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_596" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherEquity_597" xlink:to="lab_us-gaap_ProceedsFromOtherEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherEquity_598" xlink:to="lab_us-gaap_ProceedsFromOtherEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_599" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_600" xlink:to="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfTreasuryStock_601" xlink:to="lab_us-gaap_ProceedsFromSaleOfTreasuryStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_602" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_603" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees_604" xlink:to="lab_us-gaap_ProfessionalFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_605" xlink:to="lab_us-gaap_ProfitLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_606" xlink:to="lab_us-gaap_ProfitLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_607" xlink:to="lab_us-gaap_ProfitLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_608" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_609" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_610" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_611" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_612" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_613" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_614" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_615" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_616" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_617" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_618" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_619" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyCosts_620" xlink:to="lab_us-gaap_RelatedPartyCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyCosts_621" xlink:to="lab_us-gaap_RelatedPartyCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_622" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_623" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_624" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_625" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_626" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_627" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_628" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_629" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_630" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_631" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_632" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_633" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_634" xlink:to="lab_us-gaap_RestrictedCashCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_635" xlink:to="lab_us-gaap_RestrictedCashCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_636" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestments_637" xlink:to="lab_us-gaap_RestrictedInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_638" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_639" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_640" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_641" xlink:to="lab_us-gaap_RetainedEarningsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_642" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_643" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_644" xlink:to="lab_us-gaap_RoyaltyExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages_645" xlink:to="lab_us-gaap_SalariesAndWages_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages_646" xlink:to="lab_us-gaap_SalariesAndWages_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_647" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_648" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_649" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_650" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_651" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_652" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_653" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_654" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_655" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_656" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_657" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_658" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_659" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_660" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_661" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_662" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_663" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_664" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_665" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_666" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_667" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_668" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_669" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_670" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_671" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_672" xlink:to="lab_us-gaap_SeveranceCosts1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_673" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_674" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_675" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_676" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_677" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_678" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_679" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_680" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_681" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_682" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_683" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_684" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_685" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_686" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_687" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_688" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_689" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_690" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_691" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_692" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_693" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_694" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_695" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_696" xlink:to="lab_us-gaap_SharePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_697" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember_698" xlink:to="lab_us-gaap_SoftwareDevelopmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember_699" xlink:to="lab_us-gaap_SoftwareDevelopmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_700" xlink:to="lab_us-gaap_StatementClassOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_701" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_702" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_703" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_704" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_705" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_706" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_707" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_708" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_709" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_710" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_711" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_712" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_713" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_714" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_715" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_716" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_717" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_718" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_719" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_720" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_721" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_722" xlink:to="lab_us-gaap_SubsequentEventMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_723" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_724" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_725" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_726" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_727" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_728" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_729" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_730" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_731" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_732" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_733" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_734" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_735" xlink:to="lab_us-gaap_TreasuryStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_736" xlink:to="lab_us-gaap_TreasuryStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_737" xlink:to="lab_us-gaap_TreasuryStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_738" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_739" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_740" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_741" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_742" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_743" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_744" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_745" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_746" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>cmmb-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#BalanceSheetsParenthetical" roleURI="http://www.anchiano.com/role/BalanceSheetsParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementsOfOperations" roleURI="http://www.anchiano.com/role/StatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementsOfChangesInEquity" roleURI="http://www.anchiano.com/role/StatementsOfChangesInEquity"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#StatementsOfCashFlows" roleURI="http://www.anchiano.com/role/StatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#General" roleURI="http://www.anchiano.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#CashAndCashEquivalents" roleURI="http://www.anchiano.com/role/CashAndCashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#OtherReceivablesAndPrepaidExpenses" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#PropertyAndEquipmentNet" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#Leases" roleURI="http://www.anchiano.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#CommitmentsAndContingentLiabilities" roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapital" roleURI="http://www.anchiano.com/role/ShareCapital"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ResearchAndDevelopment" roleURI="http://www.anchiano.com/role/ResearchAndDevelopment"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralAndAdministrative" roleURI="http://www.anchiano.com/role/GeneralAndAdministrative"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxes" roleURI="http://www.anchiano.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#RelatedPartiesBalancesAndTransactions" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#NetLossPerShareAttributableToOrdinaryShareholders" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralTables" roleURI="http://www.anchiano.com/role/GeneralTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#CashAndCashEquivalentsTables" roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#OtherReceivablesAndPrepaidExpensesTables" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#LeasesTables" roleURI="http://www.anchiano.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalTables" roleURI="http://www.anchiano.com/role/ShareCapitalTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ResearchAndDevelopmentTables" roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralAndAdministrativeTables" roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxesTables" roleURI="http://www.anchiano.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#RelatedPartiesBalancesAndTransactionsTables" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersTables" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralDetails" roleURI="http://www.anchiano.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails" roleURI="http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" roleURI="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#CashAndCashEquivalentsDetails" roleURI="http://www.anchiano.com/role/CashAndCashEquivalentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#OtherReceivablesAndPrepaidExpensesDetails" roleURI="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#LeasesNarrativeDetails" roleURI="http://www.anchiano.com/role/LeasesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails" roleURI="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#CommitmentsAndContingentLiabilitiesDetails" roleURI="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalNarrativeDetails" roleURI="http://www.anchiano.com/role/ShareCapitalNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalShare-basedCompensationExpensesDetails" roleURI="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails" roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails" roleURI="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails" roleURI="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails" roleURI="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxesDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails" roleURI="http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails" roleURI="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails" roleURI="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#EventsAfterBalanceSheetDateNarrativeDetails" roleURI="http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cmmb-20221231.xsd#EventsAfterBalanceSheetDate" roleURI="http://www.anchiano.com/role/EventsAfterBalanceSheetDate"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/DocumentDocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AmericanDepositarySharesMember" xlink:label="loc_cmmb_AmericanDepositarySharesMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OrdinarySharesNoParValuePerShareMember" xlink:label="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_47"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentInformationTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_AmericanDepositarySharesMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_cmmb_OrdinarySharesNoParValuePerShareMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1" xlink:to="loc_dei_DocumentInformationLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityCentralIndexKey_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_AmendmentFlag_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_DocumentType_8" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_CurrentFiscalYearEndDate_9" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_DocumentFiscalYearFocus_10" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_DocumentPeriodEndDate_11" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_DocumentAnnualReport_12" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_DocumentTransitionReport_13" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityFileNumber_14" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityRegistrantName_15" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_16" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityTaxIdentificationNumber_17" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityAddressAddressLine1_18" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityAddressAddressLine2_19" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityAddressCityOrTown_20" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityAddressCountry_21" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityAddressPostalZipCode_22" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_CityAreaCode_23" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_LocalPhoneNumber_24" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityInformationFormerLegalOrRegisteredName_25" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_Security12bTitle_26" order="210" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_TradingSymbol_27" order="220" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_SecurityExchangeName_28" order="230" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_29" order="240" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityVoluntaryFilers_30" order="250" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityCurrentReportingStatus_31" order="260" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityInteractiveDataCurrent_32" order="270" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityFilerCategory_33" order="280" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntitySmallBusiness_34" order="290" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityEmergingGrowthCompany_35" order="300" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityExTransitionPeriod_36" order="310" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_IcfrAuditorAttestationFlag_37" order="320" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityShellCompany_38" order="330" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityPublicFloat_39" order="340" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_40" order="350" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_AuditorName_41" order="360" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_AuditorLocation_42" order="370" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_AuditorFirmId_43" order="380" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_WrittenCommunications_44" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_SolicitingMaterial_45" order="400" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_PreCommencementTenderOffer_46" order="410" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_5" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_47" order="420" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_32"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_DepositsAssetsCurrent_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_RestrictedCashCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_AssetsNoncurrent_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_16" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrent_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_CommitmentsAndContingencies_24" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_Liabilities_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_CommonStockValue_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_TreasuryStockValue_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_AdditionalPaidInCapital_28" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_26" xlink:to="loc_us-gaap_StockholdersEquity_30" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_32" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/BalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockNoParValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_SharesOutstanding_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_TreasuryStockShares_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfChangesInEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransaction" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransaction_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EffectOfReverseCapitalizationTransactionShares" xlink:label="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues" xlink:label="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_23"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_TreasuryStockMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_SharesOutstanding_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_12" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransaction_13" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_EffectOfReverseCapitalizationTransactionShares_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues_16" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_17" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_19" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_20" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_NetIncomeLoss_21" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_22" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_SharesOutstanding_23" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentsForInvestmentInDeposits" xlink:label="loc_cmmb_PaymentsForInvestmentInDeposits_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LongTermLeaseDeposit" xlink:label="loc_cmmb_LongTermLeaseDeposit_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashAcquiredInMerger" xlink:label="loc_cmmb_CashAcquiredInMerger_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CashPaidAndReceivedDuringYearForAbstract" xlink:label="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxesReceived" xlink:label="loc_cmmb_IncomeTaxesReceived_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InterestReceived" xlink:label="loc_cmmb_InterestReceived_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_33"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_ProfitLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_5" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_cmmb_PaymentsForInvestmentInDeposits_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_cmmb_LongTermLeaseDeposit_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_14" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_cmmb_CashAcquiredInMerger_18" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_19" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_27" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_27" xlink:to="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_27" xlink:to="loc_cmmb_IncomeTaxesReceived_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_27" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_CashPaidAndReceivedDuringYearForAbstract_27" xlink:to="loc_cmmb_InterestReceived_29" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_us-gaap_LiabilitiesAssumed1_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/General">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_NatureOfOperations_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalents">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNet">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/Leases">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CommitmentsAndContingentLiabilities">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapital">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopment">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GeneralAndAdministrativeDisclosureTextBlock" xlink:label="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_GeneralAndAdministrativeDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_11"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock" xlink:label="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_12"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SeverancePayPolicyTextBlock" xlink:label="loc_cmmb_SeverancePayPolicyTextBlock_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_17"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_SeverancePayPolicyTextBlock_13" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_16" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_17" order="160" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralTables">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock" xlink:label="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalentsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopmentTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock" xlink:label="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrativeTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock" xlink:label="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock" xlink:label="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember" xlink:label="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_FormerChemomabSecurityHoldersMember" xlink:label="loc_cmmb_FormerChemomabSecurityHoldersMember_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember" xlink:label="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareholdingPercentageImmediatelyFollowingMerger" xlink:label="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOrdinarySharesConsistedInDs" xlink:label="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger" xlink:label="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_cmmb_FormerChemomabSecurityHoldersMember_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8" xlink:to="loc_cmmb_ShareholdingPercentageImmediatelyFollowingMerger_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8" xlink:to="loc_cmmb_NumberOfOrdinarySharesConsistedInDs_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8" xlink:to="loc_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger_11" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails">
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NatureOfOperationsDisclosureAbstract" xlink:label="loc_cmmb_NatureOfOperationsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:label="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EstimatedFairValueOfNetAssetsAcquired" xlink:label="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_NatureOfOperationsDisclosureAbstract_0" xlink:to="loc_cmmb_EstimatedFairValueOfNetAssetsAcquired_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfMonthlyDepositsRate" xlink:label="loc_cmmb_PercentageOfMonthlyDepositsRate_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncrementalBorrowingRateOfLeases" xlink:label="loc_cmmb_IncrementalBorrowingRateOfLeases_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_PercentageOfMonthlyDepositsRate_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SeveranceCosts1_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cmmb_IncrementalBorrowingRateOfLeases_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRatesOfDepreciation" xlink:label="loc_cmmb_AnnualRatesOfDepreciation_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cmmb_LaboratoryEquipmentMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7" xlink:to="loc_cmmb_AnnualRatesOfDepreciation_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CashAndCashEquivalentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="loc_currency_USD_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_XXX" xlink:label="loc_currency_XXX_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_USD_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_XXX_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivablesFromGovernmentInstitutions" xlink:label="loc_cmmb_ReceivablesFromGovernmentInstitutions_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_cmmb_ReceivablesFromGovernmentInstitutions_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LaboratoryEquipmentMember" xlink:label="loc_cmmb_LaboratoryEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cmmb_LaboratoryEquipmentMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AnnualRentAndManagementFees" xlink:label="loc_cmmb_AnnualRentAndManagementFees_7"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_BankGuaranteesToPropertyOwner" xlink:label="loc_cmmb_BankGuaranteesToPropertyOwner_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_10"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_srt_CurrencyAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_1" xlink:to="loc_currency_AllCurrenciesDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1" xlink:to="loc_currency_ILS_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LeaseExpirationDate1_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_cmmb_AnnualRentAndManagementFees_7" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_cmmb_BankGuaranteesToPropertyOwner_8" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseLiability_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities_11" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_13" order="90" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalAdditionsMember" xlink:label="loc_us-gaap_CapitalAdditionsMember_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CapitalAdditionsOneMember" xlink:label="loc_cmmb_CapitalAdditionsOneMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="loc_currency_EUR_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_ILS" xlink:label="loc_currency_ILS_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentDescription_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_16"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct" xlink:label="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_17"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_MaximumPercentageOfPaymentsOfRoyalties" xlink:label="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_18"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized" xlink:label="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_21"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement" xlink:label="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountCommitmentToPay" xlink:label="loc_cmmb_AggregateAmountCommitmentToPay_24"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateAmountOfCommitmentPaid" xlink:label="loc_cmmb_AggregateAmountOfCommitmentPaid_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AdditionalWorkOrderAmount" xlink:label="loc_cmmb_AdditionalWorkOrderAmount_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LienOnBankDeposit" xlink:label="loc_cmmb_LienOnBankDeposit_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestments" xlink:label="loc_us-gaap_RestrictedInvestments_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RecoverabilityOfVatAmount" xlink:label="loc_cmmb_RecoverabilityOfVatAmount_29"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_CapitalAdditionsMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_cmmb_CapitalAdditionsOneMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:to="loc_us-gaap_LeaseAgreementsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_CurrencyAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_6" xlink:to="loc_currency_AllCurrenciesDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6" xlink:to="loc_currency_EUR_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_6" xlink:to="loc_currency_ILS_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_10" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_StatementScenarioAxis_12" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_12" xlink:to="loc_srt_ScenarioUnspecifiedDomain_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_12" xlink:to="loc_srt_ScenarioForecastMember_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_15" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentDescription_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_OtherCommitmentsDescription_16" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_MaximumPercentageOfPaymentsOfRoyalties_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized_19" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_20" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_21" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement_22" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_RoyaltyExpense_23" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_AggregateAmountCommitmentToPay_24" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_AggregateAmountOfCommitmentPaid_25" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_AdditionalWorkOrderAmount_26" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_LienOnBankDeposit_27" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_us-gaap_RestrictedInvestments_28" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_15" xlink:to="loc_cmmb_RecoverabilityOfVatAmount_29" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockTable" xlink:label="loc_cmmb_SaleOfStockTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CantorMember" xlink:label="loc_cmmb_CantorMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_InvestorsMember" xlink:label="loc_cmmb_InvestorsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AtmAgreementMember" xlink:label="loc_cmmb_AtmAgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseArrangementMember" xlink:label="loc_cmmb_RepurchaseArrangementMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsFifteenPlanMember" xlink:label="loc_cmmb_TwoThousandsFifteenPlanMember_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TwoThousandsSeventeenPlanMember" xlink:label="loc_cmmb_TwoThousandsSeventeenPlanMember_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockLineItems" xlink:label="loc_cmmb_SaleOfStockLineItems_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_20"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement" xlink:label="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_21"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ProceedsFromSaleOfAdss" xlink:label="loc_cmmb_ProceedsFromSaleOfAdss_22"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues" xlink:label="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_23"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfWarrantsPurchaseUpAdss" xlink:label="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_24"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStocksPricePerShare" xlink:label="loc_cmmb_SaleOfStocksPricePerShare_25"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockReservedForIssuance" xlink:label="loc_cmmb_NumberOfStockReservedForIssuance_26"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfStockAdssResveredForIssuance" xlink:label="loc_cmmb_NumberOfStockAdssResveredForIssuance_27"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_28"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsIssuableOutstanding" xlink:label="loc_cmmb_NumberOfOptionsIssuableOutstanding_29"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfVestedAndExercisable" xlink:label="loc_cmmb_NumberOfVestedAndExercisable_30"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfAdssVestedAndExercisable" xlink:label="loc_cmmb_NumberOfAdssVestedAndExercisable_31"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_NumberOfOptionsVestedAndExercisable" xlink:label="loc_cmmb_NumberOfOptionsVestedAndExercisable_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_33"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_36"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_37"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_38"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RepurchaseOfAmericanDepositaryReceiptsShares" xlink:label="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_39"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_40"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts" xlink:label="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_41"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_cmmb_SaleOfStockTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cmmb_CantorMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4" xlink:to="loc_cmmb_InvestorsMember_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4" xlink:to="loc_us-gaap_PrivatePlacementMember_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4" xlink:to="loc_cmmb_AtmAgreementMember_6" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4" xlink:to="loc_cmmb_RepurchaseArrangementMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10" xlink:to="loc_us-gaap_ClassOfStockDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_10" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_us-gaap_PlanNameAxis_13" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_13" xlink:to="loc_us-gaap_PlanNameDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_13" xlink:to="loc_cmmb_TwoThousandsFifteenPlanMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_13" xlink:to="loc_cmmb_TwoThousandsSeventeenPlanMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockTable_1" xlink:to="loc_cmmb_SaleOfStockLineItems_17" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_us-gaap_PreferredStockSharesIssued_18" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_19" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_20" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_ProceedsFromSaleOfAdss_22" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfWarrantsPurchaseUpAdss_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_SaleOfStocksPricePerShare_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfStockReservedForIssuance_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfStockAdssResveredForIssuance_27" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfAdssOptionsIssuableOutstanding_28" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfOptionsIssuableOutstanding_29" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfVestedAndExercisable_30" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfAdssVestedAndExercisable_31" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_NumberOfOptionsVestedAndExercisable_32" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_33" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_34" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_36" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod_37" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceipts_38" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares_39" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts_40" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_SaleOfStockLineItems_17" xlink:to="loc_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts_41" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice" xlink:label="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_9"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_15" xlink:to="loc_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_SharePrice_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_10" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_11" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_12" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_13" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_14" order="70" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ConsultantsAndSubcontractorsExpense" xlink:label="loc_cmmb_ConsultantsAndSubcontractorsExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceResearchAndDevelopmentExpense" xlink:label="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationResearchAndDevelopmentExpense" xlink:label="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_ConsultantsAndSubcontractorsExpense_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_OfficersCompensation_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaap_NoninterestExpenseDirectorsFees_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaap_GeneralInsuranceExpense_5"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense" xlink:label="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_SalariesAndWages_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_ProfessionalFees_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_NoninterestExpenseDirectorsFees_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_GeneralInsuranceExpense_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureTable" xlink:label="loc_cmmb_IncomeTaxDisclosureTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL" xlink:label="loc_country_IL_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_8"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxDisclosureLineItems" xlink:label="loc_cmmb_IncomeTaxDisclosureLineItems_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_13"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ReceivedAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_14"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc" xlink:label="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_IncomeTaxDisclosureTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_srt_ScenarioForecastMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_srt_StatementGeographicalAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4" xlink:to="loc_srt_SegmentGeographicalDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_IL_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4" xlink:to="loc_country_US_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8" xlink:to="loc_us-gaap_DomesticCountryMember_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureTable_1" xlink:to="loc_cmmb_IncomeTaxDisclosureLineItems_11" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_12" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_cmmb_ReceivedAmountOfChemomabTherapeuticsInc_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_IncomeTaxDisclosureLineItems_11" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_CurrencyTransactionLossValuationAllowance" xlink:label="loc_cmmb_CurrencyTransactionLossValuationAllowance_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance" xlink:label="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_IncomeTaxExpenseValuationAllowance" xlink:label="loc_cmmb_IncomeTaxExpenseValuationAllowance_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_CurrencyTransactionLossValuationAllowance_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cmmb_IncomeTaxExpenseValuationAllowance_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized" xlink:label="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_6"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded" xlink:label="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyMember" xlink:label="loc_cmmb_RelatedPartyMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_cmmb_RelatedPartyMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyCosts" xlink:label="loc_us-gaap_RelatedPartyCosts_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyCosts_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationNumeratorAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract" xlink:label="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationNumeratorAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract_3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_4"/>
    <loc xlink:type="locator" xlink:href="cmmb-20221231.xsd#cmmb_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4" xlink:to="loc_cmmb_SaleOfStockValueOfSharesIssuedInTransaction_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.anchiano.com/role/EventsAfterBalanceSheetDate">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cmmb_img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cmmb_img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  W '(# 2(  A$! Q$!_\0
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M.>F0:D\9?ZC2?^PG;?\ H8H\ _\ (JVG^_-_Z->KM#DY[$7ES<MP_P"$F/\
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M"9;/$PYT[(TKXN-*7+:Y]H^,O]1I/_83MO\ T,4G@,A?"EJ20 'FR3_UU>N
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MC((.T<$=C17J-%>4\2V[V.U4D(54]5!^HI:**YS4;L7^ZOY4I12<E1GZ444
M+01GK110 @4#H /H*-HSG SZXHHH 7KUI H'0 ?A110 M026=K(^Z2VA=O5H
9P3111<"6.-(QB-%0>BC%.HHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image00017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %@ ?X# 2(  A$! Q$!_\0
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M)?<%C*?2IWW[M5O0&NUN5VE1M48_==/N'\Z5M')+9U+4>;L7?$V,8_Y9=/\
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M% ')?$#QO8^$;',F)[]P#%;9(R,XW,<<"LSPO\4=&U<V5M>"2SU&X;9Y10E
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M":Z*@4X\LFD>>_%;4)[.]\/PW6H:CI?AV>28:A>V"L)$8(#$A=02BL=W(')
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MK-%-'DKOC<,,@X(R/>I:S_#VE6^AZ)9:;9QQ1PVT2Q@11A%) Y.!ZGG\:T*
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MZ"T1\N/ UQ\"]3\5+C9)XO\ [1+X.=N[:#^;4LMM+J/P2\6>+D 99?%:Z@C
M'.Q6VY_.2OINW^&V@0?#-O R1S?V,T)B9MP\PDMN+YQC=NYZ8HT[X:Z!8_#5
M_!$<<SZ/)"T<C,_[QF8[B^<?>W<CC' J;CL?,<\4VN?!/XB>*88\QW'B5+V-
M^^U7'/\ Y%KZMTVY^WZ7I]V(4=;N!)D(93OW)NX]>N:J>&?A]H.@> 3X0@@>
MXTB2.2.83MN:;?G<6(QSSVZ8'I7)>#O@=I/AOQ'IVIOKFMZE#I98Z=97=QF*
MU)XX QV[<#US1<+'H#1(/O6LB>X3_"DWHIXGDC/^\1_.MRD90PPP!'N*?,+E
M,N.>?_EG<JX_V@#_ "J5;R=?OQ(W^ZV/YU9>SMWY,29]0,5"VGI_RSDD3\<C
M]:+H+,5=0C_Y:+)'_O+Q5B*>*49CD5OH:I/:7"G*M'(/3[IJM-'ALSP.O?<!
MG'XBBR"[-JBLB&:15'D3Y'H_S?\ UZT+.:296\Q I!QD'(-)H:9#:0)+ KR;
MRQ)R=Y]3[U9N5=K:58OOE"%YQSCBH]/_ ./1/J?YFK%(9Y)H6C?$'0M.L(!=
MK.BS>;=N\@F8J4CX4,23@B0$ \LP(XX"^%]3\?:II\<X20NTOER_:$CB$8S$
M=RY4%AM$H(QPS <XS7K58'B#69[*3R;2+YL9,CC@?3UKJIRE5ERJ*N<]6<:,
M>:3=CBETKQ]%8&QMY?)MH;1%0QW"&1Y Z,<,P)!(\Q><CI2ZQ8?$:]M-6MS/
M!]GF>2.)8'C23RV20(0Y' !,>[(W<$J>:V9/$M]8PM<WUU MNGWC(@4#\16]
MH/B6QU>%6BECR3@%6RI/L?Z&M)PJ07-RIF-+%4JCY;M>IS^I:3XB&K">T4S,
MNG)%9R-=E(K2X57W-)'G]X&)3GGIVK$_L/QU<2VU]=3!;Z-%YCE3Y2!< 97(
M1C\\?H#^%>KT5S*LUT1U\B,_P_\ ;QHEC_; 4:CY2_: K!AOQSR  ?RJ:YMX
MQ!*XW!@I(.\]<?6K517?_'K-_N-_*LV[NY:'PG,2$]=HIU,A_P!2G^Z*?2 *
M*** "D=MB,QR0HSQ2U7U*SBU'3[JRN0Q@N8FAD"G!VL"#@]N#0!Q=O\ %/P_
M/9W,Z)J!>WNH;-X!;[I3)+GRP I.<D$?7K577/BKIEOX;>^TFUOKN^>TN;E+
M;[*Q,/DDHQG ^XH<;2:N:3\,-$TQ(Q%<:A*4GL[@-+,I.;;/E#A0,8.".]-N
M_A=HD]OY4=UJEMN6ZBE>WN-C317#F22-N.5W'([CUKI_<7ZF?OV#QIXSU'1=
M!\.3Z;IPN;_6+B&!?D9XXBZ;B2 02>#@9]?2LK_A9\EK/IS7=DUU:S#4#.;&
MWD>1#;2A,A2>F"22?3BNWOO#=E>V^BPS-,%TF>.YM]K8RR*57=QR,,:YZ\^&
M.D7$,*1WNK6IB-V1);W 1B+E]\JD[>A/ ]![\THRI6M) U/H3R_$OP_&]Z0U
MY);V=K'=RW,=LS1!)%5HP&[LVX +US41^)VA@V<1@U,7US=/9"R:U*SQRJH8
MAE)P/E92.>0>,U<'P_T(:;JU@L<ZVFI0P021B4CRUA0)&4/4$;0<\\BJ%Y\+
M]'O-*>PN[W59HY[G[7=R/.IDNI/E +MMXP$4#;MP*%['S#WPC^(UC;W7V2^C
MEFNYM4N=.MHK2!B6\D@'=N(Y&X9QU["N\KB=4^&NCZE936=Q<:@+2>_DU&:%
M)5 DE=E8Y.W( *C&"",GGFNVK.IR:<I4>;J%%%%9E!1110 V3_5M]#3+/_CT
MA_W%_E3Y/]6WT-,L_P#CTA_W%_E0!+114-[<+:6<]PZLRPQM(0O4@#/% $DT
M8EB>-ONNI4_0UY!XO\)QWL\,6JFXC$)(62(@"13U'(]OPKTB#Q'8S2%!YH'E
M)+G;N^\"<<9.0%)/I4[:Q8'<"[-C_IFQR.<D<<@8//M77A,9/"RYH%PGRZ,Y
MOPY92W-[;21QF.TM\8)Z<#@#U[5VU9DFMV,4;L9'VJI88C;YP#@[>/FY(Z4B
MZ]8% 3(ZDJK;3&V1N ('3K\PX]ZRKUG5E<)SYG<U** <@$=Z*Q(*^H?\><GX
M?SJ2XA6=0KYQG/!QFH]0_P"/.3\/YU8H CB@BB_U:*OOCFI*** "BBB@ HHH
MH **** "BBB@ KG;7_DH&H?]@Z#_ -&25T5<[:_\E U#_L'0?^C)*UI;2]/U
M1,NAT5%%%9%!1110 4444 %%%% !1110!#-:PR\O&-WJ.#3X8Q%&$!) [DY-
M/HHN!7T__CT3ZG^9JQ5?3_\ CT3ZG^9JQ0 4$ C!&1[T$X!-8,/B:UEAM91&
MWESC=\IWE%VL<D+G^[SZ4 2ZMX?M+^&1/+1=XPR%<H_U%<Y8^'X](22"UTXP
MJ[;F,2E@QQUSS74MKE@%)$I/4 [& .#MZXQC=QGIFH8?$-H_+AXT6(2R%E.4
MSC@C&>A!SZ5T0Q,XJSU.6IA*<WS+1D6C0ZB)EWO)':KU609)]AGD5O5EG7;$
M9^:4J%9BPB;'RD*>WJ16FK!E##H1D5E4GSN]C6E25./*G<6HKO\ X]9O]QOY
M5+45W_QZS?[C?RJ#4=#_ *E/]T4^F0_ZE/\ =%/H **** "BBB@ HHHH \]\
M9:;XANM=MX](\4)#<<W$%@\?EJRJ1G++G<.G!KN=.DN);&![Z!;>Z*CS8E;<
M%;O@]QZ53T^X^UZQJ#1W9EBMRL!@,&WRGQEB'/W@01[<5JUT5JCE&,&EIY6_
MR_KJ1&-FV%%%%<Y84444 %%%% !1110 CC*,!U(Q56"26."-#;2Y50#@KZ?6
MK=% %?SY/^?:7\U_QILSF:%XI;.1XW4JRDK@@]1UJU10!D_V?:?-C2\;B2=N
MT9R23W]2?SIFHK9V]E-<W6GN(+>-I'*XR%&6/0^YX]ZV:RO%?_(K:Q_UY3?^
M@&J@N:23$W97(([2VN_LEU'9R^0 9HX_E"DNN,XSQP3QTYJ86%J(W0::X5T"
M, P^90, 'YO0"K.A_P#(%T__ *]X_P#T$5=I25FT-;%9)71%5+20*HP "O _
M.E\^3_GVE_-?\:YOQ]X[TGP5:QOJ)>6YFYBMHL;V'<G/0>]><-^T): _\@";
M'O= ?^RUT4\)6JQYH1T(E4C%V;/9[EY9H6C6WD!;')*XZ_6KE>%_\-"6@_Y@
M$O\ X%C_ .(I?^&A+3&?^$?E_P# L?\ Q%7_ &?B/Y?R)]M#N>YUQFG:=/K6
MH:U+/K.K0""_>"..WG"(JA$(XP?[QKS[_AH2T_Z%^7_P+'_Q%9NC?'*UT^34
MF.B2O]KNVN!_I(&W*J,?=Y^[^M;4\%B(*5HZ_(F56#:U/8_^$6/_ $']?_\
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MH83%-M2CI9]NPGCL-TE^9ZI17GW_  LN#_H'M_W^_P#L:/\ A9<'_0.;_O\
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M:RM;3^D=_15*QU2SO0OD3*689"'AORJ[7FRBXNTD>I&<9J\7<****DH****
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MPP.TX/%6*;J1<>6*_$CE:>I-$[,W..W;WJW5*'[_ .7\ZNUF,**** "BBB@
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ML8BDSY4F2.O45.\,DB%'@D*G_9--CM'B)\NWD#'C)!- ]#3T>61XI%D8ML(
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M!7B)/%'A^'4DA,#LS1R1$YV,.HS^OXUNUH>7.+A)QEN@HHHH)"BBB@ HHHH
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M7'_HDUT5<[KW_(V>&/\ KI<?^B36M'XGZ/\ )DSV^XZ*BBBLB@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH " 1@C(-5+*UEMI[EF
MN6DAD8&*'8%6!0H&T8ZCOS5NN9^(FOP>'_#%S+-YOFW"M!#Y7!WE3@Y[8P3^
M%/FLF5"#J245N=-G/2BODO1/$&I:5JD-S87[IM8,H4DHY[AES@CUKZNLWDEL
MX))T"2M&K.H.0K$<BHC+F.K%X1X:VM[DU%%%4<84444 %%%% !1110 4444
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M;&5'L/\ &NDJD<511C-J+N@HHHID!1110 4444 %%%% !1110 4444 %%%%
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; "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image00018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %? RD# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZIHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3-(6H =1
MFHS(!49F [T 6,TF:JFX [TW[2/6@"YFC-4OM(]:47(]: +N:,U4%P/6GB8'
MO0!8HJ(2 T\-0 ZBDS2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%9NI:]I.F-MU#4K2V;^[+,JG\LYIQ
MBY.T5<3:6YI45SO_  F_AC_H.Z?_ -_A1_PF_AC_ *#NG_\ ?X5I["K_ "O[
MA<\>YT5%<[_PF_AC_H.Z?_W^%'_";^&/^@[I_P#W^%'L*O\ *_N#GCW.BHKG
M?^$W\,?]!W3_ /O\*/\ A-_#'_0=T_\ [_"CV%7^5_<'/'N=%17._P#";^&/
M^@[I_P#W^%'_  F_AC_H.Z?_ -_A1["K_*_N#GCW.BHKG?\ A-_#'_0=T_\
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M-UC3=3&=.O[6Z]1%*&(_ 4I4JD5>46OD"DGLR]1116904444 %%%% !1110
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M.BHKG?\ A-_#'_0=T_\ [_"C_A-_#'_0=T__ +_"CV%7^5_<'/'N=%17._\
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MG']:**Z8P43)ML**:S!>IIH+O]T8'J:<IJ.X)-CZ:9%'?/TIZVK-]XDU82U
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M^%2>+?\ GSMO_ E:(UZ$6OWJ^\'";^R&LWMKJ^O3Z>MQ).B7$EP)+IE=3M7
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MQO"GAO3O"^EBRTN(JI.Z21CEY6]6-;-?+YAC/K57FCLMCT*-+V<;/<
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MR6DS;5G7:PQD@C()!&>.* -@7MJ5D87,)6-0[GS!\JGD$^@J1IHDC5WD14;
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M",8/-.:UUB(EB]Q)NCB\QHS&)"VU\@=L!BOX=.] '4T5S,T>N+83L6DDNY'
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MY_"M.VUZTG1B4N(F! "21$,V7V<#O\U+)KUG&K,5N"JN4#+"Q#8^\R^JCN:
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MVT@EAN(_,BDQ@D=P1V(/7Z5T]<M2$J<N61JFI:G"7<(U54?RX',9#*S]0?\
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M?M5Y>7!EP\SP,G+87RR"<C.#FLBX\-7$)B"".[+W:NYFR590LG+CURP&>>U
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MD\]_^?:;_P =_P :!$]%0>>__/M-_P"._P"-'GO_ ,^TW_CO^- $]%0>>_\
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MYC\ZQ=..(5]36:%(N[5\MSVW\?6GR*,R8QDK3N-@%)(1C-/0%<S[%?/UJW!
M*QJ6_*NHKG-((77",_>C./S%='4LI!7QQ\4OC7XKU#Q%J6FZ7>#2M/M+IX46
MV7$CA&*Y=CSSCH,#ZU]@3WEM;S113W$4<DIQ&KN 6/MZURGBCPGX&UJ0S:_I
M>D3322&,S,%1V<=5W+@D^V<UT8:I"G*\XW(JQ<E:+L?&NG?$OQ7IMRLUEJ8@
M09+010I'%)GJ710 Q]SS7UC\$O%>H>+?"]EJ5Y&$,GF)(J9*!D.,C/3/I4EI
M\-?AGIUP9(]%T@2(OF'SI#(%7/4AV( KN$GTS2UALHWM+11\D<";4 [X"CZU
MTXC%0J1Y8Q,Z=.47=LOUC^)T;["DJ<-&XY]CP:V*S/$CA-*D)[LH_6O-.@S[
M+>J)SC-:AC1P/,"D5GV,BM&FW)/>G1WP^V-:7/EQS2,QMEC)8R1J!EFXPIR>
ME4DWL3H5K_"[\?=!P*731_HH/J2:BU:;",@!ZY)JS9+LM(@>NW-:4MR9$],Z
MS+0[8%1PL_G<0RN.F5QC^=:5?A%'<V;?[M6!5.*5P/\ CVG_ /'?\:E\]_\
MGVF_\=_QKE-2>BH//?\ Y]IO_'?\://?_GVF_P#'?\: )Z*@\]_^?:;_ ,=_
MQH\]_P#GVF_\=_QH GHJ#SW_ .?:;_QW_&CSW_Y]IO\ QW_&@">BH//?_GVF
M_P#'?\://?\ Y]IO_'?\: )Z*@\]_P#GVF_\=_QH\]_^?:;_ ,=_QH GHJ#S
MW_Y]IO\ QW_&CSW_ .?:;_QW_&@">BH//?\ Y]IO_'?\://?_GVF_P#'?\:
M)Z*@\]_^?:;_ ,=_QH\]_P#GVF_\=_QH GHJ#SW_ .?:;_QW_&CSW_Y]IO\
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MT?\ "R?%G_08E_[]I_\ $UQ]%'U6A_(ON0>TGW.P_P"%D^+/^@Q+_P!^T_\
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M-+P78RZEXLTBT@SNDN4)([*#N)_(&OHCXC#5-.\(W]SH374MVJ\D2DF-/XF
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M[L.5=C,_X1_1O^@3I_\ X#)_A1_PC^C?] G3_P#P&3_"M.BCVD^[#E78S/\
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M;I,^@JK*F>5^\*6WEZYZ]*YI1Y6:IW(-9DUA'4:1:V4Z>3(Q:XG:,B4#]VO
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M8 QD;1VQZYH M+K6G,T:K=1DR+O7KC'/7T/!X//!J/\ X2#2]I)NT  ))*D
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M497@CMR1^-7AI&GB9YA9P"5YQ<L^P9:4# <^X'% '+R?$&V%GY\6GW$H"EF
M=1@JF^49)Q\BX^I(%:6I>++>PU);:>!HH6M#=+<3.(T; )V+GJ1@9],BM!_#
M^D/;Q0/IUJT,4IG1#&,*Y.2WU)/-27NBZ;?7#3WEE!/,T9A+2+N^0]10!Q\_
MCR;[1;7"V9BT^.">6[5L-)O218PB].-S#G'>KTGC2=)6#:)<JD5H;J??(%=
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M .^A1Y\/_/6/_OH4GVF#_GM%_P!]BC[3!_SVB_[[% "^?#_SUC_[Z%'GP_\
M/6/_ +Z%)]I@_P">T7_?8H^TP?\ /:+_ +[% "^?#_SUC_[Z%'GP_P#/6/\
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MR,<=NOK3O[<L%A@DEE:)9HO.3S$(^7!/IZ T <;J>M>)K(7MS(&2 F9(D:V
M"D"+R\'J2S,ZC.<GZ57%[KMY:S7%O/<RSQQJDDMO;_/&1<C=%C:,LL?7Y>:[
M*[U72[L+9W@66*Y166)XRQD!)_AQ_LYS5J.;3-)L@D!@@@0X6.$#J3C 4<DD
MT <K9W.NV^L0!()_L4VHS+*HMR&:,E=LA8@@+UR/E/IZ5W=8J>([)7N1=,T
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MOFN UB6B"%57]VQE '8;L9]SS5BUU3QA=VY#0W%J6E=E9K0%E3R"P4Y '^L
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M\K35T6TQ+O\ ,D:9&CD9G)+!CD_CP/RK)>UN+J>WO8G>Z#6L*+)M 4YW;F'
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MY+_-JGJ!?^/^3_KDO\VJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@""\^Y'_P!=$_\ 0A4]07GW(_\ KHG_ *$*
MGH *@OWN([&=[*)9KI8V,4;MM#MC@$]AGO4](S!5)8@ #))[4 1VC3/:PM<Q
MK%.R*9$5MP5L<@'O@]ZY?5KR]BUZ989)]BM&5C4M\R[&W8&,$9QDYR*ZT$$
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MXK0CDTG3KS9 8A<,?+95?)C!W/R,_*O!-:,UY;0K"TMQ$BS$+&6<#>3T ]:
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M\(IH4=LUL;;;#*5W(9W^<+]U?O?='9>@]* (+CQ;#FU>U@D-K)>&U>XE7:A
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MNC*1@BF?:_\ IA+_ .._XT?:_P#IA+_X[_C0!+;016MM%!;H(X8D"(@Z*H&
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M,SP[8MGEQGHAYY(YYJGXDLKO4H8;6U*(A8R/*Y.%*\IP#D_-@^GRU?\ M?\
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?#[U9H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image00019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %. <L# 2(  A$! Q$!_\0
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M***\<Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA1117CG2%%%5+'4K*_:865W!.T,C12"-PQ1U.&!]"#32;5T%RW1112 ****
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MX6Z$KYY)'S-SY?0?[W?IVKDOA]H/B:PU*>Z\6:K/>.MG;00JER3$7"?O6*8
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MPD[6.H_X1+P__P! :P_[\K1_PB7A_P#Z UA_WY6MNBN+VU3^9_>:\L>QB?\
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M%%% !4;@F2/AL DY!P!]:DJ/&;C.%X7KGG\J: DHHHI %%%% !1110 4444
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M>G7<SW AG(;(.&Q@BA20.#1IU/!]W\Z@J>#[OYU1!+44_3\OZU+44_3\OZT
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M/FQA2RX[$+R,UEKX!OKZSEL;KQ#97#26[Q1JCLQ9# T:L1N[D@G'%-45NW^
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M@QG SP/>O'Y/!-R^FW-O!XCTJ-[B$QE%=F6*/S3)M0EBP X(/KGH*TM.\%W
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MX?R]@0)D'A0 "/0@&K6@^ ]&T+5;?4=/^U"YAA:$EYBPD#.[DMGOND8Y&.M
M'5UA>._^1.U?_KW:MVL+QW_R)VK_ /7NU:T/XD?5$R^%FXGW1]*6D3[H^E+6
M104444 %%%% !1110 4444 %%%% !2-UI:1NM "4444 %%%% !1110 4444
M%,D3=\RX$@& Q&<4^B@"%I@H(;Y3DA03]['<5EJAU"],9SY*<N?7VJUJT@6%
ML\<$9'45+I%O]GL4SG>XW,3UYH N*H50J@  8 ':EHID\JPPR2R<(BEF^@YH
MW ?16+I?B?3-0C=UE>W"1I*?M2&+*/\ =8;N,'%:":C9/-Y27=NTNSS-@D&=
MN,[L>F.<UI*C4@[2BQ*2>Q:HK,?7+ 26:QSI,MU(T:21,&0%5+'<<\<"K,.H
MV4TR0PW=N\KIYBHL@+,OJ!Z>])TIK5H+HM57O;<7$6!PXY4U8HJ!F=I\Y/R/
MD,."#6B.:S+Q?)O5D7[L@Y^O^<5H1'*B@!]%%% !7/?#_P#Y$_3O]UO_ $-J
MZ&N7L?#>IZ?:I:V/B*>*VCSL0VL3;03G&2.>M;0Y7!Q;MJN_GV)=[W.HHKGO
M[(US_H9IO_ *'_"C^R-<_P"AFF_\ H?\*7LX_P Z_'_(.9]CH-P+$ C(ZCTI
M:X[3M"UN#QS_ &A<ZJ]S8K9")RT2)YK;F(7:O'&<[NO.*[&E4@H-).X1;>Z*
M'B"^_LS0M0O>]O;O*/J%)%?(#NTCL[L6=CN)/4DU]+?$OQ%ID.@ZQH\LMQ]O
MEM&"1QVDT@8LO W*I'/UKYI\JY_Y\-2_\ IO_B:]W)N6$).6ESCQ5VTD=%X4
ML9+J2"V@13<ZK.;%'.?W<> 9'&._(_ $=Z]1\<>%]1\'VD/B3X<ILN]/A5+W
M32"8]1@7NP_YZ#DAAR1D>@KSSP+JL>E:WX<N+RROTCMYI_.<V,^8U88!QMQC
MGZ\5[?\ \+!\-_\ /Y=?^"^Y_P#C=99E5FZBY=5_P;?D50C'E=]RG\-OB3H7
MCW35ET^=;>_7 FL)G EC;V_O+[C]*[.:*.>%XID#Q.-K*>A%?*'BCP-IUW\4
M/[<\/ZTEAI,ETEVP6PNDEMV!!8(HBP<D$CD=:^B#\0?#9/\ Q]W7_@ON?_C=
M>;7H)-.G?7\#>$[Z2.#\;6/V3[19[1FS(:-^[1,>_P!"1^M>9W@S)7H_CGQ-
MIVI:C?/9I>RHULL:.+"X&X[@2!\G^<5YI<2.\F5L]1(_Z\9O_B:\[$4:CVB_
MN/HLHQ%*'QR2^:/I[P)?MJ?@_2;J3F1X%5CZE?E)_2MVO+_AWXRT32?!NG6=
M_->0W,:MOC;3[C*Y8GLGO7IT4BRQ)(A)1U# D8X-;QC*,5S*QY&(</;34'I=
M_F*6 8 D GH,]:6N.US0]:N_&UEJ%GJ;V]BML\0VQ*_DOQGAN#N]>O&*T/[(
MUS_H9IO_  "A_P *W=*-D^=:^O\ D<W,^QT-87CO_D3M7_Z]VJ/^R-<_Z&:;
M_P  H?\ "H+[PYJM_9S6EYXCG>WF4I(HM(E)!]\<4Z<81FI.:T?G_D$FVK6.
MG3[H^E+0!@ 45SEA1110 4444 %%%% !1110 4444 %(W6EI&ZT )1110 44
M44 %%%% !1110 4444 8VJ_/)''_ 'W"G\ZVP,# K%ON+ZV)Z>8O\ZVJ "HK
MN+[1:S0AMID1DSUQD8K,\8+>-X:U#^S6F6[\O,9A&7Z\X]\9KF8CJT.OO>63
MWKV\LEE&XEM\><A5@S-D J1QG&,=ZZZ&&]I'G4DK?\#_ #_ B4K.UB;3? IM
M;7R9KJW9<VP9([<JCB)]VY@6.6;IGI[5<D\(XU.^NK>Z2(W!>2.3RR98'9-F
M5.[;CZKGMFE\'W&LWDETNMNV"F&A:W:/RWR>%; ##'H3ZYYK"%IJIM;I)H;E
M_P"S?*LH-ZLPG!G5C(!_%A HS]:[N:O*I)2J*^E_G;T\B+1LK(OGP$)K407-
M\=K7!G?R4*\F'R\#+$]0"<YSTK7L- N8->BU.6Z@#" 13+!"4\\A< MEB!CM
M@ ]LXK(GGU2Y$ZW(NWG34(A]G-K^ZCB$XPR-CYODY)R<>U0'4_$P2^;R[IFC
M&Z1/LH B(F VQ\?.#'D]_P ^*4EB*BLYKM]]O+\?2W0/=70] HKAO[4UR2\L
MI%6\^SR7TJ& 6I5S%O 1B2I 4+G(."1WKN:\ZM0E1M=[FD9<Q2U91]F5L<JX
M(_'C^M2V;9C%1ZN<6+GW7'YBGV1S$O7\36!19HHHH **** "BBB@ HHHH *Y
MKXDZW<>'? NL:G8;/MT4.VVWC(\YR$CR._S,O%=+6=JTFFR1"#4$AN!N\Q8&
M02%FC^?A><L, COTII-Z(#B?"_CZ_P!3\9)H4VG1/:;[RW6_2;YI&M3&LDAC
MQ@*7<J.>HKFV^+%YI/B/Q0U_!%?Z1 ]X;1()E$D(M1%&0XV\*\KD!B3SVP*]
M6TJRLDG:>WTF*T9 RQ2^4JLRR$2/C'(RQR0<$D9-+'X=T6/[7Y>D:>OVQ2ES
MBV0>>I))#\?,,D]?6AJV@'DFI?%?58H[:YN+:WMTLKR]-W%8SB=;N*VA4$*[
M*-H,\R+NQQM-6;KXNZM;Z;<.=$TZ6ZMWOO-,5^3 ([6)&D</LR<NXC QUKU"
M/PYHL4'D1Z1IR0>4\'EK;(%\MR"ZXQC#$ D=\<T+X;T-;;[.NCZ<L&QHO*%L
M@78Q#,N,8P2 2.Y I <!J'Q5GM;+6-132838Z?-'8K$UR?M,MVYC&-@4[8P9
M,%NIQP.17=>"]5OM;\.6M_JFG_V?=2[MT&_<,!B PR 0& !P0",X/-3W'AW1
M;B6]EN-(T^62]4)=.]LA,ZCH'./F XZ^E7[2V@L[:.WM(8X+>)0J11*%5 .P
M X H EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&ZTM&
M* &T4[ HP* &T4[ HP* &T4[ HP* &T4[ HP* &T4[ HP* ,;6%*J''52&'X
M5KQN'C5UZ,,BJ][$)(R",U%I,F(C >#'T^G^?Z4 7Z*** ,/4-3OCKJZ9I<-
MLTB0"YFDN'8#:6*A5 '7@\]*K2>,+)-X,%T94+*\84%E<2B-4Z]68\>W-:NH
M:-8ZA<Q7%U"QGB&U9$D9&VYSM)4C(SV/%4+7PU;EM5?4A%<R:C*KR[$,84+]
MP#G.1C.<]>:[82PSBN=;?CW_  UZ=B&I7T*UUXI^PW=R+^VDBB2&!DAP#*9)
M'==IP=O\([UN:1J$>J:?%=PI+&CY&V5=K @X.?RJJWA[3'B='MV?<B(6:5RW
MR,64[B<Y!).<YK1M;=+6W2&+?L08&]RY_$DDG\:SK2H2C^[33_X'^8TI7U):
M***YBC.UILQQ1#J[Y_ 4"^MK2>SM9Y56XNF*PQ_Q/@9/'H .M0%OMFH,XYCC
M^5??U-4]3\*VVH>);#6'=UE@MY;6158C>CC P1R""3R/6KIJ#?ONRU%*_0Z2
MJ&OZBVDZ+>7Z6LUVUO&9!!",N^.PIW]G1^9O6:Z7Y]^!,V/N;,8],<X]>>M9
MVN%-$T6YU"2;4[A+2-)#'$^]W\O\/XL_,?:IERJ+=[&M!.52,>6]VM._E\SF
M]/\ BOH%QX/DUN>7R9HODDLMP,OF=E7U!['ICKC%=-X+UUO$OARTU22RFLFG
M!/E2_P P>ZGL:^<V\%:_K.GW7C*'38U@:X^TI8D$O+'G<6 [C\B1DBO?/!=S
M;>*/#5MJ7DW]NEPLJM!+*Z@;N&"X(RHQ\I'3MBN'"UI5)VJ.VFFF_G_P#Z?/
M<LPF#H<^%5VY6E[U^1V^#3?K[WE8ZPD#J<56>_M$8*]S"&+(H&\9RWW1^/;U
MJ-=+LQ)YGD!GW^9EB6^;9LSS_L\5/!:6]NBK!!%&JJJ@(@& OW1^':N_W3Y/
M4J+J\$D8:UBN;@%0X\N(C(+[>IP,@Y)'7 S2O+J4J.(+>"W;#A6F??A@V%.%
MZ@C)Z@CBM"BGS);(+,SY-/>XWB[NYI(V,@\M/W8V, -IQR2,<'(/-6H+:" N
M88D1G;<Y Y8X R3W. !GVJ:BDY-Z!8****D84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% ",,BLNZC>"831=1^M:M,D0..: &VTZ7$8=/Q'<&I:RI()+>7S(#@]Q
MV-6;>_C?"R_NW]^GYT 7**.O2B@ HHILDB1+F1@H]S0 ZL[4KHDFV@/[QN'8
M?PC_ !HDO'F<);@A<X+G@TZTLA$H)Z]3GK0 ZQMQ%& !5VD48%+0 4444
M     X %(H"J H  X ':EHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** $90:JS6BOVYJW10!E?9)8O]3(R^P/'Y4X->+QYA
M/U _PK3Q2;10!F$7;GF5@/08'\J6.QRVZ0ECZDYK2VBEQ0!#% J#@5-110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image00020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #> ?D# 2(  A$! Q$!_\0
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M89'YUH5X4/"?BBP\3Z%/;ZAJFI7'_"/WD<$US"B)93F-0B950!D_WL_=K/\
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M+E?8Z&BN?/BW2PS*SR CKE*?IGBG3-1OI;.&1TN(P"5E7;G/ISS1=!RLW:*
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MR+^55]0N+1KZS:^)NM24XCC@&02>^*C97O8:W+%YHMA+.9IB\L<0"QB5OEB
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M+"&XMO/O+N)IA.!LLP 7C/?GN*;:Z=/#J/VR_:,2LNV-8LA5'H5/&:C\1-+
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M47[#2,6UNX[WRX+*^^U7$L?G"WF&50GJ ^.@J&\N+?2M"*P06D=VVY1 LN\
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MM'RQQ],^_O7NQ_9A\7A-D>J:*%ZG]Y)D_P#CE*O[,7C%5VKJFA@'D_/)D_\
MCE*R;U,&SPC>I=?.564#"J. /KBA65)@NPO(I^4KTKZ D_9K\7R1+&=2T-$!
MW;$:0 GU^YFHO^&9/%PX&JZ.,'J)),_^@4N6[;-E)1=[GJ/[(P<?#2\,@P[:
ME(2,]/W<=>W5YS\"? M_\/O!]QI.JSVT\\EX]P&MV8KM*J.X'/RFO1J9A-WD
MV%%%%!(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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(I#"BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image00021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #0 NT# 2(  A$! Q$!_\0
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MK*Q&XK\S2@$%$'4$FKOA_P FYUZPUC49[@7MSX-5S>&1T9YE8ASGH& P3^=
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M'/=;9[O28V:W<Q<-& ?,<C*1]F;J,XX-9-O"EY)H0U:66XCTWQ=/;*^^7;#
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MMRLDARV-H'''2M_'/;GK2T4 )MZ=/RHV\=ORI:* $QTSCUZ=Z3;].N<XIU%
M#=G^<4;<#MQP..E.HH :44@<*<>HI=HST'KTI:* $ Q2_C110 C*#U _*C'I
MQ2T4 )CU[=#2T44 %%%% !1110 4444 %%9NOZUIV@:>U]K%Y%9VBLJ>9(<
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M6K1^'+V:RU=8#):RQ8W;UYV_\"QC\:X7X(^"KQ8=/\;>,;BZN_%UY9&%S<
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MJOO0!ZW1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %<#\0/^1Z^'7_81N/\ TEDKOJX'X@?\CU\.O^PC<?\ I+)0!WU%%% !
M1110 4444 %%%% !1110 4444 %-DC21&210R,"K*>01Z4ZB@#C/A=X"T[X?
MZ3?6.F'>+J[DNF?;@@,?E3Z*N!79T44 (1FC'UI:* "N)^,7@I/'W@*_T4>6
MMXP$MI(_ CE7H<^AY!]C7;4$]* ,+P/X=MO"GA'2]$LU4164"QD@8WMU9OJ6
MR?QK=I%8,,@@\XX.:6@ HHHH **** "BBB@ HHHH *P/'7_(MR_]?%M_Z/CK
M?K \=?\ (MR_]?%M_P"CXZ -^BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ",T@4 ' '/7WI:* "LWQ'H]OKV@ZAI5YGR+R!H7P<$9&,CZ=:TJ3=
MSC% 'F7P \ 7/@'P?-;:JWF:M=7#2SOOWC:"5C /^[S]6->G4U6R<"G4 %%%
M% 'GGQ?\7>(?!NFQ:EHVGZ7=6 ^29KN9UD\PL BHJ EB:7X.>-=4\<:'>WNL
M:=#8307'DK'$) &7:#GYP#WI/CDUP?!.+'^T!.E[;R%M-@\ZZ1!("7C7LP]:
M7X.74UWHEZUQ?^);YA<8#Z]:BWE7Y1PH &5]_7- &-XQTJZ3XBZK=6_]HSFY
M\*W<8V@R+&WF( L:\ -C)QG)KS:/39/["TR$:7--I,)N8-,FMM->V:>\(A\J
M=XARK@B1=YX.TU]1A<=S2T >)_#6RU"V\;ZW(EE<KK"07@OYKE72">9I]UOE
MNC?)G!7.%./:NQ\+R^(9?'$Q\3VFF6\HTT>5]@G>12/-YW;E&#TKNL>AK _Y
MG_\ [AG_ +5H Z"BBB@ HHHH **** "DP*6B@ HHHH **** "BBN?\>^)H_!
MWA6]UV>RN;V"T :6.WQO"YP6Y[#.30!T%%<I\-?&D'COPQ'KEI875E:RRM'&
MMSC<X7C<,=LY'X5U= ",<CBN+\+?$OPOXJUV;1M#U)[C485=I(O(D38%.#DD
M8&#65\?-+\17_@.6?P;?WUMK%G*LJ1VCE6G4_*R<=>#G\*7X1_#*V\#R:AJ4
MMY->ZSJD<37<TW+!PN7P>X+DG\J /21THH%<9\1/B1H'P^%FWB1[J)+O<(GA
M@:125QD$CH>: .SHJKI=]'J.GVUY"KK%<1+*@D4JP##(R#T//2K5 !1110 4
M444 <O\ $6[UNP\,W-[X<N=/MKBU!FFDOHVDC$2J2V%4@EN!BN'^"_C#QSXE
MU>\3Q?I3V>GBV$MO*=.DM@[$C'S,QSQSBN_\>S>7X1U>-)4BN9[66&W#,H+R
M%#M5=W!8]A7G?P-TZZL+Z1;K2?&5CMLU3=K5\)[=B".(U!.#Z>U 'L@/'/\
M*C</6N,\::WJ^E:]X7@T^*U&G7VH+;7<TAS)RK$*B_\  >6S[5Y_:_$#Q3=Q
M>4MSI\4NKR0FPD$&?L*O</$0PS^\.$R"<<DCM0![GN'J*X+X@?\ (]_#K_L)
M7'_I+)7*>'?B#XBU'7-%>=[$6$DUOI]U;K%\TLLJ2,9D?/ !087N":+_ ,>Z
M+XM^)7@6RT@WQGM;^Y:3[19R0K@6T@X9@ >?2@#VFBBB@ HHHH **** "BBB
M@ HHHH ***H:]J:Z/H][J$D$UQ':PM,T< W.P49(4=S0!?HKS/PO\9_#6O\
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M=6$*P6[*S;5500ORYP6 ) 8C/)YK'\?@?\)U\.N/^8E<'I_TZR5WU<#\0/\
MD>OAU_V$KC_TEDH [ZBBB@ HHHH **** "BBB@#G/&_B_2/!.DKJ?B&>6"R:
M40^8D3288@XS@<=*N>$_$&G^*="M]7T>226PN 3$[QE"P!(S@\]JK^.O#%GX
MQ\*ZCH6HEEM[R/874 F-@<AAGN"!6AH.F6VBZ/9:98H$MK.%((U Q\JC H O
MTC*K*0P!!&"".HI:* ./L/A_HFG>!]0\*V5N4TN\$WF*WS$F0DD_AD8^@J_X
M!\,6?@WPCIN@V+;XK./:9"N#(Q.6<CU))-;%]?6]A;&XO9D@A7JSG'X#U/M6
M-]NU35_^07#]@LV_Y>[I/WC#U2(_S;'T- &IJFIV>FPK)>3K&&.%7JSGT51R
M3]*R_,UC5O\ 4*=(LC_RTE :X<>R_=3\<GVJ[IFAVEC,;CY[F]88>ZN&WR'\
M>P]A@5D_$[5=9T+P/JVJ^&H;>?4;*+SUBG4LKHO+\ @YQD_A0!M:3I%GIH8V
M\1,S_P"LGD)>23_>8\G^5:-<7\']=USQ/X#T_6_$L%I;WE\#+'';(RJ(B?E)
MR2<D<_B*[2@ I&SVI:* ,?PWX<TWPW:3VVC6PMX9[F2ZD4'.9'.6-;%%% !1
M110 4444 5-6L+75-/GL=1@2XM)U*2Q/T8>AKYCT7QKJVA:MI]]I<.G#2M\P
M?3+?7I9SY49(8F%]VQ@!D#CFOJ9NU?+?A;QWI-KXY^WZY-H++JDT\%];0:&T
M<EL 2$S,!^\W$*#GKG- 'T=XAT:T\3:'-INH"0V=P$9MC;6X8,.?J!6/>?#W
M0KW6-1U"ZAN)'OXI(I83,?*4NH1Y%7LY55!;VKK(SE01TQQ3\4 <)_PJ_P /
MF&PCE^WS-:R-(\DETQ>ZW.KLLQ_C7<BG'^R*U?'5G;'1)+@V\/VC[1;'S?+&
M[_7Q]^M=+BL'QU_R+<O_ %\6W_H^.@#?HHHH **** "BBB@ HHHH HZUJEEH
MNFW&HZI<+;6-NN^65^B+ZFJ'A7Q9H7BRWGG\.:G#J$$#B.1X22%;&<'(]*T=
M7L;?4].N;"]C$MM=1-#*A'WE88(KF?A3X(M?A_X/MM#M)//9)'EEG*[3*['K
MCZ8'X4 =E1110 R6-)8W21 R."K*1D$'J*X7X3?#>Q^'=KK,=DRR/J%Z]P'V
MX*1?\LX_^ C/YUWIK,U36;?3V6)]\]W(,QVT"[I'_#L/<X% &D3GBL.ZULS3
MM:Z)#]ONE.'?.V"$_P"T_K_LC)^E1_V;?:N=VM2&VM3TL;9\9'_320<M]!@?
M6MRVMX;6!(+:)(H4&U410 !]* ,BTT$23I=:U-_:%VIW*&&(8C_L)T'U.3[U
MN444 %%%% !1110 4444 <+\1?'T/@R[TRWN-"U74QJ+&.-[1%9 ^1A"6( )
M[5)\+?%DWC3P[)J5SH=QI$BS/#LF4#> 2,J?PP?<&LOXIW/B.YU?2M!T&RTZ
M>TOX9Y)AJ-LTL%PT>"(&9>(\C)#'N!BI/@Y=W$ECJ^GMHT^BZ?IUTL%G93QD
M/$I0,XW'.\;RV&!P10!F>.O$OB+0_%VMB&YA:QA\-7%]9VL<?(E21%\QR>I^
M8X XP*Y6\\5^(+5/L,?B>1TT_P"U7*W[)$3=M&L#+ _&",RL#MP>!Z5[O-I=
MC/>?:IK6&2X,#6QD9028F.2G^Z2!Q6:O@[PXMC960T33_LEE+Y]M%Y"[8I,Y
MW*,<&@#S_P  ^*=7O?$^HO?7DE_%-!>3_P!F1HNZU,$XC1$Z'++V8\FNC\+:
M[+KOCB>2;1=6TGRM-"A=1B5#)F7JNUFZ=_K756.B:98:C>W]C86UO>WI#7,\
M<85Y2.FX]ZS\?\7 _P"X7_[5H Z&BBB@ HHHH **** "BB@]* $W4HKR3X\^
M(/&_AR'0KCP0UNR7EVMC-'+!YI$CG]V?8<$'\*]3T]9TL;=;R1);I8U$KHNT
M,^/F('89S0!8KD?BAXEO?!O@R^U[3]-3439X>6 R;,1YP6!P>F?RS779'K4%
M[:V]_93VEW$DUM<1M%+&PRKJPP0?8@T >1W7QCFTCX6Z3XTUSPS<K;ZA,4$-
MM*&\M#G8[%@.&QQ^%>E^$]7;7O#NG:LUG-8_;85G%M,1O0-R,X]L&LSQ9I_A
M:Y\-'P_K9M4TLHD2VN_# (05"@<\8'05/%KDTT:QZ)HUY,BC:KS+]GB ' QN
MY_(4 =&6Q3994BC:25E1%&2S, !6$+7Q!>$&[U"WL(SUCLHO,?\ [[?C_P =
MK"\53^#O!\=M>>,;XGSW*13:@[S L.< 8('Y"@#?G\5:9O,5FTVH3?W+.(R_
MJ/E'XFF-<^(+W_CUTZUL(ST>\E\Q_P#OA./_ !ZK_A_4+#5M'M+_ $9TDTZX
M020/&A164]"!@5I4 <__ ,(]<77.K:Q>W(/6*$B"/Z87G]:S?%Z_\(?X/U/5
M?#&BV=Q?6<1F$+C#2*O+?-]XG&3794V2-98V210R,I5E(X(/:@#BO@]XJU3Q
MMX+M]?UC3H=.-T[&WBB=FW1 X#'/J<_ABNWJOI]E;:?9PVEC#'!;0H(XHHQA
M44= !Z58H **** "BBB@#E_B)XCO?"OAR75=.T2XUIX6'F6]NP5U3!R_0Y ^
ME<U\*O'VM>,]:UR+4-#BL=/M/+,$T5VDPRR*=A*\$\[LCIT/-;?Q2D\0Q^'X
M%\*O/#<RW<44]Q;P+-+!"QPSJC<-CC/MFN=^'=IXCTKQS>6&K:7:VMJ;-IKB
M]L85C@U"Y\P 38'*N4^\I[CB@#U-?NBEH'2B@ K@?B!_R/7PZ_["5Q_Z2R5W
MU<#\0/\ D>OAU_V$KC_TEDH [ZBBB@ HHHH **** "BB@D#K0 44R214C9W=
M451DL3@ 5A-KDU^[1>'[?[5@X-W*=MNGT/5_^ \>] &U=7,-M;O-=2)#"@RS
MNP4 ?6L/^UKW5.-!M@L!X-]=*5C^J)]Y_KP/<U+;: CSI=:Q.VI72G*^8-L4
M9_V(^@^IR?>MS% &-8Z#;V]P+N[D>^OQ_P O%P<[?9%^Z@^@KSZ_\>^+;?XW
M6W@N/1M/?3)T%TMZ2^X6X'S-UQN# K]<>M2?'_6?&GA[0],U#P-/&K-=+:W$
M+VZR[C(0$89' #<?\"%>AZ3I[1V]E<ZH(;G6H[4037:QA2Q."P&.BEAG% &I
M39$62-D=0RL"&4C((]*YG2/'GAC6=:;2-*URSNM34N#;1OEP4^]QCM73J<B@
M!EO"EO"D42)'%&H1$08"@= !VJ2BB@ HHHH **** "BBB@ HHHH R_$^JG0]
M!O=4%G<WWV6,RFWM5W2R =0H[FO.? WQ5_X2[Q;::=:>$]2M=/N;0W2WDT:8
M7#$9."<+QCUSQ7=?$#4M1T;P9J^HZ+;&YU&V@9X8Q&9,GUVCEL#)P.N*\P\*
M-K>D>/M'^V:':I>ZP6-WK-C:ND%Y;>673<I/[F4/C((YH ]OQ1110 5@>.O^
M1;E_Z^+;_P!'QUOU@>.O^1;E_P"OBV_]'QT ;]%%% !1110 4444 %%%% !1
M02!UIK, I.0 .I]* '55U"^MK"V:>^F2"%>K.<?@/4^U94FMS7[M#X?A6Y(.
M'NY#BWC^A_C/LO'O4UAH<<=TEWJ$SZA?KRLTHPL?_7-!PO\ /WH K>=JFM'_
M $-7TRP;K<2K^_D'^PAX0>[<^U:>E:5:Z8KBVC^=^9)7):20^K,>37.?%K6-
M<\.^ ]3U?PQ%;37]BHG:.X0LK1 _/T(Y R?PI_PHU;7->\":9JWB>.WAU"]0
MSB*!"JK&Q^3@DG.,'\: .OHK)N/$6C6^H?8)]8TZ*^W!!;O<HLNX]!M)SD_2
MM4')- "T444 %%%% !1110 4444 <CXU\3ZKH%Q:1Z5X6O\ 7%F5BS6TT:>6
MPZ*=QY)'/'I6?\,+K6M2N?$6IZYIMYID=W>(UK:W,RR&-%B53C:2 -P/%4?B
M;9ZK:>,/#?B6PT677[;3DGB^P0SB.2.5\8F0,0'( (QZ'-6_A!I5[I^FZO=7
ME@=*AU/4'O(-,,XF-J" &RPX!9@6*C@9H ]!HH)Q2;A0 M<__P S_P#]PS_V
MK6_D>M8 _P"1_P#^X9_[5H Z"BBB@ HHI-PH 6BDR,XK/U'6]-T[B\OH(FZ!
M"V6/T4<D_A0!HT5SW]O7-UQI.D7MP.TLX^SQ_P#CWS'_ +YH%GXAO#_I>HV]
MA&?^6=G%O?\ [[?_ .)H V[EHECWW!C5$.[<^,#'?)Z5C2>*=-W&*R,VHRCJ
MEE&9?_'A\OZTZ+PMIAD$EY'+?S#G?>RF7]#\H_ 5I7=S9:38//=36]E9PC+2
M.PC1![GH* ,HW/B"] ^S:?:Z>G9[R7S'^NQ./S:D_P"$>GNQG5]7O;GUB@;[
M/'^2\_F:TM(UG3-9CDDTC4+2^2-MKM;3+(%/H<$X-7FZ4 9MGI6EZ/&TEK:6
MMM@?-,5 ./=CR?Q-<'X&^+4'B_QQJ7AFWT*_MI].$GVBXDD1HUVMM'0]^U8/
MQITCQGJ_C30-&T;4YXO#&N(]IJ$2PJZPA02[$D9&Y>G/45J_!3X>#X7^#]2E
MNXS=:O.\DT[1'>SQH6\M%]]O/U:@#U=>G%<E\4_ ]I\0?",VB7LA@W2)+'.%
MR8V5LY'U&1^-9GPO^*&E_$5M0_L6QU*".QVB62ZC55W-GY1@GG@UZ#0!7T^S
M@T^QM[.TC$=O;QK%&@'"JHP!5BBB@ HHR#T-% !1110 4449Q0 44 @]** .
M:\>ZQJ>@Z&;W1;&RO9UE572[O%M453QG>W&<X&/>N4\$W'B?6?B+=:AXDTJP
MTI;+3OLC06^I)<N'=PX+*/N\#C(YK4^,FCS:MX7@DMVL"^G7T%\(-0D\NWN=
MC?ZIV/ SGC/?%9GP^LM6U#QYK/B+7]/TO1K[[''926%I=">9N=RR3$< XP%X
MSC- 'IP.%]:H?VUIFZY7^T;+=:_\? ^T+F'G'S\_+^-7^W>OFV/0M0C_ +:%
MQHFHW>DKJ45YJ23Z8B32G[0Y>-"G-Q'M*MSG^E 'T4+VW,\< GA\Z1/,CC\P
M;G7^\!U(]ZXKX@?\CU\.O^PC<?\ I+)7FOA/PUJEKXJ\,?:=$OH[U&M9XKIT
M)6VLTCE#PM)_"<LH*=\CTK?U"S\96WQ*\#-XMU32+VR;4+@6\=E;-$Z-]FDP
M6))R,4 >TT444 '/I7/1>-?#4NN?V-'K>GOJPD,1M%F!EWCJNWKG@UT->=6?
MPPT^U^,=WXZ7R]TUH(UAV_=G/#2?BH ^I- 'HHSZ8HI-P/2L6\UZ%+EK33HY
M-1OEX:* _*G^^_1?Y^U &RS8SQTK#N-?$\S6^B6YU&X4X=U;;!&?]J3I^ R:
M8-'N]3PWB"XWQ'_EQMR5A'LY^\_Z#VK=@@BMX4A@C2*)!A408 'L* ,2/0'O
M76;7[@7K Y6V0;+=/^ _Q?5L_2MF2$&W:%&,0*E5*8&SC@CZ5-4%XDTEM*EM
M((9V1A'(5W;&(X..^#SB@#R7X'V?CF/7O%)\;:S>7MI9W)L;-)E 67!W&48
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MZ#J'CS_A>FH>'[J\@'A.S@^VQA+5%W1/Q'&"!U#9'_ 3ZU['7D'A+Q9XVO\
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MU9-4M3?6T5E,+58"R)<Q*[$+P07#8]A[U[;0 4444 %%%% !1110 5@>.O\
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M]]"CSXO^>L?_ 'T*\S\+_"3PB=$@.J^&;87FY]^\OG&\X_B],5K?\*C\!_\
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M);I)';%S&>QR3UKUJN;L_!/AB&.!QX;T9)D"D,+&(%6'?.WK71@8H 6BBB@
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MJ:C\/K:\FO&CU_4;:"43&V@C>/;:22\2.AQG)!88)(&XUG?\*'\!?] Z[_\
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M=];+-/%!+;*6)QY<@ =2.A!P*C\+^&]+\+Z;]AT2V^SVY<R$%V=F8]RS$D\
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MA7:,GJ?K6A0 4444 >4Z]XDU_3_B[8V+27/]E7%Q#:PP1Q(T#QO$[.[O]Y9
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MJ$DGK@G)[T ;=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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E1=JN<#+ =@?2K% &** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image00022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #4 ?0# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHHH ****  G%<[J'BO3K+Q+#H<QG^VRQ&9<)E-H&3S] :Z%AFF-!&T@D*(9
M,!BHR!]: .*7XE:"='AU(?;?LTMU]D'[GY@_N,]/>NWB;>@/KS40M8-@7R8M
MH;<!L& ?7ZU,%QTH 6BBB@ HHHH **** "BFNVP$G  Y)]*J66J6-\S+97MK
M<L@RPAE5ROUP>* +M% HH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\77O\ 9WAO4KI;VWL'2%A'
M=7#8CB<\*6/3&2*\F\.Z"CH/$NJZYI=MJT%PIAN[NYM[H31 #<LK(%4G.[:R
MX9>.3TKUWQ/>6>G>'M4OM3B$UC;6TD\\90/O15)(P>#P*\UU;P[X TKP[I_B
MNZ\$:7MNGMF>-8D/E>>RJ#C[K8+C@#UH ]1TG4;/5K"&^TVXBNK.8;HIHVRK
MC)&0>_2KG YJ.W@CMX4A@C2*&,;41%"JH'0 "L;QIK\7AS0I;V3RO,8^5")F
MVQF0@XW-V'')H W>#5#2O^/K4_\ KY_]D2FZ'J"ZCH=EJ"%'%Q LW[HY4Y .
M!ZTS0Y?-DU"3RY(]US]R1=K#Y$[4 :M%%% !1110 4444 %%%% !5/5=0MM+
MM&N;Z4Q0*0"P4MR?8 FKE'- ',_\)UX='6_;_P !I?\ XFC_ (3KP[_S_M_X
M#2__ !-=-10!S/\ PG7AW_G_ &_\!I?_ (FC_A.O#O\ S_M_X#2__$UTU% '
M,_\ "=>'?^?]O_ :7_XFC_A.O#O_ #_M_P" TO\ \37344 <S_PG7AW_ )_V
M_P# :7_XFC_A.O#O_/\ M_X#2_\ Q-=-10!S/_"<^'?^?]O_  &E_P#B:/\
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M>H)!_ XJEHLT<\NHR0.DD9N>&4Y!^1* -6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\;_ &CP#8Z#QG]]+_Z"*]DKQO\
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MCDU%9)FE87/+L "?D3T&*U.!TK/TOBZU/_KY_P#9$H T:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQS]H[_CQT'_KM+_Z
M"*]CKQS]H[_CQT'_ *[2_P#H(H \/_*CZ?G1]/I1_G% !1S1_.C H */PHS[
MT4 -D_U;?[IK[$\-_P#(NZ7_ ->L7_H KX[D_P!6WT-?8GAO_D7=+_Z]8O\
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M=0":@T/SC)J'V@1B7[3\PC)*_<3UK5&!6?I9_P!*U/\ Z^?_ &1* -&BBB@
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MVNUN^Q\=QF@"XL@\GS#\J[=V3V%9VASQW$NHR0.'C:YX9>0?D2KUI;_9K6&
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M444 %% HH **** #O11WHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %VE_P#017LE>.?M'?\ 'CH/_7:7_P!!% 'A_I1]>M'TH^G2@ _ 44?2C\J
M <^] H^N:,8[F@!LG^K?_=-?8GAO_D7=+_Z]8O\ T 5\=R?ZMO\ =-?8GAO_
M )%W2_\ KUB_] % &C1110 4444 %%%% !1110 =Z*.]% !1110 4444 %%%
M% !10** "BBB@ HHHH **** "BBB@ HHHH *CEE2%#)*ZH@ZLYP!^-25S?C;
M3;C4;.R\BRCU&*WN1--92,JBX7:PQ\WR\$@X/'% '1*V5R,$=B*H:5_Q]:G_
M -?/_LB57\+:?<:;X:LK*Y*)<11;2$.]4Y.%!/4 $#\*@TZUU#[1?XU +^_Y
M)MQ\QV+SUH Z#-&1ZUF_8]1_Z":_^ R_XT?8]1_Z":_^ R_XT :61ZT9K-^Q
MZC_T$U_\!E_QH^QZC_T$U_\  9?\: *?CP_\45KG_7E+_P"@FODE?NCITKZX
MU31[S4=.N;*YU(^3<1M$^VW4':1@X.:X(?!'1\ ?VGJ''3A/\* /!<COQ[4?
MSKWO_A2.C_\ 04U#_P =_P */^%(Z1_T%-0_\=_PH \$^F11_G->]?\ "D='
M_P"@GJ'_ ([_ (4?\*1T?_H)ZA_X[_A0!X+0/;]:]Z_X4CH__04U#_QW_"E_
MX4CH_P#T%-0_\=_PH ;^SK_R+NJ]#_I@_P#0%KUK-<?X2\%_\(I9SVVE:G-Y
M<TGFOYT2N<X XZ>E;OV/4?\ H*+_ . R_P"- &GD>M&1ZUF?8]1_Z":_^ R_
MXT?8]1_Z":_^ R_XT :>11FLS['J/_037_P&7_&HKR'4H+2:9-15FCC9POV8
M<D#..M &Q1D>M9,-MJ4D,;MJ0!902/LR\9_&I/L>H_\ 037_ ,!E_P : -+(
M]:,BLW['J/\ T$U_\!E_QI/L>H_]!-?_  &7_&@#3S7C?[1W_'AH/_7:7/\
MWR*]2^QZC_T$U_\  9?\:Y[QAX&7Q9%:QZMJ4VVV9GC\F)4Y(P<]: /E_@]:
M*][_ .%(Z/\ ]!/4!_WS_A1_PI'1_P#H*:A_X[_A0!X)QWHKWO\ X4CI'_04
MU#_QW_"C_A2.C_\ 04U#_P =_P * /!/QYHKWK_A2.C]M3U#_P =_P *7_A2
M.C_]!34/_'?\* / I/\ 5O\ 0U]B>&_^1=TO/_/K%_Z *\W;X(:.5(_M/4.1
MC^#_  KT&TTR^M;2&WBU/$<*+&H-NI. ,#O[4 ;&1ZT9'K6;]CU'_H)K_P"
MR_XTGV/4?^@FO_@,O^- &GD49K-^QZC_ -!-?_ 9?\:/L>H_]!-?_ 9?\: -
M(45DJ+ZWU"U2:Y%Q%*65@(0N,+D'(/M6M0 4444 '>BCO10 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ':D Q2T4 %%%% !1110
M 4A..U+29% %-M5L!#),;VT$,4GE22&9=J/G&TG/!R1QUJVK>@KY;U:P\0/X
M/\9-#-9+H1\6,9+1[-S<2-]HB^97SC;T/W3T/-:VJ>*_&B_%'5(_[6:V^RW\
MD<&C[)&:YM G#1QB(J2PY$A?@]1B@#Z"U?5;+1["2]U2YBM+2,J'FE;"J20!
M^9(%)JFKV.E6RW&I74-M"TB0AY&P-[G"K]23@5\KVOB7Q!KW@WQ=;ZE?7>HV
M)MM/O($F+2O#(UTH="QC3YAC#* 0".#6EXTT^:'Q/XWLFU;6!?3ZWIL]O#(-
MZ^4S1?OU&W!V'Y1S@ #(/6@#ZDW=>* <U\^WWB;Q)X2L]6U6XU/4]5TWPSKL
MEK<1W&W?<VLL*[2Q"@,4D9<$=B:]>^&\&J0>"=)_X2"ZENM5E@$]S)(<D._S
M;?HN< >U '2T444 %%%% !0>1110 @&*6BB@ HHHH **** "@G%%(: * UK3
M&U#[ -2L?M^<&V\]3(#C.-N<_I4EOJ=E<WDUI;WMK+=0_P"M@CE5GC_WE!R/
MQKP.U\$W_BCXF>*)8;?3;6SLO$4%Y)J+QM]M'EQH?+B(&-K=SN[G@UB:?#-!
M)XIT7P$D6L/<Z=?31WZV#VU_82LVXP2R$#S-Q)"]^* /I:RU6POYIHK&]M;F
M6$XE2&97:,^C 'C\:NUY=\'KSP3/;6MOX3TZ.VU2WL$2\VV3121],I*Y49?=
MD\DG@FO41TH **** "BBB@ HHHH ;MIW>BB@ HHHH .]%'>B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M8QY_6BB@!P'7\J!TZFBB@ _QIK$BBB@9F^(-%T_Q#8'3]8MA<V;.DC1,Q 8J
MP9<X(R,@<=*TTXX  &!110(=1110 4444 %%%% !1110 4444 %%%% !1110
M AXQSUXH/>BB@!%)*YIU%% !2 \FBB@!:*** "BBB@ HHHH **** #O1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image00023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #Q G$# 2(  A$! Q$!_\0
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MC56U+S@3/'+"(_*V_>W9SGMBNO\ A;X5F\*WGBN+['#9V%UJ9GLHXB,>5L4
MX'3D&@#OJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGLX?/>#RYF#-E<<\?6O-_%W[01T'QY?^%K3PM=ZE>6T_D)Y,OS2G /"X)[T
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M^C:_$I/2[/M?]D ;?A.P_P"G^;I_P&OE_P#:%_Y+-XJ_Z^O_ &1:^H?V0O\
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M]?\ LHK]#Z_/#]H7_DLWBG_KZ_\ 910!YU1110 5]8_L/_\ 'CXI_P"ND/\
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M&;>,D*>GTKX5E*M(2@P.PKOH<D8JH[/R(E)3?,NHQJ;3J;63 **6DI %%%%
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MLV1IE"@DEBHQUQ@G/&:]#H *BNO^/6;_ '&_E4M177_'K-_N-_*@#SG]G/\
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M)-(_ZZ3_ /HYZ]+KS3]G/_DDFD_]=)__ $<]>ET %%%% !1110 5^>'[0O\
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MY&[MQ71&K:DZ=Q6UN>\_L8_\E.OO^P=)_P"AI7VM7Q7^QJ0?BA?8 '_$M?\
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M?_&ZPO''AKX+V?A+4[CPQXDNKK6HXLVL+2,0[Y''W!VSWJ0/:?V._P#DD?\
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M +^/_C1_PHSX=?\ 0M6W_?Q_\:]+S29J0/-?^%&?#K_H6K;_ +^/_P#%4?\
M"C/AU_T+5M_W\?\ ^*KTO-&: /-/^%&?#K_H6K;_ +^/_P#%4?\ "C/AU_T+
M5M_W\?\ QKTK(HS0!YK_ ,*,^'7_ $+5M_W\?_XJC_A1GPZ_Z%JV_P"_C_\
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MOSP_:%_Y+-XI_P"OK_V44 >=4444 %?6/[#_ /QX^*?^ND/\FKY.KZQ_8?\
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MRSNL<4:EG=S@*!U)/I0!)15>RO(+ZUAN;.9)[:90\<L9RKJ>A![BIG8*I9B
MHY))X H =166GB#2'V[=5L"6^Z/M"@G\,UH22K&,R,J#(&6..3TH DHJE=ZI
M8V4@CO+ZUMW(R%EF5"1]":2XU:PMY/+GOK6.3 .QI5#8/0X]* +U%(IR*6@
MHHHH **** "BBB@ HHHH **** "BBB@##\7>(%\/:?#/]E>[GN)UMH($8+O=
MLXRQX P#S5*?QGHT?@NW\0ZA<?8=.NX@5:922I8<*<9YS6WK&DV.M6+6>JVT
M=S;,0Q1QW'0CN#4T-C;0V<=K%;Q+;1J$2((-J@= !0!X?\$/B/X3T+X;Z;I^
MKZS%:WD;S%XI(WW+F5B.WH17=_\ "WO G_0Q6W_?#_\ Q-=K]AM.]M!_W[%'
MV&T_Y]8/^_8H XK_ (6]X$_Z&*V_[X?_ .)KBOA+\2?".C^&[V#4M:AMYGU2
M\F57C?)1Y6*MTZ$'->U?8;3_ )]8/^_8H^PVG>U@_P"_8H XK_A;W@3_ *&*
MV_[X?_XFC_A;W@3_ *&*V_[X?_XFI-:\8:%HVNZMIE_:VD,EAIXOP\K1H)@=
MWR*#W^7]:Q;?XAP:E;VA\/>$+C5+E["/4;J",QH;:.3.U<G[[G!PHH UO^%O
M>!/^ABMO^^'_ /B:^)_C7<1ZY\4O$.I:3YEU8W%QNBF2-MKC:.1Q7Z":=':7
MUA;W(T\0>=&LGE30!73(SAAV(JS]BM1_R[0?]^Q0!^7GV*Z_Y]I_^_9I/L5U
M_P ^T_\ W[-??]O\0K&Y\:3Z%;>'7EB@O?L$MPK1^8DF,[S#]_R_]OI2>'_B
M'8ZUXIDTNW\.N+5+F6T-T&C9XWCZM)%]Y$/9CQ0!\ _8KK_GVG_[]FOH[]DS
MQ5HOA"S\0KXEOETYKB2(Q":-OG #9Q@5],Z#X@\,>(+JYMM&N;&[GMQF18T'
M3.,CCD9XR,BMS[%:GK:P?]^Q0!Q?_"W_  )_T,5M_P!^W_\ B:W/"_C/0/%4
MMQ'H&I17KVX#2A%8;0>G4#TK9^PVG_/K!_W[%/AMX823#%''GKL4#- $M%%%
M !2-2T4 >/?$W^S)?&TB7%[864AT=XY9+G3_ +3O)?Y5SV.,XZGVK"T74Y],
MU71[I1>:01I^G0W\31^8WDDRKF1BI.0-ASU&1FO7M8\8^']%OVLM4U6WMKI4
M$C1OG(4_Q'C@>];J.LB!XV#HPW*RG((/<&@#Q31?%'B?4+C1(WUH6D17*R7-
MDQ:^(F=70A5P&"A>/E^]GFO3=4EL'\'WLEW.M[8^1)NDN$#A^O48P<'CIVK0
M&KV9US^Q_/\ ^)C]G^U&+:?]7NV[L].M4M<\6:%H-TEOK&IPVEQ(AD5'SEE'
M4\#H.] 'G&EZ;=Z=;:=9:=#)=Z4]G+=Z/?+&))+%Q$28,N"<;N4./4=A45CX
MUU*XN-D^JWJ:;+!9FZO$M@&LG:-_,VY3&#(J@Y!VYKV2WN(KJVBN+:5)H)5#
MI(C95E/0@]Q4M 'AVJ:O?:=K6J-H^HKYEQ'8)>:LUJ1A-DG[T@*0,G8"<$#/
M:NQ^'>J:E=:]J]IJ^I1:C)#:VLB316GD*=RMNQD9;L>?7H*[^H[B58())96V
MQQJ78XZ #)- 'F$USXJLM<EMGO-5N((;I[9I%ACVNLXS!(N$_P"69R&_#-9O
MB#7_ !38ZIKL:Z\EG_9T$@AMYK$RR7*"(%9A@;22W?.!TQ7K.C:C;:OI=KJ&
MGR^;:7*"2)]I&Y3T.#S44.M6,^NS:/%/NU"&!;F2,*>(V) .>G4&@#S74M8\
M117OA^WMM?$%O<VD=T+NYM2XNI68;X@$7 PN,+P>>IQ71^)-7N8_%UOI]QJE
MQH]L8XI;62. 2+=R%R'C;*GH-O (/S9KJ-?UJQT'3C?:K/Y%L'2/?M+?,S!5
M&!ZDBIK"_AO;>2: R>6CO&V]"G*G!X/;CKWH \COO%'B9DU">"[NXY;9G>]M
M1; BSV3JJ!3M^97C))ZGN"*SKKQIK+:EK @\27*V5K'>SP)]A7<^PH8AN*\@
M[B!QR!^->S^']9LM>TN/4-*G\^TD9E23:5R58J>#SU!K0R: /#VUW78+*\^R
M:Y<0"YU:037=W"76TC,8:+&$X5CQD@CC'%:=KK6ORZ?XIFN/$R?:-/:&*(_9
M?L\(#(A9N59LD[@&Y [BN\O?&6AV7B*/0[B^VZH[QQK#Y;'+29*C.,<A3714
M >*Q^(+VVNKW4;_5=>MXY=+MS#"8XY&R92KNOR!?[OS= #G':L:3QSKS_8%3
M7Q%,P\EF%BLS'%T$SOV@$F,YR !QG%?01Z]ZSM4UJQTN\TZVOI_+FU";[/;+
MM)\Q\$XXZ<#O0!Y--XI\0W-Q;6=GKJVEM%=7,*ZC<VA?[2Z3 )&P5<9*'/09
M[&KFAZI-J/Q2TJ?5+J==0C^W6KV+V^Q+91M\O:VW)W*-W)(/X5Z_378(A9V"
MJHR23@ 4 >,R>*M;@OS8-K4T5U&=0AD-U;?(FQ@8'8JG!VDX(ZCG!Q6;=>,-
M<%YI<<>M3V?GI A,UG'.[ W!5RLH4 J5Y!P.!TKU<>-O#;03S+K-H8H 6D8-
MT4=6''(]QQ4^C^+-"UF6:+3-4MIY8H_-= VU@G][!Q\OOTH \JN?%^KW(L+6
M/7Y[<">6#[4(XT+;+@KOEW)C!C QM'7GI7H7Q*CU*X\*W4&FVL=[!)!(+A6G
M\IBFPXP<'.3U'>F7I\*:NH\03ZBOD1LMM)*MV\43D-Q&ZY ;ENA'.:ZOS8UN
M$M\XD9"RJ!_",#^HH X>0-I7A![NSB6#Q-J.F(D4>[>S/'%PJ<#H,G'K5+X<
M2WUI97$.AVXU72O-C\NZN&%O*24!EW';F0AL]>>V3BNT_M#2[SQ(VF;EDU:Q
MA%R4*G,2OE00>G.#6MGG&1NQG% 'SYJWB*]77EU6?4I(-7\F2VFLYK$,L&+J
M/]ROR]TRV26Z$BKVI>/-46_OX].UVZCBD:/RVN;-6=&^TA'54"_(-A)&XDD#
M/%>ROK5BFOQ:*T__ !,I(&NEAVG_ %8(!.>G4UH[@" 3SZ4 >$:MXOUBSL[Q
M8_$4LW[V_M8S-8J_RQ &-B HW,QR,]".W%9_B;Q)>RWL&J2ZA)::G:QWD45J
M]B'CA4QIY94;<MY@]21STXKZ(S1S0!XUX6\7:Q+J5MG5FU-KF:^AAMOLHAC(
MC0-%C R,GC.<$5N>"-?\07\4\MNAU>(I [_:B+5K:9@?.B!V<A<#C&1GK7<Z
M+J]GK5M+<:;-YT,<SV[-M*X=&VL.?0BF76M6%OK=EI,L^+^\21X8MI.X( 6Y
MZ#&10!QME=Z3<^-+FYT"*WDU6U@D@$"[HFN'+ N9'V_=!& 3GG.*RM8\1ZVG
MC2XL9;_RI56SDCTA(%DC9'W"</)MRRA03GC%>GZI?V^EZ;<WU_+Y5K;1F65\
M$[5 R3@<UC>'8]'O-8U#6=*^T-=74<*SR.9 CKMW)M5N.C=O4T >1Z#XCUC1
M_#-M9:/?/(C6"3$-:'%DOV@HS*%7/"')!STSCM5Z]\4^(=/#M/XI%VEOIZW<
M?V:PVK._G[0"Q7+90\X ]1BO8-(UJQU:2^CT^?SFL9S;3_*1LD !(YZ]16CD
MT <$TNJGQ%J%A=W=U+ICH=2CF,<9C^SE"IMS\N?O<^I'>O.M*\1:E86OAC3]
M/UC[!;2VEG'L6P#,@:9ED 8C(^7!YZ>E>Q:K?Z-X3WW^I7,D'VZX6/?(7DRY
M'"CKM'!.!Q6IHVIVVLZ7:ZCITIEM+E!)$^"-RGO@\T >%ZYXFN]:T/[+JNH7
M2P6TB- _V4'[>R7>&W'9P50*?EV]2>E=E-KNIW7BK4;*XE<VRO<13V$D ,0L
MQ#N2X#;<DLW!Y(YQBN^UW6++0]/^VZI/Y%OYB1[MI;YF8*HP/4FET+6++7=-
MCO\ 2YC/:2,RJ^TKDJQ4\'GJ#0!Y%X#UC6S>>';"'48K#3(;2V$5I):.QO(R
MGS[3C@AACJ-N.1S7H_Q$DE3PR_E_ZIKB%+@^D)D4/^&.OMFNEYJC:7%KJ]A(
MR(9;9R\3I+&5S@E6!![?SH \WU>[\'P>+/%,6N6EG-&]K;Q>2+3S'D(5\JF%
MR6Y4<>U9DEOJVJ>!-.\,2P"XUBRLQ=7"7-R8GM6!S;EFVG<5XR,]N:]DL[=+
M.VCMX 5BC&U 23@>F34U 'B>J:Y9>+]1\'RVL6ER:K<6MQ!.NHVKLB.44%3@
M?W@<9."*U-!T;3=$\;:3H5]+'>S6WA][:6>:+E_W@)&[' VYP,]!7JLLBQ1/
M)(V$12S'T K*L;O3?%GAZ*YM7-SI=XN5/S)O4'N.#C(Z4 5OAZ]Q)X-TLW>3
M)Y>%+')* D*3_P !Q714V-0B!5&% P !P!6<NM6#Z_)HJ3YU*.W%T\(4\1EM
MH.>G7M0!IT4F>/2N8N?'OAFSE\N\U>&!B&91(& 90<%AQRN>_2@#J**YN\\<
M>&K.\:UN-7MEG55<J,MA6&0V0,8/K5O4O%&B:9=QVU_J=M!.Z;PKMT7U/H/<
MXH V:*J3:E9PW%I!-=0I->$BW0L 9<#)V^O'-16FM:==ZI=Z;;7D4E_:!6GM
MP?GC#="1Z'UH T**H:?K&GZC=7MM8W<4\]E)Y5PB')B?KM/O4,NO:8@NC]MA
M9;240W)1MP@<@$!\?=ZCKTS0!JT4@(/2EH **** "BBB@ HHK'U_7[30S9?;
MDNF^V3"WB\B!I?G/0' XS0!L45SLWB_2;>ZU6"[DGMO[-"M<230LB#=]W:V,
M,3V SFK&B>([#6)I8+?[1%<QJ'>&Y@:%U4G .&'0XH P?$'P\T_7?$&KZGJ(
M@N&O=.%A&DUNLGV<C=^\4GO\WZ5B6?PQU+1H;?\ X1KQ1-IUR=.BTV[D-JLH
ME6,$)(H)^1P"1GD5W<.NVTWB:ZT,1SK=6]NEPSLF(V5R0 I[G@YK6W#GD<=>
M>E %;2K4V6GVUJ]Q-<M#&J&:=MTDA ^\Q]35IJQ;KQ)8VOB"/2+CS8YGM6NQ
M,RXAV!@N-_3.2.*D\.Z]:Z[;W<MJD\2VUS):N)TV-N0X)QZ<\&@#AM2^%]QJ
M7B>'4+O7FEM8;];Z(/:*;J/:<B(7&=WE^V.G%,?X52W7B6WU'4M=:Y@MKB2>
M,_952Z8."/+><<L@#'@CL*]2W*>A%&X<\CCK[4 <7X \(ZCX66*VN=;^W:=:
MVXM;.W%HD1C0'(+N.6...P[XKM1TI-PP#D8/0^M1PW,,P<PRHXC8HQ5@=K#J
M#[T 2T5D>(]>M=!M[::[2>1)[J.T7R4W;7<X!;T'O6LK G (./0T +1110 4
MC4M% 'E7Q(T_5=7\5/!H\>H(4TMT?$.+:\!<,UN\G;<N0",8)JK<#6-3UK1'
ML(]?T32(;:%;2VBM,^7*C$/'-D_*-H4;CD$9Q7KV*,4 >.>%K>]_X3 7>O6/
MB 7<EH\-Y(5<Q"87"LOED' 0J.W&!S71^/([^[\8>';?3?MML1'<++?1V(N(
MHPZ@ -G@9Q_G->@8HVT >,ZOIE]X8U+0M*T*W\0&RTY8$-S#OD22,LWFX1?E
MW<Y.[V '%3^ QXHM[JVC0ZJ]U/I[-/-K22-$)5F.T'!&&V>E>P8I,4 >/^(;
M/Q/-XCUF6:_UZW>.!C9KIEN&@EC\GH')X;?G@C=TP:SX%UY46SNK?Q3/I#I;
M/?O\_GES"P;8<YQYFS<%_P :]PVTN* /#_#]AXC-IHMC]GUFU:.WMXK<X9(U
MC&X7"S<\,>,$\\@BLNSTS5=/LX'M;'Q-%>6&F1QKM61M]P+DLPSG+C:2<=,$
MU]!X^M&/<T >&ZI8^(KBU\12:BVOW%U*2ALH[3= R><IC>-L\D(.@ /7-1_:
MO$:0:4_V3Q5)<6]SYGVB99#OB^T'*F->"QCQRW&. ,U[MBC% '%_#^.\B\%S
MQI:S6E[Y]VT4=U'Y9RTC,A(]#D5R<T.LR^$YFL5\30:C)+;C5DF!D90,^:UN
MI//)'W#T'%>P8S1B@#Q$6>IP>)-$66VUW4%C:QS>SV>"5224DOCI@.O7GUK4
M\<0ZP_BO5)+27Q-Y49L?LHLP?)3,A$Q7'!^0\YSUKUO%)B@#PW5IO$$>G)!9
MV?B<RVMW<&TG/FG$8F&P%1RY*9P6^7%%];:]+HT-Y9P:[<ZPVNN\7]HQ.RQ0
M 2;#L& HPP /KUZ5[GCZTF* /&WM=:N=6TTP3^*=-TQ+=&M46#S9/,#-YR3,
MQX)XP2"".E:EAH.JZI\';RR\W4CKM_;L)?[2D82,X;[IS]T,!CCCFO4,4;<T
M >=ZCJB:CX2O$MO#.J6]Q#I[VZH]GM>(LFT1I_>&>/EXP,U3_?ZYKWA>Z@T;
M4+:'1()'O+JYMC&TBF+9Y"*>7R>2.G [UZCBDQ0!Y3?6EV_@?Q*[66HWJ7EZ
MD]HDUK_I3<IG<GHI!"G@X J]\2Y)XK"'4A<:G:QOJ%I;E+/*S20EOG0 <G.X
M].>*](Q5/4])L-5CB34K2&Z2&02QB5 P5QT8>X]: /&GAUFVGD:YTWQ!<+)9
M1PI)'O$BQ?:'*B1U^8E4*E@/F/2H;&P\3-;R7\4&NC67T86\<L@<?,DYWC:Q
MP',>-N[DGOFO=\>]&* /#KFR\0P16HT@Z]>7 L;H175U:;)(U:2(F,9/WMJO
MMW')]>E:6@Z-J5OK^B7JS:W>$6UU';SZA&\:12%E*++&#D+C< 6Y/Y5Z_BC%
M 'EOB6S\3W/BS3A>7^I6MJL$;1R:/;[XC,&/F*VXY4%=N"V1U[US5E_PE5K9
MP(D?BFY>>W?[>T^XR;%N>D>< /Y6<8Y/UKW?%+B@#PNRL];@LVMM/M?$,%I]
MHNY+%]KB47+2AHFF).6C*$\MQUS4=QH5];ZB\+6GB(21WFHW$DT!D8-OC_=;
M'ST)[#Z&O=\>YHQ[T >)1P^)[ZZENM5DU]'_ +/'DVD=J#%.AM\,DAS\K^9N
M)!&<XP:R8SXB3PS+:1V?BLNK9M7=9$$!6!,+M3!8;PP4=.I.:^@\4N/K0!Q'
MPW:YDN?$5Q=V=Y;&XNXY5^U0F(R?N4!(_$&H=22]?QTPODUA8D,3Z;+9LWV<
M\'>LV./O==W;&*[W%)B@#PJ.S\01Z:UQJ_\ PD-]>_;K=[JT-GNCB9)"6>(@
MG<"/3C&.,UU$*WMM\(=(@.G:M]I CBEMX-T4T8W')8+\VT=2%Y->G8I-OUH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image00024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #C N0# 2(  A$! Q$!_\0
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MXJ^,'@OPKKD^D:WJ_P!GOX0IDC$#MMR,CD#'0U7N_C1X(M(8I;G5GC24@(3
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M:GWY_P - _#C_H/'_P !I/\ XFC_ (:!^''_ $'C_P" TG_Q-? =)0!]^_\
M#0'PX_Z#Q_\  :3_ .)JQ;_'/P#<)NAUAW&<<6TG^%?GX*]"\"![C38TBC1_
M*=B[8R5KLP5"%>HX3?0Y<97>'I>T1]D1?&GP3*N8]3F(SC/V63_"D_X77X'V
M@G4Y0#ZVT@_I7R[(T<^QD W1N% '&X>M)J4]J&2! JNIW?(,BN^KE4:,$Y.\
MNR_$\=9Q5;MRGU&WQJ\$+)L;4Y@V-V/LLG _*JP^/'P^)(&M/P<$_99, _\
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M;C_L75_]*#7HU>2^'+^_O_C_ *J=1TJ33?)T010[Y5?SXQ<'$@QT!]#S7K5
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M,7D/'+$Q5D81KR"*\^U?QCXBUF^M;S5-;U"ZNK4Y@EDG8M$>N5]#7=?M2?\
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M /0EKP"7QGXDET(:++KFHMI(79]E,[;-O]W'I[5[_P#MO_\ (6\*_P#7"?\
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M0DXNZ+&I30M(!;Y9!\P)ZCV-5IG20 A=K=_2E^QW7_/M-_W[-'V.Z_Y]I_\
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MH^Q77_/M/_W[- $(K=\)^)+KPW>-/:*KK(IBFC;I)&>&0^H(K(^QW7_/M/\
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M(]]Q8E2LT6#@X'1QWXYQ7-YKKM/\-:SI/AF+QFSG3K5+A$L)'&'N9>OR#NH
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MD0.![L>A8^U,\8V4MQJMH;>>U266)[=4FSEL\Y&/I4W@I9+83V3M9$6V$*P
MA@W?=FO+5WBM8]=SQE=XS6.E]_D?-OQ^U?4='\1^(I-)OY;"6;6;>*26)MI*
M_9!@$^@/->9:WJGQ"TBW2YGUK4);-QE+B&<NC#ZBNZ_:>/\ Q-?$'_8:@_\
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MR]+CC..*D#TOP!XM\0:OKEQ9:GJ]W=6DEA=[XI7W*V(7(R/K7F>>*[#X5?\
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M>GS))GH#Z8K6E55-23OK]QYN*PLY8FG7IRU6C71HYD#GGIWKWKP%I'AK2[N
MV5HNKB6&-I)[U!A6898*.V,UX,IP0<9QVKZ7\+6JV_A\6&E3Z;=W\D/VQHPP
MR<KD(!GMC%>3F$HJ*4WHS7&NIRI4SR[XC?"_6?#LFH:I# LFA*^^.X5AC:QX
M&.O>LKXM?\C1;?\ 8-L__1"5#XL\>^(O$=@-.UB^:2UCF:01 !0#TQQU [5/
M\6_^1HMO^P;9_P#HA*WP<:\:=L0TY>7;I\SKC>VIQ-%%%=104444 %%%% !1
M2T8H *>DFQ@1V[5'133<7= /=]S$GO29IM+0VV[L#[W_ &5?^2*Z-_UTG_\
M1C5ZW7DG[*O_ "171O\ KI/_ .C&KUIV"*68A5 R2>PI >%QR/8?&J[@EU''
MVK45E6"'65B7!0##VP7YCQZY-;GQOTPS7>A74)MY'DG,)LCI2WLMV0I( R0
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MFC_AEWP1_P _6L?]_P!?_B: /B2BOMO_ (9=\$?\_6L?]_U_^)H_X9=\$?\
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M'_#+O@C_ )^M8_[_ *__ !- 'Q)17VW_ ,,N^"/^?K6/^_Z__$T?\,N^"/\
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MA^'NB>![;3'T/Q1;:ZUTSK(L)0^5M P3M)ZY_2OHW_AEWP1_S\ZQ_P!_U_\
MB:/^&7?!'_/UK'_?]?\ XF@"+QGQ\)_AY_UP_P#;*2OBFOTCUKP!I^I^'=%T
MA;N^M$T@H;6>!QY@VH4YR"""I(/%<Y_PI?2O^@M?_P#?FW_^-T ?G_2U]_\
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M4 7**3-+F@ HJ"\NH+*VEN;N:."WB7<\DC!54>I)K-@\3Z+/I\][%JEHUK
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MXP&DZF\MYKYOY)HQ>1!4V>6)#N:V.[DE,<#;P,=:06'B2POEECD\67Z0K9&
MSN #^];SMR*0/]60"#G\Z[G4OB#X<TR.9[^]:#R;AK9U>)@P95#$XQDJ RG<
M..:W_M;W>GSS:;M\P B)KA65&..#QR5/J* .8\:Z7<:AX9TM]-M)[A+&]AO9
M+"9OWEQ&C$E/F/+=P">< 51\3PW>LMI>LV6@W0CT^_CN;BUFC6.>[55900N>
M2A8, 3SCBG:7XYOKZQA::RM;2]MI,:E:N7D81%2RRP[1\ZL <9[\=16RGCC1
M)$<Q2W,KK'%*L26SL\JR*60HN,MP#G'3!S0!@>,%OM;CTO\ LO2]8TN6:_#M
M>P0()H<1LOF2*<\ L!@Y)&>E4H[.^/@F+08]#U&PU6*<JSPQJ]M-('WM(SDG
M]U(?F(X/..U:L?Q!M+*ZUB77+B"#38I(/L)2-A(Z/%O.Y3SD<D\<"M[P[XCM
M=:CU6[L;V*^LK:0*GD0N&4>6&(Y^^><C'KB@#-^(D&IS0:4=+6\EFCGR\%OO
M6.7CH[HRL@[@\CU!KAM1TW7]-T>YM=,TS7OMAO[JX6>.ZD=%)<-'@!_FRO )
M.T8.0:]$L/'&D7X'V87S;H8IP#9R E)'V*1QZY!],'-4_P#A9GA3[3);QZD9
M9UE6%(XHFD,K,2!LP#N!((S0!P$D'BR2\U2<Q^+W6-)I+2-Y %+F9#'@ C.$
MW<'C'&*+&+Q8L]S=2Q>+9&A:-K=+B3Y<_:B22 1G]R>0>.W:O4;#QCH=_P"(
M6T6WO VIJA8PE2.5 ++_ +PR,CM2MXOTA9KM&FF"VZ%S+Y#^7)AMI"-C#MN(
M&!SF@#D?AA<3W7B/4+B\NK^5I(F\DRS.\4RB0GS0,E$."HVKQ@<5ZC7#6?B[
MPCIR74UG"+3Y!-<F*P*,/WGEG?A<Y5S@@\C-%Q\3O#XLFN;-KV\0,$40VDGS
M_O!&=N1SAB ?J/6@#N:*XV^^)7A:QO+JUN]3"3VW#J(V;+;@I48!R06 ([4_
M5/'VE:?:7TS0:C*;*$33QQVCEDSC"MQPW(.#VH Z^BN.U?QUI5I;72R7$UC<
M);-,DEU:2>6"%!(Z?,5W#('-&G?$+P]<PR?\3#(@CD::<P/'%F/'F %AU&1Q
M[B@#L<XHS7GGB/XEZ;'X1N=2\/3BZO &$<30.^PHP#&15Y4#<.3QDBNAU/Q;
MI>DSR0:A)/'+%#%.^V!F&QWV!@0,$;C@^G>@#HJ*XG5O'^CV\4<HO_LT"79A
M>6:UD9)0H8N(R!R1M//08JPOQ!T!]/:\CFNI$!7;&MK(9'!3S RIC)78"V<=
M : .NHK*&M6S:)#JD>\V\\:R0JZ[&?</E&#R":R_#_B.\U&Q@U"]LXK33C8?
M:IIO,W;)-QR@XY 522?<4 =31FN4\%^+!XD6\DD1+01LACMY RS"-AE6?( ^
M8<C;D8]ZPM6^(<<?BK^SK2Z@AL3"H2ZFMI65Y_/6,JK#AEY(R.AZF@#TBBN1
MF^('A^!WCGGN8I!,D"1O:R!Y6<D)L&,L"5(!JM/\0M&NK6+^SM1$$TLL2QM<
MVLFU]TFQE P.005)Z*>M ';YHKS*[^)5O'XDN;<WD%MI2+ T,\MI*3-EGW[2
M.""$^5AQ]:Z73_&^AW^FS7MI<3-!$(V ,#JTHD_U>Q2,MNZ#'<4 =11659ZQ
M#JFD"\T9H[@R*?+1SL^8'!# \C!!R,9XJGX?UR>XTN[GUN.WM9K2>6*1H7+Q
MR!.KID9QCMUR#0!T.:*\[U'XCV<PTBYT.7SK2>[BCN!);2B5X9$<HT*X&[)3
M&>>E:EQ\1_#%M+:)/JB(;J(3)\C'"D$C=QD$X. >>* .PHS7)VOC_0KNP%Y;
MS7+VY>!0WV609$QQ&P!&=I/&[H*S/$'C22PU:0++!:Z4MC<R-<7$$A=)XI%3
M.T?>3YNW6@#OZ,UQ^G_$+P_=Q2;;\MY".9)?L[HC-&0'"DCD@D<#GD53T'QW
M#)HU[?ZT'AV:A/;0Q1VT@D\N/G+1D;@0O+'&!0!WF:*X.7QY:Z;JNLMK5U:I
MI,*VSV,D(+/*LB%C]>F>.U=A8ZA;7VFPW]I,DMG-$)HY1T9",@_E0!<S17"-
MXCU^ZGT=M+BTLP:OYKP?:3(&C1%W*3MZDCGMC-6-/\7WD^@ZNTVG1IKVFSM9
MO9B;]W+-M#)L<C[K!@>1D<^E '9T5P>K>,[L>'?#VKZ5_9<=OJ<BPRM?RLBP
ML58]1Z,I4YJIH?C76=>?1%L[2P@74([K<\CNXWP,%W1X #1MD$$XXH ]'SFB
MLSP[JBZQI$%XJ>6S[EDCSG8ZDJPS[$&M.@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H%% H **** $Q1CW-+5)=
M4LCJC:<+J$WZQ^:;<-\X7UQ0!PT/_)P-Q_V+J_\ I0:]&KSJ$'_AH"X.#C_A
M'%_]*#7HM &=XC_Y%[5/^O67_P! -87PB_Y)AX7_ .P?#_Z#6]XBY\/ZF/\
MIUE_] -8/PC&/AAX7S_T#X?_ $$4 ==1110!\6?MH?\ )2M._P"P<O\ Z&U?
M/U?0/[: _P"+E:=GOIR_^AM7S]0 5I^&/^1DTG_K[A_]#%9E:GAC_D9-)Q_S
M^0_^AB@#]0**** "BBB@ HHHH **** ,+Q5H<^N1V2VVI3:>UK<+<AHHD?<R
M] =W;FN9N/AI;W*2&YU:]>>XFGGNY0B*9WEC$?0#"A548QZ<YI?C*EN^E:.L
MC60NWU&)+=;R9HXW)SE6VD'!XS7*V'B>\T7PEIVG:)=VT.HO>317:ZG+M33)
M.7%N2<X7.0I)Y4<&@#K%^'R1W@O9=<N9-2:<R>=+!$P8%%5DV%<8(C4CN"*[
M*.VF2SFA^UN7;(CD*+F,$8''0X]Z\ENO$$VJ>.=#DU'4--L)[&YFMQ 5^9"U
MJ3YP9B,HQ/ QC@<YS77^/_$EYH*Z8+:XM8(IDFEDNIX]R.T:!EB !X,A/'?C
M@&@"[%X,LRVD37MQ-<7^G0R6ZW( C,L;@@HX7@CG(]",UD6?PW^R30W,&OWX
MO;:.*.UF,49\E8PR@8QA@58@YZ\'K4TWB?5F\'M>0V\"7(M$E^W22HEL9#C<
M@W-D$<CYL#(ZURT?C_69[I5BU/2HH5DL8=MS;[)6,Y969AOP-I&1MR#QS@T
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M':PZ?+87WV>U,;W D4*2K \<*#SGDF@#:TOQ3-=QPW5UHUW9:7<1F:*[E="
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M5A'.@C,9$R[N3M8XP< UDP_#&ZM T%E?6,=JT\,A)M3YA5(&B()#8R=Q/Z4
M=GIOC'P_J4*26>KV<FZ'S]HE&Y4QG+#^'CUJC_PFUE_;<<.^W_L=[ WJZD)P
M48B0(4Q^/]*Q+'X?WZ:;K-K=7]BLE[!:1Q36UNRE6MP-I?+'<#M&1]:9<?#Z
M_ENI;EKG3)'N(Y#/&T,J*)GE5]R%7#+C:,'.<\YH ]%M;F*ZMHKBWD66&50Z
M.IR&!Z$457T.SGT_1[2TNKI[N:&,(\[]7/K10!?HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K "BBB@ HHHH **** "BBB@ HHHH 1NE"]*** %HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image00025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #E E(# 2(  A$! Q$!_\0
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M&/F&X'TH ]-R**\^C\:ZS)K'ARV'AN46VI0B6XF\S(MB>@;C@\'C^5>@CI0
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MFC^+]0\/QQ(5>.UA202DG[QW?E78T4 >4_\ "M_&'_15-=_\ X:/^%;^,/\
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ML3YR'.2@]?8YXH ^F8U"(JKP%&!2TV-=D:J,D*,#-.H **** "BBB@ HHHH
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M12O'=72O&[+ S;V1BI;"@XSC/XUG_"B^M]1\=?$2ZLW+P27MMM8H5S^Y Z$
MUZ%H6E6NB:1::9I\?EVEK&(HU)R<#U/<UP_PY_Y*/\2/^OVU_P#1 H ]&HHH
MH **** "BBB@ HHHH **** "LGQ1KEIX;T#4-6OR?L]G"TSJOWB!Z?C1J.K3
M6EUY2:5?W*XSYD(4K^IKX\^(6F_$76_C)=1/8ZHZW3D0P'(B-ID @\[=N.OO
M0![G\&OCG9_$;Q!=:/)ICZ?=+&9H/WF\2(.N>.".M>S5XS\'/"'A'PSK%U<^
M%],OY;N4^1-<RS)*MOW*\'@?K7LU !1110 4444 %%%% !1110 4444 <?\
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M(_Z_;7_T0*]'KSCX<_\ )1OB3_U^VW_H@4 >CT444 %%%-+J%9BP"KR3GI0
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M2-H3YC@';EC_ /6KK?V9]0T.Z^'WV7PO8ZA!IUG.R&XO$56N9#RS#!.<9 H
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M[^ _AJP\+PV_B_0-/O-7664O,DCL"A<E!G(Z+@5TW_"D_AU_T*ME_P!]/_\
M%5YG?:A';67C+2O#/C&Z'AJ)+,Q:E/<R3I!<.YWP^>,LJLH&6R=N:[_X":F+
MO2=:LA-<3?8+P)N-_P#;H1N0'$4Q&67V.2#0!=_X4G\.O^A5LO\ OI__ (JC
M_A2?PZ_Z%6R_[Z?_ .*KT:B@#SG_ (4G\.O^A5LO^^G_ /BJ/^%)_#K_ *%6
MR_[Z?_XJO1J* //K7X-?#^TNH;BW\,6<<T+K)&X9_E8'(/7UKT&BB@ HHHH
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M_P"%O&7BM;_3+"W$5_;7NK:I%/-<RXD1(F.%7V5>1^52?#_XC>(8-!T*SO\
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M6,890N67 .<4 >ZV^EZ=;V+65O8VD5FV0T"0JL9SZJ!BI+"RL]/MQ!86T%K
M#D1PQA%'X#BO$G\<:]K7@KPZ^D:F!J(N)[;44B:*&ZN#"/O1"4;>FURO!PPQ
M5>R\6^(/$6O6B:7JNJ36/]F6T[-;?9K4F1G=79UES_=Z*3TXH ]^HI$^XO)/
M'4]Z6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M39GAC6*,O;J=B+T4<< >E=!10 B*$4*H 51@ =A2T44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image00026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $[ KD# 2(  A$! Q$!_\0
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MIUA_QYQ?2A?^/Z3_ *YK_-J $^SO_P _,WZ?X4?9W_Y^9OT_PJQ10!7^SO\
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MJY_X_P!?^N1_F*L57/\ Q_K_ -<C_,4 2S_ZB3_=/\J2V_X]XO\ <'\J6?\
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MH* G .!ZFB5"49.#W3L/FTN?HY_PLWP3G'_"4:3G_KX6C_A9W@C_ *&C2?\
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M/K4]F8%N8VNPY@SEPGWL>WO2F^>3C+;^OD#TB^H)-M+*5#,1C'I[U]S_ +*
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M!_.DG<"/D9!Z4^1<C*D CH:3:'VEN>,TGO<=U>[.PT5M^EV[>J_UJ[5/1_\
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MM71_$>F:O>36EC.S74,:RO$\;(P5B0#A@.,@T :]%%% !1110 4444 %%%%
M!0>E%!Z4 06'_'G%]*%_X_I/^N:_S:BP_P"/.+Z4+_Q_2?\ 7-?YM0!/6)XS
MA$_A^X0V$E]G'[N(J&7_ &QN(''6MNJ6KZ9:ZO9&TOD9X"P8A7*\@Y'(H Q/
MAVT;Z)*\9BRT[;UB0(B,,9  ) ]^34&IG.H7.WJ'_I72Z;80:=;"WM0XB!R
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MS@E?7?Y6\GO?\M3!UFW:,;HZ.3XL^("V39>'NG&='MS_ .RU]@?LWZS<Z_\
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MPIGE"!C[9-<G>WW@]]2M&_M#22&9RY^UKS\O?YO6O'?VW_\ D ^&/^OF7_T
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M \8_;?\ ^0!X8_Z^9?\ T 5\BU]=?MO_ /( \,?]?,O_ * *^1: /8_V3?\
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M#-<I\4?MM_\ %VZL!K.KV=I#I,,R165X\*[S(X)(4]<4 >V+K^GM*8Q)/Y@
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M=2:WN9;>.01/A)  Z'HP!R ?Q%1R2&0GY47+;L*N,?\ UJ=;6[W,OEQ;2^.
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M_P! % 'YN_$+_D?O$G_82N/_ $:U<]70_$+_ )'[Q)_V$KC_ -&M7/4 ??\
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M]D[_ )+9I7_7"X_]%-0!]@_&+_DFFN_]<E_]#6O,E^ZOT%>F_&+_ ))IKO\
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M=3Z)XFUF[OHD'D0&. ASD#'W!VJ[?_!B+4;&:UNO%VM26\RE'4) ,CTSLIW
M]7L_^/2#_<7^52UQ*^#]=5 J^.M9  P/]'MO_C==A8PR6]G##-.]S(B!6F<
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MR.T2;$RS$X4=A70T %!Z44'I0!!8?\><7TH7_C^D_P"N:_S:BP_X\XOI0O\
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M6'_'G%]*%_X_I/\ KFO\VJ1D]%4KMV$V Q QZU#YC_WF_.K4;BN:=%9GF/\
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MFD.23QW-//\ Q_K_ -<C_,5+5AHEG_U$G^Z?Y4EM_P >\7^X/Y4L_P#J)/\
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M9F2>2Z2\5PPRKJH3 _V2HP1WR:I6_@S3H;2XM8G(MI#F-4C0/$P?>"' W'#
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M9C'X8-6M*T^+3+9X(&=D:5YB6ZY8Y-2^6V@*]RY1114E!1110 4444 %%%%
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MD D="1R*,#.<#/KBI=:ZLD-0%HHHK$T"BBB@ HHHH T(_P#CW'^[7$5V\?\
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MB5:?]=KG_P!*)*Z1K8%B?-F&?20U=1OG?J3'X4'V6/W_ #H^RQ^_YTGV4?\
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MO^=)]E'_ #UG_P"_AH^RC_GK/_W\-%V%A?LL?O\ G1]EC]_SI/LH_P">L_\
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M?_OX:/LH_P">L_\ W\-%V%A?LL?O^='V6/W_ #I/LH_YZS_]_#1]E'_/6?\
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MK;ZNG'FOW(]IK8^@YYXK= T\L<2DA078*"3T'/>F2WMK#<1V\US!'/)]R)I
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M:64DRCG&"5! /M6=_P )U9?] GQ%_P""J;_XFN-4Y-72+YD=;17)?\)U9?\
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@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image00027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #0 5P# 2(  A$! Q$!_\0
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MG85[LEMU::5$0$LQP *^D?AC;2:7H]N'''4CUKS7X;>#GO+I+BX7 7GGM_\
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M<L9!'&,&MO0_ -[>2+^YD*^I7 K[#/@6(_\ +TI.,;C#D_SH7P.5_P"7\8[
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M/^$>&[(N?_'/_KTH\/X/_'P/^_?_ ->F(PGD9U  Q36/S83YJZ Z"3_R\_\
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M<C>YG.NWHC@-+2WM+4162*B*,G/4>]$1\V=67[J_,>>,UVTGPX!8F/5"@/!
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M2HF\0:Q_T$;M3T()P:I8Z#5TA+!R>S1[-17B;>(-:&?^)G=?]]U!)XDUM?\
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MU95_X_+D?\#'^%5&\6:OGC4+L?1A36-I=P^KS['N5%>$'Q9K'_03O!^(I/\
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M$D5)MQ*B,$J#@GK7N&AG_B2V'_7O'_Z"*\;DB_=\ @=L5[+H@QHU@#V@C_\
M017=@-V<F,^&)R'Q,_UVG?[K_P#LM<>G..<=ZZ_XG_ZW3PIP2LF#_P!\UQD9
M;'. ?8UCBOXK.G"?PD6A\N>"!V'J*E7:=P49[@5 A^49_6I0QQQQV-<YT#^X
MRO'<YZ5)T7H#WS3 ?3I2_B!ZB@0[W]J8Z\@D XZ4I;:,@\XY&*B@N%F+;01C
MKF@:1+D C"J6['L*@\L9;(Z]ZL$XQQ[YJ-AG.,D]J8B)DSGH/UINSWXJ4^U(
M>O\ ]:AC(0ASS2X'7GTIV>_\ZC=OY4@.^^'/_(-NO^NW_LHKSNX+SZK=2/\
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MK+@C(([5+5P1V'PU $NH?[J?^S5RWBL.WB?4-LA $W3\!73?#&4/-J*YRRA
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M/_36N2\;> =;\7Z7>_;=1M[74S+!)9-;RR>1"8FW*S(1DL"6/&.OM7>KI_\
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;VMNEM;1019\N) BY.3@# J:BJ44MB7)O<__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image00028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #2 Q$# 2(  A$! Q$!_\0
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M+B-6;)2Z!X+'\Q0!],T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS29% "T4FX49]Z %HHS1F@ HI,T9^E "T4F:6@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *.E%'UH ;NYQWHW>N /K7F'Q2LYM.\0:=XJTE9A?:7&9
M[E(R?])M@0)$(Z'"DL/<52UR:W\4?$7PG?I(;C1XYIH[=%<B.9A"',G!P<'
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M)),3#BW49R%#')=C@ GY10!WM!JCHLEQ+I5H]ZI2Y:)3(I()!QSTX_+BKIH
MRX3=?;+G[0(?LV1Y!4_-[[JM5'(ZIG)]345K=P7D3-9S)+MXX/&:U1SVU+=
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MD^;_ &H!'$A +9SUZ"K(\9>'XK.&=]1A2&0?(3R37A&O^*9_$%W$;G9$L8P
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M"TL?!1CPP[Y]\54)V1E#V=[LHV]G*) 0ZRL%\L2XP2GI5JSN]UJ\:*7EA)"
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MTA7G@<<=0:Y^ZNPK!C!<JYY+$8F3UZ<,/UKH=)U/SE U*47$1PJRVR[9U/\
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M24::L>EA,IE@W[2H[VV+NHPFY2?:D3IDNK0]"*?ID4UW+LLK WFY?WMN3\Q
M'5:HV:W$3EHG99%!8DGY3ZYK6\.Z]<VUQ/<6,2#4H(V,38Z\=/?->5&*;Y;G
MMXBK.G#GY=?ZW*B7(,<D4#/!;N=LT#'A#ZX_PJ2"\"+<6M]$]U'MW1GKC'\0
M/O4DTMKXBA^W0'[--,VXHP_U<G\2-['J#6>52*SG:.222>(!9$8;0JD]5]:R
M2>R,U4A*%VM2\8%54BCG8@H)4??NVD_PD_TJFS7$DF67[1(AZG*MCV(J@J(=
MK&0"-6QM*G /U%6[>1UO KCRG!VK)OX'M[BE>^C0IVCYF@M],AAN-.66*6('
MS9%)>0_7V%:'A'Q'#KOB738-54272SIME8[<E3P5/K68]PKW0,4R1W&<QR1-
MAS[>C#V-:OAV_>V\4:(][8V<L<EP(_M*1[2"3_$O8^]7S.-[;,\C$0A*.Q]9
M5\_?&KPC=:WXX^T@LMMY**6., CTKZ!KR?XCWTB>)VMS;R21^4I78.I^M++I
M.-:Z1\[5;43S"S\"R"XB?4)0D,:$#[,F7_$U8N/ 6GW<R?NY]T1YDG;AQ_L@
M5TT1)S+/F(L<@&0MM(Z=*A=KF]7RI)VVYP94.W\![U[SQ%1Z7T.;D5[F7'X,
MTMVDFV_:+8C9M((VGN>*WM,\,Z7IMF(+&VC@4@$LPR6/N*KV%J\4GEF]FG)^
M8)(<*/?CK5BYCDDF6:&X&4^7<S9#'TQ1*K.>CEH*ROL8UMX;==;FU W%O:G?
M@[TW/CV7HH-=''%.HMOW>Z+)VM$F<GUQT%9EJ76Z98;)&C<[KB>1R2#Z#WJ_
M9"]>_A#F."UB0AT5B<CWHDW);C=Q]U.JF&(;KNZ;("G(5C[^PJS'J<EEI^ZZ
M@%U(_#(@QSV'TK,OM/B$R3VD\YBW?)&\FT;O4'K5S3M/L9[AI;J>2>4#F/>=
M@I-4^6[(;E>R)#K/VI8[:W7A!NE"<"/VR*(I[&"^)MYI8BJ8;>A"$^HS6I<L
MD%OBUV11X^9MG 'X5DZS>6D-@DUZ[;4(RAZR>P'O40Y6]$6W-*Q--J$,YB>V
M:XNO)<+&(1]YN^3Z53EUG3[NZFMI1+;S0MM:!\JI/KQ6I;F:9(+W2[2"-)%V
M%F;!1?I56\T&!W^T"Z$EQC :1@%SZT0=/FU%[]M!+F#[9 B-*8U494D8^7Z]
M<4V^6UM[2)YKI+&-A@S./WCJ/[OI7)W>OZ=HDKS7MS)J]^A(55;;$F/0>@KC
M-9UZX\3+>WMQ>JL-NRE80,9SVC'MW/>LJU7V9Z&%P4Z[OT.JU7QQIELTEKI5
MJEQ'MV^<_P H<?7J:S[7Q[<>9$MQIT%PJC:L:#!7\:X!)MT@62$J#S]:V-%N
MA:ZDMPL:,@&)0P_A/6N*G7G.HKO0^@JY=AZ5%VC=V/5+6*+5[B"XN#* WSB
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M%Q;PFU1A$OS1!1M)QV'M5Y+.>*TN%"J!-AY4]\<59T>WN=2D=+:-<1+N8MT
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M>X]*UQ$5S7@[K\C'"2?+:HK2?XEB]:]L_+PXVH<*YYX]#44\B-$\MN@59/\
M619RI([BJL]P9(1'$Y90<8)YQZ9J*)))2-VX(.#MZ_\ UZY)2>S.^"LKW)%N
M%SMC!B8\\CI4\5O.UU'JEG)Y=U#@$H."1_.GW<<K6T)E5',8(21#R1Z,*6WD
M\A25\R-DQO4'Y?K6KAR)*^YBJBKO5; ]Q)=7,\SH"6YQ'P.>HQ26D_V34K>2
M!)#L.20,$TIN &B:"$*&8,6ST]:OVN%D,EN6>,,'; VNHSR1ZT+WG=$SE[.F
MXM7N3R7MG+?374,'V61XS'=0K]V4= X]&%9$ZK-9Q$S,"N8)649)[@U?U)K?
M^TI[BP(EA;DJ!@8[Y!Z&JBQ2VTC3V#*R,.PR/Q'8TWO<Y(V<=-B,DQP1QQMB
MW0[ ^,[OK4AA:8*HVEE4D!!SGUS4,TXM9<, \4@!9 V[<?85?M/#>J7\BOIJ
M31IG),B[ *TC0J5%SQ6AS5<50H^Y4E9HQW1HE!^78G 9>>?0^E;?@^YE3Q1H
MYG<3&2Y0%2<XYXKK-%\%6]MNGU5A<W3]=APH/T[T]?"K1>*=,N],?<%N(S)"
M_8 ]0:<\+%;2/-EF\*B<91/IFO%_C!KD%AXCCMWNHH69%R/XB#Z5[17R9^TL
M)!\2 8U)_P!&3)%<F&DXU+I7/.HT8UI<LI6-Z;6]*T7YII&:-OFQO##/K5&^
M\<:-+=+&LI,/7S ,%3Z5X_'&ZQ'<-H/K\QS4<L13^('/MBO5C*JU94S9X3#1
M^*J>OV?CO3@EQ#Y\B1+G:63[_L#5:[\=VML/+T^%78?-YC' )]Q7E[VBQM'F
MZCRR[]N#\I]#5EK2W*^;<WQWL0=D,1X]N:U7UJVE,ET,!'>HV=_#\3;]@V88
M>F21'Q]:LCQ]>W-JL<<'FW>[Y40!5/UKSKR(_,""2Z=NI&5&?3GTJQHSZ<MX
M?M<.HSW1)91 X7!]2:VC0Q?Q.*,Y2P'PQN>AQ>,]7A_>ZGI=CB/A \H^7\,U
M$_C^X@8?9UL5>0[?*7( ^IKAXK&T:0R+:ZG,NXMG>H7.>YINJ1VT</FM;"$$
M\J9?,./SH2KU'I%)^HE3PD-92=O0]&D^('D0S-+-#:[!@1QCS3(?Z5B7VH6V
MK1%;O6I'7_61%\)M;U(KB;&]TDS^6;">1@00WF[5-:\LFB_:%-]ILXC?[TL-
MWN('TQ^E="H8N#^%&3E@NC9OQ:II;M$+G6M:8!=H7=@'']*K:MK^@LH\N+5+
MA_\ GE).40'U]:MK9^"+BTC\O4KQGSDA@=_TK$U/6]"L;C[*NB(H482XOMS%
M\=^*YG2Q3;V1M"K@E9ZME=_$164PZ=;6=C%MV;FS(=O?K6(9&$T<L3-&RCD]
MC[@5'+XD\^1I'6SLV7[GV>WRS?GT%.@U*XO"K2?ZSH&DB 0CZU$\MKRC>4T=
ME+-L-2E:%)V+5E=I SB9&G';;R<^N:G>[MXXE>20^JHJXR3ZFI[F"ZM8(Y[E
M+2"V==N^+!))[K[57B72C%Y=Q)(Z=<HHY_6LUE6(26S-99WAY7:3N3-JEA#"
MOG10J<_?;YB#Z^]1S^*],+VZ6MN\*,A6Y,)&7/8BLR2Q\-EWS<:C*^.R@ >U
M/@@TR!@T.@ZA<X[N2 ?KQ792RY1UFSR\1FCJ/W$U\SV3]EO4C>^+-;2-"L"V
MP*Y/)^:OI*XG2WMY9IFVQQJ78^@ R:^?OV;9;8^(]3CL]#;3HUM5/F.3E_FZ
M8]*^@IXDFADBE4/&ZE64]P>HKP,PIQIUW&*T(5:5;WYN[/)=0\0S:WJ>H?V=
M<ZE;HP0&T;0XY9,% 2P<N/X2&YZ CKTKU+1TC32[-(I7FC6%0LK_ 'G&.I]Z
MP(?!&G"QNK>>XOIFN)?-:83F*10%"J@9,?*% &.X'-=-9P):VL,$(Q%$@10?
M0# KB&2XHI:* "BBB@"&\<QVL[KG<L;$8'.<5YE8WGA<:,(;CP[JTDLJEI9F
MTN1I6<\D[\9SGI@UZE2T 97AF9KCP_82/YV6A4_OE(?_ ($#WK3QBEI#0!Q&
MFZI/?WEUNA=8H'8%QR&.3Q5VYO[9=,ENG$AM4!5F7C%4-!@UBQU6_2XTQC:7
M$Q=)4<<?45OBRE:W\KR2BER3TZ5WSE!.R-JRBI:+0Y*Y^UI)%)IDDUY:$9 +
M?.F?YU6MO#C7FHQ3RQ0QWQ!\V1<J-HZ8'K71:QHMVQFETR(K<I'F/+[4D?WQ
M3O#^@7$4SW^I2S->R@!H]_R1_2MOK$8PO%FWME&/NE=/$$MJL]K<6$JRVHVK
MDX6;_<-4(_%,,]O)!?:3>0EQ\OEJ)2/>M#4M'OI]3!6)VMHFRF3Z]:=XGTR_
M>XMGTFUVL$VR2+C./2I7L=+[OSV'"--M)]?,KKJ-@U];2:>J?:8(SBVD78SY
M_3-,N+R+5];MH)V,"C)RWRMN'.WWJMHNCZK;:@)M0LY+DYVAS@;.?KT%=)KO
MA^WURU@2]BD5X9EF5HVVL&'OZ4I3ITY:/YA4<*4[)W\SEO%<TXU-83%YMN$"
M!E7+-FN7L6CM5N%N+N4@,P"R?,4_.O3([&^MM3:);<263+O6;=EE;TP:R]6?
M5Q&[0>%(+L!MA5Y%5G'K]*Z*6+C"*BE^)M2Q2BDD<E9PP7\AC:YDDD VJ(P<
M,3WS4MS8:M8WA;RI_(C4,TA!*X]*UO/\0;3#!X,6W/W1(LZ@ 'TK>TF;6%4M
M?Z7="01[ @D5D.._U-.>+:U5K=KHU>,G'WE;[SB5%Y>QLRQ1&UN 2)8ER2O?
MZ&LO4-+;2Y,-=R[IO^/=^H1>X/O7HL.ASV.IK?Z=;RQPW2XN;-B,(P_B4=!Z
M'%1ZQX537XC*8[JPN%!1 2-OUQ3ACXI]D...BYIRT1Y++K%QIM_:7+6QDN87
M\J(L3LD!ZG;T)]ZZU[P>)VC1;"%;JT ,TK/ABIY 7_ U=T?X<W-O(L.I.UW$
M,D,6^Z>V.];D'A26WC-O;P1QQ/G<Z\'\?6M*F(H-IQ>O<*V(H.5X;F"=*M;R
MX62RU1X(]FXETR-X[9]*FUFVC&DI<VL;S1EPLY#_ "IZL*T[#PI-#9PPM!(I
MMW;;L8;74]C5O3='O3:?8KNV>.*3>)0I!4KV%83KQO=2N8O%.+34KV&_#=YI
M(9VEB 1?E63^]BNX6N7\(:9?:5/>6T^?L608"<<>M=0*\S$24JC:./$U/:5'
M)=1:9)]TT^F2YV' S[5BC YW5;FSLE6XO9$B(RJ2,.E>)ZQK-]XEUV9;6.)+
M),H)9!D/[_X5W?Q M/$NL6+Z7!HKRVMQ\SRJZ@I@\#K6)IG@_P 065F]H^GL
M\: &,JR_-QWYZU[F#=*FG*<E<]3 0IPUG)%2"RCTZU2*'!D499CT)--U<NEG
M)*I?>N,8&2?85O-X9ULP)_H$O"@[2P)^AYJEJGA37[G37C@TZ=)0ZL TB_=)
MY[]16ZKTY3NY(]V6*H0IV4DRC9V<%_:Q.A\Z(J5+.<;O7CVK3M[.*Q6UL--@
MVI(^6+'H3TJ'3/#'BFU::T-C@DX2Z+ @>^,UT]MX?U6.XMR(6_=E2SN0=V#R
M:JMB8=)(\V.)A"+:>I>T73[[2+B[MK<12YB#N2<;3Z>];1G^W68 !58\-*K=
MQZ?2EG^WV=]+*ELUW#*54;" Z^YSVJNFG7[:O#+.1]DV'*1C&">S>HKQ7/G?
M-+<\BI4=:3G/<9>QQZE:?:(K:*:T9=@4KRPSR15RWL3'''!+M:U)RD6/NX'3
MZ5;>VDCV):QJL6.1G 'TIUX)OL^Z*-FD4[@H[^U9N;:MT,7-M6&RVR?*44 (
MV_:.A/TJ*\B@U",VTA#1N-S!3@X'3Z5:99#$,(06QD9^[44]JZCS+6-5G& #
MCJ/0U*9FK]2&-8K"3:-["3H>6(QV^E4]4U>"WN[:W:*25Y"6"[>,#O6G#'<?
M:"TJKM*X^7L:P-1M-3N]5FE^S2+ B^3&N1EO5_:M*:BY>\S6FHN7O%:ZTY=1
MNWD^RQK'<+Y>,XQ[G%=!;F1(UMTC \I0NXGCIVI;"TDABMXVC($28!)R<U86
M&83NV/E(&*JI4YM.Q-2;EH9FJZ;'>1AFN)4N(SN1XVQCV([CVI[)]B)G:1FW
M[0X/3\!1JD=U#$S:?9F6Y9@,E@!C/))J4I=3(OF6FT!LD%@?RJ4]-R+.Q#)=
M?9A-<7>(K8 '>?X1[UJZ;=17EJDUNVZ)ONMC&:IWMG+<0-"T>Y)!M;/I5W3;
M5;.T2!.$08 ]JBHXN.FXXI6OU+8HHHK$84444 %(:6FM0!\V_M' 'QE;]<BU
M!QZ\UY*B>8Z@Y7?R#VS7UYXN^'>A>+-12]U=+K[0B>6##,4&W\*Q$^"?@]>D
M5\?K=-6BDK:GM8;,:=*FH-,^8_*F&0TC*A/53TJX21,P3):2,,#G.[UYKZ0;
MX*>$".(M0 ]!=-3D^#'A%5 6*^&.F+IN*I5$C9YI2O=)GS.I!+AH"3T#9Z58
MM@S(2Q"KD @"OI8_!_PF9 _DWN1V^T'!^M++\(/"DA^:"[Z8(%P0#3]I$T_M
MFELTSYDRT4THB"C=SM)X^M2VP9[23.7C![]0?;VKZ0D^#'A&0*&AO?EZ?Z2:
M=%\'/"D0Q&E^HSG_ (^335:*%+-Z+MH]#YD<+*RPQI]\[3DXPWUJ*YM=L;B1
MFCVGHK5]-_\ "EO")=V*:@2_)_TIJ?/\&?",VWS(KXA5V@?:34NHK6-5G5'J
MF?,%IIDUM=O-]H:X\Q>$+?*0>_O5^VN3)"TC ,K'8ZL/2OHV/X*^$(V0JFH9
M0Y7-TW%.7X,>$5\W$5]^\.6!N3355;LS6:X=744]3YN\TS+O"JPCRH4'&/<5
M+"8E4&*1XY3]YF&5/L:^C!\%_"(.1'?],8^TG%.7X,^$PNWR[]E'8W)-'M5>
MZ&\WH-6:9\XS0LLSD%&9>2%;YO;'J*+>*6%&NK=XAS@JW!&>Q%?2%S\'/"=Q
M D;PWJ^7]UTN2K#\:23X->$G*%HKXLA!W?:3DX]?6JC4AS+FO8PJ9O!Q:BM3
MQGPCH$SW]O?ZG9Q6MNIW1(!R[?WJ]'D;.>?I[UZ(/"&E;%4I,0HP,R'B@^#]
M))!*3_\ ?PUV5<?">D59(^>DISDYS>K/'O$VH?8;#"-B20[,CJOTJ#X?ZLUQ
M>6=OJ6(KZ*55.\XWC/!%>I7GPP\/7=RDUP+YV5MR@W)P#]*=<?#+PY-J5M?O
M#<_:;=PZ,)R.1TSZTOK=#V;A9D<D^:YVM?*G[22N?B&N4E$7D(3(B$XKZKQZ
MUQ'B[X9Z!XKU3^T-6;4//V!,0W31I@>PKEP=>-"ISR5S22;5D['QZ]DR,7EF
MD>(<A%0@M5>[N[<QA(;9X"#DO*"S'Z5]9I\$?"*Q[$.JJOM>M6A:?"CPU;P^
M7_I\J]O-N-Q'YBO7AF]&+OR&,Z,Y*W,?&4EP-^X2/(3W*GFDBF$<HW$E&/S*
MU?:;_"WPO(N'M9F'KYE9MW\%/!UTP,L%[QT N2 *[(\0TMI1=CG>$ET9\O)?
M62.C016]NN,, A=B?7FKT=UI\]R%N=2NX(@O#1*N<^G%?2<'P3\%1+C[#</[
MO.35NV^$7@ZWQY>GOD'()E)(KBK9CA:CO:7WG32]M35HM?<?/&AZ9X9^UQI(
MM_>L3D;F(4_51737.F^'M:;['_9LL)BXW1)L(_&O;)_AIX=ED$BQ7,,B]'BF
M*FLZ?X/^')RQDNM:.XY.+]AFN7Z]1@U*G%IFK]I4TJ3/GW7/"T6FF;[!I-O=
M1!?E::ZPR^^.Y]JX.33;MEV^4@).,>: %^M?6)^!/@PMN=-38]<M>L:LV/P5
M\&V?F;+6[<2<L)+EF%=<.(:L>@OJ>&W;=SY+T?1;J:5E&HPVR=F.2I/UKH]/
M\-RO<+'=ZQ8NW\,9<,3] :^DY_@SX4G1D;^TA&PQY:W1"_D*I/\  ?P2P :'
M4#@Y'^EMQ2EGLVK6!86CW9X7)X0LOM:K/J\$6>@-O@?GTJ8Z'H5FLD-_K9N(
M6(RENHR#7O\ #\'O"4=HT#6UW*I_BDN6+#\:SV^!'@IQS'J1&=V/MC<5E_:U
MMD/V$&]9.QXKI7AW0K^\D-G'+=VD*<1O., ^_P#A56ZUK2=,G^R6_A^))#E1
M-Q*O'^%>_P /P6\&VXD^S6UW#YB&-S'<LNX'U]Z@7X&^#%4 0ZA@# _TMN*R
MGFM674TIT,,G[R9\Y7/C.6&?R+:RLHX >98X<,?SJ636M5U>]"649MH60_.6
M#9 ZDBOH.X^ W@F9BSPZB,]0MVP%:-I\(/"EH8_LL5[$(SD*MR<5SRQU2;]Y
MG0_JL%:G'[SC/V=9(YM0O3!)<7*I!M:YE3;N.[H/:O>17*^&?!&E>&]4N+_3
MI+TS3IY;+-.711G/RKT%=2M<E2?/*YSR:;T%HHHJ"0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH #TKE-2\?^&=,U"ZL;_4_)NK49G3R)#Y8_O$A< >_2
MNK->/>*;^0?$/Q''8^(=&TT#28DF%Z%?/+\?>&#]0>O2@#T&?Q=H4&JV&FOJ
M"&\OT$EK&J,XF4]U8 C'XU8OO$6DV&MV>D7MXD&H7N?L\3J1YI'4*<8SQTSF
MO*?!.LZ5#<?#EG:/2X1I=TJ07<ZA@ 5 .3CAL9!P.*W_ (A_V?XNM;&'2-2M
M&U",RW&G2"4 _:(CP5YR02"N1ZF@#M]>\2:1H,EE'JUZEM)>R>5;QE2S2MZ
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M@8 ]S5K6=6L-$TV?4-6NXK.R@&9)I6PJBO+M!OHG^*%MJ;M&=0U/2)KA;=I
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M2WC^QWZ.WGI<1G<DA7&!@^AIFG^$]:L_%.F3DV4NG0:<]G<3B5TN)))&WO(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image00029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00029.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $! BX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZIHHHH **
M** "BBB@ HI&-8.E^(X;_P 2ZKHGDRPW>GA'._I*C=&7V[4 ;]%8.F^)+;4-
M<UC3HHW"Z642:Y8@(789VCW ZT>)O$=MH%G9W,R//'=7,=LGE$8!<X!SZ4 ;
MU%9VJ:B;32[B[M83?-%TBA<98YZ9Z"K*7"XB,C+$\@!6-F&>>WO0!8HK#T?Q
M!!J>L:SI\44B/IDBQR.Y&&++GBMB&6.9=T4B2+TRC B@"2B@44 %%%% !110
M: "BO./&GB[Q)9>,(M!\,:=IER_V3[5+)>W/E8&[&!ZU5A^(VHQ^&K^ZU#28
M8=3L+Z&SF2*;?"^\@;D?O@&@#U&BL#QMK4^@>$=2U:U@6XGM8?,CA8X#MV&:
MQ]'\<I??#3_A*)K<17"P%I+7=]V8?P?G_.@#MZ*Y3X;^)+GQ7X+LM8OK5;2Y
MF#"2!&W!2I(QG\*K>"O'FGZ_:1"[NK2VU*262,6HERQVL0/QXH [2BL:]\2Z
M+9:@MA>:I:0WCD*(GD ;)Z"G:AXBTC3KV.TOM3M8+J3&V-Y "<T :]%9.J^(
M-*TAXH]4U&UM7E_U:R28+>_TK$U;Q5/;:Y?:=;16NV#3UO([B:7;&Q+8P3V'
MO0!V-%8%QXJT>P1!J>J6-O/L1G0R_=+#C\/>K>IZ[I>EVL5SJ&H6]O;RX\N1
MW #Y]/6@#4HJO:74-Y!'/:RI-!(NY)$;(8>U6!0 4444 %%%% !1110 45S7
MCCQ;:>$-.@NKVWN[HSS""*&UC\R1F/H*S/#OQ&TS6KFYM7LM3TV\A@:X$%];
MF)I(UZE?7% '<45F^']6@US1[34K,,+>Y3?'O&#CWK)\'>--+\6SZK#I9E$V
MFW!MYUE7;\P[CU% '445S/AOQEIGB'7M;TG3C*USI,BQSLRX4D_W3WKIJ "B
MBB@ HHHH **** "BH;NX2UMI9YCB*)"[GT &37G^F_&'PEJ%S#%'<WD2S.$C
MFGM72(DG ^8C% 'HU%9EGK%G>:I>Z=;REKJS"F9<?=W#(^M4K_Q9I-AXIL?#
MMS<F/5;V-I((]IPP'7F@#H**P-<\5Z3HFL:5I>HW!2^U1S':QA<[B/7TK=)P
M: '45&KAAE"&'8@Y%8?BSQ=HWA6VCEUF[\EI3B*)%+R2'_94<F@#H**X^Q^(
MGAR^\/W^L6]ZWV73UWW2/&5EB'NAYK8L/$6FWWAI-?MKD/I;P&X$V,?(!DG%
M &Q16/X8\0:?XGT2WU;2)6FL;C/ENRX)P<=*74/$.FZ?JUAI=U=(FH7I(@@S
MEGP,DX["@#7HKC_$_P 1?#?AG5(]/U:]=+I@&98XF<1*>A<C[H^M;&K^(=*T
M?1?[5O[V&*P(#+*6X<'ICUS0!L45%;RK-"DL9RCJ&4^H-2T %%%% !1110 4
M444 %%%% !7FGQ-ND\(Z_I?C-@?LT4;V-X%&2RMS&?P;^=>EU#=6T%W"8KJ&
M.:(D$I(H8''3@T >#:W8:GIND^%H[HV\5OJMU+>ZD]VS+$\SC*)(1SC'KQ5/
M4+1Y?#5Q937MO/IC:[:I''8ES'#D_,J.>H^G2OH6ZM+>[MV@NH8YH6&#'(H9
M3^%1)IMC':QVR6D"P1D,D8C 52.X'K0!XCXPM(M"O/'>G:69;>Q.F6T_E*[$
M"0R %AZ$CK3LZ)<:AXFE\;75S'>6_D_V>$D*R+#Y8*F =V)SFO;IK"TF:1IK
M>&1I%".60$LHZ ^HIMQIEC<S0S7%G;RRP_ZMWC!*?0]J /!==N[\67BQ].:6
M-);^R6Z>?(98#&,[\<CWQ75?#&&6W\:7:6=[I9T]K0-):Z:SR1!L_*VX\ X[
M"O5/LEMF8^1%F;_6_(/G^OK3+'3K/3XS'8VL-LC'<5B0*"?PH M#I10** "B
MBB@ H-%% 'A7Q7A\/+\4K:X\8:;J%WI_]F[('M8G8+)OY!V^U826QM/ GB:?
M1M,U*W\+#4+6>QMI8F,IPP,K*I^;'UKZ1**>J@_448!&"!B@#R/Q'X[TWQ=X
M0UK3='M-4-V+8.%FM'0-AEX!/4U5ATF]3Q9#X>CM)1HUZ(]7>7;\BLJ8,?U+
M8.*]E"*.B@?A2[10!PWP@AF@\!PQSQ/%)YTYVN,$?.V.*\PT6*UF\#G0;71;
MJ+Q-+J;RQ,;<JW^NSYWF8P%Q[U]$;1Z4;1Z#TZ4 ?./C:2]O=(\36<=B+:_^
MT!A9QV#2SS;2/WQF/ !QGCI6EXEA-IJ5[<VJSIJ-U;0-]BO+(W,&H,$&-C 9
MC/8U[YM'H.F*-J\<#CIQTH \%UJ"_M_$^I76NSS::E_9P^1&MC]K4_)AH5.#
MM(-,O-&O;;1]1MVMKZ0CP\L:^<F7)\S.TX[CTKWTJ#U .#D9%&T'J,T >1Z+
MH<5QX@\53WNG"1FTBWBC:6/.<0G(&>^:Y2UL=1LD\*7^HW5S8:8NE&V60V?V
MD12[CPR$'!([XKZ'VCT%&U2,$#'IB@#B/A'826'AB02-=LDUS)-']IC$;;2>
MH4?=4]A7<"C%% !1110 4444 %!HHH \O^.2E[/PVBZI_9#-JB 7P('D\'GG
MBN4LV>P\?+;OXH7Q6]UI5RK2L%+62A<Y!7@!O>O:==T/3-?LQ::S8P7ML&W"
M.9=PSZU6T7PKH6AI,ND:39V8F7;)Y48!<>A/I0!S'PI\1:*/ ^@6G]K6/VHP
MB,1>>N_=D\8SUKSO0=1'A&-_$2*?+U"YN]/E [S;R8C^?%>N6OP]\(VEY'=6
MWA[3XKF-_,218\%6]1[UL-H>EM:BV>PMV@$OGB,H"/,SG=]<T ><_"K3!I'C
MOQ%9D[IUL[629NYD8$MG\:]8%5H;&UAO9[R*"-+J8!990/F<#ID^U6: "BBB
M@ HHHH **** ,OQ3QX;U7_KTE_\ 037SY)9^(;;X7:??:AXLTR]T>&.*9M*,
M"*TB!AB,.#G-?2=S#'<6\D,RAXI%*.I[@\$5P^F_";P3IU]%=VN@P":)MZ;F
M9E!]<$XH I^#;ZV'C[Q1+-)';B6&U<)*X4@&/IS7/?$BT-]X_P#M]@5>ZTW3
M5OK=D.<[9/F /N,UV_B/X:^$_$6J2:CK&DQSWDBA6DWLI8#IG!K5TOPMH^EB
M(6-BD?E6YM4.22(CSMY[4 >2:O>1>)O%.@>)XF#VK:I#:63?[(4E\?\  LC\
M*]>\5'5_[*E_L'[)]IP=WVG.W;CMCO4=OX5T2VLK"SM]/ACMK"7S[:-1@1OR
M<CWY-;F,]>: ///@W_PD)\,VQUG[$;/8WE^7N\W.X_>S52ZFLK3XZ&377B03
M:8JZ8\Y 4,&_>!2> :].15484 #T Q61XE\,Z/XGLA:Z[80WD*G*AQRI]0>H
MH X+XBW_ (<GL/$\.F+!+JXL5-Y+" 5\O<,*[#C/MUK#T_=:6+> 8F*M=7$<
MT*#_ )]&4,_X \5Z=IG@KP[I>B3Z38Z7!#83_P"M0 GS/]XGDU>&A:8-5AU$
M6<?V^&W^RQS8^98O[OTH \\^%NL2Z1X-TVTL]%O[V!IYD$ML%V1#S".<FKWB
MW1]/L_B'X5U*&W5;^ZO'$LS'+$!/NC/0>PKO=(TRSTBS6STZ%8+=6+"->F2<
MFEO-,M+VZM+BY@62:T8O"YZH2,9% 'F5E<Z5;:C\2TU:2WCF+%G$Q +1>4=N
M,]JIZGHEE>_ _3[W4;82W-I8*8/,)(CR1@XZ9QCFO0/$?@7PUXCU*"_UK2;>
MZNX<!9&R"0.@..H^M;-]IMG?:<]A<P(]FZA#%C"[1T% "Z,<Z38G_I@G_H(J
MY3(8UBB2.,81 %4>@%/H **** "BBB@ HI,TF: '9HIN:-U*X#J*;FDW\TP'
MT4T&C=ZT .I*3-)F@!U+3<T9I7 6E_.FY^E)NIW ?13<]*-U*X#J*C>0(FYV
M"KW). *BBO()MWE31L5X.&SBF-)M7+-%55O;=E)6>,@=2&IC:G9K(8VN[=7'
M53( 10'*^Q=I*J_VA:[=_P!IAV9QG>,4Q=4LGSLNX&P,G#CB@.5]B[2U$DJN
MNY&5EZ@@\4V:YA@3?-+'&F<;F8 4KH+,GHJD=3LPQ7[7!E>OSCBD_M.RP#]K
MM^3@?O!3#E?8O451CU2RD?9'>6[OZ+(":G>XC3!>1%4G )/!- <K[$]%5X+F
M.==T,B.H."5.<&HVU"U5F5[J %?O N.*5T%F7**@AN8IUW02I(OJIS39[R"W
MQY\\4>1D;V S1=!9[%G-%06]U#<*&@ECD4]"C9J8G%,0M%)DTF3F@!U%-Y[T
M9- "TM)S29- #J*:#FC- #J*9DT[F@!:*3.*3- #J*;FC- #J*;D^E&Z@!U&
M*;GUI<T #<5YO\0_#UQ>S7FK:KXJOM)TBUAS;164GE[9/[S'^(DXP*]'S7E/
MCKPWXWU7QE'?Z8=#NM'MD'V:SOR^U9.[L!U/I0!UW@6\U23P%87>MJSZE]G+
MOE<,^,[21ZD8KR3P)<PKXBTZ^\37'C"SOKJY8H]TQ6R:0L=L>WMQZUZ[8)XG
MFM[*+56T^'?;2+>/:[MR2G[ACSV^M<K'X3\8ZI=6.G>*-5T^ZT*QN$N%FB1A
M<W+(<J'[#WQ0!UWC7Q,GA>QM;EK26[:YN4M4CB/)9NE<U)\1=0235+8^&;HW
MVE 2WD8E7:L)&0RM_$<<XKI/&>B7&MKI(M9(XS:7T=T^_NJYR![UG2^%[QM6
M\6W(GB":O;I# .<H0A4Y_&@""Y^(!G=O^$?TFXU2."V6[NF5PGE*RY"C/5L=
MJS[GQ1)XIT7PY+IHGL_[1$EU(N[#I'&#D'\<5R^^;P3=ZCIUGJ%C;W4VGQBZ
M6\1E4R!" \)'WOI71_"SPSJ$7AZPN]2*K)_9AMH8V7#*6))8CMG(H 9\,_&_
MVW2=,TZ)GU*[B1Y=1N=_RVJ@G&X]VQVJW/\ $V2*"VOSH-VVBW=RMK;788?.
M2VW<5ZA?2J'AOX<7/AB/3I]->WCD>*2#6(H\A;N-LD./]L9KD);R^N]#T3P]
MI=]:W%I!J4:Q0A&%V8U?)613PN/7O0!]#CWI:;G%+F@!:*3-&: %HHHH ***
M* ,?Q,T:Z5)YUV;0%@!,#C::X_3[O5]6%S9?VB(HXV*I=KC,GI@5U?C".PET
M.9=6!-J""5!Y8YX ^M>:36TDFK6.I7"36\+S>6D@&/LZ#[JL/7WK&>YU4(IQ
MNSJM!UZ2&[ETV]O!-<6["!$C'S/ZN:B\?7MLHT^*>YN8WDG6,FW8@@9YS6)I
MRV-SX@OK66_D@N8&8V]SM"AR>IW?Q5M)8?8_$<45^LMZEY$%$S+D*X[GTK)Z
M&G)%,GU?Q8VC^)+72G$9MY805E+$[#_M5B)J<;-JS:R]U/;O*/+O+4G8/11C
MIBKLU@-'NHI9K1Y0)F+7.S>QC]&'\JISW']DZ?JL%I&\NBQJ7>9%PZNQR OK
MCO5)WV"T>@ZVCOV6W2Z%Q';V;CS+H7'SR*W0$>M6=,\4RZ3=76E7D%S-,LA,
M++\W!YP2>]8UU<6B6%C?*DPTAMJRQNQ+22#_  J9KJYML/L,ENTK3P^>,!U(
MXRWK3U+4$]T6-'U+7[&**2>X-^^H2L(8V.WRU]/]ZK&I0ZSH]I9#3]2D)EE)
M>WD8%R3VR>PJIH6J_99K0+;223H2UTCC/V="<YS5R^LY-;\3?;TGA73K6/*H
MZG,I/K4^]<.6SV)O"FNRV&F21:NER)A.0K\MYA/85C>(-?G?5DO[,WR0-)Y
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M4FF[-&=)J=O)<Q0W4%M#]J8R1W+G)A)'//K5.TE@CN?L]Y?PVJ3JT8N&.?M
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MN5$58F 4%)3Z^U/\2>)=,NKY;/P]!<:?>R,(DU#=Y8C;I\X/:JMT=#;7)?\
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M6T1  5[G;722^'M*N/#UQJ6E[]-N)X?-$\!P4;'I_2N9LM0O;O5EL[:UALW
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MI<RNS5N8KO6[B&6+3[U+2WA\D1P1CY7/?/<>M5VL[[3IY8;M[:.&%=K*[[@
M>H7WKJ/#^N7FGDV<!EATJ=]OVRX7[I[[3WK#\<Z0-.OELK26&>&63[2N]P6<
MG@!O;WK-2;=@C+6Q%#>Q:QJFGR_9HX]%L0%*GYG;GAB>HYKWG6IKA?"\\NF,
MJS^0&B8\@<=:\&T>]D\)7QM9K..Y:X027B.PQ'D\+&>XKW^Z59]!*HWDK)"-
MN>-N13[G'BK<T3GO"-Y%>6.Y%59P 96Q\SGU-;T@!C(*;E/!7&<USO@WP^-%
MM92TIFN)CEV!X [ 5K:U)&FGR+-<_9!)A!*.H)Z8]ZXW\6AG-+FT//YH[B#6
M;G2Y9EFL[-C,@QD;WY"D>U-N;AQ%]JNXF(+;(D!YE?L /3UJK'9W_AB[U>YU
M9C-:2D20W)Y9]O8^YIGAN^,%U>:Y?K/>Z>R[TCVY^RY/IZUMRWU.M-1AH=#\
M/;+^UH;Z]UFU\QWG#()%.%*\?*#Z5VFJ6AO+;RHY&B?.1(!]TBC3+N.^TR"Z
M@5EBE4,H88./I63;ZK<+XNN-,DC\RW*>:) >8QZ$5D[R>AQ^]*39ES17MSK.
MGV.O7*13AV>#[,/]8J]V/8FF>![X:MXEUV>YP\]O((T#+CR@.,#ZU1\,:Q<7
M?CO4Y+N&.98PR*RG_CW5?\:H:A=O8SW6MZ'<AKJ2Y\N:$+]Y#T8#O6G(]C7E
M=K,]&UR&>2PE^PQQM>8^3=QBO)-;74K73W&N7.HW,@&V%FBPB2$^H[5V_P /
M=2O)HI[*]D%PT;EUGSDG)^Z?I787"H\1$VUH^I#].*A/D=F2I.E+E:/%K2"Z
MU+3VMM)>1[R2/-VD;8W '@9[?2M?P[9W=OX;:>>Z87]NSQGS>1Y?=<=JL6-W
M/<K>-I$L-K,[S VT:C@ 8#$US>GW=R@2823>6[".8.V6N2/O#'\(![UK\2-K
MW1WFGZ;:VMM;W7E++@8,H^9IHV[^N16/K6EK<K)<V^I:A+:P?.S/+A$'H!WK
M-DNKWPYJ\K0++=:C* L* %H8%;G9]:UFT^;4K6Y?4O-L9HV%RUK ?ED7W'N:
MRY6G<A)IW.;FFB\.^);2-_/N81^^*IG)7&1^%>B?"NZ_M"WU:_5SY5S=%TC)
M.4&.A]*X74I_-O9GUFS:QAF_?!P^YB@&%50.@]:]%^&=HEOHKS!@9KAO,<!@
M=OH/KBMX6N3B-87.Q%% HK8X#@?C+>?8/#>GW#7!MXDU.W,DF[: N[G)]*P9
MO'6C/XI\7POKMK]E&G(8#YXV[MASM]Z[SQM?Z9I^A/+K5G]MMV=42V$?F&5S
M]U0OK7DGBKQ+H\<4$7@_P9IVJ:CMD-W82VP26SP/O/Q@ >G>@#NO!FJ"R^$^
MB7MP);A?LZEV!RV"?O<UH:_>Q'PY/<VS*_G(!"P&<L>AJ&21;WX:6LT8BE#V
MROM@78A..0%[8]*XS1[NU\G39+>X::9I##/8.^Q ?[V.V*PJ1N[G90A>/,B/
M4IYY;:)[B&X,BN2\T?S,[J/N_3O5BQ@NK#3+34EM(8_.^6YG<[]RMWQUR*$C
M@M+B>[N#]@:.7RU1),B,G^,KWS5FU,R_9G%P[)$\CB21=RL.PV#IFE<Z6^QF
MVNFR)?Q/9WDDN')C3JBGL<GI2R1ZM8ZC=P7LOVASQL!VJTC?Q9^G%61'+;M!
MINH(8_M-TLTL$'\2GISUP/2NE\+)!?\ ]M6TV^:!+C9MFY<>V?3TI.5@E4:5
MVB'0M4DT#1Y+:_L)DBM!DRHX<<\]:R/$-M<3P1ZE?B&R\T$MY /GR)VQ^'6M
MO4/"VGBZCMDNYK:UN<M);[\^:1Z$]*SX8YK?Q1%#>WD=]81#9:LS@E'/\+8]
MJE:ZF46F^9&9#J,6FWT=[<O'+IES;^3YT#;70D8W,M:+:D;K0[:"T22YU&-R
M;-UQNVCHS?7TK(\1F7[/?B>ULR+R7;%Y1!*E>  />L'5-'N_#6G17%_>?9I9
M75XX8,\#TSV-79,W4%+U._\ #Z2:/;_VCXID6*>XE*QQE05CSZ>E4=1EF)U?
M5-.M[*;1UC9'4<F5N[>V*YO7+^YU"S^QS3RW$J[;B.6-2PCXZ-6[X4UZ&TN'
MMM13[-;- J %<)N[L1[^M2XM.Y+IR6O4Z'P3:6\.DPRQ2Q2W#Q@.T;9&.HR/
M6LCQ3J<:>.]#M'4"-6^=F'&X]*PO"?B'1-#\0:Q'(Y99)!LN5Z-ZC'08]:U/
MB!/IVHVFG3V7ERW#7"[)P>(R.1N]JSY7S:D^S:GJCH_%\=S=6*6-D0LMRX5@
M>A7OFIX=#T[=;^990-)& N\+C\JXV2:^O;P:E/=PB?3EW>07&PGN 1US6G;^
M-HY?LT@A57:9(_+Y/F ]U^E1R-.R%*#2LCIOB9!%-X*OHYU+1!02H[X/2O(K
M&U::2RN9;N31K0,JHT@+B9L_=4]ACO7LGC_R3X2O!<M*D;*%+1C++GO7C5[I
MNK2PRWIF;[%;E8Q:R'/FICK'Z$UWWT)PK]QHZGQEX+LKR$:C"(9[9(S),/.P
M93VP1Z5YIX;M;B.^"PPV)MYT8RQ7/0 '^==%J<BQM]DU&WNK*S\M6MK%"0.G
M4GO4%SX9N7MM(N+&,7$%RS6X,K;"BG^\15TY6C9LZ8QY5JR:SGF2ZN8;6RLX
M]*N!MDDAY 8?Q9]O2M[X8WVEQ1ZS;ZE%$T/FY-U,1B;/8 \XKG+&QNX+[^S]
M%MI)FAW&Y$9P)@OH>@I+>/3TOO/N=I'ER+]A92&W^[=*EJ^Q<DIQY3?\6V.A
M:-IMU%-<_:KZ]_>)(W\$>> M<;;:UJ6K10Z7#EP[EEROS$ 8'/TK?LYK:STN
MY6[OXO-F0K#%-!YGE+WVMZ5GV=I+IK0:O:,L=H["%H2VUY<_W1UIPLHZC@E&
M.I:L8KNW@FL+F^^P6+Q?))-#N+X/(7WS5W^S;C4&CN-1U")[.R7;$9)-CR'U
MQVK0NM+\2H \&G.UE&695N&#-&#W [USVH75W;^%T?4;18XKB0^5*Z9<N#UV
M]JGXB.;F=TPM);R53!X<LKN=O,_TB56W*RC^'/K]:MG2K?4[K.LRIHT=FO[U
M@^7 /\)-9&B:VR:7.RW4L<:RK)<VUNI1I .V?>NEM-(T[Q=KGV?1DN+*S$ D
MNF<9^8]%P>II2T8Y2Y6S$GLHGU*"TTF\NKB6X;8TV20R=CM'&,5W/AJZT/PH
M;Y;V>2WG&T227!QN] HK@?$*_P#".R1Z;I-TTFK^:5:2(XP!T0?A6C=^$&U?
M08=86^:ZO5^:2"3YE'M]:F44TN9D2M*.IZ?8^+-"U"'S;35+9EP<@MM/ZUP>
MI_VEXI&HZE!?W-O81/Y-O!#G$P[G\?6N \/Z<;RYFTZ5H;<7$FYI F[9VV^H
MKT'Q-JB>%_"L6G6>I2).3CS0GS1K[#WK.5)0>A,::@[+<UOA!YKZA-)J$?V:
M]6'RA;E2"$!X)]S3_C/<P6UUI[&26&Z*,(Y4';N#2_"+^TIKZ6[U:)P\ENNR
M21<,PSU-9WQ["B\TLXS(T;",[L 'Z5T4]=&8K7$%.XN+>72;=OM/VK[.-JI'
M(-N/5L?=/J:R_#>KW%K)+%#;"'S'SY$,>_>>V'[ US>@74NF[OL=BE\UW\N6
M&-A]A_C5F;5+[2H)+2WO5C(E#2>0!]X] #Z5?)T.U0MH7[ACJMY/=[6CO%W1
MM;VPRD3GCD^]5+OPY-IEE:7NLRB8LVR2%&(D'/0_A6CIUM-IMY+'=WC:=:W2
M"2:7^\,9#+ZFN@\/Z>^LM/IT]R[1 K-O="LKQ#^)L^M)OET%*?+HSC)(K36]
M>$.DVR66GK$)(U)R2RCO]36AKZ7D5C;:CJB6%W"4,;V[?N_G/3Y?[PJ?QT+;
M2EM]-M]/$"NXDB9),L$!_,9K,OYO$FLQP^5I376FP'S8E9-S!@>!GO5;ZHES
MT3-K2E'A?PQ+-%9W#W%W^ZNVFY2(=1Q5..YE?4+G5KVRM6>&V!2/;^[EQP!C
ML:P[B_O7U C7H+BS>==@4D[9FST/IBM/Q1JLEMHL&D6B1&W1MXDF;+"3^[GN
M*5FF5%65T;GAGP!J/C"U35M;OUM;64X@M[<9V1^@/:M7Q$++P1H-SIVGQK U
MU&8XLG+S'NS?AWKC+BXUCPY_9QTO7$NK:2(O);Q-A8R>XKGM2U*^U,F2\F>>
MX3G>PR0,_P J7LY2EJ]#*,).7O;$-HT+M%%('CBD/EE0V,'T->I_"*WTN[.H
M6UW;Q&\1AY<<OS$(.XKE_ ^E"^EO$6!+B6[A9<L "O\ M#/O1HWA/5]2>XET
M:=HKK3V,#9;:7/=0:*S4E8UG9P:;L=W\9PCZ):6L$ZQW'FA5@0#+C^GUKB]9
MLA<:7!/';I%=1D(Z[LG@8Z^E:%_8WFF+:7GBS3S/"@\G*R[I#GH21T-=#:Z/
M=^)[.**1$L]-MW'DRD9ED7^Z<>GK7,GR1,H-4TNQQFJFUN(HH&LS97EN8EF0
M29:49_+WKV[Q,O\ Q1ER%#-_HX '?M7E>M^#I=,N]USNN[>5PL11MK!L\;LU
MZ]JEF+KPW+:RS- &@"M*#RN!UK2$DU=&&*E%N/*>;>([BXL9-+34=:&DZ=!&
MKQM$"7E..<U-JGB6[@T5[^YLA=K:.)(>=AF4]&Q6;J5]X<UZ?2](NXKB^9B(
MH7S@L ?O5M^/=#N[F'2;+2(X8RA* R'(V@<#WK.R;LRURII2,YO$IU:Q8-ID
MU_<S8?[(@QY8ZC/L/6ET'5C%K&[5K86-C>C:T8YBW+T.>F/:J_@=+O2X+W6M
M0B;YF>UNP@^9,< @>E03ZY!%_9MI<IFQ27_CW8?,X)^\WH.:JW1#DDVXQV/0
M-7\3V.DJB".25F98XUC7Y6)Z8/3%<5:0_P!M^(=1OFU.>U4*$9 VU@>ZCUJ>
M?4M%^T7FEZ^D::5;R;K*4L0=Q[#^E<=XBU0/8V-W);20WEM-BVG\HJ&4'HW8
M_4T0IVT(IQ<3?\.^'K'4M8G73;R\&GM(PF8@QLPQT+'WJ;5K:+P[>VO]A1SS
MP1EHGE8^82_H/?%9]OXEFU68Z5<M%86U^RDR1\;/<>F?6MZ/0;C2[9;C1]66
M\LK>X#R0/RSGH?FHDG%ZE2YHN\BIH-Z?"UU*L&DWLYN(_-EGE^7RR?[WM2RZ
MK'J%PD]Y/<76RYV7<41Q%$G;'J*M:U>0R^+(;?7;N0PQ%5,2C"2EN0#[#UJR
M?#D$VNK;/^\AF5Y]L;;8XR/ND_WJEVW9-UNS&O/MFI>)-0LM#>WM?/(C8R+@
M^6O/RUVFAZ#:V5C.DFRYN)P1/(5Z9'0#L*XZYM+N.^DAL[F.*_TI&FDN)6!>
MX)]!Z 5U7A#68YO"ZZE?W?WB=\DB[<'Z5$[VT"5VM# T]\_Z%I9D%W9NS3SS
M?,J^F!W]JH:9J,MZ=6MK^]"W5T1;JX4AFY['TQ6_K&IZ9;V\6L:=%&WG%K8L
MF06SZ#N<URDMK%;6_DNUQ)J\T9$,$O6#/\0QU)HCMJ5'5:E-8B=1GLXA+++;
MH;1[@ON0YZ#GI7KWP_TR+3-#6.,EI&.9')^\U>'Z1*VGWOF7&GW-S:0OO55?
M&7]_4YKVWX=ZDVI:,\LH*3AR)(S_  >@K5:2L1B6^4ZRB@4&MCSSFOB"NCMX
M9G;Q#++!9*RL)HL[XWS\K+CD&O'3<^$=-N+I_"'C"XTJYNH]FHO+:O<27'^V
M21D-UYKW+Q+JMIHNDRWNH0S36Z$;DBB,K'/^S7E6F^.M#M_&FM:A+I.J?8[B
M"%(C_9K<E1SQB@#MH[>&U^'EG'X?G=K.*)2LKCYGC_B//<\UY1J,4)OH8X+G
MRDEEQ&)$PS9Z;C]:]@\17L%YX)>\A2=+:1%?8$VL%SW7^E<'XA:VU6\AQ:S6
M[-&L<$\B?NG3&=WL?2LY;G?A).S1/>Z1%IY%M>7+7!NE\R]5%W,VT<8[J*DC
MO+"Y.EIH_P!ILO/?RFE?H4 Y&3WK(TB\BL;EKM949(HFMKAIW)>;/W=M7WD7
M7[."*"$6\-MC_1T8?OGST'<8K-K4V<>YUO\ PC2/931"X?>9A-%<EMSKCW_I
M7/Z(NJZ5J-J;-8)K2]G=)9)&PQ /4^K52NM5OX?M0LXKBUW'R([0?,[*!R_M
M]:S(;I-/&C:C:F=W5-OV:23<8FSRQ],\TDM"8P?*U>YVOCM-+O+BPL]3:[@E
M#>9!/ #P>XS7"Z3;B&\^R0:5>W,?G-L+$J78=-Q[?6NL\:>*+>"^L;2W9&WQ
MF5Y0-_E@\ #W)I/ NZP=A/=&9KYSN5CEXF4?=^AH7NQV%&\(79F:/-;V?C:W
MTX6"QI(S29D.YE?'*CVKIOB-IZ:EX=:)RJNLBE"?6N$U"^O+GXC:=--;S)BX
M*P;EV_(.#]:[?XG7<5MX9E\UF 9P<+U-*7Q)HTY7[2-CB_ VJOI\IM]@,C3"
M*=R/3I57XD2&2;4-R;)A<+&)1V0CY?PJ7P[##'X9LIG($U_?>>"?O*B__JJ'
M6-37Q#K^H3QV<D5BD?D,\AP),=#BJ5^;4Z;?O+FOX8^'FF7WA1?M4BS7<YWF
MXB;A?85BW0EM;@QW5M%<VL'[D^4,+,%Z@_[0K-L;+7(-L-EJ,\$2MN,29#'T
MVBMJ&SB2XM5G,S7$DY6YC23YT<_=DQZ^M)[N[(<7%MMFPME%-<-?>&](,L3Q
M+@.=JJW3(SW JG;W46E:\EC%:W9MT=-[M'EHB3RH/IFM;4M%FM]%ATB6[E5Y
M[K]PT#["_<[S_A4.G)=P>*!9WYNHEO,!(_O[MGJWI6<6KW.?FT9Z%XNNK:S\
M-W4]X<6X3#';NQGVKSGP%?Z=9V/D/'=7H$K21-LWJOH!7I'BS35U70)[.1Q&
MCXW$]P.U>3K+?>%[E[73;6\N9)%+6:9!C3ZXZUTR2:L98=<T&CJ_%GAJY\67
M%B[N+.UC4[B1^]Y[>U4]5\%VNCZ"S6+7MR(3N,)D)+>I4>M:>E>(-=FTZ)KO
M02MV1APLHV+]3VK @\3^(M8DOC:VMM]B2-XF17PR..X:LXJ14>>Z78Y_0=2B
MT75KE[=K^P%Q\BO=KE2WHW^-9ZI92/J(BUFVM+B28>8&^>-L]2#ZYK*DU"RN
M;""SO?M]Q=QN5=I9LXR>B^]1ZEX/UNUCM+MK+[%8M)N4NX9AG[NX?TKJ4%:[
M.IJ*W-*5Q?,]M=7:M)9'9%Y:^6/K]"*U=/F6[M=/MGTJ(W>=T5^TF50@_>/;
M\*CUWPY>:6(+G57@GDECQ-+$VW*]B$[U>OM"CN;6V@LKI191Q HS*T:J?1O>
MHDT$I1DC2UCQGK.AM<0Z@D.J021A_/MOE$2GC:<=ZY#4O$/]MRV&H10/&L*-
M$L+?.$;W]<UT4V@107XT2UNS!IU] 6N)=XD <>GH*T= T0>#[N56M$U&*XC
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M;(V(T09+G/\ %[>]2V,S26KV?V-VE9C)(0,L$]O:CVTMP^KH]N'Q*\+D1_\
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5** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image00030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00030.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $: 8@# 2(  A$! Q$!_\0
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M*+6,!$E\P%=@P<\=1VKI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 9NNZO8:!I=QJ.K7*VMC
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MYWPHTE#UMWFM_ILD8?TKTFO+_P!GT^3X7UFQSS9ZU>18]/WA/]:]0H ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[Q27/]:]26@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM_#[48 F^#6UBR_0!T(Y_*O0]$N+N[MO/O$A0/R@B)/YYH TZ*1:6@ HHHH
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M&_I70_#Z?[3X'\/S$[FDL87)/J4% '0T4 YZ44 %%%% !1110 4444 %%%%
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MAL9W&G9K#TNXU*:]NH[J2T,-NX1O+1@S' .>3[ULKUH ?1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!X1\4+Z7P)\9M-\;:CIEU?Z#+IQL9)H$WFS
M?<3NQ[@C]:YOXE?$K3/BOI^G^%/ VGW][?W%[#(;B2 HMLJMDMD]#[UW_B#Q
M)<P?'[3-$U74Q9:$^EM+%;N0(KN8L00V>#C' J'XZ:Y!X3\*V=SX8O[;3M9:
M_@$<%H$#70+89& Y*XH ]=@0I#&C$LRJ 3Z\5+45NS/!&SC:S*"1Z'%2-TH
MYR_\<>&M/UN+2+[6+:#497$:0N2,L>BYQC/MFG:QXV\-Z-K$6EZIJ]K;7\N-
ML3MR,G R>BY/3.*\F^+6LZ/XL\967@DW=AI]G97,=_J]].RQG<I&V*,GJYXR
M>PKF_%]S:P6GQ@TS4-O]MZI>P'3867,MQ&0@C,?J!@].E 'T\&!Z<CUK!\;?
M\B[-_P!=H>G_ %T6KV@Q2P:+IT-T/](CMHUDS_>"C/ZU2\;_ /(NS?\ 76'_
M -&+0!L7/_'O+S_ ?Y5Y;XR\+376@6'B[P_=O8>)M'M&>.=%W+<Q $M#(O\
M$IQQZ5Z;J5Q%;6DKSNL:E2 6..<5F^&+VUET& )/&PBC_>C^[]10!\N?"O\
M:$UR]^(D5OXG>PBTC4IMDAV^6+<XPI#9Z< <^M?7<$J2QK)$ZR1L,AU.X-[@
MUYSH?@OP%/J^M&'0])DEO'*M^Z!WJ5!; /3G/2J$OP[USPE*US\,=<:W@SN;
M1=28RVK>R'[T?\J /6 X/K3@<BO+M(^+%K:7T>E^/=,N/"^JMPK7'S6LI]4E
M''YUZ7;W$4\*2P2)+$XRKH05(^HXH FHI-V>@/K2@Y]J "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*:)V]%<$_E5C/3B@ HHHH ***"0.M !129_^O1N_R>* %HIN[V'YTN>>GZT
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M6S^E7O+\4X_U^C_]\24 =#D=,T9'J*Y_R_%'_/;1_P#OW)_C1Y?BC_GMH_\
MW[D_QH W\CU%&1ZBL#R_%'_/?1_^_<G^-'E^*/\ GOH__?N3_&@#H,CU%)D>
MHK \OQ1_SVT?_OW)_C1Y?BC_ )[Z/_W[D_QH W\CU%&1ZBL#R_%'_/?1_P#O
MW)_C1Y?BC_GMH_\ W[D_QH W\CU%&1ZBL#R_%'_/?1_^_<G^-'E^*/\ GMH_
M_?$G^- &^3Z8H!)_Q%<](/%"(S&;1^ 3]R2K_AN_DU31+*]F5%DFCW,$/R@^
MU &G1110 4444 %%%% !1110 'FJLNGV<UU%<S6D$EQ%_JY7C!=/H>HJU10
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MG%=I2;10!XU;?#'6_#']AW'A&_LKF[M-*;2+@:@&"NI;=YJE<D%23\OI7?\
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M ,<ZCYAGWYKU05X/\0_](^-'PFMX/]?'&\KXZ[-H_P #7O(H **** "BBB@
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E^M=J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image00032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00032.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &L OH# 2(  A$! Q$!_\0
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MPSAXC_Z#>C?E+_\ $U]1T4?7ZW</J\#Y<_X9P\1_]!O1ORE_^)H_X9P\1_\
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MR>)_^@WHWY2__$U]:=**CZ_6[E?5X'R7_P ,R>)_^@WHWY2__$T?\,R>)_\
MH-Z-^4O_ ,37UI11]?K=P^KP/DO_ (9D\3_]!O1ORE_^)H_X9D\3_P#0;T;\
MI?\ XFOK2BCZ_6[A]7@?)?\ PS)XG_Z#>C?E+_\ $T?\,R>)_P#H-Z-^4O\
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MGB?_ *#>C?E+_P#$T?\ #,GB?_H-Z-^4O_Q-?6E%'U^MW#ZO ^2_^&9/$_\
MT&]&_*7_ .)H_P"&9/$__0;T;\I?_B:^M**/K];N'U>!\E_\,R>)_P#H-Z-^
M4O\ \31_PS)XG_Z#>C?E+_\ $U]:44?7ZW</J\#Y+_X9D\3_ /0;T;\I?_B:
M/^&9/$__ $&]&_*7_P")KZTHH^OUNX?5X'R7_P ,R>)_^@WHWY2__$T?\,R>
M)_\ H-Z-^4O_ ,37UI11]?K=P^KP/DO_ (9D\3_]!O1ORE_^)H_X9D\3_P#0
M;T;\I?\ XFOK2BCZ_6[A]7@?)?\ PS)XG_Z#>C?E+_\ $T?\,R>)_P#H-Z-^
M4O\ \37UI11]?K=P^KP/DO\ X9D\3_\ 0;T;\I?_ (FC_AF3Q/\ ]!O1ORE_
M^)KZTHH^OUNX?5X'R7_PS)XG_P"@WHWY2_\ Q-'_  S)XG_Z#>C?E+_\37UI
M11]?K=P^KP,6BBBN0V"BBB@ HHH )Z GZ4 %%+M.<8.?3%2V\#2MCHHZF@")
M5+G"@D^U6H[)C]\A?8<U=CC6-<(,4ZE<"LME&.I8TOV.+_:_.K%%("C+9$<Q
MG/L:IL"IPPP16U4-Q )E]&'0T[@9=%.D1HVPXP::!GIS3 **4J1U!'X4W(SC
M(SUQF@!:GLXO,E!/W5Y-,AA:5OE&!W-:<4:Q(%7_ /70V ^BBHH;J"82&&>*
M01G:^QP=I]#Z5($M%&<]** "BBB@ HI"P# $C)Z#UI: $<;E(JJ1@X-6Z9)'
MNY'6JB["96HI2"#S25H(**=M8=0?RIM !4L"Y;)[4V.,M["K(&!@5$GT&D%%
M!.!D\"H[>XAN8O,MI8YHR2 T;!AQ[BH&24444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !65XJURW\
M->';_6+U)9+>SC\QUB7+'M@#\:YOXN>*[WPIH$$VF1H;BXF\H2.N5C&"<X]>
M*X_PG\4[^^T&_&L:+/J;P*<R6T.8V4]G'0?X5U4\+4G#VB6AG*K%/E9Z9X'\
M36OB_P -6FM6$4T,%QNPDRX92"0?U'6MVN/TSQ0J_#A]?M]&FA2WMWD6PB3!
M.W/"@#H<>E6OAUXH?QAX5M]7DT^;3VE9E,,O7@]1Z@UC.#BWIL6FF=-11168
MS%HHHJ@"BBB@ ^M>+>'-/N/BOK&N:IK6IW\&@V5X]E8V-G,8E.WJ[$<D\C\_
M:O:?K7BGAR^U#X5:QKFEZIHNHWVA7MXU[97EC"9=N[JK <YX'Y>]=%&]I<OQ
M=/U,Y[J^Q>^).@#PC\(M5M=.U35)4>YB999[@N\2E@-JMU KI/@UK\ECX%U2
MPU^X)O/#4TL%S)(W+1J-ZN?;:<9]JROB1J$WB_X,ZG/INC:I!(]Q&J0W$&V6
M0!Q\P7KBL?XH>'-=7QFEKH-M*=/\86MO9ZC*BDB!HV7<[>F8^.?4UK%<\.2;
MUN_PM^ES-OEE>)6^"%[J]Y\6+Z\U:ZN6_M72_P"TTMY')6%9)3L4#H,*H_.O
MH:?S/(D\C9YVT[-_W=V.,^U>4:;HDEO\=]06*UGBTM?#T-I',JD*,,1M#>H%
M=7X/\!6/A;49KRSU/6[MY8_+*7UZTR 9SD C@UEB'&4N;R1<$TK'F_AV/Q+9
M?'W2X?%&L&\NKO2YKA[> E;>#D@(B]\8ZGDFM3QC#-XW^,4?A&[OKRVT+3]/
M%[<0VLQB:>1CA<L.<"K^J6-VW[1FC7JVTQLTT>2-IPAV!MS<$],U4\9?:_!G
MQ;B\8G3;V_T6^L/L5TUG%YKP.IRI*CD@UIS<TDUORZ>I-K)W[DGPKNM2TGQ%
MXT\&?;)+Y=(,<VG27CEV5)%)",W4@''YFL3PE'XCLOCY;V_B?6&O;NXTA[F6
M&$E;>$EL!$7T&.IY-=%\(;'4-1\5>+?&6HV,^GQ:Q)%%9P7"[9/)C7 9AVSQ
M^5)/879_:/MKX6LWV(:*T9GV'8&W'C/3-#DN:2\OQL%M$_,["XUR_P#^$XAT
M/^P;F33)+4SMJF?W2.#]S&.OX_A7/?'=6L_A3XAN+262&:. ,K(V"/F'0UT4
MWB@Q^.X/#?\ 95^PEM3<_;PG[A<'&TGUK&^.UK<7GPH\0P64,D]P\&$CC7<S
M'<.@K"GI4A=6V-'\+/(?$5A%X)T'PMK7ACQ/J$FM7DMJLFG27GG+<"0#>-AR
M?_UUZ?I%UI?_  N37+0:=<+JD.EQ2RW+71,;K\N$$6,*>>OM5_X??#SPQHNF
MZ3J-KH-K!JGV:)WE=2SJY0;B-Q.TYSTQ61IMC=I\?/%%Z]M,MG)HT2).4.QF
M&W(!]:VE.,[KLG^:,U%QL4-/^,.J:KH,^K:%X&OKRQLF=;R07:*(]AY"9&7.
M.3@<5T^J?$W2;7P1I?B*SAGOO[59(K&SCP)9I6X">V#U/:O(?A;XVD\/_#+4
M]-?0=6O)KJYNA926MN9(YV8XVEA]T@]<U<UKX<ZU9_"/P4LEE<7EUHUT;N^L
M+:0K*8Y#E@A'\2^U7*C34K-6U^\2G*UUJ>H^'/'MY<>*8?#OBC0)M"U.Z@:X
MM ;E9XYU7[P#*!AAZ5YQX0N;6T\"?%>?4K:6[LX]4N#+#%,8F=>. XY7ZUL_
M#VT\(:AXQL+G1]$\4"_M4=A=:B)A';Y'*DN>IZ<5C:;I&HK\-OBO UA=":YU
M"=H(S&=TH.,%1WH48Q;2TV_/U!MO7U.RO_B)9^$/"W@G[/HUY<6^KP)%;P1S
M>9+&=BE%R1\Y)(&>/6KOA_XBWT_C*V\-^*/#-QH5[>0M/:,URDZ2A>H)7H:Y
M+5]*OI(_@N!97#?9)HFN/W9_<XC3[WIR.];WCBQNYOCCX#NH;::2UAM[H2RJ
MA*(3MQD]JS<*>UM[_A<I.7Y%F_\ B7?SZKJ]OX4\+7&N6>D.8KRZ6Z2%?, R
MR1@@[R!Z5V?A#Q#9>*_#EEK.EEC:W2;E#C#*0<%3[@@BOGVU\/:?X1\0>(++
MQKI7B2:.YO7N;*]TMIFBFC;G:1&>&'O7IFD?#[0M;\%:/;V2^(= L83)+%;1
MW302C>W._KUQD?6BK3IQ2M]_],(RDWJ6?&-_IL'Q8\%VMWI]Q-J$R3FWN4NB
MB0X7G=&.'S[]*IS?%'4;KQ)KF@^'?"5WJNHZ5/Y<A6Z2*/9V<LPX).0%YZ50
M\1:!/8?%;X<16<=[=6-C!/&]S*3(5^4XWOZFKWPKL+JU^(GQ(N+FUEACN+^-
MHI'0@2* W*GN.:.6"AS/6R_4+RO;S_0ZCX<>,X/&VB2WL=I-8W-O.]K<VLI#
M-%(O49'7ZUJ^)M1OM+TF2YTO2IM6NPP5+6*18RV3UW-P *\G^&OA!]9TCQII
M^KG5--BF\0SW$<EM(UO(Z[R00W=33_B=HVI>$_"V@Z?HEUXAN=!&H%]6FAG:
M:\\DX. P^;;UZ>U2Z4/:<J8^9\MV=5X9\>W=_P"+_P#A&?$OAZ71-5>W-U;C
M[2MPDR \X90,$>GM79:K'MTR\9201"Y'M\IKPKP?I$<WQET?4]%T76;+09=.
MN(A=7YD+ROCEOG)*CD 9QDYKTG1_A]8^&VU"]LM2UR\FEMI(_*O+UIDY&>%(
MZT58PBU9VT_KJ$')K4\,\/:7:+\&Y_%TGBW4].\0P_:)(L7YP[I(P1-A/.<
M?C7IX^*4FA>'_!C:YI-U=ZAK=F7(@^^90!M 3')?([C%9OP+^&N@2^"[#4O$
M'AV)M:\^8NUVC%N)6VY0G'3':MOXC:=<W'Q8^'4]O:2R6MM+,9'1,I%\HQD]
MJWJ3A.HX/6U_^&,XJ48W7D7M2^(][HOAVPN=:\,W5MKNHW1M;'1TN%DDF/\
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M["T445F48M%3FTF'\(_.@6DQ_A'YU0$%%6ULG/WF ^G-3QVD:=1N/O1<"C#
M\I^48'J:TH(5A7"\D]34G3I12N 4444@"BBB@ HHHH **** "BBB@ ILJ[XW
M7IN!%.HH Y/X8^$6\$^&3I+78NS]HDG\P)L^^<XQD]*ZRBBJE)R;DQ))*R"B
MBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI%/Y@52I._.!W!&*;\0='FUO3=/M8(6E1;^&28*^TB,$[CG/\JKZMX;^S_\
M"/PZ/!(T%MJ:7,V^4L57:P)RQSW'%94U2Y(J6[O_ %O^A4N:[L5;KQO>VR:G
M>'1TDTK3[EK:65;D"3@@$A".>HXS5S5/%%_%K-Q9Z9I*WB6UJEU*S3B-MK9X
M (Y/%<AJ'A:_EDUI8M F?4[B^>:TU#[0BI$"1M8C=GCGC%;.M>#;O6M;U.2Z
M>2/?IT44-RDNU6F&<[E!Y'3J.AKI=/#)INW]6\_7MZ$7F;$WC 7%MI T:Q>[
MOM3B,T4+N(Q&@^\SMV /'O5WP_K\M]J-WIFI69LM3MD61HP^]'1NC*WIVK!%
MGJ]K<Z'K<&CCS;>T:SNM/B=5*KD8:,YP0".F>AJSI^E:EJVN:EJ]\DVD":V6
MTMD1U,RJ&W%R1D GICFL94Z7*[6];ZWO_EY%)RN;NHZS]C\0:9IGD[OML<S^
M9G[OE@'I[YK$\/\ CB+5M(U6Y:T:"ZL4>7R&;_61C.'!]"5(J6?1+V+Q)X=E
M62>\@LX;I9KF9EWY<#;G&,^G [5SEUX3U:/P792V$ 77;6*>!X"X GAD=LH3
MG'<,*=.G0<4I/5VU^<O\EZ Y3OI_6QOS>*M2GOM/M-(TJ*YFN;!;YO-N/+"
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M-8-VU"BBBL2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D
M+ =2*1E+?Q8%,\GWII+J _S%]:4$'H:C\GWH\G'1C3LA$M%(H(ZG-+4C"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RI_$&FP33
M1RW&UXLALHW)&,A>/F(W#('J*1_$.F)$CM<XWEAMV-N7;][<N,J!D9STS6=>
M>$;:ZCOV=S]INIC()-S?NU+*2H&< G;U'--A\-7%C)(^G7<>Z021L9U+DH[;
M@2<Y+*<CW&,]*TM#N3>1L-K5@+@Q"X#LJ;V9 65!C(W,.!D<\TR/Q!ICV<MT
M;I8X8BH<RJ4*[L;201G!R,&L1?"=Q;Q"TLK[99%@[;@=^?*\LKQP5( //2D7
MP2AC%L][-]B(5G .9"P39C<V?DP6./4T^6'<5Y&_<ZWIULM\T]W&@L=IN,_\
ML]PRN?K6@I#*".01D5Q<W@F2X5_/U NTN/.)3_6[40(6]PR9_$BNSB3RXD3.
M=J@9J9**V92;ZCJ***@84444 %%%% &>VLZ>EY]E>ZC%QASL)Y.P M^613(]
M=TY[P6RW \QL;<J0K$KN #8P3CG'6LC4O"7VV:^E^U&*682&&15^:%VVX8?3
M;T[YHA\-77F+'-=0FTWQ2MM0AV=$"@>@&1GU[5I:%MR;R-J/6;&6XBAAG\QY
M%5QL4L &&5W$# SVS44GB#35MX9UG:6*60PHT,;2 N"05X!YX/Y5FV7A^^TZ
MUN+6QNX?)N47S&=#O1Q&J$KCL0HX/0T[3_"PT_9'!>S26Z7$=RJS8+ JI4\@
M#KP?K1:'<+LT;C7]-M\>;=*,EL\$[ IP2W]T \9/%2QZO82R21QW4;/'.+9U
M!Y60C(4_@:QV\.74,MX]G=Q+]M5XYO,CW;5,CN"ON/,8<\'BHX_""P7]M<6U
MT8Q'<K-(NW/FHJ@*I/J".OU%%H=PO(ZNBBBLR@HHHH RO^$@TX1WDDDSQ16A
MQ.\L3(J'ZD>X_.I&UJP6^%HTX$IVC.T[<D9 W=,D<XS5#4/#GVX312W3I;SW
M7VF01@!C\@4+SD8R.>*SH?!>'#SWLDS@QKEB0'14*?,,XW8.0<=0*T2AW)O(
MW!X@TYK<SI+(\6Y45DB9O,+' V8'S9]LU-::M:W5[):1>=Y\:AG#0NH4$9&2
M1BN=N?#&HW%ND<U[%((?)$: O&K^6<AFVGY21Q\M=%I]@UM>7-PS@F=(U*C)
MV[5QU/6AJ*6@)LOT445F4%%%% &>^L6,>I?87FVW&0N&4A2Q&0N[IDCG'6F1
MZ]ILGF%+I"D<?FR28.Q%QGEN@."#CK@U1O-"N+K59Y&GB6QFEBF=0I,A*# 7
M/0#.#GKVJB_A&62-81=)!&L C:2)3NF8 ;2ZD[2 0#Z\ 9Q6B4.K)NS9?Q#I
ML<*R23,@8G :-@V!R6QC.T#OTJ676].BM3<O=)Y(=H]PR<L 6(&/8$UGSZ5J
M<URE[]HM$OO)>U;"$QF-B#N'?<",XZ&J4O@U=MRL5TWER61MD1AP)"H4R<>H
M"].G/K1:'5A=FRVOZ>DD:2RR1,ZAL21.NT$D+NR.,D'&>M6[74+6[<+;3)(Q
MC$OR\_*>A_0USW_"*M)-%<R3!)XEA"QK([QGRW9L-N.6!W=^F*U]"T>+23?&
M+;_I5RT_ QM!Z+]!S^=)J-M 5^IJ4445!11O-6LK*ZCM[F;9(X!&5.!D[1D]
M!D\#/>JJ^)-,>$R).[#*@*(F+/N.%*KC)!/<4M]H5O?:P+ZZS(JPI&L>X@!E
M<L&(!P>2.#Z5@_\ "%-#91PV]P)&40$^:[CYHV)X8'*@YZ#T%:)0MJR6Y=#H
MY-;L(I7C>8AHTWR?(V(QC/S''RG'8\T^\U>PL@#=74<0/EG+' ^=MJ_F>*R3
MH-VEMJ=I#/ +74%=WW EHY&3:<'NO Z\T3>'9=01?[3>!LI#%)&BDJRQN6[^
MH-%H]PNS7EU>PA:<2W42>0"9-QQMQC.?^^E_.DCUBR?[-F;RVN9#%$DBE&=@
M"2 ",]!7/1^#I5CG5]1:20LS12.F2OS(4W<_-@( ?7K5G4_#MWJ\B7%]?>1<
MPIB!;;[BMNW;CD9.<+D<<#WHY8=PNSHK6XBNK>.>W<20R*&1AT(J6LOPY97>
MG:7#9W;P.($6.-X\@L .I!Z'Z5J5#T>A2*NH7]OI\:/=,P#ML4*A8DX)Z#GH
M"?PJ.'5K&:$2Q7,;Q&18@RG(+, 5'X@C\ZCUK28]5^QK,S"*";S656*EOD9<
M9!!'WJQW\'P*[RVLABE6Z2XA^9MB!%557;G!^[Z524;:LEW-B37-.C21OM*M
MY<_V9E0%F\W&=F!R3CGZ5-:ZE;75S-!"79H?OMY;!0< XW8QG!'%<VO@][:"
M1+:[\_S@I?[23\D@S^\1EP0><?08S6GH.C3Z9J%Y--,MP+C:QE+,'9@JJ<K]
MT?=SD>M-J%M&";+IUK3A9F[-W$+82B'S">-Y.-OUR:MM<1)<+"S@2LA<+_LC
M&3^HKGM0\+#4%>&>\FCMVN);AA#A6+.,#D@].?SK3TG3I;69I[J<3SF&. ,%
MP-J@_J22?RI-1MHQIL;)X@TU+2"Y^T;X)R^QT1F!"YW'@< 8.3TK3C=9(U>-
M@R, RL#D$'O7*:MX5EO+"TMXYTS#)<,68LO$I8Y&T\XW=#P:ZBSA^SVD,);>
M8T5-Q&-V!C.*)*-M 5^HE[=165K+<W+%88QN8@$_H*JPZS831RNERN(HS+("
M""BC(.1VQ@\4[7=/&JZ3<V1<H)EVEAVYK$U#P;97,EP8R\226CVZA9'R&8DE
MV.[YNO?/2B*C;4'?H;,NLZ?$;@/=Q V\:RRC/*JWW3^..*6#5K6>Y2"(S-*R
MAR/)8; <XW<?+T/7TK!_X1.1)GN?M?GW$H=)HIQ^Y="  , 9!&U,'/8^M3Z-
MX>NM/U..ZEN5N3Y2QNSNX*X+$ #.& #8RW/%/EA;<5V;=OJ-K<7DMK%)F>(9
M9"I'&<9&>HSQD5;K(TVQO(M6N[N^>WE,@V1LFX%$!X7'3W)[FM>H=KZ#0444
M4AA1110 4444 %%%% %"XUC3[9[U)[J-&LXA-< G_5H<X)_(T^VU.SN9Q#!.
MCRE2P4=< *3^C+^=8.M^$O[3O[NX^U>6MSA94"9WH$ "D^S -^?K4MKH%U8Z
MG'>6L\$A 9'64$?*5C'&._[O]:TM"VY-V:">(-/=8RLDG[R0QQCRFS(1U*C'
M('<C@4@\0Z=^_P!TDJF%Q&P:%P2QZ* 1R2.<"L:'PM<Q::MJDENDB3M)'<AY
M"\8))W+SP>?N_=/>M&YT.9IVNH+A?M*W2W4?F+E21#Y1#8]02<CI1:'<+R+D
M>NZ9(Z(EY$7>%YU7/)13ACCV/!'44PZ_IP61_.<HA"[Q$Q5F/15..6YZ#FL6
M[\'-<QS2->A+^2.0B=(_]7(YR2!_=Q\I'>G0>&)K>&]A M9TF8.IE>08(QV!
MPI&."O-/EAW"\CJX9%EB21,[6 89&#CZ4ZJVFV\EII]M;SSM<2Q1JC3,,%R!
MU-6:R904444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%Y))&JF+;D
MGG<,U5^U7/K%_P!\G_&K%]]U?K5.M(Q30FR3[5<^L7_?)_QH^U7/K%_WR?\
M&HZ*?*A7)/M5SZQ?]\G_ !H^U7/K%_WR?\:CKF_$3WTWB'2-.LM1FL(IX9Y9
M'A1&9BFS ^8'^\::@F[ W8ZC[5<^L7_?)_QH^U7/K%_WR?\ &N9_L+5?^AIU
M/_OU#_\ $4?V%JO_ $-.I_\ ?J'_ .(I^SCW_,7,^QTOVJY]8O\ OD_XU:47
M)4'?%S_LG_&LNRADM[2.*>YDNI%&&FD #/\ 4  5KRNT=ON0*2!GYC@8^M1*
M*V128W;<_P!^+_OD_P"-1M+(LZ0M<6XF<%E0CYF ZD#-3V[M)"K2!03S\IR/
MSKYA^(_BW7K3]I324MH9MMF\5K;P '$T4F/,;\<G_OFJHT75DXKHB9SY5<^F
M]MS_ 'XO^^3_ (T;;G^_%_WR?\:H^*]6.A>&M3U581.UG;O.(RVW?M&<9YQ6
M5K'B^WT?5;6&_&RVEM5GD<*3Y6Z14W,>@4;N36:@Y;%.26YT>VY_OQ?]\G_&
MC;<_WXO^^3_C7'+\3=#-TD&R]#-$9L^2<*N&9<^FY48C\/6DUKQU)!IN@W6F
MZ<Q&K7/D1B]#Q%4V,X?:JL>0O''>J]E/:PN>)V6VY_OQ?]\G_&C;<_WXO^^3
M_C7 1_$A(-::WOK=FL55]\\$;'RF%QY(W9_AR1S6C)\1M,6V6=;/4W1FF"8M
M^76+_6N.>57U[]J'1GV#GB==MN?[\7_?)_QHVW/]^+_OD_XUQ\GQ"T^:Y$5B
MLQVW,$+-)$P\Q9!D%!U.1T/2JFN?$=(?"=CK6CV+3BZO/L@BN2T90X8DD*K-
MGY>F,\T*C/L'/$[O;<_WXO\ OD_XT;;G^_%_WR?\:X:Q^)-I)"KSVTTDTT<4
MD5M:IYC@-#YKY/0A1W%33?$W1U?%O:ZE=1L,I+#;DJY\H2X!_P!PY_"CV,^P
M<\>YV>VY_OQ?]\G_ !HVW/\ ?B_[Y/\ C7(7'Q+T""YDA9[AMEF;W<L>04"A
MB/\ > 8<4RS^(-L_B6?2[NVFMG,$=Q!%(FV7RRKM([CL%" ^O-'LI[V#GCW.
MRVW/]^+_ +Y/^-&+G^_%_P!\G_&N/TWXE:/J:VOV&WU&:2ZF\J&-;<Y;*[PW
M^[MYSV[UN^%O$5IXDLY[FRCGC2&9H&6=-CAAZKU'7O2E3E'5H:DGL6S/<@]8
MO^^3_C1Y]SZQ?]\G_&D;[Q^M)4#'>?<^L7_?)_QH\^Y]8O\ OD_XTVB@!WGW
M/K%_WR?\://N?6+_ +Y/^--HH =Y]SZQ?]\G_&CS[GUB_P"^3_C3:5?O#ZT
M,_M*)>)+^Q1QP59P"/UI/[3@_P"@EI__ 'V/_BJ^7/&Y/_"8:QR?^/EN]8F3
MZG\Z]6.6J44^8\*><N,G'DV\SZ^_M.#_ *"6G_\ ?8_^*H_M.#_H):?_ -]C
M_P"*KY!R?4_G1D^I_.J_LQ?S?@3_ &U+^3\3Z^_M.#_H):?_ -]C_P"*H_M.
M#_H):?\ ]]C_ .*KY!R?4_G1D^I_.C^S%_-^ ?VU+^3\3Z^_M.#_ *"6G_\
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M .*KY R?4_G1D^I_.C^S%_-^ ?VU+^3\3[!^WQ_\_P#8_P#?0_QH^WQ_\_\
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M8O\ OD_XU8VW/]^+_OD_XU67[P^M:% $&VY_OQ?]\G_&C;<_WXO^^3_C4]%
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M*-GPH])O_)BCZU_<E]P?V35_FC]__ /(12U[#$GPFYW++_Y,5)Y?PD_NR_\
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M_7Q_[**YROIJ/\./HC@ENPHHHK004444 %%%% #&ZTE*W6DH **** "BBB@
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M>C_A4=A_T'KG_P !/_KU[311]=K_ ,WY![*'8\4D^$=B%_Y#MS_X"#_&H_\
MA4MC_P!!VY_\!!_\57M5S_J35/-'UVO_ #?D'LH=CR'_ (5+8_\ 0=N?_ 0?
M_%4?\*EL?^@[<_\ @(/_ (JO7LT9H^NU_P";\@]E#L>0_P#"I;'_ *#MS_X"
M#_XJC_A4MC_T';G_ ,!!_P#%5Z]FC-'UVO\ S?D'LH=CR'_A4MC_ -!VY_\
M 0?_ !5 ^$UCGG7+DC_KT'^->O9HS1]=K_S?D'LH=CEO"/AG1?#&6LEDDN7X
M>>5<L1Z#T%=E]KB_V_\ ODU74_,/K6A7/*<IOFD[LM))617^UQ?[?_?)H^UQ
M?[?_ 'R:L45(RO\ :XO]O_ODTC74+*0P8@\$%#S5FB@"A+]AF0I+;HZ$!2K0
MY&!T'3M4-K;Z?:W%Q/#!B:=MTC^7R> ,9QTX'%:M%.[ HPM9PHJ0P+&JY"A8
ML 9ZXXIJ+8(Z,EM&K(I5"(<%0>H'' K0HHNP*,+6<$)BA@6.(\%$BP#^&*BB
M@TR*/RXK*%(]X?:L  W#H<8Z^]:=%%V!EM;:6S2LUC 3+_K";<?/SGGCGFK:
M7,**%1655&  A  JS11=@5_M<7^W_P!\FC[7%_M_]\FK%%("O]KB_P!O_ODT
M?:XO]O\ [Y-6** *_P!KB_V_^^31]KB_V_\ ODU8HH IW%W&;>4#?]T_PGTJ
MQ;?\>T7^X/Y47/\ Q[2_[A_E1;?\>T7^X/Y4 24444 %%%% !1110 4444 5
MK[[J_6J=7+[[J_6J=:QV)844450!7.ZI_P CSH/_ %ZW7\XZZ*N=U3_D>=!_
MZ];K^<=5#?[R9;'14445)0'I6HGW%^E99Z5J)]Q?I43&BO=WUO:8$\@4GD#J
M:J?VY9=,OC_=KF[^8W%Y+(><L<?2L6YU[2[=9"]_;.8F"R+'*KLF3CY@#D#)
MKMA@XV7-N9NH=A_:L-O(_P!G8NK?[.*2"^:Y)(=PPZY-8SQ,KA,98C.!R:T[
M*U>WR9AM=AT]!53I4XQOU!-LW-/N3)E)#EAR#ZU=K)TT9N<^@-5/B';7UYX(
MUJWTA96OY;9E@$3[&+'I@Y&/SKAE%<]B[Z7.AZ4 Y&1R*\QLM!\5:3''I\5Z
MTEDT%S<2K&#(BN<".!6D8OMZG)]3TJM:P^/#';QQRS64*E(/*6WC;8GV;<6R
M3U\T!?QI^R722%S^1ZO17D\NI_$22\?R["2)?[.P1Y:$&X\D,&'/_/3*[?:M
M&TO_ !%%XZL-!.I)>0M E]>3;%#P!008BHZ;R01[*:'1?=!S^1Z/0"#T.>U>
M06\7BG3;K5#8V>K&UFU!7EO' >Z:,^82L<;.4(4[!N&,J3QD4\KXWT[5 --M
MYULKK4Y99'>)9&(/E %AN^5-N_IT-/V/FA<_D>N4$@=2!VKRW4)?'D.CVTZO
M=27$TL_F106\1>$CB!<$X*'JS=>E)(_C6YU*5+NTDFCBNK:5&6-4C3 ^<+\V
M6P>=WOTI>Q\T/G\CU.BO$]>\0^--"TN)=2N9%GNA"R-Y,:L&,3&55^;;A&"D
M@G)Y KUOP[<&ZT#3[@S/.9;=',KIL9R5')7M]*F=)P5[CC+F=A6^\?K25'>7
M$5K!+/<R".&,%G<] *SFUVU"QYBNQ+)G9#Y)\Q@,98#TY'-0DWL.YJT51.J6
MWV%[J,2RQ([1D1H2V5)#<>V#21:O92W5G;Q3AYKN(SQ* >4&,D^G6BS"Z+]%
M%%(84444 >>>(/C?X2\-ZW>:-J)OOMEE)Y4OEP;ES@'@Y]ZS_P#AHKP/ZZE_
MX#?_ %Z^;OC?_P E<\5?]?A_]!6N'KVJ> I2@I.^IQ2Q$TVC[)_X:*\#^NI?
M^ W_ ->C_AHKP/ZZE_X#?_7KXVHJ_P"SJ/F3]9F?9/\ PT5X']=2_P# ;_Z]
M'_#17@?UU+_P&_\ KU\;44?V=1\P^LS/LG_AHKP/ZZE_X#?_ %Z/^&BO _KJ
M7_@-_P#7KXVHH_LZCYA]9F?84W[0O@EVR#J7_@/_ /7J/_AH/P5ZZC_X#_\
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MT%]3_P#'?\*O^T*/<GZO,^3**^L_^&9O#G_07U/_ ,=_PH_X9F\.?]!?4_\
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M917UG_PS-X<_Z"^I_P#CO^%'_#,WAS_H+ZG_ .._X4?VA1[A]7F?)E%?6?\
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M^G^% $U%0^2W_/Q+^G^%'DM_S\2_I_A0!-14/DM_S\2_I_A1Y+?\_$OZ?X4
M345#Y+?\_$OZ?X4>2W_/Q+^G^% %ZT^\WTJS6=:V[EF_TF8<=MO^%6/LS_\
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MH **** "BBB@ HHHH K7WW5^M4ZN7WW5^M4ZUCL2PHHHJ@"N=U3_ )'K0?\
MKUNOYQUT5<[JG_(\Z#_UZW7\XZJ&_P!Y,MCHJ***DH#TK43[B_2LL]*U$^XO
MTJ)C0M8FLW%E=Q^2;G:Z-D$#(S6T_P!QOI7",H$,;=V+9_"ML+34G>^Q,W8Z
M'1[FRM(?)%SN9FR200,U?M=2M+N^O;.WF#W-F4$Z 'Y"PROYBOFCXY_$.[T*
M1-"T*4PWLD8DN+A?O1*>BKZ$]<UQ.J>)_%.A>']'UBTGU>RFO'CDCO)&^6Z"
M1E6W<_-SV/45U5,%SOF3U9C[=1T/MFBN"^"_CQ?'_@^.^F5(]1MV\B[C3H'
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MTI]4H;F41K_HLIX]13_M,O\ SZ2_F* +5%5?M,O_ #Z2_F*/M,O_ #Z2_F*
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M_</\J+;_ (]HO]P?RHN?^/:7_</\J+;_ (]HO]P?RH DHHHH **** "BBB@
MHHHH K7WW5^M4ZN7WW5^M4ZUCL2PHHHJ@"N=U3_D>=!_Z];K^<==%7.ZI_R/
M.@_]>MU_..JAO]Y,MCHJ***DH#TK43[B_2LL]*U$^XOTJ)C1#<PLXWPL$F4$
M*Q&1^(]*X[3/ VG16V[6K!=0U.5VENKI/D6X<GJ5W8 Z#'M7<441J2BK('%/
M<Y_POHDVD6+6D\\;644S/:0(FT0Q9RJ$]]OK5F[UZV@?:@,G.,YP*/%-X+/2
M9)'?8G5V]% R:\(\57]IJ>S5I))8[>)O*6%E5\D!LD=@3SD$@@J.M=>'H*M[
M\S*<^31'O=CK-O<N$8&)ST#=#^-:=>$Z/J&I7.O69MWF&GX$)B=@Y"JOS,2.
M^=O/?)^E>UZ3,UQI\,C\MC!/KCBHQ.'5*THE0GS#->N8K/1+^XN4CD@B@=Y$
MD.%90IR#P>/P-<=JWB_PF-/O6G@BN[FSLWD:V%LS!A&H<QJQ3!QN4X[ YQ78
M:^EG)H>H)JAVV#6\@N#G&(]IW?IFN'T^U\%ZS:$6+3S+*SPN@+*R?:(PI9@<
M$*508-8TU&UW<<KWLA=%\9Z%#IL\VL:9%HT49BL]JQ/(I5TWA2!&"JC=_$ *
MTH_&O@_1#+86]PMLD#.&2"SDV J1O.53!QD9/;(S3=3\(>$]9G6:YE21[E\*
M4N\>:0@0J,'G@#.*FE\-^%Y+>;?-%Y3-<1.WVD8#3[1(N<\$[1Q5/V;[B]XE
MO/B%X9L[F:"?4'$D)</MMI64;"-_(7!VY!..@.>E&L>/_#^E/J$<]S-)/8HD
MDL,5N[,58@ KQAN6'0FH[CPUX8,=T)IHU5?.2;-R!L,X <'GC.T8II^'7AV0
MWL@@F_TQ"CD3MP"5;*^ARJG/M22I=;C]\N3>.?#T$]S%/?\ E-;HSR%X9%4;
M0"R[BN"R@C*CD=Q4MGXQT.\FBAAO&\Z65(4C>"1&9G!*\%0<$*QSTXZU3N?
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M>2T?8[?_ )Y+4VY?4?G1N7U'YT 0_8[?_GDM'V.W_P">2U-N7U'YT;E]1^=
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M\&@W\ES"+II_]$BMB^W>7.P#(Y ).2?2N4M(_$5KI<4$/B1Q<10B)"ULC1C
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M>'_O@4?9+;_GWA_[X%3T4 0?9+;_ )]X?^^!1]DMO^?>'_O@5/10!!]DMO\
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M8XTY9V. ![TU9XFF\E94,NP2; >=IZ-CTJIXBL#JFCWEB-O[]0A#="-P)'Y
MUS</AK4[>]:]%Q%-<JJ1K\Q7=&C_ "+GM\O7MFKC%-:LEMW.N-S"'E0RIOB
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M8X.<,?3WJ:&6];4H]\96W:(%A_=;G//UQ0!;VW/]^+_OD_XT;;G^_%_WR?\
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63D_*?\:ZFBN"%6=/X)->ALXQENC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873652211568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001534248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CHEMOMAB THERAPEUTICS LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3676773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Kiryat Atidim<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6158002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">77-331-0156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float | $</a></td>
<td class="nump">$ 37.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding | shares</a></td>
<td class="nump">220,996,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Somekh Chaikin<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel Aviv, Israel<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm Id</a></td>
<td class="text">1057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositarySharesMember', window );">American Depositary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CMMB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of Exchange on which Security is Registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cmmb_OrdinarySharesNoParValuePerShareMember', window );">Ordinary Shares, No Par Value Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, no par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">n/a<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of Exchange on which Security is Registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmmb_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cmmb_OrdinarySharesNoParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cmmb_OrdinarySharesNoParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873652215984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,519<span></span>
</td>
<td class="nump">$ 15,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Short-term bank deposit</a></td>
<td class="nump">26,374<span></span>
</td>
<td class="nump">45,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other receivables and prepaid expenses</a></td>
<td class="nump">1,766<span></span>
</td>
<td class="nump">1,527<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">41,736<span></span>
</td>
<td class="nump">62,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long-term prepaid expenses</a></td>
<td class="nump">733<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">43,063<span></span>
</td>
<td class="nump">64,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">1,688<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,378<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee and related expenses</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,749<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current&#160;operating lease liabilities</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingent liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,840<span></span>
</td>
<td class="nump">2,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2022 and 2021; Issued and outstanding: 232,636,700 Ordinary shares at December 31, 2022 and 228,090,300 Ordinary shares at December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury share at cost (11,640,460 shares as of December 31, 2022)</a></td>
<td class="num">(1,218)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">101,260<span></span>
</td>
<td class="nump">97,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(63,819)<span></span>
</td>
<td class="num">(36,173)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">36,223<span></span>
</td>
<td class="nump">61,466<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 43,063<span></span>
</td>
<td class="nump">$ 64,353<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873651980624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common Stock, No Par Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">650,000,000<span></span>
</td>
<td class="nump">650,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">232,636,700<span></span>
</td>
<td class="nump">228,090,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">232,636,700<span></span>
</td>
<td class="nump">228,090,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, Shares</a></td>
<td class="nump">11,640,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873652043648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 16,977<span></span>
</td>
<td class="nump">$ 6,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,556<span></span>
</td>
<td class="nump">6,033<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">28,533<span></span>
</td>
<td class="nump">12,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financing (income) expenses, net</a></td>
<td class="num">(353)<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="nump">28,180<span></span>
</td>
<td class="nump">12,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income (benefit)</a></td>
<td class="num">(534)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="nump">$ 27,646<span></span>
</td>
<td class="nump">$ 12,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per Ordinary Share</a></td>
<td class="nump">$ 0.121<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per Ordinary Share</a></td>
<td class="nump">$ 0.121<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of Ordinary Shares outstanding, basic</a></td>
<td class="nump">227,589,288<span></span>
</td>
<td class="nump">207,468,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of Ordinary Shares outstanding, diluted</a></td>
<td class="nump">227,589,288<span></span>
</td>
<td class="nump">207,468,650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873650263712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Treasury share [Member]</div></th>
<th class="th"><div>Additional paid in capital [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 34,497<span></span>
</td>
<td class="num">$ (23,695)<span></span>
</td>
<td class="nump">$ 10,802<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">9,274,838<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,019<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EffectOfReverseCapitalizationTransaction', window );">Effect of reverse capitalization transaction</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EffectOfReverseCapitalizationTransactionShares', window );">Effect of reverse capitalization transaction (In shares)</a></td>
<td class="nump">152,299,702<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues', window );">Issuance of shares and warrants, net of issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">58,637<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues', window );">Stock And Warrants Issued During Period New Issues</a></td>
<td class="nump">66,381,520<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of Options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of Options, shares</a></td>
<td class="nump">134,240<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,478)<span></span>
</td>
<td class="num">(12,478)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">97,639<span></span>
</td>
<td class="num">(36,173)<span></span>
</td>
<td class="nump">$ 61,466<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">228,090,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,090,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues', window );">Issuance of shares and warrants, net of issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues', window );">Stock And Warrants Issued During Period New Issues</a></td>
<td class="nump">2,576,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of Options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of Options, shares</a></td>
<td class="nump">1,970,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Treasury share at cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,218)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Treasury share at cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,640,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27,646)<span></span>
</td>
<td class="num">(27,646)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,218)<span></span>
</td>
<td class="nump">$ 101,260<span></span>
</td>
<td class="num">$ (63,819)<span></span>
</td>
<td class="nump">$ 36,223<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">232,636,700<span></span>
</td>
<td class="num">(11,640,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,636,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EffectOfReverseCapitalizationTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of effect due reverse capitalization transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EffectOfReverseCapitalizationTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EffectOfReverseCapitalizationTransactionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares isued due to effect of reverse capitalization transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EffectOfReverseCapitalizationTransactionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>it represents number of shares and warrants issued during period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873652027808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (27,646)<span></span>
</td>
<td class="num">$ (12,478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments for operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">2,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Change in other receivables and prepaid expenses</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(2,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Change in trade payables</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Change in accrued expenses</a></td>
<td class="nump">2,823<span></span>
</td>
<td class="num">(1,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Change in employees and related expenses</a></td>
<td class="nump">907<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Change in operating leases</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(20,370)<span></span>
</td>
<td class="num">(12,374)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_PaymentsForInvestmentInDeposits', window );">Investment in deposits</a></td>
<td class="nump">19,601<span></span>
</td>
<td class="num">(45,951)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_LongTermLeaseDeposit', window );">Long-term lease deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities', window );">Sale of asset held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(68)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">19,533<span></span>
</td>
<td class="num">(45,186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_CashAcquiredInMerger', window );">Cash acquired in Merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Treasury share at cost</a></td>
<td class="num">(1,218)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Issuance of shares and warrants, net of issuance costs</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">58,637<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(808)<span></span>
</td>
<td class="nump">61,074<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(1,645)<span></span>
</td>
<td class="nump">3,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of the year</a></td>
<td class="nump">15,241<span></span>
</td>
<td class="nump">11,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of the year</a></td>
<td class="nump">13,596<span></span>
</td>
<td class="nump">15,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_CashPaidAndReceivedDuringYearForAbstract', window );"><strong>A. Cash paid and received during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxesReceived', window );">Income taxes received</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_InterestReceived', window );">Interest received</a></td>
<td class="nump">972<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>B. Significant non- cash transaction:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset recognized with corresponding lease liability</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed, net of non-cash assets received in Merger</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CashAcquiredInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash acquired in merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CashAcquiredInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CashPaidAndReceivedDuringYearForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CashPaidAndReceivedDuringYearForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_IncomeTaxesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents income taxes received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_IncomeTaxesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_InterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_InterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_LongTermLeaseDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term lease deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_LongTermLeaseDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_PaymentsForInvestmentInDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payments for investm,ents in deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_PaymentsForInvestmentInDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of other assets recognized in investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873656636576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NatureOfOperationsDisclosureAbstract', window );"><strong>Nature Of Operations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">General</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 1 - General</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt">1.<span style="padding-left:28.5pt">Chemomab Therapeutics Ltd. (hereinafter - "the Company") is an Israeli-based company incorporated under the laws of the State of Israel in September 2011. The Company&#8217;s registered office is located in Kiryat Atidim, Tel Aviv, Israel.&#160;</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0px;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt;text-align:justify"><br/>The Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical need that involve inflammation and fibrosis.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0px;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><br/>The wholly owned subsidiaries of the Company are: Chemomab Ltd. ("Chemomab"), Chemomab Therapeutics Israel Ltd. and Chemomab Therapeutics Inc.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt">2.<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="padding-left:28.5pt">The Company currently has no products approved for sale. The Company&#8217;s operations are funded primarily by its Shareholders. The Company has incurred operating losses in each year since its inception and does not expect to generate significant revenue unless and until it obtains marketing approval for its products. Continuation of the Company&#8217;s development programs depend on its future ability to raise sources of financing.</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.<span style="padding-left:28.5pt">Since </span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">January 2020, the COVID-19 pandemic has dramatically expanded into a worldwide pandemic, creating macro-economic uncertainty and disruption in the business and financial markets. Many countries around the world, including Israel, had taken&#160; measures designated to limit the continued spread of the COVID-19 pandemic, including the closure of workplaces, restricting travel, prohibiting assembling, closing international borders and quarantining populated areas. The Company's clinical trial sites have been affected by the COVID-19 pandemic, and as a result, commencement of the enrollment in our clinical trials of CM-101 in PSC was delayed, and the enrollment rate has been, and is still, affected as well. As a result, The Company expanded its patient recruiting efforts to additional territories. In addition, after enrollment in these trials, patients might still drop out because of possible COVID-19 implications. Based on management&#8217;s assessment, the extent to which the lingering effects of the COVID-19 pandemic will further impact the Company's operations will depend on future developments. These developments, which are highly uncertain and cannot be predicted with confidence,including the duration and severity of the impact on patient enrollment following the attenuation of the outbreak The Company is carefully monitoring the impacts arising from&#160; the COVID-19 pandemic and will adjust activities accordingly<span><span><span>.</span></span></span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.<span style="padding-left:28.5pt">On </span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 14, 2020, the Company (formerly known as Anchiano Therapeutics Ltd.) entered into an Agreement and Plan of Merger (the "Merger" and &#8220;Merger Agreement&#8221;) with Chemomab Ltd., an Israeli limited company, and CMB Acquisition Ltd., an Israeli limited company and a wholly owned subsidiary of the Company (&#8220;Merger Sub&#8221;). On March 16, 2021, (the &#8220;Effective Time&#8221;), the Company consummated the Merger pursuant to the Merger Agreement Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Chemomab Ltd., with Chemomab Ltd. surviving the Merger as the Company's wholly owned subsidiary. In connection with the Merger, on March 16, 2021, the Company changed its name from &#8220;Anchiano Therapeutics Ltd.&#8221; To &#8220;Chemomab Therapeutics Ltd" and the business conducted by Chemomab Ltd. became primarily the business conducted by the Company.</span></span></p>
    <div>
      <div style="width:100%;clear:both">
        <p style="margin:0pt">&#160;</p>
      </div>
    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0px;padding-left:72pt;margin-bottom:10pt">At the Effective Time(a) each Chemomab Ltd. ordinary share outstanding immediately prior to the Effective Time was converted solely into number of American Depository Shares equal to the exchange ratio described in the Merger Agreement, and each outstanding Chemomab Ltd. option was assumed by the Company, based on the same exchange ratio.</p>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For&#160;<span>accounting purposes, Chemomab Ltd. is considered to have acquired the Company based upon the terms of the Merger as well as other factors. The Merger has been accounted for as an asset acquisition (reverse recapitalization transaction) rather than a business combination, as the assets acquired, and the liabilities assumed by Chemomab Ltd. do not meet the definition of a business under U.S. GAAP. The net assets acquired in connection with the Merger were recorded at their estimated acquisition date fair market value as of March 16, 2021, the date of completion of the Merger.</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">The exchange ratio was calculated by a formula that was determined through arms-length negotiations between the Company and Chemomab Ltd. The combined Company assumed all of the outstanding options of Chemomab Ltd., vested and not vested, under the Chemomab&#160;Share Incentive Plan (the &#8220;2015 Plan&#8221;), with such options representing the right to purchase a number of ADSs equal to approximately 12.86 multiplied by the number of Chemomab Ltd. ordinary shares previously represented by such options.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:11pt">The following table summarizes the net assets acquired based on their estimated fair values as of March 16, 2021, immediately prior to completion of the Merger (in USD thousands):</p>
    <div style="margin-left:72pt">

        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Cash and cash equivalents</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,427</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Asset held for sale</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,000</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Prepaid and other assets</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">236</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accrued liabilities</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(1,187</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">)</p>
              </td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net acquired assets</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,476</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>

    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NatureOfOperationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NatureOfOperationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873656343584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 2 - Summary of Significant Accounting Policies</span></p>

      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Basis of Preparation</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S GAAP&#8221;).</p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="font-weight:bold;padding-left:26.83pt">Use of estimates</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Foreign currency</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#8220;dollar&#8221; or &#8220;$&#8221;), thus; the dollar is the functional currency of the Company.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.</p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">D.</span><span style="font-weight:bold;padding-left:26.28pt">Cash and cash equivalents</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at the date acquired.</p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">E.</span><span style="font-weight:bold;padding-left:26.83pt">Restricted cash</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt">Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office rent payments.</p>


      <div>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">F.</span><span style="font-weight:bold;padding-left:28.31pt">Property and equipment</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets are ready for their intended use.</p>
        <div>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">Annual rates at depreciation are as follows:</p>
          <div style="margin-left:36pt">

              <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

                  <tr>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">%</span></p>
                    </td>
                    <td style="vertical-align:bottom">&#160;</td>
                  </tr>


                  <tr style="background-color:#CCEEFF">
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Computers</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">33</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Laboratory equipment</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">10</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:#CCEEFF">
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Furniture and equipment</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>

              </table>

          </div>
        </div>
      </div>

    <div/>

      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">G.</span><span style="font-weight:bold;padding-left:25.72pt">Impairment of long-lived assets</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company&#8217;s property and equipment are reviewed for impairment in accordance with ASC 360, &#8220;Property and Equipment&#8221;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2022 and 2021, no impairment losses have been recorded.</p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">H.</span><span style="font-weight:bold;padding-left:25.72pt">Research and Development</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and wages.</p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">I.</span><span style="font-weight:bold;padding-left:26.83pt">Income taxes</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.</p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">J.</span><span style="font-weight:bold;padding-left:28.5pt">Fair value of financial instruments</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.</p>
      <div/>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company&#8217;s own credit risk.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company&#8217;s non<span style="font-weight:bold">- </span>financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">K.</span><span style="font-weight:bold;padding-left:25.72pt">Share-based compensation</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The fair value for the Company&#8217;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C).</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt">The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">L.</span><span style="font-weight:bold;padding-left:26.83pt">Government-sponsored research and development</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Chemomab records grants received from the office of the Israel Innovation Authority (the &#8220;IIA&#8221;) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.</p>

    <div/>

      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">M.</span><span style="font-weight:bold;padding-left:24.06pt">Severance pay</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $142 thousand and $116 thousand for the year ended December 31, 2022 and 2021, respectively.</span></span></p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">N.</span><span style="font-weight:bold;padding-left:26.28pt">Concentrations of credit risk:</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash <span>and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold the Company&#8217;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments</span>.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</p>


      <div>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">O.</span><span style="font-weight:bold;padding-left:25.72pt">Leases</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Under </span></span>Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 5% and 5.2% in 2022 and 2021, respectively. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants<span><span>.</span></span></span></span><br/>&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></span><br/>&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment &#8211; Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize. See Note 2(G).</span></span></p>
      </div>

    <div/>

      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">P.</span><span style="font-weight:bold;padding-left:28.31pt">Principles of consolidation</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The <span>consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.</span></span></span></p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">Q.</span><span style="font-weight:bold;padding-left:25.72pt">Earnings per ordinary share</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt">Basic earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant, gives effect to dilutive potential ordinary shares outstanding during the year. &#160;Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873655610912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note 3 - Cash and Cash Equivalents</span></p>

      <div style="margin-left:36pt;margin-bottom:11pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In USD</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">10,663</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">10,720</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In NIS</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,756</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,116</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In other currencies</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">100</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,350</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">13,519</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">15,186</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873743734624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables and Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock', window );">Other Receivables and Prepaid Expenses</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note 4 - Other Receivables and Prepaid Expenses</span></p>

      <div style="margin-left:36pt;margin-bottom:11pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Government institutions</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">459</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">179</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Prepaid expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,307</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,348</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,766</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,527</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other accounts receivable and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873741236352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note 5 - Property and Equipment, Net</span></p>

      <div style="margin-left:36pt;margin-bottom:11pt">
        <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Cost:</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Computers</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">70</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">43</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Furniture and equipment</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">33</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">27</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Laboratory equipment</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">399</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">364</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Website development</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">14</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">14</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Leasehold improvements</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">16</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">16</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><strong><strong><strong>532</strong><strong> </strong></strong><strong> </strong></strong><strong> </strong></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">464 </p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Less - accumulated depreciation</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">165</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-weight:bold">)</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(107</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">)</p>
              </td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><strong><strong><strong>367</strong><strong> </strong></strong><strong> </strong></strong><strong> </strong></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">357 </p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>

        </table>
      </div>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873656658272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 6 - Leases</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">On May 10, 2020, Chemomab entered into an office and lab space lease agreement (hereinafter &#8211; &#8220;The Agreement&#8221; .(According to the Agreement, Chemomab &#160;rented a space in Atidim Park, Tel-Aviv for a period of three years, through <span style="-sec-ix-hidden:Fxbrl_20230131233234992">May 2023</span>. Chemomab was granted an option to extend the lease term by additional three years.&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">On October 24, 2021, Chemomab signed an amendment to the Agreement ("The Amendment"). According to the Amendment, On December 12, 2021 Chemomab returned the previous office and lab space to the property owner and rented a larger space in Atidim Park Tel-Aviv, for a term of 3 years, through <span style="-sec-ix-hidden:Fxbrl_20230131233722905">October 2024</span>. In addition, Chemomab was granted an option to extend the lease term by additional three years. The annual rent and management fees are approximately $122 thousand. Pursuant to the Amendment, the bank guarantee issued in 2020 was canceled and a substitute bank guarantee of approximately $77 thousand was issued to the property owner during 2022.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The above operating leases are included in &#8220;Operating lease right-of-use assets&#8221; on the Company&#8217;s Consolidated Balance sheets as of December 31, 2022 and 2021 and represent the Company&#8217;s right to use the underlying asset for the lease term. The Company&#8217;s obligations to pay lease payments are included in the current liabilities as &#8220;Operating lease liabilities&#8221; and in the non-current liabilities as &#8220;Non-current operating lease liabilities&#8221; on the Company&#8217;s Consolidated Balance sheets as of December 31, 2022 and 2021. Based on the present value of the lease payments for the remaining lease term of the Company&#8217;s existing lease agreement, the Company recognized operating right-of-use assets and operating lease liabilities of approximately $345 thousand on December 12, 2021.&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">During the years ended December 31, 2022 and 2021, the Company recognized an increase in right of use assets of $17 thousand and $345 thousand, respectively.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As&#160;of December 31, 2022, and 2021 operating right-of-use asset was $227 thousand and $345 thousand, respectively. The operating lease liabilities were $214 thousand and $343 thousand, respectively.</span></span></p>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">As most of the Chemomab&#8217;s leases do not provide an implicit rate, Chemomab uses its incremental borrowing rate based on the information available at the commencement date of each lease in determining the present value of lease payments. Chemomab&#8217;s incremental borrowing rate is a hypothetical rate based on its estimation of what its credit rating would be the rate was 5% in 2022 and 5.2% in 2021.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">Maturities of lease liabilities under noncancellable leases as of December 31, 2022, are as follows: (in thousands):</p>
    <div style="margin-left:36pt;margin-bottom:11pt">

        <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">2023</p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">126 </span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">2024</p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">93 </span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Total future minimum lease payments</p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">219 </span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Less imputed interest:</p>
              </td>
              <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">5</span></p>
              </td>
              <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px"><span style="font-weight:bold">)</span></p>
              </td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Present value of operating lease liabilities</p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">214 </span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>

        </table>

    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873656658272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingent Liabilities</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt"><span style="font-weight:bold">Note 7 - Commitments and Contingent Liabilities</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Exclusive License Agreement (hereinafter- &#8220;the License Agreement&#8221;)</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:72pt">In December 2011, Chemomab entered into a License Agreement with the Medical Research, Infrastructure, Health Services Fund of the Tel-Aviv Souraski Medical Center (&#8220;Fund&#8221;), pursuant to which it was granted with an exclusive license to certain inventions (as defined in the License Agreement) including patents, knowhow and products and the right to sublicense to third parties the rights granted, pursuant to and subject to certain terms and limitation fully set in the License Agreement.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:72pt">Chemomab has agreed to pay the Fund a non-refundable and non-creditable sublicense fees as a percentage of all Attributed Income (as such term defined in the License Agreement), and shall further pay the Fund royalties from sales made by sublicensee;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(i)<span style="padding-left:26.56pt">Royalties in percentage of the Net sales or Service Income (as defined in the License Agreement), subject to </span>certain additional terms set forth therein.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"><span>In addition, with respect to each Licensed Product (as defined therein), Chemomab has agreed to &#160;pay the Fund the following non-refundable, non-creditable amounts:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:144pt;margin-bottom:11pt">(a)<span style="padding-left:24.9pt">$100 thousand upon submission of a New Drug Application (&#8220;NDA&#8221;), Biological License Application (&#8220;BLA&#8221;) or equivalent for each Licensed Product to the United States Food and Drug Administration (&#8220;FDA&#8221;), $100 thousand upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;text-indent:-36pt;padding-left:144pt;margin-bottom:0pt">(b)<span style="padding-left:24.34pt">$200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once.</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:108pt">As of December 31, 2022&#160;no payments were made to the Fund.</p>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:72pt">In addition to the payments described above, upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than $3,000 thousand.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:72pt"><span>Chemomab partially financed its research and development expenditures under programs sponsored by the Israel </span>Innovation Authority (&#8220;IIA&#8221;) for the support of certain research and development activities conducted in Israel.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:72pt">In return for the IIA&#8217;s participation, Chemomab is committed to pay royalties at rate of 3% of sales of the developed product (linked to U.S. dollar), up to 100% of the amount of grants received (100% plus interest at LIBOR). In addition, the IIA may impose certain conditions to transfer technology or development out of Israel.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt">Chemomab did not receive any grants from the IIA in the years ended December 31, 2022, and 2021.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">Since Chemomab &#8217;s incorporation through December 31, 2022 Chemomab received $1,227 thousand from the IIA, which were recognized as a reduction of research and development expenses.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt">As of December 31, 2022, Chemomab has no commitment for royalties payable.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="padding-left:26.28pt">In </span></span></span>June 2015, Chemomab entered into a license agreement with subcontractor (&#8220;the Subcontractor&#8221;), under which the Subcontractor granted to Chemomab certain licenses to use proprietary rights of the subcontractor, materials and know how in the techniques and use of the same, for purposes of research and development of Chemomab 's product CM-101, as well as commercialization thereof. Further to the agreement, the Subcontractor also provides manufacturing services of intermediates and active pharmaceutical ingredients. According to the related manufacturing agreement, the manufacturing of the product is carried out by the Subcontractor in accordance with Chemomab's specifications and timeline.&#160; From time to time, Chemomab and the Subcontractor have been signing additional agreements for additional manufacturing and final process lock of the product for clinical use Under the agreement, Chemomab is also obligated to pay the Subcontractor royalties determined as a percentage of net sales of each licensee product.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:0pt;padding-left:72pt;margin-bottom:0pt">During 2022 and 2021, Chemomab recorded expenses related to the above agreements in the amounts of $5,222 thousand and $2,590 thousand, respectively. The expenses were recorded under research and development expenses.</p>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:11pt"><span style="font-weight:bold">C.</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><span style="padding-left:26.28pt">As&#160;</span></span>of December 31, 2022, the bank imposed restriction on a bank deposit in the amount of $77 thousand for the purpose of secure lease payments under an office lease agreement.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">D.</span><span><span style="padding-left:26.28pt">During&#160;</span></span><span>2022, the Israeli tax authority ("ITA&#8221;) notified the Company that it had initiated a routine VAT audit to include tax years 2017 through 202</span><span>2</span><span>. The ITA raised several claims, mainly in respect with the recoverability of VAT with respect to Merger Agreement related expenses and the classification of the Company as a holding company. On July 2022, the ITA proposed a settlement, which the Company rejected. As a result, the ITA issued assessments in the aggregate amount of $1,046 thousand. The Company filed an appeal against the ITA&#8217;s assessments. The Company has recorded an appropriate provision which considers inherent uncertainty of these matters and the judicial process. Therefore, the outcome may differ from the estimated liability recorded by the Company during the period</span><span>.</span></span></span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873649337648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Share Capital</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 8 - Share Capital</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Right attached to shares</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-weight:bold;font-style:italic">Ordinary shares</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:72pt;margin-bottom:0pt">All of the issued and outstanding ordinary shares of the Company are duly authorized, validly issued, fully paid and non-assessable. The ordinary shares are not redeemable, and each ordinary share is entitled to one vote. The holders of the ordinary shares have the right to vote and participate in shareholders' meetings, the right to receive profits, and the right to participate in the accumulated earnings when the Company is dissolved.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">1.</span><span style="font-weight:bold;padding-left:28.5pt">Voting</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:108pt">The holders of ordinary shares are entitled to vote on all matters submitted to shareholders for a vote.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">2.</span><span style="font-weight:bold;padding-left:28.5pt">Dividends</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:108pt">The holders of the ordinary shares are entitled to receive dividends, when and as declared by the Board of Directors, and out of funds legally available.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:108pt">Since its inception, the Company has not declared any dividends.</p>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="padding-left:26.83pt;font-weight:bold">Financing rounds</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>1.</span><span style="padding-left:28.5pt">In&#160;</span></span></span>connection with the Merger, on March 15, 2021, the Company entered into Securities Purchase Agreements with certain purchasers, pursuant to which the Company agreed to sell approximately $45.5 million of its American Depositary Shares (ADSs)&#160;in a private placement transaction, (or "The Private Placement"). The Private Placement closed on March 22, 2021, at which time the Company sold to the purchasers 2,619,270 ADSs together with warrants to purchase up to 261,929 ADSs at an exercise price of $17.35 per ADS. The warrants will expire five years from the date of issuance, and if exercised in full, will provide to the Company proceeds of approximately $4.5 million. 20 Ordinary Shares are equal to 1 American Depositary Share (ADS).</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>2.</span><span style="padding-left:28.5pt">On&#160;</span></span></span>April 30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Cantor Fitzgerald &amp; Co., ("Cantor"). According to the ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $75 million through Cantor or the ATM Agreement. From April 30, 2021, through December 31, 2022, the Company issued 699,806 ADSs at an average price of $22.75 per ADS under the ATM Agreement, resulting in gross proceeds of $15,917 thousand.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>3.</span><span style="padding-left:28.5pt">On </span></span></span></span></span></span>April 25, 2022, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $18,125,000&#160;of its ADSs in connection with the reactivation of the ATM Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits the amount of securities the Company is able to offer and sell under such registration statement to one-third of our unaffiliated public float. During the year ended &#160;December 31, 2022, the Company issued&#160;130,505 ADSs at an average price of $2.11 per ADS under the ATM Agreement, resulting in gross proceeds of $275 thousand.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>4.</span><span style="padding-left:28.5pt">O</span></span></span></span>n September 19, 2022, the Company entered &#160;into a share purchase agreement (the &#8220;Repurchase Arrangement&#8221;) with Dr. Adi Mor, co-founder of Chemomab Ltd., Chief Scientific Officer and a director of the Company and Professor Kobi George, co-founder of Chemomab Ltd. (together with Dr. Adi Mor, the &#8220;Co-Founders&#8221;), whereby the Company agreed, subject to the requisite court approval required under Section 303(a) of the Israeli Companies Law, 5759-1999 (the &#8220;Companies Law&#8221;), which the Company received on November 14, 2022, to repurchase up to 582,023 ADSs owned by the Co-Founders, for consideration not to exceed an aggregate amount of $2,500,000, depending on the market price of the ADSs at the time of any repurchase. Accordingly, on November 16, 2022, the company repurchased the entire amount of 582,023 ADSs from the Co-Founders at a weighted average price of $2.0848 and for total consideration of approximately $1,218 thousand.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:110%">The Company accounted for the repurchased shares as treasury share&#160;in accordance with ASC 505-30, "Treasury Stock".</span></span></span></p>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Share-based compensation</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt">(1)<span style="padding-left:24.34pt">Share-based compensation plan:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:108pt;margin-bottom:0pt">The Company maintains (i) the 2011 Share Option Plan (the &#8220;2011 Plan&#8221;), (ii) the 2017 Equity-Based Incentive Plan (the &#8220;2017 Plan&#8221;) and (iii) the Chemomab 2015 Share Incentive Plan (the &#8220;2015 Plan&#8221;), which was assumed by the Company from Chemomab upon the effectiveness of the Merger. At that time, outstanding options under the 2015 Plan became exercisable for such number of ADSs of the Company as was determined based on the exchange ratio in the Merger Agreement, with a reciprocal adjustment to exercise price.<br/>&#160;</p>
    <p style="margin-top:0pt;margin-left:108pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>As of December 31, 2022, a total of 28,443,060 of our Ordinary Shares (equal to 1,422,153 of ADSs) were reserved for issuance under the 2015 Plan, of which 3,445,520 Ordinary Shares (equal to 172,276 ADSs) had been issued pursuant to previous exercises options, and 23,460,740 &#160;Ordinary Shares (equal to 1,173,037 ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase 12,400,720 Ordinary Shares (equal to 620,036 ADSs) had vested and were exercisable as of that date, with a weighted average exercise price of $0.30 per Ordinary Share (or $5.96 per ADS). During the year ended December 31, 2022, options to purchase 1,240,120 Ordinary Shares (equal to 62,006 ADS) were canceled.</span></span></span></p>
    <p style="margin-top:0pt;margin-left:96px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    <p style="margin-top:0pt;margin-left:108pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>As of December 31, 2022, a total of 12,511,620 of our Ordinary Shares (equal to 625,581&#160;ADSs) were reserved for issuance under the 2017 Plan, of which 11,730,800 Ordinary Shares (equal to 586,540 ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase 427,540 Ordinary Shares (equal to 21,377 ADSs) had vested and were exercisable as of that date, with a weighted average exercise price of $0.35 per Ordinary Share (or $6.98 per ADS). During the year ended December 31, 2022 no options were canceled.</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:11pt">(2)<span style="padding-left:24.34pt">The expenses that were recognized in the consolidated statements of operations for services received from employees </span>and service providers are as follows:</p>
    <div style="margin-left:108pt">

        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Research and development</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">448</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">137</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">General and administrative</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,763</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,882</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Total share-based compensation expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">3,211</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,019</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>

    </div>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:11pt">(3)<span style="padding-left:24.34pt">The number and weighted average exercise price of options are as follows:</span></p>
    <div style="margin-left:108pt">

        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted </span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">exercise </span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">price</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Number of </span><span style="font-weight:bold">options</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average </span><span style="font-weight:bold">remaining </span><span style="font-weight:bold">contractual </span><span style="font-weight:bold">life (in years)</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average </span><span style="font-weight:bold">exercise price</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Number of </span><span style="font-weight:bold">options</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average </span><span style="font-weight:bold">remaining </span><span style="font-weight:bold">contractual </span><span style="font-weight:bold">life (in years)</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding at January 1</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.38</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">27,003,260</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">8.12</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:10%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.07</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">10,455,580</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7.8</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Acquired in Merger</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%;text-align:right">-</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">-</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:10%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right">609,535</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Exercised</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.07</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">1,970,000</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">)</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">-</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:10%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.08</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(134,220</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Forfeited</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.32</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">1,240,120</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">)</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:10%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1.25</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(1,712,275</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Granted</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.16</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">11,398,400</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">7.8</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:10%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.62</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">17,784,640</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">9.79</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:10%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding at December 31</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.33</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">35,191,540</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">7.42</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:10%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.38</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">27,003,260</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">8.12</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>

    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt">(4)<span style="padding-left:24.34pt">Fair value measurement:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:108pt;margin-bottom:11pt">The fair value of the options is measured at the grant date using the Black-Scholes Option pricing model and the assumptions used to calculate the fair value of the options are as follows:</p>
    <div style="margin-left:108pt">

        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">2022&#160;grants</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Weighted average share price (in U.S. dollar)<sup>(a)</sup></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">0.16</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Exercise price (in U.S. dollar)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">0.10</span><span style="font-weight:bold">-</span><span style="font-weight:bold">0.257</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Expected life of options (in years)<sup>(b)</sup></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">5.51</span><span style="font-weight:bold">-</span><span style="font-weight:bold">6.28</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Expected volatility<sup>(c)</sup></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">83.69</span><span style="font-weight:bold">%-</span><span style="font-weight:bold">84.31</span><span style="font-weight:bold">%</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Risk-free interest rate<sup>(d)</sup></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">1.75</span><span style="font-weight:bold">%-</span><span style="font-weight:bold">4.14</span><span style="font-weight:bold">%</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Dividend yield</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">0</span><span style="font-weight:bold">%</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>

    </div>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(a)<span style="padding-left:24.34pt">The weighted average share price is based on the Company&#8217;s Ordinary Share valuation as at the grant date.</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(b)<span style="padding-left:24.34pt">Expected life for the periods presented was determined according to the simplified method since, at the date of </span>grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions and for performance conditions that are probable of achievement. If meeting the performance condition is not probable, the Company will use the awards&#8217; contractual term if the service period is implied, or the simplified method, if the service period is explicitly stated.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt">(c)<span style="padding-left:24.34pt">Expected volatility is based on historical volatility over the most recent period commensurate with the expected </span>term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:11pt">(d)<span style="padding-left:24.34pt">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the </span>yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873650734688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research and Development</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note 9 - Research and Development</span></p>

      <div style="margin-left:36pt;margin-bottom:11pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Consultants and subcontractors</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">13,052</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,894</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,867 </span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,789</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Rent and maintenance</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">245</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">114</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based compensation</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">448</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">137</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Other expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">365</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">400</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">16,977</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,334</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873735609648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_GeneralAndAdministrativeDisclosureTextBlock', window );">General and Administrative</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">Note 10 - General and Administrative&#160;</span></p>

      <div style="margin-left:36pt;margin-bottom:11pt">
        <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">3,435</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">943</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Professional services</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,596</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,695</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based compensation</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,763</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,882</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Fees to Directors</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">231</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span>244</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Insurance</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,084</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,024</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Rent and maintenance</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">24</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">29</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Other expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,423</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">216</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">11,556</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,033</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>

        </table>
      </div>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_GeneralAndAdministrativeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_GeneralAndAdministrativeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873655610912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Note 11 - Income Taxes</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Tax rates</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary taxable income in Israel is subject to a corporate tax rate of 23%.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s US subsidiary, Chemomab Therapeutics Inc. ("Chemomab Inc.) is taxed separately under the U.S. tax laws.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Chemomab Inc. is subject to a federal flat tax rate of 21% and state tax as applicable.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Capital gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">B.</span><span style="font-weight:bold;padding-left:26.83pt">Tax assessments</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of December 31, 2022, the Company&#8217;s tax reports through December 31, 2017&#160;are considered closed to audit inspections by the Israeli Tax Authority (&#8220;ITA&#8221;) due to statute of limitation rules effective in Israel.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has not yet been assessed by the ITA since inception.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Losses for tax purposes carried forward to future years</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of December 31, 2022, the Company and its subsidiaries had approximately $159 million&#160;(approximately $143 million as of December 31, 2021) of net operating loss carryforwards which are available to reduce future taxable income with no limitation on the period of use.</span></span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On March 27, 2020 and December 27, 2020, the President of the United States signed and enacted into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and the Consolidated Appropriations Act, 2021 (CAA). Among other provisions, the CARES Act and the CAA provide relief to U.S. federal corporate taxpayers through temporary adjustments to net operating loss rules, changes to limitations on interest expense deductibility, and the acceleration of available refunds for minimum tax credit carryforwards. The CARES Act also includes provisions for a carryback of any net operating loss (NOL) arising in a taxable year beginning after December 31, 2017, and before January 1, 2021, to each of the five taxable years preceding the taxable year in which the loss arises (carryback period).</span></span></span></p>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>Chemomab Therapeutics Inc., a wholly owned subsidiary of the Company, filed an application with the US Internal Revenue Service to carryback net operating losses. Chemomab Therapeutics Inc received $351 thousand in December 2022 on account of 2016 and 2017 and expects to receive the remainder $183 thousand in 2023. Accordingly, a tax benefit in the total amount of $534 thousand was recorded in the Company&#8217;s statement of operations during 2022.</span></span></span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">D.</span><span style="font-weight:bold;padding-left:26.28pt">Deferred taxes</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In respect of:</span></span></p>
    <div style="margin-left:72pt">

        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD thousands</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD thousands</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net operating loss carry-forwards</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">36,550</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,396</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation expense</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">1,774</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,147</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2,858</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,449</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">13</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">38</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross deferred tax assets</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">41,195</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36,030</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less - Valuation allowance</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(</span><span style="font-weight:bold">41,195</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(36,030)</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>

    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. A valuation allowance is provided when it is more likely than not that the deferred tax assets will not be realized.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has established a valuation allowance to offset deferred tax assets on December 31, 2022 and 2021 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The net change in the total valuation allowance for the year ended at December 31, 2022 was an increase of approximately $5.2 million.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">E.</span><span style="font-weight:bold;padding-left:26.83pt">Roll forward of valuation allowance</span></span></span></p>
    <div style="margin-left:72pt">

        <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at January 1, 2021</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">6,200</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency transaction loss</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2,425</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax assets acquired through merger</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">24,535</span></span></strong></td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2,870</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2021</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">36,030</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency transaction Income</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(1,316</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">6,481</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2022</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">41,195</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
            </tr>

        </table>

    </div>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">F.</span><span style="font-weight:bold;padding-left:28.31pt">Reconciliation of theoretical income tax expense to actual income tax expense</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A reconciliation of the Company&#8217;s theoretical income tax expense to actual income tax expense is as follows:</span></span></p>
    <div style="margin-left:72pt">

        <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD thousands</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD thousands</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before income taxes</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(</span><span style="font-weight:bold">28,180</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12,478</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p>
              </td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statutory tax rate</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">23</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">%</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></p>
              </td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical tax benefit</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<span style="font-weight:bold">6,481</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,870</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p>
              </td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in temporary differences for which deferred taxes were not recognized</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(1,696</strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,332</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax rate differential</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>20</strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(101</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-deductible expenses</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>744</strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">239</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>6,879</strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,064</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Actual income tax expense (Benefit)</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>(534</span></span></span></strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:1.5px">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>

        </table>

    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">G.</span><span style="font-weight:bold;padding-left:25.72pt">Accounting for uncertainty in income taxes</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the year ended December 31, 2022, the Company did not have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12 months. The Company&#8217;s accounting policy is to accrue interest and penalties related to unrecognized tax benefits as a component of income tax expense.</span></span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873655444064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties Balances and Transactions</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 12 - Related Parties Balances and Transactions</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:10.28pt">Balances with Related Parties:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">The following Related Party payables are included in the consolidated Balance Sheets:</p>
    <div style="margin-left:36pt">

        <div>
          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
                </td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
                </td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
                </td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>


              <tr style="background-color:#CCEEFF">
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Employee and related expenses</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">891</span></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">278</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accrued expenses</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">58</span></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">72</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr style="background-color:#CCEEFF">
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
                <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">949</span></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
                <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">350</p>
                </td>
                <td style="vertical-align:bottom;width:1%">
                  <p>&#160;</p>
                </td>
              </tr>

          </table>
        </div>

      <p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On September 19, 2022, the Company entered into a share purchase agreement with the Company's Co- Founders, see Note 8B(4).</span></span></span></p>
    </div>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="font-weight:bold;padding-left:10.83pt">Transactions with Related Parties:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">The following transactions with related parties are included in the consolidated Statements of Operations:</p>
    <div style="margin-left:36pt;margin-bottom:11pt">

        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,409</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,255</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based payments</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,466</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,775</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Professional Services</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">231</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">244</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Research and development</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">36</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">36</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">5,142</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,310</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>

    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873656978624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Ordinary Shareholders</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share, as the effect of potentially dilutive securities is antidilutive.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt">The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented:</p>
    <div style="margin-left:36pt">

        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year ended</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year ended</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">In USD thousands, except share and per </span><span style="font-weight:bold">share data</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Numerator:</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net loss</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">27,646</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">12,478</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Denominator:</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-10pt;padding-left:10pt;margin-bottom:0pt">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">227,589,288</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">207,468,650</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net loss per share attributable to ordinary shareholders, basic and diluted</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.121</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.060</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>

    </div>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt">The potential number of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows:</p>
    <div style="margin-left:36pt">

        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year ended</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year ended</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:center">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:center">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:center">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Number of shares</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding options to purchase ordinary shares</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">35,191,540</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">27,003,260</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>

    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873656671616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Events After Balance Sheet Date</a></td>
<td class="text">
    <div>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Note 14&#160;- Subsequent Events</span></span></span></p>
      <p style="margin-top:11pt;margin-bottom:0pt;padding-left:36pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">On January 13, 2023 the Company filed with the SEC a registration statement on form S-1 for the issuance and sale of up to $20,000,000 of its ADSs.</p>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873651991264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">A.</span><span style="font-weight:bold;padding-left:26.28pt">Basis of Preparation</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S GAAP&#8221;).</p>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">B.</span><span style="font-weight:bold;padding-left:26.83pt">Use of estimates</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">C.</span><span style="font-weight:bold;padding-left:26.28pt">Foreign currency</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#8220;dollar&#8221; or &#8220;$&#8221;), thus; the dollar is the functional currency of the Company.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.</p>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">D.</span><span style="font-weight:bold;padding-left:26.28pt">Cash and cash equivalents</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at the date acquired.</p>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">E.</span><span style="font-weight:bold;padding-left:26.83pt">Restricted cash</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt">Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office rent payments.</p>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text">
      <div>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">F.</span><span style="font-weight:bold;padding-left:28.31pt">Property and equipment</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets are ready for their intended use.</p>
        <div>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt">Annual rates at depreciation are as follows:</p>
          <div style="margin-left:36pt">

              <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

                  <tr>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">%</span></p>
                    </td>
                    <td style="vertical-align:bottom">&#160;</td>
                  </tr>


                  <tr style="background-color:#CCEEFF">
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Computers</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">33</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Laboratory equipment</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">10</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:#CCEEFF">
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Furniture and equipment</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>

              </table>

          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">G.</span><span style="font-weight:bold;padding-left:25.72pt">Impairment of long-lived assets</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company&#8217;s property and equipment are reviewed for impairment in accordance with ASC 360, &#8220;Property and Equipment&#8221;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2022 and 2021, no impairment losses have been recorded.</p>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">H.</span><span style="font-weight:bold;padding-left:25.72pt">Research and Development</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and wages.</p>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">I.</span><span style="font-weight:bold;padding-left:26.83pt">Income taxes</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.</p>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value of financial instruments</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">J.</span><span style="font-weight:bold;padding-left:28.5pt">Fair value of financial instruments</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.</p>
      <div/>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company&#8217;s own credit risk.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company&#8217;s non<span style="font-weight:bold">- </span>financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</p>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">K.</span><span style="font-weight:bold;padding-left:25.72pt">Share-based compensation</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The fair value for the Company&#8217;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C).</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt">The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock', window );">Government-sponsored research and development</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">L.</span><span style="font-weight:bold;padding-left:26.83pt">Government-sponsored research and development</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Chemomab records grants received from the office of the Israel Innovation Authority (the &#8220;IIA&#8221;) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.</p>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SeverancePayPolicyTextBlock', window );">Severance Pay [Policy Text Block]</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">M.</span><span style="font-weight:bold;padding-left:24.06pt">Severance pay</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $142 thousand and $116 thousand for the year ended December 31, 2022 and 2021, respectively.</span></span></p>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">N.</span><span style="font-weight:bold;padding-left:26.28pt">Concentrations of credit risk:</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash <span>and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold the Company&#8217;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments</span>.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt">The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</p>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
      <div>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">O.</span><span style="font-weight:bold;padding-left:25.72pt">Leases</span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Under </span></span>Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 5% and 5.2% in 2022 and 2021, respectively. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants<span><span>.</span></span></span></span><br/>&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></span><br/>&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment &#8211; Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize. See Note 2(G).</span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">P.</span><span style="font-weight:bold;padding-left:28.31pt">Principles of consolidation</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The <span>consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.</span></span></span></p>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per ordinary share</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"><span style="font-weight:bold">Q.</span><span style="font-weight:bold;padding-left:25.72pt">Earnings per ordinary share</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt">Basic earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant, gives effect to dilutive potential ordinary shares outstanding during the year. &#160;Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.</p>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SeverancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for severance pay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SeverancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873655479760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NatureOfOperationsDisclosureAbstract', window );"><strong>Nature Of Operations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of net assets acquired based on their estimated fair value</a></td>
<td class="text">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Cash and cash equivalents</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,427</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Asset held for sale</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,000</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Prepaid and other assets</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">236</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accrued liabilities</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(1,187</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">)</p>
              </td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net acquired assets</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,476</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NatureOfOperationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NatureOfOperationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873649337648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock', window );">Schedule of annual rate of deprecation</a></td>
<td class="text">
              <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

                  <tr>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">%</span></p>
                    </td>
                    <td style="vertical-align:bottom">&#160;</td>
                  </tr>


                  <tr style="background-color:#CCEEFF">
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Computers</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">33</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Laboratory equipment</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">10</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:#CCEEFF">
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Furniture and equipment</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:top;width:88%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement</p>
                    </td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                    <td style="vertical-align:top;width:9%">&#160;</td>
                    <td style="vertical-align:top;width:1%">&#160;</td>
                  </tr>

              </table>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the annual rate of deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873649337648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of components of cash and cash equivalents</a></td>
<td class="text">
      <div style="margin-left:36pt;margin-bottom:11pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In USD</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">10,663</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">10,720</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In NIS</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,756</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,116</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">In other currencies</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">100</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,350</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">13,519</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">15,186</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873655479760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables and Prepaid Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock', window );">Schedule of other accounts receivable and prepaid expenses</a></td>
<td class="text">
      <div style="margin-left:36pt;margin-bottom:11pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Government institutions</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">459</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">179</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Prepaid expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,307</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,348</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,766</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,527</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of other accounts receivable and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873655578320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, Net</a></td>
<td class="text">
      <div style="margin-left:36pt;margin-bottom:11pt">
        <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Cost:</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Computers</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">70</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">43</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Furniture and equipment</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">33</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">27</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Laboratory equipment</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">399</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">364</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Website development</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">14</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">14</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Leasehold improvements</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">16</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">16</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><strong><strong><strong>532</strong><strong> </strong></strong><strong> </strong></strong><strong> </strong></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">464 </p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Less - accumulated depreciation</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">165</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-weight:bold">)</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(107</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt">)</p>
              </td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><strong><strong><strong>367</strong><strong> </strong></strong><strong> </strong></strong><strong> </strong></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">357 </p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>

        </table>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873656671616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturity of lease liabilities under our non-cancelable operating leases</a></td>
<td class="text">
        <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">2023</p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">126 </span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">2024</p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">93 </span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Total future minimum lease payments</p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">219 </span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Less imputed interest:</p>
              </td>
              <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">5</span></p>
              </td>
              <td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px"><span style="font-weight:bold">)</span></p>
              </td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Present value of operating lease liabilities</p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">214 </span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873652024896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of the effect of share-based compensation on the statements of operations</a></td>
<td class="text">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Research and development</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">448</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">137</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">General and administrative</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,763</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,882</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Total share-based compensation expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">3,211</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,019</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of number and weighted average exercise prices of option</a></td>
<td class="text">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted </span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">exercise </span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">price</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Number of </span><span style="font-weight:bold">options</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average </span><span style="font-weight:bold">remaining </span><span style="font-weight:bold">contractual </span><span style="font-weight:bold">life (in years)</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average </span><span style="font-weight:bold">exercise price</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Number of </span><span style="font-weight:bold">options</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Weighted</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">average </span><span style="font-weight:bold">remaining </span><span style="font-weight:bold">contractual </span><span style="font-weight:bold">life (in years)</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding at January 1</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.38</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">27,003,260</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">8.12</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:10%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.07</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">10,455,580</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7.8</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Acquired in Merger</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%;text-align:right">-</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">-</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:10%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right">609,535</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Exercised</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.07</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">1,970,000</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">)</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">-</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:10%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.08</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(134,220</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Forfeited</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.32</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">(</span><span style="font-weight:bold">1,240,120</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">)</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:10%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1.25</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(1,712,275</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Granted</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.16</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">11,398,400</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">7.8</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:10%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.62</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">17,784,640</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">9.79</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:10%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:27%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding at December 31</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.33</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">35,191,540</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">7.42</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:10%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.38</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">27,003,260</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">8.12</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to calculate the fair value of the options</a></td>
<td class="text">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">2022&#160;grants</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Weighted average share price (in U.S. dollar)<sup>(a)</sup></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">0.16</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Exercise price (in U.S. dollar)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">0.10</span><span style="font-weight:bold">-</span><span style="font-weight:bold">0.257</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Expected life of options (in years)<sup>(b)</sup></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">5.51</span><span style="font-weight:bold">-</span><span style="font-weight:bold">6.28</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Expected volatility<sup>(c)</sup></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">83.69</span><span style="font-weight:bold">%-</span><span style="font-weight:bold">84.31</span><span style="font-weight:bold">%</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Risk-free interest rate<sup>(d)</sup></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">1.75</span><span style="font-weight:bold">%-</span><span style="font-weight:bold">4.14</span><span style="font-weight:bold">%</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:84%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Dividend yield</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;width:12%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-weight:bold">0</span><span style="font-weight:bold">%</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873656680304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock', window );">Schedule of research and development</a></td>
<td class="text">
      <div style="margin-left:36pt;margin-bottom:11pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Consultants and subcontractors</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">13,052</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,894</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,867 </span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,789</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Rent and maintenance</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">245</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">114</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based compensation</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">448</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">137</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Other expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">365</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">400</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">16,977</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,334</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873656708240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock', window );">Schedule of general and administrative</a></td>
<td class="text">
      <div style="margin-left:36pt;margin-bottom:11pt">
        <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">3,435</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">943</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Professional services</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,596</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,695</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based compensation</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,763</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,882</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Fees to Directors</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">231</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span>244</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Insurance</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,084</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,024</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Rent and maintenance</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">24</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">29</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Other expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">1,423</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">216</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">11,556</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,033</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>

        </table>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873656326736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of the company's deferred tax asset</a></td>
<td class="text">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD thousands</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD thousands</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net operating loss carry-forwards</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">36,550</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33,396</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based compensation expense</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">1,774</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,147</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2,858</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,449</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">13</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">38</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross deferred tax assets</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">41,195</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">36,030</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less - Valuation allowance</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(</span><span style="font-weight:bold">41,195</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(36,030)</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax assets</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of roll forward of valuation allowance</a></td>
<td class="text">
        <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at January 1, 2021</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">6,200</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency transaction loss</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2,425</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax assets acquired through merger</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">24,535</span></span></strong></td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2,870</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2021</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">36,030</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Currency transaction Income</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(1,316</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax expense</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">6,481</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance at December 31, 2022</span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">$</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">41,195</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of theoretical income tax expense to actual income tax expense</a></td>
<td class="text">
        <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31,</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD thousands</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">USD thousands</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before income taxes</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">(</span><span style="font-weight:bold">28,180</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12,478</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p>
              </td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Statutory tax rate</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">23</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">%</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></p>
              </td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Theoretical tax benefit</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<span style="font-weight:bold">6,481</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,870</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p>
              </td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in temporary differences for which deferred taxes were not recognized</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(1,696</strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,332</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tax rate differential</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>20</strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(101</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-deductible expenses</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>744</strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">239</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>6,879</strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,064</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(204, 238, 255)">
              <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Actual income tax expense (Benefit)</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span><span>(534</span></span></span></strong></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:1.5px">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">)</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873655414144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock', window );">Schedule of related party payables</a></td>
<td class="text">
        <div>
          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
                </td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
                </td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
                </td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td style="vertical-align:bottom;text-align:right">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>


              <tr style="background-color:#CCEEFF">
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Employee and related expenses</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">891</span></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">278</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Accrued expenses</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">58</span></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">72</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr style="background-color:#CCEEFF">
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
                <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">949</span></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
                <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">350</p>
                </td>
                <td style="vertical-align:bottom;width:1%">
                  <p>&#160;</p>
                </td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of transaction with related parties</a></td>
<td class="text">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">Year ended</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">December&#160;31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-weight:bold">USD thousands</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Salaries and related expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,409</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,255</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Share-based payments</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2,466</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,775</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Professional Services</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">231</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">244</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Research and development</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">36</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">36</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">5,142</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,310</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873655425920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted net loss per share</a></td>
<td class="text">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year ended</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year ended</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">In USD thousands, except share and per </span><span style="font-weight:bold">share data</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Numerator:</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net loss</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">27,646</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">12,478</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Denominator:</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-10pt;padding-left:10pt;margin-bottom:0pt">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">227,589,288</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">207,468,650</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Net loss per share attributable to ordinary shareholders, basic and diluted</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">0.121</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">0.060</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of weighted average number of shares excluded from computation of diluted net loss per share</a></td>
<td class="text">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year ended</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Year ended</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:center">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December&#160;31</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:center">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2022</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;text-align:right">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">2021</span></span></span></p>
              </td>
              <td style="vertical-align:bottom;text-align:center">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Number of shares</span></span></span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#CCEEFF">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">Outstanding options to purchase ordinary shares</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">35,191,540</span></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">27,003,260</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873657667888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember', window );">Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger', window );">Number of ADS issued and outstanding after the merger</a></td>
<td class="nump">12.86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ADS issued and outstanding after the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873652187360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General (Schedule of net assets acquired based on their estimated fair value) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NatureOfOperationsDisclosureAbstract', window );"><strong>Nature Of Operations Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale', window );">Asset held for sale</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Accrued liabilities</a></td>
<td class="num">(1,187)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EstimatedFairValueOfNetAssetsAcquired', window );">Net acquired assets</a></td>
<td class="nump">$ 2,476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of of asset held for sale recogized prior to the completion of merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued liabilities to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EstimatedFairValueOfNetAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated fair value of the net assets acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EstimatedFairValueOfNetAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NatureOfOperationsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NatureOfOperationsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873656379072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_PercentageOfMonthlyDepositsRate', window );">Percentage of monthly deposits rate</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncrementalBorrowingRateOfLeases', window );">incremental borrowing rate of leases</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_IncrementalBorrowingRateOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents incremental borrowing rate of leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_IncrementalBorrowingRateOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_PercentageOfMonthlyDepositsRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of monthly deposits rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_PercentageOfMonthlyDepositsRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873650288928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_AnnualRatesOfDepreciation', window );">Annual rates of depreciation</a></td>
<td class="text">over the shorter of the lease term or the estimated useful life of the improvement<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_AnnualRatesOfDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual rates of depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_AnnualRatesOfDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873652017488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 13,519<span></span>
</td>
<td class="nump">$ 15,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">10,663<span></span>
</td>
<td class="nump">10,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_ILS', window );">NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2,756<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_XXX', window );">Other currencies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 3,350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_XXX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_XXX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873652121024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ReceivablesFromGovernmentInstitutions', window );">Government institutions</a></td>
<td class="nump">$ 459<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">1,307<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other accounts receivable and prepaid expenses, Total</a></td>
<td class="nump">$ 1,766<span></span>
</td>
<td class="nump">$ 1,527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ReceivablesFromGovernmentInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government institutions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ReceivablesFromGovernmentInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873736612736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 532<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property Plant And Equipment Net</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Website development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmmb_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873652294400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 10, 2020</div></th>
<th class="th"><div>Oct. 24, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiry date</a></td>
<td class="text">May 31,  2023<span></span>
</td>
<td class="text">Oct. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease term, option to extend</a></td>
<td class="text">three years<span></span>
</td>
<td class="text">three years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_AnnualRentAndManagementFees', window );">Annual rent and management fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_BankGuaranteesToPropertyOwner', window );">Bank guarantees to property owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities', window );">Operating Right Of Use Assets And Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Increase in the carrying amount of the right-of-use asset due to impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Incremental borrowing rate based on credit rating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_AnnualRentAndManagementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual rent and management fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_AnnualRentAndManagementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_BankGuaranteesToPropertyOwner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bank guarantees to property owner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_BankGuaranteesToPropertyOwner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating right-of-use assets and operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873652016192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">$ 126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest:</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability, Total</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873736615136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Decsription of occurrence for payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than $3,000 thousand.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_MaximumPercentageOfPaymentsOfRoyalties', window );">Maximum percentage of payments of royalties (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized', window );">Cumulative Amounts Of Grants Received And Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royality expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,222<span></span>
</td>
<td class="nump">$ 2,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestments', window );">Bank restricted deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RecoverabilityOfVatAmount', window );">Recoverability of VAT amount</a></td>
<td class="nump">$ 1,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember', window );">New Drug Application and Biological License Application [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentDescription', window );">Description of application payment for licensed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$100 thousand upon submission of a New Drug Application (&#8220;NDA&#8221;), Biological License Application (&#8220;BLA&#8221;) or equivalent for each Licensed Product to the United States Food and Drug Administration (&#8220;FDA&#8221;), $100 thousand upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct', window );">Royalty payments on sale of product (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=cmmb_CapitalAdditionsOneMember', window );">Capital Additions One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentDescription', window );">Description of application payment for licensed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amounts of grants received from the IIA and recognized by the company, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_MaximumPercentageOfPaymentsOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of royalties payable on the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_MaximumPercentageOfPaymentsOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalty payments on sale of product developed with funding received from the IIA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RecoverabilityOfVatAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents recoverability of VAT amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RecoverabilityOfVatAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the terms of a significant arrangement with a supplier (excluding an unconditional purchase obligation) to acquire goods or services over a period of time beyond one year or the normal operating cycle, if longer, which may include identification of the goods or services to be purchased, pricing, effects on pricing of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=cmmb_CapitalAdditionsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=cmmb_CapitalAdditionsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873649856608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 15, 2021</div></th>
<th class="th"><div>Nov. 16, 2022</div></th>
<th class="th"><div>Sep. 19, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 23, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options to purchase ADS cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,120<span></span>
</td>
<td class="nump">1,712,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsFifteenPlanMember', window );">2015 plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockReservedForIssuance', window );">Number of stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,443,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockAdssResveredForIssuance', window );">Number Of Stock Adss Resvered For Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfAdssOptionsIssuableOutstanding', window );">Number of ADSs options issuable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,173,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfOptionsIssuableOutstanding', window );">Number of options issuable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,460,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfAdssVestedAndExercisable', window );">Number of ADSs vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfOptionsVestedAndExercisable', window );">Number of options vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,445,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options to purchase ADS cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod', window );">Options to purchase ordinary shares cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsSeventeenPlanMember', window );">2017 plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockReservedForIssuance', window );">Number of stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,511,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfStockAdssResveredForIssuance', window );">Number Of Stock Adss Resvered For Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfAdssVestedAndExercisable', window );">Number of ADSs vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfOptionsVestedAndExercisable', window );">Number of options vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,730,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">The Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ProceedsFromSaleOfAdss', window );">Proceeds from sale of ADS's</a></td>
<td class="nump">$ 45,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_NumberOfWarrantsPurchaseUpAdss', window );">Number of warrants purchase ADS's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,619,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStocksPricePerShare', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_AtmAgreementMember', window );">ATM agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement', window );">Aggregate offering price of at the market offering agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ProceedsFromSaleOfAdss', window );">Proceeds from sale of ADS's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues', window );">Number of ADSs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">699,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStocksPricePerShare', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_RepurchaseArrangementMember', window );">Repurchase Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockLineItems', window );"><strong>Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RepurchaseOfAmericanDepositaryReceipts', window );">Repurchase of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares', window );">Number of shares repurchase of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,023<span></span>
</td>
<td class="nump">582,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts', window );">Weighted average price of repurchase of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts', window );">Total consideration of repurchase of ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents as a aggregate offering price of at the market offering agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfAdssOptionsIssuableOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ADSs options issuable outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfAdssOptionsIssuableOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfAdssVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ADSs vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfAdssVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfOptionsIssuableOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents number of options issuable outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfOptionsIssuableOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfOptionsVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents number of options vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfOptionsVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfStockAdssResveredForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock option ADSs resvered for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfStockAdssResveredForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfStockReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents number of stock resvered for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfStockReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_NumberOfWarrantsPurchaseUpAdss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants purchase ADS's.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_NumberOfWarrantsPurchaseUpAdss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ProceedsFromSaleOfAdss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of ADS's.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ProceedsFromSaleOfAdss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RepurchaseOfAmericanDepositaryReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of repurchase of american depositary receipts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RepurchaseOfAmericanDepositaryReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RepurchaseOfAmericanDepositaryReceiptsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents repurchase of American Depositary Receipts shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RepurchaseOfAmericanDepositaryReceiptsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SaleOfStocksPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by the company for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SaleOfStocksPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Forfeitures In Period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Outstanding Period Increase Decrease Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stocks of American Depository Shares ("ADS") issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents Total consideration of repurchase of american depositary receipts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents weighted average price of repurchase of american depositary receipts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmmb_TwoThousandsFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmmb_TwoThousandsSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmmb_TwoThousandsSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_AtmAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmmb_AtmAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmmb_RepurchaseArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmmb_RepurchaseArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873652311280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Schedule of Share-based Compensation Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">$ 3,211<span></span>
</td>
<td class="nump">$ 2,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expenses</a></td>
<td class="nump">$ 2,763<span></span>
</td>
<td class="nump">$ 1,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873651868288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning</a></td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice', window );">Acquired in Merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise</a></td>
<td class="nump">0.07<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">0.32<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">0.16<span></span>
</td>
<td class="nump">0.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end</a></td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning</a></td>
<td class="nump">27,003,260<span></span>
</td>
<td class="nump">10,455,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger', window );">Acquired in Merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">609,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1', window );">Exercise</a></td>
<td class="num">(1,970,000)<span></span>
</td>
<td class="num">(134,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(1,240,120)<span></span>
</td>
<td class="num">(1,712,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">11,398,400<span></span>
</td>
<td class="nump">17,784,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end</a></td>
<td class="nump">35,191,540<span></span>
</td>
<td class="nump">27,003,260<span></span>
</td>
<td class="nump">10,455,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years 5 months 1 day<span></span>
</td>
<td class="text">8 years 1 month 13 days<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm', window );">Granted</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">9 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of shares acquired in merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options acquired, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873651626576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average share price (in U.S. dollar)</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">83.69%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">84.31%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.14%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in U.S. dollar)</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (in years)</a></td>
<td class="text">5 years 6 months 3 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in U.S. dollar)</a></td>
<td class="nump">$ 0.257<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (in years)</a></td>
<td class="text">6 years 3 months 10 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The weighted average share price is based on the Company&#8217;s ordinary share valuation as at the grant date.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions and for performance conditions that are probable of achievement. If meeting the performance condition is not probable, the Company will use the awards&#8217; contractual term if the service period is implied, or the simplified method, if the service period is explicitly stated.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873651946160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development (Schedule of Research and Development) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ConsultantsAndSubcontractorsExpense', window );">Consultants And Subcontractors Expense</a></td>
<td class="nump">$ 13,052<span></span>
</td>
<td class="nump">$ 3,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Salaries and related expenses</a></td>
<td class="nump">2,867<span></span>
</td>
<td class="nump">1,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense', window );">Rent And Maintenance Research And Development Expense</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense', window );">Share-based compensation</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other expenses</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">$ 16,977<span></span>
</td>
<td class="nump">$ 6,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ConsultantsAndSubcontractorsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consultants and subcontractors expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ConsultantsAndSubcontractorsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RentAndMaintenanceResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development related rent and maintenance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RentAndMaintenanceResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development related share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873652223712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative (Schedule of General and Administrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries and related expenses</a></td>
<td class="nump">$ 3,435<span></span>
</td>
<td class="nump">$ 943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="nump">2,596<span></span>
</td>
<td class="nump">1,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense', window );">Share-based compensation</a></td>
<td class="nump">2,763<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Fees to Directors</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance</a></td>
<td class="nump">1,084<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense', window );">Rent and maintenance</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other expenses</a></td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="nump">$ 11,556<span></span>
</td>
<td class="nump">$ 6,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative related rent and maintenance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative related share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseDirectorsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseDirectorsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873652299600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net change in the total valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ReceivedAmountOfChemomabTherapeuticsInc', window );">Received amount of Chemomab Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (534)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Capital losses carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,000<span></span>
</td>
<td class="nump">$ 143,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. [Member] | Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc', window );">Expects to receive amount of Chemomab Therapeutics Inc</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount expects to receive of Chemomab Therapeutics Inc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ReceivedAmountOfChemomabTherapeuticsInc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The received amount of Chemomab Therapeutics Inc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ReceivedAmountOfChemomabTherapeuticsInc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873650274672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">$ 36,550<span></span>
</td>
<td class="nump">$ 33,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation expense</a></td>
<td class="nump">1,774<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development costs</a></td>
<td class="nump">2,858<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">41,195<span></span>
</td>
<td class="nump">36,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less - valuation allowance</a></td>
<td class="num">(41,195)<span></span>
</td>
<td class="num">(36,030)<span></span>
</td>
<td class="num">$ (6,200)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873653253184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at January 1</a></td>
<td class="nump">$ 36,030<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_CurrencyTransactionLossValuationAllowance', window );">Currency transaction income (loss)</a></td>
<td class="num">(1,316)<span></span>
</td>
<td class="nump">2,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance', window );">Tax assets acquired through merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_IncomeTaxExpenseValuationAllowance', window );">Income tax expense</a></td>
<td class="nump">6,481<span></span>
</td>
<td class="nump">2,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at December 31</a></td>
<td class="nump">$ 41,195<span></span>
</td>
<td class="nump">$ 36,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_CurrencyTransactionLossValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance due to currency transaction loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_CurrencyTransactionLossValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_IncomeTaxExpenseValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance due to income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_IncomeTaxExpenseValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance due to tax assets acquired through merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873651881264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Theoretical tax benefit on the above amount Decrease (increase) in tax refund resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (28,180)<span></span>
</td>
<td class="num">$ (12,478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Statutory tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Theoretical tax benefit</a></td>
<td class="num">$ (6,481)<span></span>
</td>
<td class="num">$ (2,870)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized', window );">Change in temporary differences for which deferred taxes were not recognized</a></td>
<td class="num">(1,696)<span></span>
</td>
<td class="num">(1,332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Tax rate differential</a></td>
<td class="nump">20<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded', window );">Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards</a></td>
<td class="nump">6,879<span></span>
</td>
<td class="nump">4,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Actual income tax expense (Benefit)</a></td>
<td class="num">$ (534)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents as a change in temporary differences for which deferred taxes were not recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents losses and benefits for tax purposes for the year, for which deferred taxes were not recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873649509136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee and related expenses</a></td>
<td class="nump">$ 1,560<span></span>
</td>
<td class="nump">$ 653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,378<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cmmb_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee and related expenses</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related Party Payables</a></td>
<td class="nump">$ 949<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cmmb_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cmmb_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873656221712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty', window );">Salaries and related expenses</a></td>
<td class="nump">$ 2,409<span></span>
</td>
<td class="nump">$ 1,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty', window );">Share-based payments</a></td>
<td class="nump">2,466<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty', window );">Professional services</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty', window );">Research and development</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Total related party expenses</a></td>
<td class="nump">$ 5,142<span></span>
</td>
<td class="nump">$ 3,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to research and develeopment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to salaries and related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party expenses related to share based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873652290320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EarningsPerShareCalculationNumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 27,646<span></span>
</td>
<td class="nump">$ 12,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic</a></td>
<td class="nump">227,589,288<span></span>
</td>
<td class="nump">207,468,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted</a></td>
<td class="nump">227,589,288<span></span>
</td>
<td class="nump">207,468,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net loss per share attributable to ordinary shareholders, basic</a></td>
<td class="nump">$ 0.121<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net loss per share attributable to ordinary shareholders, diluted</a></td>
<td class="nump">$ 0.121<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_EarningsPerShareCalculationNumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share Calculation Numerator Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_EarningsPerShareCalculationNumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873649494352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding options to purchase ordinary shares</a></td>
<td class="nump">35,191,540<span></span>
</td>
<td class="nump">27,003,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139873656375344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Jan. 13, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmmb_SaleOfStockValueOfSharesIssuedInTransaction', window );">Issuance and sale of of ADS upto</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmmb_SaleOfStockValueOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of sale of stock value of shares issued in transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmmb_SaleOfStockValueOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmmb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>zk2329403_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cmmb="http://www.anchiano.com/20221231"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cmmb-20221231.xsd" xlink:type="simple"/>
    <context id="C_20220101to20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cmmb:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cmmb:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20200510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2020-05-10</instant>
        </period>
    </context>
    <context id="C_20200501to20200510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-10</endDate>
        </period>
    </context>
    <context id="C_20211001to20211024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-24</endDate>
        </period>
    </context>
    <context id="C_20211024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-10-24</instant>
        </period>
    </context>
    <context id="C_20211212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-12-12</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220701to20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">cmmb:CapitalAdditionsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20200101to20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmmb:TwoThousandsSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-23</endDate>
        </period>
    </context>
    <context id="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-15</endDate>
        </period>
    </context>
    <context id="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-19</endDate>
        </period>
    </context>
    <context id="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmmb:RepurchaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="C_20221231_srtCurrencyAxis_currencyUSD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_srtCurrencyAxis_currencyUSD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtCurrencyAxis_currencyILS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_srtCurrencyAxis_currencyILS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtCurrencyAxis_currencyXXX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_srtCurrencyAxis_currencyXXX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:XXX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_srtStatementGeographicalAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_srtStatementGeographicalAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_srtStatementGeographicalAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20231231_srtStatementScenarioAxis_srtScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cmmb:OrdinarySharesNoParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cmmb:MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="C_20230113_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001534248</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-13</instant>
        </period>
    </context>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="USD_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_20200501to20200510"
      id="Fxbrl_20230131233234992">2023-05-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_20211001to20211024"
      id="Fxbrl_20230131233722905">2024-10-31</us-gaap:LeaseExpirationDate1>
    <dei:EntityCentralIndexKey contextRef="C_20220101to20221231" id="FFact_0000000000489">0001534248</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus contextRef="C_20220101to20221231" id="FFact_0000000000490">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="C_20220101to20221231" id="FFact_0000000000491">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317110031039">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317110047759">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317115904802">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317115920444">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317115943030">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317110333107">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317110426398">001-38807</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317110431452">CHEMOMAB THERAPEUTICS LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317110501023">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317110522585">81-3676773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113139733">Kiryat Atidim</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113157615">Building 7</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113215641">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317120727388">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113235355">6158002</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113259509">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113315303">77-331-0156</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"
      id="Fxbrl_20230317113401299">American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"
      id="Fxbrl_20230317113420950">CMMB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbAmericanDepositarySharesMember"
      id="Fxbrl_20230317113425782">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"
      id="Fxbrl_20230317113407348">Ordinary shares, no par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"
      id="Fxbrl_20230317113501184">n/a</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20220101to20221231_usgaapStatementClassOfStockAxis_cmmbOrdinarySharesNoParValuePerShareMember"
      id="Fxbrl_20230317113450391">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113557797">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113613031">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113649242">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113712117">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113737895">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113803418">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113819251">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113837997">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113902158">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317113939282">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_20221231"
      decimals="-5"
      id="Fxbrl_20230317153101775"
      unitRef="usd">37900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230317153138658"
      unitRef="Share">220996240</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317114952055">1057</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317115222105">Somekh Chaikin</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230317115227929">Tel Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000038"
      unitRef="usd">13519000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000039"
      unitRef="usd">15186000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000040"
      unitRef="usd">26374000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000041"
      unitRef="usd">45975000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230213102216110_Fact_0000000000040"
      unitRef="usd">77000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230213102216110_Fact_0000000000041"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000042"
      unitRef="usd">1766000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000043"
      unitRef="usd">1527000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000044"
      unitRef="usd">41736000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000045"
      unitRef="usd">62688000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230207200450049_Fact_0000000000050"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230207200450049_Fact_0000000000051"
      unitRef="usd">55000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000048"
      unitRef="usd">733000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230131220311598"
      unitRef="usd">908000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000052"
      unitRef="usd">367000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000053"
      unitRef="usd">357000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000054"
      unitRef="usd">227000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000055"
      unitRef="usd">345000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000056"
      unitRef="usd">1327000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000057"
      unitRef="usd">1665000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000058"
      unitRef="usd">43063000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000059"
      unitRef="usd">64353000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000060"
      unitRef="usd">1688000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000061"
      unitRef="usd">1336000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000062"
      unitRef="usd">3378000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000063"
      unitRef="usd">555000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000064"
      unitRef="usd">1560000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000065"
      unitRef="usd">653000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000066"
      unitRef="usd">123000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000067"
      unitRef="usd">106000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000068"
      unitRef="usd">6749000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000069"
      unitRef="usd">2650000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000070"
      unitRef="usd">91000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000071"
      unitRef="usd">237000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000072"
      unitRef="usd">91000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000073"
      unitRef="usd">237000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20221231"
      id="Fxbrl_20230207202310124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20211231"
      id="Fxbrl_20230207202348403"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000074"
      unitRef="usd">6840000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000075"
      unitRef="usd">2887000</us-gaap:Liabilities>
    <us-gaap:CommonStockNoParValue
      contextRef="C_20211231"
      decimals="0"
      id="Fxbrl_20230201163052384"
      unitRef="USD_Per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="C_20221231"
      decimals="0"
      id="Fxbrl_20230131220607422"
      unitRef="USD_Per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20230131221123913"
      unitRef="Share">650000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230131221114549"
      unitRef="Share">650000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_s_20230213101830929"
      unitRef="Share">232636700</us-gaap:SharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230213101830930"
      unitRef="Share">232636700</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_s_20230131221353660"
      unitRef="Share">228090300</us-gaap:SharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20230131221353661"
      unitRef="Share">228090300</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230131221528825"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230131221535249"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockShares
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230207202558860"
      unitRef="Share">11640460</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230207202444619"
      unitRef="usd">1218000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230207202534021"
      unitRef="usd">0</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000086"
      unitRef="usd">101260000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000087"
      unitRef="usd">97639000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000088"
      unitRef="usd">-63819000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000089"
      unitRef="usd">-36173000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000090"
      unitRef="usd">36223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000091"
      unitRef="usd">61466000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000092"
      unitRef="usd">43063000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000093"
      unitRef="usd">64353000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000094"
      unitRef="usd">16977000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000095"
      unitRef="usd">6334000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000096"
      unitRef="usd">11556000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000097"
      unitRef="usd">6033000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000098"
      unitRef="usd">28533000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000099"
      unitRef="usd">12367000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230131223230473"
      unitRef="usd">353000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230131223237304"
      unitRef="usd">-111000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207212310873_Fact_0000000000102"
      unitRef="usd">-28180000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207212310873_Fact_0000000000103"
      unitRef="usd">-12478000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230131223639023"
      unitRef="usd">-534000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000101"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000102"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000103"
      unitRef="usd">-12478000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230131213305203"
      unitRef="USD_Per_Share">0.121</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000104"
      unitRef="USD_Per_Share">0.121</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230131213312166"
      unitRef="USD_Per_Share">0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000105"
      unitRef="USD_Per_Share">0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230214141238310"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000106"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230131213329528"
      unitRef="Share">207468650</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000107"
      unitRef="Share">207468650</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207232832534"
      unitRef="Share">9274838</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004148281"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004108785"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004208753"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207232638785_Fact_0000000000128"
      unitRef="usd">34497000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207232638785_Fact_0000000000129"
      unitRef="usd">-23695000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231"
      decimals="-3"
      id="Fxbrl_20230207232638785_Fact_0000000000130"
      unitRef="usd">10802000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004236209"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004232608"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207232932528"
      unitRef="usd">2019000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004229458"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207232938175"
      unitRef="usd">2019000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cmmb:EffectOfReverseCapitalizationTransactionShares
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207232946871"
      unitRef="Share">152299702</cmmb:EffectOfReverseCapitalizationTransactionShares>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004310594"
      unitRef="usd">0</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:EffectOfReverseCapitalizationTransactionShares
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004631164"
      unitRef="Share">0</cmmb:EffectOfReverseCapitalizationTransactionShares>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004302609"
      unitRef="usd">0</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207232952864"
      unitRef="usd">2476000</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004258843"
      unitRef="usd">0</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:EffectOfReverseCapitalizationTransaction
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207232958504"
      unitRef="usd">2476000</cmmb:EffectOfReverseCapitalizationTransaction>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233006128"
      unitRef="Share">66381520</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004339738"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004626295"
      unitRef="Share">0</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004335122"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233012248"
      unitRef="usd">58637000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004332317"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207233018475"
      unitRef="usd">58637000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233039147"
      unitRef="Share">134240</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004521301"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004621028"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004724885"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233033563"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004807831"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207233028090"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004352160"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004349447"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230208004345432"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233044479"
      unitRef="usd">-12478000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207233049858"
      unitRef="usd">-12478000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207234506438"
      unitRef="Share">228090300</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004359870"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004449318"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004357072"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233106443"
      unitRef="usd">97639000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207234203847"
      unitRef="usd">-36173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230207233116634"
      unitRef="usd">61466000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207234515566"
      unitRef="Share">228090300</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004830175"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004835440"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004846448"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233129314"
      unitRef="usd">97639000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233133644"
      unitRef="usd">-36173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230207233141194"
      unitRef="usd">61466000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004855201"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004852649"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233154315"
      unitRef="usd">3211000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004943313"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233147476"
      unitRef="usd">3211000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233201211"
      unitRef="Share">2576400</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004904248"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004910523"
      unitRef="Share">0</cmmb:StockAndWarrantsIssuedDuringPeriodNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004901083"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233210018"
      unitRef="usd">267000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004950211"
      unitRef="usd">0</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233216009"
      unitRef="usd">267000</cmmb:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233237975"
      unitRef="Share">1970000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004927217"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230208004915442"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208004923369"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233227671"
      unitRef="usd">143000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004959684"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233221400"
      unitRef="usd">143000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208004938057"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230207233301376"
      unitRef="Share">-11640460</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230207233406606"
      unitRef="usd">-1218000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230208004934609"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230208004932393"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233411324"
      unitRef="usd">-1218000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208005011611"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230208005008418"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230208005005802"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233416622"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233422744"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230207233430996"
      unitRef="Share">232636700</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230208005022333"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="INF"
      id="Fxbrl_20230207233657770"
      unitRef="Share">-11640460</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapTreasuryStockMember"
      decimals="-3"
      id="Fxbrl_20230207233728393"
      unitRef="usd">-1218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230207233439472"
      unitRef="usd">101260000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230207233445148"
      unitRef="usd">-63819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230207233450251"
      unitRef="usd">36223000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000149"
      unitRef="usd">-27646000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000150"
      unitRef="usd">-12478000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000151"
      unitRef="usd">58000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000152"
      unitRef="usd">34000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000153"
      unitRef="usd">3211000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000154"
      unitRef="usd">2019000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000155"
      unitRef="usd">64000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000156"
      unitRef="usd">2058000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000157"
      unitRef="usd">352000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000158"
      unitRef="usd">1175000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000159"
      unitRef="usd">2823000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230201002431792"
      unitRef="usd">-1279000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000161"
      unitRef="usd">907000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000162"
      unitRef="usd">215000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000163"
      unitRef="usd">-11000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230201002424683"
      unitRef="usd">-2000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000165"
      unitRef="usd">-20370000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000166"
      unitRef="usd">-12374000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <cmmb:PaymentsForInvestmentInDeposits
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000167"
      unitRef="usd">-19601000</cmmb:PaymentsForInvestmentInDeposits>
    <cmmb:PaymentsForInvestmentInDeposits
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000168"
      unitRef="usd">45951000</cmmb:PaymentsForInvestmentInDeposits>
    <cmmb:LongTermLeaseDeposit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000169"
      unitRef="usd">0</cmmb:LongTermLeaseDeposit>
    <cmmb:LongTermLeaseDeposit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230131235620864"
      unitRef="usd">4000</cmmb:LongTermLeaseDeposit>
    <us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000171"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities>
    <us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230131235631064"
      unitRef="usd">1000000</us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000173"
      unitRef="usd">68000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000174"
      unitRef="usd">239000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000175"
      unitRef="usd">19533000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000176"
      unitRef="usd">-45186000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <cmmb:CashAcquiredInMerger
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000177"
      unitRef="usd">0</cmmb:CashAcquiredInMerger>
    <cmmb:CashAcquiredInMerger
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230131235649216"
      unitRef="usd">2427000</cmmb:CashAcquiredInMerger>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000179"
      unitRef="usd">143000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230131235658097"
      unitRef="usd">10000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230201000241409"
      unitRef="usd">1218000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000182"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000183"
      unitRef="usd">267000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000184"
      unitRef="usd">58637000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230201002754453"
      unitRef="usd">-808000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000186"
      unitRef="usd">61074000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230201002721687"
      unitRef="usd">-1645000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000188"
      unitRef="usd">3514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000189"
      unitRef="usd">15241000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20201231"
      decimals="-3"
      id="FFact_0000000000190"
      unitRef="usd">11727000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000191"
      unitRef="usd">13596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000192"
      unitRef="usd">15241000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cmmb:IncomeTaxesReceived
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214142748754"
      unitRef="usd">351000</cmmb:IncomeTaxesReceived>
    <cmmb:IncomeTaxesReceived
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214143241770"
      unitRef="usd">0</cmmb:IncomeTaxesReceived>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214142431448"
      unitRef="usd">5000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207233750059"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <cmmb:InterestReceived
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230207233819452"
      unitRef="usd">972000</cmmb:InterestReceived>
    <cmmb:InterestReceived
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230207233829491"
      unitRef="usd">74000</cmmb:InterestReceived>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000193"
      unitRef="usd">17000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000194"
      unitRef="usd">345000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LiabilitiesAssumed1
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000195"
      unitRef="usd">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230131235456185"
      unitRef="usd">49000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:NatureOfOperations contextRef="C_20220101to20221231" id="FFact_0000000000208">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Note 1 - General&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;1.&lt;span style="padding-left:28.5pt"&gt;Chemomab Therapeutics Ltd. (hereinafter - "the Company") is an Israeli-based company incorporated under the laws of the State of Israel in September 2011. The Company&#x2019;s registered office is located in Kiryat Atidim, Tel Aviv, Israel.&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0px;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt;text-align:justify"&gt;&lt;br/&gt;The Company is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high-unmet medical need that involve inflammation and fibrosis.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0px;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;br/&gt;The wholly owned subsidiaries of the Company are: Chemomab Ltd. ("Chemomab"), Chemomab Therapeutics Israel Ltd. and Chemomab Therapeutics Inc.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;2.&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="padding-left:28.5pt"&gt;The Company currently has no products approved for sale. The Company&#x2019;s operations are funded primarily by its Shareholders. The Company has incurred operating losses in each year since its inception and does not expect to generate significant revenue unless and until it obtains marketing approval for its products. Continuation of the Company&#x2019;s development programs depend on its future ability to raise sources of financing.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.&lt;span style="padding-left:28.5pt"&gt;Since &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;January 2020, the COVID-19 pandemic has dramatically expanded into a worldwide pandemic, creating macro-economic uncertainty and disruption in the business and financial markets. Many countries around the world, including Israel, had taken&#160; measures designated to limit the continued spread of the COVID-19 pandemic, including the closure of workplaces, restricting travel, prohibiting assembling, closing international borders and quarantining populated areas. The Company's clinical trial sites have been affected by the COVID-19 pandemic, and as a result, commencement of the enrollment in our clinical trials of CM-101 in PSC was delayed, and the enrollment rate has been, and is still, affected as well. As a result, The Company expanded its patient recruiting efforts to additional territories. In addition, after enrollment in these trials, patients might still drop out because of possible COVID-19 implications. Based on management&#x2019;s assessment, the extent to which the lingering effects of the COVID-19 pandemic will further impact the Company's operations will depend on future developments. These developments, which are highly uncertain and cannot be predicted with confidence,including the duration and severity of the impact on patient enrollment following the attenuation of the outbreak The Company is carefully monitoring the impacts arising from&#160; the COVID-19 pandemic and will adjust activities accordingly&lt;span&gt;&lt;span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.&lt;span style="padding-left:28.5pt"&gt;On &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 14, 2020, the Company (formerly known as Anchiano Therapeutics Ltd.) entered into an Agreement and Plan of Merger (the "Merger" and &#x201c;Merger Agreement&#x201d;) with Chemomab Ltd., an Israeli limited company, and CMB Acquisition Ltd., an Israeli limited company and a wholly owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;). On March 16, 2021, (the &#x201c;Effective Time&#x201d;), the Company consummated the Merger pursuant to the Merger Agreement Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Chemomab Ltd., with Chemomab Ltd. surviving the Merger as the Company's wholly owned subsidiary. In connection with the Merger, on March 16, 2021, the Company changed its name from &#x201c;Anchiano Therapeutics Ltd.&#x201d; To &#x201c;Chemomab Therapeutics Ltd" and the business conducted by Chemomab Ltd. became primarily the business conducted by the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;div&gt;
      &lt;div style="width:100%;clear:both"&gt;
        &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
      &lt;/div&gt;
    &lt;/div&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0px;padding-left:72pt;margin-bottom:10pt"&gt;At the Effective Time(a) each Chemomab Ltd. ordinary share outstanding immediately prior to the Effective Time was converted solely into number of American Depository Shares equal to the exchange ratio described in the Merger Agreement, and each outstanding Chemomab Ltd. option was assumed by the Company, based on the same exchange ratio.&lt;/p&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For&#160;&lt;span&gt;accounting purposes, Chemomab Ltd. is considered to have acquired the Company based upon the terms of the Merger as well as other factors. The Merger has been accounted for as an asset acquisition (reverse recapitalization transaction) rather than a business combination, as the assets acquired, and the liabilities assumed by Chemomab Ltd. do not meet the definition of a business under U.S. GAAP. The net assets acquired in connection with the Merger were recorded at their estimated acquisition date fair market value as of March 16, 2021, the date of completion of the Merger.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;The exchange ratio was calculated by a formula that was determined through arms-length negotiations between the Company and Chemomab Ltd. The combined Company assumed all of the outstanding options of Chemomab Ltd., vested and not vested, under the Chemomab&#160;Share Incentive Plan (the &#x201c;2015 Plan&#x201d;), with such options representing the right to purchase a number of ADSs equal to approximately 12.86 multiplied by the number of Chemomab Ltd. ordinary shares previously represented by such options.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:11pt"&gt;The following table summarizes the net assets acquired based on their estimated fair values as of March 16, 2021, immediately prior to completion of the Merger (in USD thousands):&lt;/p&gt;
    &lt;div style="margin-left:72pt"&gt;

        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Cash and cash equivalents&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,427&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Asset held for sale&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,000&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Prepaid and other assets&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;236&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Accrued liabilities&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(1,187&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Net acquired assets&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,476&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

    &lt;/div&gt;
  </us-gaap:NatureOfOperations>
    <cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger
      contextRef="C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember"
      decimals="INF"
      id="Fxbrl_20230131220949272"
      unitRef="Share">12.86</cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201024915457">
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Cash and cash equivalents&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,427&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Asset held for sale&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,000&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Prepaid and other assets&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;236&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Accrued liabilities&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(1,187&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Net acquired assets&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,476&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_0000000000202"
      unitRef="usd">2427000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_0000000000203"
      unitRef="usd">1000000</cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_0000000000204"
      unitRef="usd">236000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_0000000000205"
      unitRef="usd">1187000</cmmb:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <cmmb:EstimatedFairValueOfNetAssetsAcquired
      contextRef="C_20210316"
      decimals="-3"
      id="FFact_0000000000206"
      unitRef="usd">2476000</cmmb:EstimatedFairValueOfNetAssetsAcquired>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000234">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Note 2 - Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;

      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Basis of Preparation&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S GAAP&#x201d;).&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Foreign currency&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#x201c;dollar&#x201d; or &#x201c;$&#x201d;), thus; the dollar is the functional currency of the Company.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;D.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at the date acquired.&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;E.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office rent payments.&lt;/p&gt;


      &lt;div&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;F.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.31pt"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets are ready for their intended use.&lt;/p&gt;
        &lt;div&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"&gt;Annual rates at depreciation are as follows:&lt;/p&gt;
          &lt;div style="margin-left:36pt"&gt;

              &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;


                  &lt;tr style="background-color:#CCEEFF"&gt;
                    &lt;td style="vertical-align:top;width:88%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Computers&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;33&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Laboratory equipment&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;10&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:#CCEEFF"&gt;
                    &lt;td style="vertical-align:top;width:88%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Furniture and equipment&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;

          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;

    &lt;div/&gt;

      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;G.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The Company&#x2019;s property and equipment are reviewed for impairment in accordance with ASC 360, &#x201c;Property and Equipment&#x201d;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2022 and 2021, no impairment losses have been recorded.&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;H.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and wages.&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;I.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;J.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.5pt"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity&#x2019;s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.&lt;/p&gt;
      &lt;div/&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company&#x2019;s own credit risk.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company&#x2019;s non&lt;span style="font-weight:bold"&gt;- &lt;/span&gt;financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;K.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The fair value for the Company&#x2019;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C).&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;L.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Government-sponsored research and development&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Chemomab records grants received from the office of the Israel Innovation Authority (the &#x201c;IIA&#x201d;) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.&lt;/p&gt;

    &lt;div/&gt;

      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;M.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:24.06pt"&gt;Severance pay&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $142 thousand and $116 thousand for the year ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;N.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Concentrations of credit risk:&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash &lt;span&gt;and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold the Company&#x2019;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/p&gt;


      &lt;div&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;O.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Leases&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Under &lt;/span&gt;&lt;/span&gt;Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 5% and 5.2% in 2022 and 2021, respectively. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants&lt;span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment &#x2013; Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize. See Note 2(G).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;

    &lt;div/&gt;

      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;P.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.31pt"&gt;Principles of consolidation&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The &lt;span&gt;consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Q.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Earnings per ordinary share&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt"&gt;Basic earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant, gives effect to dilutive potential ordinary shares outstanding during the year. &#160;Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.&lt;/p&gt;

  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000209">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Basis of Preparation&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S GAAP&#x201d;).&lt;/p&gt;
    </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_20220101to20221231" id="FFact_0000000000210">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;
    </us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000211">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Foreign currency&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#x201c;dollar&#x201d; or &#x201c;$&#x201d;), thus; the dollar is the functional currency of the Company.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The transactions and balances of the Company denominated in U.S. dollars are presented at their original amounts as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Monetary assets and liabilities denominated in a non-U.S. dollar currency are translated using the current exchange rate and nonmonetary assets and liabilities and capital accounts denominated in a non-U.S. dollar currency are translated using historical exchange rates.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Statements of operations accounts denominated in a non-U.S. dollar currency are translated using the exchange rates in effect on the transaction dates, except for depreciation, which is translated using historical exchange rate.&lt;/p&gt;
    </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000212">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;D.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at the date acquired.&lt;/p&gt;
    </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_20220101to20221231" id="FFact_0000000000213">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;E.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;Restricted cash is primarily invested in highly liquid deposits. These deposits were used to secure office rent payments.&lt;/p&gt;
    </us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201130501547">
      &lt;div&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;F.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.31pt"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair expenses are charged to operation as incurred. Depreciation is calculated on the straight-line method based on the estimated useful lives of the assets and commences once the assets are ready for their intended use.&lt;/p&gt;
        &lt;div&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"&gt;Annual rates at depreciation are as follows:&lt;/p&gt;
          &lt;div style="margin-left:36pt"&gt;

              &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;


                  &lt;tr style="background-color:#CCEEFF"&gt;
                    &lt;td style="vertical-align:top;width:88%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Computers&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;33&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Laboratory equipment&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;10&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:#CCEEFF"&gt;
                    &lt;td style="vertical-align:top;width:88%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Furniture and equipment&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;

          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201131108956">
              &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;


                  &lt;tr style="background-color:#CCEEFF"&gt;
                    &lt;td style="vertical-align:top;width:88%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Computers&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;33&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Laboratory equipment&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;10&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:#CCEEFF"&gt;
                    &lt;td style="vertical-align:top;width:88%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Furniture and equipment&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:top;width:88%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Leasehold improvement - over the shorter of the lease term or the estimated useful life of the improvement&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:9%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:top;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            </cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="2"
      id="FFact_0000000000214"
      unitRef="Pure">0.33</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"
      decimals="2"
      id="FFact_0000000000215"
      unitRef="Pure">0.10</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"
      decimals="2"
      id="FFact_0000000000216"
      unitRef="Pure">0.07</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <cmmb:AnnualRatesOfDepreciation
      contextRef="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      id="FFact_0000000000217">over the shorter of the lease term or the estimated useful life of the improvement</cmmb:AnnualRatesOfDepreciation>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000220">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;G.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The Company&#x2019;s property and equipment are reviewed for impairment in accordance with ASC 360, &#x201c;Property and Equipment&#x201d;, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs. During the periods ended December 31, 2022 and 2021, no impairment losses have been recorded.&lt;/p&gt;
    </us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_20220101to20221231" id="FFact_0000000000221">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;H.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Research and development costs are charged to operations as incurred. Most of the research and development expenses are for subcontractors and wages.&lt;/p&gt;
    </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000222">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;I.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the income taxes expense.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50 percent likely of being realized.&lt;/p&gt;
    </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000223">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;J.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.5pt"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;ASC 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. The ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity&#x2019;s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price.&lt;/p&gt;
      &lt;div/&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company&#x2019;s own credit risk.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The carrying amounts of cash and cash equivalents trade payables, other receivables and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The fair value of long-term restricted deposits and restricted cash also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. None of the Company&#x2019;s non&lt;span style="font-weight:bold"&gt;- &lt;/span&gt;financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.&lt;/p&gt;
    </us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_20220101to20221231" id="FFact_0000000000224">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;K.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The Company accounts for share-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company recognizes compensation cost for an award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant-date value of such award that is vested at that date.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The fair value for the Company&#x2019;s stock options granted to employees, consultants and directors was estimated using Black-Scholes option-pricing model at the grant date, using the inputs detailed in Note 8(C).&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/p&gt;
    </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <cmmb:GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000225">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;L.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Government-sponsored research and development&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Chemomab records grants received from the office of the Israel Innovation Authority (the &#x201c;IIA&#x201d;) as a liability, if it is probable that the Chemomab will have to repay the grants received. If it is not probable that the grants will be repaid, Chemomab records the grants as a reduction to research and development expenses.&lt;/p&gt;
    </cmmb:GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock>
    <cmmb:SeverancePayPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000229">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;M.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:24.06pt"&gt;Severance pay&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant to Section 14 of the Severance Compensation Law, 1963 ("Section 14"), all employees of the Company are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made on their behalf with insurance companies. Upon release of the policy to the employee, no additional liability exists between the parties regarding the matter of severance pay and no additional payments shall be made by the Company to the employee. This plan has been accounted for as a defined contribution plan. Severance costs amounted to approximately $142 thousand and $116 thousand for the year ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </cmmb:SeverancePayPolicyTextBlock>
    <cmmb:PercentageOfMonthlyDepositsRate
      contextRef="C_20220101to20221231"
      decimals="4"
      id="Fxbrl_20230215220314714"
      unitRef="Pure">0.0833</cmmb:PercentageOfMonthlyDepositsRate>
    <us-gaap:SeveranceCosts1
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230215220321806"
      unitRef="usd">142000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230215220329094"
      unitRef="usd">116000</us-gaap:SeveranceCosts1>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_20220101to20221231" id="FFact_0000000000230">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;N.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Concentrations of credit risk:&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash &lt;span&gt;and cash equivalents and short- term deposits are invested in banks. Management believes that the financial institutions that hold the Company&#x2019;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The Company have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/p&gt;
    </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230213125125767">
      &lt;div&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;O.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Leases&lt;/span&gt;&lt;/p&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Under &lt;/span&gt;&lt;/span&gt;Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (ROU) assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be 5% and 5.2% in 2022 and 2021, respectively. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. When determining the probability of exercising such options, the Company considers contract-based, asset-based, entity-based, and market-based factors. For leases agreements, the Company has elected the practical expedient to account for the lease and non-lease maintenance components as a single lease component. Therefore, for those leases, the lease payments used to measure the lease liability include all the fixed consideration in the contract. The Company's lease agreements generally do not contain any residual value guarantees or restrictive covenants&lt;span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&#160;&lt;/p&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify;margin-left:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ROU assets for operating leases are periodically reduced by impairment losses. The Company uses the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment &#x2013; Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize. See Note 2(G).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:LesseeLeasesPolicyTextBlock>
    <cmmb:IncrementalBorrowingRateOfLeases
      contextRef="C_20221231"
      decimals="2"
      id="Fxbrl_20230213132631771"
      unitRef="Pure">0.05</cmmb:IncrementalBorrowingRateOfLeases>
    <cmmb:IncrementalBorrowingRateOfLeases
      contextRef="C_20211231"
      decimals="3"
      id="Fxbrl_20230213132641931"
      unitRef="Pure">0.052</cmmb:IncrementalBorrowingRateOfLeases>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000232">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;P.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.31pt"&gt;Principles of consolidation&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The &lt;span&gt;consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000233">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Q.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Earnings per ordinary share&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt"&gt;Basic earnings per ordinary share is calculated using only weighted average ordinary shares outstanding. Diluted earnings per share, if relevant, gives effect to dilutive potential ordinary shares outstanding during the year. &#160;Such dilutive shares consist of incremental shares, using the treasury stock method, from the assumed exercise of share options.&lt;/p&gt;
    </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000244">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"&gt;&lt;span style="font-weight:bold"&gt;Note 3 - Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;

      &lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;In USD&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;10,663&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;10,720&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;In NIS&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,756&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,116&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;In other currencies&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;100&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,350&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;13,519&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;15,186&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;

  </us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000243">
      &lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;In USD&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;10,663&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;10,720&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;In NIS&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,756&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,116&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;In other currencies&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;100&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,350&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;13,519&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;15,186&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
    </us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231_srtCurrencyAxis_currencyUSD"
      decimals="-3"
      id="FFact_0000000000235"
      unitRef="usd">10663000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231_srtCurrencyAxis_currencyUSD"
      decimals="-3"
      id="FFact_0000000000236"
      unitRef="usd">10720000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231_srtCurrencyAxis_currencyILS"
      decimals="-3"
      id="FFact_0000000000237"
      unitRef="usd">2756000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231_srtCurrencyAxis_currencyILS"
      decimals="-3"
      id="FFact_0000000000238"
      unitRef="usd">1116000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231_srtCurrencyAxis_currencyXXX"
      decimals="-3"
      id="FFact_0000000000239"
      unitRef="usd">100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231_srtCurrencyAxis_currencyXXX"
      decimals="-3"
      id="FFact_0000000000240"
      unitRef="usd">3350000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000241"
      unitRef="usd">13519000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000242"
      unitRef="usd">15186000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000252">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"&gt;&lt;span style="font-weight:bold"&gt;Note 4 - Other Receivables and Prepaid Expenses&lt;/span&gt;&lt;/p&gt;

      &lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Government institutions&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;459&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;179&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Prepaid expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,307&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,348&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,766&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,527&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;

  </cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock>
    <cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000251">
      &lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Government institutions&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;459&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;179&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Prepaid expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,307&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,348&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,766&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,527&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
    </cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock>
    <cmmb:ReceivablesFromGovernmentInstitutions
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000245"
      unitRef="usd">459000</cmmb:ReceivablesFromGovernmentInstitutions>
    <cmmb:ReceivablesFromGovernmentInstitutions
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000246"
      unitRef="usd">179000</cmmb:ReceivablesFromGovernmentInstitutions>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000247"
      unitRef="usd">1307000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000248"
      unitRef="usd">1348000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000249"
      unitRef="usd">1766000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000250"
      unitRef="usd">1527000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000270">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"&gt;&lt;span style="font-weight:bold"&gt;Note 5 - Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;

      &lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Cost:&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Computers&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;70&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;43&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Furniture and equipment&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;33&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;27&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Laboratory equipment&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;399&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;364&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Website development&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;14&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;14&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Leasehold improvements&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;16&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;16&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;&lt;strong&gt;&lt;strong&gt;&lt;strong&gt;532&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;464 &lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Less - accumulated depreciation&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;165&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(107&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;&lt;strong&gt;&lt;strong&gt;&lt;strong&gt;367&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;357 &lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;

  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000269">
      &lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Cost:&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Computers&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;70&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;43&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Furniture and equipment&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;33&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;27&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Laboratory equipment&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;399&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;364&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Website development&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;14&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;14&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Leasehold improvements&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;16&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;16&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;&lt;strong&gt;&lt;strong&gt;&lt;strong&gt;532&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;464 &lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Less - accumulated depreciation&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;165&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(107&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;&lt;strong&gt;&lt;strong&gt;&lt;strong&gt;367&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;357 &lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
    </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000253"
      unitRef="usd">70000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000254"
      unitRef="usd">43000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"
      decimals="-3"
      id="FFact_0000000000255"
      unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapFurnitureAndFixturesMember"
      decimals="-3"
      id="FFact_0000000000256"
      unitRef="usd">27000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"
      decimals="-3"
      id="FFact_0000000000257"
      unitRef="usd">399000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cmmbLaboratoryEquipmentMember"
      decimals="-3"
      id="FFact_0000000000258"
      unitRef="usd">364000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember"
      decimals="-3"
      id="FFact_0000000000259"
      unitRef="usd">14000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapSoftwareDevelopmentMember"
      decimals="-3"
      id="FFact_0000000000260"
      unitRef="usd">14000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000261"
      unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000262"
      unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230201032006902"
      unitRef="usd">532000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000264"
      unitRef="usd">464000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000265"
      unitRef="usd">165000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000266"
      unitRef="usd">107000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230201033845372"
      unitRef="usd">367000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000268"
      unitRef="usd">357000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000294">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Note 6 - Leases&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;On May 10, 2020, Chemomab entered into an office and lab space lease agreement (hereinafter &#x2013; &#x201c;The Agreement&#x201d; .(According to the Agreement, Chemomab &#160;rented a space in Atidim Park, Tel-Aviv for a period of three years, through &lt;span style="-sec-ix-hidden:Fxbrl_20230131233234992"&gt;May 2023&lt;/span&gt;. Chemomab was granted an option to extend the lease term by additional three years.&#160;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;On October 24, 2021, Chemomab signed an amendment to the Agreement ("The Amendment"). According to the Amendment, On December 12, 2021 Chemomab returned the previous office and lab space to the property owner and rented a larger space in Atidim Park Tel-Aviv, for a term of 3 years, through &lt;span style="-sec-ix-hidden:Fxbrl_20230131233722905"&gt;October 2024&lt;/span&gt;. In addition, Chemomab was granted an option to extend the lease term by additional three years. The annual rent and management fees are approximately $122 thousand. Pursuant to the Amendment, the bank guarantee issued in 2020 was canceled and a substitute bank guarantee of approximately $77 thousand was issued to the property owner during 2022.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;The above operating leases are included in &#x201c;Operating lease right-of-use assets&#x201d; on the Company&#x2019;s Consolidated Balance sheets as of December 31, 2022 and 2021 and represent the Company&#x2019;s right to use the underlying asset for the lease term. The Company&#x2019;s obligations to pay lease payments are included in the current liabilities as &#x201c;Operating lease liabilities&#x201d; and in the non-current liabilities as &#x201c;Non-current operating lease liabilities&#x201d; on the Company&#x2019;s Consolidated Balance sheets as of December 31, 2022 and 2021. Based on the present value of the lease payments for the remaining lease term of the Company&#x2019;s existing lease agreement, the Company recognized operating right-of-use assets and operating lease liabilities of approximately $345 thousand on December 12, 2021.&#160;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;During the years ended December 31, 2022 and 2021, the Company recognized an increase in right of use assets of $17 thousand and $345 thousand, respectively.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As&#160;of December 31, 2022, and 2021 operating right-of-use asset was $227 thousand and $345 thousand, respectively. The operating lease liabilities were $214 thousand and $343 thousand, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;As most of the Chemomab&#x2019;s leases do not provide an implicit rate, Chemomab uses its incremental borrowing rate based on the information available at the commencement date of each lease in determining the present value of lease payments. Chemomab&#x2019;s incremental borrowing rate is a hypothetical rate based on its estimation of what its credit rating would be the rate was 5% in 2022 and 5.2% in 2021.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"&gt;Maturities of lease liabilities under noncancellable leases as of December 31, 2022, are as follows: (in thousands):&lt;/p&gt;
    &lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;

        &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;2023&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;126 &lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;2024&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;93 &lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Total future minimum lease payments&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;219 &lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Less imputed interest:&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;5&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Present value of operating lease liabilities&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;214 &lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

    &lt;/div&gt;
  </us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="C_20200510" id="Fxbrl_20230131233210356">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_20200501to20200510"
      id="Fxbrl_20230131233301410">three years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="C_20211024" id="Fxbrl_20230131233734834">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_20211001to20211024"
      id="Fxbrl_20230201000916081">three years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <cmmb:AnnualRentAndManagementFees
      contextRef="C_20211001to20211024"
      decimals="-3"
      id="Fxbrl_20230131234005244"
      unitRef="usd">122000</cmmb:AnnualRentAndManagementFees>
    <cmmb:BankGuaranteesToPropertyOwner
      contextRef="C_20211001to20211024"
      decimals="-3"
      id="Fxbrl_20230131234014829"
      unitRef="usd">77000</cmmb:BankGuaranteesToPropertyOwner>
    <cmmb:OperatingRightOfUseAssetsAndOperatingLeaseLiabilities
      contextRef="C_20211212"
      decimals="-3"
      id="Fxbrl_20230131234456429"
      unitRef="usd">345000</cmmb:OperatingRightOfUseAssetsAndOperatingLeaseLiabilities>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230131234508150"
      unitRef="usd">17000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230131234513790"
      unitRef="usd">345000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230214143811730"
      unitRef="usd">227000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230214143818906"
      unitRef="usd">345000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230214143827206"
      unitRef="usd">214000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230214143833566"
      unitRef="usd">343000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="C_20220101to20221231"
      decimals="2"
      id="Fxbrl_20230131234937485"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="C_20210101to20211231"
      decimals="3"
      id="Fxbrl_20230131234957047"
      unitRef="Pure">0.052</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201025037730">
        &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;2023&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;126 &lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;2024&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;93 &lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Total future minimum lease payments&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;219 &lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Less imputed interest:&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;5&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;background-color:rgb(255, 255, 255);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Present value of operating lease liabilities&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;214 &lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000288"
      unitRef="usd">126000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000289"
      unitRef="usd">93000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000290"
      unitRef="usd">219000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000291"
      unitRef="usd">5000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000292"
      unitRef="usd">214000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000311">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Note 7 - Commitments and Contingent Liabilities&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Exclusive License Agreement (hereinafter- &#x201c;the License Agreement&#x201d;)&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:72pt"&gt;In December 2011, Chemomab entered into a License Agreement with the Medical Research, Infrastructure, Health Services Fund of the Tel-Aviv Souraski Medical Center (&#x201c;Fund&#x201d;), pursuant to which it was granted with an exclusive license to certain inventions (as defined in the License Agreement) including patents, knowhow and products and the right to sublicense to third parties the rights granted, pursuant to and subject to certain terms and limitation fully set in the License Agreement.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:72pt"&gt;Chemomab has agreed to pay the Fund a non-refundable and non-creditable sublicense fees as a percentage of all Attributed Income (as such term defined in the License Agreement), and shall further pay the Fund royalties from sales made by sublicensee;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;(i)&lt;span style="padding-left:26.56pt"&gt;Royalties in percentage of the Net sales or Service Income (as defined in the License Agreement), subject to &lt;/span&gt;certain additional terms set forth therein.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"&gt;&lt;span&gt;In addition, with respect to each Licensed Product (as defined therein), Chemomab has agreed to &#160;pay the Fund the following non-refundable, non-creditable amounts:&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:144pt;margin-bottom:11pt"&gt;(a)&lt;span style="padding-left:24.9pt"&gt;$100 thousand upon submission of a New Drug Application (&#x201c;NDA&#x201d;), Biological License Application (&#x201c;BLA&#x201d;) or equivalent for each Licensed Product to the United States Food and Drug Administration (&#x201c;FDA&#x201d;), $100 thousand upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;text-indent:-36pt;padding-left:144pt;margin-bottom:0pt"&gt;(b)&lt;span style="padding-left:24.34pt"&gt;$200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"&gt;As of December 31, 2022&#160;no payments were made to the Fund.&lt;/p&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:72pt"&gt;In addition to the payments described above, upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than $3,000 thousand.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:72pt"&gt;&lt;span&gt;Chemomab partially financed its research and development expenditures under programs sponsored by the Israel &lt;/span&gt;Innovation Authority (&#x201c;IIA&#x201d;) for the support of certain research and development activities conducted in Israel.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:72pt"&gt;In return for the IIA&#x2019;s participation, Chemomab is committed to pay royalties at rate of 3% of sales of the developed product (linked to U.S. dollar), up to 100% of the amount of grants received (100% plus interest at LIBOR). In addition, the IIA may impose certain conditions to transfer technology or development out of Israel.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"&gt;Chemomab did not receive any grants from the IIA in the years ended December 31, 2022, and 2021.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;Since Chemomab &#x2019;s incorporation through December 31, 2022 Chemomab received $1,227 thousand from the IIA, which were recognized as a reduction of research and development expenses.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;As of December 31, 2022, Chemomab has no commitment for royalties payable.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="padding-left:26.28pt"&gt;In &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;June 2015, Chemomab entered into a license agreement with subcontractor (&#x201c;the Subcontractor&#x201d;), under which the Subcontractor granted to Chemomab certain licenses to use proprietary rights of the subcontractor, materials and know how in the techniques and use of the same, for purposes of research and development of Chemomab 's product CM-101, as well as commercialization thereof. Further to the agreement, the Subcontractor also provides manufacturing services of intermediates and active pharmaceutical ingredients. According to the related manufacturing agreement, the manufacturing of the product is carried out by the Subcontractor in accordance with Chemomab's specifications and timeline.&#160; From time to time, Chemomab and the Subcontractor have been signing additional agreements for additional manufacturing and final process lock of the product for clinical use Under the agreement, Chemomab is also obligated to pay the Subcontractor royalties determined as a percentage of net sales of each licensee product.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:0pt;padding-left:72pt;margin-bottom:0pt"&gt;During 2022 and 2021, Chemomab recorded expenses related to the above agreements in the amounts of $5,222 thousand and $2,590 thousand, respectively. The expenses were recorded under research and development expenses.&lt;/p&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:11pt"&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="padding-left:26.28pt"&gt;As&#160;&lt;/span&gt;&lt;/span&gt;of December 31, 2022, the bank imposed restriction on a bank deposit in the amount of $77 thousand for the purpose of secure lease payments under an office lease agreement.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:11pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;D.&lt;/span&gt;&lt;span&gt;&lt;span style="padding-left:26.28pt"&gt;During&#160;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;2022, the Israeli tax authority ("ITA&#x201d;) notified the Company that it had initiated a routine VAT audit to include tax years 2017 through 202&lt;/span&gt;&lt;span&gt;2&lt;/span&gt;&lt;span&gt;. The ITA raised several claims, mainly in respect with the recoverability of VAT with respect to Merger Agreement related expenses and the classification of the Company as a holding company. On July 2022, the ITA proposed a settlement, which the Company rejected. As a result, the ITA issued assessments in the aggregate amount of $1,046 thousand. The Company filed an appeal against the ITA&#x2019;s assessments. The Company has recorded an appropriate provision which considers inherent uncertainty of these matters and the judicial process. Therefore, the outcome may differ from the estimated liability recorded by the Company during the period&lt;/span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
  </us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:LongTermPurchaseCommitmentDescription
      contextRef="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember"
      id="Fxbrl_20230215222406006">$100 thousand upon submission of a New Drug Application (&#x201c;NDA&#x201d;), Biological License Application (&#x201c;BLA&#x201d;) or equivalent for each Licensed Product to the United States Food and Drug Administration (&#x201c;FDA&#x201d;), $100 thousand upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once;</us-gaap:LongTermPurchaseCommitmentDescription>
    <us-gaap:LongTermPurchaseCommitmentDescription
      contextRef="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_cmmbCapitalAdditionsOneMember"
      id="Fxbrl_20230215222519809">$200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once.</us-gaap:LongTermPurchaseCommitmentDescription>
    <us-gaap:OtherCommitmentsDescription
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230215222713212">upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than $3,000 thousand.</us-gaap:OtherCommitmentsDescription>
    <cmmb:PercentageOfRoyaltyPaymentsOnSaleOfProduct
      contextRef="C_20220101to20221231_usgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_usgaapCapitalAdditionsMember"
      decimals="2"
      id="Fxbrl_20230201002925810"
      unitRef="Pure">0.03</cmmb:PercentageOfRoyaltyPaymentsOnSaleOfProduct>
    <cmmb:MaximumPercentageOfPaymentsOfRoyalties
      contextRef="C_20220101to20221231"
      decimals="2"
      id="Fxbrl_20230201002935951"
      unitRef="Pure">1</cmmb:MaximumPercentageOfPaymentsOfRoyalties>
    <cmmb:CumulativeAmountsOfGrantsReceivedAndRecognized
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230201002951961"
      unitRef="usd">1227000</cmmb:CumulativeAmountsOfGrantsReceivedAndRecognized>
    <us-gaap:RoyaltyExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213125722009"
      unitRef="usd">5222000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230213125731080"
      unitRef="usd">2590000</us-gaap:RoyaltyExpense>
    <us-gaap:RestrictedInvestments
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230213125744104"
      unitRef="usd">77000</us-gaap:RestrictedInvestments>
    <cmmb:RecoverabilityOfVatAmount
      contextRef="C_20220701to20220731"
      decimals="-3"
      id="Fxbrl_20230207215117039"
      unitRef="usd">1046000</cmmb:RecoverabilityOfVatAmount>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000385">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Note 8 - Share Capital&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Right attached to shares&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold;font-style:italic"&gt;Ordinary shares&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"&gt;All of the issued and outstanding ordinary shares of the Company are duly authorized, validly issued, fully paid and non-assessable. The ordinary shares are not redeemable, and each ordinary share is entitled to one vote. The holders of the ordinary shares have the right to vote and participate in shareholders' meetings, the right to receive profits, and the right to participate in the accumulated earnings when the Company is dissolved.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.5pt"&gt;Voting&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"&gt;The holders of ordinary shares are entitled to vote on all matters submitted to shareholders for a vote.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.5pt"&gt;Dividends&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"&gt;The holders of the ordinary shares are entitled to receive dividends, when and as declared by the Board of Directors, and out of funds legally available.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"&gt;Since its inception, the Company has not declared any dividends.&lt;/p&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;span style="padding-left:26.83pt;font-weight:bold"&gt;Financing rounds&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1.&lt;/span&gt;&lt;span style="padding-left:28.5pt"&gt;In&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;connection with the Merger, on March 15, 2021, the Company entered into Securities Purchase Agreements with certain purchasers, pursuant to which the Company agreed to sell approximately $45.5 million of its American Depositary Shares (ADSs)&#160;in a private placement transaction, (or "The Private Placement"). The Private Placement closed on March 22, 2021, at which time the Company sold to the purchasers 2,619,270 ADSs together with warrants to purchase up to 261,929 ADSs at an exercise price of $17.35 per ADS. The warrants will expire five years from the date of issuance, and if exercised in full, will provide to the Company proceeds of approximately $4.5 million. 20 Ordinary Shares are equal to 1 American Depositary Share (ADS).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.&lt;/span&gt;&lt;span style="padding-left:28.5pt"&gt;On&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;April 30, 2021, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Cantor Fitzgerald &amp;amp; Co., ("Cantor"). According to the ATM Agreement, the Company may offer and sell, from time to time, its ADSs having an aggregate offering price of up to $75 million through Cantor or the ATM Agreement. From April 30, 2021, through December 31, 2022, the Company issued 699,806 ADSs at an average price of $22.75 per ADS under the ATM Agreement, resulting in gross proceeds of $15,917 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3.&lt;/span&gt;&lt;span style="padding-left:28.5pt"&gt;On &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;April 25, 2022, the Company filed a prospectus supplement with the SEC for the issuance and sale of up to $18,125,000&#160;of its ADSs in connection with the reactivation of the ATM Facility and pursuant to General Instruction I.B.6 of Form S-3, which, subject to certain exceptions, limits the amount of securities the Company is able to offer and sell under such registration statement to one-third of our unaffiliated public float. During the year ended &#160;December 31, 2022, the Company issued&#160;130,505 ADSs at an average price of $2.11 per ADS under the ATM Agreement, resulting in gross proceeds of $275 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;4.&lt;/span&gt;&lt;span style="padding-left:28.5pt"&gt;O&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;n September 19, 2022, the Company entered &#160;into a share purchase agreement (the &#x201c;Repurchase Arrangement&#x201d;) with Dr. Adi Mor, co-founder of Chemomab Ltd., Chief Scientific Officer and a director of the Company and Professor Kobi George, co-founder of Chemomab Ltd. (together with Dr. Adi Mor, the &#x201c;Co-Founders&#x201d;), whereby the Company agreed, subject to the requisite court approval required under Section 303(a) of the Israeli Companies Law, 5759-1999 (the &#x201c;Companies Law&#x201d;), which the Company received on November 14, 2022, to repurchase up to 582,023 ADSs owned by the Co-Founders, for consideration not to exceed an aggregate amount of $2,500,000, depending on the market price of the ADSs at the time of any repurchase. Accordingly, on November 16, 2022, the company repurchased the entire amount of 582,023 ADSs from the Co-Founders at a weighted average price of $2.0848 and for total consideration of approximately $1,218 thousand.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt;margin-left:108pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="line-height:110%"&gt;The Company accounted for the repurchased shares as treasury share&#160;in accordance with ASC 505-30, "Treasury Stock".&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"&gt;(1)&lt;span style="padding-left:24.34pt"&gt;Share-based compensation plan:&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:108pt;margin-bottom:0pt"&gt;The Company maintains (i) the 2011 Share Option Plan (the &#x201c;2011 Plan&#x201d;), (ii) the 2017 Equity-Based Incentive Plan (the &#x201c;2017 Plan&#x201d;) and (iii) the Chemomab 2015 Share Incentive Plan (the &#x201c;2015 Plan&#x201d;), which was assumed by the Company from Chemomab upon the effectiveness of the Merger. At that time, outstanding options under the 2015 Plan became exercisable for such number of ADSs of the Company as was determined based on the exchange ratio in the Merger Agreement, with a reciprocal adjustment to exercise price.&lt;br/&gt;&#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-left:108pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;As of December 31, 2022, a total of 28,443,060 of our Ordinary Shares (equal to 1,422,153 of ADSs) were reserved for issuance under the 2015 Plan, of which 3,445,520 Ordinary Shares (equal to 172,276 ADSs) had been issued pursuant to previous exercises options, and 23,460,740 &#160;Ordinary Shares (equal to 1,173,037 ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase 12,400,720 Ordinary Shares (equal to 620,036 ADSs) had vested and were exercisable as of that date, with a weighted average exercise price of $0.30 per Ordinary Share (or $5.96 per ADS). During the year ended December 31, 2022, options to purchase 1,240,120 Ordinary Shares (equal to 62,006 ADS) were canceled.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-left:96px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin-top:0pt;margin-left:108pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;As of December 31, 2022, a total of 12,511,620 of our Ordinary Shares (equal to 625,581&#160;ADSs) were reserved for issuance under the 2017 Plan, of which 11,730,800 Ordinary Shares (equal to 586,540 ADSs) were issuable under outstanding options. Of such outstanding options, options to purchase 427,540 Ordinary Shares (equal to 21,377 ADSs) had vested and were exercisable as of that date, with a weighted average exercise price of $0.35 per Ordinary Share (or $6.98 per ADS). During the year ended December 31, 2022 no options were canceled.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:11pt"&gt;(2)&lt;span style="padding-left:24.34pt"&gt;The expenses that were recognized in the consolidated statements of operations for services received from employees &lt;/span&gt;and service providers are as follows:&lt;/p&gt;
    &lt;div style="margin-left:108pt"&gt;

        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Research and development&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;448&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;137&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;General and administrative&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,763&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,882&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Total share-based compensation expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;3,211&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,019&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

    &lt;/div&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:11pt"&gt;(3)&lt;span style="padding-left:24.34pt"&gt;The number and weighted average exercise price of options are as follows:&lt;/span&gt;&lt;/p&gt;
    &lt;div style="margin-left:108pt"&gt;

        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted &lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;exercise &lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;price&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Number of &lt;/span&gt;&lt;span style="font-weight:bold"&gt;options&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average &lt;/span&gt;&lt;span style="font-weight:bold"&gt;remaining &lt;/span&gt;&lt;span style="font-weight:bold"&gt;contractual &lt;/span&gt;&lt;span style="font-weight:bold"&gt;life (in years)&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average &lt;/span&gt;&lt;span style="font-weight:bold"&gt;exercise price&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Number of &lt;/span&gt;&lt;span style="font-weight:bold"&gt;options&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average &lt;/span&gt;&lt;span style="font-weight:bold"&gt;remaining &lt;/span&gt;&lt;span style="font-weight:bold"&gt;contractual &lt;/span&gt;&lt;span style="font-weight:bold"&gt;life (in years)&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:27%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Outstanding at January 1&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.38&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;27,003,260&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;8.12&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.07&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;10,455,580&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7.8&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:27%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Acquired in Merger&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;text-align:right"&gt;-&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;609,535&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:27%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Exercised&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.07&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;1,970,000&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(134,220&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:27%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Forfeited&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.32&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;1,240,120&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1.25&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(1,712,275&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:27%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Granted&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.16&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;11,398,400&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;7.8&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:10%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.62&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;17,784,640&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;9.79&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:27%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:27%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Outstanding at December 31&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.33&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;35,191,540&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;7.42&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.38&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;27,003,260&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;8.12&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

    &lt;/div&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:72pt;margin-bottom:0pt"&gt;(4)&lt;span style="padding-left:24.34pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:108pt;margin-bottom:11pt"&gt;The fair value of the options is measured at the grant date using the Black-Scholes Option pricing model and the assumptions used to calculate the fair value of the options are as follows:&lt;/p&gt;
    &lt;div style="margin-left:108pt"&gt;

        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;2022&#160;grants&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:84%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Weighted average share price (in U.S. dollar)&lt;sup&gt;(a)&lt;/sup&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:12%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;0.16&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:84%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Exercise price (in U.S. dollar)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:12%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;0.10&lt;/span&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;0.257&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:84%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Expected life of options (in years)&lt;sup&gt;(b)&lt;/sup&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:12%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;5.51&lt;/span&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;6.28&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:84%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Expected volatility&lt;sup&gt;(c)&lt;/sup&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:12%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;83.69&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;84.31&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:84%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Risk-free interest rate&lt;sup&gt;(d)&lt;/sup&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:12%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;1.75&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;4.14&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:84%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Dividend yield&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:12%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;0&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

    &lt;/div&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;(a)&lt;span style="padding-left:24.34pt"&gt;The weighted average share price is based on the Company&#x2019;s Ordinary Share valuation as at the grant date.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;(b)&lt;span style="padding-left:24.34pt"&gt;Expected life for the periods presented was determined according to the simplified method since, at the date of &lt;/span&gt;grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions and for performance conditions that are probable of achievement. If meeting the performance condition is not probable, the Company will use the awards&#x2019; contractual term if the service period is implied, or the simplified method, if the service period is explicitly stated.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:0pt"&gt;(c)&lt;span style="padding-left:24.34pt"&gt;Expected volatility is based on historical volatility over the most recent period commensurate with the expected &lt;/span&gt;term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#x2019;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#x2019;s expected term.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-36pt;padding-left:108pt;margin-bottom:11pt"&gt;(d)&lt;span style="padding-left:24.34pt"&gt;The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the &lt;/span&gt;yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.&lt;/p&gt;
  </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20210301to20210315_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="-5"
      id="Fxbrl_20230213133908909"
      unitRef="usd">45500000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:NumberOfWarrantsPurchaseUpAdss
      contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20230213133843633"
      unitRef="Share">2619270</cmmb:NumberOfWarrantsPurchaseUpAdss>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="INF"
      id="Fxbrl_20230213133849363"
      unitRef="Share">261929</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:SaleOfStocksPricePerShare
      contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="2"
      id="Fxbrl_20230213133830904"
      unitRef="USD_Per_Share">17.35</cmmb:SaleOfStocksPricePerShare>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20210301to20210323_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember"
      decimals="-5"
      id="Fxbrl_20230213133820824"
      unitRef="usd">4500000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="-6"
      id="Fxbrl_20230213133808746"
      unitRef="usd">75000000</cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="INF"
      id="Fxbrl_20230213133801744"
      unitRef="Share">699806</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:SaleOfStocksPricePerShare
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="2"
      id="Fxbrl_20230213133754484"
      unitRef="USD_Per_Share">22.75</cmmb:SaleOfStocksPricePerShare>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20210401to20210430_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="-3"
      id="Fxbrl_20230213133747440"
      unitRef="usd">15917000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="0"
      id="Fxbrl_20230213133711976"
      unitRef="usd">18125000</cmmb:AggregateOfferingPriceOfAtMarketOfferingAgreement>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="INF"
      id="Fxbrl_20230213133726969"
      unitRef="Share">130505</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:SaleOfStocksPricePerShare
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="INF"
      id="Fxbrl_20230213133719951"
      unitRef="USD_Per_Share">2.11</cmmb:SaleOfStocksPricePerShare>
    <cmmb:ProceedsFromSaleOfAdss
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_cmmbAtmAgreementMember"
      decimals="-3"
      id="Fxbrl_20230213133734136"
      unitRef="usd">275000</cmmb:ProceedsFromSaleOfAdss>
    <cmmb:RepurchaseOfAmericanDepositaryReceiptsShares
      contextRef="C_20220901to20220919_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="INF"
      id="Fxbrl_20230317122555966"
      unitRef="Share">582023</cmmb:RepurchaseOfAmericanDepositaryReceiptsShares>
    <cmmb:RepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20220930_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="0"
      id="Fxbrl_20230317122603582"
      unitRef="usd">2500000</cmmb:RepurchaseOfAmericanDepositaryReceipts>
    <cmmb:RepurchaseOfAmericanDepositaryReceiptsShares
      contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="INF"
      id="Fxbrl_20230317122610135"
      unitRef="Share">582023</cmmb:RepurchaseOfAmericanDepositaryReceiptsShares>
    <cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="4"
      id="Fxbrl_20230317122616711"
      unitRef="USD_Per_Share">2.0848</cmmb:WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts>
    <cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts
      contextRef="C_20221101to20221116_usgaapSubsidiarySaleOfStockAxis_cmmbRepurchaseArrangementMember"
      decimals="-3"
      id="Fxbrl_20230317122623672"
      unitRef="usd">1218000</cmmb:TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts>
    <cmmb:NumberOfStockReservedForIssuance
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207224906305"
      unitRef="Share">28443060</cmmb:NumberOfStockReservedForIssuance>
    <cmmb:NumberOfStockAdssResveredForIssuance
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223247056"
      unitRef="Share">1422153</cmmb:NumberOfStockAdssResveredForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225529762"
      unitRef="Share">3445520</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223254041"
      unitRef="Share">172276</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:NumberOfOptionsIssuableOutstanding
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225556251"
      unitRef="Share">23460740</cmmb:NumberOfOptionsIssuableOutstanding>
    <cmmb:NumberOfAdssOptionsIssuableOutstanding
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223300376"
      unitRef="Share">1173037</cmmb:NumberOfAdssOptionsIssuableOutstanding>
    <cmmb:NumberOfOptionsVestedAndExercisable
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225618055"
      unitRef="Share">12400720</cmmb:NumberOfOptionsVestedAndExercisable>
    <cmmb:NumberOfAdssVestedAndExercisable
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223309640"
      unitRef="Share">620036</cmmb:NumberOfAdssVestedAndExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207224602275"
      unitRef="USD_Per_Share">0.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223316544"
      unitRef="USD_Per_Share">5.96</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207224845387"
      unitRef="Share">1240120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207223324626"
      unitRef="Share">62006</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod>
    <cmmb:NumberOfStockReservedForIssuance
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225827725"
      unitRef="Share">12511620</cmmb:NumberOfStockReservedForIssuance>
    <cmmb:NumberOfStockAdssResveredForIssuance
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225729518"
      unitRef="Share">625581</cmmb:NumberOfStockAdssResveredForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225858382"
      unitRef="Share">11730800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225738550"
      unitRef="Share">586540</cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues>
    <cmmb:NumberOfOptionsVestedAndExercisable
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225916606"
      unitRef="Share">427540</cmmb:NumberOfOptionsVestedAndExercisable>
    <cmmb:NumberOfAdssVestedAndExercisable
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225743877"
      unitRef="Share">21377</cmmb:NumberOfAdssVestedAndExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225929980"
      unitRef="USD_Per_Share">0.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsSeventeenPlanMember"
      decimals="INF"
      id="Fxbrl_20230207225750293"
      unitRef="USD_Per_Share">6.98</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201040228557">
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Research and development&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;448&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;137&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;General and administrative&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,763&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,882&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Total share-based compensation expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;3,211&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,019&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="FFact_0000000000338"
      unitRef="usd">448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="FFact_0000000000339"
      unitRef="usd">137000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="FFact_0000000000340"
      unitRef="usd">2763000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="FFact_0000000000341"
      unitRef="usd">1882000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000342"
      unitRef="usd">3211000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000343"
      unitRef="usd">2019000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201040244110">
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted &lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;exercise &lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;price&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Number of &lt;/span&gt;&lt;span style="font-weight:bold"&gt;options&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average &lt;/span&gt;&lt;span style="font-weight:bold"&gt;remaining &lt;/span&gt;&lt;span style="font-weight:bold"&gt;contractual &lt;/span&gt;&lt;span style="font-weight:bold"&gt;life (in years)&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average &lt;/span&gt;&lt;span style="font-weight:bold"&gt;exercise price&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Number of &lt;/span&gt;&lt;span style="font-weight:bold"&gt;options&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;average &lt;/span&gt;&lt;span style="font-weight:bold"&gt;remaining &lt;/span&gt;&lt;span style="font-weight:bold"&gt;contractual &lt;/span&gt;&lt;span style="font-weight:bold"&gt;life (in years)&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:27%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Outstanding at January 1&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.38&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;27,003,260&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;8.12&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.07&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;10,455,580&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7.8&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:27%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Acquired in Merger&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;text-align:right"&gt;-&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;609,535&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:27%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Exercised&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.07&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;1,970,000&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(134,220&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:27%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Forfeited&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.32&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;1,240,120&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1.25&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(1,712,275&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:27%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Granted&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.16&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;11,398,400&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;7.8&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:10%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.62&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;17,784,640&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;9.79&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:27%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:27%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Outstanding at December 31&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.33&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;35,191,540&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;7.42&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.38&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;27,003,260&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;8.12&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20211231"
      decimals="INF"
      id="FFact_0000000000345"
      unitRef="USD_Per_Share">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20211231"
      decimals="INF"
      id="FFact_0000000000346"
      unitRef="Share">27003260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20210101to20211231" id="FFact_0000000000347">P8Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20201231"
      decimals="INF"
      id="FFact_0000000000348"
      unitRef="USD_Per_Share">0.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20201231"
      decimals="INF"
      id="FFact_0000000000349"
      unitRef="Share">10455580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20200101to20201231" id="FFact_0000000000350">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <cmmb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="0"
      id="Fxbrl_20230214225414206"
      unitRef="USD_Per_Share">0</cmmb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000351"
      unitRef="Share">0</cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230201024457584"
      unitRef="Share">609535</cmmb:StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000352"
      unitRef="USD_Per_Share">0.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000353"
      unitRef="Share">1970000</cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230201024523067"
      unitRef="USD_Per_Share">0.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230201024530820"
      unitRef="Share">134220</cmmb:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000356"
      unitRef="USD_Per_Share">0.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000357"
      unitRef="Share">1240120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000358"
      unitRef="USD_Per_Share">1.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000359"
      unitRef="Share">1712275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000360"
      unitRef="USD_Per_Share">0.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000361"
      unitRef="Share">11398400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="C_20220101to20221231" id="FFact_0000000000362">P7Y9M18D</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000363"
      unitRef="USD_Per_Share">0.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000364"
      unitRef="Share">17784640</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="C_20210101to20211231" id="FFact_0000000000365">P9Y9M14D</cmmb:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231"
      decimals="INF"
      id="FFact_0000000000366"
      unitRef="USD_Per_Share">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231"
      decimals="INF"
      id="FFact_0000000000367"
      unitRef="Share">35191540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20220101to20221231" id="FFact_0000000000368">P7Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20211231"
      decimals="INF"
      id="FFact_0000000000369"
      unitRef="USD_Per_Share">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20211231"
      decimals="INF"
      id="FFact_0000000000370"
      unitRef="Share">27003260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20210101to20211231" id="FFact_0000000000371">P8Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201040432498">
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;2022&#160;grants&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:84%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Weighted average share price (in U.S. dollar)&lt;sup&gt;(a)&lt;/sup&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:12%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;0.16&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:84%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Exercise price (in U.S. dollar)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:12%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;0.10&lt;/span&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;0.257&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:84%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Expected life of options (in years)&lt;sup&gt;(b)&lt;/sup&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:12%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;5.51&lt;/span&gt;&lt;span style="font-weight:bold"&gt;-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;6.28&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:84%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Expected volatility&lt;sup&gt;(c)&lt;/sup&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:12%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;83.69&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;84.31&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:84%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Risk-free interest rate&lt;sup&gt;(d)&lt;/sup&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:12%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;1.75&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%-&lt;/span&gt;&lt;span style="font-weight:bold"&gt;4.14&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:84%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Dividend yield&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:12%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-weight:bold"&gt;0&lt;/span&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="C_20221231"
      decimals="INF"
      id="FFact_0000000000373"
      unitRef="USD_Per_Share">0.16</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20221231_srtRangeAxis_srtMinimumMember"
      decimals="INF"
      id="FFact_0000000000375"
      unitRef="USD_Per_Share">0.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20221231_srtRangeAxis_srtMaximumMember"
      decimals="INF"
      id="FFact_0000000000376"
      unitRef="USD_Per_Share">0.257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember"
      id="FFact_0000000000377">P5Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember"
      id="FFact_0000000000378">P6Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20220101to20221231"
      decimals="4"
      id="FFact_0000000000379"
      unitRef="Pure">0.8369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20220101to20221231"
      decimals="4"
      id="FFact_0000000000380"
      unitRef="Pure">0.8431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20220101to20221231"
      decimals="4"
      id="FFact_0000000000381"
      unitRef="Pure">0.0175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20220101to20221231"
      decimals="4"
      id="FFact_0000000000382"
      unitRef="Pure">0.0414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000383"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000399">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"&gt;&lt;span style="font-weight:bold"&gt;Note 9 - Research and Development&lt;/span&gt;&lt;/p&gt;

      &lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Consultants and subcontractors&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;13,052&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,894&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Salaries and related expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,867 &lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,789&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Rent and maintenance&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;245&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;114&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Share-based compensation&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;448&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;137&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Other expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;365&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;400&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;16,977&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,334&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;

  </us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000398">
      &lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Consultants and subcontractors&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;13,052&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,894&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Salaries and related expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,867 &lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,789&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Rent and maintenance&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;245&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;114&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Share-based compensation&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;448&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;137&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Other expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;365&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;400&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;16,977&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,334&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
    </cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock>
    <cmmb:ConsultantsAndSubcontractorsExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000386"
      unitRef="usd">13052000</cmmb:ConsultantsAndSubcontractorsExpense>
    <cmmb:ConsultantsAndSubcontractorsExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000387"
      unitRef="usd">3894000</cmmb:ConsultantsAndSubcontractorsExpense>
    <us-gaap:OfficersCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000388"
      unitRef="usd">2867000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000389"
      unitRef="usd">1789000</us-gaap:OfficersCompensation>
    <cmmb:RentAndMaintenanceResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000390"
      unitRef="usd">245000</cmmb:RentAndMaintenanceResearchAndDevelopmentExpense>
    <cmmb:RentAndMaintenanceResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000391"
      unitRef="usd">114000</cmmb:RentAndMaintenanceResearchAndDevelopmentExpense>
    <cmmb:ShareBasedCompensationResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000392"
      unitRef="usd">448000</cmmb:ShareBasedCompensationResearchAndDevelopmentExpense>
    <cmmb:ShareBasedCompensationResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000393"
      unitRef="usd">137000</cmmb:ShareBasedCompensationResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000394"
      unitRef="usd">365000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000395"
      unitRef="usd">400000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000396"
      unitRef="usd">16977000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000397"
      unitRef="usd">6334000</us-gaap:ResearchAndDevelopmentExpense>
    <cmmb:GeneralAndAdministrativeDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000417">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"&gt;&lt;span style="font-weight:bold"&gt;Note 10 - General and Administrative&#160;&lt;/span&gt;&lt;/p&gt;

      &lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Salaries and related expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;3,435&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;943&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Professional services&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,596&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,695&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Share-based compensation&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,763&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,882&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Fees to Directors&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;231&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span&gt;244&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Insurance&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,084&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,024&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Rent and maintenance&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;24&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;29&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Other expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,423&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;216&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;11,556&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,033&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;

  </cmmb:GeneralAndAdministrativeDisclosureTextBlock>
    <cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000416">
      &lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Salaries and related expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;3,435&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;943&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Professional services&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,596&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,695&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Share-based compensation&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,763&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,882&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Fees to Directors&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;231&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span&gt;244&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Insurance&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,084&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,024&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Rent and maintenance&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;24&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;29&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Other expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;1,423&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;216&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;11,556&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,033&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
    </cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock>
    <us-gaap:SalariesAndWages
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000400"
      unitRef="usd">3435000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000401"
      unitRef="usd">943000</us-gaap:SalariesAndWages>
    <us-gaap:ProfessionalFees
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000402"
      unitRef="usd">2596000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000403"
      unitRef="usd">1695000</us-gaap:ProfessionalFees>
    <cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000404"
      unitRef="usd">2763000</cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense>
    <cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000405"
      unitRef="usd">1882000</cmmb:ShareBasedCompensationGeneralAndAdministrativeExpense>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000406"
      unitRef="usd">231000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230201004651041"
      unitRef="usd">244000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:GeneralInsuranceExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000408"
      unitRef="usd">1084000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000409"
      unitRef="usd">1024000</us-gaap:GeneralInsuranceExpense>
    <cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000410"
      unitRef="usd">24000</cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense>
    <cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000411"
      unitRef="usd">29000</cmmb:RentAndMaintenanceGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000412"
      unitRef="usd">1423000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000413"
      unitRef="usd">216000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000414"
      unitRef="usd">11556000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000415"
      unitRef="usd">6033000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000458">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Note 11 - Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Tax rates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Ordinary taxable income in Israel is subject to a corporate tax rate of 23%.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s US subsidiary, Chemomab Therapeutics Inc. ("Chemomab Inc.) is taxed separately under the U.S. tax laws.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Chemomab Inc. is subject to a federal flat tax rate of 21% and state tax as applicable.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Capital gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Tax assessments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of December 31, 2022, the Company&#x2019;s tax reports through December 31, 2017&#160;are considered closed to audit inspections by the Israeli Tax Authority (&#x201c;ITA&#x201d;) due to statute of limitation rules effective in Israel.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has not yet been assessed by the ITA since inception.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;C.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Losses for tax purposes carried forward to future years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As of December 31, 2022, the Company and its subsidiaries had approximately $159 million&#160;(approximately $143 million as of December 31, 2021) of net operating loss carryforwards which are available to reduce future taxable income with no limitation on the period of use.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;On March 27, 2020 and December 27, 2020, the President of the United States signed and enacted into law the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and the Consolidated Appropriations Act, 2021 (CAA). Among other provisions, the CARES Act and the CAA provide relief to U.S. federal corporate taxpayers through temporary adjustments to net operating loss rules, changes to limitations on interest expense deductibility, and the acceleration of available refunds for minimum tax credit carryforwards. The CARES Act also includes provisions for a carryback of any net operating loss (NOL) arising in a taxable year beginning after December 31, 2017, and before January 1, 2021, to each of the five taxable years preceding the taxable year in which the loss arises (carryback period).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Chemomab Therapeutics Inc., a wholly owned subsidiary of the Company, filed an application with the US Internal Revenue Service to carryback net operating losses. Chemomab Therapeutics Inc received $351 thousand in December 2022 on account of 2016 and 2017 and expects to receive the remainder $183 thousand in 2023. Accordingly, a tax benefit in the total amount of $534 thousand was recorded in the Company&#x2019;s statement of operations during 2022.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;D.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.28pt"&gt;Deferred taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:11pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In respect of:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;div style="margin-left:72pt"&gt;

        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net operating loss carry-forwards&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;36,550&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33,396&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;1,774&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,147&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2,858&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,449&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;36,030&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less - Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(36,030)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

    &lt;/div&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. A valuation allowance is provided when it is more likely than not that the deferred tax assets will not be realized.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has established a valuation allowance to offset deferred tax assets on December 31, 2022 and 2021 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The net change in the total valuation allowance for the year ended at December 31, 2022 was an increase of approximately $5.2 million.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;E.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:26.83pt"&gt;Roll forward of valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;div style="margin-left:72pt"&gt;

        &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;6,200&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currency transaction loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2,425&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax assets acquired through merger&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;24,535&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2,870&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;36,030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currency transaction Income&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;(1,316&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;6,481&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

    &lt;/div&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;F.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:28.31pt"&gt;Reconciliation of theoretical income tax expense to actual income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:72pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;A reconciliation of the Company&#x2019;s theoretical income tax expense to actual income tax expense is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;div style="margin-left:72pt"&gt;

        &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;28,180&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(12,478&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Statutory tax rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Theoretical tax benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(&lt;span style="font-weight:bold"&gt;6,481&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(2,870&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Change in temporary differences for which deferred taxes were not recognized&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(1,696&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,332&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax rate differential&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;20&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(101&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-deductible expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;744&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;239&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;6,879&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,064&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Actual income tax expense (Benefit)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(534&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:1.5px"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

    &lt;/div&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;G.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:25.72pt"&gt;Accounting for uncertainty in income taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:72pt;margin-bottom:11pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the year ended December 31, 2022, the Company did not have any unrecognized tax benefits and does not expect that the amount of unrecognized tax benefits will change significantly within the next 12 months. The Company&#x2019;s accounting policy is to accrue interest and penalties related to unrecognized tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryIL"
      decimals="2"
      id="FFact_0000000000418"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20220101to20221231_srtStatementGeographicalAxis_countryUS_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember"
      decimals="2"
      id="FFact_0000000000419"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_20221231_srtStatementGeographicalAxis_countryIL"
      decimals="-6"
      id="Fxbrl_20230213140532094"
      unitRef="usd">159000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_20211231_srtStatementGeographicalAxis_countryIL"
      decimals="-6"
      id="Fxbrl_20230213140537759"
      unitRef="usd">143000000</us-gaap:TaxCreditCarryforwardAmount>
    <cmmb:ReceivedAmountOfChemomabTherapeuticsInc
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213140710654"
      unitRef="usd">351000</cmmb:ReceivedAmountOfChemomabTherapeuticsInc>
    <cmmb:ExpectsToReceiveAmountOfChemomabTherapeuticsInc
      contextRef="C_20230101to20231231_srtStatementScenarioAxis_srtScenarioForecastMember"
      decimals="-3"
      id="Fxbrl_20230213140716671"
      unitRef="usd">183000</cmmb:ExpectsToReceiveAmountOfChemomabTherapeuticsInc>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213140722797"
      unitRef="usd">-534000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201025152633">
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net operating loss carry-forwards&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;36,550&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;33,396&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share-based compensation expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;1,774&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,147&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2,858&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,449&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;36,030&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less - Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(36,030)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000422"
      unitRef="usd">36550000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000423"
      unitRef="usd">33396000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000424"
      unitRef="usd">1774000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000425"
      unitRef="usd">1147000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000426"
      unitRef="usd">2858000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000427"
      unitRef="usd">1449000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000428"
      unitRef="usd">13000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000429"
      unitRef="usd">38000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000430"
      unitRef="usd">41195000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000431"
      unitRef="usd">36030000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000432"
      unitRef="usd">41195000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000433"
      unitRef="usd">36030000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230201010225989_Fact_0000000000426"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230201010225989_Fact_0000000000427"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_20220101to20221231"
      decimals="-5"
      id="Fxbrl_20230201010356964"
      unitRef="usd">5200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201025212924">
        &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;6,200&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currency transaction loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2,425&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax assets acquired through merger&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:9%"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;24,535&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2,870&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;36,030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Currency transaction Income&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;(1,316&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;6,481&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:88%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;41,195&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20201231"
      decimals="-3"
      id="FFact_0000000000438"
      unitRef="usd">6200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <cmmb:CurrencyTransactionLossValuationAllowance
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000439"
      unitRef="usd">2425000</cmmb:CurrencyTransactionLossValuationAllowance>
    <cmmb:TaxAssetsAcquiredThroughMergerValuationAllowance
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230201010515039"
      unitRef="usd">24535000</cmmb:TaxAssetsAcquiredThroughMergerValuationAllowance>
    <cmmb:IncomeTaxExpenseValuationAllowance
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000440"
      unitRef="usd">2870000</cmmb:IncomeTaxExpenseValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000441"
      unitRef="usd">36030000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <cmmb:CurrencyTransactionLossValuationAllowance
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230201010936607"
      unitRef="usd">-1316000</cmmb:CurrencyTransactionLossValuationAllowance>
    <cmmb:IncomeTaxExpenseValuationAllowance
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000444"
      unitRef="usd">6481000</cmmb:IncomeTaxExpenseValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000445"
      unitRef="usd">41195000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201025228669">
        &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;(&lt;/span&gt;&lt;span style="font-weight:bold"&gt;28,180&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(12,478&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Statutory tax rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:3px;margin-bottom:1.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Theoretical tax benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(&lt;span style="font-weight:bold"&gt;6,481&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(2,870&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Change in temporary differences for which deferred taxes were not recognized&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(1,696&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,332&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Tax rate differential&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;20&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(101&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-deductible expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;744&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;239&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;6,879&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;background-color:rgb(255, 255, 255)"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,064&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
              &lt;td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Actual income tax expense (Benefit)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(534&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:1.5px"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000447"
      unitRef="usd">-28180000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000448"
      unitRef="usd">-12478000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_20220101to20221231"
      decimals="2"
      id="FFact_0000000000449"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_20210101to20211231"
      decimals="2"
      id="FFact_0000000000450"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000451"
      unitRef="usd">-6481000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000452"
      unitRef="usd">-2870000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213113429979_Fact_0000000000453"
      unitRef="usd">-1696000</cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized>
    <cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230213113429979_Fact_0000000000454"
      unitRef="usd">-1332000</cmmb:ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213113425908_Fact_0000000000453"
      unitRef="usd">20000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230213113425908_Fact_0000000000454"
      unitRef="usd">-101000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213113423827_Fact_0000000000453"
      unitRef="usd">744000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230213113423827_Fact_0000000000454"
      unitRef="usd">239000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230213113421604_Fact_0000000000453"
      unitRef="usd">6879000</cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded>
    <cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230213113421604_Fact_0000000000454"
      unitRef="usd">4064000</cmmb:LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230219165815757"
      unitRef="usd">-534000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230201011121606_Fact_0000000000454"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000477">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Note 12 - Related Parties Balances and Transactions&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;A.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:10.28pt"&gt;Balances with Related Parties:&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"&gt;The following Related Party payables are included in the consolidated Balance Sheets:&lt;/p&gt;
    &lt;div style="margin-left:36pt"&gt;

        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;


              &lt;tr style="background-color:#CCEEFF"&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Employee and related expenses&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;891&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;278&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Accrued expenses&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;58&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;72&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:#CCEEFF"&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;949&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;350&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;
                  &lt;p&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;p&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;On September 19, 2022, the Company entered into a share purchase agreement with the Company's Co- Founders, see Note 8B(4).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;/div&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;B.&lt;/span&gt;&lt;span style="font-weight:bold;padding-left:10.83pt"&gt;Transactions with Related Parties:&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:36pt;margin-bottom:11pt"&gt;The following transactions with related parties are included in the consolidated Statements of Operations:&lt;/p&gt;
    &lt;div style="margin-left:36pt;margin-bottom:11pt"&gt;

        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Salaries and related expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,409&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,255&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Share-based payments&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,466&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,775&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Professional Services&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;231&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;244&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Research and development&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;36&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;36&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;5,142&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,310&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

    &lt;/div&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230207220029774">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;


              &lt;tr style="background-color:#CCEEFF"&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Employee and related expenses&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;891&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;278&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Accrued expenses&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;58&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;72&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:#CCEEFF"&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;949&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;350&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;
                  &lt;p&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000459"
      unitRef="usd">891000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000460"
      unitRef="usd">278000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000461"
      unitRef="usd">58000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000462"
      unitRef="usd">72000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000463"
      unitRef="usd">949000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_20211231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember"
      decimals="-3"
      id="FFact_0000000000464"
      unitRef="usd">350000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201025305978">
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-weight:bold"&gt;USD thousands&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Salaries and related expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,409&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,255&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Share-based payments&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2,466&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,775&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Professional Services&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;231&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;244&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Research and development&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;36&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;36&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;5,142&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,310&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000466"
      unitRef="usd">2409000</cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000467"
      unitRef="usd">1255000</cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000468"
      unitRef="usd">2466000</cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000469"
      unitRef="usd">1775000</cmmb:RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000470"
      unitRef="usd">231000</cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000471"
      unitRef="usd">244000</cmmb:RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000472"
      unitRef="usd">36000</cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000473"
      unitRef="usd">36000</cmmb:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyCosts
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000474"
      unitRef="usd">5142000</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000475"
      unitRef="usd">3310000</us-gaap:RelatedPartyCosts>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000488">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:0pt"&gt;Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share, as the effect of potentially dilutive securities is antidilutive.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented:&lt;/p&gt;
    &lt;div style="margin-left:36pt"&gt;

        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;In USD thousands, except share and per &lt;/span&gt;&lt;span style="font-weight:bold"&gt;share data&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Net loss&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;27,646&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;12,478&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-10pt;padding-left:10pt;margin-bottom:0pt"&gt;Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;227,589,288&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;207,468,650&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Net loss per share attributable to ordinary shareholders, basic and diluted&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.121&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.060&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

    &lt;/div&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:36pt;margin-bottom:11pt"&gt;The potential number of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows:&lt;/p&gt;
    &lt;div style="margin-left:36pt"&gt;

        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Number of shares&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Outstanding options to purchase ordinary shares&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;35,191,540&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;27,003,260&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

    &lt;/div&gt;
  </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201025331788">
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;In USD thousands, except share and per &lt;/span&gt;&lt;span style="font-weight:bold"&gt;share data&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Net loss&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;27,646&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;12,478&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-10pt;padding-left:10pt;margin-bottom:0pt"&gt;Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;227,589,288&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;207,468,650&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Net loss per share attributable to ordinary shareholders, basic and diluted&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;0.121&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;0.060&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000478"
      unitRef="usd">-27646000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000479"
      unitRef="usd">-12478000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_s_20230215224008037"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230215224008037"
      unitRef="Share">227589288</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230131213429326"
      unitRef="Share">207468650</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000481"
      unitRef="Share">207468650</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230131213444247"
      unitRef="USD_Per_Share">0.121</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000482"
      unitRef="USD_Per_Share">0.121</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230131213458553"
      unitRef="USD_Per_Share">0.06</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000483"
      unitRef="USD_Per_Share">0.06</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201025347421">
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December&#160;31&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Number of shares&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#CCEEFF"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;Outstanding options to purchase ordinary shares&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;35,191,540&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;27,003,260&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="FFact_0000000000485"
      unitRef="Share">35191540</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="FFact_0000000000486"
      unitRef="Share">27003260</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230201020943165">
    &lt;div&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;Note 14&#160;- Subsequent Events&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="margin-top:11pt;margin-bottom:0pt;padding-left:36pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;On January 13, 2023 the Company filed with the SEC a registration statement on form S-1 for the issuance and sale of up to $20,000,000 of its ADSs.&lt;/p&gt;
    &lt;/div&gt;
  </us-gaap:SubsequentEventsTextBlock>
    <cmmb:SaleOfStockValueOfSharesIssuedInTransaction
      contextRef="C_20230113_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="0"
      id="Fxbrl_20230213104715713"
      unitRef="usd">20000000</cmmb:SaleOfStockValueOfSharesIssuedInTransaction>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#FFact_0000000000373"
          xlink:label="FFact_0000000000373"
          xlink:type="locator"/>
        <link:footnote id="FN20230201025135527" xlink:label="FN20230201025135527" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The weighted average share price is based on the Company&#x2019;s ordinary share valuation as at the grant date. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000373"
          xlink:to="FN20230201025135527"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000377"
          xlink:label="FFact_0000000000377"
          xlink:type="locator"/>
        <link:footnote id="FN20230201025203207" xlink:label="FN20230201025203207" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to service conditions and for performance conditions that are probable of achievement. If meeting the performance condition is not probable, the Company will use the awards&#x2019; contractual term if the service period is implied, or the simplified method, if the service period is explicitly stated.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000377"
          xlink:to="FN20230201025203207"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000378"
          xlink:label="FFact_0000000000378"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000378"
          xlink:to="FN20230201025203207"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000379"
          xlink:label="FFact_0000000000379"
          xlink:type="locator"/>
        <link:footnote id="FN20230201025249960" xlink:label="FN20230201025249960" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option. As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#x2019;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#x2019;s expected term.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000379"
          xlink:to="FN20230201025249960"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000380"
          xlink:label="FFact_0000000000380"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000380"
          xlink:to="FN20230201025249960"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000381"
          xlink:label="FFact_0000000000381"
          xlink:type="locator"/>
        <link:footnote id="FN20230201025314607" xlink:label="FN20230201025314607" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000381"
          xlink:to="FN20230201025314607"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#FFact_0000000000382"
          xlink:label="FFact_0000000000382"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="FFact_0000000000382"
          xlink:to="FN20230201025314607"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MNOOLJ-T8O:.'H&3>.;:-M@L"D\-9X3.*>WH/=OP'@YRS^&)P4LW+.Y SHX&
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M,R;5;[6HU4]>D$$*?G'COU*T_:0[1D9A1OXB,UY2^03J[)5I)*,>)+BG><7
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M?%_G)514G\@E".R92U51@U6U\/52 2U<4L7]* @2OZ),>-G0M4U4-I2UX4S
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MLFXQP>>\K=GDQ,R++N"2(RX9Q7THJZTY=W\$F+P-F/P(\/%LPZ-G2?JMZ8J
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M9GKX)\'A@I-M\^3[GG!.JN;C!J<YIA(@?E\1PI\NY,/T[O\<B_\ 4$L#!!0
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M5!)+DQ9:HOE^-X,< (38[2-M&[%<.Q5KF<RZ+25#<*,<4D?LDZ))_#'A#92
MB]FG]GU_F)?GGPYBP/H9B%0F@[$F<NQVL(EU?75S*9;IMP; <0C^WZG(24@G
M2W& ST34S<IC1*$V-NZ?8G]L\EVSZHQE=&^D0U+.3QE:C,CL<GOD9RX;W&W$
M/:Y+W;$Q_$A.OG9Q$\%ZJZ9NG&]DK,C!\A;MVQ<;$)6J+]"7NQ.QM1[M"X]M
M:3 M4B1?0/Y]&("0P^#6I6LK#\DR+O,=H#()PE737OE8_E9.0F7V$LD12H4T
MZY:$C:Q4+(\6YMWIVD(N[FVW=^=X/>F;2#\[P%Z:KV)[&X-!+%RIP5BY^^#
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MV1!LQ8\%[M[*T0:\SZT-W0]2T']=O_@?4$L#!!0    ( %8Q=%9*,A/FE1$
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MA6\B:!> ZQN%YSH8;H/QE<W_ E!+ P04    " !6,716,'N3JF0"  "4!0
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RE5$MOVS ,ON=7"!ZP4U<_
MXCS:)0:2MGL<N@4-NAV&'12;B87:DB?12?;O1\F.EQ9I,& 7693X??PHFISL
ME'XR.0"R?5E(,_5RQ.K:]TV:0\G-I:I TLU:Z9(CF7KCFTH#SQRH+/PH"(9^
MR87TDHD[6^ADHFHLA(2%9J8N2ZY_SZ%0NZD7>H>#![')T1[XR:3B&U@"/E8+
M39;?L62B!&F$DDS#>NK-PNMY;/V=PS<!.W.T9S:3E5)/UOB<3;W "H("4K0,
MG#Y;N(&BL$0DXU?+Z74A+?!X?V#_X'*G7%;<P(TJOHL,\ZDW]E@&:UX7^*!V
MGZ#-9V#Y4E48M[)=XQO''DMK@ZILP:2@%++Y\GW[#D> <? *(&H!D=/=!'(J
M;SGR9*+5CFGK36QVXU)U:!(GI"W*$C7="L)A\A5ST.P!4A!;OBK ,"XSMM!0
M<9&QNST5WX"9^$BQ+,)/6]YYPQN]PAM&[%Y)S V[DQEDSPE\$MDIC0Y*Y]%9
MQEM(+UD_O&!1$$5G^/I=YGW'UW^%[T6.+N_F-6;& !KV8[8RJ.FW^7DJ_88\
M/DUN6^G:5#R%J4>]8D!OP4O>O@F'P?LSTN-.>GR._3^*=I;WM.HO"H'%[!W[
MMZ@]JA.4*_*D6CTW;.'L$O8>E[<,<U4;8C OK(]J"UI2WR,3TJ# VK:OZ<6#
MJUXXNNH= L(A8'C1#T9VC<>TCH9#6@?1B)UZ:/^H4TK0&S</#$M5+;%IFNZT
M&SFSIM/^NC?SZI[K#0ED!:P)&ER.!A[3S0QH#%25Z[N50NIBM\UI;(*V#G2_
M5O2RK6$#=(,X^0-02P,$%     @ 5C%T5I*A#3:I @  [@4  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&ULE51M3]LP$/[N7V%ETL0D1E[;0M=6HC"T
M28 J$./#M ]N<FTLXCC8EQ;^_<Y)FY6I=)H4V3[?W7//^7(W6FOS9', Y"^J
M*.W8RQ&KH>_;- <E[(FNH"3-0ALED$2S]&UE0&2-DRK\* CZOA*R]":CYFYF
M)B-=8R%+F!EN:Z6$>9U"H==C+_2V%W=RF:.[\">C2BSA'O"AFAF2_ XEDPI*
M*W7)#2S&WGDXG";.OC'X(6%M=\[<93+7^LD)W[.Q%SA"4$"*#D'0MH(+* H'
M1#2>-YA>%](Y[IZWZ%=-[I3+7%BXT,6CS# ?>Z<>SV AZ@+O]/H;;/+I.;Q4
M%[99^;JU32AB6EO4:N-,LI)ENXN7S3OL.)P&[SA$&X>HX=T&:EA>"A23D=%K
M;IPUH;E#DVKC3>1DZ8IRCX:TDOQP,C-47X.O7)09__I<RXI>'(_Y+>#(1PK@
MS/QT S9MP:)WP,*(W^@2<\N_EAED;P%\8M;1B[;TIM%!Q$M(3W@<'O,HB*(#
M>'&7;MS@Q?](]YC/"E'BVZSYS_.Y14,_RJ]]N;?(R7YDUSQ#6XD4QAYUAP6S
M F_R\4/8#[X<X)UTO)-#Z/];IH-@^ZG>:@3>XY_Y@5",R@%J#L:5Y*W@ZN.6
MD#W<7W+,=6W)W_XE76B+0UI552,8RP8!2V)V59M28FV@"0G;D"R.631@UV*N
MC4!M7G=59V<L[B?L$>96$O$,5C1?6EV8N.\:J%=S761<JLKH%3B=96'??;TX
M8DG?&5E+*8LTK55="(2,D.A-4BG<S&!'/.SWV"=V% 8#VN+^@,6] =]74'^G
M!Q6893-I+$]U76+;CMUM-\S.VQ[^8]Y.PAMAEK*TO( %N08G@Y['33M=6@%U
MU73T7"/-A^:8TT &XPQ(O]!4S(W@ G0C?O(;4$L#!!0    ( %8Q=%;A]X'S
M; 4  !(.   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;+57WV_;-A!^
M]U]Q4+LB!1+;DIVTS0\#3K)A Y8V:+OM8=@#+9TMHA2IDI0=[Z_?'?4C2F)[
MV,,>$HO4W7???3P>J<N-L=]<CNCAH5#:746Y]^7Y:.32' OAAJ9$36^6QA;"
MT]"N1JZT*++@5*A1,AZ?C0HA=32[#'/W=G9I*J^DQGL+KBH*8;?7J,SF*HJC
M=N*S7.6>)T:SRU*L\ OZW\I[2Z-1AY+) K631H/%Y54TC\^OIVP?#'Z7N'&]
M9^!,%L9\X\$OV54T9D*H,/6,(.AGC3>H% ,1C>\-9M2%9,?^<XO^4\B=<ED(
MAS=&_2$SGU]%[R/(<"DJY3^;S<_8Y'/*>*E1+OR'36V;?(@@K9PW1>-,# JI
MZU_QT.C0<W@_WN.0- Y)X%T'"BQOA1>S2VLV8-F:T/@AI!J\B9S4O"A?O*6W
MDOS\[%>DE-SER!,6SXS2QN^Z]DOV^,4)W!GM<P<_Z@RSIP C(M$Q25HFU\E!
MQ%M,AS")CR$9)\D!O$F7V23@3?9FYAPBW$J7*N,JB_#G?.&\I3KX:U>^-=IT
M-QKOC7-7BA2O(BI^AW:-T>S-J_AL?'& Z[3C.CV$?F 5#OKM9O71>(0S.($:
M%3YIN!-;B,=!6OI_0QO;%&(!J#U:S$!J;T!H,,NE3)&>,E#T.B"#8A00*XM(
MF]'#44X^4HLE^<*;5^^3.+X(O\GXXFN.,&\MPQR]&Q[-T]383.H54!S?M^F1
ML<PF ]&$E1KF7E(#@'MAOQW#5U0G\[5< S4B,BK12I,18\(C+-BBL.Z8!Z9:
MY2%A2G;"R7]*O5D0UV0:!(A[,9U<:8Y)W8'89"&_YQ3A* IIM0;1VR&\3*A]
M>\P1J92QX)!Q4H?L9^DKRS'9B]9L+4WE=@O?0)>6.K#U6S ;39!LTTFEA%W1
MW"[%.L&.&\5HN0K6:_)<JTZ?<3(%3E4LS!J!HPK/.:JZCH3E&*FJLE R[9I_
M>FH'EOO@B5F>5%PVM >]:RN!NC!G=&.*4NAMJ)UW%X[&VADE,\%)70LE-&43
M6AH%97$>!6W[0Y A*%OK$:J?%V\'?"#$:C(A-JBH8UFU9<J!7Q"(7]0)L%##
M(,1S)+-0<B7X-'&,5U*1U2[TQ(O_4B-&32O+"P9*BH54TDL,:>V1KV?5RL8I
M-EC:Z)/#>!][%N;?L?^')1F2@R.W!KI=FK50%=8;%I_+UBZ 1;Y'/!)N:W87
M17R0KI>;>&PI/6M"3,U*R[^93Z?&CA(-[ _HQ2Q$27OQ0=)5 -467D^FIQ2*
MMF]PW;'KAW!;V= D\J9!4<?EPMBOW5[RU**HKFR@1;50US1QZF5 H]?QNT=*
M_/>$Y#$!NA+#/4AMJ8OM7LCCQ\UU2#+84"&\3I+_$I$WU2&1-W2T$&8\?8$Y
M.91%89SORJ3IM%V=--TK,[1Y/'?3M<PPZ%F42J;2 ]'!WJ%0L;DD08/@7%)"
MP<)8.M.#$F0=+H)=A4M=7X[#+7,M)+5P11'J;I2:@B#2^BCA_<1$4:1YDSXM
M9H9<YW7=[]PQ3W?+\&6.!YA**FW(MZ4A9"]3,GB: ">*M)$:_A1MDQ-UGB;,
MK):'T3:F4ADLZA8:,+@ 3G_@#+H:/ATF[025_YV@PZ[;/B^7.S1B[FDI]Q=5
MZ]:>-GN+TW(!4LM0]$'ASN$HM,:Z-MS;\P$?^X,X.>.'Z>##9/#5L"S+RO,=
MD&4NJN*9I(,D_C#@"R,71>7K*Q'5HO/G@R,X';P=W#]?DP-E/. "WG4K'/7N
MZ072T<U?(Z2SJ;2OK^S=;/?!,Z_O^8_F]=?2'9W\4G-U+\EU/'QW&M5[M!UX
M4X9;_\)X^H8(CSE]M*%E WJ_-'1-; 8<H/L,G/T#4$L#!!0    ( %8Q=%8*
MRV/  PD   87   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;+U8;7/;
M-A+^*SNJVY%G%+W9CM/X94:VDZEODM1C.[T/-_<!(B$1,4BP &A9]^O[+$!2
ME"N[N;N9?D@L@MBW9W<?+'BZ,O;!95)Z>LIUX<YZF??E^]'()9G,A1N:4A9X
MLS V%QZ/=CERI94B#4*Y'DW'X[>C7*BB=WX:UF[L^:FIO%:%O+'DJCP7=GTA
MM5F=]2:]9N%6+3//"Z/STU(LY9WT7\L;BZ=1JR55N2R<,@59N3CKS2;O+PYY
M?]CPFY(KU_E-',G<F =^N$[/>F-V2&J9>-8@\.=17DJM61'<^+W6V6M-LF#W
M=Z/]8X@=L<R%DY=&_U.E/COKO>M1*A>BTO[6K'Z1=3Q'K"\QVH7_:17W'DU[
ME%3.F[P6A@>Y*N)?\53CT!%X-WY!8%H+3(/?T5#P\DIX<7YJS8HL[X8V_A%"
M#=)P3A6<E#MO\59!SI]?FCQ7'BA[1Z)(Z=(47A5+/-,G)>9**Z^D.QUYV&*)
M45+KO8AZIR_HG4SI,U1ECCX4J4RW%8S@9.OIM/'T8OJJQBN9#.E@,J#I>#I]
M1=]!&_E!T'?PWT:>(&"Z4B[1QE56TK]F<^<MRN??NV"(1@YW&^&6>N]*D<BS
M'GK&2?LH>^<__3!Y.SYY)83#-H3#U[3_'\E[7>\7XR4=TQOZ/@,T&]*'IT17
M#@V&%PEZ5M)L::5D4>IGTDI5B(67]@W]],.[Z71\XK,=6\.[R<D^71>$?,M\
M+BWR/4'6+\%&)A=SPC:H2TD5WI#886ZE?$:L_K-,52(TW0)X89-L +4+*Y#,
M*O'([(!^D4)C\QWR C6./E8(TBR"]+W4;V:/ZI'N3 6A!]7JNPPN4+^.A(4:
MQP=45M95 F[ NU6FDHP47!*.EA:K\#NX)PJ2+6*Z#@$2B;0>3(K@'F$$M.6H
M#UG0#%+$,=-.W/;Q!MI2Y(9*X3E? WHHS"I#07'B2FM2!!VSR"HLLQ5;=-6\
M8]]GRF*WL"&O[<;6^^WX6!GDOX%AN\X#G#Q:T@KE(P+]+BJMU^1PS+P4Q'"3
MXPPQ"UY/66\IUD$B9$=088HWH&X\B+F6P0XO)2@*&..E3DP+B3A8&Y728LGC
MI.$,"ZUIYKU5\XJ3<ETD)I<!:U<A9QS"7Z,^B ADK&Q166RRV\Y:LT:!,90+
M:W)R0N-G+E))\W7'2WE"?;5/M^UN6-QVES5^ 791@[%-R78=_PYW.\E"AXD4
M@"$W@UB3X*>R?BD%,*@5I'03BV?+B(\]O3_XKJ3QCX71F "X0K<3.'B>/9&;
M"@7\'O;V:6\R'D/<5(ZAKDI4$H+(E0M3 2<2N*SHRE9+FI4E (WEUC3GEZO9
MIC<OE-%F&7JX16>'S,6G5H:AEK]7ZA&XH^87_+@3F] [DKX6BLOI#D7/=&),
M&DHDNI?B_%9\E&Q9^]CU\"_#=>@H+2R)CM^O>L5,LQ4 YA0>IY:5%M[8-5*&
M(V_-5?.ALACV@L.FD)0A03:DNG8G10:%=7^W6S.GQ)!NQ#JP>UW=8HE*6P+E
MNOT*XVDN*8<BO(?VO8,NDNBFW;X,F!H?51KB%)T,?ZNL<N#[V"!E;3T:8T/<
MQ*8 I9DBX?Z=HU:G?TH>NQJHDT%"II_54QTDQN$'R0<KXP=W4)];Z1A!BE%X
M&=+_ 9^W?R,^0[C/"+1G>C/'P:]&UM$*E!(%ZVYB[AAVF:IYT8JDTB7@<'@G
MYN817-*B;I*DLA;P!OZ4*I SLRR/=0QUX(XR<#!^+Z2M%X.PQ5&*.PK'8V5P
MO:&Y$TYA7T&1P)HH(C_S8&0QO-\CUT[4H+3,&%%Y=HPEPF4M;J@))!W1<>/5
MU$_]R8_[C4?(0@)F=62%XO3@_&C5\[S@^=  1M#R+*8!.SSYL5&48*9 .FL2
MLD@(1I!M?=C/^D+LF='8#&+W4;H+WJOA@[UYWD.&N(P:LH[4CK!5RJ>R5NB%
M-+J"^1@.AX356=YRH),""K>YA%7542D;)B;GFQ9HM@Y(P6JQ!K7BH.<W>"#)
MPU5HB2Y?#,:=CN@,(V$:$CR]X.@3\"\-\-AZJ@Q\F4*E-F7,Y1-NS*C7BBL'
MN>:AP!JP (8BA_)TQD; .<9K9X747.-60B*R9GAQ'8Z%R?&)BQXDJA3/ZDHY
MI),G=+\Y<S<C!U)FF0  T4%(?ST\Q#JH/9;M;$A]7 ,>HJ*OP[MA3??[W%.\
MAI.I+:*81WX*Y.8V==0/VTI,MCR@(Y_.LR.?KB]^O=T?;D\==9AH>?!\7AH<
MQ\T(B2J-NUPH!BXK% ?&LB0K^ Q?<Y%V03=5<"?"V4E>JM*0Z-K!D/[:YS"2
M-3[4M+F6?,!)OK+^F:SBN(=?DR'=*2[4UDR;*BP;6YJZO7QF3;7,=O!>*]DB
MMS<93*?'&TKNNC>HKQ*!(2%AEH7ZCTSC8&N['?9Z53KI7J3B9Y,<B#EI;W^A
M*C>5A3KC26U(%R&C5U7@SA!7@]!@*T+P*;QM7, *#OE8::&:F+KCZ!A9O3G#
M:K: MWM' &>Z 8?_[4T'1S]O.G;0#+! 4Z^'= \-K<46N.!(;,KO@.HRH'4U
M[(8XZ/2M(B^>2%3PP2J_IG[O^GXS.Z+NU$+%89FOTB477SA%<27,1%HS-B.!
M+**",5G3;[-[*$3Q,SKQ5B>#E5B:N P?MV4%=VA*,508;LX&AU@L#H)$"Y7C
M(LC?YG08I9H1O[TB,R2\.5SEUXPTVW]^'?@L[1* ;:[830);?)MK)4QB)EPT
M(V!-%TWLH5R9T!G+)"X.Z=>"_E'!OPZXB 6LQ(S T.#2Z'4PW/1!5ZF5?*61
M:4@5=X.KM-_HP8Q:A4Z!FVZ[O-H1:4-G:,+QX=O.*7#?L;10FC45/*5)X"N6
M -;YQE3+ 1U;VPJXK]HBC'H0I>42B&-6&*=CB,TYS>[R70O^545-CS%3,.MX
M7@+[VTT&OJ%VDC &\,3@H@<X6@U_[PBS3>7#E9%9-U4\)&RH!FRM\I!9K9J:
M:!VN3ZPFF#2V1!A.,&C@IC/<]4EKU/DVF7,=\1=8/K> >/Q,V:ZV'WEG\=OF
M9GO\0OQ9V"4 )RT7$!T/CX]Z\?-$\^!-&;YTSHWW)@\_,XEYTO(&O%\8XYL'
M-M!^^C[_ U!+ P04    " !6,716O?J4>!T)  !J%P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6R]6%MOVS@6?M>O(#R7M0%9T<6VG#8)D$L[VP4Z
M+9IV!HO%/C 2'7,KB2Y)V<W^^OT.*3FVZZ0S#SL/<70Y]_.="W6V4?JS60IA
MV=>Z:LSY8&GMZL7)B2F6HN8F4BO1X,U"Z9I;W.K[$[/2@I>.J:Y.TCB>G=1<
M-H.+,_?LO;XX4ZVM9"/>:V;:NN;ZX4I4:G,^2 ;]@P_R?FGIP<G%V8K?BUMA
M/ZW>:]R=;*64LA:-D:IA6BS.!Y?)BZL)T3N"WZ38F)UK1I[<*?69;MZ4YX.8
M#!*5*"Q)X/BW%M>BJD@0S/C2R1QL51+C[G4O_;7S';[<<2.N5?6[+.WR?# ?
ML%(L>%O9#VKS=]'Y,R5YA:J,^V4;3YOE U:TQJJZ8X8%M6S\?_ZUB\,.PSQ^
M@B'M&%)GMU?DK+SAEE^<:;5AFJ@AC2Z<JXX;QLF&DG)K-=Y*\-F+VR77@EWS
ME;2\.CNQ$$DO3HJ._<JSIT^P)RE[JQJ[-.Q54XIR7\ );-D:E/8&7:7/2KP1
M1<2R)&1IG*;/R,NV#F9.7O:4@U85GY>J*H4V?V.OOK32/K!?E17L7Y=WQFK
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MS@#4JU^$L_B /]C&*,"F5V:4LR[_EJ(0*]=\?& 4-5>>-[)?3.)QRV@+[(1
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MI04B@0E->/*Z$=#8.F?WQS$CU>HVEI(/BQ\Z\.][:G^ 0Y>">1+G40!<IT)
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M5H'.=Y+JI%M8!Z>YO_@,4$L#!!0    ( %8Q=%9"V$@9)P0  $@+   9
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MUUW ZX$N\AMLEH,A<=U_&[WHCN%'PAUOKQ2JTP>7=<V9$,,91-07!D_'MI9
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M:!EM*Q994:<02>><>ZN[_C(,L]Y4%8T@X,5:[Q&D8R(%N[,-F!,H>F\*LUF
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M188) &(&W UAZS1>F#R5#R2*$9-)S0M.".BF:;Z#ELX-J=K;Q@0N_D)EJE2
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M^&R<8J3Z >\=(UL_5$MI[(AZL[)O(BB78/=74IJ]XQH,KVS^%U!+ P04
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MYPBD<<#SE1!Z;Y@$W0<N^0-02P,$%     @ 5C%T5@=Z'U(T P  $0@  !D
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M,45,-0]0,S&R<I?^2AIZ0MPPIS<;E3U ^VLIS6YB'73_ N:_ 5!+ P04
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MX-;D4C;EN^EH4;L*N!+:U%/7+,V+!](&F/E""+WOV 6Z-S3[#5!+ P04
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MX'P&>"@B1FVJ3\G)# QE7)^.7(,D[59N5!.:5H2"=PCY ;F3PJ2:7(D8XM<
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M -($X/Q<"/W<,;=,_5,1_0%02P,$%     @ 5C%T5I[[E;V>!@  %AP  !D
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M]8QANMT57]"F 8HF*]M$9$0=D?V590AJ]&1KH1D9E$:A- :E\9K6MM8B[L#
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MJ"Y5MUHO,'F+>TOY*DH%B6&)D-9Y#R]=GG>-^42R3#=>"R:QC=/#$#MMX,H
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M3TL[GM[\X\:_9^^NP7"1ZO=G X,TR=@@JBA=.DKA'DI!R&YD;A+-/N8QQ&V
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M8]PZ*7?KZ!Z,+.S%W5P:(S/[,P&.ZR0-P.\+*4W]0 ::N]_9OU!+ P04
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MG(BJ(5<#Q;=E3UMQA1VR?$SP&P:$!N#[->?J.- +U%]%X1]02P,$%     @
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M-R_#+_7\_WT9)$A$F#*QX4"^_H/=R)6$3'SK8UYI#OLU5=RX$ 4-869A8!#
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M:H,T!KB_$4(_34QSUC;OT4]02P,$%     @ 5C%T5KXY_JL8 P  G@@  !D
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M:J/K =CG1<O'<%;T81R=G1YT<_A<Y-;W_'Y\XQ;?^"J^/Z2XI>I;44->4>O
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M76^;,!3]*Q:KID[:RE<@24>0VF33*JU2U+3;0[4'!VX"JL',=I+FW\\V!)%
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M)7&<IGX$,+^#.,80N!MQ!', 'C DCNOWX,[[*%J]IZ+U_SB'?P!02P,$%
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MPR5<V%])7<VMB!_#JFY1QI67=:?U6=AWTUX96>_?K]J_&_;Q7U!+ P04
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M;%!+ 0(4 Q0    ( %8Q=%:C#G>>[0   "L"   1              "  :\
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M2P$"% ,4    " !6,716CFKVMZX"  #]!P  &               @(%*%0
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 5C%T5G3O:M;6
M P  G@P  !@              ("!+A@  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( %8Q=%:E']+R_@4  -LA   8              "
M@3H<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !6,716
ME-CAP*(&  #S'   &               @(%N(@  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ 5C%T5B4O:O7#"0  :1<  !@
M     ("!1BD  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M %8Q=%9*,A/FE1$  $$P   8              " @3\S  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " !6,716N<P A5X"  !Q!0  &
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M970Q,RYX;6Q02P$"% ,4    " !6,716O?J4>!T)  !J%P  &0
M    @('V6P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M %8Q=%8FR+*9H0(  .<%   9              " @4IE  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ 5C%T5M#"GA.^ @  ( 8  !D
M             ("!(F@  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " !6,716^5*;NY8)  #S%P  &0              @($7:P  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( %8Q=%8(S%%S70,
M  ,(   9              " @>1T  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ 5C%T5D+82!DG!   2 L  !D              ("!
M>'@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !6,716
MU&?*P6@"  !*!0  &0              @('6?   >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( %8Q=%97O(A"TQ(  !<Y   9
M      " @75_  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ 5C%T5IOXICJ, @  ;P4  !D              ("!?Y(  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !6,716^/"8%(8"  "'!0
M&0              @(%"E0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( %8Q=%;*HV+6<@(  '$%   9              " @?^7  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 5C%T5M@"DDEX
M @  @04  !D              ("!J)H  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " !6,716"*0D\K0"  #>!0  &0
M@(%7G0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( %8Q
M=%; +3\3? (  &D%   9              " @4*@  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ 5C%T5MXL2@)Z!   F H  !D
M         ("!]:(  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " !6,716=ADD)*X"  #:!0  &0              @(&FIP  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( %8Q=%9U1U5^R@(  ! &
M   9              " @8NJ  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ 5C%T5A4QNWQN!   QPH  !D              ("!C*T
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !6,716NQ9U
MO^0"  #L!@  &0              @($QL@  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( %8Q=%8'>A]2- ,  !$(   9
M  " @4RU  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M5C%T5HIC&NAF @  ,P4  !D              ("!M[@  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " !6,716N'&6(:0"  !7!@  &0
M            @(%4NP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( %8Q=%9?R0^*P0(  $\'   9              " @2^^  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ 5C%T5DXT;)XK P
MSPL  !D              ("!)\$  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " !6,716CJ>_&)<"  #T"   &0              @(&)
MQ   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( %8Q=%9<
MXGR^C (  +0&   9              " @5?'  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ 5C%T5K<35170 P  <!,  !D
M     ("!&LH  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %8Q=%9YYW@/*P,  ,<+   9              "
M@8+G  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ 5C%T
M5JK%:]N$!   -18  !D              ("!Y.H  'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " !6,716_O6AP90&   '%@  &0
M        @(&?[P  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( %8Q=%8U8'K8'@,  "$)   9              " @6KV  !X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ 5C%T5J&_^YM( P  -PH
M !D              ("!O_D  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " !6,7166>Y![A@$   M%0  &0              @($^_0
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( %8Q=%9$D T+
M5@,  ,@+   9              " @8T! 0!X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ 5C%T5KXY_JL8 P  G@@  !D
M ("!&@4! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !6
M,7160E&M_.P#  !-"P  &0              @(%I" $ >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( %8Q=%:/U^2GU0(  +X)   9
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M970U."YX;6Q02P$"% ,4    " !6,716CJ?Z:4D#  #P%   #0
M    @ %E&P$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %8Q=%:7BKL<P
M !,"   +              "  =D> 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M %8Q=%8>,JZ^M@0  )\F   /              "  <(? 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " !6,716$R?LNN\!  "E(@  &@
M@ &E) $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !6
M,7168B/G&-@!  !((@  $P              @ ',)@$ 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     0@!"  42  #5* $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>82</ContextCount>
  <ElementCount>283</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>33</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementsOfChangesInEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - Statements of Cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - Other Receivables and Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses</Role>
      <ShortName>Other Receivables and Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - Commitments and Contingent Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CommitmentsAndContingentLiabilities</Role>
      <ShortName>Commitments and Contingent Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - Research and Development</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ResearchAndDevelopment</Role>
      <ShortName>Research and Development</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - General and Administrative</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralAndAdministrative</Role>
      <ShortName>General and Administrative</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - Related Parties Balances and Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions</Role>
      <ShortName>Related Parties Balances and Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/EventsAfterBalanceSheetDate</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - General (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralTables</Role>
      <ShortName>General (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/General</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/CashAndCashEquivalents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0025 - Disclosure - Other Receivables and Prepaid Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables</Role>
      <ShortName>Other Receivables and Prepaid Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0026 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0027 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0028 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapital</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0029 - Disclosure - Research and Development (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ResearchAndDevelopmentTables</Role>
      <ShortName>Research and Development (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ResearchAndDevelopment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0030 - Disclosure - General and Administrative (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralAndAdministrativeTables</Role>
      <ShortName>General and Administrative (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/GeneralAndAdministrative</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0031 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0032 - Disclosure - Related Parties Balances and Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables</Role>
      <ShortName>Related Parties Balances and Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0033 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0034 - Disclosure - General (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralDetails</Role>
      <ShortName>General (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/GeneralTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0035 - Disclosure - General (Schedule of net assets acquired based on their estimated fair value) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails</Role>
      <ShortName>General (Schedule of net assets acquired based on their estimated fair value) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/GeneralTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0036 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0037 - Disclosure - Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0038 - Disclosure - Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CashAndCashEquivalentsDetails</Role>
      <ShortName>Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/CashAndCashEquivalentsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0039 - Disclosure - Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails</Role>
      <ShortName>Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0040 - Disclosure - Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/PropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0041 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/LeasesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0042 - Disclosure - Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails</Role>
      <ShortName>Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/LeasesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0043 - Disclosure - Commitments and Contingent Liabilities (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingent Liabilities (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/CommitmentsAndContingentLiabilities</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0044 - Disclosure - Share Capital (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalNarrativeDetails</Role>
      <ShortName>Share Capital (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0045 - Disclosure - Share Capital (Schedule of Share-based Compensation Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails</Role>
      <ShortName>Share Capital (Schedule of Share-based Compensation Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0046 - Disclosure - Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails</Role>
      <ShortName>Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0047 - Disclosure - Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails</Role>
      <ShortName>Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ShareCapitalTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0048 - Disclosure - Research and Development (Schedule of Research and Development) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails</Role>
      <ShortName>Research and Development (Schedule of Research and Development) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/ResearchAndDevelopmentTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0049 - Disclosure - General and Administrative (Schedule of General and Administrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails</Role>
      <ShortName>General and Administrative (Schedule of General and Administrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/GeneralAndAdministrativeTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0050 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0051 - Disclosure - Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails</Role>
      <ShortName>Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0052 - Disclosure - Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails</Role>
      <ShortName>Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0053 - Disclosure - Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/IncomeTaxesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0054 - Disclosure - Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails</Role>
      <ShortName>Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0055 - Disclosure - Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails</Role>
      <ShortName>Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0056 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0057 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="zk2329403.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0058 - Disclosure - Subsequent Events (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails</Role>
      <ShortName>Subsequent Events (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anchiano.com/role/EventsAfterBalanceSheetDate</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockShares in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. zk2329403.htm 14781</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockMember in us-gaap/2022 used in 24 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. zk2329403.htm 15472, 15478, 15574, 15615, 15621, 15662, 15668, 15709, 15715, 15777, 15850, 15860, 15949, 15955, 16004, 16045, 16051, 16092, 16098, 16139, 16147, 16213, 16286, 16298</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. zk2329403.htm 19677, 19683</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyCosts in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. zk2329403.htm 19850, 19856</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:LeaseExpirationDate1 -  zk2329403.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="zk2329403.htm">zk2329403.htm</File>
    <File>cmmb-20221231.xsd</File>
    <File>cmmb-20221231_cal.xml</File>
    <File>cmmb-20221231_def.xml</File>
    <File>cmmb-20221231_lab.xml</File>
    <File>cmmb-20221231_pre.xml</File>
    <File>exhibit_23-1.htm</File>
    <File>exhibit_31-1.htm</File>
    <File>exhibit_31-2.htm</File>
    <File>exhibit_32-1.htm</File>
    <File>exhibit_32-2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cmmb_img01.jpg</File>
    <File>image00017.jpg</File>
    <File>image00018.jpg</File>
    <File>image00019.jpg</File>
    <File>image00020.jpg</File>
    <File>image00021.jpg</File>
    <File>image00022.jpg</File>
    <File>image00023.jpg</File>
    <File>image00024.jpg</File>
    <File>image00025.jpg</File>
    <File>image00026.jpg</File>
    <File>image00027.jpg</File>
    <File>image00028.jpg</File>
    <File>image00029.jpg</File>
    <File>image00030.jpg</File>
    <File>image00032.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="411">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "zk2329403.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 411,
    "http://xbrl.sec.gov/dei/2022": 41
   },
   "contextCount": 82,
   "dts": {
    "calculationLink": {
     "local": [
      "cmmb-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cmmb-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2329403.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cmmb-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cmmb-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cmmb-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 446,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 5
   },
   "keyCustom": 71,
   "keyStandard": 212,
   "memberCustom": 10,
   "memberStandard": 23,
   "nsprefix": "cmmb",
   "nsuri": "http://www.anchiano.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0010 - Disclosure - Other Receivables and Prepaid Expenses",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses",
     "shortName": "Other Receivables and Prepaid Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0011 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.anchiano.com/role/PropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0012 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.anchiano.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0013 - Disclosure - Commitments and Contingent Liabilities",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.anchiano.com/role/CommitmentsAndContingentLiabilities",
     "shortName": "Commitments and Contingent Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0014 - Disclosure - Share Capital",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.anchiano.com/role/ShareCapital",
     "shortName": "Share Capital",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0015 - Disclosure - Research and Development",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.anchiano.com/role/ResearchAndDevelopment",
     "shortName": "Research and Development",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0016 - Disclosure - General and Administrative",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.anchiano.com/role/GeneralAndAdministrative",
     "shortName": "General and Administrative",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0017 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.anchiano.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0018 - Disclosure - Related Parties Balances and Transactions",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions",
     "shortName": "Related Parties Balances and Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0019 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepositsAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0020 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.anchiano.com/role/EventsAfterBalanceSheetDate",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0021 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0022 - Disclosure - General (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.anchiano.com/role/GeneralTables",
     "shortName": "General (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0023 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0024 - Disclosure - Cash and Cash Equivalents (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.anchiano.com/role/CashAndCashEquivalentsTables",
     "shortName": "Cash and Cash Equivalents (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0025 - Disclosure - Other Receivables and Prepaid Expenses (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables",
     "shortName": "Other Receivables and Prepaid Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0026 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.anchiano.com/role/PropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0027 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.anchiano.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0028 - Disclosure - Share Capital (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.anchiano.com/role/ShareCapitalTables",
     "shortName": "Share Capital (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0029 - Disclosure - Research and Development (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.anchiano.com/role/ResearchAndDevelopmentTables",
     "shortName": "Research and Development (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_Per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.anchiano.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_Per_Share",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0030 - Disclosure - General and Administrative (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.anchiano.com/role/GeneralAndAdministrativeTables",
     "shortName": "General and Administrative (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0031 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.anchiano.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0032 - Disclosure - Related Parties Balances and Transactions (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables",
     "shortName": "Related Parties Balances and Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0033 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0034 - Disclosure - General (Narrative) (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.anchiano.com/role/GeneralDetails",
     "shortName": "General (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20210316_usgaapBusinessAcquisitionAxis_cmmbMergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cmmb:NumberOfAdsIssuedAndOutstandingAfterMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20210316",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0035 - Disclosure - General (Schedule of net assets acquired based on their estimated fair value) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails",
     "shortName": "General (Schedule of net assets acquired based on their estimated fair value) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20210316",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "cmmb:SeverancePayPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "cmmb:PercentageOfMonthlyDepositsRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0036 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "cmmb:SeverancePayPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "cmmb:PercentageOfMonthlyDepositsRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0037 - Disclosure - Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails",
     "shortName": "Summary of Significant Accounting Policies (Schedule of Annual rates of Depreciation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cmmb:ScheduleOfAnnualRateOfDeprecationTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0038 - Disclosure - Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
     "shortName": "Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231_srtCurrencyAxis_currencyUSD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cmmb:ReceivablesFromGovernmentInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0039 - Disclosure - Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails",
     "shortName": "Other Receivables and Prepaid Expenses (Schedule of Other Receivables and Prepaid Expenses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cmmb:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
       "cmmb:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cmmb:ReceivablesFromGovernmentInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0004 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.anchiano.com/role/StatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "strong",
       "strong",
       "strong",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0040 - Disclosure - Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Schedule of Property and Equipment, Net) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "strong",
       "strong",
       "strong",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20200510",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0041 - Disclosure - Leases (Narrative) (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.anchiano.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20200510",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0042 - Disclosure - Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails",
     "shortName": "Leases (Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCommitmentsDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0043 - Disclosure - Commitments and Contingent Liabilities (Narrative) (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
     "shortName": "Commitments and Contingent Liabilities (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCommitmentsDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0044 - Disclosure - Share Capital (Narrative) (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.anchiano.com/role/ShareCapitalNarrativeDetails",
     "shortName": "Share Capital (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231_usgaapPlanNameAxis_cmmbTwoThousandsFifteenPlanMember",
      "decimals": "INF",
      "lang": null,
      "name": "cmmb:StockIssuedDuringPeriodAmericanDepositorySharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0045 - Disclosure - Share Capital (Schedule of Share-based Compensation Expenses) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails",
     "shortName": "Share Capital (Schedule of Share-based Compensation Expenses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "USD_Per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0046 - Disclosure - Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails",
     "shortName": "Share Capital (Schedule of Number and Weighted Average Exercise Prices of Option) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "0",
      "lang": null,
      "name": "cmmb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_Per_Share",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_Per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0047 - Disclosure - Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails",
     "shortName": "Share Capital (Schedule of Assumptions Used to Calculate the Fair Value of the Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_Per_Share",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cmmb:ConsultantsAndSubcontractorsExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0048 - Disclosure - Research and Development (Schedule of Research and Development) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails",
     "shortName": "Research and Development (Schedule of Research and Development) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cmmb:ScheduleOfResearchAndDevelopmentTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cmmb:ConsultantsAndSubcontractorsExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalariesAndWages",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0049 - Disclosure - General and Administrative (Schedule of General and Administrative) (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails",
     "shortName": "General and Administrative (Schedule of General and Administrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cmmb:ScheduleOfGeneralAndAdministrativeTableTextBlock",
       "cmmb:GeneralAndAdministrativeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalariesAndWages",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "strong",
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0005 - Statement - Consolidated Statements of Changes in Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.anchiano.com/role/StatementsOfChangesInEquity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "strong",
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0050 - Disclosure - Income Taxes (Narrative) (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.anchiano.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0051 - Disclosure - Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails",
     "shortName": "Income Taxes (Schedule of Significant Components of the Company's Deferred Tax Asset) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0052 - Disclosure - Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails",
     "shortName": "Income Taxes (Schedule of Roll Forward of Valuation Allowance) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "lang": null,
      "name": "cmmb:CurrencyTransactionLossValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0053 - Disclosure - Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails",
     "shortName": "Income Taxes (Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0054 - Disclosure - Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
     "shortName": "Related Parties Balances and Transactions (Schedule of Related Party Payables) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cmmb:ScheduleOfRelatedPartyPayablesTableTextBlock",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20221231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_cmmbRelatedPartyMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0055 - Disclosure - Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails",
     "shortName": "Related Parties Balances and Transactions (Schedule of Transaction With Related Parties) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cmmb:RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0056 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Computation of Basic and Diluted Net Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsPerBasicShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_Per_Share",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0057 - Disclosure - Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails",
     "shortName": "Net Loss Per Share Attributable to Ordinary Shareholders (Schedule of Weighted Average Number of Shares) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20230113_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cmmb:SaleOfStockValueOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0058 - Disclosure - Subsequent Events (Narrative) (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails",
     "shortName": "Subsequent Events (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20230113_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "cmmb:SaleOfStockValueOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0006 - Statement - Statements of Cash flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.anchiano.com/role/StatementsOfCashFlows",
     "shortName": "Statements of Cash flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0007 - Disclosure - General",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.anchiano.com/role/General",
     "shortName": "General",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0008 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0009 - Disclosure - Cash and Cash Equivalents",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.anchiano.com/role/CashAndCashEquivalents",
     "shortName": "Cash and Cash Equivalents",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329403.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 33,
   "tag": {
    "cmmb_AdditionalWorkOrderAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional work order amount.",
        "label": "Additional Work Order Amount",
        "verboseLabel": "Additional work order"
       }
      }
     },
     "localname": "AdditionalWorkOrderAmount",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_AggregateAmountCommitmentToPay": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount commitment to pay.",
        "label": "Aggregate amount commitment to pay"
       }
      }
     },
     "localname": "AggregateAmountCommitmentToPay",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_AggregateAmountOfCommitmentPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of commitment paid.",
        "label": "Aggregate amount of commitment paid"
       }
      }
     },
     "localname": "AggregateAmountOfCommitmentPaid",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_AggregateOfferingPriceOfAtMarketOfferingAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as a aggregate offering price of at the market offering agreement.",
        "label": "Aggregate Offering Price Of At Market Offering Agreement",
        "terseLabel": "Aggregate offering price of at the market offering agreement"
       }
      }
     },
     "localname": "AggregateOfferingPriceOfAtMarketOfferingAgreement",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_AmericanDepositarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depositary Shares [Member]",
        "label": "American Depositary Shares [Member]"
       }
      }
     },
     "localname": "AmericanDepositarySharesMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_AnnualRatesOfDepreciation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual rates of depreciation.",
        "label": "Annual Rates Of Depreciation",
        "verboseLabel": "Annual rates of depreciation"
       }
      }
     },
     "localname": "AnnualRatesOfDepreciation",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_AnnualRentAndManagementFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual rent and management fees.",
        "label": "Annual rent and management fees"
       }
      }
     },
     "localname": "AnnualRentAndManagementFees",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_AtmAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM agreement [Member]",
        "label": "ATM agreement [Member]"
       }
      }
     },
     "localname": "AtmAgreementMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_BankGuaranteesToPropertyOwner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank guarantees to property owner.",
        "label": "Bank guarantees to property owner"
       }
      }
     },
     "localname": "BankGuaranteesToPropertyOwner",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails": {
       "order": 20.0,
       "parentTag": "cmmb_EstimatedFairValueOfNetAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of of asset held for sale recogized prior to the completion of merger.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Asset Held For Sale",
        "verboseLabel": "Asset held for sale"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetHeldForSale",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails": {
       "order": 0.0,
       "parentTag": "cmmb_EstimatedFairValueOfNetAssetsAcquired",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued liabilities to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses",
        "negatedLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_CantorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about Cantor.",
        "label": "Cantor [Member]"
       }
      }
     },
     "localname": "CantorMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_CapitalAdditionsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FDA or equivalent agency marketing approval [Member]",
        "label": "Capital Additions One [Member]",
        "verboseLabel": "FDA or equivalent agency marketing approval [Member]"
       }
      }
     },
     "localname": "CapitalAdditionsOneMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_CashAcquiredInMerger": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash acquired in merger.",
        "label": "Cash acquired in Merger"
       }
      }
     },
     "localname": "CashAcquiredInMerger",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_CashPaidAndReceivedDuringYearForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Cash Paid And Received During Year For [Abstract]",
        "terseLabel": "A. Cash paid and received during the year for:"
       }
      }
     },
     "localname": "CashPaidAndReceivedDuringYearForAbstract",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as a change in temporary differences for which deferred taxes were not recognized.",
        "label": "Change In Temporary Differences For Deferred Taxes Not Recognized",
        "terseLabel": "Change in temporary differences for which deferred taxes were not recognized"
       }
      }
     },
     "localname": "ChangeInTemporaryDifferencesForDeferredTaxesNotRecognized",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_ConsultantsAndSubcontractorsExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultants and subcontractors expenses.",
        "label": "Consultants And Subcontractors Expense",
        "verboseLabel": "Consultants and subcontractors"
       }
      }
     },
     "localname": "ConsultantsAndSubcontractorsExpense",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amounts of grants received from the IIA and recognized by the company, as of the balance sheet date.",
        "label": "Cumulative Amounts Of Grants Received And Recognized",
        "verboseLabel": "Cumulative amounts of grants received"
       }
      }
     },
     "localname": "CumulativeAmountsOfGrantsReceivedAndRecognized",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_CurrencyTransactionLossValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance due to currency transaction loss.",
        "label": "Currency Transaction Loss Valuation Allowance",
        "terseLabel": "Currency transaction income (loss)"
       }
      }
     },
     "localname": "CurrencyTransactionLossValuationAllowance",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share Abstract",
        "label": "Earnings Per Share Calculation Denominator For Basic Net Income Loss Per Share [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareCalculationDenominatorForBasicNetIncomeLossPerShareAbstract",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_EarningsPerShareCalculationNumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share Calculation Numerator Abstract",
        "label": "Earnings Per Share Calculation Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareCalculationNumeratorAbstract",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_EffectOfReverseCapitalizationTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of effect due reverse capitalization transaction.",
        "label": "Effect of reverse capitalization transaction"
       }
      }
     },
     "localname": "EffectOfReverseCapitalizationTransaction",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_EffectOfReverseCapitalizationTransactionShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares isued due to effect of reverse capitalization transaction.",
        "label": "Effect Of Reverse Capitalization Transaction Shares",
        "verboseLabel": "Effect of reverse capitalization transaction (In shares)"
       }
      }
     },
     "localname": "EffectOfReverseCapitalizationTransactionShares",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_EstimatedFairValueOfNetAssetsAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated fair value of the net assets acquired.",
        "label": "Estimated Fair Value Of Net Assets Acquired",
        "totalLabel": "Net acquired assets"
       }
      }
     },
     "localname": "EstimatedFairValueOfNetAssetsAcquired",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_ExpectsToReceiveAmountOfChemomabTherapeuticsInc": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount expects to receive of Chemomab Therapeutics Inc.",
        "label": "Expects To Receive Amount Of Chemomab Therapeutics Inc",
        "terseLabel": "Expects to receive amount of Chemomab Therapeutics Inc"
       }
      }
     },
     "localname": "ExpectsToReceiveAmountOfChemomabTherapeuticsInc",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_FormerChemomabSecurityHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents former Chemomab security holders.",
        "label": "Former Chemomab Security Holders [Member]"
       }
      }
     },
     "localname": "FormerChemomabSecurityHoldersMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_GeneralAndAdministrativeDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of general and administrative expenses.",
        "label": "General And Administrative Disclosure [Text Block]",
        "verboseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeDisclosureTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrative"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Government Sponsored Research And Development [Policy Text Block]",
        "verboseLabel": "Government-sponsored research and development"
       }
      }
     },
     "localname": "GovernmentSponsoredResearchAndDevelopmentPolicyTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information pertaining to income taxes.",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_IncomeTaxExpenseValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance due to income tax expense.",
        "label": "Income Tax Expense Valuation Allowance",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseValuationAllowance",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_IncomeTaxesReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents income taxes received.",
        "label": "Income Taxes Received",
        "verboseLabel": "Income taxes received"
       }
      }
     },
     "localname": "IncomeTaxesReceived",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_IncrementalBorrowingRateOfLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents incremental borrowing rate of leases.",
        "label": "Incremental Borrowing Rate Of Leases",
        "verboseLabel": "incremental borrowing rate of leases"
       }
      }
     },
     "localname": "IncrementalBorrowingRateOfLeases",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmmb_InterestReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest received.",
        "label": "Interest Received",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceived",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_InvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investors [Member]",
        "label": "Investors [Member]"
       }
      }
     },
     "localname": "InvestorsMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_LienOnBankDeposit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lien on bank deposit.",
        "label": "Lien on bank deposit"
       }
      }
     },
     "localname": "LienOnBankDeposit",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_LongTermLeaseDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term lease deposit.",
        "label": "Long Term Lease Deposit",
        "verboseLabel": "Long-term lease deposit"
       }
      }
     },
     "localname": "LongTermLeaseDeposit",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents losses and benefits for tax purposes for the year, for which deferred taxes were not recorded.",
        "label": "Losses And Benefits For Tax Purposes For The Year For Which Deferred Taxes Were Not Recorded",
        "terseLabel": "Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards"
       }
      }
     },
     "localname": "LossesAndBenefitsForTaxPurposesForYearForWhichDeferredTaxesWereNotRecorded",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_MaximumPercentageOfPaymentsOfRoyalties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum percentage of royalties payable on the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR.",
        "label": "Maximum Percentage Of Payments Of Royalties",
        "verboseLabel": "Maximum percentage of payments of royalties (as a percent)"
       }
      }
     },
     "localname": "MaximumPercentageOfPaymentsOfRoyalties",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmmb_MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents Merger Agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company inclued proposed merger of CMB Acquisition Ltd, wholly owned subsidiary of our company.",
        "label": "Merger Agreement With Cmb Acquisition Ltd Subsidiary Of Ours And Chemomb [Member]",
        "verboseLabel": "Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member]"
       }
      }
     },
     "localname": "MergerAgreementWithCmbAcquisitionLtdSubsidiaryOfOursAndChemombMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_NatureOfOperationsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Nature Of Operations Disclosure [Abstract]",
        "verboseLabel": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "NatureOfOperationsDisclosureAbstract",
     "nsuri": "http://www.anchiano.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cmmb_NumberOfAdsIssuedAndOutstandingAfterMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ADS issued and outstanding after the merger.",
        "label": "Number of ADS issued and outstanding after the merger"
       }
      }
     },
     "localname": "NumberOfAdsIssuedAndOutstandingAfterMerger",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfAdssOptionsIssuableOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ADSs options issuable outstanding.",
        "label": "Number of ADSs options issuable outstanding"
       }
      }
     },
     "localname": "NumberOfAdssOptionsIssuableOutstanding",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfAdssVestedAndExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ADSs vested and exercisable.",
        "label": "Number of ADSs vested and exercisable"
       }
      }
     },
     "localname": "NumberOfAdssVestedAndExercisable",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfOptionsIssuableOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of options issuable outstanding.",
        "label": "Number Of Options Issuable Outstanding",
        "verboseLabel": "Number of options issuable outstanding"
       }
      }
     },
     "localname": "NumberOfOptionsIssuableOutstanding",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfOptionsVestedAndExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of options vested and exercisable.",
        "label": "Number Of Options Vested And Exercisable",
        "verboseLabel": "Number of options vested and exercisable"
       }
      }
     },
     "localname": "NumberOfOptionsVestedAndExercisable",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfOrdinarySharesConsistedInDs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the number of ordinary shares consisted in one American depository share (ADS).",
        "label": "Number Of Ordinary Shares Consisted In Ds",
        "verboseLabel": "Number of ordinary shares represented by each ADS (in shares)"
       }
      }
     },
     "localname": "NumberOfOrdinarySharesConsistedInDs",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfStockAdssResveredForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock option ADSs resvered for issuance.",
        "label": "Number Of Stock Adss Resvered For Issuance",
        "verboseLabel": "Number of stock option ADSs reversed for issuance"
       }
      }
     },
     "localname": "NumberOfStockAdssResveredForIssuance",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfStockReservedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of stock resvered for issuance.",
        "label": "Number Of Stock Reserved For Issuance",
        "verboseLabel": "Number of stock reserved for issuance"
       }
      }
     },
     "localname": "NumberOfStockReservedForIssuance",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfVestedAndExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of vested and exercisable.",
        "label": "Number Of Vested And Exercisable",
        "verboseLabel": "Number of vested and exercisable"
       }
      }
     },
     "localname": "NumberOfVestedAndExercisable",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_NumberOfWarrantsPurchaseUpAdss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants purchase ADS's.",
        "label": "Number Of Warrants Purchase Up Adss",
        "verboseLabel": "Number of warrants purchase ADS's"
       }
      }
     },
     "localname": "NumberOfWarrantsPurchaseUpAdss",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_OperatingRightOfUseAssetsAndOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating right-of-use assets and operating lease liabilities.",
        "label": "Operating Right Of Use Assets And Operating Lease Liabilities",
        "verboseLabel": "Operating right-of-use assets and operating lease liabilities"
       }
      }
     },
     "localname": "OperatingRightOfUseAssetsAndOperatingLeaseLiabilities",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_OrdinarySharesNoParValuePerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary Shares, No Par Value Per Share [Member]",
        "label": "Ordinary Shares, No Par Value Per Share [Member]"
       }
      }
     },
     "localname": "OrdinarySharesNoParValuePerShareMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_OtherAccountsReceivableAndPrepaidExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other accounts receivable and prepaid expenses.",
        "label": "Other Accounts Receivable And Prepaid Expenses [Text Block]",
        "verboseLabel": "Other Receivables and Prepaid Expenses"
       }
      }
     },
     "localname": "OtherAccountsReceivableAndPrepaidExpensesTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment on commencement of agreement.",
        "label": "Payment On Long Term Purchase Commitment Commencement Of Agreement",
        "verboseLabel": "Payment on commencement of agreement"
       }
      }
     },
     "localname": "PaymentOnLongTermPurchaseCommitmentCommencementOfAgreement",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_PaymentsForInvestmentInDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payments for investm,ents in deposits.",
        "label": "Payments for Investment in Deposits",
        "negatedLabel": "Investment in deposits"
       }
      }
     },
     "localname": "PaymentsForInvestmentInDeposits",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_PercentageOfMonthlyDepositsRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of monthly deposits rate.",
        "label": "Percentage of monthly deposits rate"
       }
      }
     },
     "localname": "PercentageOfMonthlyDepositsRate",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of royalty payments on sale of product developed with funding received from the IIA.",
        "label": "Percentage Of Royalty Payments On Sale Of Product",
        "verboseLabel": "Royalty payments on sale of product (as a percent)"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsOnSaleOfProduct",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmmb_ProceedsFromSaleOfAdss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of ADS's.",
        "label": "Proceeds from sale of ADS's"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAdss",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_ReceivablesFromGovernmentInstitutions": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government institutions.",
        "label": "Receivables From Government Institutions",
        "verboseLabel": "Government institutions"
       }
      }
     },
     "localname": "ReceivablesFromGovernmentInstitutions",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_ReceivedAmountOfChemomabTherapeuticsInc": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The received amount of Chemomab Therapeutics Inc.",
        "label": "Received Amount Of Chemomab Therapeutics Inc",
        "terseLabel": "Received amount of Chemomab Therapeutics Inc"
       }
      }
     },
     "localname": "ReceivedAmountOfChemomabTherapeuticsInc",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RecoverabilityOfVatAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents recoverability of VAT amount.",
        "label": "Recoverability Of Vat Amount",
        "verboseLabel": "Recoverability of VAT amount"
       }
      }
     },
     "localname": "RecoverabilityOfVatAmount",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party [Member]",
        "label": "Related Party [Member]"
       }
      }
     },
     "localname": "RelatedPartyMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_RelatedPartyCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to professional services.",
        "label": "Related Party Transaction Professional Services From Transactions With Related Party",
        "verboseLabel": "Professional services"
       }
      }
     },
     "localname": "RelatedPartyTransactionProfessionalServicesFromTransactionsWithRelatedParty",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "order": 30.0,
       "parentTag": "us-gaap_RelatedPartyCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to research and develeopment expense.",
        "label": "Related Party Transaction Research And Development Expense From Transactions With Related Party",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_RelatedPartyCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to salaries and related expenses.",
        "label": "Related Party Transaction Salaries And Related Expenses From Transactions With Related Party",
        "verboseLabel": "Salaries and related expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionSalariesAndRelatedExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_RelatedPartyCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party expenses related to share based payments.",
        "label": "Related Party Transaction Share Based Payments From Transactions With Related Party",
        "verboseLabel": "Share-based payments"
       }
      }
     },
     "localname": "RelatedPartyTransactionShareBasedPaymentsFromTransactionsWithRelatedParty",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RentAndMaintenanceGeneralAndAdministrativeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": 50.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and administrative related rent and maintenance expenses.",
        "label": "Rent And Maintenance General And Administrative Expense",
        "verboseLabel": "Rent and maintenance"
       }
      }
     },
     "localname": "RentAndMaintenanceGeneralAndAdministrativeExpense",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RentAndMaintenanceResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development related rent and maintenance expenses.",
        "label": "Rent And Maintenance Research And Development Expense",
        "terseLabel": "Rent and maintenance"
       }
      }
     },
     "localname": "RentAndMaintenanceResearchAndDevelopmentExpense",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RepurchaseArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Repurchase Arrangement.",
        "label": "Repurchase Arrangement [Member]",
        "verboseLabel": "Repurchase Arrangement [Member]"
       }
      }
     },
     "localname": "RepurchaseArrangementMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_RepurchaseOfAmericanDepositaryReceipts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of repurchase of american depositary receipts.",
        "label": "Repurchase Of American Depositary Receipts",
        "verboseLabel": "Repurchase of ADSs"
       }
      }
     },
     "localname": "RepurchaseOfAmericanDepositaryReceipts",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_RepurchaseOfAmericanDepositaryReceiptsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents repurchase of American Depositary Receipts shares",
        "label": "Repurchase Of American Depositary Receipts Shares",
        "verboseLabel": "Number of shares repurchase of ADSs"
       }
      }
     },
     "localname": "RepurchaseOfAmericanDepositaryReceiptsShares",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_SaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Sale Of Stock [Line Items]"
       }
      }
     },
     "localname": "SaleOfStockLineItems",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_SaleOfStockTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Sale Of Stock [Table]"
       }
      }
     },
     "localname": "SaleOfStockTable",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cmmb_SaleOfStockValueOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of sale of stock value of shares issued in transaction.",
        "label": "Sale Of Stock Value Of Shares Issued In Transaction",
        "terseLabel": "Issuance and sale of of ADS upto"
       }
      }
     },
     "localname": "SaleOfStockValueOfSharesIssuedInTransaction",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_SaleOfStocksPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by the company for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stocks Price Per Share",
        "verboseLabel": "Share price per share"
       }
      }
     },
     "localname": "SaleOfStocksPricePerShare",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cmmb_ScheduleOfAnnualRateOfDeprecationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the annual rate of deprecation.",
        "label": "Schedule Of Annual Rate Of Deprecation [Table Text Block]",
        "terseLabel": "Schedule of annual rate of deprecation"
       }
      }
     },
     "localname": "ScheduleOfAnnualRateOfDeprecationTableTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_ScheduleOfGeneralAndAdministrativeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of general and administrative expenses.",
        "label": "Schedule Of General And Administrative [Table Text Block]",
        "terseLabel": "Schedule of general and administrative"
       }
      }
     },
     "localname": "ScheduleOfGeneralAndAdministrativeTableTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of other accounts receivable and prepaid expenses.",
        "label": "Schedule Of Other Accounts Receivable And Prepaid Expenses [Table Text Block]",
        "verboseLabel": "Schedule of other accounts receivable and prepaid expenses"
       }
      }
     },
     "localname": "ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_ScheduleOfRelatedPartyPayablesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party payables.",
        "label": "Schedule Of Related Party Payables [Table Text Block]",
        "terseLabel": "Schedule of related party payables"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyPayablesTableTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_ScheduleOfResearchAndDevelopmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of research and development expenses.",
        "label": "Schedule Of Research And Development [Table Text Block]",
        "terseLabel": "Schedule of research and development"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentTableTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents security holders of Anchiano as of immediately prior to the merger.",
        "label": "Security holders of Anchiano as of immediately prior to the merger [Member]"
       }
      }
     },
     "localname": "SecurityHoldersOfAnchianoAsOfImmediatelyPriorToMergerMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_SeverancePayPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for severance pay.",
        "label": "Severance Pay [Policy Text Block]",
        "verboseLabel": "Severance pay"
       }
      }
     },
     "localname": "SeverancePayPolicyTextBlock",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Forfeitures In Period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Ads Forfeitures In Period",
        "verboseLabel": "Options to purchase ordinary shares cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsForfeituresInPeriod",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents Share Based Compensation Arrangement By Share Based Payment Award ADS Outstanding Period Increase Decrease Weighted Average Exercise Price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Ads Outstanding Period Increase Decrease Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price of ADSs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cmmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants In Period, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cmmb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of shares acquired in merger.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award, Options, Acquired In Merger, Weighted Average Exercise Price",
        "terseLabel": "Acquired in Merger"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAcquiredInMergerWeightedAverageExercisePrice",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cmmb_ShareBasedCompensationGeneralAndAdministrativeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and administrative related share-based compensation.",
        "label": "Share Based Compensation General And Administrative Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationGeneralAndAdministrativeExpense",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_ShareBasedCompensationResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "order": 30.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development related share-based compensation.",
        "label": "Share Based Compensation Research And Development Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationResearchAndDevelopmentExpense",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_ShareholdingPercentageImmediatelyFollowingMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "shareholding percentage immediately following the merger.",
        "label": "Shareholding percentage immediately following the merger"
       }
      }
     },
     "localname": "ShareholdingPercentageImmediatelyFollowingMerger",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cmmb_StockAndWarrantsIssuedDuringPeriodNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "it represents number of shares and warrants issued during period",
        "label": "Stock And Warrants Issued During Period New Issues",
        "verboseLabel": "Issuance of shares and warrants, net of issuance costs (In shares)"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodNewIssues",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_StockAndWarrantsIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock And Warrants Issued During Period Value New Issues",
        "verboseLabel": "Issuance of shares and warrants, net of issuance costs"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_StockIssuedDuringPeriodAmericanDepositorySharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stocks of American Depository Shares (\"ADS\") issued during the period.",
        "label": "Stock Issued During Period American Depository Shares New Issues",
        "verboseLabel": "Number of ADSs issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodAmericanDepositorySharesNewIssues",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options acquired, including both vested and non-vested options.",
        "label": "Stock Issued During Period Shares Stock Options Acquired In Merger",
        "verboseLabel": "Acquired in Merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsAcquiredInMerger",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_StockIssuedDuringPeriodSharesStockOptionsExercised1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised 1",
        "negatedLabel": "Exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised1",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cmmb_TaxAssetsAcquiredThroughMergerValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance due to tax assets acquired through merger.",
        "label": "Tax Assets Acquired Through Merger Valuation Allowance",
        "verboseLabel": "Tax assets acquired through merger"
       }
      }
     },
     "localname": "TaxAssetsAcquiredThroughMergerValuationAllowance",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents Total consideration of repurchase of american depositary receipts.",
        "label": "Total Consideration Of Repurchase Of American Depositary Receipts",
        "verboseLabel": "Total consideration of repurchase of ADSs"
       }
      }
     },
     "localname": "TotalConsiderationOfRepurchaseOfAmericanDepositaryReceipts",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cmmb_TwoThousandsFifteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 plan [Member]",
        "label": "Two Thousands Fifteen Plan [Member]",
        "verboseLabel": "2015 plan [Member]"
       }
      }
     },
     "localname": "TwoThousandsFifteenPlanMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_TwoThousandsSeventeenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 plan.",
        "label": "Two Thousands Seventeen Plan [Member]",
        "terseLabel": "2017 plan [Member]"
       }
      }
     },
     "localname": "TwoThousandsSeventeenPlanMember",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cmmb_WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents weighted average price of repurchase of american depositary receipts.",
        "label": "Weighted Average Price Of Repurchase Of American Depositary Receipts",
        "verboseLabel": "Weighted average price of repurchase of ADSs"
       }
      }
     },
     "localname": "WeightedAveragePriceOfRepurchaseOfAmericanDepositaryReceipts",
     "nsuri": "http://www.anchiano.com/20221231",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "country_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel [Member]"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro [Member]"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_ILS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILS [Member]",
        "terseLabel": "NIS [Member]"
       }
      }
     },
     "localname": "ILS",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "USD [Member]"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_XXX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other currencies [Member]"
       }
      }
     },
     "localname": "XXX",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Name of Exchange on which Security is Registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r221",
      "r322",
      "r341",
      "r363",
      "r364",
      "r372",
      "r376",
      "r382",
      "r426",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r221",
      "r322",
      "r341",
      "r363",
      "r364",
      "r372",
      "r376",
      "r382",
      "r426",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r219",
      "r221",
      "r250",
      "r251",
      "r252",
      "r321",
      "r322",
      "r341",
      "r363",
      "r364",
      "r372",
      "r376",
      "r382",
      "r423",
      "r426",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r219",
      "r221",
      "r250",
      "r251",
      "r252",
      "r321",
      "r322",
      "r341",
      "r363",
      "r364",
      "r372",
      "r376",
      "r382",
      "r423",
      "r426",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r222",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r153",
      "r222",
      "r398",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r373",
      "r381",
      "r428"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r347",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r373",
      "r381",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r153",
      "r222",
      "r398",
      "r399",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r421",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails",
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r0",
      "r13"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DueToRelatedPartiesCurrent",
       "weight": 1.0
      },
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r92",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Recognized liability for royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r53",
      "r120"
     ],
     "calculation": {
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less - accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r8",
      "r380"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r415",
      "r416",
      "r417",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "verboseLabel": "Additional paid in capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r58",
      "r59",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Exercise of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based compensation expenses"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Outstanding options to purchase ordinary shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r90",
      "r100",
      "r121",
      "r137",
      "r178",
      "r180",
      "r182",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r285",
      "r289",
      "r294",
      "r380",
      "r424",
      "r425",
      "r466"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r116",
      "r126",
      "r137",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r285",
      "r289",
      "r294",
      "r380",
      "r424",
      "r425",
      "r466"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r137",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r285",
      "r289",
      "r294",
      "r424",
      "r425",
      "r466"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of presentation",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r283",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r79",
      "r80",
      "r283",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails": {
       "order": 30.0,
       "parentTag": "cmmb_EstimatedFairValueOfNetAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails": {
       "order": 10.0,
       "parentTag": "cmmb_EstimatedFairValueOfNetAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Prepaid and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralScheduleOfNetAssetsAcquiredBasedOnTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalAdditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to increase property, plant and equipment either through construction or future purchases.",
        "label": "New Drug Application and Biological License Application [Member]"
       }
      }
     },
     "localname": "CapitalAdditionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r36",
      "r118",
      "r366"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r37",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r31",
      "r36",
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r31",
      "r85"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r137",
      "r156",
      "r157",
      "r159",
      "r161",
      "r168",
      "r169",
      "r186",
      "r202",
      "r205",
      "r206",
      "r207",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r294",
      "r365",
      "r397",
      "r412",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r93",
      "r104"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingent liabilities"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments and Contingent Liabilities"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r415",
      "r416",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Ordinary shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r380"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2021 and 500,000,000 shares as of December 31, 2020; Issued and outstanding: 228,090,300 shares at December 31, 2021 and 9,274,838 shares at December 31, 2020",
        "terseLabel": "Ordinary Shares no par value - Authorized: 650,000,000 shares as of December 31, 2022 and 2021; Issued and outstanding: 232,636,700 Ordinary shares at December 31, 2022 and 228,090,300 Ordinary shares at December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred taxes"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computers [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r99",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of credit risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Incremental borrowing rate based on credit rating"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r78",
      "r457"
     ],
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Research and development costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r78",
      "r457"
     ],
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carry-forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r78",
      "r457"
     ],
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "order": 30.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r78",
      "r457"
     ],
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Share-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less - valuation allowance",
        "periodEndLabel": "Balance at December 31",
        "periodStartLabel": "Balance at January 1"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfRollForwardOfValuationAllowanceDetails",
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfSignificantComponentsOfCompanysDeferredTaxAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Short-term bank deposit"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r34",
      "r51"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r13",
      "r204",
      "r205",
      "r206",
      "r210",
      "r211",
      "r212",
      "r315",
      "r414"
     ],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "totalLabel": "Related Party Payables"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r133",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r154",
      "r156",
      "r159",
      "r160",
      "r161",
      "r165",
      "r292",
      "r293",
      "r336",
      "r339",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic and diluted loss per Ordinary Share",
        "terseLabel": "Basic loss per Ordinary Share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r133",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r156",
      "r159",
      "r160",
      "r161",
      "r165",
      "r292",
      "r293",
      "r336",
      "r339",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per Ordinary Share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings per ordinary share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Net Loss Per Share Attributable to Ordinary Shareholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r138",
      "r263",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Corporate tax rate (as a percent)",
        "terseLabel": "Corporate tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DueToRelatedPartiesCurrent",
       "weight": 1.0
      },
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r59",
      "r114",
      "r130",
      "r131",
      "r132",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r167",
      "r187",
      "r218",
      "r255",
      "r256",
      "r257",
      "r273",
      "r274",
      "r291",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r311",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Functional currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Equipment [Member]",
        "terseLabel": "Furniture and equipment [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative",
        "terseLabel": "General and administrative",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralInsuranceExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": 40.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).",
        "label": "Insurance"
       }
      }
     },
     "localname": "GeneralInsuranceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r21",
      "r88",
      "r95",
      "r109",
      "r178",
      "r179",
      "r181",
      "r183",
      "r337",
      "r371"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedLabel": "Loss before income tax",
        "negatedTotalLabel": "Loss before taxes",
        "positiveTerseLabel": "Loss before income taxes",
        "positiveVerboseLabel": "Loss before taxes",
        "totalLabel": "Loss before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r20",
      "r94",
      "r96",
      "r106",
      "r133",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r156",
      "r159",
      "r160",
      "r293",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per share attributable to ordinary shareholders, basic and diluted",
        "terseLabel": "Net loss per share attributable to ordinary shareholders, basic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r20",
      "r106",
      "r108",
      "r133",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r156",
      "r159",
      "r160",
      "r161",
      "r293",
      "r336",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Net loss per share attributable to ordinary shareholders, diluted"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r190",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r138",
      "r264",
      "r265",
      "r271",
      "r275",
      "r278",
      "r280",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r139",
      "r151",
      "r152",
      "r177",
      "r262",
      "r276",
      "r279",
      "r340"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "positiveTerseLabel": "Taxes on income (benefit)",
        "positiveVerboseLabel": "Actual income tax expense (Benefit)",
        "verboseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails",
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Theoretical tax benefit on the above amount Decrease (increase) in tax refund resulting from:"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r129",
      "r260",
      "r261",
      "r265",
      "r266",
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Tax rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Theoretical tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesScheduleOfReconciliationOfTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "negatedLabel": "Income taxes paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 40.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Change in trade payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 50.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Change in accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 60.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Change in employees and related expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r410",
      "r462"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 70.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Change in leases",
        "terseLabel": "Change in operating leases"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Change in other receivables and prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "2020 Lien [Member]"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease expiry date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of Maturity of Lease Liabilities Under Our Non-cancelable Operating Leases",
        "terseLabel": "Schedule of maturity of lease liabilities under our non-cancelable operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lease term, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r14",
      "r137",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r286",
      "r289",
      "r290",
      "r294",
      "r370",
      "r424",
      "r466",
      "r467"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r12",
      "r91",
      "r102",
      "r380",
      "r413",
      "r422",
      "r459"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities assumed, net of non-cash assets received in Merger",
        "verboseLabel": "Liabilities assumed, net of non-cash assets received in Merger"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r117",
      "r137",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r286",
      "r289",
      "r290",
      "r294",
      "r380",
      "r424",
      "r466",
      "r467"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r137",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r286",
      "r289",
      "r290",
      "r294",
      "r424",
      "r466",
      "r467"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.",
        "label": "Payment for licensed agreement"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of items purchased under a long-term purchase commitment.",
        "label": "Category of Item Purchased [Axis]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the terms of a significant arrangement with a supplier (excluding an unconditional purchase obligation) to acquire goods or services over a period of time beyond one year or the normal operating cycle, if longer, which may include identification of the goods or services to be purchased, pricing, effects on pricing of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.",
        "label": "Description of application payment for licensed product"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r170",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "General"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/General"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r31",
      "r32",
      "r35"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r35",
      "r97",
      "r107",
      "r115",
      "r127",
      "r128",
      "r132",
      "r137",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r151",
      "r152",
      "r158",
      "r178",
      "r179",
      "r181",
      "r183",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r293",
      "r294",
      "r371",
      "r424"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss for the year",
        "negatedLabel": "Net loss",
        "negatedTotalLabel": "Net loss for the year"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant non- cash transaction:",
        "terseLabel": "B. Significant non- cash transaction:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoninterestExpenseDirectorsFees": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": 30.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits.",
        "label": "Fees to Directors"
       }
      }
     },
     "localname": "NoninterestExpenseDirectorsFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Financing (income) expenses, net",
        "terseLabel": "Financing expenses (income), net",
        "totalLabel": "Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficersCompensation": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salaries and related expenses"
       }
      }
     },
     "localname": "OfficersCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Decrease in the carrying amount of the right-of-use asset due to impairment",
        "terseLabel": "Increase in the carrying amount of the right-of-use asset due to impairment"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Operating Lease, Liability, Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails",
      "http://www.anchiano.com/role/LeasesScheduleOfMaturityOfLeaseLiabilitiesUnderOurNon-cancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Non-current operating lease liabilities",
        "verboseLabel": "Non-current\u00a0operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/LeasesNarrativeDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the nature and terms of commitment.",
        "label": "Decsription of occurrence for payments"
       }
      }
     },
     "localname": "OtherCommitmentsDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": 60.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "verboseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "order": 40.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Other expenses"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Treasury share at cost"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred shares par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r6",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Other receivables and prepaid expenses",
        "totalLabel": "Other accounts receivable and prepaid expenses, Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r125",
      "r188",
      "r189",
      "r367"
     ],
     "calculation": {
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/OtherReceivablesAndPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Long-term prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "The Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from preferred shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the issuance of equity classified as other.",
        "label": "Proceeds from Other Equity",
        "verboseLabel": "Issuance of shares and warrants, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the sale of other assets recognized in investing activities.",
        "label": "Sale of asset held for sale"
       }
      }
     },
     "localname": "ProceedsFromSaleOfOtherAssetsInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r69"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional services"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r115",
      "r127",
      "r128",
      "r134",
      "r137",
      "r143",
      "r151",
      "r152",
      "r178",
      "r179",
      "r181",
      "r183",
      "r186",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r284",
      "r287",
      "r288",
      "r293",
      "r294",
      "r337",
      "r371",
      "r377",
      "r378",
      "r406",
      "r424"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Loss before taxes",
        "verboseLabel": "Net loss for the year"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "verboseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r56",
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r52",
      "r119"
     ],
     "calculation": {
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r54",
      "r103",
      "r338",
      "r380"
     ],
     "calculation": {
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Property Plant And Equipment Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r54",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.",
        "label": "Annual rates of depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentSalvageValuePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of Property And Equpment, Net",
        "terseLabel": "Schedule of property and equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyCosts": {
     "auth_ref": [
      "r24",
      "r204",
      "r205",
      "r206",
      "r210",
      "r211",
      "r212",
      "r414"
     ],
     "calculation": {
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.",
        "label": "Related Party Costs",
        "totalLabel": "Total related party expenses"
       }
      }
     },
     "localname": "RelatedPartyCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfTransactionWithRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r220",
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r220",
      "r314",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r312",
      "r313",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Parties Balances and Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r72",
      "r112",
      "r474"
     ],
     "calculation": {
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.anchiano.com/role/StatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopmentScheduleOfResearchAndDevelopmentDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research and Development"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ResearchAndDevelopment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r400",
      "r411"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r349",
      "r401",
      "r411"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestments": {
     "auth_ref": [
      "r348",
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.",
        "label": "Bank restricted deposit"
       }
      }
     },
     "localname": "RestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r60",
      "r101",
      "r345",
      "r346",
      "r380"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r114",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r187",
      "r255",
      "r256",
      "r257",
      "r273",
      "r274",
      "r291",
      "r342",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Accumulated deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r308",
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-use asset recognized with corresponding lease liability",
        "verboseLabel": "Right-of-use asset recognized with corresponding lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royality expenses"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold",
        "verboseLabel": "Salaries and related expenses"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralAndAdministrativeScheduleOfGeneralAndAdministrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Weighted Average Number of Shares Excluded From Computation of Diluted Net Loss Per Share",
        "terseLabel": "Schedule of weighted average number of shares excluded from computation of diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of components of cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Summary of the effect of share-based compensation on the statements of operations",
        "terseLabel": "Schedule of the effect of share-based compensation on the statements of operations"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Significant Components of the Company's Deferred Tax Asset",
        "terseLabel": "Schedule of significant components of the company's deferred tax asset"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Computation of Basic and Diluted Net Loss Per Share",
        "terseLabel": "Schedule of computation of basic and diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense",
        "terseLabel": "Schedule of reconciliation of theoretical income tax expense to actual income tax expense"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalShare-basedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails",
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of net assets acquired based on their estimated fair value"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsScheduleOfRelatedPartyPayablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Transaction With Related Parties",
        "terseLabel": "Schedule of transaction with related parties"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/RelatedPartiesBalancesAndTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Summary of assumptions used to calculate the fair value of the options",
        "terseLabel": "Schedule of assumptions used to calculate the fair value of the options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Summary of number and weighted average exercise prices of option",
        "terseLabel": "Schedule of number and weighted average exercise prices of option"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r402",
      "r403",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Exercise price (in U.S. dollar)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life in Years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Options to purchase ADS cancelled",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails",
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r229",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end",
        "periodStartLabel": "Outstanding at the beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the weighted average exercise price of options outstanding.",
        "label": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r229",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end",
        "periodStartLabel": "Outstanding at the beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Exercise"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r228",
      "r247",
      "r248",
      "r249",
      "r250",
      "r253",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Weighted average share price (in U.S. dollar)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of options (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfAssumptionsUsedToCalculateFairValueOfOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalSummaryOfNumberAndWeightedAverageExercisePricesOfOptionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r64",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Share Capital"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapital"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r43",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Website Development [Member]",
        "terseLabel": "Website development [Member]"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/PropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r137",
      "r156",
      "r157",
      "r159",
      "r161",
      "r168",
      "r169",
      "r186",
      "r202",
      "r205",
      "r206",
      "r207",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r294",
      "r365",
      "r397",
      "r412",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/DocumentDocumentAndEntityInformation",
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r19",
      "r59",
      "r114",
      "r130",
      "r131",
      "r132",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r167",
      "r187",
      "r218",
      "r255",
      "r256",
      "r257",
      "r273",
      "r274",
      "r291",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r311",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r167",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/CashAndCashEquivalentsDetails",
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfWeightedAverageNumberOfSharesDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r7",
      "r59",
      "r60",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of Options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r7",
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Treasury share at cost (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r59",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r6",
      "r7",
      "r60",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r59",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of Options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r6",
      "r7",
      "r59",
      "r60",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Treasury share at cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r49",
      "r380",
      "r413",
      "r422",
      "r459"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets",
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' equity:",
        "terseLabel": "Shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Reverse stock split conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/GeneralDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r301",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r301",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r301",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r301",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/EventsAfterBalanceSheetDateNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r318",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Events After Balance Sheet Date"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/EventsAfterBalanceSheetDate"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/ShareCapitalNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Schedule of Roll Forward of Valuation Allowance",
        "terseLabel": "Schedule of roll forward of valuation allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplementary cash flows information:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Capital losses carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r18",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "verboseLabel": "Treasury share [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r18",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r18",
      "r62",
      "r63"
     ],
     "calculation": {
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury share at cost (11,640,460 shares as of December 31, 2022)",
        "terseLabel": "Treasury stock (11,640,460 shares as of December 31, 2022)"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r171",
      "r172",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Net change in the total valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r155",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of Ordinary Shares outstanding, diluted",
        "verboseLabel": "Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r154",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of Ordinary Shares outstanding, basic",
        "verboseLabel": "Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.anchiano.com/role/NetLossPerShareAttributableToOrdinaryShareholdersScheduleOfComputationOfBasicAndDilutedNetLossDetails",
      "http://www.anchiano.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org/subtopic&trid=2197926",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r383": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r384": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r385": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r386": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r387": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r388": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r389": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r391": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r392": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r393": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r394": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r395": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r396": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001178913-23-001041-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-23-001041-xbrl.zip
M4$L#!!0    ( %8Q=%8Z!?H) !0  %S<   1    8VUM8BTR,#(R,3(S,2YX
M<V3M75]SV[@1?^^G8/W2ZTP5Q\[EVF22ZRBQG7K&L3RVTER?.A )29Q0@ X
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MIE2@1&U?B?+]@!#!:3FUM@^3HZBD)SI=TI3+ 22_BN<"8W(G<UG!GQUT_9I
M-86%& [Q4JN6LE^*588S^4G_K8UZ/S9_]*CIW2D/EW(<_?/_ %!+ P04
M" !6,71687*X(3H-  #*M0  %0   &-M;6(M,C R,C$R,S%?8V%L+GAM;.4=
M77/:NO+]_ HN]YE2Z/EH.\TYDZ_V,I,VF22][7WR*$: YAB)*]E)Z*\_*X.#
M#9(MV8YLIT\AH)5V5ZO]TDKZ\-?C,NC=8RX(HT?]T:O7_1ZF/IL2.C_J1^%L
M\+;_UY^_? @(_?L."=R#YE0<]1=AN'H_'#X\/+QZO./!*\;GP_'KUV^&2</^
MIN7[1T$RK1_>)&U'P^^?+V[\!5ZB :$B1-3?0<EN5'"C=^_>#>-?H:D@[T4,
M?\%\%,8$%.+5T[:0_PV29@/YU6 T'KP9O7H4T_Z?O_1Z'_XU&/0F7V[//TV^
M]^[6O?,?@^\GUQ>]P2#^E;, 7^-9+\;N?;A>X:.^(,M5(*F*OUMP/#OJ^\OE
M'70_'H_&F\[_?1.B$"\Q#4\9%2P@4_AW>H("R9&;!<:AZ/=D[U^O)QD*X?<%
M092]\MER*!L,#7H:UH6LN)Q=KC"/&6^/8!:Z3J1.D5A\#-A#*9QVP%51^H0I
MD!=( 9]& ;Z<?<'AL1 P!<?^_R/"Y;P(/+VDMPM,^+D(R5).UD=$^']1$.$S
M'"(2&!-1UW!5R;X,%YA?8Q^3>W078'%,IU<<KQ"9GC^N,!586!)FWF%5U*\X
M XD,US#".;!L)44"N&B);T$O59&\P#"-8C?-GU$8<1*N+V?Q+Q<$W9& A 2+
MKW2*^67$OS Z\*4"""3_MHN.SC<=61+W3*-79<HU%AAQ?P$\/\/W.& QUW=H
MJG^WI+W:(#6I$^C\>+HDE(A0,O(>[\;7M2BG2"H,5)74"?@?2WR+'M.2=D/F
ME,P(B!+8MN6*T:V^AL^(KD&29IB#D@.H6.M9$EWGD-6%.9":^0IQN8ZVQENJ
MO5N.J$!^;#'38O?4?'V%UK&.M);LVD9T3'SJVV\D7&2AGY<+1D-OV.&CP(^"
MV-6Y .(S;,&/(095.4T8(U&I[N3)86'@@/F9P0+I)S.>G00YEH#!8F]XAL1=
M[!)'8C!':#64LS/$02B2;^+YBN=J^X6W<3.23D'/XR >RLLV\%YOV.$8K],(
M%BD-"]';MO-&CK&4'B<(F?PC_85[%$@U<QR>(L[78"EC[RP'>R-XYU1E733
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M(!* "%MM9JK?>\ R]CKJCUI"4PIG-6FFV:H71+)9,BLA>/0"*-:EOA(:QR^
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MM/-BEA;3MEP%VOD34YUI6^("W5/.5&S:ELI ^Y0S-9RV93AH@OQ('RK*:6#
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M$5@[FK?]N=](6='1/'L!O9^4NGN2KGJS=Y:"O0P(T(ZF$Q_:?ZAUPVPI ,O
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MPXC@T_EUD<<K]8VM>0L VHY.= O:4C@)QZ MZ;@BCPB)R_,B7[ OZ/:5\M(
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MVK%A'H )E*[H:5M>T&ZLJB*Y7U74LRO'@#BXA\Y30/$@[FZ,1LKFAZ"GG-L
MK[:GG-L4.P2N\HKLQ;Q=$9@XMRZD@%BNPV6:5"=Y!AM#3+MQ@_L(K;=*SZ:
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M1HONII] 3PZ#!!2TR%](&F-2L# ETO&\>VSO*-#>PEK!(U0+YGD1E% 1U@:
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M3X^HIX!4ZC6=,I*IL$\GZ)\!T]3%;*C')O&,"/VCXM2E0^1S?LTK3OJ.N [
M(;_/J\=V0M,LS][R'WFUT<BY03_T%'0NU*R$N S?/;P;F:@;],/83]I,B8GS
MP_A=5_9X]GJ9#^&;7+Q^7F5)57Y;WSUN+./1JJ"O38=8SGLDB=JG,V1R+OX\
MWNG:(B ]?.@Y4>OF@G?>)/DN?.$I4?GLNGLL\M7#(YM@:)2Q$W7<;2O3S4_J
MQ[6)\#5X$_-[]V_%F_LGT580BL9 F FU^\.7.I6JF.05P^'M)*-WQ\A$&AJI
M4^0*8KP=OH0%=4M!W92OY;HW9=DDN.L<2W^RGE=A>@(S+XEIKMX\0U_SO<,^
M;3I2T<9QQ]FT/O804 ?TAU38:0]LM,<>'HP]6M0!_2"= 2:2X-5UZ.XYOWO,
M5R7&Q#M/YNCS<@T4-(\-WO_P[J=@";_REPI##UHJD,]Y4%<)>)W@>F@61B*G
M)2.3*C<CT%M\T,,],Q.@GRE\#\M<!]QNT:EK#2\\W2X/7704PO/S2(1GR\&"
M.E985,//2F^A,6OB@SI%)K\[SCHL8M2K4,<'=8:1)Z]")JSK9+--]*I\^Q"&
MR]DD@NFSHBX)+))(0B<2_#LEU.[.,,E;427_H+^_+G+8^%=KG/H8Z/<,C&UZ
M/RX/M4?*,GB+S\/$-WB4D62P^W&5Q%OG*YL K<:#=NM'0=T^/2YL?^$H$-\X
MH@M]Q=R"ZP]YE(U3,B<%[LC$%LUP9\Z'7;+W'F+$V4'466:%CFQ4C\.4!7NJ
M\#$#"^W\89##$T;E%M:6R@89V;+4(O/_A-D*E]Y!J'3-0Q/\'R3X1;V@.>4X
M&OPXH]^TN<BB?$$N\Y*FG$!_ZR1;)=G#=,DW9N4QF><%8>7N,,+GV4M5A.(-
M&0V9>95G]"(Y3^$S#Q=@;P%BQ2H+7PKN:9-X% 9MXMG6@!U ]YH^>T$V2]N]
M4&%K@TQ0U/P8H4AG,+OH =G4ELO!L!WQF]ZT<M$5LE7"B3!T+7%#DOY1MB=A
M8_X&O_@M2RC>?#1HOBHZAI>G'SX*-C\4B"\-LMWTO7[\Y%QD]M$@E--UF,17
M1)%VN#7) PSIY$_*-[#*EN>VL 58$"2.#"-=YFOS!FJI\\^@/=Q;*#;>EEYD
M/$B8,(FXBS+L4EA<,6H<207GY!%?JM!0XS126!,@K'06(<Q KO:AJY ]?C]X
MVKX?W H11YGSH'*T+8]CC3LH0OA2ESU<(N;+A.>T_I)A&"F\_,1.B*"H)C4Y
MW8LEBR5U1TSX OAG'P.Z'R>IJ4=;.@KJM@+:V%%0-W<4M!L,6(M#I#'O-ZRP
MS#1J3>Z;0:H@A3_ZMMXWD<H&02"E;Z+QJAW?-_N0JTVH4G^UP:'V%(,\RX7H
M,NBZET3G+#4%2/D;9M5_6Z_+U/G42Y\K&4A%I55:6)UO>(5!/,V-3  U!YD,
M-:-0YPP5PS'8*!C9R6H:LHV1=BB.F#^!QYDA<G7RX.S"]_H$7:KE\>A0G:]$
MW!T\U4+W:Q]30@M=-BOJ[*JYB)A?NYJ?6'<AWV\8[G+NE-/OV/^Z=;VQY#6I
M=44&.=3N.4 &I+3#5>7"K6J\)_>'AI(P#<#&RPWC_=TUH$.0E(V\+-X7QI\:
M)L97OX$6ZU^3RZ+',AF\>??NZ..//QS]^/&'^FT+78]:]QQ'P?L?WK\?1$UW
M#;"$G-1M0I"CY=AM@/O($!K04G^M>D3HTN]Y)(SOT$["\A'_AXO<4Y@2&K>\
MK(HD F'%/]#4].U?M$K*SR*@S!',I?*1J@=>E*>D%PVQOX/8$O@U?YXWU'ZC
MQR7<8;TAD^5^O7%/'I*,QC :N$^Z9NIA'2&;'ZPC\/\'K:)'0=,*^R/VS/;O
M6A6\3I9#%50KO!Q[LR&=0.W@>R 3[#GK( JYQ\RP3UVJF7>IUU/B-5HDNZR[
MPDT<&BBM]<6C@'WSCS)E>L?\^J-/I-[1O?[ TZMWQ*W!)IV'"&?]9F.[VZ3S
MYHQ)R#WW+'J3#!I%HN_<V8 O=>^JC2A'#(S$? .VU$!B"6?YGH?5V1 MOY*#
ML'@^!#3'JK6!Z/@6EUW,1O+B149VL2H?A_)B?PI8P6#"\\32#"Q5CBF%!CJ2
M,SK EE"1G5RS!TYU4"I*B-#B(W'TN@M?^$'Z,<G(/)&?C3('")BXW$/KS3TK
M/,Q:N8^7UBX/N:LSC9?;^)F)>Y'@S?& C+KFA8J"QKD#'4G/7&#O>(;014$V
M*1K_E(#+D=-7)'B=7JQG%Y=R]Z2R".'K7M[N<61?;J7(OGQW^YT?7#1X0K2>
MG7VYD2O$59'[179Q*>\S^+W'-VAM=-(KYHMAT75VVY?;4[FHW9[Z!?;7O_Y5
MOMNEGDZ\6(*I!#V@C$DRF\ >*<9]TGD:RC<8=8D BSC'MXHQ,M)Y4BPNY+=@
MO$2 18(+IW=A+8"7.4O>K(4H"GG">!4N%,$\.#XLX!K;"=B0DX*$)WDL!W="
MK68H$6 1Y_!8P)WSI(S"]&\D+&#3=!I6"J@\.@\K'6#QX RC[D(%U\!/^<M<
MGJV<YL20)Y/C!>LD[+2H+[BLZ]A]\#G\3GYM56/F/<U#[M *?I'CF)OCIA+B
M%?5%QK*KP*ITF62$^NWKH;=J!'_'.@&MY%QS21C0?*$]T-/RWH!?B^,<Y7I2
MH^;R[7LMN2O"#/>T&*:[>SUI2GM>4^Z@]0ZH4,(UNC,:]782QP7Z6[/_X'22
MAXUCI0->[DC\(Z 3<)J-!OW[_NCOGG.OZ-' F!9W^;/<>-O&3NT1,):P@E_<
M?)MM!)J5]8KW.B^K,/W?R5)IZFVC9C4"J.+%]F-P3@BF;$HOLIB\_!?1=C<O
M&M"R 13VA)A>3M"37=,[) 9?<JDQ])V& 1MF5#,5 BANJ[!2F%>"!S?#ZRH!
MJ^,'_QF&P ,0GXK\N7K$V\LPTTJ1J!"P&@&OX@G]2Z/&-:ZH OI+6^L/EXRV
M&_=YDA*-VP['BZ4&=+PP@UF<@$GWD.M7<EHP$"7]@,7S[@*F%+6><4H1KE:Z
M%O2-BD=T-F+27J&5/"[NK>W .?R#%)?D(4RGQ0UY2$I\KA<K#TUJ;G4+1P%K
M(Z"-(,&F&2]G*X(C( @CO(J"S4/(5T<]I[H&[C="L:+ZP7^]ND^3Z#S-0RUH
M5BR@Y?P 9:.-B0FZA*8IZ5$N;A])FAKH(UK.KQ:Z781I>KPJ8;N@>+HIL&+!
M0)3T _8N?+F(,:?)/&''O=UZ"&]!-^MXU4J_Y2DLS&'!U).VP^NB3$-YZO*O
M(*'_E<&&[):$99Z1F$;DUG8Y5@EHG4!48G&\G??Y130O^ G\I*I(R8(IJN]C
M^&%]JZR7FQF\S$BO'Z'C-/)-"P6TE">)OBX([FM(%E$O03;$=P0S 4WG<P5L
MJ/0V:M7BDA&P>@&MZ)E(;PH^L=^2:%7 K'OW_OXNJ11GM/0O^);BW?LW]]\&
MHHXOK&<O$0W4H=3E^ >$*PJB7]'S8Q(]UM Q4U5C CHGDH,]E.#^]S/8VT42
MIE(:3;% E'.-%/:,>+YPNU[<YW*0O$3 BKC&]Q4&LR(93K]5QA6T7"ORDL%F
M49=XRZ+BEY;1>O*2*)Y]\0+!W[&(TQL0Q/<Y?$D6JX4F=C0OX<4M@B),LBZ$
MK(0WA#>XY"@'&+?8L.PDJ'T_T[>.3 GX&>_;B&1AD>2P/2916%::;A5%O/6K
MP/HE*Y<D GN<Q*?Y(DSDEP.B=/!W5L@]7#Q+P:']1/*'(EP^XI KQ:)=R)<L
M","BZ]0R7/>M%Z#4')G.+[(X>4KBE:97:\.E*>L!<RO&,AZK84XCJME).;G'
MLX9(?GK2% ]$>0#/:_@D4%Z':[R?1]5/=(=6M$"P9*6]1$L#Q,6*Q"( %G2A
M#B\O[36^&\=PDZ_#M(5WDL48M%$#_H9$^4.6_ /PIR+>%XWL5(BFO-")8WKE
M !O2,(DOLI-PF50*>[<I2V,*ODVR(&+%1X1<HR%;^+$*IOSCE7RF.#'C(WW+
ML#D>03,>7FR ALC_6965B%DC9\53V[+T;_+#)O&<$+2#2%KKG0W.X2S""[)V
M\+:[')_O7Q<Y:# 2'Z^_E)B<L8[R-\'K +JVZ=5)\R&Z+#3QKL*Z 2\!$#$V
M>81!7>3O6'4QX-JO2J/VZU.O*SCH[#A)5WA)P\\;$@S"2Q-EQRQJ+P:>Y,FM
MSL("7\V5UZ2@=#1!*]L/CW-)]!T1XY>_TGR%Y(_7\@:4%EZ[>-"4]VGEJ>/+
M#A _M<^+0DTH6/:*,!P,GUFGZ=>OV]NSNUM_X+2&(T^X,.!M;(\1%DC5 RV2
MU?H><&'<ZL;]9 /K(!K**("5'+$T6-%(>K=CPR"$MBGF66Y;>-6BBRG%QR*^
M#6"M!%^- S)&VT!W:K4NQ1+4X]JC^@3[+RFG\ZVSDC7[_W?DI3H&:_%W*7Y:
ME077I GH!GO19;1>&!*19U;B1*X')M(Y&-Q=@P;V9+Z#2ND198-689]RQ.&
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MXV99G79B\;B)5)<=6W]KG0C]D:7E4[)J8M*7+@F/FSIUV;'UMTX\;H+4:2<
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M)Q4MS<'F-%T&296)BRA(KD(C-6N&5>LF(1!4'NJ'K?\.Q@O(PD _;/UX,%[
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MU6GP\HIL..M?"^'HZP45-\"J;]L%&2,F1AL7M[.=5UNKZO\?U6OYC4K_DZ#
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MKM:;&BSCN5.2L04?@B3(*[GF/X.Y/A^"I3NMLK+BAFS"*LO81ZJ#7.;8D[Y
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M%7W6!.^T6UM$OMD$ 5\ 7'6(=]JMS2&-$,+[51R);<[A,._4ALVIQ$;7^ >
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MF1%SM?%J'YIXR.U7*];] "32420@F3 89FFC6Q1:*_:HO"=1"N<$)NS:/(*
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M*2Z$,7;[:U#:751;XRX'"*%F8\JNQAF50N>@R/GRXAH?US2Z)E\?5@,YUX.
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MPCA*]@5%]<HC#81;;V+]1"Z'AUC):RSI+(C/P0+S:H6MKUXPJ%A28>2C+:T
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MATT>+7OB*DWTD) 30MZ,S"&$>4W%^#;.5:SLL';50CJ; 56!G9,!5C"EKC)
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M?KV[5C.:]ZL/(C_8?MG]!U!+ P04    " !6,716W#[:S"X(   Q'0  $
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M28KHNLQGT9QIJ%6*-E55(4B%6&6)47 DYY:;,%NKV9>4:V9S8V+-[1T^(L>
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MPN,M=^::67";=L1L=RS_G>.H+H*7_GM!.]^QFWG2U9> 9:;DKB34BGTLH:3
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M(T"(T\3G9"1?9Y<^4Y)"K4LAJVJ6/@N2_3>KYKB@YVJ9$.G0O\&H[-Y=N5D
MAY.9_AAK/:E] 1"E00 !AQ6>O$_7*QO2<T:7=@]'K3WY6=_('Y@-PE\ /G6W
M8]=:+>^?'^S."G<S$$4&\+/!*S;/7#[Q;%*O(;OP:.GY#^52S>G6=V9^G8$/
M?:XQ@@!>F_!?C&D''"K"=8;Q2*-YS>#%'5Y:W8W'AXZDOML5H>"(D>N5E^O
M?,QLW3QJAD&<8,^!;='NB(30, +[-K'HUDEV&@OCR(O>CCH83NB'OX+@1L'U
MWJ?5PQH!^[@U*9MA7D9W!/WT+E_"VDG;4OGJ"-D-5XF-\,[9&<G/=4&"[BH$
M5%KKX1^SR-N4!  ,EU1(-0R\N"8XRI)P@3C*8O#_9'.OTBOM(RZ.2<RLIB@O
MY AKGP]3W(-S*]@^\&P&MK"483Q5T4\O%Y\E @+)S-O_N8(%(:11C@[?VV=\
M^IRU?D3!-5'U5U#_8YH,AS]CKZ4#='(CAR#V:(_8.J@R,6'A^$O#P8XWO #(
M,&[SS!TYHN10*S&N\=19[F&UE$=<S LMOYAS]%$+9"TK$@LU3Y<3J#.*AC <
MBC;);H_F#KW/?[)PFQI> ?<^Y(!G F>>@]&<?FP<)(N&G=\*:@<MSW><][$Z
M%T=(*+P >K['A)W.$CR3>5841N*EDVCWV>5K :V(.;H2)&?)I4WH[(?=T +\
M9D03%$B%QCUSLU=&MY,K!>>E#.L7Q?K:^O:MAFLBR?0C?]R3^5_RV=AVZO:Y
M%/<Z)9O ;O:@P] 1$S]M714+I,RXS114>HPEEVK FJ(V<TCCH48;5Z:0#7K.
M\+<(>!\>E923_PD8KOX))-V6[YP"POD:3EX-WQ('3YSD*UYA[^-C=>XJ-1"2
MJ2"50?P4A"I!I%YGNDIIPS>=ITN61!$):W.;ORSQ:Y$[/AE^ZPJ<Q() W<@=
MQ0BW&ZZFZ<"85F,K!YZ+O+6GO-<L64PEO#PO %-4&FM:DH$3ZFA$1@!L:^F*
M3_ZAT].WC[;79$S#U+2/#DW$&\(.!G+F9Z+ZM17C=C6EM,.Z7@,/"YH_/J\P
M9[)$ZP_"QI%YOC)=TXDX MO:D[%>W2EM(7ZHBX_!]&VWN8,YSDQE2>0?DN[G
M\0H\Y*/TI8TMDX4TC^M6&'W]Y5NZCPV3X7TM\?UT*8M=E#\;E*/[!8BO2_39
MUL'!W*)8.A;QCHO"0^-28PUA< ,=M.I"QPA?$?B@UCN0X[]%T1LD-@K(%GE4
M1^\&4UI0?HDHYGP\@U-85MG,]:5H89FFVIG7K>W^N& D^Q%=[X66[2?^72_(
M?@39O"2?L +#^E-L4D&U,!%D<-PEQ&XDX;G,GD,I96?7:SK5:1@KH#JB0"U<
M<@C?^742 /][_L7MLWQF:E'$$0G,L("J-M8&"29#O>+\**2-<-Z(+T*MB.T_
M"$Q)L>HB-=FZ5&LR^6PL(7>J3EJST=0';??,Z]9AV*X*.80U2$0F R+B2%X
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M$*YE3J7,SYN4SVDI)?\ -7VDQ> %W(&5\!2--]X \GNRN,&J*U2#$1T4BS>
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M@8>%_P@/_Y$2%Q.7\O]V>^\"4&'!]""H(,!( '!4, A4L/<^@!  P*# _M&
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MR\*@WQ<(1P:CTB$E<2V2V'M[MJILM7H,28;\]6HI/'11PA$,IGA\77]=%L(
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M0BKV\;QW)&W^[X!64\NEP(^Z8M/:V:SJNA\C<W2DBS7%^M^M[)L\/><;?S"
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MIM_2E0>%^2P\%5_-LM&$**!K$-)>UT\0BMD\UY\\P1V-<]8X?1'@SYLY@1C
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M+4</%7G<I-;)6DA[3J>H$K\:_F*DN3$5R->^;*@NU;.T$R\>(0D]=0T1K58
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ME@P@'@M$I;TS,Z=/6(#.-#^R'MREL'QX 'E; /6L#)<&16Q+O?V+#[6Z%KE
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MZ_/76,Z-EH[,L5,302#)=5>\,?^/<5B8_6^86L<+^V\#'+ HWSC_WQ?V^JO
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MOHA(0>=# ;3:***(42R2Q6:HTN$1P3N+ZBZ([F6.7KX:,?U3(8^W1+>DTZU
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M%FP)+F99ZTOI6,R;$IX_\A5FUW9_!;AZ._Y5)L6JJT&73-T<295;DT@V^?F
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M^A6 .]@()333"S(MH6FLH,G34$Y@B_C1)ZH!7DX]JZ 1%NRS?21WBWU?)ZW
M^.0E^;<?.XM,_S@6$CSA)E9@F6@QQ?A1//HF?$WCXN9T.7R5-7UV'<4<0G+R
MK&(XD.-WK9_<.0H747"?;G%RK:J2V<Q \0^9& 8*=!3T]_>92!92YZ)OE7B,
M5;GR%0B.NS*V)=.EUA>T78Y+C([@;]INH[@-J^$;2PNO26FTAJK!(BZNBB5%
M,"E!'(7Y6E>2MWCGN=+]H*\^Q"O=S!GP+4XA;B-B)?IN;C/7;,LD4:.3PJUO
MA+\K/A8!AG_#3I"@-0/%*B C RO#C@I.P]<)AR9E%Y>2B'3[2 (SK\BU>JU'
M4<MLPS3+0L2Q 9TK'!]("TW/?>L:26N)>AY$EOL@#N?+$!23IA ,X'9V&F9C
MQB0]L@\;%A#Y=F/11Z<2I25:VD5FY6&(!"(_/(K6=2\FUMYMI&O56;*E3(N&
MD5YM.R#9K55(;DM.JR)F:Q>+FEH7K!.K"9)3V>9Z]O@[](LZOBU,E.43<V9.
MXLGP>^6)NU2)*Y\D()]IX"N0?M9E#QAA.,>(H_<@'.,8!VN=@:4W[9<!DMD6
MS$?S]E]$T2D275#'U3'CE*-;7;JZ!*1&:Q9.K\D#Z%[&,"YDASU_KIQ$ZCF2
M&Q)$ 7PUR3]GKCSP$?GQ>5PQA##@+<'.<'[YZ([GML[0G<%R<ASL"@)7Q X#
M1$KWD] Z$55.WK_T)/0C%D6TH15W[[\*?XW@5_)W2+TJ0\3R:&E1;F[BV**>
M,@PF58J%-$&0W+DZ@*+H*T]"B+\8(T!EH] /;C]=2:4Y7^:#8GT4D*EI:HA6
ML5K-^\"N2E.^J]4@&Q!!!<%OI27O]5'ZV*>:7(ZK(8!<S%AI'W:$&8%U9<.@
M@>W.249XZ^3JKKT_P;;FW8>O_1P R;T:]\0X"VL_SWQLLFP&<]+2$L?E[W%Q
ML @AF(A[8'\I<.KJIB$$W0P[ 1U+$!HN9G:_@N_9%%RKI<O<:K+_8HS54CF2
M(.H=)0B:"='D%>@6@9B E.]B;6D?@AGFS;E\/G5_"A_(^V+%,G7R':UO3XR<
M)7R G)E\AZCW!?/+A&A]@#$KS03; I&Y"PWV?B<0YM@)>'O7@@G[H'>#-#(8
ME"/L&U45FD6=*. V-@PC[@;<TSR%T' AJSYW<TOQ9 .%O#,XXUJ4T<O':CG3
M;'=S<_0D<#OQ^.X[!O?H?1)LQX)A_FM\I?8]A+(GZQ/)0!Y6&V3]+;JXE?,0
M7. 68WON-NV]X0.2^8=S^N2$;ME#/&@W,ODCEA;?0?[$_7PYS2D=CBFR)#0H
MY=C=;A"+0T9/AI3^(0><V+*$[\53*5B7M@&D(R\>4,'?1-B4*&=E'X@AYHVQ
MT=1= 0.248GI-:=4?N2='$B\Y0V>L;,+,Q&X&+T<+%.>H9M>W=1RO,B5+\TU
ML25DO9_QJ2[U'$Q=)G'UA1L ,4D2?2FH*,J$$^]E,JQ8M XK;EEBPJ9I<3$Y
M,RAHM]"GQE('?=K5$4'.*JY_T EO]2"I#\=.!ZYQ!#+[M$25194!FC" !P[0
M_..8@3_#WX\<*/_G5HU\?4Q)?8  9(Y/='?1\ J46SP5-0>DXH6'W;@$[VF-
M!W*CDULK,HF)@M,AFQ=PY$"J^2^C23* >?V0"'L?$&D==%'"]"E*B( 9L:H_
M"\,=8*+YGFQ!*&SQHV"9L)M&#OW#R<]!2(+?MG9KOECKZO5IV3]K()-N/IW@
MPE-"[LKE@^VE._$8-26_<^F=(HE*0BFN#@,7.H46WU=>$&^2H-O&'EXWL)V,
M#TK+DMILVO^V$!%;EEU[*7O;(,.8K!P8AK,(GEKLC_SY\M1]$FK0B<<L?C$N
M275+@!T^O-40R6'RJ2<DY22^1:=]!FF6RV /@<'+BY;V!?6@U]T66XDMGOMB
M32[#CAR]T64#]23U)M^GFQ./C=&&):</+WN/>+A/FJ#R[#;R,A-1NDQX:=WZ
M'C,I"8,F2FOO:^;V#&79YUL4<F&U9/;P9NZO8$\6$"^HZNU][$E-#E;,81TC
MP2PM[OSV8,LS]>9CX_X4_D#-ENN"F;',8(_U>E,J1*04,)M^L;:&'6^V+9$S
MOF>,H^TTQCN&HOCY!P#$-#KR"7S<W_G=Z&KB^X6I(<8#BMF_*TEX)_VNWP>O
MS2N'?G>U]6)4/#[%Z ?5(@?_J7@F>:K')-2A#7'$N%8%$R]JD;'A?2.ANXKX
M_*]>4'^@)'F$RO=<4TECHQ7FXWZW&[9FZ\1YY_XER=[Y/@W/[$3@?>=.JD$8
M7D&>JSD]_U:_GAU=A15ZOXO?8[]!3X8M/-BO63#O >7 BWF>']MI9-'^%4GO
MI[U^>RB=UO%(>[P[PU,!P8KM,WON>(-GO@SI_CK6DF.OLN[Z9A"_$7FLD!^$
MX#S3&5E'$4+U Q; Y]E>\Z5(T:P*<?D^.$;:"]J43PWBDN>3Y"L"6=17<6ED
M-X?"DMM/1I$I2D"U<4,7BV\F;D7>NBC>ARQO.<LO,W5FWL(!VN[*"YJ\MXI2
M1FV '%H/ET2EAI#!1>IY5*]+)J*DM7Z(<'6C(+:=,=>7QF,%;7..2C?\/6%C
M(_7N2HH& G"^MJ/2)7(T';KE%%,:9\[Q=VJK:T45@=$4P@E$+4CEP_J03Z42
M<#[?/7]F(@XQ? WG'&(S3R4<[41R]W8,=[%,N5T1;D$B8H!>K\C3']@\Q,QT
M;D6F:!0-=20S55'5332)"3S^.4/VN]5V!3<KCG>*3**"W&-B5)*DVE9\U&ZF
M#C 5+=>0J"_P8%SZ:O'#3VFX<.AF'%E*HZX%Q_.,19$W477S1:2[06Y@><5]
MCO/WBDU>CZDU 1O'%NRN"E "#FLK@)0>A(&,) 9R.V:VR&G2V-4Y&%1F&$OJ
M9RJYEX>Z+%[.99&DBF=D(&$MR4(H 7WTAL[W.#9L!%'&*>2H&-/90COX97Q!
MQ@SQI+:@J(U>88I;(L-C%4..NV3U3#J _@5VHKH[U=N<&S,XK&]&F@)I>"I*
M&YD/FXF(7"\H]3V.B+XV]JMP*OI$ 7C"2?RN<NY4^X84Y%?I[9GY*MWNWVRH
MGSX8*0?KW\LC;!(ZO&6:ES@R4["*KRUQ6_&F<=ZZ=-F[[VB4(09TW8'%NG2>
M%-=]OP9QTD"E(T1)Y5HMLH)#YYN\!C:+2]1)D+W=28R:Z=_/SOX;@%/_X^=,
MS>'S#U4&F3_I7PJ8 M<XCV>KEFR!4QG7^;;S',5D8QVL<7A3L/LO>FV#+R+7
MY:T<</64FA:R>TXT_1F]'G.8E[I/]!V8/A-C'<]WF@*;5G<5+]Y6K\!9]RL0
MX.RCK\]3T?$"EC"?Z?5!S!R7#+K=_NWSAJV.^_NW+-D!_\>>HN5SW:>GY5=@
M/>"/?[M5,1,NK+\" '\=Q &UU3,-..SCRN-M!<3;8W5;.:\ (\<K<(?4L2EC
M$[)&9=V M7Z'E+&I7&WYV=GB[!7PI0S.G_#J=W<X60NYOWM2.&<F.C]_ZXJ]
ML9^H"[:"0I"?VK1>.(ZUZ$I0Y]=]GL#?DQ(B9QY49 ALFKKFO#'>\9OPCY>;
MLK8B[^_K7X%.IX+G.-WFEW;AAUZYS$-F7?ZWRCQY+O[&K\_&QS]>'1+I([J\
M?)/7]UC\1L7[^.$>9I[4"\KO@*K/\_%?;S_1(V.\J:GA!:*,:%'EJ:,BRDN?
M<M)QP%)MXA7X7<NK\ H(<+Q)4]M_E[1E,+_WI@2P^>3A$B>+OQ'U&*U6X3:L
M0+8)?D_.9_TW#<_\\1Y\$#<GBL]Z0)E!_)Q.P,F6QY=%"JO"W)B?<$T6>=@D
M!0*_41<N*U CMWR"R72*V*LC+1S?M!SM3>N:Y:ZM]2:$3X )+S3U(5;"Q N8
M5!M_P63\?$@(IC+- UP+P5>U<;*MA9"@I]8W\VQ\?%,,XQ_&?@7^9FW=W^5J
MH*TO)UYO[".^F>N0B=IBK^-.RYOVCWV//H^_.S;%_P4][SGXQVG[F_G K@N)
MI!1TV=^4^2_&;\E_,CR':NU<ZS-Q(7*BKGPQ>*+F34"+FVO_K5Y()/3/!;]%
M[&^!L*MUK-(*8TW:PBG/93/DT=9T\<+],B>G/>4"&GO;Y!IQ81"H^:U<9QHQ
M5HT]U]Q,U(_MN+U76V3B;5NNZ5C@VBIH^ZZM,?9.Q>I #8$%F?#(G IB@JA;
M,]>=OBROI=0**X6P2MV8^1M+H[[[UPJ"APCJP\UU%%$7MD-R.A<MZ<J5=L*I
M!/NB@>'O$%T3 II7<%00WZ9:V<NTCAZLQIZ7AS"8PWZ<2L N>G7Z\SM9C1S.
M+!7,>PJ4Z*Q;T*-'7N4I6-DSI.%!X;/X 9T[S"M\%G79OEP6$_!'!NK.-6GS
M@PAB6Q>"Q]BQRMU@@[OC)_L?8GI>B.9+Z_A(/8K(F)<'R)4@>)B6I*U(?/8+
MR"BSK@YUYC# ]F_7T.8,JR-'6A*';QVD;4N<AW7>V3!:H C_@K2+W/W<\GL]
M^,,L.W7 K#!U+)5HHR$ZS>!W"+\+D%]LY?55A<@;"V*_VVYO8B][$.1S]\8:
MFYV92S]S#LRD1ES%MV/.0X;>E*PSDS9=;#U?VID7$6L_-#&POASLM0Q308Q=
MI6$]+*A/.O:9A.!815_C;$4O<GZ2B^^*@!F7HSUH7<C]TT"X_Q7\CV%Q*F9T
M9A9PM3]P2/TYD;B*6N]\]DM];B>+J#(_>7L*7,X+/!XH[/>\ GP&KT![@*0H
M(/[/J_=_1U".E8?\?P99:34.VZ%2X4B61J"VZ^UF]MO-/H Q _GI.O+E </M
M]YO;J[]%:9;D3:+ ?JWN[<^<$R:?"=..LRI!^/],3M$K'_G^!/OYANKQ,]'E
M$N/C+WGP^W_0$/\?9#/,OKUXB+X"7B'\,S!/-Z$OCQA ^W]FF7+IZRN0/N6S
MKA_YOYG[M\R!72;T3Z!(EMPU:Y%'I= +W$ID_M8.J_&1ZVZ]:?8)CJI]SS.O
M4NFBS18B-"[BV7._P*SK]/V[GC <C\9[4=6593U1##4AP+6,3T2DHS)H+)V<
M-D[U(E<##@O?]RN2&ME\#8Z11'FU+@;E$SF1:8,"8@)"/U<5>405AN+*I;]<
M@_MP;G[RCJ@H0P'#Y.>07[^'BX,LT+Y#\0=-SH42<IP^7*PM+:V)Q6\_JRK[
M]C1-%+19+EE4,<2'.O"-C,9?=%%40>4TFI 'XP8?L7P,>\K!S&ZGJHUX9D#S
M&$!VN/'-L[M1N5CTK-V/DB1D8LK.5J&AS4,M'"CANJF/U9:$(Y,F18_&BS^<
MO1JG,6,[3JP=9-P1K)]ID@@^VG$B=E<-]"L:L$"<=<%6XZ@>H[-_+D;1&9^V
M#XJR=<@HW,N;K]MMTT*WKB9=7AFSVV&^QW9,B45:I4G='QM.N-;3T-QSNHEV
M,T!C'^XM'\4>0J>5R@WS'402WU81K=U3_:$U:J3;ZL_:Z"7&J@/,.C;6W<YE
MI>_4]0Q/H(L$-;#0>G;5!-+(BLNF%6L\?8I>NN=(4+/Z&.IH48KAULU3@SXN
MC@ ,[6/2Y,FN9]X;K.SVVN,L">$GSFXT*M42";LKO8S8&C'#NSU-S?'6KP@@
M&#<'\PH9W(SPQ+KUJB[0DVFXN4;8&C$07/K^)/,7^.Z@!EV%N5M>_ HL.0@1
MV F&.D BE NXC_G#QPMHO\2FF574/&MSJSF$@\;W:"7*<_U5ZA.K!ZAUXWX<
ML<HTUL>O9J.3J(+8HV$459J]G29=(S5KY_7\1%8$HU>E3J!7ON%7\@0B<2*Y
M#K@7(!68>RH\Y_!^OIF2, Q!7R%^7LH0ZMX_+PG;FUMZ6[P ,K0'PVI+1B?Q
M611Q?;791[S6X6IVN+B$_'4PB_E4886C.DG@A2.&!KQ.I[1YC>=TK.K:0W"2
M1D72%C>Z*ZPH@G':'!?V2)S(G0H>6U2$Y;EU'C]VHZTYN'1RV8)Q8+BW8RV3
MXQ0+U"/C^<:-,I.<3P-55OK4J,2V/OH=>16+53=J:>R[#I,C50T2[1H90T8@
M\X4[7MQ%C%_<)[](-UD]#9(+.ERP?%*)A"1J%>(BCEXK<8W1JIVE(P^$CMXS
M;% \>3^YQTQL,$1YEX#[(4 QQXPKB,ZE*;X9*WLI/"]D>>_HE#T><X5I^(_Y
MYQMX$Z:YZJ.!G*B!/W7-EC,^7XTYW:135@=D1D_;\,.$<.V\FT9#&?YX/4S@
MP5Q(NG!"5J/3[[)L3?_2J78K^CVE=64?EVR9^RQ$*N]+%7Z81^JEN@Y]JQ(;
M&E3<4ZU.@0,!1.>1&.Q>9*5VBE&B<)^F@34&N*XK+IG-E\#FCCM)2]"A]JK.
MZFG\EN!EK\]4;TBF%7ZU\\85V5*.#5KW+<W>#FUHH'&L9J5J6&_1K8CUT(#V
M?KOI39U/++?!R@ZN!DY)D2H,)*H_=9V%<OR[.MHD*][UFM: F#&KB4@'%8LL
MGI*DRNP0:K^BS33C[9Z'D_P\TUY>!GBPJ9F[V$=476VM-:T)2 =Q%HQHD:(5
M;DA#M?ZJ(C-,9<,87SZ+XV?DD9HI2_J\9$86?-=MFU0G.+"*] D](GL=)QY;
MJZ/0E_^+.=7S?.E_I_S_KS)7-4*0=+&J1>B<.G, +L!/='],]'Q%=;GYQDK5
MVW)8.#?;E^R?5Y%_1Z"1HOIO1FZ2(Y4[C1Q5T_WW"S(AMUNR5Z \^!7(@DN!
MF%3FS+ 7>#C(>$ I.@!CXH/">>\?'P)\1A82@\G,R_9%AYA4\#N@-LV$[+S"
M^.H.ITGU?QL)F>VN8X.:5QS<W%VX:(Y^QD)\9D*V<>(VR&:XW:/9WT(ZR/^(
MFC@-"8\;HP3BBOW&2WZ.38=55:<Y+J!L\F2O'R>RO\T3RX*.URMU;FI,#2G_
M/GY_0".'_3KRB7@-^Q7(Q,IX:Q$#B'Y_<]5]\=7T>7[ //"QGGY1-;B6=.&7
M'<.M*/79A/[=\0S4O@*/5W]L1\5_ZV^OP&?>3#J9\^B<<%'YD-N206D<MC O
M\$\J;\TMXJ;/ YC9*W![H/#<(GVO[J6H,Q%3(V9Q3'0GU,KX"@C2"[P\PPG\
MF?K+:MY3*7\1P_[0XO^*18R_<4BDG."P\VM*]\VY_OQ=KP LYUM'=0!5\&;C
M+/&;$\9=O?^_R)+\,/""8@/_"DS"R[T"'<*1_T*]P<R'%KE8NNG"V73,R^!_
MDO-?Z2_7=L0%S5&LW/.PF:2Z\$']S^BJ5V<(INZ6[581,4:0&>L2:F3GN9=+
MSM,(?S <Z4EVY^)D5RA4=EQ_ I4+*6D#61(8U\(,DQW1>EWA^N:VM6H!H7UR
MF/QN:8Z'Q>:#_\-MF\+_^QS_+Y#*6W4E7P'MA/LZ]4+L%X&=M\"4?EHJR 0/
MH?HO 2PC_X[/]93 %8G2+/8_ QHHG<" C]ELDU=WZ[#@J';C5W4Y6[)K(+S4
M=,*<Z^6(GU[1'JP20DN(7MF@\0/) '8?51*"+7-G3G);[*"ZXMWZYQM1"I67
ML6[W8QI?R)'BE&03^K[(9B!X.Z626)$Y/A);M<P]S8\X7$1U?+[\$F3#YH(B
MSH94+4H:)*X4-2PFA)GA42ID5B1NN,W"*\,@@L3T#CZBB9CS^<(4(CQ2\]Q"
M\FM^]Z;<XL32NX9[G1L)$21^I29Y [X'!]6<64]QJT)3+$[TTFISNU)0DY_\
M<NS]+I077%0.'Z+-XET(?F.6:=DN,FD652]XV%B#V0/1=/SPQ9INK;G#8H^-
M U&2-;F)XJ_" 3+^)-Q,).=MY7,:79U>Q;-?_K_ G*#2+PG(^<&S< VB,C,2
MO^ZXP[VX!)<Q)O/@Y$F[G>U%[R9#QY QG^  <8J<EYT3=CI)\[\P=U4SH.D"
MASE88"$A(B3($9 UC2*:+!QC6#D3=FL0F(A/$!O(40?X"B'B6MO.#3^:RR+L
M[L9O[X0,LG["M@UVOD7VBW]P'#>UZ$!=,1>F;='X0MY2%RTE+"R6^W2<"B[Q
M<B/1_U%-A?,'VR IBXPC&M\N1!R7_L?H 6(#$%<^?X<Y.WF]V*BW=K4D\Z *
MZLDX$I/WK4$_%<2/#)USG;0P6L=Q!NM/=$EU<,.CH"0, $GXE[ K)>3#_/VL
M$_?NE&?1;G+WUJ@DQ5Q9_76Z4@0R$6ET3"KR="VC36V:K&'MK%6\.EQN=-*&
M)?CH,&OTQ=61^UX^WLEW79.(E<R&78U*!0-1L:^=!G'=&P8AP'9MTY-2P2%'
M?37\!(6!;VWWQ&@\L<(ML>Y6#PVXK,2J3&/[N4Y>V?4H%K:(0O,%SJ](=S+Z
M=G6HKHT& H/TZQ71+40.2UAKWGZ:L3IY$/CUX !A\\-,1P,=%@YYO&JP<>BX
M'#/LO:U<028;6/^1^T)P:<#)J!\(W%@BNLP73C!TI.M(FO5CV#[EH4K?:8N;
M!7M?ZRW+!($Y2-K&YK)?=' 5BR.L>F!A=Z^%MDU-N@7>Q!5+O5Q!0]]U!!>,
M\L[N9?S-PU(^3UOZ"W[UA^12WX0HXNI4&"*?A*$U<2A?/D:!]/>IDBD<K2YL
M($EF4;,,^$',J!T9^^"NYJ)>M,5#X1'M. 8$"J<DX2-P%%T=7SH>*XV4'YZ[
MI5ON0EJTC9 AV+XC_.@K3NB6B?B1EKKN&#,*@F2'@*%_O1&%XU>_PYB<4_'B
MTL>RT78-0Q;$87$ S<,=8J .^))=>=8JHV>CQ]?[^:+55%M\MY(2($CG@B%+
M3YU?2BWDS_;%^B/@FQBQZ5^!F[6H&P&;. @K$*Q(J0\K\AKV%Y8VYP9(DS:G
M.DV/98DSDJIDU_B]3?4!>,XQ8MTVO_6W. !?UCX7G:MJ#)<.]9@R(I<7Q"U8
M[ 71?@V C%Z  ,)"/+[<5<.6;?FNL(6[V'\ >2AV 3ZK5$NM64JW03.D+67Q
M#[+Q6TN0(6MK'$XA%'  D JF@;5&%:@$+XDW  ]MDC"&4 @.<_3QN@_XJKWF
MVO:YNG=Z@_R"CG3TO:)M8=+Q)0GE0EA(79[VL8(%BA O)\<\HYWM;D[]^AYG
MJG,@)0^V"?<V][$.N>9I"F/"[DJ)6Y!I=TSMOC5^9$(Z=Q\SKV@^/]P*&BPD
M$7V5_SNEF:RN@7(JB-1Y)T8TH1)S9LT^.XI$TS#[/HN6(>%A(B!L<,,P#(UY
MF;1P769+6JMET;&VB=;!#LOZ0[UQ=ZC=MUU?6_@P B2^Y@7KI;ZH)#V-AN&?
M) K2MH+<&XY=!(\A1O5->CR?_+^21X%S\0A1=^!7A9WL'PH2S/6M!\_COJ4)
MB?"SF'IX^C,,$H<]FG1=>K]?--\;UJB;?O1YF-#>QT\.&D2 8W%#Y&\,$(!8
MO%6W(5'[G*N/5>6K-/(&1CNM%)\0#%.1@!4:G"<A$X;<^JIVA012;13<T!/
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M^((!MC E/O_/A<C_"^N9O\T 3_N5K5$>S\$L=E++8^ KIY=^S4?&I$+Q T
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M6R)@<;9(9]7H5&PM<9]]\M]D&8(MS:,]:<D?S2QBHPRAU49^U-'87/#];OM
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MX?*232=F@[4A8-272+88SGNJI)B3"YX3IK:ZD#9#V:Z6?C\_.<.&.D2K'SI
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MRZ$ 1;8!7*.IV8(,]#+SU**V6[T^L<)3D89;F*?< WE#N<7"[W'?;%K>(QN
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M\/\XNJ.1GZ>K^W<JVJ'Y'JBB<=B]YG'^FE,Z#FM8CMGF//C-P'U]W31RF(%
MMJ53_F;?IC GO[N..VXTD^]1G P""$AQ7M#WDG)@W"9I7B.N&]^-CU;>LV C
ME<7UJJHVZB.=SNI7APG[_ $6<TY2/H5/^@1ON,O,P\TID[$/'8AQT?"DXF;A
M9N-(8A2/C4O%MVB3GU.[>^?%#U=K(8B['E0FX,H%PUV*'#@MIV0;>4A;UBB^
M2'A1GSX^2&$+#3))D30W+.HZYYI0D:9U2:O1S578C6.679FLK9V.JX0)Q24/
M'L M]Z:[#$ZU[E#KN /R!Q4&G[ZZ29G^:_=2;@/C?$1N_!3N2&K>V OMU>#
MI*3$"L(_[.\GO1;45+-<#\KQS7[%_CPMQW1LHVAE.8B(,: 6+V:W:ISVY%IR
MG)HV[%M'\:K+VM%CVY=O8MV2._1E7;*'J]913$58&0) HK;FT_&]X#A1Y9(T
M/A8G-H"GN"R(J<G9II,)'!AZ#W>)54B<"+:TDDXJ%%!A$[><2(OAN\W<(,7W
M+>/;-.?OH30+YQ[VTB +>#0O'L *0><CXZ9[JOPCDLPUSAP;\-XJK5<DA!9S
M;Y)IOAY?$F7:@CPAV"1*N\#%\)/<A1Q3,!FOSKLPD21);<8V>01CNBL3EZ;
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M"<>J]]MT']55!QR0X_)^2\50NS.POJ]B=[HFG,L0WY",T2!9U&U-FY#VNUW
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MM@+EBUOM4UH;KR H_D'L/7:WQ@SRL2ZBRGJ)]*=3'N;VA0>\C[#8]O?1260
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M4<=M[TM/46-IV2)9&XM&"'!U'(1VAL^XD$O+_2%4>^GLCABQ)BGK'^SQC0;
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M!1T 30Z&5R^-_^YO_@-$D'_\%U!+ P04    " !6,716G4'![4%J  !];
M#@   &EM86=E,# P,C N:G!GS+I55)Q!MS;82 )!@[N[!PL.(02WX"[!&VB@
M<0T!@@9W)[@V!&W<W;5Q".X.C<.?[ZPY9_Z+N9B9BUFS:]5%R:ZUG[5K6[WO
MZ\+K7\![!1EY&0 " @+ ]%\#O"X#I !OD=^\?8/\]NV;MR@H;U'1WJ.AO7N'
MAH^%C?&>")^8F B?D)"4@H&*E(R.G)"0FIV:CI&)A96%A(KC P?S!P9F%N;_
M'(* @H*"AHJ&AX:&QTQ*2,K\_YA>.P$XJ( UA'LD!%H (@X"$@[":R^ "@!
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M-K@](VW$8%Y;.T_H(]!0RY*D7D,I[RYJH2-1< #]"!4@VXI8>_\89.TRW%X
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M OT"FFE? :SQ?CYSI05AK&T]E]PSHMXP(W@5J-A VM-='L^TLI^L(6$(J9'
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ML?/ I,C]0-D<O8*;/1?2X)O@N\=9^;._T95:&?\)FAVK4$M/5R"FKGF=QN3
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M>2#K4]7ZQUV&P[Z-==YO"Y6Q\?B+VVUA6!W2*O&F\U]Z=Z,N5,G!XFP&!(^
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MI! ">[B%(R^Q^W__)>'_!#7.#3X@#_;&:-P<)>_\=]SD<BZ[XJB@T,;2<D1
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MAW"J.TDWB*2N1P8+>=5E@.ZJ\X!)[RF)\!.MXE&;<4TH>Z6#_]QD"4H_Y3J
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MC?XT+Q*@,^FPAU!-?NR+PA$Q3$YGG+T&I#4B-)JCX'\$QWJ<_W\ 4$L#!!0
M   ( %8Q=%9FB]71\$X  #E5   .    :6UA9V4P,# R,2YJ<&><>P58E-W6
M]H/$2$MW*"%*23<#*BT2(ATJW=)#EW0)"KR@,'1(=W=W@PX=T@,SY$C-C^><
M[YSW/=_Y_GJXUG5-[-G/7FOOM=9]KV>!_HY> >XIRRO) Q@8&,";VS\ /0\\
M W"PL'&PL7!PL'% ()R[>/?P\'!Q\<B)B GN49%34U.14U+2,K QT=*QT%-2
M,G,QL[ _?/3X$0T3]Q-NCB=L'(\X?D^" 0*!\.[BD>'AD7'04M)R_#]?Z':
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M[)]G"87AI.I((2)Q1>E3<XECJE72B+I>5S9X%WF?'Y5DA[);FSM]S7C90&?
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M<;[.\F#]Z^Q<=Y24_F6'?K4??4OJD(XN05)E3\S\7%H;@LL464JU$A=41LD
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MS#5JY7UKG@R"M_G$L.22]?EBM2TF%W'OW>%BH@5&4*YW,\PH^AQJDSI+PT-
M:&=FCO7''QOYESF!/19EP<VBM<+:SYY/W0R8\T+MJ3XVO?LDMI!-3PL<HP$
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M-GFGQ=P4?D<(I LL4Z0@+H:TIR4]BU%1)E,G+;27^TX_E-Y:NSY,:5BH?*$
MK&- 1@5D&+\24<T6^-M;?RG5N90?<BN[\B&NYGF[Q00&\Z[K7'J4?3$=K[F+
M!FI#>B,*%G<X"^4\"UDOWK%.0JO%(./Y(B3PQPM;%^J@B:=G"V/T=R ^.V3#
ML> G#FXW" ;%\U+.OSZYT$E%J77IYY9%-O.=I9%>2$S;ZJTUNK+9%T^*/>N<
M],<=XGBTS#)9=XH/IC'P448(0.JT)GGMOJC74R)_& B^C#FS?J*;X,PGPSCU
M^V''6*[+!&2N2W,/^GUBS\M[M_,92;5>8#)DM\EK*]B(T',&VD4H/;?.L!R;
M/+0HE!'S=O[<4E(0&AD@G3,.RHJ^>!>IVGY2;##B1=Y@JRHN)D3W<S4KX*KP
MYO+$9 LN0\?U?8R!DVC=A&QX]H*M8=J!?'71P(X$>I:S@R)(?3-Q<"HI$LXC
MTNW_LW<A\8.WV.78!;'-8M#=DE7%-S$/(G H[KW!V.? ))7".#2RF#O WL-,
MK)6M7 2O@'M.[:XY+11EZZPTHF4*7S\*K(J]>Z$U@[VFRE9=:,\<ZBY/TJ_C
MWLL2'(N27 N03%[QA<::SC5K^M@7+QG#]!:^T FFR.B]]Z"1!T9E38;GRN<2
M?$ S5RXEORO]+DXTL;WP8N8([B2IR?N_EED*MK&]%@&A&=VW 2QB'>39@2/<
MY!A;-Z0HVWR(QYI(A(^.G?I T>.[:[AQ+,U?;_E+.^T)QN_SJJC(8+4@$/W7
MYI7?+"1MC6XO1D"^L:6J_(M&?8@(6S$7Q<\S+.2O"YTO/U!1/8SLR.30!#4\
MFT:VF.))-1?!.8U*Q5#VUUB/-LSB;.#2;-94C>>!0BT"*I_EO-WL)GJ'?V(<
M:)5OW\6R7&J^Q7GNL-J:=1-"8_].-G (O%I"B7LCP;;[$_Q>(JP\JU#BHS"=
MTPEC-<9^==>#@_G$L3S/_+E1/W&5992:I*$K*GU+O;XN7I<[I]#)TJ&\%[./
MQ[VR?JF>?DOZ,\:)]DW:$R_ZTV+>/S^4:G=86[3/^W+WU&1_-G4#8O=@Z&C8
M(>NQ3CV=R+H'G8=. >3"D0X-6%=KZ&U;=D)M:Q8E5!_":G]5''2N.WA8TI]D
M$*O^KEUBK6C[CM;DZ2]<I^]I5(2NQRTJO?]V=;+R]5AG/K['4RVNE10&*5L+
M"Y748 Z7-876]7:EG/E,^/HY$-< 7O4;&G+L<@ WUHI%H4UJ8FD:D'3TEOHA
M7HO>6%;!!O2MG@E29-:_+><[XP)="N@H[A2L#-05VJH;&.+KDAR<XC!Q5].7
MGYO>QN1KFX*)TAKA8TE9_F:QP>\&"0^8#M/+;D_GS)3@GI$P&>%G?%*RACC-
MK9F(#:B+]J67.BAV6SPL#KSJ9</(U-@< 'DY2ES;2SI#Y:K6[10$4O_!A"#;
M,^XSEEWEI83 ;G.,=-UJFO;42R,ZU>CA.5PRSH%;\Q0"6S1B6]=3QJWBZEC.
MW96]R,%OR/K'OUO4=@FY^+CXOLE_*\AX_"T:&S/C#E0.\/0/EZ;X88,&:%P=
M:<&??L)D?%"*FTISX5#$P&T&D_."4(_P_,;<XIIFZG<F%/3_62G '+YAU[.I
M;7V"6(ZP$U2)NZ>W$S\:8VK_1.E!XAD\1>LC'<"_7FMSV,G]  VH3KEY?X&+
MG4#<N&4/N4_ZOHS8FK\1^#1.^4:W8,6BZ8(#$]Q--9)GY15R)&_N;>O)KMO^
MT/,U*Y&48H\G=WZ/KX4]3Z^NG6M341F/2LE3UN-,842V?-Z34A'/AD^2JXJ,
MIWL7-1_$\[ZXF+JU]=?'9/G&:@2PT& Y$[>\AR.RY1)$I:<\B]2<*ZN3J30-
M-PUJ[%-B7\7JG%NW]RUFX*!,^NK$TYL*% KU]6%6>Q3#9\FX]WDKETQXGG%L
M"YR'2K@5^5$C7T:L0>E51<)J.+U1JU-/^]^RPMD-HS=\;15D$"]3,O?.+TJ^
M&%;7&;2'ZHG( 1[+S#'>.'YJ^NFBDV F$MK'F'G.Y*8W^N,@N=N@B<E.]-:)
M:()]JKR\'U1KV]M*@5KO6WHR*REK7KC3*)Q&&2_R@^US\8>4JGZ-= C-KGCD
M6?!49!!L<NE'GBWD042^"U<N.<]Y.UU<83O]I3H.[Q7+E%'9E>JI]UZ& M_S
M9<OH&]RQ35N%EQ,G<($;V3-UF;ZB;U=]NXMJ6_H4_3YZB(4E3@1E2>Z/(5:1
M$:H4&V2_QH>BP>@X33[4.,@0=TRPIN>*$3$R]J&5:4??(INU<E?:),U]4M%,
MVO:HB_6$ 8P'YP!*3=:T8(+2H-FVU8=<@I[<,(DDQ:'/VNON($E2XAHWBE?:
M4_!3(YZ#SC,^MIII58)P>>?B)_YI@*?E?IMYYG<?H7O;5"8.CM4-34WWJM_I
M^>*L]N-7ZY3I@%>8\'Z@>#O=:8E2]59J-"5[J:VI$U28G%5=R8%H 65YJZR
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MY""!(8YN2PP6<'9:IOVOFNZ?GW?:9I3ZWUC>AH]0?[@^L/U?59Y'=T$EW.1
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M/&"%E!S32>U.-$WL2M <AGGJCK3,G!L$%>E"34$_ROEUNU.C1I6(M/FSIH>
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M7CR:HJ7VP'8%QY9CM=TGX2)Q(S8S/I3Y\0/M3ZYY!<'UOH^\_"208LT1G9E
M>M!3(,3P0*@/T4C&?9\-H@3IL1'TD$OB?J6K#J>>$1<#=UQC@R UT@JB)2(E
M8B49^8#"0@5 $"A4NT@!S@Q2@,6/%,#Y3 7",]&ZS:,Y&Y>82@OH!89I[[(>
M3KFGY-65_Q*<$Y^&Y3VGO<6)5H;_F^SXH\BT4P#X"DML>#LJ1)X<)O/N^Q>?
M-U=[O2B )M5E>W4!_UMO>L:A2.%QFM1&*)!FU7M!\X3>X@1D-QC_Q:;>X(54
M[O5Y%?977[,..7EM1+HG5[1#E$ H. F*=-#>,H]6]]!BCK?JN@495]Z0CZ0
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MUY")NA(AB@EU9JGCB2^EPA"#^F?^TG.XC?@%_C>TXF_%20A%M1($-/P%Y[T
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M.N'2H_Z^-V!O,+KGU$Y.'^!F;5MBXSKN-$<I$=WTX"3TYN%13+L[>^$BZ/'
MLL4G-J%NUM(#YYF-ID"5IX.Z[-1TDB=&*VN=IGV*1U@M3?1'Q!6>WI L:6VM
MD?NQW;P]%ETE-VWY8_(G 1L"&?CJ0>WDM///8B2_J5?9&O#.CF<BC#N4JQSZ
MA<:@+#HC<&OVD;<-@5M0NF.&XV2W!'HNC9N)*.OY>Q/JG7S!3N;8PU!>SS!-
M.(< @;!C"\UQU=W>5+^G21T2"&@B2FZI3F/YMOMA:E+?QL*3<9F&6JL=6'1>
M)0<."K)" ,;_#1HS"^SR//FN Z'))N6"!*@K?&L6>OR$-\Z=D$"T7 X2F)!#
M J=.$[D323[]OL=R/!'76V*(<(_3NC^G2V2<D6435JK<L_WSMY%J2'ZQLI-M
M_JRRJ94]>Q2_C!TMSCI(L=-?CR/0R[UTQ^=%_?#,K^,9[T#G3^=:S6%?,!,^
M/$,[^2 C#YQZ,&&R 82J4O]NVIQ'-.V''TE:M#W.YDJJ/\R4WP^A1PM?[U3O
M]#@ZN\NO/(^?ICOTJ3&KU1]\QI(H4Q2^LB4.DAPR%)WT&1ZO^]3_7IA@^4&4
M/:*FA>BV^:)LN&)@SS@3_?-2HPKH>H<*\*:3\II! H],,Y# 8'61[\+D)A((
M+!M4ONWUR+^["_<3C<[F7>0#559%>/5476/>$"- HL((3;S<&R5K#V=_.V'.
M(N.F'9SL9Q-O?L1E*T_7W#3VZ9/E]MGB9S+"DE?NBIT9!*@I1T\.>)S%]G0S
M.V9T6\$%8F?C0@-3RC%ITZ0+F:<!1"?VM[R!GY& Q'PA$O US4:0=[Y& IGV
M&DB@N6S<5#0ZJ\GVSV7Y;NJ.B1WL.ONVOML4.V7;3K\X%P*N%7BT^Y_XC"41
M!J&W)GV_[J7B10(V>YBDA8?K>3XQ,F A;A5-\D'M\<YA'NV^YL-Q<APDD/@/
MX:,#-QI6-LD10;S<:2U6VX7&VV-**MH*'VS9!K)1ZQ\YAPZF^E&3CW$C 7W3
M_,X;C<WP-OQ'-N[4%3)O7I[9\&03[Y/(#%5J]QVC[D]I&W@X7H!_YQ*>C#*I
M\5\FW1%L4;'CTC)=,-UB9EE?N(1082$"&M41B$Z96][P?^M=B([J#[O47NDU
M_)I&@I@IJTCK!XDL'J\;]<5U"GM#^F[U;UY3874F((@K#^'SN>ZV8I%I;YMY
M\H'#&H9&P'.,Z*2JXD;*!LQV2NQ1[<>KJU!XM-K.F@Q6<CB^;3C94IYHMO)6
M;AUJN]YHO=-6EO,=@[<EHWO>TX;!>9*'T$YYB8ZO$>/$?:E-1#4"2" _$T&(
M,O2TVV'#RHZS6$LZ;3W:&2;1"7!7PN:!!%K8')" /\TMT\+A6/R\]G<O-@&#
MA2W)].%2'F8%\W66=*7UD*LI,6N4I++ ;(X@KX*Y-H=L_;!^Y7PJ8'48-&TP
M9%)O[?Q&IAKXPN^7R'TWSR0?FTUM6990'>2T6<2R=G )85%% ER52."24*PE
M 4'>,P(Z9AE(O[X&+:G$6'2.$FKW+AR.NZ:?LBBCEB)YRXARD@K4\$RP[RTN
M:$D6O\ *EM"\5+(GMJF5C@3N!5VBY#VRM$99_)]"_40SLYH,_GL::E-2\^]P
M1Y# H@H2P 6N T.N/!'D_2.( -3,0T;? -!_W11]F_S/Q;Y2OB8J%?NCG^.6
M-RYS:PD2\8<X<9"*JB%']9[Q>VC@8>45$H!E(HA8?>'Z]9G&2]9'*:9["C'7
M6I'9@M6D4)5DV6N[T(G?J-N,EKF'D=R^J*:VV6!D?RWL0\2#!"I//X!;A9N(
M$[6,OR.!X=A]],-\<B(Z:JOB3,'<VM-X*QCYI=A1$_[7>?IDV0BI^%]9U9 (
MSCP\/&S2#I&=*4Q+VN7='N(0QIP_8>Q?357?M[-D89__N-#F7Z%0 VU#K"+]
M-EJ1!E&'TC([K9&]8>2? ='W7_%P\"\)<HTR6NA'N;"!A6ETK=',R_;ECTNC
M'#1A=A^**EX"MI1H2< =,-\\;]C?<+ TA;Y,TN85*3:R5X\$1C!A?LU59X;7
M. N^BY)(((Q/Q%!5.FH8<60@F6">ZF]Z,,"#=AW4Z-O0G,IHY$%YQW)\<6.O
MB00R4B\0&&*7$V.@,LVSN;6@8,2$D_"-69!]\O/W'^:XQ4&*0U*$@.H?3=$T
M@&$D:9'^LCBSG39D7.B*49;6NORQPU:[M5*8?/.]&GY3BG-4G(_F@/HVXR,"
M6;IN>8LN[3@>>X$4):;EX#PC+Y[HYV[G:"$![L.=\.QMH8DBGV$W:]]#&K7Z
M +-WZ\>TJB_BC!Z$9YSR'KHJ0Z6@V>B;<'VW=X<70=F7+B6_C,Z%PF9L9NR&
MT2D[3+2L':5/IT8*]D(.FTFXFX//I.//YQ'2M8X36KU5@N'NYJ24Y-W=A*G6
M@'JV_N_[#DG??S9;/ W"V,"TP9W72*6O';^^#6CJF AR@< >09XLO";G"<&-
M<XCL\0@9'SGSW?MVI75CDA.NKUG'[HF[JC/5=,1 Q63\4%\BY>D'/ ]5M6S%
MHD<Y+D;%#2+F:A/[]:G493G%\^F[IZT<=*]70GXV1,W;SY>2/B2?"7^0RK>4
MNC8_^9!,EU=;(Q"2"YGXTH;__@-D+)P\]RU-1<-,?<@4W4+9QWTY#<=00:]0
MG]'870=9::&0(]O1%=QH1FIQ^8<K4!FMDMPG\1@K+^H.>0HU8:1:KM_H%7.=
M1;%I#4QI?!TTZ;5TL!T^:]GY!4I9Y<PJ,U 5588/\VT(BL+'O@OQK.P^M5'U
MWH<NC*HV+3]OO>=.!J6K>4HZSH->+5+,GH/W2QPKGS?-,"+^2665YY?LWP9U
M?FWH4C'5A04F]@OVR31;6FP#Z3@G(-Q7EH5Y>HSAO&]Z\:#MWG@OOH#?]9!+
MRMB+5'$IWK)"WKM'8'[&8ZZ.[G1[[UIL#3]W-V3!.YW"X:[^SMV! UYI-\[4
M8LZY;AR?+D5(M<](A#,Q'81UVCFH\S ;X>58UL#ND5IK.*K<T(=-WIB>"Z.\
M208)V)_X[L)7ZCJRV>-NU'8NM*;CT_/ZZ:-4SS#I<1Y(8\7_%E2<ZM@?VS4L
MV[B-%KOQ3;YB\VJ]D?#MMCC2OO/VW2W6:Q5A:>-W%;*=^&3W8GSW5,1D0<-=
MM,4%O7!J.A.T$[R:8>I?+8+GJ=[P89KVFI!M^=N,M_  M)5U7,BNU-ZHX6OU
M@26VH\E/!E*1:^W^>RE*#ATOF:.UZM$G13ED*,$NOP+QL7^95+=9!RE$4B2R
ME?UZ+M>S0L;1#^D<8. I:F:'U!RNY267S+ZS&GJ]IBQ*+->%9>D5H;ZGJWOA
MF*H#YM0&[:_@:!2R,!:GJ+@>5^VO#%<Y>S*R+[ZP'B-TW/?U\\!WTA)6S)VY
M=&OG G=U>SZTI',W_#D>L(9(Q$]@CS6^,8L*,(I<,EFAM&QN=%ED]K:4M]N6
M[VX6K4LA@.T])U-7&A[?$"PBCC=2=7T=&?5,V/?ZSGJBSG.Z?$:.>&KF4;0[
M^G!5Y@@[_)4.!YD:U2ME)3.[T/G/HV/*3_6Z/QQ1!*/K$>G#PG*UJ798W_K
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M]F35<>_6XHTJ0BR^/G&_WV)PS]<]V&QZ@XFE(DV7="BE-@)M;&5IY/]*72*
M5Q-4NEY!46Z[I3"+[I\3G>9IN/_D)&]E0 ^ZMS):/5.X')MSB%L?,!UN&:$9
MUWW:*WE?=5F#4-:XLJ7:-N7*[#_[!]$^Y@#GA8-N $9D1!L%;\R>!W+0#N4!
MX*JHY;^V@X,'=@=T51]/KB?$)!"M_?=()#GX9G^YB6&1LT8!D4T:?H([S+D-
M(8DIZ:7>L2K.)P]70E^#UA)8W.;?'G.[CR(NN,3=%=DDEJ ,X/M;1M/CJ6_
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MU\WW7Q^S_K\[N?]?=C/]'U!+ P04    " !6,716&5_2R]YQ  "P>@  #@
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MG;/1#;01)8BH_9X;:K4Z5\PN>9,5S+1W008'B173[FI$;<GJ/!4-\5NKUFU
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M1NCY[UV.:9+;=Y<A3S[F<BPJ FH[EX4D8_B4/]+;QCQP=?O1C-5&<(/Y]"9
M+CM\J+!(-_4M"'F-BMXUQ!#V)W\4=.$]?5["U3AI\1;3*]J+8K6*R48\#7!
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MM_SQ17FVES!=M[G!:LIM#6E6SU? EP> !(X^LA-]RWL>HQ!G!(#*P/0IOR
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MC(\G^2999T;UA6,$0LZ"JR:S@AD"RKVVMJR)]&;QKB32?K+/VB [:8U33^-
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MZTAXT^S#,7IRD5:$BLA;@%H=H2_-C3*Z<$V4B^PMZGE].:\$>V>4_R)UTB)
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M<^$W%PVWP-J;P*Z4\8XM[J+ _V@$:.EMX?ROVEA%S:"0_D?_?R4]TZ?_0GJ
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M#Q']M/%UQZ/F9;Q?Z=!.SEIC[(OODLU3S_5;.C__3E <E?0#WYH.+8NH.7*
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M":D:%I%N#J#GL6H:GC=)<U7Y[@ZQ;^(M'%E+%F&!WO%-R"F0>KT_7*J6;3A
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M.IZX<K_68+0X:*F;+71Q(A5#74H;C_XXA32(GX,2F-F>[G['FX%M9E'Z#/W
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MK5):'#)Y5*##7M/=WA N:=O-X+-(^RSCD34HK//F]>BW9@GR2AF4J(75^)
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MMF?=Z ?2P@.+!PR8E(/N03425LY.GM\'W*D@@_Y)@II?.A%MZ45[R:'Q(@0
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M2]'%KG_/=!^Q1W?QAT!#R#[S2@39J2GZE-QS2&&*/;$FFG=.YZQ>Q-E_0G6
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M.V;M_\PX:;QA^E1341@9.X<6_FF+!_)=%'F0>\C.8G?IRK ;M&T!V\H Y '
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M^+SC 6#1E6)>()<\V8O\Q"MR7A@MM8IFI^DJ($INKH!1+;D-6GE:]P!\J^\
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M.\@ 43P<3B>-9M6;_(]W%=6]Z,:R)QJX\LPNR@FH:WU6)>!Q:<2[['AP\T0
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M9/'"+I5>4:0-W)TI_)MVMZ82UUPJC;@&">QW:NSB=\_ 0:4$ FUUB7^X9=<
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MK51A/,F/-<#=(R.ACE\ZD8;*JDOTL&:(_1'&6XS1]/0_IE@K(@:?HYP5[H[
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M)^D\XT02QS?VTH54QGE<INCZV KEE/)&#:;DI%PNE^V7:^W[^=_X1FC"O]-
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MRZG-%=#(P)/(RZD\/*2;]-,MF.ZLY'H^VY_1Q0PA1YRU_"JIOS^_GBK:)5:
MEA+>LG)3H3$+7Q,?LV].MO_OEY@?Z,T]FV'S-F9S-=H)G8V9"MZ2#/.>F6,4
MYTHJLJM;";A(['_]8>U?HVCXA<6%T#IVH.+$-B5_=]=^%I-O!]!M(ZJD]&_(
M\P[T<FUYZ]#)6 DLU#KXM YS/^E$'0?\''?6%)X%+&=MF#=*/#I,!>!M'%DY
M9#B-7O6+R2N.F[00PZ/OD%5O/N4MO#&/(]B^R:$>N)W_] S ^/FZWOFJA P@
M,X,H+NTH5&T%TF>'[=:"8C+:'9',$Y#:(P%X6H8)-\HESX#X:=#1B^4WK=*_
M"3 <K7T=.PJAWWD&P.<:1,;\OVJ'6ZHFQ';&^CUUTN/87[(^28+>FCQ6,&%X
MIZVXOPBNP,2!)(E01MB\E.,"H]-R0,7VV1@_.E,%F@]5KF(&^2?7L4;J<M#3
MF^/._0')#KV7=T(W5A =4M?P%Y[JN.D/1I\E/1JP[\D1LQWPG@PF[^ V[QN&
M]J!@![8^ ]Z"$/MG-VH.!"Z8Z(UI\7"9KE'1L%JC7#XRZT')0KWA3M('#L[0
MZC$?!WQ1IV5R_&0W2AH#O.WIC@X05BL/T_T"'CL$;K"4%OP6ZL30V-QJ\"[I
M!"V4_A:J*L0/T>A>N>%O+DZKKD#@+7;*M&07QF@E OR6?KL] W[I^#X#K&,Y
MC#@JA_].+C\#KG32V \][VUI.186Q@(%!XG^!*4<=+R^"?I'W-86>XI'_>>2
M^-A0J!M'2''I2^?*L#MF(_++#57I 6C#F7J:VT]-H"MM=Z'F+'ACOC .!\<1
MQV==^9)H7@^H_Q3^A8VN64LG#PP\[\3\-UC_)^)C\.F'B!=>#I0IF46$K,I3
M)(B<[/P7A)O)**6(K8W^YH@'LZ3^!.BTVG!:OR')JO>8"85ANWJ8/1H4H;S<
MN>5PW?*TW0A9VS<9 ]-:U30V<K3U40RT4KOR9-20>,BXKN/7OU[&=$1-&?V-
MKK>ZFV5#UN<>4PU'1[Z7A3W=5QG^;)I)8Y=3$7]?)I?.M\A234=Q50&T%Z*]
MGA6&+[UPYF?LQ"-" ['GS7^7?)_3FL%G^F'I7W4CO683^N/!]T ?PPNT5=D-
MF]A?!U]_?F2[^O+?J1%9AX$TH[E3].5C=]&'1Y!B5)MT!6A2]DCM(V9WF?Z>
M@&?8;W=_?G\!XBVG+1Q;FR<F'[/K56GF*('ZEP<KUQ]?RGFN /[[4*I4K?G8
M+[^-]HG Q,MII*'29U#XMAWH75:]E>WK.<<E(?DRH6&!C.._Z!*XE%X2$U_,
M^$)Z <^ P2\73W?%SX >O2W<NW;8X[4:_,?+;1/-EY*V8ZZYF C*(S6Y]C3-
MEM3=.9A]700#3D'\>/-^VU<_XL<=K1$?BK_TX%)LP>_"+VY6=VU)O$RM-/&7
MB$*_Z )BF'W8\BS!FO[^X\Z&S?%LR8,6/;=9_>HK4%M3T='FB@N.AG.\<G[;
M_!-!07;QG=NR\& I_1E#XN 0]>4H?-95FO9G<;DT@O"7AJ<$1?0%2YL!K.([
MCJ(<S_FVF.*3;\E,'^]P9@&44S G@NBQXM,!@L.?ID#&S\@W[A!F7>"JU@#J
M*1W9:@U[3ZF7HHB@; E*]M>_)JW)M5Q@J2;*[$OK(L@871@7#D*HNI#:.^3>
M9!N#O6"0?;GZR,>P>YH3F8"'-?Y94;F*-7D/\-N)RV)0S]<JFI;4O- ]S%*O
MC48+A-^59-@8,4P*$Q%SI&NB;+:ZLN+WA3??,:!Y-2M(^\C#K*EAKII.:6B*
M0!F5&OU59B7&0'H[IO;.[C"0D?B?TI92%FC@J+M4K[>1]N+"5<4&T6(R?$5X
M")2UK1:69&QZHHP)O8FV.!-8MZN2.OFE!$]NC9B%+5R6L8]&1+G$*]@\ SK*
MF,XX\X,.+_!N:)\!AFGS=CZTLV7>$DK\UFW9#TJESX")T?70E\R4D9P)EN;>
MW&>!NEY4'MK1JM04: BQG/\CX]O;P3J; MH^WP%U#=SHR)Y95^<(O*ZYM%"Q
MM//!*Y^H.=;6"Z,E<:"])&RCC2Q\!H3]>1&LO,IUV OSRO1;3(:N^ []^X@W
M*K=6S= IVB>W[]<?[:_:<65S97ZGRMGX-,:FQ^LRRJHXJ%;8![R/DA[PB+_)
MXQ/,S#T>>@;4SK\IF&L%1;U(:]WFP"KH,;4)2DYE0X/8_9)V8@"WD J+X"K&
M#:J3'7GW_5/* (H/I.0X* 02_6KG2F.(X9)XPO)7*S'48R8'RBT.MH1JCP,V
MY8:%)RIE0F^TWGP^P7CW#DWU$#\AMTAXA"HO)A((=ANDV4 0]>!!^/NORK4<
M/GY%Y9!3^4J*@[W![BJ$\_>B EZN%+P@G_%!%?DM"I[''MO?4X6]0(\G#QTS
MH-5WEN4_S7SQ3_4$&>O)R<4MWR%..\O]P3 4KKG:5;ZD 56V;25ZG,0:BZQC
M\8T9)C#8RC\T)[](6T>2V+PX2Z=0@PT(M992E]O4PWJ43)[[8)C^Z\ ,39TI
M(@@P<*?W-%P_9*_T#""D'-C[/&T#WK&Z.C&)[T&*);E_Z@!=Z53Q:7)=W5>4
MH$+<LIX!=0YEG:=Y[A;/@-BWJ:<R++*4D1BB8/,[//ML\W/>/>(N$4^+[*U4
M8@RL<Z([[W+\#6#&-@P*=_=A798A'DX?/R1ABTD4Y 1JKAA\CJ[J^VGEC')<
M3L#^<4+<.'0TZO'0A^;RGZ0]V+7, _&2'*U_![AJGI>L'.#/__1GYT7Z> ^&
MB/A_A-0*BB4J'!ERW$(_AS7)?5G8$\QM/;#K:XW223GQD)R;%J&_L#(Y243;
M_L$-RB8TZ@^ZM'>;>5?)'8=)01G0YI!(=G==DK7C\^"O(0B-<G=:&6RIEPWL
M @"?3!'J1N6OC-X7[*JKT1KK0LO7S\L<.WGVHT56*W!5"H1[RYX!;"4#YJP5
M$&8!9^D+*LOHJ'D)O'JFT6N)UQLEO7<=H%;2"_N"K5_/ &*F C"H\BFDK@.G
M:K'>Y?H+[.FN3))9/4"A)&G)=%W:1*#^;R^LZ,''0T1O=_\'VV< H@B,?*O=
M[8M,=57%X&5L06Y,(S;C*D>?D:V8^(%NNU(B65!"1@RSMMP&)TX"E<94SAQ=
M0-B8UOEIEBBNM"G(&)&_^O%ZBEC#'28"UQCMY*(./.@UMZJ1"N?5](_6I02F
M3W-ZY+2[LK4E$+@#@7.A2!-:<'51K\LQ 3=!&W'?$K!IED_YN(1D"KXQ1;XB
M%_Y79PGX'@C7;?/H/6BFPNP.H_K5UYU']O4'<:DMZ1?QGJ\#W6%4/>#UCBN;
M#NX$,;_8B!G0:M(SX&N5(!^B:F3+=_3.Y[X6=%@_P-*U31MK$0UJM[$FO)'/
M1L.@RT@FO/88T!C[V"XL99A"&2<:*%SE\>O71]C=C&(PI)J:[8."1+OPKZ9Q
MT<EW?["!E]O[&H/"UV.J-Q/ST9&('6QU5!^:_#R7$0E[/UQ<CTMBPAW$(\NK
M\MXB-60)M^F"VZNRL+70A+C\"OP+X(P?3LJ@Q60<FS'AO(6B$)UOI,F]>S;?
M#,W )-2QB9R>^;Q2V ;-:9[<.+8",/S[FKI,@?^$CVDU ME#]N\S0/I=HWK+
MY)CVG[KQDTT:4$VU.\]3PHN*1&\C +A%7B_:9@I#""P&,+-Y&A4K;TSD@%:)
M!\P*<%1APO3CEBDP6I[*&MKN;^%XV\KT0\*P'!7EL-#!?CQBLF/@CA?18=CN
M;[DB-T>O1)['99YQT4"[J;?X"=WD&T!MF?/NZ-K^"LR37 ]=XE 6%G=(@=:'
MF1I*9O5U4S964HRU#6@BW[MSY&!,86%QK'+VUEN+T/>.'QRILFB@4X+^/XQ^
M9OHD5B3\X*V$-GI\#DT4P[T\8?90R JNY2U!1T$:,+3\_/>XU7-H<)QMMQS=
MX<=0'+??OOK@KR8)OL_],@G"NHXYP9<0*Z%1/(VU_%%5#D?-U'>)9W_^F8H4
M>B'G%&KMO!UT*LP_)U<+V"IF(U?%#4J&3%*(N81VPA$NUR_CV&(Y5Q]OV4VN
MAE;"_5IG<&5G6&F#D]KJ_^Q0]FE\/Q.XX)9ZWYG[JJ7,(2*^=$SIYKQ94_S.
MDEB0\L8UT-V>R).>?$PYUUCOG9P"FUO6]2/KV/B'_@_%EO% #1*_$^7W+='F
MH-_U\YED9)MB.;[DB+(<W7^,%R=C1BD&[E,/'4TGZF46'OVBB/*4[(JP3,4=
M27U5I FWC.^JD"H9 U<UU6P%B7"]Y1Q_35M3*P)S?QV%G0'R<F>,E]9U6>8N
M]T]R!DR1F)>">(?]RE*BZ6X::37.[U_V56 DMT+W=D[='C1T@LA>A*4]TFI3
MC09Q8DH+DYX!P9>D'E'TO@^1&F=<2Z#'XJG17I[0/H6P=R*?\842UXK01JW#
MZTZNS?XK$P$Y\8U[9).TWG7$D@_H9?*\,MR>Q(6 W;*\*GC,^OZG6(!Q*] R
MX>M]1*&VN/E]ULQL\!!3\UB?QC?P3.;%G68I.@.-Z)E<,0C+]C,!SE@(KA@5
MU&5"*U17GM$.W)$55]=5,I(PKB([*&$/#8VS9]X6)[S,PP)GG;+&THKKC!5^
MZ\<5Q1*TNEB91.6(:%=S>M\P]I/2Y0N8%_+ 9E+@4_DV/H=%I6\56:&<;_*)
M:I!IYH1*EIXIH&'FA^K4F!OI^CE!\\##%>@18][A=-)2J77BX<4<+LJXD8Z6
M@X!C/U"J)QXPYG7?-FN&VM!0&]8ELB\%GROM-O,@?YM F5V89%XU]:?2$7M3
MT]^G-Z+G& S4&?<)Y@UT=8@\2F#9]1@:^\3@SE[W@QOE7*=%Z$9[$5GJ%UJP
M.\^)<LHO%08[6/^'Y;\LSP#Q.^O"%J>:;72&8,GFK8)V)O2+Y-/RQ()RC]!X
MH&]]Z^PL:IOLTCNU$QNRE_9OY5-I^3(7:2?>Y$1^=X@,[PWC83LT8K!,@FKB
MRE&SH3;:^7*EQ"[Z'-$*XIE!B&IEQ/W;&G%6.'E>>C!KY>>-!F5(R>?SX*C.
M=>H(K=R>S)V8E)6]A%+D'6/$-7.[F@/5&+T"?4C>!O$$<_/ [;YN=$ O.&"6
MTUL7T^XXO7:Q7_]--"UU*;VFCN+O1; G_,20\L.!V+8D@BS"(@ (NRAUG\QL
MJ!<S"S>_74IU^]]U1-_[]XE-XE/\K<,CJM,#%Z4U-.A%@0YGH[:^#T36X^;"
M07E5S:#6WAW(@Q^1EMT&HD\9@$(\P%Q2=G\6EW4)*7'$IAWT,+:QX7+O.7<7
MC?83?V0M8..#7@Y!N$95CXM+@B6$2Q;P,S*IA8L%T;649:S%<^K&LL#7EQ)L
M(]BLU\72V&G.(Z0CC:GNPC3KAO8<K6^%OGIK-"TTHT9 J&90I#^(!ZQ<EA:&
M%V38KH8Z.A5N+Z5HT3G!3S[I>EOZVVK]>.,[45+\K<E#=Q')3!H!U\CT-%<8
M%]LJ))!1:"3(YU8,#0'.-[U,&@P-M(C_*9?^G9CK@%?HCGJU>Z$4 L$2>?$O
M0DR\&KR:]7/B._/;,[Y'[^RGE\GUI;E A&'4\.J;W*=&-2Q7Q:$7YQDP3T[N
MZ!$<&&L9_<0NZIK;(_/K'!:";G' IK/D@TI^C/HA8I?\T5Y]@,IM85YD4JII
M^&P%5J0P!41>Y^\*%-5\H@-&HXBM+_V$#S(@QR47-8!#QT7(2O*:#&*<4"RK
M;"D^-P/ ;*F'_EBA(^2.<>T'W<(#-+<E"S;"0Q*ED5%)(GM2ALX306Q:1_+
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M];@(\;N9E[;-C33SCZ@PMO!B_[+X>*"=/6#PPT3>JS!2,CG )35KV#;$T",
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M/D64MN7)&GG<)^D<[=(8/D"0+\HQ5)$86"6SRS0FF)V^KR'1=]/(OG:FI_X
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M(P7,D<T\6!M?I/5@B- .F\S2SW^=] 0WA^LZY4NY"*RIT-^/ _SE2HZT]&*
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MCM<=Y!@Z F U&1P;"<@2G"^ 7&R_!_<=?6/RP[3%1H]ZO:*BW52[NI_T=>;
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MY$W)O]4.A#ED0"M_S:;+NGVBXJ?935***[F*YOJ^YSR!XG,D;1EQU(,>!:I
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MJE&%I2:TDNT*9/<;[2>K>181EDU\;U"50HY@ 3._:VO<=1APSG:62_[1H+:
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M@\:U4L3G>:#>[8E;1MN<UO=>7/=XBEVU^3^Q--4GHFR#W.O _I:FIG!R*P^
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M>C.T>(J/0UZJ8NQK12C4QS_?BMH9GK3*ET]$KE%5R_EUVLY5-+E#D TQQ:M
M"O8+@1WQ8/%@1+5.FM?Z?SLP"753+OS:33P2!4,6"VGI8GA/1%O^ :QB0.MD
M53X3J7UM[A)19(&W_4C 62V2[)LCV1)V@,$SD;WA7RLQ\!A=TDAS(GW?V)0*
M8I<Z>-\X]_Q4J74&[F<::3N]U-AV\KU_F7"MT6LGO]S66R*Y9&EQJ4 U[1_
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MWUCEA_:HM'=)5\SZ0DH,^%+:M"L,Y9L=L_X!F"'7!V#Q^8%F:G,E2*F44X5
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M2>KOSZ2=>LBX"2,5,&%)VQ-.Z#Y.AW>3J&7_CRQQECHN&?85P%"I!C=6JRF
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MH /4A57;N;,5RC-382'QOD#=?P#\)^EU!GCSV7AEI<V-RXBHCF:^8Q;:-RT
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M2\#G+3-J^ME G.N=*&_Q\EUN7YOR[/$%D(]'KW^PGO8:&<X!7>L$NT_TKU+
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M<T(6X*G=X^DKWD965BYNFK]/Z>U_9=_/,,MJ4NVP2=\Z\R.Q=ZH]G25#;DJ
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MUC/#D2'&]<<._[?P^K<MOW X@D2IO"DV(:GPU9DR;)N*U'>RC\::-N4;67G
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M5NVD6'HP%W=@=3<YO;RG]?Z$^.UMVMB9.3)D)+(\-84_-;3\F.Z3EMSS^+G
M!5EU9Y!:;QK<YJ"4R_XX"Y%@'_*#2]?]?&<RMW&VUH#)28$YYB]@B*W7!04L
M>3?5G9BC$?ZIX7%Y(],\2I/VO@%5EL%%ZWA8&!M5VFY^)O"K@#WN3_S\#HK
M7'M<^TB[NL^%KJDZ*(##L)T!,7$C;Q!M.*6UIK(@&<4W0]3BE,[4X*<^^&KV
M+3 :J4%M5U/N_1W9U$(RNX*1<K3Q$4Q%R;[ZK#:/93FYN(<-UAF&03[M'(09
M4TEO,T:&EK#.K@\ZXH+H/V"S=,;I@\?L7NJ-0GP@AHR'223Q#C6#O K.*I[4
M$@C)2/Y; 7^B$0CT71_C"\W^T?<N/8[JQH@E0:3%A$$97$G]LI$N^.E9P8$!
M2L.Y6K2P]VP)X;]6,*5C !Y?[*\MN:^-231%D6>M*:NMS(*Y6R<$'DR:0^O0
MM&LQS#WM(#B/V0PN4%Y>.,1I:##G&U%FOL!H!L;C)M_JJK^=4K+K*)G(4>S\
M%\1$ZD(+];A_YT>!%HHC^"YKT,MKI]$E@$_\GJZW06T=3;C>?@1TO8:6H#28
MG9'X^OL)K"@?1#^:4-CAV_HIB@([,SJ0=6,\7GV$['/_]9%X[#Q';$=E_A[Y
MMS\^^.,)WV5EX=9=XJ(@$(0DMW^*!Z+;T4EZK0M4%@)-OI[C*I58Q,PAXQK.
M]<IX9;KDK970LEU6,BBT9_5'WP +%/,LG>B#SVQBQ 02,G=8QV!Y[]L[+$'.
M-\"XIYI:>0M39B2\[O*N37/A>&\;JWPU'/S]E'[#N-'E3K,)XG7\=<&M>.D'
M/(KLRSVC<ZYWU!^MD962@@,&<]UYX%()*=<#U*+/(<_IJXO4VN9/?7>H[/9P
M[#>YW;%K/R?UU,0U:D$$1AWO,C-J!#&R.8Z9D*MU:RDS'[6D]8.F;$DOHL3:
M<T+_0[:/#YO<8SM*3D RF%NRYJ2Y*2X ;ULG'A#S@2Y"*R)T;81D4T\/G2ZI
MM'^*=9B1<?HJ6S5+'=S$;ZU8M#C@0B;T65_F*I]7WGF'A41>_&Y&3-$D:N?P
M.ND4F;L_$?Y3Y/[#V'/KK.N2.Z,@J(N71^YJEFFLN 8CYJ"_*ZQW#II=>Z89
ME52XX)>_.O""J[NS?.,\02([KI*5(>#&07K:?G:=G3V0(?$\"!*Y(*(QNGI6
M_F3(19T#!S7DQI9M:>NF!@NC!%A232%9>R50>W=]:3R2G<QCQ=+P$_+=(Y(^
MJ ?]\.A^T4M&$8$DOE\)$;E+Z<&&ZY ?B EKF*5U)(!9NZ@""S:I;*XVR\V?
M>GU/D\'+G_3.P_\%]<F>T=1&?_-? ,Y2CD'XQ\[$7QF-8NO-&3K31VY@^#T8
M:H0=IXGG].)UGM12(:K\4:NKTU 6+OLOJ5ST-MKI6>BKT'X]G8SX"Z#]"P@2
MZIOSMYI[-6F=#FE0(S<S(2/[=7>O\:"X;LB[?VOW ,3HS?!AQ([_O+P5LE@P
M2F1;XNHJ.,?\%_"CY@NHT#14T!"9T7PP+2BV_5MC.?5";*4'S)\ZHG\OS0UG
MCI__H4CBTK0-G([JS:& :98'T=E$LE3M?#U;Y A^.:RY.*(*\BIHFD3G+#*L
MIL!4Q$;=T80AUPG$/E&&5*7.A021//OT(4-5SUXU"TYJNW7@]09Q^E!1L)^4
MJ%>%:4YE\ HXN'.KY1]H!I]!B86W?-T'\/PBB<R7/UZ@9PN;!"UZ<B% )>"U
M.F-.*,["6ZS5?)^PL%YVJ$#ZZ*H*>-MC#%G^M E9$BH#DI H&H"4Y7949R(2
M8V\O>ABK/S*N9$LZG!4>H\*KUO% H:5E?Q+1V]X%;B_/1>_I-UI.ZAKZ@W5(
M!##P(RXBNMZX=M[Y:%EE91GN4TH?9:9YU,<L]G?HGGJ_O2QJ)%CI4W;(ZBBX
M?6(,5 _S"9T;T__X <UH!^H:=^.C5'^*ZLW+.YFR9PT>(6UW5*O:>V1/J9[F
MMD=9UM0B?HZT$R^)RA$MF/6]$OC<JKL"4994FF5)4JEQ3SR?-7O1+/.[Z$1G
MD+,&1TZ=O:-H)1S(]UG_;87XS_=53=#!S8R6J(;R="CO\8Y2O'HZ]J78L0N^
M0T_GU8-M0EMPF0"(==:U:8%C(X(Z2S&5 \LW:F4FVK6Q+11^SQK*5#_]@9.:
M^YS0J?Y.?1DFF%Z2932FX24Q95>IQ,3Z%LRBTX"B'W$SHA]'E"A"&:[5(!HB
M2[..'W&_S_.@RBJ>WQA>&HP4OZRUC6H36*3;> RZ?-:8CWI4++75W".EGH4N
MX(_#YSG+\]/,HX\():PU.P1&'D"3O65^EA"ZXB22+)T!Z475AD,"\(VY;NWT
M@ZP?1AM,;\8]_@%K3_,KLV$?^#G+VW*2.ZEJ@1]_$L9$KLK#M#>;1.9XR[X6
M8+V><AWR\5P99$,!)?YP7-0S8="KR-MYSWYQD8>6[C-*ZYZ\3B[KYFW_JE/S
M( Q$$W!7UO,ILH;7($AD>=XR*C-T\=?O$*PR_*R!ED.Y!-@]+]E%. N$H[R$
M8DJB\%ZP:_H8IITA#\=K8*M:M?4UL%GLX[+P3U=]C/%S$-<1PZA]77@UC4UR
M-9FG?8;Y"U%VPIM#"-Z](+;R9MW;5W6*[ZN[6'F]?QDAC%4"ME<$Z]-M=B+S
MZ)2'WHZASQ7HN:NJWY).(X#3[C6Z7J0R.%&\50/;KO9;T7G:]5$K-JFCT_':
M?!$&@ )7F?(_?L!B(I+:)'_?8)4P<?1:S>C\BRF&[ SZE,E2^ZU&]N<AO2R.
M[1AVCL".8H4BN?L$E -"GHU8BJX(2G++W40M,Q[MKU>0U\-__ATG\KFMD:+%
M9N JZV0C'@%%E_KDCYCE)4/##^)#M6J5LB\-BX$004Z(0K3J-"?_ 0YCV&[Q
ML[\ 3X 7Z_S4]B[;D#XY@UB. V/'R^/.M3"7;_YA)89&0]V)9VLYM/0S+G5_
M >40-81#I8VV^ZD\]YTN\69D*>F-NW>T'N*/L@2GXOIY/LYSCJG5UR+X11/Z
MDS HEQ5ID44__SW.[-T, R8<#^>WTD%B#$/JW-+L\FP1/HWA40H\U"&MQO%0
M!HIU_(,\S6>=S8UBNKR<9(O;TK'P]/UYCE1GT0,[+U(2L<3D)$_FO$&;Z]?&
MY26"*MUL0%CD#9>/Z">7HYI"+,-56T @3]]8.N+HA#'?:P:$8>D)?&_KY]%1
MSD]RY.!)/< [Z+H\I^MN:SM=^3>FCFO1JL,B%^5Q^KVJ=]?9: S_P58U/)%Z
M+5$57GZ-\3L=X.#@/:)89Q*!J"(3JH+0Y&=P+^1$RU:A*66D+*93I>? KM-L
M(4&GS>=[$262,30LXM_[]$ZA#%>J.,:TNJ4;#9 ?)$:,E=U>XAS6]17^C9H9
M4N\B-TMC(ALV[&4E=AC>+4V(G&"OR'J9-Y!K.:(E5%V(H 1:7F'RXMIK=!A8
M"XS>"'5MR")^P?,AH5&&W_\0MFO5(IC !?TU!H\QBC](HC+3DZ_+A<YLK/D;
MX.)/-L>O9NU=&ZQT2P_GAP.I:5=C<GTT[.WI9*]*ZI,#%M]\\$JX!P"!MJ7N
M'D]433/';E9\>DH?8Y;2=:^N)+93UIHV,&:V&[[6K.P=-DT"&^ZY5 O*H$-^
M*O!ITZSQ!V#UT^S/NVM=Q 7]#GZ K+!ZLV_FG3:X6(]VR.&=" WKZ,=O?I-L
M4UP;K5.O&K_KFB7(L)D&1N=9+.[7X:T?1/(J/ PYI]O$,)@S_-!2.?>F^WJ9
MNY#$KUTG.IIA7F&0JQ%L'7C8]6A6X0X,S?=DN+%=89ZS;N@:<W@5B<XEGBG<
M?C?S$A]"2?E5;'JSZ:=(XOO^TH(GX(Q_;Z$MI8,Y<+8N:^EG8]S.$.Q%FQ>1
M''H+N/]*8,N]!DAK\-.+@_D>WPFQ+:&\9-8<KV^H-*?J5&ZP+\2+5DMA4QGZ
M6B('X?X70.3&/I"=/G@EY3C1X)8APLIZG)'G3HD;34P*M;F+>10N5(U=B,O=
M R7D])2]:IR&7]5.&LDWQXDOYT(CVQDP??S8C;MJ/=R?:,$[C:;^]F/4%UX,
MQFY]ME7F'L#!%<%8#L$:L6$"N*TPP(1'8&3OVH.-Q)1I1;\RRN0HL8'Q!-\?
M&ZL%<L8(6:;?SLA'(A?UE[U 7)CX.=O@'/NG!O+H,C#$N=I@<5_O1VVE[^$8
M%S%6)OV!(*ADE=#V'(['.9O#AH<+T*,B;UA E5E-;4^7V1NK7]A9108-Z;5_
MU:5<\H$-)10XDX"7MK=AW(0WB9-"%\>F+UO?I0P86'PEW\W /6Z#<Z(@*)<M
M@V5*A0$1J:C@R7I#)7_!*^M9.V0O=9LOG<0V&R;Y%\+ V1;*M;1L_=V*]R96
M]0X\[2;N=T3E[)YZF^L"0:/=:A^R:X4)L38X=^;%A0J6!#KJ0@7$7)A2:[\U
M-0Q<EE(WN^5(AOD:XQW4MEG2.%,1I0L>S[O4K32-T1KOP;[^.#_0\H?667\!
MF;Y,MG2Y_L)=YL4:U@S*Z2,C]I3L@+D7%1[%+,^#[$CTQ8F:'TS0]E:^B55@
MV@8,K4F$^C@RUQO7%+EC<09\O1;(JECI]A4!CM2PW_8_Y\!T[LLJM(AU^$JC
M-T(5]OEJ\-[$,$1%!,W'?+)^A.%X;F#*HJX>G _&YYL7._S@WQ(U7_I.[GC'
M$MM(O#]:/=T+FNT38H\?MMD\\3!\G'/\*#833L55RC^DK A]'3UZ:V_MTN9<
MY^O6G\48,+GNTQ1XA1EES*G&U!^1L<&^*F U/=QFY>1X&"L>Q13KP4[89;('
MTQ;5/[1"[E4S/ZA:>S'5.YNK%!94#>R!F+P143D>&(=M-BZ][>XE"JL]&07D
M%O*<35+Y^]CF]\J3(QPO_$G2?Z/:+\N3.@<P_@*N9N"+V]^Y!*&I20P+EY>Y
M6R8)<@G(U^,(17X"!A#D'B>.72K^G;#3&!#"V"TX1]K!D/?U=?6%%.<F^DY_
M6M6-6UF+3"?2LS%J@6N[%M$PI.C0)@%F^'%9>F,.6^TAEO'QHD?]D+$LX0M0
M&SNM!19K-:;(YM_&IA#F4*3ZT1\-]7&EN#ALWHX+SDG+"?'.AMO*'<C4!DPP
M-4R;.]LM.S79[(Z@+DNCB5.^CGUE1=2\.3>L\OI(DN<)(/+NF.'W:2, 3Q@8
MK_C!= V-A$W&T*> D8;Q0I_546+_QC(7!FR[B@ZST"FH_U7JE(!A/E:0IS9M
MF9QF_&6J[#!_8E907FT@H:FNECUUCOO8#4^R:D2\CJ1\,60K$H1]LSO3M*;L
M30L*KIW6.)P=>9:)X9C:5,7PA.#B%(O;&X!,[_J2@AT(X_&K0&1U1%2$$[5R
MHA'1>OUG*@4TGB<R<+=G @YIR4[UEZ7<.#?!'\<?I$KE&1-UF6BYM'.\(URI
M4&6J(:1[R,C\-&!2$F>7 == QSJO"&U+B83V2)'$2-%^5'3/V=*R3EYD+![G
M4)")-_D)+)V>2&7985OWPZ3<LQ.\Z,'Z!9;6EF::7]>.H9=;RYN4M#C':/0N
M>NY/@E'&-0JO-=U3&,]O)4R <WMJ_5/59)F3U:(.H3&R0@$5.6F@CV0D.:U$
M2N?LM%HP$'N*_>9$&?J[' 6\T%1)-U73*-1ANN2YZH\*C"&EV.H@3JHA+I^Y
M2*.]1GCED+>50Y5^0H1>O\MVOFC?KK+'JK1CQ9+-OJ_EGR;V?KD<[)\^%A$#
M[R\J+8&5\GE>!3^/[!E;\? %659<S3FT@0"LVSG9HOZJN@4!6I\2=DE./60/
M#GJ!NL\TI01U@P_TS7HOCQ/&D$ ];VUGF'^SK*&(GJ#=7H275BELU"MN?YM6
MGUWXLN1[K>+K3<R7/1D.2BLWYGYY/0PU#D6RI#+;F\N?Y%C&3(B$RYU[>X_Q
M3@X?*9"*,/K>33E'%KQ=;UR0Y^5EZ\6Q>^Q6?YNIY>NZ^SJEQ(HJ9R6G+:$'
M??,L&R1T6L/@L?CN^CJ4T?^YUQ].IUKD;%Z)+&$2H8%8HD'%\ <JND?VKZ,0
M")!KR_YD_<)*NK*'G\'Z5\M579[U A*4#Z=IR>%PC^JD^%$[ER2Y3 _N'!2-
MPI$332PU:ZH+@."EGE3J-!LSQ<O4MQ*]]KO0]J^Q%\",VE";?N,CQKQ('*<<
M_1K59SO>./F@]$V<Q@7QRS)%:RV0W^0:O<4%&32SW!8T@:*5C6(/)4I@SS>H
M![I?%=V$;&][?.)D;D[XQ$!7W936/'89JEG'SO9$=_=HNS!9AA(K/>#-CZ2'
M/:$"M]HE.Y4M;&"++$EBG--5O=6E28*S^VJYZ+5^!WGP2?X32DB&]43<^N#P
M!Z9&:^K;:-F.?3!(3@244$/BPY:A'C"EV-Q8G[A6R[_ Q.LN)D_5XR%!TSC^
MP.:0>.7%N4/[,<Z SOX2E_W[&>Y?0*<8D[=]O.ND[1-8*XXQ FT":TU/Z.L+
MJ+%4L([^=F.+,4R!Z?:7CY^M)=GDMH729%1!P?Q-C?3TZPNH ,C*@"Y@4?7
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MJ]((YMA:>WQ9O (S+9G9G?=-B4^"I,VQ!F>.W5O%E+G.USO'-"#US 3;4N*
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M;(V(T09+G/\ %[>]2V,S26KV?V-VE9C)(0,L$]O:CVTMP^KH]N'Q*\+D1_\
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M7"6%*UZ73*5^?&[5=<>[^QNATM*(DQX_M@NF=M+VLI6WR X#_^$JPY5_\9Z
MM5HEZ(*?0131Z,#B&$.?K4^DRX8_*8)*&UK9$>-99-RIX)=%.I/9)XT++7^
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M[ABV9B11&KU!B/DVK/!XT/=N5:GRA?D_S!X$82RF(QF,A8[6O4E41?NI])O
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MZW.!,=CG"^#9^"K6RJ1R6-)W<M7XX'Q9::KE=C 9?^Z?2O*11Z'C_GH5<-\
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M-)<C->X3R?Q#N?>6906^/9,^+I!'\&>3_SJP$$/>X?V:\40\;+6IO53S)-Y
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MY&?(.,C(. S$^,0,_]L7] < ZQE,,>PM' P5 !8+!@X+!MH)H   8!!@_K@
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M>J_H+2-%85 R+UH&MS'RNQ#SWU6T9&5&E$T?4FCXG6[=<P5]@0*V^;)\5*"
M$V[?#GZWB$=_#[X-=B@ QT!Y3&9FSQ6CZ,>-XR-11Z?O.<E8*Z/O=:+82K*P
M#!0@T4QR&@\%!)?E;V<]80R:6O:J_QT3Q>^(9R:=E"]N%SIVCT5U_S.S&6X?
M;%8NW"C8?L<D\SMBG@LR7&\?L-UM$T;\?T"5]1ODV_ 0T5:=.N__#1HW^:$
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M$.^*S/!#)9@RL^)67'.7%IKCA\L('V,=G=Y[,$?M-%P9TG%IHEMA9% 54%)
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MK>;F"CM(+C/99V/T(^ '$;SU&])+T1K1L)6]$C'5\%V=V'I1E>[]P^52%$S
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M^<\];9&O2FQEHKU4]:Q$DH$TD85#:?&Y7$/(H7=(PDI'UB-7JW]X=NQOZ:#
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M?U!2-8JT>Q6%742,HR*0?+?2F#^O1U*5$#9X\Q1\V)RP;@4N1KY7N6(2+7"
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MIQP'[8?'OH #:L4<* ?E$>V@!;(=[WZ.L=]7M44*!V1KD<J!#FPIV4[:.O/
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M@!^OQH<A#9!EKP@'!"PB1)VMGKU(_DHITO9+^/XZ4&X70)0KA?O$9?W4$?H
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M-!PK:LDCV=2G?.@[ES[[$-HJCN"XS 5%[#'7]KUY98X@*4-/7DY9C">Y=/X
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M.).^(\"T$A?224%T2&<*P\)0J8,6CN_$D9/!P_OQ9"JBV7_]YRZ8 A]2)T[
M^A+)3/WH4H0Y49TC4D=D]),+4+29XP,9;CLT;3U/--5NG':[U6FWZJ8-U"T]
MG'(8C*0#2IQ>-*6336'F,H6MAJ^O8!:^S&0R 64-"_0\FN^%D\7TBS283&&(
M +X#$3N.??@$;**&GCI.VHE'O(2&O0&.'_@.S-H9PZZ!%1KG%V-G'*19#'L!
MHT_$=^F(R)%I%DQHZ>?PK7Z+'(U@_L&E#&>P42F<80J#PTOEM4R\((67>J!H
M87OA2*RU.:,DGH %#(/"(D!U!R'\1',Z3#OR\>E$PI9(^IW4.X6;@*>)'TX"
M?QH'<"A#F5U)R2>;RN023UR]20U%I)H &>8BY#%@._!S<242'U=5MXOP'C&%
MSSPQ#"5NAQX<1O,#G&M*+\"3@_>1%1:5OZ;M8#J,AS0,O%B FI27$AEIVSD>
MP>LD[83:H?EQ<"9X2GJ0\AE>!6'HY*DL%I0JPIY?=C"JVR48GA8O_8:CJ'!N
M-QJ+?PNG YL$6A;X)P,J\;?OR2"@*79:-S'(91P";80@ADNLS)0*YQ/:3QAJ
MF\1IYB32@WW6LP7+!+8]S1-DB:L@&]>0ER*->(I;O^WLI:7='J-( #D1)\!<
MB2 ^U!R#A!!D57&2-IRKL2P)GO\C-;\MMI'&I*F+:'Y:C?)'Y1T!-0]LJ!B+
MR$ )06N'E&C3OPN 66&EJ<0G@7ZB1(9X=LXT'\)IXD[!3/$IW*:@7FX&D9^G
M&<J*L9(U>IN \M( II4BWPPE#Y=H1J)-NHJ<80Z22J9*0@B]&60>BA#/38DX
M/@SSWM+.W)/:.FYWIU8<HQ!(@O1[<Y1(^!=2B);)-Q!(.J=</H7"^]X$AS8.
M<8_IJ2;J(3SN2>S+4#\Y"V3HTS'\OGT&4B@!FR='LI$@-OF(B$9!].J_02 E
M,0QVX^PD\&X\DUH'\A24:)C?K7>%?<A[!X)7HG<D4]N@1&?^?4IN.FA\AYS[
M]^A"_+I%P@)]</ILG*!!@-Y!4UL"V]>I#]:[-=J[\GOXM6F<)_07N?WOE7U!
M1UAK7^@')5EH9GCU*9 ?? XB+'%HVK+6(=\__NM6R1RK_OBC_DB]18W.I&HO
MB3\'"9AD:*U^9%\<764]0O'=W,_ L"I^Y+;)/BU_8V]>:0KZ3[5=BW=O:?>,
MHSA9S>+U-P]>O+L*BW>?:O&&;Y9W&TI\X_X(W[A/R3?_S%-T2T]929[ ?&;G
M&'H#XPJ5P*>9_<W>=9#^$P6@_>$7.1G*Y+GV7FV<O$ KD__TX:7*4N.Y@/6/
MQA"%H;7;??<%;GW$%;Z?7^(O[VK?9O;;3&HI9<3ZH)?GH)]*'E;L"'7D>S ]
M/PAS]&C/C 5V>.V%N2_](S"MT;C-,_)2OXT.11*!19>>R.0,S:Q/L_H!B$;X
M#8?*+CO+8N_[-[+*5H-8GG!KMC[JERS<G:>AL^4UU"KJ>DV>KYX\E]8>.@%G
M5()". %/.MN+_$/PW*>XVD\SO-2QB(M/0";FB=4@K3LLL""1!6M\$0;1^J27
MX:2?S"+ZH9,^RD&09GDBX:FCX!K_E;[ PUZ\S%?&V>OS?BW\C1[?9S&,$X$7
M&R]1DI-/NW")KX:QUP?]2CB:GSR+1]D5N#P'\E*&\4L[:OWPPE6^&K9>G_;K
MXVW*F!O'H7\\F28QYY>\1//LAG6^,OY>G_CJ\C@GSR[C3:RU^!8F[KJMIUA\
M*8=X&;>A%("EC;AO +:R>X]W/U#)>5[ZW7,QX_H'PM>M9KO[%+NWI'M6ECKV
MXA]3S[CM%5@\ZMEGNO;]'$<7YS*9G.2)-P8]LQ]/)D'&JF@?*.X"G,9OH^-,
MFB=\.]@MID$FPCU?9?RNAO;]P35;\>_:9;^VB]IVJZ\)JM5?A;PJV+W^#^P>
M_.A)=N\QV1'#/%6J_!;)%\Z/%-Q:N.S7QX]U%+7VIWZZ/[5J)',<>?%$GF$Q
M"Z[V<^Q1ZHA%*J<RE0)8$;;:BCMAP4J4KHC0N6&1!:G<89VOC63JT[/6)+-<
M)+-<*5,_*&5^DQ%69\%.[OF3( K2#&LD+^7+(YH[K70M:=9DLYQDLU32IK6T
M13ZET/)3Q=4USRSO-E1#R_<GG=:3YO:F278JH@MVC>"/+\!9DWRRW'(#YOG>
MS'KK(_Y9FO?*W@TN.!-QO9IG8L][=<^D8M"M.>8%F%NW'NJ:Y5;_4%5,,!31
M5S$I<B#/K^+S<9RG(O+3HV"421GA,\M]UB;X9ZU&Q81O7,^:!FZE@3-Y":M^
M2510LZ(U'5"69#Y, S\0R>Q,A/+;B K\#%'L99.]BT3*U4F>7+@>113S*WIM
M=."VNCJNTNIV6FLZ>#XZ "+H_D"@!'[4>8)$JE;'T$&GW;F5#O1]8G )KP<Q
MZKT,:BCN$.L6]CQ$T?D1HN@T$=_U*8G"[:V)8N6(PNT]@>4P,)D^ W=P)XUQ
M*J<J66,O2= C>Q%TH;!@%B[M>6R)P8]D,0V:[N I*...%L2:'IXHQ <'VWG\
M''5,%-;.@NONK(_XY[*\^T/N@]MT=Y[NDF1?=1'@\U=__'YVL*QGC<% >\YP
MM.JO]S#KE0W&N^OS^*'S>-KRQ47G<?SY; 7/ V;]0OEC?1[+Q1]___O?5_ \
M8-8OE#_6Y_'L_#%_#VO2P'Z3\44BIF.$M.=CXMY/QY^7^9 63A].C.</ NVU
M1>%_Y)A_/RLE09Z+Z[T\&\=)H+!X^<L#^"K- F^??[3<#M@=Z>/WQ?KNSCY>
M_:85L;[:?7MU9+F6.:NDL]>GM,2:O&-$?&?NO,X\&0D836=7Z;^/XD1Z(EWR
ML%GI[.RE<,I5_6*>091V?D24=IXR$5T'3O5F865B-D, U3B"/VT ZE.9"6QQ
MI@&:EYL$3.3TII7995%UBWMRUGZR//M[GJVN3A;AB0C\XT@5+;^H([YQC:_F
MI+%X/8[H_N!%G>[<NE;V1.OKRM9<_-.X>'EKR7Z<5-9B8$T2:_ONU1''6J$L
M@T)YCJ:":^;_Z<[=\S9(6_/S<AB(RQ4N_V%261N(:Y*HD(3N@/WRB*)F96NR
M6)L./]-O6"[B6"N/GQ1D?%K8DK7EN#R>X+*<]%J<O]RS75MPJW"JZUC^S]*V
M3]9.9LVG/Y%/E^^B=GV^ZTN6-3&LE B_)3ZR'XHTG4.EF< [/!$=R&F<@BL!
M.S$6*].5>>':-$+-C:M[=2&2'Z"/;XD?1&;?OL8G(OF;"'-Y(A/ZZ&70R=U6
M^=KH!>%K=I82_[@D3!&P9>?1A2DM7K'(ISP%CSQ-]SS0)6E@P-*1=K[(Y$(F
M!@?K?X)LO ]BM7CR<^87T C?1M_R)-V+_'W8JQA_O0KLLV#]BGD>8P>>0><^
M#9ET6JYKXW[)/W*T.1 IL=I+N?SM:IS\@B59O9/K5O7DITE%"F[GH:>91P$?
MY4F>2',4$[((Y4<U OQ3_UQ_H__&W\-+JZ.1RE@P7$H:YIX#_GYV\$]01?\L
M#^P'EW#$]EJ^YF#O8)/ZZKN#-.ZVW7X!"E'_ZKG?XX<',HHGH!UKAKWKDDI#
MO"O/_N:5YZD_MY%W7 R.%ER_3V1(;1_2<3!U1DD\.96C]->MHR/A9?]LF?_K
M]#M;3A:K+[\29Z.]U.ZYG5ZOW=]Z]_%>H_47C-9N==JM>X^V^ZBC#1:-UAT,
M=EKW'&VW]:BCN0M&Z[C=G7NO=+=]ZVCO:+@TSA-/IOSG6 J?A!60Z,=?\+]0
MKIA_\#^=-)N%((Y1G#1%&%Q$[ST08S+Y$(*J;(YE<#'.WKO;[=Z'$0B=YDA,
M@G#V_AQ$;.I\E5?.:3P14<-)04"-^)$T^+=\[W:G&?]YQ4,,X]#_,!')11 U
MLWCZO@7?JS^'<9;%$_QDJU <XT1/;1@GL(YF0L-$X/Q^4)^$<E3^()B("PE2
M%+2U"/6':G1W>NVD<1CXSC 4WG?]+4ZE6_E*+[HUO?[@Q6&<O$\NAF_:O5[#
MT?_U]L,0GKQ(XCSRFPN?X?7APAR19_&'N4W><M[ILWBWW.?R2SH5D9Z4-9SU
M^+U^O6B^](&>]CT'OOWQ__I/=Z?UX9=W^*N/U?]9D@, :GS0%O(.TFL7'UOW
M!S;OGH___O7X_/# .3O?.S\\^V68 *D_Y+3.#O=_/ST^/SX\<_:^'CB'?]__
MR][7WPZ=_6]?OAR?G1U_^[K@6)_K=!_*3P\YSA\YGWL^_C\"M%1TD<6PZH/M
M_6VGW>IU!RNUYYJ>ZJ<U-XE[**O'&::D]=00[9(.:C4<_,\"[6.^K>H=UG6L
M*F_0064M])/%X,[<7NW<I(?F!=J/,=6C\\W1M],O#AI[L/ODEP0>>01':.&S
MY]UQ^ZX+9I[;ZH!)&PETCWT9O#^(O7RBO-4M1_E\8 76AT&W/KJMYE_)\BM>
MM8@SYQCTA1+QTLF@&D6X/-;4FR\B^>Y\B^3;&R1Y)H:A=#P9AE/A^Z 2?MT"
MUPG_AF<]_?>]9U?9A:O S\;PS]:?[<-&B[^.DNY.GA:99LG=N;CX&?[0US^\
ME$F&."5J>C# S61SK_-0>]!>:OO[+H*MV^_W:@7;7A3E(CR5TSC)[B#@G%&<
M3$3VZU9PG;T?!=?2;V9)+E&Q#_K=G0^WR;[,O\<YSDN(.YX7"JLRP91%SX_(
ME2H+K*R_MO?UZ^][GYW3PY-OI^?.R>^G9[_O?3UWSK\Y8-^?@Q'ON!WGVZGC
M]M[X;YUO1\[Y7PX=R_0W9O_>_CE^[0XZW9N4&NN TL'#GTE%',!'*-0>QRB\
MV<I<(H=C*0CB*$Z<;"R=49 "_SDS*1)'1K[T[V(S]0:M[FZK72=:3BA@?LA7
MB/>5+3[\ICF!GXQQX*8O9DV<6%-&=Y)XO4&[U>UV[6DQ.&5V1*O\!XSU>#/#
M21U(CZ\^\/:T+ 0;=]O(+ORK5;>1Q92/X)/T+G8H_FM>%M\LFQ_-)UNSWWW8
M[]OI<Q[$VG1<FX[W,AT['7"*^[4^<2(BOI5_B/DX$F&J[<?NVGY<?GEU?KKW
M]>R8#,6U#;E68F4;,C,RP>%\";I3=;+X)QD;CQ11?ISC7MG3G1_XGD1[!SW3
M;>]T!KNVGCFD5)ZC()3P0TQPNH/=VVJYS<[N;JM_QR#LT\;:;]R9G>GUBSWP
M-UC,%*28  9N)1B<$9W@7$SSYY_" AFRXK'XFFN;%8C.WWB[-/_ELO#'(\F_
MCMOMM>?EWZF\"%)4JQGVT[Z+#-S_R^&7;U_V/J'1=;IW<OC[^?'^F?/Y_&#[
M7C=32WU+<G@MO(SVRHE'3F+VR!&IDTZEA[FJOA-$3I"ECC<6238G?6K2G![.
MG[8O<2<.Y723[/8LI)]W-UYC8:TC"O5.*,^RYVX/VG_^4..1WF_@GR^15\8H
MI<WQI1<GE,WY'IA4)K@_CV2=]C#7LS,OG;&+23)5;Z72(-6O9#_V[QM9;J;2
M>R_]"Y%,D_A2=5S T/)QF@@9_H!%6^,VUY!K=W>[M;LFUQ=%KNUV;[<W3Z[G
MXOI8E7)X].:[>U:[X%CM]'?Z_<[C$&(I?K.6OJM&SF](V#EQXL396";.O_(D
M2/W H]!//%I+I1NG=(M-]H+(Y'C[=/MLVSF<3,-XAN5<-]-%-?]Q+3A>FN (
M;(N)Y$=R(:+@W_3W#4EO:[GQFN1&V4IQOL;;MY+&JHH.[5Z_,L*NB[FNRI$M
MX78N*1_?P5GIN)U!OU/C6^_Y?H)( ?P_GV$?W;LX*G\-DIG(G+TL\(/)#Z5B
M==Q>?\>M<9_F9]2^RXP^Y4&(@3'GUENIYU5WM9)GS7"KS7#/&&;HM-W>3M==
MR"?[\,]OR7E\%=V%2\YEZ.Q=!I<_PK+M5K_=[^S67!_KJ7 T[4<B<BH0AP.O
M@W%K+OD!+NGT.KW%VN0D3C,1_M_!](XAXX^@FG9;K9KTWG48[M41\AM%1'@+
M.DW MPZF(G3DM?3R++C$RU'PH62Z]JM7Y3Q!#C@H".Y[8NMTR&4ZQB)IX[_^
M<[?M]C^D3B9#.1W'D<Z%:CC K6%.?H%(I #![\OWSO]Y)XW2&_1:I7(^-+7V
M8)2[ZI!!?TY_-._R9G"-X)_VFS_'( U.<&%WOTOJ]YLP4K,%YN.Z*&4I"?@,
M%$@29 $,PLDU,I&^,\V3-,<LFRQVX D*S;GM-\.WJ'XP_7?/R]ZOJUGNJ@Z?
MPNSJMK9;:[/KR6L@@BRDS#,IO+'C(1+LPRTL=[ ]V%D?W5,?72)(YY[-)K"0
M-X]B&J]Y[AD.[JM*]B26D]?>6$07\$'D7(T#^*104\OB :_)8EEN&+HMMSTH
MV<O*OIFY[2')\MNMUD>!P-??.\4##C_18+I.Y!3^P+M/$%'9%?QCYKQIM\#
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M4,AN;67>DU3O08E,B/3.RJ_N.8/;'S\'F20N+D"JH=B;$)*, MX"B55!.76
M:DC#4EKC",U#^%6=)1FS 1EB;<U0W4MAA<T->GD2IZ1UX83 A*2@G<1@'YC'
M<83&9.J!)?E'+BBI'#/'_Z0XX(C2A.&5-2S0ZP E]_LU=_TG%"DX"F-1FU3,
M=)]' 7^8I_Z6@S. ,7:V0,9[P00XX->M9J_,'5$^:?HQ-3#")[8^=OK; \T>
M>J8?'3CW$/[1<-B64?OEA7%*L4=X#_:/\>0-&[88O-:AM'J,9Q1#,X90!3,(
MO_SO/)).I]5P<-7;SA'8:F#KP(A\L#X<0C()(C:0L#I6M<O ,K(:6PH#2GZ
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MC2M1NH73U6Q''(4Q"&#'M,1CU.N+X3G!#N4;,#9+G>/(EU/LAH96Y[*PVQH
MX]6P6U>SVTJ4=N%T3Y(@\H(I*+?BSM@YDE)E;LCD$GR[I;G%<EN]-;[8.@!X
M_+=2_.]O2T"7.S^%+E]W '"U=$-/ZX:5*.3"Z1Y>CX-AH)+X:K+[G#-O+/T\
M7![]H$VN]?W0JV$K4VWE[JP"6^%TB]X;9_ED(I+9LK'/7(3<=!!_:CSD"O#T
M)X05WX/_,C8(XX$[! CNV #9;AU"MJN0QF\8W8R,L.5-&\?<$>&5F*6(E;T
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M0#/!N&5I)N1]F@U2"T/+8?]+TVVYX%>!]1[%7DA*%,,JP]B'R<L4SHQ-DV&
M_A3\_S",O>_JU<H\G&T[/) SIC3Z"<8<$S9JT/W0X0ZZV@$AG3D3<'D#\";
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M?YBSH1J<E_9NKLNJ*6WCSIG$P/PV4SH(6XT!&(9)P6:."2$N1@9*G^U<!&*
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M;J&PDFJ"F;A6\?>RR,,5-=5$R1S3@LY@2=L^L]DC]:I71( VRAB)2G*J=(@
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M#V948#*8U00Z4F+#",&Z&U'C"+Q<R;1-GJ]<1X(DX1PCP:S. Q56S*;%U_5
MJT TB_0&.SX=E>IJ*;1+>!BFK\::2&/]@9$J#OO+2>ZXLR)1Z-A4QZB(EA7D
M^3BILA)VC+1RYR:,!;139[GQ0+CMK::>K+C^Q+BHM%D(Z6G'ELPY7[$>$^@-
M2>0E>R@4:MR)JKTE3 !BUZ>?=3:%!UAZ/N8%ISJO5-=C6]\RSX=VQ>YFYPYG
MPC>1]:MJC+_!&5Q/DIP2.6L5P%$XSW1ICH\YADR?"L,).KVNZXCV5\M9JR90
M.X6O\?Q/1^8&,%5Y@6*>DGDK-!O NYF4PN3NC8,E1;<9R"1"+A\BO\L<F$T
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MR@-Q.4!-W:@K\<]Z/"+GRG@R1O<PWNO6>0=W)-7<$P1*Z"TP) FY&2)7,S^
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M^DF8LX'[K"YX=A@<+%*1E^NP#>>)R2D3I($B+N3^I$?ZRGYM]N#E3^= 83A
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M]AM!P.+1LM\K_)T\2"UM#.19R(L1P >M//=_1,J%[RL!-'J4WMAKP1C3)VV
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MUT*;-%C/$@_\U]/S7W[(5M&734GJ[#KS!2*X%5)L5DREZ^7K4:=H;T:F++U
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M*?OD38P4:N&18B/#_@W$]. OSC-]I0'C('M63>EU+)M5+O7$7ZR984 :X%4
M;#Y=>=)0\DD_X.KN\A+X]@,/*6G\O3[(S>"\6G%/$_0-DXMQ>HB](_^W!Y)X
M>>C<:K<K?CA  C"2HK7+ZB+W+/.1W>4DWG2(!4 8T'_O[+^F:7_GZCEO"-(@
MOKRSMNU)V;;5$7%M,G"H=W,Z8?OFO5+N*PT6W*,C6G#5V]X:AJ^J^&2S4:RG
M^YKN%K (JXF[KG@5S);@[\7YC@CD0&\&C9(*%G.U#MDF>AMY4TZT"<66-QC
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M(E*:<[+%$BEMA%)<R:4[K= 0D^E]W;PVHTR1/"'_U- (V]!N,+A&?5!Y<P]
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M>][RZHIURV=/GPCQ7$[[8I%Q4Y7M#6C,J<$[3^,8&V8JB/K)E67AF?M5?8!
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ML#2*5%E>O_:K$$@LE.KE5\6F\F/+OS<4_3VDO0Y+*_W,E!YAV#GU;"6=82G
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MI2)VR(^EWR?<JB'+I>,7[];O!)RNE=N,U3B@H"M+V;^8C"N@9$UTIE0@3 C
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MR2\ZWG$:"L&MT&USA6WS#]DVM _7*]:6O_K'*Q597 *@#]6^<L'"@0I\\TY
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MFW1OF[);O)G=QR8'C^W,!U+--Z&AHV@LA]!P&QD23V*#M*-@NQ'Z$:PK9?I
MK#>BQD/OUBNL=^S<_,$[T77[?H7U<H,'E+QN.'@?YGU#9428DZTMW?(B.F^=
MYJ/KCQD=R'<R^H\5VO7A[=[@2-ZUYS.-?+?2?<D$A+4T@\CXG>,T>YZU-YP.
MIW]A*7C3&1(4LZQZC50MZOG$+CW4*QK\\902A79%F>)D M?DH 3\]'!_+S#?
M][SPJZ>OO!$I%^L5NY7UO:PY0L% .$</Z_;&N^<WWFE2UG=8B$ASPSA#/RA<
MDHV&LML\ =B>_7 +4S076*M_VZY)5),[C3ME!Y;!13>^8?'KIT=)A(69H=I.
M)FVF&NS8V>#U7[(>=(6#9;V\744=999MK=G^^;=PCQ;.#NZ%:X#NS4U&))1X
MEU$M8L"%;VOO[<FX338WCG=;,6O ?_FC_<^?9 ,.Y&A+OP<*DK%E%86 "^%C
MU7H.\O83,\EMO0,GUDA5/X@'2-K6;)DIN!'$C;"_!Q<UPLC&*>+WWS^RC?R=
M_BGGXG.W6+2(7ZOK__C3T9_HYUM,F/[,&;:GKUX\^ZEL5[_B2W\B-/UOI^X\
MF[CIR>ET,IU>G&6SB_E949Q/STZGT^/Y_#CA-N0LX]N8#9/<FEUB"S=?=:TH
MGF,T^O]6#?T7_RKTCG(=-L=_P-5>%5NOB1;6OZ!805@$'=^JONT/#ROT^.PO
M#UXN6Z_J+9<;W&*_A[MF)/]G5\,@#8WQ@>'20K[LFJD_U%\?+)R)7VQI2:Y)
M"[ENVS(5> PN?AQ5]/7?YLO%]>TG$O_+;]S_ ZOQDQ#_#'6HV+CLD^^]X\L\
M.SDNYB?N9#J?99?Y^>3\XM1[@Y.+J3NZW.V]+VGO=;LIAAVIH&/2E3[2D-/L
M40D0Y+@SFPY97"+T5RQ0W.*0+ C-J+L]U]MS%[.3^;S(IA?%\?GT*)]>7!;'
MD].CX]/SXO+HXN)DM^>^E#W7QZ\;E]%)X<)Y3ZY5<43XW[0)!?KR7UE;9/\3
M:(M^I@V<[!DSG,>X>;[X6O*G(<R^_,KKSI_:AF8G^6QZ=EZ<7[CY-#L[NBR\
M[S*9G%V>S"Z+^6FVLZ%?B@T50;*1R^NJ7OK F9MD1?HM($!;Z2C55/M6YR5T
M3,74/.#L.AY;:B >YK(64*DX3^:.@@P-M!@Y1'P;HE102@1J;@H(U9@(OO&C
MP=B02IVYU3T@\"_7/IS)..6FP_GGZP;MPSLOJ;_#C]S1V<7IR<7IJ9O.\BS+
MS^?'Y\?9_&26Y_/B8K?#OY0=_I"7E.HN=BMG:0IYMTEZFV1:7$[G%_FLR#,W
M/9^>9Y=N=G)Q<G)ZY$Y.SB_.=IOD2]DDB<01\T$08T]+/&KXH7!S%QG"'5JK
MA#X97/PD%^A72KE,>7P&FH3CJ!JLR/8O^,)N;W7W5GY<'!W/\DE67,RF%R?%
M99%=G,PN)O,LS\_/)[/=WOJ2]A84-]J K!,'3RKR(8\%#E(PE&;$7,B@<1]+
MMH-,I.^[5SX[O.>3L P39Z)V:O<3B^Q5T_K =NVB$!+VEZBPD B5HBP,!QQT
M"^N&:6.D IP 49A4P6W'R&&9^*"!:IZ</\7DS+PWPFUJ5'F>^4F4BK:A1""T
MF?VTZ9UP5<DB1&QMB;E *]3*>*.U9**\X44J?$:41 ('0I55@6F/_HBR=U-"
M(7/=&"_)5).S15LKEE::2UG24'F2,N[49UFYF6$$I+X4(J?PXUYS-TEG;@<Y
M1K>60 ]'KYBB*?XU6ZQ  K@B&F1THP^45Q6J%PGO,1SJ]^C]"3%8#HT?_B#V
M>P>>ZS]N((2.82G$Y<#Y; 8ZM&XEE.( $A';(;>E2=NM] L3:)S2.WA934L+
M)K;.*&/,6/1N1=K&//-88 5AB 2<:.ASA&4:=P6W67RZ"W$*KSYI<%6H@FO
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MZ ;7,V1-1)I[R3RL'#72Z"3'LE$'OB2LL>M;]::+<%:)[T"Z;;[F U.-'W%
MIFPSL2'U71K438^K4LK=N7C(A+LCT&V$'*\WC+17/L388L>;<AE\::0!N\]N
MAN#7$_D//(1P^YG0IGN3+$QK2?RLYO%P?X\"&LH;A$63@4_0A[5+1#-@E1HU
M(H<$\37#)T=]$W)&#A/&TDGHDC:Y/D_4"_X>.J5BMU[%$\B+J4UH'>PTT+I#
M&'\C*M$X(J!Y)B0_X@\%EA_2T/"?N2V95#A(Q"=B0HA-^TN.DQ7\IGIK[\HT
MGB3,AQA4GQPQ0'!X#Z[G<U)JLYNQ=2L8/([<A6QKX!05&,W"?Y0TX?5AB=/1
MI&QE0IC :(SU X<3"= BW8RZB,P&U%>UO_<S<$#;2,&H(Q'^37_J&B?19Z"G
MRL+N:M\EWR$^=C_3* R.P]Z%"<M3 D*TD(D?KEGA09+@T&8:EFGOJ?T3^7FB
M=(;,H+QU-C.W-Y3F)$!4O*Y=N_Y$S6\L7S\\8\U[H7^.^$>",[>E0>D3G'#O
M5O1E?%%^7)S,YN?9Q=ED>G$ZO[PX/3D^N[@X/[L\.\^GCP Z<?IO6RJG[ULD
M?5?ME '1M ?5LXV_]I8B\^'T?/CAWF_('T"P54K:O*(^ZTB28LH#DWDY?913
M:;(7,6^1=&T]E, HRI8*[A(:*AT\EPW@A, _(!WRD-[O%1\Z]O8QO]44WO]X
M;<(6^?EW7ZR[G?_U[_R8ZHR;VP"P>9?_%N4S@E.6L:\JH) 6+%I2Y=MB)9!3
MP3?"GF<#\9C?XFZG?^[EN=OI'^P!*"[@3'#$Q\41#2!R>#NK1A*2 CW=D82-
MD$NT3U[^(HG=-*H=H8(BR"R^?*#JEC"M71/R((X)['QO5E)3J-QU3<GM.N(Y
M[J".D9)Z,(('N@542:#A<$08!_&8U]/.YGSNC;*S.1_!NWC^\H<!.HAL-:)L
M!:L6>^/QO(J$\RP:/'KB/8YRM7+R 8@3AQH?*I@E$>ZL5P!)DG'Y9T54+*2Z
MOMOJNZV^V^J?X@%\D"]J8L)8'(H4.BA@D:'S,QP?/%!?-DBT).U,:5?L>H8H
MT,^F@& .?$(Q%4@))\Z%&8G@ QC*B.L0@9-<PUN;5>WG9V=-=M9D9TT^Q0,,
M5>?B@$)Y;JAT1.".!8J=$;E$!'F!J/8[=WA].#8V2H VW,>A=92E<RL!895+
MQ!G>+;FMRVKU7?O]]]0#82P)U=W2 EG',*WJ-V5.ENXQ+Y OQ8CLZAV/<?5\
M,>9%O00D&%2K-PXHF 7=\;$T"WAEE^3.Y#CO.\KV<J'%QB@//N87^*5L_YT/
ML=OD[U34))QM:!'%'^JU)9AA]4=6NV1\34!O,20;Y,% ,5)0<TV?$D LBY8:
ML'>U.]MWFWNWN3_- S!""/U#@<P\CL=@YU(/?Y?]W^W1W1[]5 ^0BJ4-;=3_
M6:/-<R5]-7TL.!4@C5R!_SPU  +2B';\ 3CS8WYSN]W]N9?D;G=_L =0N+OV
M3&D;@/&N(T2H<=X*5$(OWZX. F^ )-H/UK>/^:7L-N[G7FV[C?L!@4!!RKA=
MEZL4ZANV,X3;J.F6.!B88H*W,_^SI'Z>)9HQ&^EEL2<UN^"[TWBWJ7>;^I/$
MP] G8G:,CE*M#NI=NA&C^-W*CX[S6G5%]F#FN &[H,ZRV68TV#/PME:!56W*
M9LY?O,F:<D'M9;>N\2/GYO_V9KT:%>#YD7ZTN[)>9($'4!A[1M=UW95DOFW0
M\IDS6"C_V\\O@C*S"I\*N5?(Y<<!60S F+LGYRXJIN9-W;;$$>!?2!5',Z0.
M6$D#5CHTZN-_"S.N-F)]9<S]?[RW?/(M]):_6R_<-][DMCL(=P?A.U1]RJ8X
M@.NZ&<"@L3P 6$'KIATMZE8Y5Y@[EH] G$0 ?E0.]AK0#SC#KO%GV_+MK6MC
MIN3BCU/_[JK_H01W3]0]ANY,*4:TMZ9LB3 ZR!WW^6$(G38>_>W)BW$\XK:@
MVQ[S*MNYY)][^^PLT<>Q1&"68@%14Z9*[0014H'5V@7%YJS*%IN6B+%BS(W?
MHZR-L)SC[\?\NG9;^G.OP]V6_D@5+:8EC0/"1I9(,Q"C0-Y1F,M\8+R<@7R:
M"1KE ^&X%GUA%8M^C1;;?D5L7:GV$@*FNGG$;W6W\S_W<MWM_ \*)@.];E.Z
M%2("U0?0(4$< -LXL ])]HS)%U-J(I??5'XTUX&!D:7A"83V3FDZHLOBA!SU
MXS>0A2]_,VKOC_!5I^:@D^UZ<(P?FNHN(4O33N'<":DUU3B$O$35X(A[J<.^
M-K)$7D/T;*9WX354">A6(#%=26-SD]W61&"><KWM[RE15I^OLQ8>LS[MV<]U
MX\ 3/3;,4W H,VJ&6A%Q6XONA%(T%= [S?12_H*W4$ 5Z3[_..QW$MLLMUJ#
M/#30D-&:I8Z'F?/CO'.ZX(<HV]B_)0JU5=GR(5<2EV#_\>B:55V!^),Z.(#3
M)M$.L-(3)3%S6A'TRQ"])K=_Q'S0'W4E$V 5!&Q94_BUO&[3/#TKE;QKHIZH
M_C1S#H)Z)6F55()_IN*:'!GE^@57_K4;!S6-U\B#K_;WDE4?E$V(G9@)?GUX
M)/T\FT#:3NEYL+8_\_[1$IS,)9H F1$?Z4TWHL.MTP'2I\S^TU]?ENWKT3.-
MO0Y&^+D=O8QZ,#V+^S).R96R/!_2[29_&4Y&?[TK[%4DN5,R8:C0#!$HDC*!
M?\&1+IL$$6;HWK:<\+)Y U.U\$7I&FU+/ZRL&?YPX ]5BJJ'E_&8$"?48MYW
MI?T_QLQ=\S]K*COQ%E*2/]-ESCM'SEDS,"'KONTS3FXG:Z[<M1!LHKX$E=+%
MFO@MY "(&\B**.'T<'E9$/TIOKF2\U]Y_I/&6MCMR-QL192&B$\5\MX$HO^V
M9N[C;+'H,I%;UD'1 @A#SBVO/Z80%X94D(#L [M_;\?MF/RM[LW^'EX^J5LE
M[XX5!YMAZF]#]=W5Y4C7KU59(2[*4/5EMN[>&?YX7\K'TL3I[%DH*PPPK$OA
M6R:][Y$]7[&H5]< K/V+J->M;6N7_A/F@&=F\:0%'GPZF^WDI$*7BMU'(V4"
M=(XGJ+A@E>YS!VLSY$<U:33QT/*PMNY+(Q,MSJ=G1[.+XL)-9]/BJ,@F[N1R
M-LVF&63)CQ^!'/DN(;)+B#SVA(AQ-D#N0YG,.*#G/SZ)Q.+*(FCD\VK6=4C+
ML2F]8*?*R;50]F>Z?T-O;L)3%JD_'L.['G6E<7<ITD>SC'<6X6.0"'<ED"S&
M;C#= %.A-,*<''@89[&1#)UE#1+R43("I%O(Z(X%/&'O Q5+__UVY4@438=3
M,OIBFZB,#<9ZGE4P9JQ'&AW#(< 'CXZT;)KRNJQ$3P,J.W8\-OOXF!?ESG!]
M[MV6&*X_9B\^\TMXNYR54I:.E=DKZ!N8JFO@,GTW"E/+"B;*@N%O3%TZQ$GZ
M5BK2.)[WXR3=P8+?$19\O(,%[V#!WY*-?Y1^P!=SV)#,=*"%$*L>97*I3C"D
M]9CD]W54'?TN\,U!R;EAGKEPKD5,+U-5ZDW)FVSJ6[#62O6R'<CJ)6?>EO99
M"SZ2/EJ.AB&T!0PPEY<SJB"8\7RL-34<[.Y<Q9T9^3K,2"\JW0+R312YJ$JP
M(5=T,!#N<L\&YDF]X!K9^=D">3*M@08CT^_&-<JD]$\.7N]*F((@M-=OC4B;
M"4B>/;51[*VF]4G& J02\MXS(=W=(>X=KGJ:I-_.$.T,T<X0_?[5('VQV);E
MTL<&VX68#<28I)>3IF#69AZ)-//J!GZ%CQ/"7K[)6A.:%^.@O '35%8\B/B!
ML0;O3 C@0ZQF?1MQ&[WL6KE*8^=^%D U3.UU2O*A4FZA6UC8_"8K*\5'<#V4
MM3"WY13* >G$WY=:L/:?E&ASPHG>@?^3-(_N;Y <7$$;_".R$^W,W<[<?<WF
MSL!@'K(P6XL&J9N#Z(K- ^7T"D;,H*-*@#'!V]'[Y!!.9:!N34JJ"L?Q-YVC
MKG"3?*<E&S4OWZ"FP"K8D*RM5P@"@=&$ZN]B8[U!'V'Z#S,"1)YQ9RQVQF)G
M+-ZWL+#@]/V86["ZH(6GP,B_8E61G^NJ!#K=.D@_U$!3$^J.Y8ARE2-J^R&0
M/^:'@ UC0.^A:D1H2S275R1TK^Z0$5-3"X),SUU&;,5!L]E6+;7F6=4519<E
M25MWY1>[@64&6R7RZ7ZXU-.B'$^5&"F&E7I'K&X9'IVH&HBCV !#O3-/._.T
M,T_O:9[@$Q!B&IO1[TZ_CTLV"?6ZR5&CO//!228].S/GPS<3GTA+!V@7>3<+
MCH&M")D\2O9X%Z3'AMQ/< _DM:\1$&IBNY-"QNUW)N";,P&C3@4ZC.@+W(K4
M,L6Y []5E%UX2*"\OT5,[Z?F5[3GH4,=H[C%H>UG>ROZVZ^L#*4BI4*RPI_I
M&??6".3(&21ZPKYZ7=ZY3I?=YO#=8 :?%';?75&?$?G??=^ _L=&"@[EJ$<M
MA(0EWJ%)7+6C?JQJ>QU7\ NY>\#_.@ID]@'YIHG(#Z/V5\9A\;JJ[]&=QRQV
M3-:W!7!&K737*! $A-N8?UTY]NUFU':T:M9(I#GR3[4#3Q=4@226,A)Y'S34
M%@Y'S^,^&87Q(;OFIVQKT]!UC?TA!'FH6XSF3;:D7D'_.%6]YCFL"M'K$L7@
M+<U8TLQ"#6D/;R5Z%?R( N#S/_C_]?[Q8G,X>A4!.WVD(2<<T,LA2<6;ND%'
M+9V=T!0IM'=C?X^K(Y)8#">[>Q/:O+!  ]0Y]%IL&;RF6S-2(RR%9MFO$P5,
MSY1:D/O+H5M&"VE_;^;07I*^H?'HM@:75,GPP^5M5C:*6#1-(FUH^EMLWGV<
M-UGDN]*&+NX?CKW-H]K/%U>Q#D=7U<;LD.V SZ&>,YG>9IG<;FQ<*%C=4B%:
M^WN#8TAQ6H^WT>E3=I_I_/L]55W7+!A>C+:U'G$,?.<(QA:W4$=8!\9NN5Q7
M];6KH(*'[W#_+?"Z-1&OZ5*/38^9R'WN[_FW/B\7[L%&)XLL-BU-O!TT>R]"
M0(.K^/&^_H_6YQ:-? DRBQ<W.-$F&;T+^6%F?CC.MOHP"Y<5_2D=2P\98-J2
M.]B,[NK%VEM?A\3(?UT]^^DI_O/J[W0?K5[M[_G/@)O@O]?^?2HI]9A[=@,1
MGK>J[C9*SD9\3^-N8:']@BHK'%CI:OPNYD_\9!486.&/+9A';F(G>S1;U'6!
MI>?M"I8^K4__\8-E7;B&.;'9!Z"/+[QQ;_R!\ML&$_T]?;RNG&I.I6,8?0<R
M[:QJ2Z8"\C=?EKD_6%=9_IJP0J[\;2U=]D* , /Y3Q/;UA70'K/6/-??ZZ2/
M[OVY7\]0E0JGO=]_E+W>C.[=8G&PJA?T*(7?'V"WI8[?HI9'RF8H_I\?J0JN
M214=[N^]0I-P.$[P/IKLUJU72)*)Q7:%'O2SLKZ%M<YR^@2QB!=^><-!ILP9
MN;(+HOZM[YE00B^'9;4L6>W#$G%PD+N_1X<LTV+,T$PY![Z23M@,&B&)$"?=
M+)[_S!LQ7S?D375[9K43O',(TGP?CGZ$<^V]/WM]^&E,Z]8X+#$WK%+*,(SH
M^Y&9*JOMKN#8OWHT!31]:5%N%;XI9^1R=&P=^471?7)QBTK]N"2? 8M 3G\L
M4K]:.9[AEU#V6X"_/;CQR;< -_ZZ3[T7C3=6,.Q=6X34>C@2QJ-E7=7Y@N(W
MI+MF-6,5L$FO9OX?&IM'AT8;"9;U2G[OK&-S[?=U2^GV9>L6=]0;7HDY]2Y+
M,Z;['!3-^AK^<G++JZ=7\9:\>9GL(0@U,/"3F7SFW@_V9P'&&?RIPI\1ZV;&
MEHB?NW[MYY$,M3</_%"5GXN&77PRBOM[U@*#4_U.=)H:,MUHT5PL "?)J;*P
M7M7RX.UF>>MW-:)7]14ZOA]:*QJ<LVP'<:B.S7$H,[")4^BC*ASY50T[EE$+
M1?!#_&LNYQ!Q#47@1=VJ@&-X (<L2I9O.+"$Y5[X;QTPX,55S*21Y1*8O')4
MXXU6TUS*OB$E0;*'CDQ.F$]VH.,[16UXL5C3N1T)>L*=:"7\^E_/,O,EO-A%
M^:9D3+'_3.$OO%Q37L!?#B<Y+MN_SO.?#B;G>,&C\HU[[3T*_Y7#=\AM&;<-
M- 0W:TSR;W)5>C4X1\>!JH7XF>C$,!_5D?#Z@B^"H[WB.>+#L95YKNKJX-HU
M2VSO$=.QY)8;C5P8ID3@M#C5QSJKBCV-H==D5J(ATJ*#6!BGO ,",^.C%WK(
M3=R071. _>@CUYCB$>3WMO3+_AYR+>JQ%7 FF>X+K$3PG=.'(/_6.Q5^T^8
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MR9;>E:2#(9[R9D2'^WO_MUX;!&D0THOR6/>RNPK'\'Q' [B)O2#AZ_=H8C#
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M/2$%MMPI8)XP]BF&_JWJ:U$(&BOUQ:LG_S][;[H<MY&MB_YG!-\!U]$GPHZ
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M?7B@OQ=YYQC]X[$V7Y7=)54YC,_S='5VZK>:W&^%ZF043@_O&>R>L1F#MFM
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M.@5Y01CUG!M'MZT@[9C=RJ6EU2H9M?WAUJU=UE+; SETZLR1+T%1UE2U'*J
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MIX,.&$; W]U00[Z\,J'X1.8._X?=F&WARMQS%/OBLL\%K?_[0/7SIV?/CE_
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MU@5!)CGX;P3.L(<[<:-]<Z]-<((;YN&- RV)A^</P'ZI8%YY?*H+;):K% #
M(_A+%R[L! %041)JJ3 QV 7Z@;@>=34-ZY&\%QX%==Y:.HFVK*^IYK92",TL
MSS:=8"W!_!G#S/W&J 8#M 9!.<SKC0IG!4L^_(RN*G63%O'["5!/WCP%V1G
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M^_\4W[A-IWN#33,*]5^(2BFNL)[0E__5S06,1'+\)+R==AWZ#Z6TA%CL@V^
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M5JX)+LDAK(D;@' I/3GLORM7?.D5T;7-G9S4LU]%QRD9G2;ZUI9%DN2-9C3
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M.KH">1A!M$:L<;;G\'5%$4!8O*TC!UQ>@CP;"X2B498*3-WCX<_!@P?U2RV
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MEO0M$Y-V1;L"GQ-..].>QJDZS[9+>FF%.?*A0S#%:^_[/Q9D_8*B?5?5UT]
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MXIE H#VF<F06Y!1C,^=*E+90\ Z 7C"]@?,+0W373 )"2040*GK:8M,Y#=!
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MHM,&^V<ZZ8V[$S&<"-D2TAU,^F.OY59BK1)K^RS6=/AT(6BV(B6C210(*G;
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M%UB G3ZLN<>@#S8TDR^H^4(Y@VN5>NH+2QJ7SEQ+T =YH4V21"Z#-9 EPY
M0G]#@8BM=#5B  ,CSG;C=XY>9#<=4.U."=0/_)ULOL#_*K%-4I_51,[\T#HH
M4[13( .PQN(H4%IBS<L2N0F+KP>?D;Q4E$4H*/)^!@MB= 68DQ/[9$"RY-.9
M.()S@1.J.A'NNQ/AK<8QK=?RUH,/5>O!3L+7'*I5)A/*5&OXW'TDEPI8C!!N
MXU(/*2Z&*S'L >M4O=&N-@PHZ ."QSR,FY0F(OR*D2>$RZC:>';JKU1ME'9S
M)8%05VQR]S;! B OIQ.3;(&L\3=&7SCL84[=0J9&A8)&"4<P),'HO):NI/[^
M;KN!Z!0=!9K2:;^,=IM\I 5]7F5>Q73<E_W!4(C)H->9=B:3P7@T](8#UW7[
MW8YWA\SK3<G6@LM^3>;UX<8,WF*6Y(/E9O=@,,TMIJOJ90UN.QU)W;D]67C7
M#6US51PQNZ50+0KT?V&'\+KH.)QY23N/_JSX<&_YL/-R^)!T]7/CNHKR#H#R
MT#9\;H1WC;B/H\O'FO2\@<CL%>S,'>6_W^;-VQL[F][Q0.2YZ61U]FB'25$K
M"9\CWZI<UUC,R6Y#H8X+.<-5EBJ_^_MBKRV(X9ZMH/N=]?X@9E&. :5#>S\]
MD(VTRR'M[I)L__;_.CM[\^;MVR=C8#O]^_ Z9^/^;R$\G])]4&&$X6#C+-R=
MV&-3D=+>^A';CSU^ZIFRN\XN_OZF.]BW\;/CG;?<'C3&.'OK4,S1[8FQXI>*
M7^Z?7P:-;K?W/-CE_G7L_1JGMB9^O*#>YI*I_5?0I:>TFSF\FZQ:B=G8)VT'
M;NZ;;G:7S'<17'NVV0>U&MJ-?G_P= [% Y/'@85;*_ZO^/^QK:!6M_OBV?\9
M!RF^T*#6R$3R9*$:?Y]MH -PNAY ]NRWN.B,&OW'DQ=5D*&B]R<VCSN-[N"9
M!-4.*4KP$JM\+*OE">W\YV' [X5E?L/&#M:J/@!=6K%0Q4('QD+[X8,^7G@^
M[W$ZXIZC8^V;6J-K]EM-WR6V^)#1M[V7*8^UC8=T"8ZZ_4-T@&_%V-N>Q7'%
MI167[B67MML'5)F]!_'J@W+E2XOQ_T!0O G!NCFI^'8($>[*2WD>7LK.,?7V
MJ/5L<W!5M& O*+CBPRUB_3T<COYR^' _0@X/D_9&"P!13!2>R9%"/#L CZ7*
M ^Z?;#CJ'VBM\+/W[RMNV3]NP7D-[<Z-F=:]9)C*UZ[2YI457^7\*D>X8J&*
MA?:?A9ZQ#_M!IDX0)0<0R#X ([SJC[UM6'K8&/0>K3/L9>G9BE^>'[\\;OCX
M,97JLYQ"^-#HQ+<YC(]97*\II&*G"%1,DXEP*#3/C:9A@R+A60FN")V)'O7$
M8-_PR:OR@0O <#+&R=(X62V*>?Y!80P O-2/O),T.N%_U6LT12#V$UR(&J20
M-Y+I]>JA<J'$26X\=F0A10B?F6;<?9_,HRSPZ%,3&J^&N\F6.$TQH<%XKMHM
MXI/SJN$U-",1V&5U\-+6U]4>/<QU%?'%]QL-?6L<?T2SK=<V(6&?$24PC2%M
M$?;MF](/M_<&TGQO#CR'BN+1%V7CU_;FU X1"'[CN$ S$,',FZG7)FK,R3=_
MP3,POV^WFD.<)!> $&K@'(7V8/0#C>A<_>"PV=(?+&#(;X20=RW&*3RL7OM^
MT.S>YF'MIO/%FA*H!+#TK&&"TSA:X(1:>^C*RGP=/1F/)M72S"41ICP[%&?^
MX=";F#4$K<D,&N3A//(D_T4^?K.:C%>4J-=-QL-*GVHR7C4>Y/H1>AM&O%5*
MXH%'Z%VK)OK-04%+C#OE2J*=?VY')>& CFC5:[=5$GZ^$>=2).O39J_1#VOS
MUW@ZD!I89H:\*;N^?'9@-:/OKA1]!Y=E18Q<TU95K]E]5=75/,$$KX8U^'!5
MP(!%V!OT#)@VB9A>6QFB./U+C^::.M]W^UWSP3O(&'H<IA;H8>UVN_ PG!I]
MDY!9VQ\/*-MJ*4619(TJ6YE-=H72QIV+< ;&+DX?]/SI5.)?\#2CZ32!-TZN
MRF:7F9%EUD+YK_DZ<2.;U[+R4!R=:)YJOWQUS<[&)5=2\>FDHBD'?4>W><O8
M3745=QW05JS"52+P&B%1K^52 M@&;*YN+A'9_TW%-SV^V/$+DPX%_2V6:1;3
MJ,.SN5S GB?XM5@L99;Z;H(4T&S 9R_G$4VVOPPE>;Z)[_D8/84OPN+JM3,>
MH=H KH_!1B1Y[8HXOD)?"#^%<B0/AZ(TQ:FRFU\**W,E/0G$MR5QP08S,I)V
MCG%1GC0+K\%ISO+"Q\@M#ZO#KW#(-^'QCO10.M!8+@1>5 PR?=0MO $>W#V,
M^8U;1RSWTH\K7>F92.;UVML@NJP\N >>]^C"43M3/.EZK1KRN.V0Q];4&[=Z
MX\ZP,^KVIN/16':Z/;<SZ([;<M)VQ]60Q^=;/UL->;RNJS@?\JAFKSSG48\5
M11X 1;Y3 80?CSS)_[JQ2^?0Z/ I:SHKK7!7'GQ!@Q^KD:,5Y3T-Y3W'D:,O
MB/ V@2GMOJLR.BNAG^\KJGDJJBD?8%I2Z7UO5+4;]5Q[9D6J^H&=HX+U]CRH
M[.E,T9=G=3[<(-<G5^(KZ:@C*M%60Y,/QGW;5R&\NY;>G6X>J>/RI5WATS9$
M'0ITQR&3W_TKV >"U^AW'J[+E[)66<(]/GE..2^QWE.-_7*A _:P/7(_H =V
MQ-GJM!K=X7,&PWSV@%R5(*@$P3T( IR\-7PTS+V#(YQ*$.P%"U2"X,$%P; Q
M'C_? =65''AN<N#9@HKM1JB#?L7#&X[F!_MDGAK,[,'#',LXNO ]KJ<_4C&/
M8_C?A4P.+NBQGV'+EPT^W!Y7(ZHK>G\Y]'[4ZS?:H\,$ZGOVMF_%,/O',(->
M8]@>'R2_5 JBHO<[A%)[AVD.[:@='M*M>K@<\^-U(-S@D4T-<,(A>62EQ_>D
M$:CM2C6?2:!JOS;[H%)UU'J^L^*J8=&5]*BDQT/Z(.U&ZQEGMP^LAZ/B_XK_
M']EZ  $P&CU:"^F^"(#*@*@$2"5 [B>HTWJT/N!G(CU>0)J]M#GS T.',N!O
M#AJ"K088_FEP$$C^)_,O1" )#%XO"[&Q$ 0S]FG "'YP_V7P <2@=Z'D36W=
M]U\^N,\2L/04CMJ-0>_1ZHSVFR(.P%BJ&/6E,FJWT6\_6O2CRL!63/42F.JH
MWVCW#[.NH=)^>\FH+ZQ48H--V1M6/$4\M<F!WG8^:#7QJ8@"\U$W^M=KJR46
M>W!0AP@0OA66@K/-B!.>4K(RC*G3:O;,9"<&UG>##+]>F*?2&=J#HI8"6%70
MJ $S-"14ZZS7,C4)AF>&)"MK3N#SC/@?^&+B![Q^>,?*PGK66$+\=!B%)W0.
M\-AXQE_YOIN/&VR@_''G#HX+"*[,-NJU31.=S!2;:HC)WE+R)HC[=ADIMSM;
MD3)\K+\M*=ME9+<DY^_;S?'-!-S)J7P# =L3R7A\\:X$7.FLHLYZI_NT*IUU
MWYQN\T]9.UQQH,5M]%9[;',Q<\XU@Z_PU30]%[@WF4=Q>@*NTL),OZK7<NY?
M9C%P:((+Q=G=_C=X!K-Y-11VQ8B^=BALNQH*6]D+]VHOE$F0K2Q?-A>^[_6;
MG:UEAA(#<E4(*,O"%B@3$7[-Q_/=<A#;^CGN="EJI,?>*5DSL[!2L@_%'F7=
M#7=W#%O-4<XK.%;=9]9#J[5E37F'G^%[KI1>PK/:\66)"(AQ3E^?@RJ!S[?U
MYU'3EGQ!?I.QZS.W)6F$T^B6:.,FEEG.X^!LOB33F"QR_)M8J/ER:'L;1J^\
MNR>T^<I(<BN;3TGL03NGG#4J[(^:P]N082[F\0/,%9]B_P)GFGX*!"P Y?D1
MO->3L'"4^"#J/9FXL3_!_<@@NCQF^9\D&<Z.3IR,9A/BH\[A98ES.HLE/^C2
M3^?.F0C3*&[0E[ZW_5-8%9V6</^3^3&Z=HJ*WTMP#N/*I=M!VY2&>M_"39'Z
M^2SIQ/&.*@6T"\?_)=703II2:.;-V[/8<09I"BQ $1;0_(ES"7+:NT#>(6IW
MX648]'?2&#Y#,1%\&+"RE[DH4.#2/&#0IO,N=+" +F7;S;P:W@9B 62"F0(/
M7]<?A.>Z48(V6Y)$KD^F';(E*"$K@N,(,/8F0#<4'A3A5:4R'HV 0*;ZDD:]
M"DU&2L)OJN-#25HPN.%&@P#4",V*S(C^IL#K]+3\F@UYXO==L41)P;\$4LEB
MM"QRL># 8L!_3("\YN ,SN;.>P%6AU9.O6:]!FN?"U@XQY6!E(':T3E!\XG&
M P/)90MEP]#N%N**="/1Z40ZEW$4SE@S #F[419X:D%JZB>O$0P<^!%531)%
M(>D:</ - \!2WDWQ1STT-Y:S#)R8*%:CV.'@T B$]UQMY*YDA:.8BQ*X:'\*
MW G*##AC@18:W/[?Q>"C]IE GT;FR4!*V114?A;[N$?4P_ .T+Y?)3,=*E8?
MBS G65H9:8_&<7^"I Q *@,M ZG*AN-/'6 _,%"(1($(9C)$EI$4^Z:[C.$#
M*%V3; K$X*-I@X.IW3DQ+GQJ"G1*D>^K%3)BZT_F0VQ#,L\T3VD+S4C]1 +9
ML=N"!*(^!\(:/@F\G*4)V)7$W$A#BBV:8#M.4MO2A*\N8SF5,9A5)#M2RQ"E
M+8L+X0<H+QK$E>#-1P'L16C;37&L"L'#4<()")(^@;_PV0"-314Q_8A:AP\!
M=YZ*K[ W. ?D'[)]00PT^.!%POP5TV)S3>7!-G ]7UGZK4FH!-_I23<0,=DQ
M0"9P'*$')Z D@$ 'RGHBGE1^W#/811R2:8I'Q(>:SOW8.\$DR)4^6+2S SB=
M*&9&ST\%-I B;<QP3V#&D@7<P$-Q0130=N(8DR1\AK#<S1Q?^"B2GR2AAM=!
M<I7&@ -9P_4!X8 0RTB^4W4$R7@\\52Z\Q#H?.;3.J:9DN2*8%,P0A;P<#@[
M2?(;B'46PZ]P:>M"$'\+?X;SX0VQ',<XL27!PRA%X3T5%W ^N")82F:N -S1
M>BT+]1]NN!%%FW2M-@F#2L/C0&Z17O%L)D9149#* ]D+7$=4B?N$'4E\'BX:
MGH9L; M\#TXFB)9$ _ I=5XELGT*&B.U#B0_=O4(ND^^7?WT3:>*1U>OP?HO
M2<41W5WBN3"3EC^T\G]NY_\4?9T_?" 1(+HK-I?.E##YK$V)RNW908>"(P(>
M1RA)J+.7G_OM#109;"RV^R"2,)3!6A'3,Q2G WH_SQ7=)QW..LV5#SW3E7$J
M3- [BC& D<48=B#=JJ+72FF1,$@DV,&K513]/$U&H3=<*H9#,&@F,"1"X8^E
M"7^ @ \35EC.46F$Y+CI?"F-G+A!A+:P.8!.AT,Y#32G>;UH=) L2(!.G4YC
MT!XW.L,6KRB-9I*4$NW_DA0$"QT3\\N6^&-GT&Z,.V/^ED!UEL</84>NY!C@
ML-GM.^  X.=XS>:9H%9]%-53M)BYT, $C5!JX0-TC(=,=+:4U$LXVIH%08-]
M#Q7QR@-09=4L_9<0D'QH[KO-87P$@C\%<@B<;DL3XBHCWA"W<][ZZ=_ U0*(
M];_%8OFS<Q8UG2/^(_#!)XLA2Q[54%J;LLLR)O6&3-I0Q :KI6^2)<['320-
M!A";3,#<\*P9$R0\ 7]K")QYX?NA(2QC5ZC%$_N>?GGOO!4N6:;'X"R>:X,[
M?Q^;Q"'8$=<%,X'.P?A IE"!46)A6R2AI?$9C$,R$G$]YRFLG(V-T'D;Q0OG
M_*3+D@"$ ,59T9I%*QUVAP%BR=+CRFD/51B8W&/U\H4 )L,$/BW.PZ5YRIF&
ML_KO_QIU.JV?14H;4+:)/C;Z8_MGQPKNPH,^9P$(@5Z[?R2.CWK'R,"++)A1
MG,@ZBUQ:GX+#K4[NQKM7MS#' ).1T2!9<0V\ S%39R-@"PD82=KNFHC$9Q\H
M2VS[C#*4(HG8P-2?UJ(?H\IP!1,Y%\$4#73'EO>7;#G">\RAT0VB'G#=*/;(
M5>/H6.E^5/1]A47P8-O#GQ.5]T?]X6E[GW>YC%&=H*> *UR S4D;T6>"YO5S
M*:RX>[%$YYD72]Q>+;1'#Z,6;FVQ/[*RZO0Y)TO*8^H'*&U1,&$T(<U =&3+
M96!I*N+5-V>.3JIIL\5PH*4KVJ-&&YZ/8\)55HPZIHO6++,_D!4*9!;D6HY8
MNH3#+)8,_)4"1X'S+@3YG_'CWC5?-0?X;2W\5=4%1D(F_];A>V7HRF^N7*I
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M1E8B")DY7Y"PY#=EIU@K@$W8AP>0:EB4JX2F?7J;(  K"GSN%+A"@B;#S?G
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MTU=*"MPBQ<9XK%84"S@'HY%VL)@;UQ+=D:/3,:O?S-M>\-ZH/(<P>S#LB7T
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M"/RY/_'3I!"-+LCN7.61?)+AC(%3-:2>;NS#,!+U!2'P ;P29?I2N;?<18$
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MUA$DN@D<?[;4D0!L[L\P"VZOM;RTI?58>$I*3I%3.J&:14YI-L=FX0*C6FF
MDF%E^IZ,<2_S0&&T3.UFH)!]S:;L[QP> R3K9E"Y$O$]D6JEOT016NC"KR9F
M2Q%(:GF9Q4Q*;LF3FX^D#>1Y3-:=&GA)64@8YE,^.HI%%7\HZEP5_0:8C$>M
M85>N2@J/=99+T^NXWZ03U$@M7N_+KZ/R!_#>RSP7[;TSPWD'=53BO5M63=SW
M6SCCRZ;%2H_1UK5-&V_7A;.8>K%=-/UYM7LE@&Y]S@ K9!S<F*&P!CNER01+
M >.<TL&)RK, ,S5U8\M7:;A[&#='/V+]"3EJ>5"1YQ&?RY5P.L@#W:9^TP?_
MQ.=*Y>-J:>+51>AS1_FV/GV4 5@5CU[* IBG22JC];AIF=!(7KA4R&'Q]!^\
M["LS,5(?1F^6S(+1E*7CHHTQP581 :O!_ VK_+2?#(GD:FD)&D"Z]XWJ>J,@
MF@,)3Q#/A7[Y^.T9ZK#O8)F!:9**_(0=K T'C1671QB>)R\15D<+6*%N E=V
M4H1#4-: 2A/%))*EO(_.;;8FH]S41[B(XCC!N/JYY\CD#C+,$*ZN=&\+[8^S
M%L7P88Z.KBB-4;S1OI*NER?7CQL T[Z// !^DCS7U]$=,H'ET;]E'\FC$)TO
MDQ_9+D#% ^0+!^B9Q8Q!G4"9I7C,!5R')[DRY8)\*8-*,DI29%N@@BS@,0LO
MA42F/C%05J<; OT;1\;62!T;;*???:MSW)*,X+4'N7<^LS7.#S%V\^QGMDC
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MV+)5T[AS?H7#8MU',E[+@5':+F1%T&@-(Q<9:P;)UYDU4,3WE5;S/9#77-J
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MJ59]E.U&;^XL4F\ZW65T+[R(&U_@ >VJ*%(8OX,A>L][4LI;ZV*NZC8T!:B
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MU=\UI[QAPJIN8U>9T!KN7&2L8<*J;F-GF;#;WKUCHMI8[_<)4/\]]:^8-:
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MY/\Y.L)"@V%T=/2+DG=TPB]]UL^7 9BE,V]!$25YL,/>T,D]Y3K(WPD='WD
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MV9MWG]Z]/STY/?[ /O_^Z=W71VJYN.Y[A?T,@@"T=6V5]&3VBP>"?MG1Q /
M^:Z-9[YAU1?-,L^VBCQ(^.Q+R8.8!Q@0.UQ9T!UZ2Y7VD"IKB?0 !'M?GBF9
MJIQH=Y-?OF36("C!9R=6ZL?QQC! 'WU%VJ-:.42X#[^Y.LA_EU&5>]5[O70
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M$E\',I)+R"R!5;2TV9+(*VS L@'SGV%KYT(+NGQ)OWO^'"9/0N#RM\+G  3
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MS( 94K"9"^&'"Y*40,_G$9_+<_TO9R?$ 6=GCK032+Q&X;\S\4N&0A(N<+$
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M#W'5L907.:P+ZA.!K+*?N0J"@1V9P_EZ,.\HHZ5K\CC6\1>=/6<"\T8HHX6
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M,/QND5?#Z!79PG8Q^I;9_Y^$Y[.3<"::,B$5P$AC^U<'%UMM^S=L7R5L-.9
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M A;;RA,2*.M^E:A0ORZA-T=3M]MBW6&+]2SJ]G%R_/D-.WW+?O9^X 8_I7/
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MKHQ2H179;#FGEX;,'B/LA8 =/?C]EWQ$]2?N<OR:("_E:5%QD5<EJ=(C%RD
MGV?F+63X@LVE0)XJ@8Q2@P8Y]\,)F#QA=,X#[X_,.C*#&\:K(%JF4\_WR& B
MWW=5LK,/WASC*"V,TT3>!3S+WH'CXL4SID+SS)>/H!5W#C0%]IT0X.2 F49$
M@6ZRE'"WJ'+V )E+:VFE6/SQX3-+LW6ON0ZK3K#-&ZLRVJH+1Y9>#BS-E;ME
M=M9SYV<M)YB7Q[8+51?+2RT6MQ#K:[9ZW5@VY(4L2OG7%V:QAVSB0HK>1J41
M)8TM07.Q"85<6^)Q)7_Q/E4$U]3161008*0K%E(5[P&3DD3=AQGZ=;%PO87:
M11:K9RNE+Q\>(93\>RT^>KFH0#OEEC<O\17G[I<U"YDP)RL'*/F?Z]]:=[%2
MGLFM$4&/3DX/C%$#@[URCCH-V&]G;S$&D\; 0C$[$#_P4(_%,SJBD%$<_4D&
M5 XW X04:'GJ[]J"M#_TOO,=KZV6E*W]A^8]IEE0K^DA*N242= -2\QN+B@>
MZL7UDJ*@@3<@N8<6(_<HW5E@5LR[+V7"LDM#SX(*4/PR/]]>5M%50<M-2%C1
MQS=B1><,2+!TK=8:%%5T^852;_<DJI+9[TAEMQNI(;LZDIWUR+*LI#KIDO+*
MB&79=4$:L3N]%K.[(_BCWS]\<3ORW6!$Y50-^BN7T9[:B-U$]QS'L5EOX[Z"
M8G/X6-?< WRX6<9/,LO3[&6;9FGP4LU9GADO2U<L;Q3E_3Z-^X"BO#!BQ43Y
MLBOXL$*Z;.</3W1ELSP\T3W?7K9IE@8OU9SEF?%R6R'=V-MF.#>-(CRNXXW=
M79>];-,L#5ZJ.4MC=U?8[J:J4=FE/TQ>O^"^O$VZC:9X)8Y,NML'VVV:Y;'I
M9-.4B1NL+95R^#[B#N5,4<[A>_CPKT[^7W>D\PW3^.C_9^_+N]M&CGV_"HZ2
MN;'/H10"X.K)^!Q9MG-UG\?RL^SDOK_F@$131$P"#!99RJ=_5=U8"9 $*8!L
M@#6);8D+>JOZU=*U/!C&Z@TR_+5MXC\?$FZ_]F\,U\6,Y7\8BZ P:IG''RJ!
M;8D7 \^\4#S89GBV?J&8;&HMC87WV\4E_(:Y X;_VX7UY+^Q@^6EZ?!"[Y9H
M,:MW^NHX"ER,YE]\54^\(=<HTO!&*>(?5T7\:G7$W^^HHT$!\4M ]63\;B.Y
M^[GC8B<,=ZE,#/L''#JO#4#VK<QK:=,HTF!O!7I)K[L.S>\%.WGBTC9T)=6J
MAVB#CC[L'5L/:3N5GADOE")V]5!BKT[OZ/4[XV'_:'K'67AH$LHI3W*[2>HK
M\WS7XD4?T"<CA6;8IBL>&N50VZX.>B^,P@N[J!5A:Y)4J:FZBNK 0%6[?^S6
M+Q*V0NOO&/K%<%BD6T0=XMK&U?*/DA/O^['&B\@QIP&4)<>#-8"9]<3,R_\P
MU[EX>UE B.1?D,R_<,=KLKALRJQ'3(,1U4]6+EL9%A9163';6T^,:X-9(LVU
M3*]]>_NB4<IE(S1T,M(8D%4X4[1UZ?)%H,8' 1K7MLG!Y7BN%;4S'!0YN<FS
M0FPFL9]&KX:/*KPMZO2U(BM" @9JJM.&PMG)=].^4>A<Y!R%PMDEMKAWZ-[?
M'!\KXU)0>]/6(I4&+-5DI%''J[!Z>^O:^O'LVQX8N#H9N,11\G!4*9;I[\LR
MU9FR ZTS&(W(EB5;EG1S&H7.I7FCD"W;7%OVLV-?DB7;N+6T:10Z%SE'H?1L
MB8)_:VGTO19/O+DP,FGU<JU%_E%>&E,9A</6UI%E8[AF=ZBA0P3^C'/AFOT=
MT<.@34VK]S+NBMA<JVL>!1(?\<A.1"GG-:S@"[GX84?X\E9^J,Z%V"_*7\IR
M!=FEDMFEGP"D1-+T>40RM\4J:-,HTMS15''KF2OHDHU1K$<UR><VZ3K=?C9Q
M%*EX89=2HNJJIG5U5>V/7T+VU6D@XV[1#:8\9-]49\IQ=)$OKK."I3SSQ"HL
M=;<2K9MM5EL5%XFS>8^55M5OW]ZV:12I!,(+E:-^02*48/DO"\/VKVWS0\3U
MGUF]"I(^*,S^;J?/M4VC2,,/I0B^(&-I+X*O3C72^\=+5"+_3'59YT MAF_9
M#\J"&1X3W8\OG=EE +]$D0(2:+:-,H)*ZT:#]NVM5-&Y4DU&&LE2A::5"[Z/
M@>03XLA7?.#=[+O'>(1QO77\"E-DY3'*Y1F%V$L:Q2T7B;\O_U2HN?6H+F #
MO5D4EB__6MHT"IV+G*-06+[$YG6I%'.;@O.;N!:IM%^I)B.-*EZ%I3LHSID]
M4J"%VM')O"6>DHBG2C'-\ "FJ;)LVF! -BW9M*2CTRAT+@T<A6S:IMNT9,<V
M9BW5J;F]U9-B.L%DP93) L9OVB2DT;&KL%MS$=-"!:^W+IK>Z0XH,X!8YW2L
M4XHW<HUA-_)&A070>AV]7\0;$C %6:5DE39[+6T:A<Y%SE'(*FVN51J6.%46
MEC&Q%I9O,3).F["6-HU"YR+G*%0!36+E^YMKF$Q9&<^\)R(IX3*OI4VC2./0
MJ, 7.,C5,[N>3F$3?.^+X"O.9,=I#%A<!)X28Z4?11J&*$7QN8IE^U%\E;$H
M>F&G$ E(G0S*;70&!.,&C.J5-6,M;1I%&J2M0O7(E>0(^>I3XH@YAN*A=_2A
MW+6;:!39V:$4O><J<NQ#[U762J4 V 9Z.SXL5POGF3%>HLQE"\,_@@9"S@\:
M15);KPH-)%>J(F*RKX*_CJR)J)W^H$LND":.(@U;E*+[7(F)0^B^POBG(P8_
MD1NDM@)AF0MT"?3)1ID:5!A,DFQ*J28CC5BI0MO*I4MG"QM%0N?Y**J61K'H
MQ%_R\%<I!LJE3N_-0!5>7G6/=W5%7B0*6"=W42-'H7.1<Q0*6)?8L"Z51CVE
ML/5&KD4J_5>JR4BCC%=A[.9RK(]\ES#H#'MC,G&)JZ3AJE)LDTN_/O)5A-89
M](NNX"3@%S)LR;!M]EK:- J=BYRCD&';7,/V<ZK:-9FUS5I+FT:A<Y%S%,K&
MEE@!3X.W<_S(H/:&_IT^,JBA.N-+/"G23T8:MTX%SM)A+@E]0V##D3HKC%4*
MPB8.DX;#2K%0+JO]$!:JT(^J4\_G!AKH]7I1S]9RH%'H7!HU"EG:$EO:>W<.
M/)XO]6S]_O*,0CIY4ZS>7/V35*P#6;IRC4)<)8VEFRNC4I9MR+HEZY:L6\G7
MTJ91Z%SD'(6LV^9:MS?.<FGY2Y#P'J^$A5+>LA_.R<R5XK)YV+Z]E7^4G$Z]
M'^$4ZM=/$W>!VK'>U< DA7_5KJKE"F.EV.[:-F\BIIL"KY4U4)\\ZXUM+7Z[
M\-V P63R"K2<F]ZF48Y"0+U1KYLSTO8CH$)334H"(HN++*YFKZ5-H]"YR#D*
M65S-M;C$?>*Y&%=RZV^GN& HV?I9VDE(<[M1Q9UASC!+77[47$\ M'JZ+"3V
MD?MR,%?9>#M_5%DX8#2B2T$R44GEIE'H7!HX"IFHS351[^>&R^;P(W.]ORCL
MWX'E/[=6-97F"G#4OKUMTRCDS9!S%*I00]; N6DW- J=2Z-&(6M %FN OVW9
M)FBE;R[Y%U:&:5KVPR5^6CRBJ#F5"Y\QW&>%VP:>LC-T154'>K</)U08^^38
M][XS_?'9^6*X_S 6 2OA3/Q^__Z/+\S]@\\@=BMVTV[%;L:K>.FQ*7H6?SJN
MZ3%[9[R-JJN:UAUTASTMETM4=M+K-P0OG[3M%+A!UUY05H:K/.*4E$OE.O#G
MC@OT8+[9=4Q\Q;C/8[4PPBA<L3CSY+DE#BM<;[+*V\\?=[A\R\U5[?5[N:JV
M^\UU_8P.F.N@W^UTN_R/LOMX/,$SAJ<X,^4]F[+EA+F*K@(:P&QXW"UNX:]4
M=%7^M;1I%#H7.4<ADU86D_9 ;>G6\P)F<F!W M_SX0?XSC9Q[(5ZDXKQXB.]
M.]9R0DY(MKOD>?6(MEV:73Q#/5=F+">&Q3[4,T]-USH#?= 9=HOB*-85I%A_
MC62QOT$0[SPBH8?H?7TPR&U F2,ZEJ;$9Y@K8U7^B"J8IZ:-.MUQMZ-7=40J
M>9)D7DN;1I$F3N> ,+=U*.AKHY&6"^5)04%9:[9T/,_,>F+FY7^8ZUR\O:2V
M.4T<11H&*$7A>E_;ZA8HZV2JC,(E(.VF>CT3<BE/9X< :<EQ^  7;[^YS/""
M2#U![63J>+[RJE027[\_&N75Q>B1*76L'EU953N#7K?3&^3U,"7CG(J0^85[
ME5.M*WKNZU9'H;3%?=&F479*P3K *B<F$;U\U[$?7LQ!Y>"JU^L-U)PXS<!5
MY2IC'K0ZFCK:K#M&&W)D*)!"<F5,@/:"HNRI^7V]!QKD06Q2F]Y)_F+)0J"N
M3=/"LS$6RLJPS$O+5J;&RO*-A11& CFSSF 4:6SY"G(V1X-UP$TX[ LPV*U]
M(]BK7N6D"^I)@3E%KJT&C"(-.Y2B]^'A]%Y=/N9XV!GH10W0):#SIOJYCJ1_
M3*?!,E@8/C/AP&?6U/+;9RF0^Z0H39T*:Y]$C7FUT=MY@+8S6D?_K\PW+)N9
M'PS7MNP'+\7?[P5[UZGX*!YL%'SLXNU [XS4(HEP$F?$R8%V[15]];3V"J?_
M]CES"'". #C%7ML<5N0\M@=A165*8X(5^J"C#O63E_-H#$B\WK$SY'&CI,-F
MKZ5-H]"YR#D*)1U*[)8H52732Q4B^:\_C31U^.LYE".1W,?03%U>JLG(8EA4
MX:(8Y],@\.8[9-L/G%UKO8L!ZT+3BJR+ED*$5)0LU62D8:M2?).+'"G%-]7=
MZ0S43F\P.+E53C$EM9<8YYEM)U.FSM8"D&>40ZH72SL):5"^"N5I6]?B:]L\
MLBK5TSO=P=%5*6*JTT]"&J8JQ37;FA:7Y9H*%:E>1^\?[WKC<"^4^!=>,H!$
M^*M_^ZMI/8J?:E5DU$'Q<?]1])]8B/*R?PJ?'!U)W5K;^KT.7^O-W&(SY<,3
MFP:^]<B4N]G,FC*WDM5&_X@Q/EJV84\M4 +#,4ZZ[NQ]S$FF\-[P&>:W&:N5
MZSS"OL#/_IPILWBC/!\^POOIO5$^LHD;8"4"#0Q0C/<_W=R?:MB^W4-^@ZTQ
MIE-G"5+_V;(?%-OQT8K O$> 9 #2!Y?'L[M^M), K]QTYW%F1=MZ=<05Y.LO
MY[8Q@CWQ8S2C$$R[W5]^G2Z8X2(0SQ/!>/S*T/PZ^*-RJ>B)-$DP&WZ>)X:Q
M4 4XVJ9<*7\2(O/7E?' +B<N,WY<&C,8]XVQ^&D\>^L7T,@NRE\SLH'_S$6&
M,F6+15@!AQ>NRPX-2N(4Z]QTPX>^,0+?N5#XIOYV@;L:;66\H6M6OEEP$(6B
M<<W$ET3_CQ]7].:&68E)A>EY-W.VA%<G"G"@:ZP8"(JIIWSRS2MNPEN^IWC!
MQ+-,RW#3K<,*U/.,'I#1 EZPZ04J1C6/WN(+# FXSA/?C<2]Y$Q1([U;P?&@
MDN>!8@CP]PQ8P6R3F7]P<+2>KNWIW''7\S;QJVF@O(_1\6Z6//*CX\+Q_S]X
MY(?B1^)AWZ3Q-GD.PG'R)%1;.3KC_!0^P762B=,HCT5"%9]BZM1Z1V/36UOY
M?O\>=M8)/.!+3WG%GJ8,*5;4!@!6A3.(?EN" N][KP]A5@'#*74]):MVB_%0
M1*S6OK%-3JYQ0<3QA<IF2B()Z2!XF N&=4&!OX?B(2TX$G(I%!.)H%@GN=W&
MT\$V=9DOEKRY*,$"IU JZF*+'0ZQSZ!$YN"G$K]2/6<-)C=.[[<+;5W1D>7<
M#RHD<.QCCXJ!B)W6U4XI&CB?_4G71ZF6+0J65U4Z/3$.,<ZI]T<4A#RB/"GP
MI:YI*'1)?4H%(S1\[ >%/:V8[>4-Y&9<8\&FUGW)O=\01UA%.X:@LY!GB%.>
M!<5^GRY!I[(HQ<VT4%G@]GY#'&$5[1B"SD*>(4YY%A1%>F0%_2OSF.%.Y]P%
M;K)'MG!6>"_1>@6\K2[=<64G)YU^V(XAI(G;.[JU7RY2,-=^,(*H:]M\GP#4
M!^$P* JN[:I=U7>JK1XWZ(R'PRVU;8GE)!ZBS2Q7BJ=RK43VY2DUYJD*@W [
MNM[;R5*GYB5R#)!CH/HAVF$ITEF<U1#D&#@CQ\#?F<TP9!S] H:YM&S+\_&N
M[C$7$42N@8:X!M2N;,J5#$.\I*2!W#-IL]E3A:<A5Y<^Q#PPBJXSB'=D7X/:
MZ?>+JCR0KX%8N$4L7(I'<[7T]^?1>GP777U+UKTDO$F^"_)=5#]$.XQ9.HNS
M&H)\%V?DNRA5;<NAV&/9]/@S&Z+-RGT5]GFNDTJ<+A J^X7-MVNPR+51IU]"
MW9=$ZZ<ASH?-2O%1KLM(&3ZJPVI6M8X^V!U%<VH&DMALEK16<7-T<1J"SD+6
M(<A&W=]&321R>5%^.HWX;5CG#XS.5Y8]=9;L=6Q]=A2;Y<+NR0255:NL=8C-
M]TBB2JPT4]BI6]?!GX6U#-)5NRIEW.)6?D\3=X%JLMY5=573=/BA-\P5N?WL
MV+&;Z9;S^W&ODHN*W.;*6L4%Q4ZM=S=DB)J9,V=95LNMM8FVDFPR!$9Y"9O4
M8)<F;2]552WKY2&CE(Q2^4R(=@Q!9R'/$&24MMHH3:G-;S\YGJ=,&(A*IOC&
M4_I"=*WF+)FE\JFE;1JB*6:ENFL"V^YI$MU8ZPZYS=<=#?4_UJYOU&ZNX9!0
MD9%;/[K.\@;&M^P 5.>DC/0[SL3B<]^0DS\\^:X!-H)E&^[SK<^6'NC<J%N[
MSF+!M6Z?N<PKZBY?@UV:*-S:J*..NEMT[J/9ICFSZPC$?BYCRL;4)V3FG(OH
MN,Q<K_6L=7K#40V]R,B$)A.Z3385G<59#4$F]+G%'K_E<EI!Y8"+;>75A-EL
M9OGYRY>66M(G5?2B#F+HS3^UTB'#$)0?V<38SNTAU.6NI0?Z&'XIMCD H\)K
MMG<"G(YM_/=+E'\ZONE08RC!YJMW@@R"C..$@P,_'PX'%;@/9M83,R__PUSG
MXNVE3*'@)U='UU[1<RWB./&7S%N6V-=Q\HVFU&^)C>5V#$%G(<\0Y'XY-_?+
M9JOI,_.5!88YI/OLGHM/1EK_Q+&MB-[J23&=@'? Y>&Q39I!F^V7EV>-%X1+
M ,\GEZQ'#W 8=@8]*N9&G-HR3BW%BOE\F!VL>-+P!$EXD"QWLMRK'Z(=IAR=
MQ5D-09;[&5GN[PS/FHHV=-8B\)DI#/45<Y6[,-91N9\;+M6?;VS]>5TV7:LA
M0V0M$GWE9RT266;09GOG ,]$-A9#U?5N7\N;1!\,U[;L!^\+<SFZO1?@MY>?
MXOO]^S_@^W_P!Z2-H]O/'W=4""AGR.4RMM=GS<'[6'/N7L%V%MAQY&,AS&D3
MYI0"%?AKD&MD41Y4-GM<:@>57%/"LJ!2RYR[5]U!42(:>8O(6T16,0U!9R'[
M$.0M.B-OT3^Y^<5,Q8!-,AZ8 @)]PES%F:UYBSS%"7S/-VQX\:&C3%"GZ*3=
M3.1.(G>21':7+(;503/8@P7.WKI[D4=)4WOP/]A-7>VNFU$1-%X+9/S,@?%N
M%MJ  A3O$DS<RVM3FS&8,V$WK"(W_?T]3P>L0=.&G?YHW-%&1?$#-?N=CB-7
MI!N%4$H&E"KE@]+&?2W7K.7E,+39SU,;#.7:3;X4ABI=@]8==GJ#46?0;[JG
M2OP++QG 3/S5O_W5M![%3\<HII?U#)VH?M_60D/K@"#V7>#.[L&^S9EB3*?.
M$L9\QGKSMN/#($!R8/LH%E#I W9W7QFNCS83AL(#[?+$2@/-JIDH5 \? 0KW
MV1+T?.]JC9;^!B<6K6?WC,(C3WTG))AN]Y=?IPMFN C,\Q)KBXCH1*9,WJEX
M_(GT=^!]I>2X)YU_5"Z5WB;T2=@<?IXG7A(A9_&IFU-\76;\N#1FL#EO5H#%
MZ]F1^65?*'_-8 O_F4..,F6+Q<HP$;I_NP 5.CL/F#0V:7C3#1_XQ@A\YT+A
M!/O;!5)L1(4Q":SY?\P"(B]40]:</R=1'&[F; D/GBB &JZQ8@%,TU,^^>85
M=Y18OJ=XP<2S3,MP+2P+NLKB>@+S&9!_P9X42)!J'KTEG_Q/0@FH\T!V^\MZ
M"6NBAG(S-^P'YEGVAW\'EO_\!P=NZ^G:GLX=-_W!-'C?QXA]-PL?<+OU 1NM
MT)NT2+A?X^GD[\T/B&>"0B:<"T@?1<RFA*54"W4=[X![Q0QW:RO?[]^#U'4"
M#SC,4UZQIRE#2IQS";T$3<OW7I?;"H%P*4UJDUA^BH6PP$#!"AS^UN$0?P]!
M, V/R=8FFYCQ>F]2*>>"*-3^ZJF4N_U@-:R8Z<.E\3U0'OE;B/5IK%%VFY$'
M3#R][BH7L<WHA;DA(_UVH5THKO-3_*Q>''T5.4%48EE;S>ACE8W:_]98'LK8
MMIX6SI]HO;VT?LB>2D3J-/U3Z@$'3#^G&!"#DC ZP_D3C[:(1TD*I:=/ZF)[
M*9W0G&B=:)UHG6B]7;1>F0I03ZI,;E&U>*W+*.*;/-O;3O%(W%QJ@\OP]Z"0
MOT]$9Z6LH^Q]H[9Z2O=EWLS]^S/QP=2W\Q8P"JC?$$HDZ[1%C-8!\4\2D]/1
M>/H$TS\_)C^JB(_Z&GQSF>$%P,T35_GK6R^LJ+)_GT5Y1,=ARFYCY[]#V95Y
M78UBE&M8+$;2&@O!*BL#)FK9XI>IL;)\>(<XIT'S)\XY$N=,I\$R6/"HL?=L
M9DTMGQBE2?,G1CF2+N: #!%YRG.P69CK_46(%Q;%1YZ(:8ZJ_I-C1F;H.#E0
MG+7-MKV;!<]&.Y6'XP GOE0NCE/,7P[!>M"ZVL PW^_?$[<T9_[$+21>B&&(
M89K","1>&C5_XA;B%N(6XA;B%OFHK>GS)VXY5VZ1Q'6^.XNG7 W:D[K1BPI,
MZ<-?RJ<!9>L?;"<M7KOAX"6&BTE*+=1=,W)AV>PR.AT5*_U&MTKOC(5A3YEB
M\*H;_V/8 5;#56$7NYJJI"Z57EBG\*1W%(>7))2+RP]?1R6<6>LZ!C5QJIAI
M5:R:>_+Q>;=P"B&7[B@$VQUJNC;2M;Z>:])3IL9B%ZL2_A%X^(6X;I"HSG/C
M+%>.C<5[KI\L+_P,O+AT['O?F?[XG:%[\&45#<<=;=CKC/3"MJPRP90$_$[K
MD&L=A+^$OP"@HVZWI_9&VDC-X2^B9!C7(R"U9@ NW21[9CTQ\_(_S'4NWEX2
M])X-9+5E'02]!+T1]'9'PU&NE5P=JF^4.'.H\DN@>YY@U99U$.@2Z(:@"W\/
M^[E6QK7HN]M1ES1> JVS6 >!+X%OZ.P=Z*CQ_K'>NR;?@:<6/$ZR8K\8EGEK
MWXA$V,.1.><3UGN=WGA(&'TVV-:6=1!&GP-&OWH12(^/ M)?F6_ BLP/AFO#
MQGK5H;/B<>*YO'BKZ9W!N-\@F.;Q'56CPG;N6:?FAH>8;.AT$DU&G/MK>2F
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M39?+R1N! '>SKX+_;S+L_RWA?M%"XVB1*0<TCU/[6D<;CSO#XH)?$F"7!"!
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MR]CI^>&)N5/+X^&7S@J9I.&!EI0S(9>TIIR)4TIK?3C>T(XT+Z5%JSS^YIU
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M?2RC(+Y((SP?+;"<$JAWQ^-\I2Y>@?(N\#W?L'&[BA3!"L-)]Z\U^5;3M<Y
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MW.@7\N!* !B;Q1X6'9]B+X8 <]$S5HMDC1@J]N:\1!))/I7S%(I',EIRN5W
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M#&V>!\,U(P<*K#(LC^6E629LJ)1^>-26 =VKP@KBZPKSH"-R6)LANAG10%L
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M-4NT7+4VA\(ZC'$^Y^];M@D[4\3F^!F\D?<#-W9IYNT^[AQ'/[.XWQ%,&-T
M%'M^.^+B#-VXBX7STWNCO.+NZK")[.LW65-D36G=A$IBNK$4V'FWJ/6[^K#
MSU!TMQC;;N%N/'_#9;XX^D>$5?$=$V*9*]WK2CC^'JK>::4\C)D#!3RKC1>'
M3HFA:H[F+O'44),8C7Z1)II;Q)M4%057?@_47UX86BGA2.,C'.LQBRJ.<M&;
M6^'A2Z@KO _8_V.&^^VG4V]^L#8H"NBL.$RZ(CH[119<B:?*"4B]NH^O: _J
M@8GBD38'AD\6\)AC362\>R*M@K-<8?J]X SCI6H%M+%^,CS;FR%.D2[73 7K
MFX,&\BS@G3C1X%X&RS7C6CII5?%()X"[8O7LK. N'U]0%NYJOG4<D]I6/'4X
MCH5ELX8J;KPREL6[4_/,$^YL>E/%D>Z_+X>CVR%CU81O^T^E/0A79?VK<:D(
M^A@(O]NFY4UANX&./SQ-X:/72_RMWFJ]=4+B8?PC!:SDJ]%47=B*--FR /]E
M_8IH2T24=)*<5-J:B.>H*FVNZ,.)XN8:K,%N2RC/)Y&GXPL.3BC7U9P$OG&6
M2\L7!@=(VX7C@7DL?4+Y>BFTTM$/0^5222V97^QBYB,0+B+JIS1PUIIP?LA5
M:)E57E^54=BRP17:X$H;X;,_8+"'9STRV(@IL[U,"FTJ*_TR2MO!:(#<1\,D
MG8* DJ/$C6Q47?A:AQHN]#:5' ($K6Y,V2_8B)^6/^=A$+\SDX=4? 5I;+C3
M>4>YM6>N@=?\4W0R=93_9L8"/GS/W$=XC*=\#&PS"E6)$^WOG0"^],.*GW?#
MIZ"\"O<8OQ1M:4=9I1(@?\ZMZ5RQ_$S^*Y\>G#R+SW(1+@&^,06$,RS,#WF$
M07A&V"OXKLEFEIVD?N76_#K,#D,-8V7XR#D=Y8?M_)P[/SD+K5S'A$4+?N(A
M(E'VF@<B,!G?GULN?-IP^:5]_,%X]MGUX</@^_]B4S\]>8R7$2,M+&!D$;HR
M"Q:+9P4C_#<MXNAI$F4(,2:[.<;GX53-*$>/1_(%/$L5\^=<-H-?1' 1O,A3
MZGB(#G\IM<TB)]@3Q1LPV-AX$-FLBX5R[?NN->&.@5M[ZBP9/WXO #+B26L[
M"4&D67AS?-@L<.%#;G:RKO,,-(^G.W.=I>*!6/>4I6$RS+I.9LF.GH25QM9+
M#JX9#%2[HPU%5ZW7&2A=1\[^ #_U-5XV;%UVWW%K/@-=BJUPW @.TB=08M]3
MC! ":\0/J5QVP1IA<JB *01MR4B?[W44WIK)Z.?@%68'\/Q]#)4+=\-4O@B4
MR>Q8N,+7*03/LI)0R#(TBC^(H!\$M"QS==8YR^ ^!^_-B:39+K+M]7+;+4*0
M7AG;Z+9W-4[5CMH4GZ3V-4WK=0?=?)[,)\=^P,(17P*0?*#Q)TK5>U (78N7
M0=BM/D:-X38^[=WS#0B<!\=]OIO=^BS^A)EJ*W=CK."P%M<A&44=Y=[^6>UV
MDSR:8 5B KAH:7E>&.QH\(-Z[P8/RO4*XT&%+(DD[^?WUXG@?6>!\O_ !73,
MG@7?>?<I_@[R.OMW8(&9SFLUX*^%]!R&;7\'BPA>Y3';H"LXCLC]$=,S\<8*
M5(OL:!_3,]RY7 _$Y<)P,2,XGO?66:$:D5D :) V\.<#%I.&(P$V8_;T&6'K
M0X E T0^LLV4.;"3R]DSG(X)_(99K4>>UK5G&5=*>*42P:OQ .CP@$&L0I!A
M:/"$*4MX$+P/3_^SGMY)@//BN72B@&)<IY$ZX7\%KN6!,B= +;Q=# ?#@5 <
M.C;H*XX]14F8->>.CS3=PX!&R,?)=IS!T/QR0--7QZ-N/C1 "J#!%/AUF+FS
M68PT6H[UD-"X5HLD#GRZA@8AB<*&_F#<<\?3].'-+#/]%;Z%-+R9(0Z@[L$1
MJ?OJR-1=:%>74D>NB\.$A?Y@.TG9!YYCRE<9Y=L V%U1XN(1$A?[E+@HB].8
M$A<I<9$2%REQ\6B)B^5=][L2&\F7O[<O7_)<T9(^_\C1%)>YBU0ZDYL2$RR>
MA%7D.KL2M[B],E1U7LIJ[2(4/5+I6[5]K)2+M['MX$Q%/;2IR!FUN*OUE?5:
MP3LZ-!BX_V+%/:I8?)2YX8O\RUC9U !+&+1R5^3,12+V5S1$7EGP( ->,VSA
MI.35/YV%\@TL%L^8KM77%+K]FE-Z:GCS6/L'RP;=CPXW_D/_I_)*_>5U-".P
M)::,F9[B&A8:&9/GY/&6'6;<PN' 4];6U,$)J[]$#X(M!#V A8X0%\0"T'CV
M>?!YKC'@VN? (<SUXH3<].9M7;[R2A1@!OLGF$;9L:$S$)8-.B0(IH4%%ITI
MIK)R&4R8'UA(7ID)I(X ,V^-*8]L"E=EN?Q*QO,C0R[Z:$>Q8%3[^75'F03\
M'2SVQ?#VAAMV:9]%IYNRZPKL+IE<P((EUY0_?B]DX#W.C"L"3&A^;GB_QA'?
MA+4OG)4@NJ<5LX&C S?.  4R Z,;?> KK 7H"LK P[CU7(,M(M_YK6V#L<W/
M[3J /<-LRMBK=GN;^/"B&G]>L%HY+C^OR.^^<5Y(0(]"$@&U(OD(U[Z8@F3.
M^!@<15GC>,'A)O ,<WXP4VMEK.&"Y?$,=\OWDVNKY +($,GUJ8+%V[J)8%!)
M?Y24ON9%![_$-REW,W'%$H='W]GWQ@)>#KT5IW4U5Y* GB^9Q$$OO#<2Z!>2
M&8NO7)57"\O^(;;_^]7]5>AH!;P(5ORNJ-3.Z_UQ7\WL_._&$R9(I \@WOE9
M?-MUK-Q\F&3QYG"'US)"4NYO\Q*A\ HU;F4%>E <!XU4^>GVW=W7UVO%I$.:
M5Y9 P]9RY7@L9G1D8BNNG^JCC "D5WPVG=MX*?",$B<- $[ IU,SO^]4.Y&U
MB]3.F']-R^12)-PP+EO"/>2WM]&>A)[%K74IDP)\IZU'N&G1]Q9*YE0SA*1Z
MAN,"M MA$%4LSY?=3)5_#ZEK9U$VP5M]=3S(\M:-Z,8)#Q$!S<!1?^>[_C5\
M]+5M?HWK>=:;N]O97E8P30:=,."$^S_3]48QUL!-JTG;);;'/#E)9(,'>.UJ
MV79"H;>,;O42D0<"$(WSHR]OQ^7-I@7OL#_?;;8_7US+<VM,A;!@ 9X+W3K_
M$X"- <S5WQRU%<7"&-FH+2^8("\AF3M)@!62]WWZG>1*52B5@NQS'XM#KF#(
M>"*1S AGX$45O+&BNFLQ'XVR,.8I%%^92744K-/L@A8L'!P89*5@E%4(P5SF
M@-'!Q-OXY.@Q@"^B3\0J<%%\>5LY,6V._,6+M8F;WR]!?'>0IW\RL/D,H>&!
M%@!3"OL#BY@+9W8%EJ"(  KMG;5BUMG-@A4YT8T21@39P<S ,#FTQKPH0 YF
MQ07UDID6OP7G!3!YI4AE!=;4TIARWS"_)GO ( U1$RG7S,-EO-WQVCAK$\R^
MF1BJ?"=0MS5<.#*3B_/0BLBNR1)VG&OR0N.<Q*)-_0N:(("RL_!&.PR- Q;
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MYGY- 8K-V6\RB2M?_K.$+4\]F_Z1SDB, \&];Q.PL](W!J6/GE?B ?]S[ 9
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MM_M\;TXJUCX'8+[;CO0;-A&9^1=SGU%/MM$'IB)@WP&'S*6;&?;.P ()="8
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MJBCV#C@7%#JY0Y0EGK?5B-\8K/"&]1G[.;*A7V:_\#^U,'T5K^HO=F'69Y+
M_M>,,MEQ <2N5X@9JM5%$5A@\+PI^]4))8;;@-$H(= 6LKQ7CM>A]"V 5:W@
ME7.&ISB[GDN-?$W"H C93HHM=H;A71T8YM-#P":CIU[05GDA@)&$J+?;TC.
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MO<<^9!*/1>\QT7M,]!X3O<=$[[$5+6-3W['TF?@G^G-U6;:AYI,&_T8\;.L
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M$TEWA'B< N!28OC?3J40E&6J,9,% K,O(.L/W[G<QSC[U4>0H_"EE+18@AS
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MN^ZKY#^C997&06.MESME9%!_76IZQ6$C:@U0<YC::3>P(&A+V!3]!WDBWI*
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M_26, M^[/U@4QE1-986QI1,6.';<,N3XC>+&X?B;(9MZ#0;'X2D4QS-5'/G
M.70KM]S?K(]ZG- 8>Z0Q&DJ.L:Z.JCJ@JC@>]<0H/TM5\6AY:\8AO!ID.P67
M<+U,=N$Y[HGGN.GK$A*M6J)5%X3VHW1!>)B%H;"+AYGI:#W7@8[T3>?-7\MK
MPU;],1-].%1&C3F:6YUYJ\JZ6MT5_J DU,(U%XKBA(G2)ZY^:/?/T1@FO=K0
M>8N&>JJWL;\SJ05Q\'$H&V.U'U) Z-_'Q*DW.),*TTU/70$_7]YWF/Q"89[L
M)H.J!V&<1;^<MF(9>Q7XX8]XB^1EYB[MS*/I=^)?\\GWF'#_8>82*\#S/>2I
M(,5_AJ:;6E346+K9D::KY#4C@&A!/8+:C696R9#_>R5=,)!H^AK42S"0W=DO
M#ZF:P91I>IZ,)OT3H[D/"^N>7-P%Q/KWA36'T[VWW&?K-<R" 9LA27_]6%)#
M$@,)=LL*-%:K,O)[X/49[Y658@SL$)$ABLS=KM 'O*^1.VZ$939ZPY</Y!$>
MO\,:M<!:D"4<.Y1^C>P!+6K#ZK=P>1<ZMF,%#EDWQ3;%@H/ *"5;RHTH_SGD
MW58KGVOZ?#5ZM162\:L?P4MX7>25XX%,<RQ7NHFLB)8.AQ)6%]908M<RA!VO
M(F4A#VR_E'W$QCE[6OG ^R-Q;E)LG,0_R+PL<R$7ZD WTDNA)6DE=TBY3WH,
M+KNRTFE;89)_=N6W$S& :N"=I*K2!0]*2*!CP6)O49OZWY_&FCKZ8%?UHZ-J
M0ZP0M-<.8)="SP-!]6J7.L_Q0*=EJ3\( '_FN$Y2:P\\P0\(I<VXT#[C>D2N
M 1KILO3#JJOK]H9*BMK7W<+>5S25@C) QI7N'+G#?8"+G0> +<]]M$+"]QV4
MW6KCX; PC.!F]D#LI4N^S;_,YP1LDR>2..Y^@/S((]0MLLTC+,?=VH#:R[52
M^3 (-KSF_WNCO:E8J!5SO[*[Z:KB=@@V&"LK#)2@L;1L,1?/W&32O4")XT.)
M]GL4=LYE:H;%!.:M8-X&8^ET^8] EIV1I9!K+#B30+96D.WWF\_8'&T96IZ]
MSJ<G6)3 FH-AS6[1I<Y;*B7=HNMD;IQRT@-F;DIW9(Y-$5.O13%>T'2;T7IP
M;Z:[;C=OFO0$E_H;TF]R4HY1:,O+_%B(SU>!_W@)RSK>TO'NORUX*]+P$T7S
MQ-]%PB\O46"!3'$\*WB]CLAC^-7WT,D5^*X+CUYC]):$NW=(W#&161O+ZKCS
M&I+M".9T66)/1NX(#GF"'++>0!ZCT#:M6^;60HUWIDI#DXU1]P.*^X%ZA^-J
MN\U..D1"<I5N7K'^Z5P99G0L(S]XI8%$H//6)U36@WB'H^!ZMJ&U$JQCG.RO
MCE]/OA7BTN71Z#(YMY4N_GT9D$1>76A9@:55]231>Z9_]Y'M]7<PYL^]NBS!
M,0^-SGV;/K3*$DVE49:X7H-OER4*7G@(7EA@=JWI]L+OWM"5W692"3.S:_IA
M!0NGTE$)F+=-Z.1FH9-2*G=R2:&KA=Z?&.9.HRL":H'E)E9K3FYU[4(_2!6X
M\#4)#[I@=GWPH)M:U]RL59]YO0:I@HT)E_GQV$OKBK9;P]L&72!=OZFN%^68
MSG2*;SJB>SH%Z_]H1IQ<IO-C2V<:X]Q8-ODX.X86/GB&;]#1PUB@>._AY.%^
M2/VSU)K;P+>N$H39&)+*II^JKJJZH4TFH\F?!:5:S_<!Y5.$;V.4_IQB])4?
M9#KQD/"K'_U(,+C[OJ##26E?T'@T2Q\(JL5+?[?VJ,= O8)/=,@G]N,/1FO\
MH=V,-%G7B[/)3Y8MM-,PN&\F[-'HAK<\MRM1""/'<OL15^V!F=*XZ77"S#N9
MW5>/AYL39;Q!QZMPG (')W"<G%OT<P:#.^KVJY6Z10^JV!TQ$0ER[:&N54ZG
M1GMTVJZRI52'90]#J$>C:@DWW([7\=7W "/M)6 ==J/BK;E$K>O6;Q*6\K;*
MEC[61KLK6X"X*=[R2'5'"M;(,'JG81TQY0@:[9)&]Z'-N@I63=IL96ZN/NF+
M+E47?85KJ>/F'O I]@/WHP<22 Z6 6>BC9;T%(]'D*QX/H+T;(72(O"?',!K
M";[+<Y.E>> _2BXV#)E90? *RSQ;0;&AC#"SA?';M/H$$#>JXI$,VZ>>S7/X
M,,@ W/K[,ECX(0TY_)-8 ?SG'XC[N?##/\ :YB&(P.XJ0/EQ*(]'I0Q<N*_Z
M_B9!P?M1KM$=Y;:A>!FR,BPUB_I,L*?@:CK:7.+IVL;P;SG2[Y9MW$/#$]^4
M*Q'6%B^\0/C.A2UT:0#OOX\3+J5(=#"&<)E_JT,3$W5HCE5S9*[IPU:HJ.@Z
MZ<O4JQET_)_^.+.2.1^9FN&74S))S[ T3/#"8^"%%0P/617HCW /PVU<A94\
ML 'M=.Z\$/OBOR3PWWR\Z(M2NK,_,/UYAY&3YSI$ZF^[#)$R!VRJT'0V@]N+
MX /J&5QZ,[APR_&B5RQ8V-04> 6EF@7_OY9AY,Q?"S>0.T39E"BUI3L ^Y-.
MA7H%6U0BZ/0OCMB3LW.C)!O8*Q9O/%A/1,(_++VTCB/;]H'Y:&T?7H[?1]-@
M%L%25D37LQ[Q@G JU?H%GAW7E6:LS@25(&<.-.M%[BM\$CU@Y0DLY %X)563
M'N',#^$ 9T<6AEQ9*3HL0$#,7G%T%1UM-0N66,/"VD;2'0-SL]S(@6T'Q+4B
MW)._Z9#P/V"!CPO?(^P\17MH4(Y=1>*G?RT9A+7*G4<%#?4'V^MW*XA>;P/+
M"QFK##\[X<SUPV6P_\RKGIBM)?/[-.E"X@"0$ )X>7SR.</"+$0./02N/H?-
MG72Z SM4E8$VQK438"#=K(+J?0\APA@>DC*;+H>4F]WVJ[2P7E&2POVR+N\X
M?=&6.$\ !*>*(/T^/[QT\T!(A*>M&DR'^ZD_F&X$U*-HD]$H[_]+I])E2?,[
MWW6#4^@*\S_+AQ#O,8MN=9*!5#J/I5J_VJCT-_+X/B/(&D'[1MS8-2>&%;7>
M-7IO#<UWJTDF[:PG[JX%LBCQCQ\5]38]':>GB)(;SG;Z='T^MZH*BA>X488;
MY>.K!.F+ZZUW'=OR@$I]?FW,_*?+RR]?KJY*/>6U0^6M7=WV'H4OCPO7?R6$
M.@9B%T]:-M$D"<;^Y'U)K]EU)IW<QNYQCQWZ?!9[[_-+YK;WKXYUY[@.>CLN
MEP%6B969W&AH_[D,<8%U[K1/K]E/IB].^"=:^]D__D95_D92<L:3#75EIX^H
M)XKP=3!Z6&R=O@-&J[W#:*UT2E+GJ-R@DMQ+&3>E<8V^B[4MIT!T^KJ>\8P&
MA.2PT R;8\F1"D=SP[RU/F*[H)I^2MI"5^5MR*)_$G94UO6I-P+V;*S,]7V
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MTTQK_7OGVZ_PGX?HT?TH_7]02P$"% ,4    " !6,716.@7Z"0 4  !<W
M$0              @ $     8VUM8BTR,#(R,3(S,2YX<V102P$"% ,4
M" !6,71687*X(3H-  #*M0  %0              @ $O%   8VUM8BTR,#(R
M,3(S,5]C86PN>&UL4$L! A0#%     @ 5C%T5F.%!#3H(0  _O4! !4
M         ( !G"$  &-M;6(M,C R,C$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M %8Q=%90$WFX@I8  *AW!P 5              "  ;=#  !C;6UB+3(P,C(Q
M,C,Q7VQA8BYX;6Q02P$"% ,4    " !6,716$UDCOFL^  #&!@0 %0
M        @ %LV@  8VUM8BTR,#(R,3(S,5]P<F4N>&UL4$L! A0#%     @
M5C%T5JUCE+ 0"@  _PH   X              ( !"AD! &-M;6)?:6UG,#$N
M:G!G4$L! A0#%     @ 5C%T5HX_Q-N2 P  X@T  !               ( !
M1B,! &5X:&EB:71?,C,M,2YH=&U02P$"% ,4    " !6,716W#[:S"X(   Q
M'0  $               @ $&)P$ 97AH:6)I=%\S,2TQ+FAT;5!+ 0(4 Q0
M   ( %8Q=%9PXPCDE @  $(G   0              "  6(O 0!E>&AI8FET
M7S,Q+3(N:'1M4$L! A0#%     @ 5C%T5I?-%;YM!   HQ4  !
M     ( !)#@! &5X:&EB:71?,S(M,2YH=&U02P$"% ,4    " !6,716Q6=T
M](4$  #?%0  $               @ &_/ $ 97AH:6)I=%\S,BTR+FAT;5!+
M 0(4 Q0    ( %8Q=%8P!U'805D   =?   .              "  7)! 0!I
M;6%G93 P,#$W+FIP9U!+ 0(4 Q0    ( %8Q=%8,1:M:6[X  /[4   .
M          "  =^: 0!I;6%G93 P,#$X+FIP9U!+ 0(4 Q0    ( %8Q=%8;
MEF_U:E$  +A5   .              "  699 @!I;6%G93 P,#$Y+FIP9U!+
M 0(4 Q0    ( %8Q=%:=0<'M06H  'UL   .              "  ?RJ @!I
M;6%G93 P,#(P+FIP9U!+ 0(4 Q0    ( %8Q=%9FB]71\$X  #E5   .
M          "  6D5 P!I;6%G93 P,#(Q+FIP9U!+ 0(4 Q0    ( %8Q=%;P
M832!7QT  -$C   .              "  85D P!I;6%G93 P,#(R+FIP9U!+
M 0(4 Q0    ( %8Q=%8+M%>[XEP  #EC   .              "  1"" P!I
M;6%G93 P,#(S+FIP9U!+ 0(4 Q0    ( %8Q=%897]++WG$  +!Z   .
M          "  1[? P!I;6%G93 P,#(T+FIP9U!+ 0(4 Q0    ( %8Q=%:K
M3F7CYC0  &L\   .              "  2A1! !I;6%G93 P,#(U+FIP9U!+
M 0(4 Q0    ( %8Q=%:V.N6;/7D  ):)   .              "  3J&! !I
M;6%G93 P,#(V+FIP9U!+ 0(4 Q0    ( %8Q=%:[95D$0#H  /XZ   .
M          "  :/_! !I;6%G93 P,#(W+FIP9U!+ 0(4 Q0    ( %8Q=%;6
M!8X^77D  &A\   .              "  0\Z!0!I;6%G93 P,#(X+FIP9U!+
M 0(4 Q0    ( %8Q=%8-OV5(XYH   "<   .              "  9BS!0!I
M;6%G93 P,#(Y+FIP9U!+ 0(4 Q0    ( %8Q=%:R7DTY"24  *\J   .
M          "  :=.!@!I;6%G93 P,#,P+FIP9U!+ 0(4 Q0    ( %8Q=%9@
M8BU1<X0  -FE   .              "  =QS!@!I;6%G93 P,#,R+FIP9U!+
M 0(4 Q0    ( %8Q=%9^KELSZE\# *KV(  -              "  7OX!@!Z
B:S(S,CDT,#,N:'1M4$L%!@     ; !L ? 8  )!8"@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
